Clustering O 0 6.728574953740463e-05
of O 0 2.11841074815311e-06
missense O 0 0.00012844923185184598
mutations O 0 4.860527042183094e-06
in O 0 1.2336194288309343e-07
the O 0 4.696769337897422e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
gene O 0 1.0137838216905948e-05
in O 0 4.184904511816967e-08
a O 0 2.2044596903469937e-07
sporadic B-Disease 0 1.2351983968983404e-05
T I-Disease 0 0.005685971584171057
- I-Disease 0 0.02497849427163601
cell I-Disease 0 0.02245725691318512
leukaemia I-Disease 1 0.9631456136703491
. O 0 4.142357283853926e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.5787524580955505
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 5.802011315836353e-09
is O 0 6.657772666507356e-10
a O 0 2.364427098555666e-09
recessive B-Disease 0 2.7976341243629577e-06
multi I-Disease 1 0.9999874830245972
- I-Disease 1 0.9999992847442627
system I-Disease 1 0.9997743964195251
disorder I-Disease 1 0.9999997615814209
caused O 0 1.4233989986678353e-06
by O 0 2.7192492701999527e-09
mutations O 0 4.4971951496108886e-08
in O 0 1.7325033629944642e-09
the O 0 6.655300310853818e-09
ATM O 0 4.870852080784971e-06
gene O 0 6.279769593220408e-08
at O 0 2.3222287381940987e-07
11q22 O 0 3.242053571739234e-05
- O 0 8.525766133971047e-06
q23 O 0 6.546619988512248e-05
( O 0 1.699831670975982e-07
ref O 0 5.1415536290733144e-05
. O 0 3.3857116221724937e-08
3 O 0 2.2952200140480272e-07
) O 0 2.016213329625316e-08
. O 0 1.378204785851267e-07

The O 0 1.2954362773598405e-06
risk O 0 1.9410219465498812e-05
of O 0 2.3795495508238673e-05
cancer B-Disease 1 0.9999997615814209
, O 0 3.711321312493965e-07
especially O 0 1.2329542187217157e-06
lymphoid B-Disease 1 0.9999998807907104
neoplasias I-Disease 1 0.9999932050704956
, O 0 7.333170071177619e-09
is O 0 1.6356835885744658e-09
substantially O 0 1.1555459700218762e-08
elevated O 0 3.4271974413968564e-07
in O 0 1.4941559101089297e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 4.888722315854466e-08
and O 0 1.4490165733960225e-09
has O 0 4.2813104172978456e-09
long O 0 7.754048070296449e-09
been O 0 3.1134095301865727e-09
associated O 0 2.0256726074308062e-08
with O 0 4.967100863950691e-08
chromosomal O 1 1.0
instability O 1 1.0
. O 0 0.0005950121558271348

By O 0 4.0221593167188985e-07
analysing O 0 9.567985216563102e-06
tumour B-Disease 1 0.9999988079071045
DNA O 0 1.1512471473906771e-06
from O 0 3.3913540420371646e-08
patients O 0 6.9317911410848865e-09
with O 0 1.3002359189329127e-09
sporadic B-Disease 0 1.1550495401024818e-05
T I-Disease 0 0.0009843319421634078
- I-Disease 0 9.494521509623155e-05
cell I-Disease 0 4.01512770622503e-05
prolymphocytic I-Disease 0 0.003758826293051243
leukaemia I-Disease 1 0.8016045689582825
( O 0 7.743263097381714e-08
T B-Disease 0 6.26137807557825e-06
- I-Disease 0 5.632362444885075e-06
PLL I-Disease 0 9.117513400269672e-05
) O 0 1.6074186426351389e-09
, O 0 1.1995344717519174e-09
a O 0 6.7048762097954295e-09
rare O 0 4.3420694595397435e-08
clonal B-Disease 0 4.2546071199467406e-05
malignancy I-Disease 0 0.23998720943927765
with O 0 1.0439602515788238e-09
similarities O 0 1.9935335160425893e-08
to O 0 5.972706773604841e-09
a O 0 1.0877282363708218e-07
mature B-Disease 0 3.1736408345750533e-07
T I-Disease 0 3.699620719999075e-06
- I-Disease 0 6.814955668232869e-06
cell I-Disease 0 6.131543159426656e-06
leukaemia I-Disease 0 6.253307219594717e-05
seen O 0 1.3317464464535078e-08
in O 0 3.972628892512375e-09
A B-Disease 1 0.9999773502349854
- I-Disease 1 0.9995693564414978
T I-Disease 1 0.999990701675415
, O 0 4.199943948179907e-09
we O 0 8.723745614780398e-10
demonstrate O 0 5.2668014394186e-10
a O 0 7.624152420504515e-10
high O 0 3.2356743950856526e-09
frequency O 0 1.641816993469547e-08
of O 0 9.808038825553922e-09
ATM O 0 2.1816535081597976e-05
mutations O 0 7.310744081223675e-07
in O 0 2.92338597773778e-07
T B-Disease 0 0.00042769036372192204
- I-Disease 0 0.0007181898690760136
PLL I-Disease 0 0.005305411759763956
. O 0 3.7327642985474085e-06

In O 0 2.9546151836257195e-07
marked O 0 1.5013054621704214e-07
contrast O 0 2.4754433169960066e-08
to O 0 4.394247632433235e-09
the O 0 1.8494368703159125e-08
ATM O 0 1.0858540917979553e-05
mutation O 0 1.515308554189687e-07
pattern O 0 1.4290297656316397e-07
in O 0 4.2363677010825995e-08
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 7.733680362775885e-09
the O 0 2.4261415099147143e-09
most O 0 2.3416135697118534e-10
frequent O 0 8.486591984713243e-10
nucleotide O 0 1.012578909609374e-08
changes O 0 4.716495527468112e-10
in O 0 1.0196329336409349e-09
this O 0 9.645155785165116e-09
leukaemia B-Disease 0 0.00021881044085603207
were O 0 2.578811404418957e-07
missense O 0 8.224423072533682e-05
mutations O 0 2.245288123958744e-05
. O 0 2.419508291495731e-06

These O 0 9.242793197472565e-08
clustered O 0 1.4815864233241882e-06
in O 0 7.575827076777841e-09
the O 0 6.185238987654884e-09
region O 0 3.2556407347783534e-08
corresponding O 0 1.2282717953837619e-08
to O 0 2.1388544269029808e-09
the O 0 6.011312780884737e-09
kinase O 0 7.136986255318334e-07
domain O 0 1.242465117456959e-07
, O 0 1.016906114870153e-09
which O 0 4.543281861835169e-10
is O 0 8.732501943775617e-10
highly O 0 2.0776520504028895e-09
conserved O 0 2.5049288865375274e-08
in O 0 2.1335411215517297e-09
ATM O 0 2.4602439225418493e-05
- O 0 8.262002779702016e-07
related O 0 3.2997835575088175e-08
proteins O 0 1.036948971133711e-09
in O 0 1.4174196261151906e-09
mouse O 0 3.173800777744873e-08
, O 0 4.90073492898091e-09
yeast O 0 4.4899618956151244e-07
and O 0 3.4302964024846005e-08
Drosophila O 0 3.332514324938529e-06
. O 0 2.476440386089962e-07

The O 0 7.392436032205296e-07
resulting O 0 6.056516212993301e-07
amino O 0 2.7276277592136466e-07
- O 0 1.0154261786965435e-07
acid O 0 1.4780447088469373e-08
substitutions O 0 1.3501277429384118e-08
are O 0 3.7951922160495144e-10
predicted O 0 1.9324409095133888e-07
to O 0 9.899737918317442e-09
interfere O 0 8.022087882864071e-08
with O 0 7.314856276252613e-09
ATP O 0 0.00030198341119103134
binding O 0 3.445049685524282e-07
or O 0 1.0828718899347223e-07
substrate O 0 6.09577955401619e-06
recognition O 0 5.493649837262637e-07
. O 0 1.0186672625422943e-06

Two O 0 3.4021289252450515e-07
of O 0 7.764409701849218e-07
seventeen O 0 3.694515498864348e-06
mutated O 0 7.019484655756969e-06
T B-Disease 0 2.412627509329468e-05
- I-Disease 0 9.21715582080651e-06
PLL I-Disease 0 2.55125378316734e-05
samples O 0 5.847895945265691e-09
had O 0 4.018513966030923e-09
a O 0 6.266115626374358e-09
previously O 0 1.7400415330826036e-08
reported O 0 6.117846851338982e-08
A B-Disease 1 0.9999909400939941
- I-Disease 1 0.9999752044677734
T I-Disease 1 0.9999946355819702
allele O 0 0.00012040622823406011
. O 0 2.6743070975498995e-06

In O 0 3.172155231823126e-07
contrast O 0 3.073830896482832e-07
, O 0 1.902605895054421e-08
no O 0 1.8292436010369784e-08
mutations O 0 7.77865594159266e-08
were O 0 5.730009799975733e-09
detected O 0 1.7954580044943214e-08
in O 0 9.288752544911461e-10
the O 0 3.444475815683745e-09
p53 O 0 3.6863671226683437e-08
gene O 0 1.0294629149143475e-08
, O 0 4.839703082737401e-10
suggesting O 0 1.1027600166357843e-08
that O 0 5.808108993754502e-10
this O 0 3.497198974855564e-08
tumour B-Disease 1 1.0
suppressor O 1 0.9939768314361572
is O 0 7.352721986819688e-09
not O 0 8.090783598646567e-10
frequently O 0 3.2335090160984237e-09
altered O 0 1.876187205596125e-08
in O 0 5.937155211910294e-09
this O 0 8.438434662139116e-08
leukaemia B-Disease 0 0.054247982800006866
. O 0 5.106798198539764e-06

Occasional O 0 5.3733369895780925e-06
missense O 0 2.6940997486235574e-05
mutations O 0 7.835955670998374e-07
in O 0 1.3968032952504927e-08
ATM O 0 0.0005282759084366262
were O 0 1.0131449457162489e-08
also O 0 2.092119144592175e-09
found O 0 7.72332864329428e-10
in O 0 1.6829385662830987e-09
tumour B-Disease 1 0.9999719858169556
DNA O 0 1.4193335573509103e-07
from O 0 6.328332080585142e-09
patients O 0 3.4051239605759065e-10
with O 0 2.5866009334407636e-10
B B-Disease 0 4.1432558646192774e-05
- I-Disease 0 6.555236268468434e-06
cell I-Disease 0 3.8440852222265676e-05
non I-Disease 0 0.00013250461779534817
- I-Disease 0 0.3348371088504791
Hodgkins I-Disease 1 0.9999982118606567
lymphomas I-Disease 0 0.00011660403833957389
( O 0 2.4032068779433757e-08
B B-Disease 0 4.236685072100954e-06
- I-Disease 0 2.723243142099818e-07
NHL I-Disease 0 8.880980573167108e-08
) O 0 7.114832611954114e-10
and O 0 2.3578913821431513e-10
a O 0 1.9680733487348334e-08
B B-Disease 0 9.837971447268501e-06
- I-Disease 0 2.8724409730784828e-06
NHL I-Disease 0 9.688498721516225e-06
cell O 0 3.2017025660024956e-05
line O 0 1.6848905943334103e-05
. O 0 5.627288373943884e-06

The O 0 9.980545456755863e-08
evidence O 0 3.1303699188356404e-08
of O 0 1.71545160299047e-08
a O 0 1.1131020549726145e-08
significant O 0 3.508082002667834e-08
proportion O 0 6.926005369223276e-08
of O 0 4.6059685843147236e-08
loss O 0 4.7185611151689955e-07
- O 0 7.322606734305737e-07
of O 0 7.031371751509141e-08
- O 0 5.228363164633265e-08
function O 0 1.4947822979394232e-09
mutations O 0 3.158555084148418e-10
and O 0 2.145499923555949e-11
a O 0 8.973258247557681e-10
complete O 0 9.384636179277095e-09
absence O 0 1.34911658733472e-07
of O 0 1.4005835602404204e-08
the O 0 1.6077221776100714e-09
normal O 0 2.106726793016378e-09
copy O 0 2.414383803994724e-09
of O 0 5.726545904138902e-09
ATM O 0 2.955042191388202e-06
in O 0 2.2074770900104568e-09
the O 0 4.7544692627354834e-09
majority O 0 7.298244675268961e-09
of O 0 1.7336272151169396e-07
mutated O 0 3.190388815710321e-05
tumours B-Disease 1 0.9999979734420776
establishes O 0 2.4778723854979035e-06
somatic O 0 2.6893021640717052e-05
inactivation O 0 1.4685778296552598e-05
of O 0 2.1194397348267557e-08
this O 0 1.783909131525263e-09
gene O 0 7.202796581395887e-09
in O 0 1.3450558444816352e-09
the O 0 8.289688047113941e-09
pathogenesis O 0 6.174996542540612e-06
of O 0 7.976116194186034e-07
sporadic B-Disease 0 0.0010172040201723576
T I-Disease 1 0.9916440844535828
- I-Disease 1 0.949395477771759
PLL I-Disease 1 0.8566650152206421
and O 0 4.4356780470877766e-09
suggests O 0 6.391397633365159e-09
that O 0 5.273677605721616e-10
ATM O 0 1.0111344863616978e-06
acts O 0 2.1572594377516907e-08
as O 0 3.1313970083601816e-08
a O 0 1.978104364752653e-06
tumour B-Disease 1 1.0
suppressor O 1 0.5708252787590027
. O 0 4.924960194330197e-06

As O 0 1.0461377542014816e-07
constitutional O 0 3.1689137358625885e-07
DNA O 0 2.1162065877433633e-07
was O 0 2.2909921071345707e-08
not O 0 2.0978681292138646e-10
available O 0 3.655604430274906e-10
, O 0 4.0877703999520065e-10
a O 0 1.9224428271513716e-08
putative O 0 4.587991861626506e-05
hereditary O 1 0.9999960660934448
predisposition O 1 0.9999996423721313
to O 0 0.0001922364899655804
T B-Disease 1 0.9999881982803345
- I-Disease 1 0.7901527881622314
PLL I-Disease 0 0.010171673260629177
will O 0 6.567596244622109e-09
require O 0 3.181350738401534e-09
further O 0 2.7120767853716643e-08
investigation O 0 2.0117657584250992e-07
. O 0 9.511394694072806e-08
. O 0 8.814706120574556e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
protein O 0 1.809903551475145e-05
kinase O 0 8.383492058783304e-06
is O 0 6.511691630350924e-09
involved O 0 2.0138486434007064e-09
in O 0 5.298055882896335e-10
the O 0 9.552384439004413e-10
modulation O 0 1.3094505391109124e-07
of O 0 2.372501128888871e-08
the O 0 2.6674291220274426e-08
Ca2 O 0 1.4274118029788951e-06
+ O 0 2.213622792623937e-06
homeostasis O 0 5.7147381085087545e-06
in O 0 9.344736895400274e-08
skeletal O 0 4.155269198236056e-05
muscle O 0 1.2792194866051432e-05
cells O 0 6.323837624222506e-06
. O 0 2.6707693905336782e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9932929277420044
DM B-Disease 1 1.0
) O 0 2.877247595733934e-07
, O 0 5.7831517352724404e-09
the O 0 3.257800917921827e-09
most O 0 5.366525890337925e-09
prevalent O 0 0.0002036897640209645
muscular B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.365530463066534e-06
adults O 0 8.729327305445622e-07
, O 0 9.690721114452572e-09
is O 0 7.461392392826838e-09
caused O 0 2.1630894408986023e-08
by O 0 1.9789809790893287e-09
( O 0 2.3217276989839775e-08
CTG O 0 4.99974021295202e-06
) O 0 2.2209449834775796e-09
n O 0 3.474248444490513e-08
- O 0 4.92959379982949e-08
repeat O 0 2.8616625513677718e-08
expansion O 0 2.9449592986452444e-08
in O 0 1.1185157244852917e-09
a O 0 2.604240378900613e-09
gene O 0 2.0652382026753457e-09
encoding O 0 4.95899499242114e-09
a O 0 1.2064508503328852e-08
protein O 0 6.348741976580641e-08
kinase O 0 6.419243163691135e-07
( O 0 5.242352685286278e-08
DM B-Disease 1 0.9999935626983643
protein O 0 1.304795915757495e-07
kinase O 0 3.719356982401223e-07
; O 0 9.235775699778515e-09
DMPK O 0 0.0007478718762286007
) O 0 2.0413097878702047e-09
and O 0 1.9120881267209455e-10
involves O 0 1.4293541905630036e-09
changes O 0 1.8730577089343114e-09
in O 0 1.2005559213434935e-08
cytoarchitecture O 0 8.243339834734797e-06
and O 0 1.0321509336108647e-07
ion O 0 8.973673539003357e-05
homeostasis O 0 0.00013258046237751842
. O 0 8.713976058061235e-06

To O 0 1.704358822962604e-07
obtain O 0 3.4389049119454285e-07
clues O 0 6.862767349957721e-07
to O 0 8.057707390207725e-09
the O 0 1.4143200388616606e-08
normal O 0 4.924142871232107e-08
biological O 0 1.1400152999385682e-07
role O 0 1.6926613000123325e-08
of O 0 4.7732260810562366e-08
DMPK O 1 0.7608497142791748
in O 0 3.093457223712903e-08
cellular O 0 1.7362314963520475e-07
ion O 0 2.5147721771645593e-06
homeostasis O 0 4.167558927292703e-06
, O 0 4.887647175877419e-09
we O 0 3.462649722507649e-09
have O 0 5.080640907983991e-10
compared O 0 9.272206114019355e-09
the O 0 5.720880213999635e-09
resting O 0 7.390745082602734e-08
[ O 0 2.1024165519634153e-08
Ca2 O 0 3.1325438243356984e-08
+ O 0 5.277275505477519e-08
] O 0 5.4763308554584e-08
i O 0 1.4013157745296212e-08
, O 0 6.662904672438685e-10
the O 0 1.5438004208334632e-09
amplitude O 0 1.200487815822271e-07
and O 0 7.614227026664366e-10
shape O 0 4.8806164443249145e-08
of O 0 7.60384324394181e-08
depolarization O 0 3.3819217151176417e-06
- O 0 1.8275960655955714e-06
induced O 0 3.897665919794235e-06
Ca2 O 0 2.597555237571214e-07
+ O 0 1.6242491085449728e-07
transients O 0 3.2397494464930787e-07
, O 0 3.7218222947998925e-10
and O 0 1.391961407248843e-10
the O 0 8.999379019769549e-10
content O 0 7.771356891339565e-09
of O 0 1.3516556762738219e-08
ATP O 0 1.044273994921241e-05
- O 0 4.4301759771769866e-07
driven O 0 1.6531568292066368e-07
ion O 0 7.865251632210857e-07
pumps O 0 1.994365135260523e-07
in O 0 2.114880537362751e-08
cultured O 0 6.838267836428713e-07
skeletal O 0 4.799188673132448e-07
muscle O 0 7.735601315062013e-08
cells O 0 2.5652560964317672e-08
of O 0 2.0386417887152675e-08
wild O 0 2.845899160774934e-08
- O 0 7.148914704657727e-08
type O 0 1.1009635869640988e-07
and O 0 1.2997605658426892e-08
DMPK O 0 0.00025713216746225953
[ O 0 1.1697782156261383e-06
- O 0 7.908576662885025e-06
/ O 0 5.069274629931897e-05
- O 0 9.418935951543972e-05
] O 0 2.7716418117051944e-05
knockout O 1 0.8460674285888672
mice O 0 4.526196789811365e-06
. O 0 7.129781351977726e-07

In O 0 1.4614612382501946e-06
vitro O 0 1.1455005733296275e-05
- O 0 1.0707276487664785e-05
differentiated O 0 6.408883564290591e-06
DMPK O 0 0.07561247050762177
[ O 0 1.0319563443772495e-05
- O 0 0.00015726643323432654
/ O 0 0.000542720896191895
- O 0 0.00015555428399238735
] O 0 3.5594994187704287e-06
myotubes O 0 6.526006927742856e-06
exhibit O 0 1.907718605309583e-08
a O 0 2.7240577793463672e-08
higher O 0 2.8515319172583986e-07
resting O 0 4.0350874996875064e-07
[ O 0 5.8216791387621925e-08
Ca2 O 0 4.8905594240977734e-08
+ O 0 5.993912566282233e-08
] O 0 5.841098982273252e-08
i O 0 1.954956374561334e-08
than O 0 2.928383757705433e-09
do O 0 3.4324412201414134e-09
wild O 0 2.156695622090865e-08
- O 0 6.313734246532476e-08
type O 0 6.054419827705715e-07
myotubes O 0 6.11233917879872e-05
because O 0 7.000457546979533e-09
of O 0 2.9510192067760954e-09
an O 0 4.288393806728408e-10
altered O 0 6.0301115212269e-09
open O 0 9.268917189331205e-09
probability O 0 4.973328771029628e-08
of O 0 1.5585676749196864e-08
voltage O 0 2.436763134028297e-05
- O 0 3.245663947382127e-06
dependent O 0 1.9923176353131566e-07
l O 0 4.546519605241883e-08
- O 0 9.218585006465219e-08
type O 0 1.153894544358991e-07
Ca2 O 0 1.338970179176613e-07
+ O 0 9.531444788990484e-08
and O 0 2.3356655276529636e-08
Na O 0 2.1255743831716245e-06
+ O 0 2.4944023380157887e-07
channels O 0 3.8653143974443083e-07
. O 0 6.868280593153031e-07

The O 0 5.084803433419438e-06
mutant O 0 3.6280445783631876e-05
myotubes O 0 0.00018630869453772902
exhibit O 0 7.95477248516363e-08
smaller O 0 5.869857488960406e-08
and O 0 1.2973407237382162e-08
slower O 0 7.268685067174374e-07
Ca2 O 0 2.6109046302735806e-07
+ O 0 4.9833655424436074e-08
responses O 0 5.054700213946717e-09
upon O 0 6.603130042748262e-09
triggering O 0 9.241365006573687e-08
by O 0 7.030805715402266e-09
acetylcholine O 0 2.336361831112299e-06
or O 0 1.120008903399139e-07
high O 0 7.175456744334952e-07
external O 0 5.113806764711626e-06
K O 0 1.4981252206780482e-05
+ O 0 2.888544258894399e-06
. O 0 6.533814485010225e-07

In O 0 8.811245777451404e-08
addition O 0 1.8539576984721862e-08
, O 0 6.616430958672481e-09
we O 0 2.5214506038651052e-09
observed O 0 2.4121515895814127e-09
that O 0 5.60901360080468e-11
these O 0 1.674836103138233e-10
Ca2 O 0 5.4515592040615957e-08
+ O 0 2.743968252616469e-07
transients O 0 4.676851688145689e-07
partially O 0 2.092678741405507e-08
result O 0 2.8674416174823136e-09
from O 0 2.5585114027393274e-09
an O 0 1.6614989384322598e-09
influx O 0 1.4226966271735364e-08
of O 0 6.866457624710165e-09
extracellular O 0 6.131690355459796e-08
Ca2 O 0 2.650545560811679e-08
+ O 0 1.100228441686113e-08
through O 0 7.244664312899829e-10
the O 0 7.88362619630334e-09
l O 0 9.174906523412574e-08
- O 0 2.6110814133062377e-07
type O 0 7.362976361946494e-07
Ca2 O 0 8.124360988404078e-07
+ O 0 8.481500799462083e-07
channel O 0 2.2946539957047207e-06
. O 0 9.232236948264472e-07

Neither O 0 1.367376967209566e-06
the O 0 8.379156923865594e-08
content O 0 7.719565076058643e-08
nor O 0 9.809033940655354e-08
the O 0 2.3846096652846427e-08
activity O 0 7.784414890465996e-08
of O 0 2.6893249582826684e-07
Na O 0 1.3142214811523445e-05
+ O 0 1.2230967740833876e-06
/ O 0 4.198498572804965e-06
K O 0 4.007183633802924e-06
+ O 0 1.122332946579263e-06
ATPase O 0 3.391281325093587e-06
and O 0 2.865485804193213e-08
sarcoplasmic O 0 3.867825398629066e-06
reticulum O 0 3.6342003113531973e-06
Ca2 O 0 9.950757657861686e-07
+ O 0 6.463299655479204e-07
- O 0 5.645126179842919e-07
ATPase O 0 1.0788533018057933e-06
are O 0 1.2475992461347118e-09
affected O 0 7.4469603816851304e-09
by O 0 3.4922997826924984e-08
DMPK O 1 0.9983494281768799
absence O 0 0.00011312904098303989
. O 0 1.6381423847633414e-05

In O 0 2.8069294444321713e-07
conclusion O 0 7.7824387290093e-07
, O 0 1.913206304493542e-08
our O 0 2.973693735697225e-09
data O 0 7.0261814144600976e-09
suggest O 0 7.449248329294278e-09
that O 0 3.3119325060226856e-09
DMPK O 1 0.9998650550842285
is O 0 1.2910314595160344e-08
involved O 0 1.5348835535888838e-09
in O 0 3.9635597581799686e-10
modulating O 0 1.9483380242490966e-08
the O 0 1.2180479957990542e-09
initial O 0 3.907579593231958e-09
events O 0 6.523447892980982e-10
of O 0 3.5920051377758e-09
excitation O 0 6.192434284457704e-06
- O 0 0.0001465674868086353
contraction O 0 2.658144148881547e-05
coupling O 0 1.3693213531951187e-06
in O 0 5.827500970667643e-08
skeletal O 0 3.480235818642541e-06
muscle O 0 4.7196502350743685e-07
. O 0 3.40913118179742e-07
. O 0 1.3176121456126566e-06

Constitutional O 0 0.00021572961122728884
RB1 O 0 0.0027292994782328606
- O 0 1.4388458112080116e-05
gene O 0 3.119129701190104e-07
mutations O 0 3.170630691329279e-07
in O 0 1.1880411321385509e-08
patients O 0 1.4884670385129084e-08
with O 0 8.431706000067152e-09
isolated O 0 0.00019159146177116781
unilateral B-Disease 1 0.5795366168022156
retinoblastoma I-Disease 1 0.9999973773956299
. O 0 0.00022282812278717756

In O 0 5.149593107489636e-07
most O 0 5.5243379648572954e-08
patients O 0 1.4848205331929876e-08
with O 0 1.6808821001745855e-09
isolated O 0 1.1266587534919381e-05
unilateral B-Disease 0 0.1409534364938736
retinoblastoma I-Disease 1 0.9999998807907104
, O 0 2.580518867034698e-06
tumor B-Disease 1 0.9987769722938538
development O 0 7.459758677441641e-08
is O 0 2.4491748629174026e-09
initiated O 0 9.28572774228087e-09
by O 0 1.2559605577777688e-09
somatic O 0 1.1598095852605184e-06
inactivation O 0 2.1238076897134306e-06
of O 0 1.154100992550866e-08
both O 0 3.5078997484561114e-09
alleles O 0 4.833140110349632e-08
of O 0 6.633935356603615e-08
the O 0 5.116774559610349e-07
RB1 O 0 0.0019163748947903514
gene O 0 5.103847797727212e-06
. O 0 1.6703958181096823e-06

However O 0 6.575457973667653e-07
, O 0 1.5707199096937075e-08
some O 0 1.0458216515019103e-09
of O 0 8.465579348637675e-09
these O 0 2.398040876983032e-09
patients O 0 2.442574853489532e-08
can O 0 1.7853123424060868e-08
transmit O 0 2.872747927540331e-06
retinoblastoma B-Disease 0 0.19070826470851898
predisposition O 0 0.18504124879837036
to O 0 3.343329524341243e-07
their O 0 2.320769709740489e-07
offspring O 0 3.9374062907882035e-06
. O 0 1.274472197110299e-06

To O 0 6.264958329893489e-08
determine O 0 3.351306787635622e-08
the O 0 5.069472841512379e-09
frequency O 0 2.3001568649760884e-07
and O 0 1.8912404975424124e-09
nature O 0 1.608416155818304e-08
of O 0 4.193902114479897e-08
constitutional O 0 3.3736557725205785e-06
RB1 O 0 0.000229300232604146
- O 0 6.450337650676374e-07
gene O 0 1.8973475235384285e-08
mutations O 0 2.5200433739769323e-08
in O 0 8.543663554405612e-10
patients O 0 1.7813861497018024e-09
with O 0 1.2799359350168515e-09
isolated O 0 2.4114682673825882e-05
unilateral B-Disease 0 0.28029027581214905
retinoblastoma I-Disease 1 0.9999916553497314
, O 0 6.136850316806886e-08
we O 0 5.256838964129429e-09
analyzed O 0 1.1632192098431915e-08
DNA O 0 1.6500012023357158e-08
from O 0 2.415802669020195e-09
peripheral O 0 2.195981551267323e-06
blood O 0 3.9407535012969674e-08
and O 0 1.2472811228292358e-08
from O 0 1.1233651093789376e-06
tumor B-Disease 1 0.9175992608070374
tissue O 0 0.00010751479567261413
. O 0 3.748674998860224e-06

The O 0 2.1939709426987974e-07
analysis O 0 3.475216772130807e-07
of O 0 3.2266154903481947e-06
tumors B-Disease 1 1.0
from O 0 1.1963086308242055e-06
54 O 0 1.0020389709097799e-06
( O 0 9.510448428784457e-09
71 O 0 2.807807675253571e-07
% O 0 1.5547019671657836e-08
) O 0 5.08906861096392e-10
of O 0 5.4054289932992106e-09
76 O 0 3.9899450143821014e-07
informative O 0 1.9369061021734524e-07
patients O 0 2.165525003761104e-08
showed O 0 3.720867525203175e-08
loss O 0 9.512408496448188e-07
of O 0 9.231866897607688e-07
constitutional O 0 0.008538724854588509
heterozygosity O 1 0.9999986886978149
( O 0 3.173765435349196e-05
LOH O 1 1.0
) O 0 2.730222377067548e-07
at O 0 9.035563834913773e-07
intragenic O 0 5.655615677824244e-05
loci O 0 2.7950531148235314e-05
. O 0 2.2538861230714247e-06

Three O 0 2.476700160514156e-07
of O 0 3.138536897040467e-07
13 O 0 1.2501270703069167e-06
uninformative O 0 0.4486781656742096
patients O 0 4.785838427778799e-07
had O 0 1.0988463827743544e-06
constitutional O 0 7.289477798622102e-05
deletions O 0 0.0002803643874358386
. O 0 2.2443247871706262e-05

For O 0 1.142836140388681e-06
39 O 0 1.9849510408675997e-06
randomly O 0 3.053070827263582e-07
selected O 0 7.9356306059708e-07
tumors B-Disease 1 1.0
, O 0 4.013735178887146e-06
SSCP O 1 0.9999998807907104
, O 0 7.874364200688433e-06
hetero O 0 0.00012765555584337562
- O 0 1.976422254301724e-06
duplex O 0 1.2357488685665885e-06
analysis O 0 1.4292949046534886e-08
, O 0 1.4669111481069308e-09
sequencing O 0 4.443741730142392e-08
, O 0 2.438063528842349e-09
and O 0 1.1801989385773481e-09
Southern O 0 5.049749773888834e-08
blot O 0 9.223497841048811e-07
analysis O 0 1.0855059962011637e-08
were O 0 1.2844015850888013e-09
used O 0 1.7377521643879845e-09
to O 0 7.638129240206126e-09
identify O 0 1.5570144284993148e-07
mutations O 0 4.364398591860663e-06
. O 0 1.7565396319696447e-06

Mutations O 0 6.621838110731915e-06
were O 0 1.1044613046351515e-07
detected O 0 1.7544425645610318e-07
in O 0 1.0127334526544018e-08
21 O 0 2.9430895054360917e-08
( O 0 1.9727175448736034e-09
91 O 0 4.793105290445965e-08
% O 0 1.1987048686989965e-08
) O 0 9.094942576837184e-10
of O 0 3.34334515628143e-08
23 O 0 6.506456429633545e-06
tumors B-Disease 1 1.0
with O 0 1.8685446775634773e-05
LOH O 1 1.0
. O 0 0.0008887519943527877

In O 0 3.636699261733156e-07
6 O 0 2.980191595725046e-07
( O 0 8.638378901082433e-09
38 O 0 6.627409732118394e-08
% O 0 7.906124643852763e-09
) O 0 6.406504216016629e-10
of O 0 2.233431040110645e-08
16 O 0 9.603499165677931e-06
tumors B-Disease 1 1.0
without O 0 0.004369539674371481
LOH O 1 1.0
, O 0 4.2956514789693756e-08
one O 0 3.767728795622816e-09
mutation O 0 1.126656989924868e-08
was O 0 1.689709883123669e-08
detected O 0 1.6514022149749508e-08
, O 0 5.75888836618077e-10
and O 0 2.849394331594368e-10
in O 0 9.164282666063173e-10
9 O 0 1.5873446557179705e-08
( O 0 1.4596934772015402e-09
56 O 0 2.12827071521815e-08
% O 0 2.325484693699309e-09
) O 0 1.5825121768564543e-10
of O 0 2.777418073307558e-09
the O 0 3.3032100077434734e-07
tumors B-Disease 1 1.0
without O 0 0.17032217979431152
LOH O 1 1.0
, O 0 6.414151698663773e-08
both O 0 1.0331077326952709e-08
mutations O 0 3.474758614174789e-08
were O 0 1.5544115328225416e-08
found O 0 5.038359063291864e-08
. O 0 3.862845403546089e-07

Thus O 0 8.027091098483652e-07
, O 0 1.4734623299261784e-08
a O 0 1.7668163820871996e-08
total O 0 5.6051367991472034e-09
of O 0 7.14820247438297e-09
45 O 0 4.0215756058614716e-08
mutations O 0 1.403715277348283e-08
were O 0 3.1906606245968305e-09
identified O 0 6.540809494026689e-08
in O 0 1.1671345134800504e-07
tumors B-Disease 1 1.0
of O 0 1.1415994777053129e-05
36 O 0 3.0212499041226692e-05
patients O 0 7.044634457997745e-07
. O 0 3.8086154745542444e-06

Thirty O 0 1.0727492735895794e-05
- O 0 1.5574672715956694e-06
nine O 0 3.284900884636954e-08
of O 0 9.547616919292068e-09
the O 0 5.40288302985914e-09
mutations O 0 5.455147089605816e-08
- O 0 1.9824318542305264e-07
including O 0 4.748686777134026e-09
34 O 0 1.1667817290117455e-07
small O 0 1.0570889052985422e-08
mutations O 0 6.86490153611885e-08
, O 0 4.686063981296229e-09
2 O 0 2.5850508222902135e-07
large O 0 1.0796830984816097e-08
structural O 0 6.163608077258687e-07
alterations O 0 6.895832598274865e-07
, O 0 5.685895754226067e-09
and O 0 3.4258353931448937e-09
hypermethylation O 0 0.0014258456649258733
in O 0 4.800414998840097e-08
3 O 0 1.1985688615823165e-05
tumors O 1 0.9999998807907104
- O 0 5.90722493143403e-07
were O 0 6.486514880776895e-09
not O 0 1.6149354076233635e-09
detected O 0 2.4382460495075975e-08
in O 0 8.512173188535144e-10
the O 0 2.9303279802661564e-09
corresponding O 0 1.0081431156550025e-07
peripheral O 0 5.8436864492250606e-05
blood O 0 1.6076578503998462e-06
DNA O 0 1.0593742445053067e-05
. O 0 1.3000055787415477e-06

In O 0 7.047355552458612e-07
6 O 0 6.577351427949907e-07
( O 0 6.106116945403528e-09
17 O 0 1.7262305362919506e-08
% O 0 2.668348653145358e-09
) O 0 7.909253113558279e-11
of O 0 9.973400993956716e-10
the O 0 5.094403121574942e-09
36 O 0 1.3045806213085598e-07
patients O 0 3.204242204901675e-09
, O 0 1.1216433337679632e-09
a O 0 2.7079572362254112e-08
mutation O 0 5.413251642494288e-07
was O 0 2.1836966368482535e-07
detected O 0 1.7567286292319295e-08
in O 0 4.276778098333267e-10
constitutional O 0 2.7723967122028625e-08
DNA O 0 1.4936408376797772e-07
, O 0 7.088892250983747e-10
and O 0 6.751069703270218e-10
1 O 0 5.381421530614716e-08
of O 0 1.0209367795610547e-09
these O 0 1.3744856641739744e-10
mutations O 0 5.473185016313664e-09
is O 0 4.073006654170541e-10
known O 0 9.252926758129831e-10
to O 0 4.638079920127325e-10
be O 0 3.40823813615998e-09
associated O 0 2.5300368022840303e-08
with O 0 4.699812539143977e-09
reduced O 0 2.764281816780567e-06
expressivity O 0 0.0004936873447149992
. O 0 4.5412602958094794e-06

The O 0 1.2445903507796174e-07
presence O 0 9.246757137759687e-09
of O 0 7.106752963892404e-09
a O 0 5.712909256772036e-09
constitutional O 0 1.4823832827914885e-07
mutation O 0 2.2603363447615266e-07
was O 0 1.1010870437644371e-08
not O 0 7.634334830974865e-11
associated O 0 1.629237578182341e-10
with O 0 2.5582942014823473e-11
an O 0 5.910374967221799e-10
early O 0 9.514878485106237e-08
age O 0 1.6210411502015631e-07
at O 0 3.700294541886251e-07
treatment O 0 8.011810450625489e-07
. O 0 2.0321274405432632e-06

In O 0 1.113696498578065e-06
1 O 0 3.418486812734045e-05
patient O 0 3.0727044304512674e-06
, O 0 2.254914903687677e-07
somatic O 1 0.9790741205215454
mosaicism O 1 0.9999912977218628
was O 0 2.329604740225477e-06
demonstrated O 0 1.7074345493028886e-08
by O 0 7.90099430325597e-10
molecular O 0 2.2411974498481868e-08
analysis O 0 1.4820553673189352e-09
of O 0 2.5999227215578458e-09
DNA O 0 2.4305521151291032e-08
and O 0 9.92003368338601e-10
RNA O 0 8.954302757047117e-07
from O 0 7.692506187595427e-08
peripheral O 0 0.00010333203681511804
blood O 0 1.771295956132235e-06
. O 0 1.3934086382505484e-06

In O 0 2.1351681880332762e-06
2 O 0 8.598487511335406e-06
patients O 0 3.111974677949547e-08
without O 0 8.146611385484448e-09
a O 0 6.059479318309968e-08
detectable O 0 1.1742685273929965e-05
mutation O 0 5.379548042583338e-07
in O 0 9.913058818256104e-09
peripheral O 0 0.00013498493353836238
blood O 0 3.954325791255542e-07
, O 0 2.9359968678477344e-08
mosaicism O 1 0.8347333073616028
was O 0 3.183037051712745e-07
suggested O 0 1.26261694433083e-08
because O 0 1.3214777050407633e-09
1 O 0 5.287955673338729e-08
of O 0 1.2685399397582842e-09
the O 0 5.025821536719377e-09
patients O 0 8.321038080794096e-09
showed O 0 4.0713410953685525e-07
multifocal O 1 1.0
tumors B-Disease 1 1.0
and O 0 6.270314401035648e-08
the O 0 7.03367959431489e-08
other O 0 4.6390020713715785e-09
later O 0 8.953690411317439e-08
developed O 0 2.8066136792403995e-07
bilateral B-Disease 0 2.554187631176319e-05
retinoblastoma I-Disease 0 0.03925672546029091
. O 0 2.6383897420600988e-05

In O 0 1.506129621020591e-07
conclusion O 0 2.6528704211159493e-07
, O 0 7.686122849293042e-09
our O 0 3.1260780630759655e-09
results O 0 3.362676581630808e-09
emphasize O 0 1.145058625695583e-08
that O 0 3.2938191063536237e-10
the O 0 9.941499179433322e-09
manifestation O 0 3.7610896015394246e-06
and O 0 1.3474291904458369e-08
transmissibility O 0 1.777458419383038e-05
of O 0 6.929573714842263e-08
retinoblastoma B-Disease 0 4.545419869828038e-06
depend O 0 2.2941886612670714e-08
on O 0 1.2900442492025377e-08
the O 0 1.886837353026749e-09
nature O 0 3.725645569829794e-09
of O 0 1.5506026462830391e-09
the O 0 7.294135295765614e-10
first O 0 1.8003162294277786e-09
mutation O 0 4.28236379690361e-09
, O 0 1.232875607160011e-10
its O 0 6.32524796428946e-11
time O 0 1.159820239848841e-09
in O 0 4.1651040949552964e-10
development O 0 5.225230026439931e-09
, O 0 5.816523374058136e-10
and O 0 1.6985521322787633e-10
the O 0 6.751121883752376e-10
number O 0 4.849867729639357e-10
and O 0 6.829916493478194e-11
types O 0 1.1387244480687286e-09
of O 0 2.0296977432110452e-09
cells O 0 5.471076480745296e-09
that O 0 3.37801953076422e-10
are O 0 8.756903535633853e-10
affected O 0 2.7573300087624375e-08
. O 0 1.0170602848802446e-07
. O 0 1.0628588142935769e-06

Hereditary B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
of I-Disease 0 0.0002596880658529699
the I-Disease 0 1.4333936633192934e-05
fifth I-Disease 0 4.6958386519690976e-05
component I-Disease 0 3.473335709713865e-06
of I-Disease 0 1.0380758652672739e-07
complement I-Disease 0 9.492437413882726e-08
in O 0 1.4486958832549135e-07
man O 0 7.076651854731608e-06
. O 0 1.625150503059558e-06

I O 0 0.02199246548116207
. O 0 0.00011364977399352938

Clinical O 0 0.00016586820129305124
, O 0 1.1884783361892914e-06
immunochemical O 1 0.9823493361473083
, O 0 3.2586919473942544e-07
and O 0 9.072617501715285e-08
family O 0 3.570592923551885e-07
studies O 0 1.7334648418909637e-06
. O 0 1.947114014910767e-06

The O 0 4.6478481863232446e-07
first O 0 9.859096650188803e-08
recognized O 0 1.9097707593118685e-07
human O 0 7.329482087925498e-08
kindred O 0 5.224293545325054e-06
with O 0 1.778049352196831e-07
hereditary B-Disease 1 1.0
deficiency I-Disease 1 1.0
of I-Disease 1 0.9999984502792358
the I-Disease 1 0.7771499752998352
fifth I-Disease 0 0.01751238852739334
component I-Disease 0 6.128117092885077e-06
of I-Disease 0 1.9915918869628513e-07
complement I-Disease 0 1.833127925010558e-07
( O 0 9.802447493711952e-07
C5 O 1 0.9999966621398926
) O 0 3.870167830655191e-08
is O 0 2.3882465782776308e-08
described O 0 5.595130687652272e-07
. O 0 1.1578513294807635e-06

The O 0 7.523723866142973e-07
proband O 0 7.000342884566635e-05
, O 0 6.36699004630259e-09
a O 0 1.30629205230548e-08
20 O 0 1.6324616325391617e-08
- O 0 3.1939013211967904e-08
year O 0 1.0551027607164087e-08
- O 0 2.721020848639455e-07
old O 0 1.566516800721729e-07
black O 0 1.909272917544058e-08
female O 0 2.57303156558919e-09
with O 0 5.1566177994288864e-09
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 1 0.9999939203262329
age O 0 0.2439669519662857
11 O 0 4.920735250379948e-07
, O 0 4.582464629976357e-09
lacked O 0 1.1589366977204918e-07
serum O 0 2.8048233957633784e-07
hemolytic O 0 2.6582607461023144e-05
complement O 0 5.372540101689083e-08
activity O 0 5.086754484295852e-08
, O 0 5.298735672454313e-09
even O 0 3.7428051768984005e-08
during O 0 6.02674560923333e-07
remission O 0 1.7381713405484334e-05
. O 0 1.892809450509958e-06

C5 O 1 0.9788278937339783
was O 0 6.837890396127477e-06
undetectable O 0 3.2890939110075124e-06
in O 0 1.2395211967941577e-08
her O 0 1.2162325591091872e-09
serum O 0 1.2322421305555054e-08
by O 0 2.0267227895942597e-09
both O 0 5.089141907888006e-08
immunodiffusion O 0 0.2325485795736313
and O 0 1.8361495222052326e-06
hemolytic O 1 0.9999973773956299
assays O 0 0.15914888679981232
. O 0 3.3319804060738534e-05

Other O 0 2.1625490731480568e-08
complement O 0 1.643383562566214e-08
components O 0 4.3949203387683156e-08
were O 0 3.1655771337568694e-09
normal O 0 7.943503632645843e-09
during O 0 2.0418678303713023e-08
remission O 0 7.717090966252727e-07
of O 0 2.213541563378385e-07
lupus O 0 0.005183193366974592
, O 0 4.7699856509098026e-08
but O 0 3.518113089739927e-08
C1 O 0 5.0501475925557315e-05
, O 0 6.591292134316973e-08
C4 O 0 0.0013568958966061473
, O 0 2.6029210786759904e-08
C2 O 0 7.541131708421744e-06
, O 0 9.309367499099608e-09
and O 0 3.757282129868145e-08
C3 O 0 0.34996119141578674
levels O 0 2.905923338403227e-06
fell O 0 0.0006905815680511296
during O 0 2.6343529953010147e-06
exacerbations O 0 0.0008177294512279332
. O 0 6.4873120209085755e-06

A O 0 3.6423261917661875e-06
younger O 0 3.4856722663789697e-07
half O 0 3.6363181266096944e-07
- O 0 2.736227770583355e-06
sister O 0 3.4881531973951496e-07
, O 0 1.0510534664831539e-08
who O 0 4.669515973887428e-08
had O 0 1.662251634115819e-07
no O 0 5.385928716350463e-07
underlying O 1 0.9999995231628418
disease O 1 0.9815911054611206
, O 0 2.4883714644374777e-08
was O 0 6.21652475274459e-07
also O 0 1.6629255750189031e-09
found O 0 2.170299939763254e-09
to O 0 1.3111445262836696e-08
lack O 0 3.060281642319751e-06
immunochemically O 1 0.987616240978241
detectable O 1 0.9990246295928955
C5 O 1 0.9998581409454346
. O 0 1.919678834383376e-05

By O 0 1.2161216318418155e-06
hemolytic O 1 0.9870973825454712
assay O 0 0.00020342579227872193
, O 0 2.909357306180027e-07
she O 0 1.616523270797643e-08
exhibited O 0 1.0329422650556808e-08
1 O 0 1.8294238657290407e-07
- O 0 7.91113521358966e-08
2 O 0 4.500173034216459e-08
% O 0 2.764137363442387e-09
of O 0 5.229634503223224e-10
the O 0 4.726238844732222e-10
normal O 0 7.950112568266832e-09
serum O 0 2.820243594214844e-07
C5 O 0 0.000223882743739523
level O 0 9.214681995217688e-08
and O 0 8.422958441833828e-10
normal O 0 9.130874722984572e-09
concentrations O 0 1.717307895887643e-08
of O 0 1.6724873708184873e-09
other O 0 8.224435577020017e-10
complement O 0 6.01454956949965e-08
components O 0 1.7992138054978568e-06
. O 0 2.355290007471922e-06

C5 O 0 0.03949660807847977
levels O 0 1.8519031641517358e-07
of O 0 2.4158730127510353e-08
other O 0 8.642296323024823e-10
family O 0 1.0302402264628086e-09
members O 0 8.313906507684266e-11
were O 0 8.901237524838734e-10
either O 0 4.273795983777973e-09
normal O 0 8.170761844894514e-09
or O 0 2.0137986833645982e-09
approximately O 0 2.1716539677640867e-09
half O 0 1.2421791595329523e-08
- O 0 3.4086042433045805e-08
normal O 0 6.2658767063794585e-09
, O 0 6.31324659217114e-10
consistent O 0 3.954485627843951e-09
with O 0 7.741468577293631e-10
autosomal O 0 1.3320241123437881e-06
codominant O 0 0.0003010867803823203
inheritance O 0 4.573570095089963e-06
of O 0 1.2945542948727962e-07
the O 0 6.666877538918925e-08
gene O 0 1.144952420872869e-06
determining O 0 0.0004392255505081266
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.00010595546336844563

Normal O 0 0.00021315505728125572
hemolytic O 1 0.9995085000991821
titers O 0 0.0004196508671157062
were O 0 1.3418296873624058e-07
restored O 0 7.356189968277249e-08
to O 0 8.710016707880186e-09
both O 0 3.246810109658327e-08
homozygous O 0 1.051511299010599e-05
C5 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 1.0
( O 0 1.5627698303433135e-05
C5D B-Disease 1 1.0
) O 0 1.375120888269521e-07
sera O 0 5.099392978991091e-07
by O 0 5.72221992012345e-10
addition O 0 2.037715551850283e-09
of O 0 2.4090306638413495e-08
highly O 0 2.5159232563964906e-07
purified O 0 2.900391791627044e-06
human O 0 2.379699253651779e-06
C5 O 1 0.9690056443214417
. O 0 9.402855539519805e-06

In O 0 4.337525467690284e-07
specific O 0 6.520238571283699e-07
C5 O 1 0.9995532631874084
titrations O 0 0.0010622026165947318
, O 0 9.544612211698222e-09
however O 0 6.890584991481319e-09
, O 0 6.00442306986082e-10
it O 0 2.927701137078742e-10
was O 0 2.867651005544758e-08
noted O 0 2.132003462662624e-09
that O 0 1.392139320488539e-10
when O 0 4.0246256327591823e-10
limited O 0 3.4645175617242785e-10
amounts O 0 3.9206811131009545e-09
of O 0 1.7712601163566433e-08
C5 O 0 0.00021801369439344853
were O 0 1.1290792301110741e-08
assayed O 0 1.8378473498614767e-07
in O 0 3.270936854704587e-10
the O 0 4.216524629452323e-10
presence O 0 6.955971909583525e-10
of O 0 3.4770111234649903e-09
low O 0 5.595451924023109e-08
dilutions O 0 1.8588458488011383e-06
of O 0 5.087919063839763e-08
either O 0 1.4479226138064405e-06
C5D B-Disease 1 1.0
serum O 0 7.750805707473774e-06
, O 0 8.452961886007415e-09
curving O 0 1.242695049086251e-07
rather O 0 1.6466991104024942e-09
than O 0 3.072198051512487e-10
linear O 0 3.046618957114333e-08
dose O 0 3.202380867151078e-07
- O 0 1.768927226919459e-08
response O 0 2.00339722589149e-09
plots O 0 1.7185037393119273e-08
were O 0 1.1869351057569588e-09
consistently O 0 7.629743059567318e-09
obtained O 0 6.496506887998521e-09
, O 0 3.120472547024633e-09
suggesting O 0 2.9767480924647316e-08
some O 0 1.7960298137609243e-08
inhibitory O 0 8.937257007346489e-06
effect O 0 4.29843157689902e-06
. O 0 2.693210490178899e-06

Further O 0 2.551033730924246e-07
studies O 0 3.898841072214054e-08
suggested O 0 1.3437539081451177e-08
that O 0 1.2474469235357333e-09
low O 0 7.221011060210003e-07
dilutions O 0 2.9419690690701827e-05
of O 0 2.17806132241094e-06
C5D B-Disease 1 1.0
serum O 0 4.6452643687189266e-07
contain O 0 1.943778915602934e-09
a O 0 4.649117979482753e-09
factor O 0 3.527876302200639e-08
( O 0 5.235782363222086e-10
or O 0 1.3099764606394615e-09
factors O 0 7.688878866929372e-09
) O 0 4.1095185587813887e-10
interfering O 0 1.5902628547337372e-08
at O 0 1.978562913507176e-08
some O 0 1.1687273371308038e-09
step O 0 3.866419717724057e-08
in O 0 2.9400359924380837e-09
the O 0 1.0593070420839013e-08
hemolytic O 0 3.242396633140743e-05
assay O 0 3.983887381764362e-06
of O 0 1.9870399228238966e-06
C5 O 1 0.9999876022338867
, O 0 3.0347977464373344e-09
rather O 0 1.5844097145389924e-09
than O 0 1.3898133754963737e-09
a O 0 1.4736730946651733e-08
true O 0 1.833657847782888e-07
C5 O 0 0.000293299846816808
inhibitor O 0 2.882754188249237e-06
or O 0 2.4678396925992274e-07
inactivator O 0 6.836847023805603e-05
. O 0 2.21190066440613e-06

Of O 0 2.736457645369228e-06
clinical O 0 3.121780537185259e-05
interest O 0 5.286604505272408e-07
are O 0 5.571656913616607e-09
( O 0 1.535519800199836e-08
a O 0 4.673293574342097e-08
) O 0 2.1636659131019087e-09
the O 0 1.4890058075422985e-09
documentation O 0 2.552147648771097e-08
of O 0 7.186044825857607e-08
membranous O 1 0.999998927116394
glomerulonephritis B-Disease 1 1.0
, O 0 2.8614485927391797e-05
vasculitis B-Disease 1 1.0
, O 0 3.818646291620098e-06
and O 0 1.5191651073109824e-05
arthritis B-Disease 1 1.0
in O 0 4.835588356399967e-07
an O 0 2.263994502982314e-08
individual O 0 1.5893682814294152e-08
lacking O 0 1.1742574315576348e-05
C5 O 1 0.9999991655349731
( O 0 1.4280660209919915e-08
and O 0 7.030668269791818e-10
its O 0 6.165095101096085e-10
biologic O 0 1.7899139947985532e-07
functions O 0 9.241903353718328e-10
) O 0 2.5759222532784065e-10
, O 0 2.3972759888302164e-10
and O 0 3.1248068022016184e-10
( O 0 1.594103626878507e-09
b O 0 5.5668159859578736e-08
) O 0 2.3156486450570668e-10
a O 0 1.9637602655109276e-09
remarkable O 0 6.248940476183407e-09
propensity O 0 7.940520845295396e-07
to O 0 6.807945851505792e-08
bacterial B-Disease 1 1.0
infections I-Disease 1 0.9449936747550964
in O 0 7.064303808590466e-09
the O 0 1.531492266337864e-08
proband O 0 9.345792022941168e-06
, O 0 9.013654822531691e-10
even O 0 6.121717022189443e-10
during O 0 2.1075425848948726e-09
periods O 0 6.346414505031817e-09
of O 0 3.0031506170757893e-09
low O 0 1.1064559402029772e-07
- O 0 5.241463085781106e-08
dose O 0 1.6144318237820698e-07
or O 0 9.956945490330327e-09
alternate O 0 4.80206345798706e-08
- O 0 7.447304142260691e-07
day O 0 2.6078984660671267e-07
corticosteroid O 0 3.278605072409846e-05
therapy O 0 4.555592113320017e-06
. O 0 2.0034001408930635e-06

Other O 0 4.620354943085658e-08
observations O 0 1.2411067018547328e-07
indicate O 0 2.7445905104173107e-08
that O 0 1.905121393974696e-09
the O 0 9.369865949793166e-08
C5D B-Disease 1 1.0
state O 0 2.9961952918711177e-08
is O 0 6.800415786045733e-09
compatible O 0 6.197215896008856e-08
with O 0 4.115527363346416e-10
normal O 0 1.1972036695340194e-08
coagulation O 0 3.8846565075800754e-07
function O 0 3.750650012790402e-09
and O 0 9.012172258460183e-11
the O 0 9.495163544315233e-10
capacity O 0 3.470928433557674e-09
to O 0 2.5760809041486255e-09
mount O 0 7.343551828853379e-07
a O 0 8.779629183663928e-07
neutrophilic O 0 0.4853828251361847
leukocytosis O 0 0.0011427993886172771
during O 0 3.949334768549306e-06
pyogenic B-Disease 0 0.05468513071537018
infection I-Disease 0 1.330588202108629e-05
. O 0 5.000800342713774e-07
. O 0 1.4825955076958053e-06

Susceptibility O 0 0.0020072725601494312
to O 0 3.613845183281228e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.0003749414172489196
twins O 0 2.211192168033449e-06
: O 0 3.9903609305724785e-09
the O 0 4.971211442494905e-09
role O 0 8.175407906207965e-09
of O 0 7.81043851816321e-09
genes O 0 2.0878944795299503e-08
, O 0 2.5725174879198676e-08
HLA O 1 0.5831109881401062
, O 0 2.3680977179196816e-08
and O 0 1.856576226089146e-08
the O 0 2.0935536326760484e-07
environment O 0 3.1128704449656652e-06
. O 0 3.5617067624116316e-06

OBJECTIVE O 0 2.1695721443393268e-05
To O 0 1.7163058529945374e-08
determine O 0 2.0694741920124216e-08
the O 0 1.0660830440656355e-08
relative O 0 5.746867373090936e-07
effects O 0 5.209410574025242e-07
of O 0 8.411358720650242e-08
genetic O 0 7.060345410536684e-07
and O 0 1.4979731899344984e-09
environmental O 0 2.5974910045079014e-07
factors O 0 3.2391280768706565e-08
in O 0 4.620784199715899e-09
susceptibility O 0 2.67977848125156e-05
to O 0 5.248533398116706e-06
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 1 0.7135717868804932
AS B-Disease 1 1.0
) O 0 8.152099439939775e-07
. O 0 1.4503107195196208e-06

METHODS O 0 1.933643034135457e-05
Twins O 0 1.315655822509143e-06
with O 0 4.924215701862522e-09
AS B-Disease 1 0.9670706987380981
were O 0 1.2402496807339958e-08
identified O 0 5.336974862046873e-09
from O 0 7.096589982324986e-10
the O 0 1.873686539255459e-09
Royal O 0 2.5192989028255397e-07
National O 0 2.2578551579499617e-06
Hospital O 0 0.012988417409360409
for O 0 3.3372784855600912e-06
Rheumatic B-Disease 1 1.0
Diseases I-Disease 1 1.0
database O 0 0.013317006640136242
. O 0 6.699091318296269e-05

Clinical O 0 8.035736391320825e-05
and O 0 8.89669635739665e-08
radiographic O 0 9.308851076639257e-06
examinations O 0 2.76858736469876e-06
were O 0 2.8529319351378035e-08
performed O 0 1.866193199973054e-09
to O 0 6.037347288767592e-10
establish O 0 2.946088528688051e-08
diagnoses O 0 0.10505419969558716
, O 0 4.364305539183988e-07
and O 0 7.683369744881929e-07
disease O 1 0.9701660871505737
severity O 1 0.9999362230300903
was O 0 2.708081638047588e-06
assessed O 0 2.5620929022807104e-07
using O 0 2.283029987282248e-09
a O 0 5.0133657225615025e-09
combination O 0 4.218290428070759e-08
of O 0 9.181857052453779e-08
validated O 0 1.5616735709045315e-06
scoring O 0 7.819562028998917e-07
systems O 0 1.3806789866066538e-05
. O 0 3.823325187113369e-06

HLA O 0 0.0011333845322951674
typing O 0 3.6497392557066632e-06
for O 0 3.595311000026413e-07
HLA O 0 0.0005890933680348098
- O 0 1.789486668712925e-05
B27 O 0 9.566480730427429e-05
, O 0 1.860818485965865e-07
HLA O 0 5.523704021470621e-05
- O 0 2.598095534267486e-06
B60 O 0 1.7129465049947612e-05
, O 0 1.9490961733481527e-08
and O 0 5.189694363139097e-08
HLA O 1 0.9152515530586243
- O 0 0.000640019541606307
DR1 O 1 0.9997783303260803
was O 0 1.1984356262928486e-07
performed O 0 1.6646773959294592e-09
by O 0 2.407195553999486e-10
polymerase O 0 1.8905728893514606e-07
chain O 0 8.244323446149338e-09
reaction O 0 2.027086276612522e-09
with O 0 9.38922828375155e-11
sequence O 0 2.5478223975028413e-09
- O 0 6.047331080338836e-09
specific O 0 6.62569721310291e-10
primers O 0 1.5647549389541382e-07
, O 0 2.8001307939007347e-09
and O 0 5.144691339609153e-09
zygosity O 0 2.5474175345152617e-05
was O 0 6.682128059765091e-07
assessed O 0 1.1883944353030529e-06
using O 0 1.9215212887502275e-07
microsatellite O 0 0.00021378151723183692
markers O 0 1.9419663658482023e-05
. O 0 3.7558099847956328e-06

Genetic O 0 2.130824032064993e-05
and O 0 2.379475816383092e-08
environmental O 0 1.3592726588740334e-07
variance O 0 1.8168739757129515e-07
components O 0 5.2333312794417e-08
were O 0 1.749091538272296e-09
assessed O 0 3.268139892043109e-08
with O 0 1.1034406721677215e-10
the O 0 3.2197911004061552e-09
program O 0 5.0824264796744956e-09
Mx O 0 5.471507051879598e-07
, O 0 1.9744331170024054e-10
using O 0 1.471096300331709e-10
data O 0 4.681988130528225e-10
from O 0 3.3480640482252966e-10
this O 0 1.208992767010031e-10
and O 0 1.0845239289958286e-10
previous O 0 1.2788257119922264e-09
studies O 0 2.8490967363126174e-09
of O 0 7.272828561610822e-09
twins O 0 4.565994871086332e-08
with O 0 1.7676523356158214e-08
AS B-Disease 1 0.9999926090240479
. O 0 1.1603070561250206e-05

RESULTS O 0 7.739859029243235e-06
Six O 0 1.4416642102332844e-07
of O 0 1.351932183979443e-07
8 O 0 2.106974534399342e-06
monozygotic O 0 3.891986489179544e-05
( O 0 1.2241715694472077e-06
MZ O 1 0.5596795082092285
) O 0 2.1470915712029637e-08
twin O 0 1.5238849471188587e-07
pairs O 0 6.223628279400373e-09
were O 0 3.528320746681857e-08
disease O 0 1.8199258420281694e-06
concordant O 0 6.732194015057757e-05
, O 0 6.665234142388954e-09
compared O 0 1.2740570376479354e-08
with O 0 2.976268398402482e-10
4 O 0 5.281685844238382e-08
of O 0 1.0162163555094139e-08
15 O 0 3.0851783350271944e-08
B27 O 0 1.9649098703666823e-06
- O 0 2.269421059963861e-07
positive O 0 2.560914857951957e-08
dizygotic O 0 2.9255911613290664e-06
( O 0 1.2525144654773612e-07
DZ O 0 0.00030973993125371635
) O 0 1.0417926077366246e-08
twin O 0 3.1348271534170635e-08
pairs O 0 7.519262990030029e-10
( O 0 2.7777729005862284e-09
27 O 0 5.833572558344713e-08
% O 0 1.359889267860126e-08
) O 0 6.978257416356826e-10
and O 0 7.880615604527463e-10
4 O 0 6.55751080103073e-08
of O 0 5.13655606937391e-08
32 O 0 1.263135573026375e-06
DZ O 0 0.000312511547235772
twin O 0 4.89975604978099e-07
pairs O 0 1.4344129439791686e-08
overall O 0 8.249345029298638e-08
( O 0 1.7400083152097068e-08
12 O 0 6.269429064786891e-08
. O 0 7.337703333831769e-09
5 O 0 1.219443817035426e-07
% O 0 1.337212864882531e-07
) O 0 3.91111569797431e-08
. O 0 4.531023591880512e-07

Nonsignificant O 0 0.006453836336731911
increases O 0 1.0740469633674365e-06
in O 0 6.6547798382998735e-09
similarity O 0 5.826074733761288e-09
with O 0 1.6917493794732508e-10
regard O 0 9.949655321861428e-09
to O 0 1.8246603117333393e-09
age O 0 3.181359033987974e-07
at O 0 8.918194680518354e-07
disease O 0 6.383764230122324e-06
onset O 0 0.053009841591119766
and O 0 2.3361810264077576e-09
all O 0 1.1295675506062253e-09
of O 0 1.950256489635649e-08
the O 0 3.8515519662496445e-08
disease O 0 8.02488671070023e-07
severity O 0 3.3777314456528984e-06
scores O 0 8.262809103598556e-08
assessed O 0 4.663094443912996e-07
were O 0 1.1218835638260316e-08
noted O 0 5.113652079558051e-08
in O 0 3.843127416303105e-08
disease O 0 5.202754891797667e-06
- O 0 3.042663593078032e-05
concordant O 0 0.03586241602897644
MZ O 1 0.7387096285820007
twins O 0 5.141711767464585e-07
compared O 0 3.4915746027763817e-07
with O 0 8.066814416451962e-08
concordant O 0 0.019159480929374695
DZ O 1 0.9999717473983765
twins O 0 3.781990380957723e-05
. O 0 9.238400707545225e-06

HLA O 1 0.9773789644241333
- O 0 0.00039789924630895257
B27 O 0 0.0004295505932532251
and O 0 6.993306556069001e-08
B60 O 0 2.2687621822115034e-05
were O 0 4.167537426269519e-09
associated O 0 1.3563242751146731e-09
with O 0 1.0959546464794911e-10
the O 0 2.0359255614721405e-08
disease O 0 2.6274931315128924e-06
in O 0 1.633458346361749e-08
probands O 0 0.012177200987935066
, O 0 1.9008457030622594e-09
and O 0 3.743244325615791e-10
the O 0 3.2527467386245235e-09
rate O 0 1.1239830399745188e-07
of O 0 7.826666603705235e-08
disease O 0 8.952612233770196e-07
concordance O 0 1.2990079767405405e-06
was O 0 7.838797699832867e-08
significantly O 0 8.007623009120834e-09
increased O 0 1.2280187533519893e-08
among O 0 2.432824786069432e-08
DZ O 0 0.0004978259676136076
twin O 0 1.2266812632333313e-07
pairs O 0 1.1178118430876793e-09
in O 0 2.873161153438275e-10
which O 0 1.5324637392399865e-10
the O 0 1.8293228043475551e-09
co O 0 4.827133537332884e-08
- O 0 2.752336740741157e-07
twin O 0 1.3103650076118356e-07
was O 0 4.929123420538417e-08
positive O 0 1.935251736639998e-09
for O 0 1.7747526781519696e-09
both O 0 6.327622514845643e-08
B27 O 0 0.0004894921439699829
and O 0 1.750920205267903e-06
DR1 O 1 0.9997370839118958
. O 0 1.9091921785729937e-05

Additive O 0 2.1350671886466444e-05
genetic O 0 2.4433450107608223e-06
effects O 0 3.2146172657121497e-07
were O 0 5.172121841923172e-09
estimated O 0 3.976912132941379e-09
to O 0 4.916780316222003e-10
contribute O 0 5.410648373782578e-09
97 O 0 1.551951669398477e-07
% O 0 1.798998816582298e-08
of O 0 3.7088065951706994e-09
the O 0 5.925593793421058e-09
population O 0 9.548982937701567e-09
variance O 0 1.721967578305339e-06
. O 0 7.901180651970208e-07

CONCLUSION O 0 0.0002512184146326035
Susceptibility O 0 0.0006035796832293272
to O 0 1.5704269173966168e-07
AS B-Disease 1 0.9996441602706909
is O 0 2.2447055769703184e-08
largely O 0 2.652689978788203e-08
genetically O 0 1.0017063623024569e-08
determined O 0 2.0643572185008452e-08
, O 0 8.821511299217377e-10
and O 0 3.818143301526078e-10
the O 0 2.7840478811214098e-09
environmental O 0 1.9522759941992263e-07
trigger O 0 4.910412485514826e-07
for O 0 1.0587415388840782e-08
the O 0 3.9699122567071754e-07
disease O 0 0.0005601520533673465
is O 0 1.4959417171667155e-07
probably O 0 2.6830894057638943e-06
ubiquitous O 0 6.855088031443302e-06
. O 0 1.768679453562072e-06

HLA O 1 0.9362726807594299
- O 0 8.636677375761792e-05
B27 O 0 4.218939648126252e-05
accounts O 0 4.3122234671955084e-09
for O 0 6.528924623161458e-10
a O 0 6.972845856267895e-09
minority O 0 6.969867349937431e-09
of O 0 3.845970653060249e-09
the O 0 1.3406127763460063e-08
overall O 0 3.004201118983474e-07
genetic O 0 6.090131137170829e-06
susceptibility O 0 0.0004858250031247735
to O 0 6.1603640233443e-07
AS B-Disease 1 0.9999998807907104
. O 0 2.825319825205952e-05

Cell O 0 4.358838850748725e-05
cycle O 0 5.314656846167054e-06
- O 0 3.4412187233101577e-06
dependent O 0 1.4371357792697381e-06
colocalization O 0 5.572824375121854e-05
of O 0 1.001794316835003e-06
BARD1 O 1 0.9844868779182434
and O 0 2.19677858126488e-07
BRCA1 O 0 2.4339190076716477e-06
proteins O 0 1.6029678917561796e-08
in O 0 7.545542857201326e-09
discrete O 0 1.5333621377067175e-06
nuclear O 0 4.7839235776336864e-05
domains O 0 2.9916331186541356e-05
. O 0 3.190630877725198e-06

Germ O 0 0.0013495879247784615
- O 0 1.6359816072508693e-05
line O 0 8.936370932133286e-07
mutations O 0 3.649157065410691e-08
of O 0 9.486497809518823e-09
the O 0 1.1749483164180674e-08
BRCA1 O 0 3.472798368875374e-07
gene O 0 2.0847032544679678e-08
predispose O 0 1.2396753845678177e-07
women O 0 1.0862505339659378e-10
to O 0 3.645654056416703e-10
early O 0 5.380682068789611e-07
- O 0 0.0015607657842338085
onset O 1 1.0
breast B-Disease 1 1.0
and I-Disease 1 0.9999980926513672
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 1.1488491225009057e-07
compromising O 0 7.087465405675175e-07
the O 0 2.3690102324280815e-08
genes O 0 5.8585833073721005e-08
presumptive O 0 5.4496940720127895e-06
function O 0 1.9152254893128884e-08
as O 0 4.052357560624387e-09
a O 0 1.633147519441991e-07
tumor B-Disease 0 0.0022705853916704655
suppressor O 0 0.0014671148965135217
. O 0 4.611331405612873e-06

Although O 0 6.971013135625981e-07
the O 0 1.702031227068801e-07
biochemical O 0 4.72047895527794e-06
properties O 0 4.221309097829362e-07
of O 0 2.877168299164623e-07
BRCA1 O 0 9.576831871527247e-06
polypeptides O 0 3.2990604381666344e-07
are O 0 4.3142200922829943e-10
not O 0 1.614587463727446e-09
understood O 0 9.925322785875323e-08
, O 0 1.3560397249534617e-09
their O 0 1.3089843098335052e-10
expression O 0 4.765236649717508e-09
pattern O 0 2.5926247815277748e-08
and O 0 2.661821651983587e-09
subcellular O 0 3.5479765756463166e-06
localization O 0 2.0622851479856763e-06
suggest O 0 1.8386741018616704e-08
a O 0 9.053564120620194e-09
role O 0 1.5308087242260626e-08
in O 0 9.643445153528774e-09
cell O 0 1.0490225577086676e-06
- O 0 9.060008210326487e-07
cycle O 0 1.229347276421322e-06
regulation O 0 2.5938991257135058e-06
. O 0 1.1464810540928738e-06

When O 0 2.061264694930287e-06
resting O 0 8.429300578427501e-06
cells O 0 3.454392683011065e-08
are O 0 1.3761993766792102e-09
induced O 0 1.905911517496861e-07
to O 0 6.46126352421561e-09
proliferate O 0 1.0729007726695272e-07
, O 0 1.150520123616161e-09
the O 0 3.628548794765152e-09
steady O 0 6.062207091872551e-08
- O 0 6.762414184180443e-09
state O 0 3.3098407348219894e-10
levels O 0 1.5746816073303194e-09
of O 0 1.3382897012803596e-09
BRCA1 O 0 2.5749425702770168e-08
increase O 0 1.69512237579994e-09
in O 0 2.709903634823263e-09
late O 0 2.911922081239027e-07
G1 O 0 1.1017802989954362e-06
and O 0 2.1758195245524803e-10
reach O 0 3.4330829290496467e-09
a O 0 5.7932751929001824e-09
maximum O 0 8.298709275322835e-08
during O 0 2.605365239105595e-07
S O 0 1.7416527043678798e-05
phase O 0 2.1620808183797635e-05
. O 0 2.904205985032604e-06

Moreover O 0 8.79614981386112e-06
, O 0 1.4119218860741967e-07
in O 0 7.437963489564936e-08
S O 0 1.3297762052388862e-05
phase O 0 6.576124633284053e-06
cells O 0 1.8423958181301714e-07
, O 0 1.2382641578767561e-08
BRCA1 O 0 7.265399517564219e-07
polypeptides O 0 1.709876187305781e-07
are O 0 2.36681407805861e-09
hyperphosphorylated O 0 1.9020779973288882e-06
and O 0 1.1741820848953921e-08
accumulate O 0 9.395314037874414e-08
into O 0 5.9007387420706436e-08
discrete O 0 2.1081002614664612e-06
subnuclear O 0 4.6397701225942e-05
foci O 0 1.0678131729946472e-05
termed O 0 3.1190008940029657e-06
" O 0 2.571674485807307e-06
BRCA1 O 0 2.191713429056108e-05
nuclear O 0 0.00010613890481181443
dots O 0 7.010336412349716e-05
. O 0 1.1195726074220147e-05

" O 0 5.1677921874215826e-05
BRCA1 O 0 0.0003852764784824103
associates O 0 2.5274686777265742e-05
in O 0 3.517882021242258e-07
vivo O 0 6.79365166433854e-06
with O 0 7.1273045243458455e-09
a O 0 1.551201648908318e-06
structurally O 0 8.98253420018591e-05
related O 0 1.6930025594774634e-06
protein O 0 8.086044545052573e-06
termed O 0 4.7585712309228256e-05
BARD1 O 1 0.9997552037239075
. O 0 1.6856587535585277e-05

Here O 0 2.615218193113833e-07
we O 0 9.804747236330513e-09
show O 0 9.993204042046955e-10
that O 0 1.3479675708971683e-10
the O 0 1.2648698755057808e-09
steady O 0 3.622292510385705e-08
- O 0 7.4372659142341035e-09
state O 0 3.2861696697139564e-10
levels O 0 1.5766771221947806e-09
of O 0 6.226858140223612e-09
BARD1 O 0 0.016773652285337448
, O 0 1.2527068271594999e-09
unlike O 0 1.0441354447721096e-09
those O 0 5.42406841663734e-10
of O 0 1.7185824319199128e-08
BRCA1 O 0 2.356703362238477e-06
, O 0 1.0226445468219936e-08
remain O 0 3.760494138305148e-08
relatively O 0 1.0717509546509518e-08
constant O 0 1.0100312408667378e-07
during O 0 1.4132352532669756e-07
cell O 0 5.04884383190074e-06
cycle O 0 2.49909567173745e-06
progression O 0 8.728096872800961e-06
. O 0 8.801468425190251e-07

However O 0 1.8628032876222278e-06
, O 0 3.814799356405274e-07
immunostaining O 0 0.0007416719454340637
revealed O 0 9.46824115999334e-07
that O 0 4.600639158525155e-08
BARD1 O 1 0.9763901233673096
resides O 0 5.191298555473622e-07
within O 0 5.409825831748094e-08
BRCA1 O 0 1.0638262892825878e-06
nuclear O 0 4.547925982478773e-06
dots O 0 2.824668854373158e-07
during O 0 4.021100252771248e-08
S O 0 3.5457199487609614e-07
phase O 0 7.686141145768488e-08
of O 0 1.2506846669424476e-09
the O 0 1.3902720086278464e-09
cell O 0 5.8581921535960646e-08
cycle O 0 1.8852341909791903e-08
, O 0 2.733094861540053e-10
but O 0 4.009179932484841e-10
not O 0 1.2466668808386316e-09
during O 0 2.6222551241517067e-08
the O 0 1.222543630774453e-07
G1 O 0 4.075383913004771e-05
phase O 0 1.5405179510707967e-05
. O 0 1.7037508541761781e-06

Nevertheless O 0 3.1927538657328114e-05
, O 0 5.278292292132392e-07
BARD1 O 0 0.03908053785562515
polypeptides O 0 6.089917974350101e-07
are O 0 1.3625731654087758e-09
found O 0 1.2817096273209927e-09
exclusively O 0 2.0871926409427033e-09
in O 0 6.821405662549296e-10
the O 0 4.355180660553515e-09
nuclear O 0 1.0123588936039596e-06
fractions O 0 5.185638087823463e-07
of O 0 2.3293567963378337e-08
both O 0 2.2629583540378917e-08
G1 O 0 7.165061106206849e-06
- O 0 5.076345246379788e-07
and O 0 1.4474620613214029e-08
S O 0 9.027027772390284e-06
- O 0 2.2986926069279434e-06
phase O 0 9.507342838332988e-06
cells O 0 4.622223741534981e-07
. O 0 4.824032089345565e-07

Therefore O 0 3.344702463436988e-06
, O 0 6.566321530954156e-08
progression O 0 9.123459108195675e-07
to O 0 2.501672469179539e-08
S O 0 8.135090865835082e-06
phase O 0 3.2292630294250557e-06
is O 0 3.6172300710290983e-09
accompanied O 0 1.0475944556276318e-09
by O 0 2.459050185699141e-10
the O 0 3.6445018114505956e-09
aggregation O 0 1.3010409816160973e-07
of O 0 3.70373953728631e-08
nuclear O 0 2.6605635866872035e-05
BARD1 O 0 0.0019902021158486605
polypeptides O 0 1.2660794936891762e-06
into O 0 5.739385642300476e-07
BRCA1 O 0 8.253849955508485e-06
nuclear O 0 3.0178518500179052e-05
dots O 0 2.0681722162407823e-05
. O 0 5.6995741033460945e-06

This O 0 1.6228524657435628e-07
cell O 0 2.1124028535268735e-06
cycle O 0 6.53001450245938e-07
- O 0 4.271842328762432e-07
dependent O 0 1.3959289901777083e-07
colocalization O 0 6.7054174905933905e-06
of O 0 1.7591956691376254e-07
BARD1 O 1 0.9430938959121704
and O 0 3.004034709874759e-08
BRCA1 O 0 7.425007879646728e-07
indicates O 0 2.5918435397898065e-08
a O 0 7.710497129664873e-09
role O 0 1.044199660071854e-08
for O 0 8.629831960149659e-09
BARD1 O 1 0.8264163732528687
in O 0 1.894955659054176e-07
BRCA1 O 0 1.962261740118265e-05
- O 0 6.258307257667184e-05
mediated O 0 0.1575978845357895
tumor B-Disease 1 0.9999890327453613
suppression O 0 0.005791127681732178
. O 0 1.0840227332664654e-05

Ethnic O 0 1.2101184438506607e-05
differences O 0 3.899313014699146e-06
in O 0 3.3124084097835294e-07
the O 0 1.0370720247010468e-06
HFE O 0 0.00176804861985147
codon O 0 3.6664598155766726e-05
282 O 0 1.700320171948988e-05
( O 0 1.9430626707617193e-06
Cys O 0 0.0054045203141868114
/ O 0 0.00022495986195281148
Tyr O 0 0.0003628594276960939
) O 0 4.5701858653046656e-07
polymorphism O 0 2.312348260602448e-05
. O 0 3.540344550856389e-06

Recent O 0 5.02383045386523e-07
studies O 0 1.1711573222328298e-07
have O 0 2.655482944646792e-09
shown O 0 4.767791050852566e-09
that O 0 9.258638300480015e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 1 0.9999816417694092
HH B-Disease 1 1.0
) O 0 6.61418795289137e-08
is O 0 4.969997746684385e-09
likely O 0 3.4827856154606707e-09
to O 0 4.432106626151011e-10
be O 0 1.4600887165983067e-09
caused O 0 9.127253619567455e-09
by O 0 1.6113232970127456e-09
homozygosity O 0 4.172211447439622e-06
for O 0 3.288234129428247e-09
a O 0 4.5977969875821145e-08
Cys282Tyr O 0 1.021775824483484e-05
mutation O 0 1.683037993416292e-07
in O 0 8.783622718055994e-09
the O 0 4.230868455579184e-08
HFE O 0 0.000770419486798346
gene O 0 5.308267532200261e-07
located O 0 6.616104428758263e-07
4 O 0 2.8181191282783402e-06
. O 0 1.423868752681301e-06

5 O 0 7.105673284968361e-05
Mb O 0 0.0003853141388390213
telomeric O 0 0.00013926508836448193
to O 0 3.3676769817247987e-06
HLA O 0 0.11579301208257675
- O 0 5.68774230487179e-05
A O 0 5.6549142755102366e-05
. O 0 7.292358986887848e-06

Population O 0 7.929020995334213e-08
studies O 0 1.0870682132235743e-08
of O 0 3.353971544939327e-09
this O 0 1.5868654168471608e-09
polymorphism O 0 2.1143991091321368e-07
are O 0 1.8743361029915917e-10
facilitated O 0 6.029732269041688e-09
by O 0 5.30257449060656e-10
the O 0 2.6053434964978806e-09
fact O 0 1.788603820607193e-09
that O 0 3.8556641213105536e-10
the O 0 1.4936173187152235e-08
Cys282Tyr O 0 1.6992324162856676e-05
mutation O 0 3.365117038356402e-07
creates O 0 8.255577910176726e-08
a O 0 1.9201985423933365e-07
Rsal O 0 5.1116920076310635e-05
restriction O 0 1.792530952116067e-06
site O 0 1.4567010566679528e-06
. O 0 1.0316593943571206e-06

We O 0 7.771046739435405e-07
have O 0 1.6625014254145754e-08
studied O 0 1.9967269793141895e-07
the O 0 5.6057707809031854e-08
codon O 0 2.1228438527032267e-06
282 O 0 2.9694949716940755e-06
( O 0 6.628710593759024e-07
Cys O 0 0.00932193361222744
/ O 0 0.00015347602311521769
Tyr O 0 5.9656169469235465e-05
) O 0 1.3578029367522504e-08
polymorphism O 0 2.1744553180269577e-07
in O 0 2.0539481226933276e-09
different O 0 1.029904272975557e-09
ethnic O 0 5.093395216704266e-08
groups O 0 2.899230011621512e-08
. O 0 4.6742385961806576e-07

In O 0 1.0984988563222942e-07
agreement O 0 7.972803217626279e-08
with O 0 2.4124966468974662e-09
previous O 0 2.62556856256424e-08
observations O 0 4.5458257602604135e-08
the O 0 1.756259671026328e-08
Tyr O 0 7.66804350860184e-06
allele O 0 7.523824478994356e-07
appeared O 0 9.275938239738934e-09
to O 0 1.0485020629502628e-09
be O 0 4.44431558221936e-09
rare O 0 1.585308417872966e-08
or O 0 3.761767857213272e-07
absent O 0 1.5906738553894684e-05
in O 0 2.4457683878154057e-08
Asiatic O 0 8.402249136452156e-07
( O 0 1.6035672345537932e-08
Indian O 0 4.969754030526019e-08
, O 0 6.078948011634111e-09
Chinese O 0 9.944191248223433e-09
) O 0 1.8085426489733436e-08
populations O 0 1.2480110456181137e-07
. O 0 4.183508508504019e-07

The O 0 5.833016416545433e-07
highest O 0 7.149997713895573e-07
allele O 0 4.255135479525052e-07
frequency O 0 4.218757112539606e-07
( O 0 1.1246559239452836e-08
7 O 0 4.7975959205359686e-08
. O 0 1.1339258421116938e-09
5 O 0 2.2149981404595565e-08
% O 0 1.537154936670504e-08
) O 0 1.445800368315986e-09
was O 0 6.08855827977095e-08
found O 0 1.1485846940217925e-08
in O 0 7.62679235322139e-08
Swedes O 0 5.159648208064027e-05
. O 0 6.149068667582469e-06

Saamis O 0 0.001434375299140811
( O 0 8.036765279939573e-07
2 O 0 3.2550437936151866e-06
% O 0 9.502890208068493e-08
) O 0 1.6340309105800088e-09
and O 0 2.196695270129112e-09
Mordvinians O 0 8.375212928513065e-06
( O 0 9.711352610963786e-09
1 O 0 2.117466380013866e-07
. O 0 5.699563043748412e-10
8 O 0 8.159051212430768e-09
% O 0 4.719575397160725e-09
) O 0 2.985148517264946e-10
had O 0 2.8043960487167396e-09
significantly O 0 6.857125534054376e-09
lower O 0 2.7361595655861493e-08
frequencies O 0 9.13945115144088e-08
of O 0 6.840173227828927e-08
the O 0 3.7293159493856365e-07
Tyr O 0 0.0003189200651831925
allele O 0 6.450393993873149e-05
. O 0 5.7988777371065225e-06

Comparisons O 0 3.032536596947466e-06
with O 0 1.756588119405933e-08
allele O 0 3.311738794309349e-07
frequencies O 0 9.193527716888639e-08
based O 0 1.2024993445436394e-08
on O 0 3.192342035163165e-08
prevalence O 0 2.3670008886256255e-07
estimates O 0 3.5880763249451775e-08
of O 0 8.676394003259702e-08
HH B-Disease 1 0.9390161633491516
showed O 0 9.874847961555133e-08
some O 0 4.741790071705054e-09
disagreements O 0 2.949721817913087e-07
with O 0 7.38429817292996e-10
the O 0 2.2258952014908573e-08
RFLP O 0 5.913440418225946e-06
data O 0 2.4648613816680154e-08
, O 0 3.1707978465078668e-09
particularly O 0 4.233217865134975e-08
in O 0 1.5042017764699267e-07
Finns O 0 2.119899363606237e-05
. O 0 3.5013688375329366e-06

The O 0 1.8324933535041055e-06
newly O 0 2.521270516808727e-06
described O 0 3.6662329421233153e-06
HFE O 0 0.46037358045578003
marker O 0 7.27305086911656e-06
provides O 0 5.6737623488345434e-09
a O 0 2.995205194977757e-09
new O 0 1.3935819165311614e-10
approach O 0 3.8370537858156695e-09
to O 0 2.5324578545316e-10
the O 0 9.760203756314922e-10
screening O 0 5.136994385424032e-09
of O 0 1.7267112184526923e-08
HH B-Disease 0 0.0005441551329568028
as O 0 7.278726954496051e-09
well O 0 1.2840218888143795e-09
as O 0 6.358394921690547e-10
studies O 0 1.5922561047432282e-09
of O 0 1.5111970563808086e-09
the O 0 2.9305853299632645e-09
relationship O 0 6.534945917735513e-09
between O 0 5.016849868866302e-08
the O 0 1.5089791816080833e-07
HFE O 0 0.0029385623056441545
Tyr O 0 3.580881093512289e-05
allele O 0 1.0644077974575339e-06
and O 0 6.216605008546594e-09
different O 0 4.799499819796438e-08
disorders O 1 0.895995557308197
including O 0 1.7632564777159132e-05
cancer B-Disease 1 1.0

Autosomal B-Disease 1 0.9999479055404663
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
associated O 0 9.211199767378275e-07
with O 0 3.9925232009352385e-09
a O 0 1.3856933378519898e-07
missense O 0 4.608641120285029e-06
mutation O 0 2.6369565375716775e-07
encoding O 0 3.789034508372424e-07
Gly23 O 0 8.04107912699692e-05
- O 0 1.4137114703771658e-05
- O 0 1.1368822015356272e-05
> O 0 2.5260853362851776e-05
Val O 0 4.311347311158897e-06
in O 0 1.1750282880029772e-07
neurophysin O 0 0.0002252986014354974
II O 1 0.9998778104782104
. O 0 1.7168193153338507e-05

Autosomal B-Disease 1 0.9997782111167908
dominant I-Disease 1 1.0
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 1.1030178029614035e-05
ADNDI B-Disease 1 0.9999998807907104
) O 0 1.3110120100634504e-08
is O 0 7.800612600306067e-09
an O 0 6.155067211466303e-08
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.01698930561542511
by O 0 1.919913046322108e-07
progressive O 1 0.9999994039535522
degeneration O 1 1.0
of O 0 0.035433363169431686
the O 0 3.00457304547308e-06
magnocellular O 0 0.0003451347001828253
neurons O 0 2.851784870472329e-07
of O 0 6.5160421058863e-08
the O 0 6.904216576231192e-08
hypothalamus O 0 2.9788436677335994e-06
leading O 0 3.767099201468227e-07
to O 0 1.1170601332821661e-08
decreased O 0 1.1633318308668095e-07
ability O 0 1.2469759669286873e-09
to O 0 3.810440851736985e-09
produce O 0 1.823534034883778e-08
the O 0 7.824696268698972e-08
hormone O 0 2.315987330803182e-07
arginine O 0 1.0728389270298067e-06
vasopressin O 0 7.312903107958846e-06
( O 0 1.6122282886499306e-06
AVP O 0 0.0003509330563247204
) O 0 4.755197551276069e-07
. O 0 7.391012104562833e-07

Affected O 0 1.4729921815614944e-07
individuals O 0 2.19807838597319e-09
are O 0 5.832654914605939e-10
not O 0 5.42254996460656e-09
symptomatic O 0 0.00014140421990305185
at O 0 1.0876810847548768e-06
birth O 0 9.586981519760229e-08
, O 0 9.82649739356134e-10
but O 0 1.1264543742228739e-09
usually O 0 5.411949111078229e-09
develop O 0 2.427388494652405e-07
diabetes B-Disease 1 0.9999994039535522
insipidus I-Disease 1 0.999950647354126
at O 0 1.792896364349872e-05
1 O 0 5.318258990882896e-05
- O 0 5.603382760455133e-06
6 O 0 3.1861277420830447e-06
yr O 0 2.2288779291557148e-05
of O 0 1.4679199011879973e-07
age O 0 6.693749128316995e-07
. O 0 8.204152095458994e-07

The O 0 3.404907431558968e-07
genetic O 0 9.95326331576507e-07
locus O 0 5.985475581837818e-06
of O 0 1.74192024360309e-07
the O 0 9.584839517629007e-07
disease O 0 0.11320316791534424
is O 0 2.7254384349362226e-07
the O 0 1.388377540934016e-06
AVP O 1 0.9997127652168274
- O 0 0.012501085177063942
neurophysin O 1 0.9992406368255615
II O 1 1.0
( O 0 6.951375439712137e-07
NPII O 1 0.9939448237419128
) O 0 4.5828576489270745e-09
gene O 0 5.802221370032612e-09
, O 0 2.685390243506447e-10
and O 0 1.8240260690749466e-10
mutations O 0 1.3662744713371922e-08
that O 0 1.2760408285572566e-09
cause O 0 0.0021375459618866444
ADNDI B-Disease 1 1.0
have O 0 5.8313669448750716e-09
been O 0 9.332367101322347e-10
found O 0 6.984045980429343e-11
in O 0 4.7665222463466606e-11
both O 0 2.7470371463667043e-11
the O 0 2.2142608580022483e-10
signal O 0 9.552917568100838e-09
peptide O 0 1.3385508701446724e-08
of O 0 8.622707881045244e-09
the O 0 2.6930047525297596e-08
prepro O 0 0.00035300300805829465
- O 0 0.0005159844295121729
AVP O 0 0.009857098571956158
- O 0 1.8107062714989297e-05
NPII O 0 0.0041559673845767975
precursor O 0 1.4305270497061429e-06
and O 0 1.1754638151728614e-08
within O 0 4.174692378455802e-07
NPII O 0 0.030808907002210617
itself O 0 2.8427582492440706e-06
. O 0 2.9590976282634074e-06

An O 0 3.8131042856548447e-07
affected O 0 7.718444976489991e-07
girl O 0 4.5308681251299276e-07
who O 0 4.704368894437039e-09
presented O 0 1.060394705376666e-08
at O 0 1.521708625773499e-08
9 O 0 1.1943800615199507e-08
months O 0 1.345964339982686e-09
of O 0 1.5989667367932725e-09
age O 0 6.336049462873916e-09
and O 0 2.979574087458303e-10
her O 0 2.381520813887761e-10
similarly O 0 5.693817861640582e-09
affected O 0 8.626129144317929e-09
younger O 0 3.3966561119314065e-08
brother O 0 5.7495764593795684e-08
and O 0 2.634847895421899e-09
father O 0 2.696761924880775e-08
were O 0 1.9301611420274867e-09
all O 0 1.9482764013201148e-10
found O 0 2.5742033504805306e-10
to O 0 3.6916406043197014e-10
have O 0 3.201076348435805e-10
a O 0 4.809118880899632e-09
novel O 0 5.34402602170303e-08
missense O 0 7.848520340303367e-07
mutation O 0 1.2314613684338838e-07
( O 0 1.8578656835188667e-08
G1758 O 0 1.9269788026576862e-05
- O 0 8.792333574092481e-06
- O 0 6.8714780354639515e-06
> O 0 1.0387644579168409e-05
T O 0 4.622902451956179e-07
) O 0 1.1578883407636908e-09
encoding O 0 4.110210838348394e-09
the O 0 2.6486997040109372e-09
amino O 0 4.405509734795032e-09
acid O 0 4.026055488992597e-09
substitution O 0 4.9862563855640474e-08
Gly23 O 0 1.2761415746354032e-05
- O 0 7.756840204820037e-06
- O 0 1.0882447895710357e-05
> O 0 2.114625385729596e-05
Val O 0 8.388514288526494e-06
within O 0 2.4814694370434154e-06
NPII O 0 0.00621308758854866
. O 0 6.271035545069026e-06

The O 0 1.5271423308149679e-06
mutation O 0 2.795338104988332e-06
was O 0 2.74994647497806e-07
confirmed O 0 1.6416228376670006e-08
by O 0 3.815378679661308e-09
restriction O 0 3.690483083573781e-07
endonuclease O 0 1.6829842934384942e-05
analysis O 0 1.532983333163429e-06
. O 0 2.301776930835331e-06

A O 0 0.0006010368233546615
T1 O 1 0.9818630814552307
- O 0 6.617900362471119e-05
weighted O 0 2.839268518073368e-06
magnetic O 0 1.119824673878611e-06
resonance O 0 2.9669936907339434e-07
imaging O 0 6.821033480264305e-07
of O 0 9.766022657231588e-08
the O 0 4.4257589593144075e-07
fathers O 0 9.782288543647155e-06
pituitary O 0 0.00023181058350019157
gland O 0 4.642505518859252e-05
demonstrates O 0 4.024791451229248e-07
an O 0 7.578778848937873e-08
attenuated O 0 0.0001638204703340307
posterior O 1 0.99986732006073
pituitary O 1 0.9999455213546753
bright O 0 0.0002695917210076004
spot O 0 0.0004934259923174977
. O 0 7.504564564442262e-06

This O 0 1.585287776606492e-07
mutation O 0 2.9767024898319505e-06
may O 0 3.8389075029954256e-08
be O 0 6.053908929715135e-09
valuable O 0 5.982705886253825e-09
for O 0 6.866192059362675e-10
developing O 0 2.38430386545474e-09
models O 0 2.787278186033859e-09
of O 0 4.1835320985228464e-08
dominantly B-Disease 1 0.991168737411499
inherited I-Disease 1 0.999998927116394
neurodegeneration I-Disease 1 1.0
, O 0 2.6855261126002006e-08
as O 0 2.0871568917613104e-09
the O 0 1.0055996035873704e-09
early O 0 5.357617904877543e-09
age O 0 6.087139681199005e-09
of O 0 5.7638254169489755e-09
onset O 0 0.11830263584852219
of O 0 5.869751475984231e-06
symptoms O 0 0.0001116486091632396
suggests O 0 1.1991181736448198e-07
that O 0 9.257198896328589e-10
this O 0 2.698906431675141e-09
mutation O 0 2.2588430681480531e-07
may O 0 2.3690509109997038e-08
be O 0 6.291972276528668e-09
particularly O 0 1.5842413603195382e-08
deleterious O 0 1.6687368997736485e-06
to O 0 3.126425696109436e-08
the O 0 1.7462247114963247e-07
magnocellular O 0 0.00012947074719704688
neuron O 0 7.549308065790683e-05
. O 0 7.378996542684035e-07
. O 0 2.081716957036406e-06

Frequent O 0 1.000897646008525e-05
inactivation O 0 0.0008325168746523559
of O 0 3.08803137158975e-05
PTEN O 1 0.9999990463256836
/ O 1 0.9994372725486755
MMAC1 O 1 0.9999995231628418
in O 0 7.937083864817396e-06
primary O 1 0.9999997615814209
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.12326314300298691

Sporadic B-Disease 1 0.9999998807907104
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 4.588324372889474e-05
the O 0 1.7932680407284352e-07
most O 0 5.478334230701876e-09
common O 0 1.187915756872826e-07
male B-Disease 0 1.3749556160291831e-07
cancer I-Disease 0 2.4542177357034234e-07
in O 0 1.0875197409276893e-09
the O 0 2.2066604099535425e-09
Western O 0 2.3402233750857704e-07
world O 0 2.745244742641262e-08
, O 0 2.674665766644324e-10
yet O 0 3.885103905254539e-10
many O 0 4.4081360089931465e-11
of O 0 4.0914521770574197e-10
the O 0 9.79653580479578e-10
major O 0 2.9472575491240605e-08
genetic O 0 4.4098332097064485e-08
events O 0 6.574035205098028e-10
involved O 0 7.283875724795053e-10
in O 0 5.588150497892741e-10
the O 0 3.2530758087290224e-09
progression O 0 4.2218039197905455e-07
of O 0 3.6330018993169233e-09
this O 0 2.984575253606181e-09
often O 0 1.2097936519239738e-07
fatal O 1 0.9949803948402405
cancer B-Disease 1 0.9997121691703796
remain O 0 5.740579354096553e-07
to O 0 5.672769276543477e-08
be O 0 5.668150606652489e-07
elucidated O 0 7.883713260525838e-05
. O 0 2.998092895722948e-06

Numerous O 0 1.539254867566342e-06
cytogenetic O 0 0.00042020712862722576
and O 0 2.156737366476591e-07
allelotype O 0 0.05638790503144264
studies O 0 4.2228873553540325e-07
have O 0 1.1290663515239885e-08
reported O 0 6.103941530000156e-08
frequent O 0 1.267116829239967e-07
loss O 0 4.153322606725851e-06
of O 0 8.643193723401055e-06
heterozygosity O 1 0.9999144077301025
on O 0 7.451221335941227e-06
chromosomal O 1 0.7860322594642639
arm O 0 0.0008996130782179534
10q O 1 0.744483232498169
in O 0 1.526181335975707e-06
sporadic B-Disease 1 0.999970555305481
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.06633734703063965

Deletion O 0 1.66092358995229e-05
mapping O 0 1.3403440561887692e-06
studies O 0 1.220156917725035e-07
have O 0 6.8126841945570504e-09
unambiguously O 0 4.693831385793601e-07
identified O 0 2.5639351974859892e-08
a O 0 8.910294724273626e-09
region O 0 1.4432460204716335e-07
of O 0 1.5392240015899006e-07
chromosome O 0 0.00014305306831374764
10q23 O 0 1.0968217793561053e-05
to O 0 1.155287532306204e-09
be O 0 1.2804977078673119e-09
the O 0 1.125279647240518e-09
minimal O 0 2.1958067009109072e-07
area O 0 3.21005558134857e-07
of O 0 2.983353226682084e-07
loss O 0 1.3029003639530856e-05
. O 0 8.922167580749374e-06

A O 0 6.928687525942223e-06
new O 0 3.156851278163231e-07
tumor B-Disease 0 6.853414379293099e-05
suppressor O 0 5.484808934852481e-05
gene O 0 2.82521313010875e-07
, O 0 5.913932454859605e-08
PTEN O 1 0.9998610019683838
/ O 1 0.8995804786682129
MMAC1 O 1 1.0
, O 0 2.507843248622521e-07
was O 0 1.8545113107393263e-06
isolated O 0 1.7957907516574778e-07
recently O 0 6.399888174968282e-09
at O 0 4.217757254565413e-09
this O 0 2.4240359719485127e-10
region O 0 3.602724163442872e-08
of O 0 3.4357967138021195e-08
chromosome O 0 8.778423216426745e-05
10q23 O 0 1.8489577996660955e-05
and O 0 8.73490058062032e-10
found O 0 5.017753990088636e-10
to O 0 4.072175374680853e-10
be O 0 1.2471377264233752e-09
inactivated O 0 1.4229136091614691e-08
by O 0 2.8298741128196525e-10
mutation O 0 2.2085647088943006e-08
in O 0 1.92217495253999e-08
three O 0 1.406958062943886e-06
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9835055470466614
lines O 0 1.3388234037847724e-05
. O 0 5.267217147775227e-06

We O 0 3.4301376672374317e-06
screened O 0 4.2478372051846236e-05
80 O 0 3.3042964787455276e-05
prostate B-Disease 1 1.0
tumors I-Disease 1 0.9999998807907104
by O 0 5.977962302949891e-08
microsatellite O 0 4.468136830837466e-05
analysis O 0 1.1444302572272136e-07
and O 0 3.884750299221196e-09
found O 0 1.016435469125554e-08
chromosome O 0 2.9141324375814293e-06
10q23 O 0 2.9527884635172086e-06
to O 0 5.786627177428727e-09
be O 0 1.2403869042998394e-08
deleted O 0 1.2793294956736645e-07
in O 0 1.237156954658758e-08
23 O 0 1.0207021006181094e-07
cases O 0 3.7478844916449816e-08
. O 0 5.440983272819722e-07

We O 0 4.113616967060807e-07
then O 0 5.013100690121064e-08
proceeded O 0 2.391245779165274e-08
with O 0 6.05422656452248e-11
sequence O 0 8.928408568031898e-10
analysis O 0 1.3118417463431342e-09
of O 0 3.5724434521711146e-09
the O 0 1.720625775192275e-08
entire O 0 5.8322821132605895e-06
PTEN O 1 0.9997782111167908
/ O 0 0.00011831858864752576
MMAC1 O 0 0.015121251344680786
coding O 0 2.478827354934765e-06
region O 0 8.40016767256202e-08
and O 0 1.3822155642273515e-09
tested O 0 6.96015600709643e-09
for O 0 1.5303234235375385e-09
homozygous O 0 5.875962827417425e-08
deletion O 0 1.8643302723830857e-07
with O 0 1.5596552938035302e-09
new O 0 1.9593240807580514e-08
intragenic O 0 0.13512755930423737
markers O 0 3.6240940062270965e-06
in O 0 7.266935497796112e-09
these O 0 4.101163575409572e-10
23 O 0 8.976994259057847e-09
cases O 0 9.168775738643831e-10
with O 0 2.01092009710635e-09
10q23 O 1 0.9722002148628235
loss O 0 0.00044638579129241407
of O 0 0.00044246617471799254
heterozygosity O 1 0.9999808073043823
. O 0 2.7494807000039145e-05

The O 0 9.193054495426622e-08
identification O 0 5.1959148095193086e-08
of O 0 4.7383391432731514e-08
the O 0 4.6448306534330186e-08
second O 0 2.823186832756619e-06
mutational O 0 0.016809239983558655
event O 0 2.2462523929789313e-07
in O 0 4.295264144360544e-09
10 O 0 4.845672307851601e-09
( O 0 3.4613951704898227e-09
43 O 0 3.2360316026824876e-07
% O 0 2.4312646473845234e-07
) O 0 1.3141230681412708e-07
tumors B-Disease 1 0.9999998807907104
establishes O 0 2.498013600416016e-05
PTEN O 1 0.9999995231628418
/ O 1 0.9807234406471252
MMAC1 O 1 0.9999271631240845
as O 0 1.8251416378234353e-08
a O 0 7.448750949379246e-09
main O 0 4.2238536224203926e-08
inactivation O 0 1.4738803599811945e-07
target O 0 1.488166123664314e-08
of O 0 1.1050993897754324e-08
10q O 0 0.00024302794190589339
loss O 0 4.430110038811108e-06
in O 0 7.374226811407425e-07
sporadic B-Disease 1 0.9999951124191284
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.2227521185413934e-05
. O 0 1.8188628018833697e-05

Risk O 0 0.00060445093549788
reversals O 0 6.063595719751902e-05
in O 0 3.772635537302449e-08
predictive O 0 1.1672864275169559e-06
testing O 0 8.168566978383751e-07
for O 0 2.987691914313473e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.00045125363976694643

The O 0 3.817317804077902e-07
first O 0 4.0573869597437806e-08
predictive O 0 4.386980947401753e-07
testing O 0 2.848696851742716e-07
for O 0 1.5459485211977153e-06
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.1622987585724331e-06
HD B-Disease 0 0.1012386903166771
) O 0 7.733960138978091e-09
was O 0 3.2640905089920125e-08
based O 0 2.3024990802866796e-09
on O 0 2.4450348412585754e-09
analysis O 0 2.7508255673325266e-09
of O 0 4.561857558371685e-09
linked O 0 7.357944298291841e-08
polymorphic O 0 1.5537733588644187e-07
DNA O 0 1.3113938734932162e-07
markers O 0 1.8487527952970595e-08
to O 0 3.4605682208699307e-10
estimate O 0 1.1427981227996042e-08
the O 0 2.243232044563115e-09
likelihood O 0 1.1566048385702743e-07
of O 0 3.831650730035108e-08
inheriting O 0 3.0212822821340524e-07
the O 0 3.540975157534376e-08
mutation O 0 4.1340595657857193e-07
for O 0 1.7412492070434382e-07
HD B-Disease 0 0.000639550038613379
. O 0 5.912358574278187e-06

Limits O 0 7.345926178459194e-07
to O 0 1.839308971796072e-08
accuracy O 0 2.034305595088881e-07
included O 0 6.2949734314088346e-09
recombination O 0 1.5081332094268873e-07
between O 0 2.459981551794499e-08
the O 0 1.7228753534936914e-08
DNA O 0 1.2408723648604791e-07
markers O 0 3.232067768976776e-08
and O 0 7.806443269586794e-10
the O 0 1.016127271213918e-08
mutation O 0 5.957275561740971e-07
, O 0 4.696766087164406e-09
pedigree O 0 9.860413285878167e-08
structure O 0 2.166070167675116e-08
, O 0 1.1958110057719296e-09
and O 0 1.865473192586009e-10
whether O 0 9.497918007639328e-10
DNA O 0 6.9537207103564924e-09
samples O 0 2.176961111377551e-10
were O 0 2.146049310480791e-10
available O 0 7.600804985408161e-10
from O 0 7.516198330392854e-09
family O 0 1.020875028956425e-08
members O 0 1.24734533812898e-08
. O 0 3.9456804756810016e-07

With O 0 9.89130111150871e-09
direct O 0 2.6646270967489727e-08
tests O 0 4.5882808663577634e-09
for O 0 1.209265354518152e-09
the O 0 1.7337768554170907e-08
HD B-Disease 0 4.345424895291217e-05
mutation O 0 6.91361151439196e-07
, O 0 3.621330568748249e-09
we O 0 1.32537514296871e-09
have O 0 3.1667710120864e-10
assessed O 0 3.512527513294117e-08
the O 0 8.596002243344003e-10
accuracy O 0 2.5252351321114475e-08
of O 0 1.566016538667725e-09
results O 0 5.914118084149322e-10
obtained O 0 4.157516275693496e-10
by O 0 2.2886793848986287e-10
linkage O 0 1.5817329312994843e-07
approaches O 0 2.6839231281883258e-08
when O 0 3.7893552184975476e-10
requested O 0 6.250129302998175e-10
to O 0 4.0238962162320036e-10
do O 0 6.85741019523789e-10
so O 0 1.8642426491410902e-10
by O 0 3.759572098083197e-10
the O 0 6.2786655874447206e-09
test O 0 2.264106768734564e-08
individuals O 0 8.706760645793565e-09
. O 0 7.069656930980273e-07

For O 0 3.034579165728246e-08
six O 0 2.7751041464796344e-09
such O 0 5.197901553621875e-10
individuals O 0 1.577465269519962e-09
, O 0 5.588185469918017e-09
there O 0 1.083621459230244e-08
was O 0 4.264271638021455e-07
significant O 0 7.421185443945433e-08
disparity O 0 1.1021187447113334e-06
between O 0 4.438473055756731e-08
the O 0 5.112150347486022e-08
tests O 0 6.523205087205497e-08
. O 0 4.194982352601073e-07

Three O 0 2.1919716175489157e-07
went O 0 1.5916958773232182e-07
from O 0 9.405279222107765e-09
a O 0 2.889381534032509e-08
decreased O 0 3.8092116483312566e-07
risk O 0 1.278285033379234e-08
to O 0 1.5738971237411192e-10
an O 0 2.8317317934956066e-10
increased O 0 1.8846083804646696e-08
risk O 0 2.401374956662039e-07
, O 0 1.4714310880847847e-09
while O 0 9.436323944456149e-10
in O 0 2.888194128303212e-10
another O 0 1.112814840276144e-09
three O 0 4.2223349816516986e-10
the O 0 4.518093899008591e-09
risk O 0 2.3041437202664383e-07
was O 0 1.9770595827139914e-06
decreased O 0 3.0310216061479878e-06
. O 0 1.1127940524602309e-06

Knowledge O 0 1.7775538481146214e-06
of O 0 2.6904794481197314e-07
the O 0 8.447340604789133e-08
potential O 0 8.472042054563644e-07
reasons O 0 3.013974847476675e-08
for O 0 4.2081366169455237e-10
these O 0 4.0516499877352175e-11
changes O 0 3.8415848280237697e-10
in O 0 8.248959293410962e-10
results O 0 1.390415227398023e-09
and O 0 3.034587858774529e-10
impact O 0 2.3376443891720555e-08
of O 0 1.5894463523125069e-09
these O 0 1.8192521100690584e-10
risk O 0 3.7651734174914964e-08
reversals O 0 2.5604319375815976e-07
on O 0 3.505332912823178e-08
both O 0 2.104413532322269e-09
patients O 0 7.130047663395089e-10
and O 0 3.3123984111149696e-10
the O 0 2.8773579074936606e-09
counseling O 0 1.2854536990403176e-08
team O 0 3.391673886188329e-10
can O 0 1.9350146485130892e-10
assist O 0 1.4762239208820915e-09
in O 0 5.851575335391601e-10
the O 0 8.264282591596839e-10
development O 0 1.263167792586728e-09
of O 0 7.027222692634894e-10
strategies O 0 7.728618300895107e-10
for O 0 1.9198208300874597e-10
the O 0 2.683107958034725e-09
prevention O 0 7.682022129529287e-08
and O 0 6.456012391353738e-10
, O 0 4.3611134148413555e-10
where O 0 3.952251304006893e-10
necessary O 0 2.1701467289858556e-09
, O 0 8.571705567561594e-10
management O 0 3.0616933432980886e-09
of O 0 5.505632394431359e-09
a O 0 8.396852280156963e-08
risk O 0 6.789052235944837e-07
reversal O 0 2.8796992523894005e-07
in O 0 2.1124686444551344e-09
any O 0 2.1231731928139652e-09
predictive O 0 4.401085718086506e-08
testing O 0 9.003933598705771e-09
program O 0 6.202227176288488e-09
. O 0 9.044761384302547e-09
. O 0 1.6216921494560665e-07

A O 0 9.406712706550024e-06
novel O 0 9.731917316457839e-07
common O 0 2.787158166484005e-07
missense O 0 3.778810423682444e-05
mutation O 0 4.595527116180165e-06
G301C O 0 1.4886260032653809e-05
in O 0 6.518526163290517e-09
the O 0 1.505415347935468e-08
N O 0 2.1842477053723997e-06
- O 0 1.91394565263181e-06
acetylgalactosamine O 0 2.491509440005757e-05
- O 0 1.1783923582697753e-05
6 O 0 1.9787382825597888e-06
- O 0 6.187176495586755e-07
sulfate O 0 8.116879826047807e-07
sulfatase O 0 1.0925871720246505e-05
gene O 0 2.7542404268388054e-07
in O 0 2.1947244022157975e-07
mucopolysaccharidosis B-Disease 0 0.006248132791370153
IVA I-Disease 1 0.9999995231628418
. O 0 8.486321894451976e-05

Mucopolysaccharidosis B-Disease 1 0.9999858140945435
IVA I-Disease 1 1.0
( O 0 0.002239492256194353
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 3.6020239235767804e-07
is O 0 3.3922077591341804e-08
an O 0 5.540926295566351e-08
autosomal B-Disease 1 0.999997615814209
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.0004389289824757725
by O 0 1.3971177104110666e-08
a O 0 2.24685322791629e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999992847442627
in O 0 5.769712529968274e-08
N O 0 2.8840465802204562e-06
- O 0 8.750147912905959e-07
acetylgalactosamine O 0 2.0111961930524558e-05
- O 0 3.267864713052404e-06
6 O 0 1.861025907601288e-06
- O 0 1.0298575716660707e-06
sulfate O 0 2.8176355044706725e-06
sulfatase O 0 9.746348951011896e-05
( O 0 7.556794230367814e-07
GALNS O 0 0.03795939311385155
) O 0 8.487974128001952e-07
. O 0 1.262293835679884e-06

In O 0 1.5225121785533702e-07
previous O 0 1.3231863249529852e-07
studies O 0 9.593274086228121e-08
, O 0 4.877077852682987e-09
we O 0 4.080558557717495e-09
have O 0 5.087584242779997e-10
found O 0 3.2056160503834974e-10
two O 0 1.123642706657435e-10
common O 0 3.863999786801742e-09
mutations O 0 4.801999509140842e-08
in O 0 1.895361734227663e-08
Caucasians O 0 3.276790266681928e-06
and O 0 1.3860337766402608e-08
Japanese O 0 1.2219087466291967e-06
, O 0 5.468127284302682e-08
respectively O 0 1.009897005133098e-06
. O 0 1.137808567364118e-06

To O 0 2.763032682651101e-07
characterize O 0 7.857560376578476e-06
the O 0 7.851439818296058e-07
mutational O 0 0.0020983186550438404
spectrum O 0 3.402770744287409e-05
in O 0 5.026674632091499e-09
various O 0 9.193887873237827e-10
ethnic O 0 1.3379612084918335e-08
groups O 0 6.222343196249369e-10
, O 0 5.100671551794278e-10
mutations O 0 3.9420595676631365e-09
in O 0 5.880620990161844e-10
the O 0 5.703132632817187e-09
GALNS O 0 0.0002054963551927358
gene O 0 1.516140457624715e-08
in O 0 3.297189854478688e-09
Colombian O 0 7.2233774517371785e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 1.0
patients O 0 1.445902313434999e-07
were O 0 1.5425912991418045e-08
investigated O 0 6.599877906410256e-07
, O 0 7.980025529263912e-09
and O 0 3.799004222315716e-09
genetic O 0 3.504237611196004e-07
backgrounds O 0 4.399885611405807e-08
were O 0 6.872078017750027e-09
extensively O 0 5.483749454526787e-09
analyzed O 0 5.548475012773224e-09
to O 0 4.2584394344125087e-10
identify O 0 3.140642634846813e-09
racial O 0 1.6139745184773346e-07
origin O 0 9.057882444096776e-09
, O 0 1.0784064752300537e-09
based O 0 4.719251656126744e-09
on O 0 3.864134257014484e-08
mitochondrial O 0 3.404728943223745e-07
DNA O 0 1.6587740958584618e-07
( O 0 2.9751644703424063e-08
mtDNA O 0 5.869700885341445e-07
) O 0 3.746419352523844e-08
lineages O 0 9.414343367097899e-07
. O 0 6.364661544466799e-07

Three O 0 3.937846315693605e-07
novel O 0 1.2207183317514136e-06
missense O 0 0.0001383147609885782
mutations O 0 1.2644911294046324e-05
never O 0 5.023960056860233e-07
identified O 0 6.981419176099735e-08
previously O 0 9.540608303382214e-09
in O 0 8.433648224226431e-10
other O 0 1.6262136082190182e-10
populations O 0 1.3091596695602448e-09
and O 0 2.502734131049067e-10
found O 0 1.3806241705438538e-09
in O 0 8.740184131994511e-10
16 O 0 5.200214925338287e-09
out O 0 7.709169969061236e-10
of O 0 8.142386320741934e-09
19 O 0 9.589779637053653e-08
Colombian O 0 4.707827883976279e-06
MPS B-Disease 0 0.3488975465297699
IVA I-Disease 1 0.9999998807907104
unrelated O 0 1.7714141904434655e-06
alleles O 0 1.6701697802545823e-07
account O 0 1.7524182993611248e-08
for O 0 5.539806124943425e-08
84 O 0 8.502974196744617e-06
. O 0 3.9356718843919225e-06

2 O 0 6.075315468478948e-06
% O 0 1.1685656886584184e-07
of O 0 1.5029165467694838e-08
the O 0 1.4906461842656427e-08
alleles O 0 7.41282519811648e-08
in O 0 4.114163676405269e-09
this O 0 5.947469627898272e-09
study O 0 1.2791110748366918e-07
. O 0 8.075956543507345e-07

The O 0 5.799032351205824e-06
G301C O 0 0.0013014072319492698
and O 0 5.302843533172563e-07
S162F O 0 0.00018299874500371516
mutations O 0 8.649714686725929e-07
account O 0 7.202002194617307e-08
for O 0 1.4724585639669385e-07
68 O 0 2.4727905838517472e-05
. O 0 4.248223831382347e-06

4 O 0 1.556782444822602e-05
% O 0 1.1963759334321367e-06
and O 0 8.029680742538403e-08
10 O 0 1.338703668807284e-06
. O 0 2.9538473427237477e-06

5 O 0 2.28747421715525e-06
% O 0 1.98933307160587e-07
of O 0 2.2589391690530647e-08
mutations O 0 1.460361858107717e-07
, O 0 5.511221701226532e-09
respectively O 0 5.083301957142794e-08
, O 0 1.1240720576566332e-09
whereas O 0 5.920125722980174e-09
the O 0 9.677735945956556e-09
remaining O 0 7.828367074580456e-07
F69V O 0 0.06566610187292099
is O 0 4.69660488278123e-09
limited O 0 1.0391367766260373e-09
to O 0 1.242716374250108e-09
a O 0 7.070696028677048e-08
single O 0 3.720009544849745e-07
allele O 0 5.1019887905567884e-06
. O 0 9.563036655890755e-07

The O 0 7.003390578574908e-07
skewed O 0 6.0241291066631675e-06
prevalence O 0 4.716914645541692e-06
of O 0 1.6014620030091464e-07
G301C O 0 0.00014231361274141818
in O 0 1.5165481315193574e-08
only O 0 2.056615144852003e-08
Colombian O 0 1.4076908882998396e-06
patients O 0 5.470993436063054e-09
and O 0 1.2244256719640134e-09
haplotype O 0 5.533174203264934e-07
analysis O 0 6.7614087662093425e-09
by O 0 4.738731629316817e-10
restriction O 0 2.186897241074348e-08
fragment O 0 9.553303925713408e-08
length O 0 2.6053648127799534e-08
polymorphisms O 0 7.631172138644615e-08
in O 0 1.0453111709551877e-09
the O 0 7.488194952998128e-09
GALNS O 0 0.00033173782867379487
gene O 0 3.401472881137124e-08
suggest O 0 8.717329080809577e-09
that O 0 1.164524032759573e-09
G301C O 0 3.3650990189926233e-06
originated O 0 1.0635484493093372e-08
from O 0 2.8761948378530633e-09
a O 0 1.1570501889934803e-08
common O 0 1.1700108615286808e-07
ancestor O 0 1.2793756468454376e-05
. O 0 2.8708091122098267e-06

Investigation O 0 3.6460864976106677e-06
of O 0 2.9184664640524716e-07
the O 0 9.969681968868827e-08
genetic O 0 4.0498258613297367e-07
background O 0 7.0072170288426605e-09
by O 0 7.661559164873211e-10
means O 0 2.5954451032816905e-08
of O 0 2.1503906211250978e-08
mtDNA O 0 1.0857072396674994e-07
lineages O 0 5.8991602713831526e-09
indicate O 0 8.060009326626982e-10
that O 0 1.3761750072838197e-10
all O 0 8.291897723999853e-10
our O 0 1.045929343135299e-09
patients O 0 1.1218872497664734e-09
are O 0 4.127554964483693e-10
probably O 0 8.85211193235591e-08
of O 0 1.2584243336277723e-07
native O 0 4.781882694260275e-07
American O 0 2.0993647922296077e-06
descent O 0 0.000390134024200961

Low O 0 5.445989700092468e-06
frequency O 0 1.4491603224087157e-06
of O 0 7.150345595619001e-07
BRCA1 O 0 3.5888289858121425e-05
germline O 0 3.447492781560868e-05
mutations O 0 1.278847605590272e-07
in O 0 5.31438359985259e-09
45 O 0 3.551419069935946e-07
German O 1 0.9999890327453613
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.7744384826510213e-06
. O 0 4.531051217782078e-06

In O 0 1.267232789814443e-07
this O 0 3.330277387192382e-09
study O 0 3.9333696300047905e-09
we O 0 1.4868970499293255e-09
investigated O 0 2.367415774529036e-08
45 O 0 1.1052916448761607e-07
German O 1 0.9999498128890991
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.3906949902775523e-07
for O 0 4.638597772554931e-08
germline O 0 1.133304522227263e-05
mutations O 0 1.4631108058438258e-07
in O 0 1.9442804699565386e-08
the O 0 9.778305098961937e-08
BRCA1 O 0 8.510462066624314e-06
gene O 0 1.827592541303602e-06
. O 0 7.828845127733075e-07

We O 0 5.216549538999971e-07
identified O 0 1.0162012387127106e-07
four O 0 1.658257708925248e-08
germline O 0 4.985475243302062e-06
mutations O 0 1.1108097908163472e-07
in O 0 5.717923912129663e-09
three O 0 3.6245250356614633e-08
breast B-Disease 1 0.9999992847442627
cancer I-Disease 1 0.9999850988388062
families O 0 6.837822752459033e-09
and O 0 1.7799800522411147e-09
in O 0 2.1106654202185382e-08
one O 0 0.00011444233678048477
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 4.177399750915356e-05
. O 0 9.00286867278055e-09
among O 0 6.498597771020798e-10
these O 0 5.725732041272913e-11
were O 0 5.8352139786777e-10
one O 0 1.3885149696690746e-09
frameshift O 0 4.982401833331096e-07
mutation O 0 1.0362875713099129e-07
, O 0 2.1896300328450025e-09
one O 0 2.742746918471539e-09
nonsense O 0 1.0624980859574862e-06
mutation O 0 3.7887309645157075e-07
, O 0 1.3805503407127162e-09
one O 0 9.303114389958012e-10
novel O 0 1.0128976768442044e-08
splice O 0 1.9490855152071163e-07
site O 0 1.132091753675013e-08
mutation O 0 1.2053766873520999e-08
, O 0 1.3193545145284702e-09
and O 0 4.0856522609544754e-09
one O 0 1.4467367748238757e-07
missense O 0 0.0003759134269785136
mutation O 0 0.0001190564944408834
. O 0 6.527009190904209e-06

The O 0 1.0098210623255e-06
missense O 0 4.1099403460975736e-05
mutation O 0 7.258070127136307e-06
was O 0 1.3618771390611073e-06
also O 0 7.237569210616357e-09
found O 0 1.9042358800902548e-08
in O 0 4.3066197719099364e-08
2 O 0 5.9019025684392545e-06
. O 0 2.425223556201672e-06

8 O 0 3.951610324293142e-06
% O 0 2.0204640804877272e-07
of O 0 5.8215428033747685e-09
the O 0 4.197501457525732e-09
general O 0 7.697819626173441e-08
population O 0 6.6525971398334605e-09
, O 0 6.460236789962437e-10
suggesting O 0 3.1964104696413642e-09
that O 0 5.916507561654072e-11
it O 0 2.431621015652752e-10
is O 0 3.35842065268821e-09
not O 0 1.3953998845295246e-08
disease O 0 1.4195380799719715e-06
associated O 0 5.479444098455133e-07
. O 0 1.9281733329989947e-06

The O 0 2.6215707293886226e-07
average O 0 2.2890446871315362e-07
age O 0 2.3456955489109532e-07
of O 0 3.5811780207950505e-07
disease O 0 0.05428331345319748
onset O 1 0.9999433755874634
in O 0 1.485765892539348e-07
those O 0 1.849281794363833e-08
families O 0 8.67639027291034e-09
harbouring O 0 5.426864390756236e-06
causative O 0 1.5315353039113688e-06
mutations O 0 5.398862299443863e-07
was O 0 8.640093369649549e-07
between O 0 4.829288400287624e-07
32 O 0 4.222317784297047e-06
. O 0 1.240533265445265e-06

3 O 0 7.368213118752465e-05
and O 0 1.6795070223452058e-06
37 O 0 2.926428169303108e-05
. O 0 6.691880571452202e-06

4 O 0 1.0961775842588395e-05
years O 0 1.3455407099627337e-07
, O 0 6.261527740747397e-09
whereas O 0 2.0602270112135557e-08
the O 0 1.1864309534814765e-08
family O 0 1.701296881151393e-08
harbouring O 0 2.817974689151015e-07
the O 0 8.355995895215074e-09
missense O 0 8.877235018189822e-07
mutation O 0 7.845363825254026e-08
had O 0 3.67732022610312e-09
an O 0 1.6596990448647375e-10
average O 0 1.6279708692223949e-09
age O 0 3.9463778911397185e-09
of O 0 9.937100031720547e-09
onset O 0 1.3260860214359127e-05
of O 0 1.4427481573875411e-06
51 O 0 2.2624293706030585e-05
. O 0 2.5264644136768766e-06

2 O 0 0.00024992116959765553
years O 0 1.5092788999027107e-05
. O 0 1.0745104191300925e-05

These O 0 1.70291034606862e-08
findings O 0 1.8601241436044802e-08
show O 0 3.1807620981538776e-09
that O 0 8.174655952153387e-10
BRCA1 O 0 4.274256752978545e-06
is O 0 1.2495623202823936e-08
implicated O 0 1.9277013052487746e-07
in O 0 1.2979934904677748e-09
a O 0 2.1768293834156793e-09
small O 0 1.229220392140462e-09
fraction O 0 5.041531281335665e-08
of O 0 1.606732098480279e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 6.892138770808742e-08
suggesting O 0 3.9476368840496434e-08
the O 0 5.424039883905607e-09
involvement O 0 2.800912213274387e-08
of O 0 6.387327555756883e-09
another O 0 2.7872317787114298e-08
susceptibility O 0 4.518696187005844e-06
gene O 0 4.366811765521561e-07
( O 0 1.638556312855144e-07
s O 0 1.3682086319022346e-05
) O 0 2.345472466913634e-06

Paternal O 0 0.00043073174310848117
transmission O 0 0.004641000181436539
of O 1 0.9999420642852783
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9999957084655762

We O 0 4.829578301723814e-07
report O 0 2.6215751347535843e-08
a O 0 2.510362229202201e-08
rare O 0 2.2063584736997655e-08
case O 0 1.2620598965895624e-07
of O 0 9.580617188476026e-07
paternally O 1 0.9999939203262329
transmitted O 1 0.9999998807907104
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999998807907104
DM B-Disease 1 1.0
) O 0 1.428080395271536e-05
. O 0 5.0307917263126e-06

The O 0 9.532460580885527e-07
proband O 0 0.00018376109073869884
is O 0 1.9933928285809088e-08
a O 0 3.3106648089642476e-08
23 O 0 5.39131512766744e-08
year O 0 1.2571979013387136e-08
old O 0 7.774086157041893e-07
, O 0 3.717654806223436e-07
mentally B-Disease 1 1.0
retarded I-Disease 1 1.0
male O 0 0.0020445368718355894
who O 0 0.0008608870557509363
suffers O 1 1.0
severe O 1 1.0
muscular B-Disease 1 1.0
weakness I-Disease 1 1.0
. O 1 0.999971866607666

He O 0 8.591090363552212e-07
presented O 0 3.523966540797119e-07
with O 0 7.587602368630542e-08
respiratory O 1 0.9999265670776367
and O 0 8.279946086986456e-06
feeding O 0 3.846380423055962e-05
difficulties O 0 3.6627872759709135e-05
at O 0 0.00010967140406137332
birth O 0 1.2215359674883075e-05
. O 0 7.333372650464298e-06

His O 0 3.595774614950642e-06
two O 0 1.9616520603449317e-06
sibs O 1 0.9999960660934448
suffer O 0 0.015326476655900478
from O 0 2.8042748454026878e-05
childhood O 1 0.9997172951698303
onset O 1 1.0
DM B-Disease 1 1.0
. O 0 0.00038968652370385826

Their O 0 2.452186365076159e-08
late O 0 1.2218097253935412e-06
father O 0 1.1657962772915198e-07
had O 0 1.2579871366824591e-08
the O 0 1.670711458068297e-09
adult O 0 2.0682027201957e-09
type O 0 2.9992254013677666e-08
of O 0 5.14630414727435e-07
DM B-Disease 1 1.0
, O 0 4.6183195934190735e-08
with O 0 6.498651394792887e-09
onset O 0 0.0008838530629873276
around O 0 9.684461588221893e-08
30 O 0 2.0557038737933908e-07
years O 0 1.4792425417908817e-07
. O 0 4.075894253219303e-07

Only O 0 9.481508556064e-08
six O 0 4.8324926282816705e-09
other O 0 1.6128597069009487e-10
cases O 0 4.930876817965668e-10
of O 0 8.741305457249382e-09
paternal O 0 4.9934124035644345e-06
transmission O 0 0.016088897362351418
of O 1 0.9999995231628418
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 7.794339035172015e-05
been O 0 5.457238216877158e-07
reported O 0 9.759747143789355e-08
recently O 0 2.6740571001937496e-07
. O 0 4.927525765197061e-07

We O 0 2.555258049596887e-07
review O 0 4.390831520595384e-08
the O 0 1.453166031950559e-08
sex O 0 1.1661072107926884e-08
related O 0 9.847609838686822e-09
effects O 0 1.6069482455804973e-07
on O 0 2.702767005757778e-07
transmission O 0 2.702065830817446e-05
of O 0 0.1250978410243988
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9835143089294434

Decreased O 0 1.1256923244218342e-05
fertility O 0 7.837226121409913e-07
of O 0 1.277419858780604e-08
males O 0 2.9331241879759773e-09
with O 0 3.108696911002795e-10
adult O 0 2.638460898651829e-07
onset O 1 0.9986129999160767
DM B-Disease 1 1.0
and O 0 1.0661201343964422e-07
contraction O 0 4.4809280552726705e-06
of O 0 2.6245418283110666e-08
the O 0 6.02857053166872e-09
repeat O 0 1.93780138602051e-08
upon O 0 2.4226363137813678e-09
male O 0 1.4644173651490178e-09
transmission O 0 9.934479905382432e-10
contribute O 0 2.6914717676795874e-10
to O 0 6.497172799768691e-10
the O 0 4.405241060823073e-09
almost O 0 2.9239872745279172e-08
absent O 0 1.0394429494908763e-07
occurrence O 0 1.6717706330382498e-08
of O 0 1.7707568744640412e-08
paternal O 0 9.88439865068358e-07
transmission O 0 1.6889878679648973e-05
of O 0 0.003614158369600773
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.5003624558448792

Also O 0 1.6881546116565005e-07
the O 0 4.643501938517147e-08
fathers O 0 2.76390494491352e-07
of O 0 3.089960642910228e-08
the O 0 8.049983790670012e-08
reported O 0 1.6587662230449496e-06
congenitally O 1 0.9951469302177429
affected O 0 4.811295752915612e-07
children O 0 3.707066653646507e-09
showed O 0 4.407476605905458e-09
, O 0 9.66839497351657e-10
on O 0 1.6945154612812985e-08
average O 0 2.295742440594495e-08
, O 0 6.918912553999235e-09
shorter O 0 1.021155298985832e-06
CTG O 0 3.344622382428497e-05
repeat O 0 2.392537510331749e-07
lengths O 0 1.1449578778410796e-06
and O 0 7.677020685825653e-10
hence O 0 1.6344339215379478e-08
less O 0 3.44166046772898e-08
severe O 0 7.395286957034841e-05
clinical O 0 0.00030953416717238724
symptoms O 0 1.3951263611033937e-07
than O 0 4.316362378631311e-09
the O 0 1.1568515034809934e-08
mothers O 0 2.2885453532239808e-09
of O 0 3.6723997176579815e-09
children O 0 5.0717936517230555e-09
with O 0 2.2637296126504225e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 1 0.9971093535423279

We O 0 1.7839667521002411e-07
conclude O 0 2.4838698209350696e-07
that O 0 1.3239601637238252e-09
paternal O 0 4.329078251430474e-07
transmission O 0 5.975870408292394e-06
of O 1 0.9707038402557373
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 0.19453109800815582
rare O 0 5.405761882570914e-08
and O 0 7.470216667471163e-10
preferentially O 0 3.796345460216344e-09
occurs O 0 2.6470720060345343e-10
with O 0 4.420504587376861e-11
onset O 0 1.904819100673194e-06
of O 0 8.456301543446898e-07
DM B-Disease 1 1.0
past O 0 2.6145249876208254e-07
30 O 0 1.728793996846889e-08
years O 0 7.456806838668228e-10
in O 0 1.963103984925496e-10
the O 0 1.5490033700160666e-09
father O 0 2.817791155962368e-08
. O 0 2.7121803469754013e-08
. O 0 7.459999551429064e-07

The O 0 1.6718316828701063e-06
RB1 O 0 5.922248965362087e-05
gene O 0 7.514997690805103e-08
mutation O 0 3.5992833602449537e-08
in O 0 3.25754001551104e-09
a O 0 8.695479891684954e-08
child O 0 8.834315394778969e-07
with O 0 5.161078320270462e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 1 1.0
. O 0 0.026596354320645332

The O 0 9.233714081346989e-06
RB1 O 0 0.000257796433288604
gene O 0 3.9485260572291736e-07
mutation O 0 5.285999691295729e-07
was O 0 1.9001619477876375e-07
investigated O 0 1.8392148604107206e-07
in O 0 7.43499617428256e-09
a O 0 1.3072470039787731e-07
child O 0 6.388231668097433e-07
with O 0 1.4883016774547286e-07
ectopic B-Disease 1 1.0
intracranial I-Disease 1 1.0
retinoblastoma I-Disease 0 0.00011146309407195076
using O 0 1.1315283821033972e-08
DNA O 0 3.520616687069378e-08
obtained O 0 2.5106339229807872e-09
from O 0 2.3710204910543098e-09
both O 0 1.5547724219189263e-09
the O 0 2.84524794835761e-08
pineal B-Disease 0 0.008090588264167309
and I-Disease 0 4.342873296536709e-07
retinal I-Disease 1 0.9999998807907104
tumours I-Disease 1 1.0
of O 0 0.00023801576753612608
the O 0 2.3485241399612278e-05
patient O 0 8.029921445995569e-05
. O 0 1.1269554306636564e-05

A O 0 1.2849292033934034e-05
nonsense O 0 3.351845225552097e-05
mutation O 0 1.6930412130022887e-06
in O 0 2.6772919881068447e-08
exon O 0 1.472559688409092e-06
17 O 0 3.5709739165668e-08
( O 0 3.890207267431833e-09
codon O 0 1.881444831042245e-07
556 O 0 6.092368920462832e-08
) O 0 8.477257229522195e-10
of O 0 4.5993906461205825e-09
the O 0 2.1038367492565158e-08
RB1 O 0 4.5334105379879475e-05
gene O 0 4.090418315172428e-08
was O 0 4.171285539200653e-08
found O 0 3.609736676235542e-10
to O 0 1.5991549751070977e-10
be O 0 1.1743381822526544e-09
present O 0 8.525111283574915e-09
homozygously O 0 0.00022849687957204878
in O 0 5.2702513464453205e-09
both O 0 4.444485224297523e-09
the O 0 4.3168256524950266e-08
retinal B-Disease 0 0.013116066344082355
and I-Disease 0 5.76953084419074e-07
the I-Disease 0 5.437459913082421e-05
pineal I-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 0.00010754382674349472

The O 0 7.588064931951521e-08
same O 0 2.5627814537187987e-08
mutation O 0 2.5601147513043543e-07
was O 0 6.334022373266635e-08
present O 0 6.800078722335456e-09
heterozygously O 0 4.084753527422436e-06
in O 0 9.777457732340622e-10
the O 0 6.256952178596009e-10
DNA O 0 5.129073610277146e-09
from O 0 2.2168894497909264e-10
the O 0 4.0143752211285744e-10
constitutional O 0 1.4112185198200677e-08
cells O 0 2.1721426879395267e-09
of O 0 1.5274306264245752e-09
the O 0 6.076571690272203e-09
patient O 0 5.0273101237507944e-08
, O 0 2.5848663209870892e-09
proving O 0 1.3833945899932587e-07
it O 0 5.213241505153121e-10
to O 0 1.2486276457224221e-09
be O 0 1.1539095012835787e-08
of O 0 2.3635746515537903e-07
germline O 0 8.335164602613077e-05
origin O 0 2.1567509520536987e-06
. O 0 1.8908591528088436e-06

The O 0 1.824268593964007e-07
initial O 0 1.9533467821020167e-07
mutation O 0 4.41261818195926e-07
was O 0 6.738070368328408e-08
shown O 0 1.0396243865784527e-09
to O 0 5.670048319750265e-10
have O 0 8.649783111991383e-10
occurred O 0 7.932953849376645e-08
in O 0 4.57226700945057e-09
the O 0 3.145463978171392e-08
paternally O 0 4.9834789024316706e-06
derived O 0 1.7623117400944466e-06
RB1 O 0 0.0004276414110790938
allele O 0 4.072773299412802e-05
. O 0 3.694747874760651e-06

The O 0 3.265411123720696e-07
mutation O 0 6.460206236624799e-07
is O 0 4.273763565265654e-09
in O 0 6.619280124020577e-10
an O 0 3.8546640879211225e-10
area O 0 2.983039948389887e-08
of O 0 5.94842264334261e-09
the O 0 3.860051389636965e-09
gene O 0 2.9305349258379465e-09
that O 0 1.010559760872276e-10
encodes O 0 1.0966452190785958e-09
the O 0 2.270309912288937e-10
protein O 0 1.6256902490852099e-09
- O 0 2.583850911008767e-09
binding O 0 2.2495232343544558e-08
region O 0 1.5250073204242653e-07
known O 0 2.3527991999117148e-08
as O 0 5.351408649545419e-09
the O 0 1.9499141856726965e-08
pocket O 1 0.7481514811515808
region O 0 1.787137080100365e-06
and O 0 6.308495059670349e-09
has O 0 6.905083171915294e-09
been O 0 3.275139492942003e-09
detected O 0 1.5734125113908703e-08
in O 0 6.729163892771339e-10
other O 0 3.448418217644189e-10
cases O 0 3.6015341819961577e-09
of O 0 2.544701658280246e-07
retinoblastoma B-Disease 0 0.0012994881253689528
. O 0 2.099465064020478e-06
. O 0 6.981670594541356e-06

Low O 0 2.6342522687627934e-06
levels O 0 3.828699490782128e-08
of O 0 2.1323502963355168e-08
beta O 0 3.222307441319572e-06
hexosaminidase O 0 8.941539272200316e-05
A O 0 1.116595626626804e-06
in O 0 2.023324796596171e-08
healthy O 0 4.1075693957282056e-09
individuals O 0 2.787446939933602e-10
with O 0 4.849074919377472e-09
apparent O 1 0.9999103546142578
deficiency O 1 0.9999983310699463
of O 0 0.00010118434147443622
this O 0 1.2039380408168654e-06
enzyme O 0 8.803232958598528e-06
. O 0 1.4730710518051637e-06

Appreciable O 0 0.0003043546457774937
beta O 0 0.00016452082491014153
hexosaminidase O 0 0.0009545611101202667
A O 0 6.427269545383751e-05
( O 0 1.2606144537130604e-06
hex O 0 6.670386210316792e-05
A O 0 2.15937302527891e-06
) O 0 9.096369879557642e-09
activity O 0 1.9179232424448855e-08
has O 0 1.4048019414403257e-09
been O 0 5.331806107733428e-09
detected O 0 1.3908369567161571e-07
in O 0 1.4260953307143609e-08
cultured O 0 2.9897612421336817e-06
skin O 0 7.877992175053805e-06
fibroblasts O 0 3.002023959197686e-06
and O 0 1.868237120561389e-07
melanoma B-Disease 1 1.0
tissue O 0 0.08695113658905029
from O 0 3.3833498491731007e-07
healthy O 0 1.1806722710616668e-08
individuals O 0 2.605873850036744e-10
previously O 0 8.023844699778238e-09
reported O 0 8.121106453984339e-09
as O 0 1.720806430682842e-08
having O 0 2.515280357329175e-07
deficiency B-Disease 0 7.8919118095655e-05
of I-Disease 0 9.626355677028187e-07
hex I-Disease 0 1.3578150173998438e-05
A I-Disease 0 6.184190937119638e-08
activity O 0 3.4998464126800855e-09
indistinguishable O 0 7.0915198158161274e-09
from O 0 2.881887783967585e-10
that O 0 6.852203526808154e-11
of O 0 5.292533966638757e-09
patients O 0 4.7598951447014315e-09
with O 0 2.9446175631164806e-07
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 0.00012043354217894375
TSD B-Disease 1 0.999847412109375
) O 0 1.0979161970681162e-06
. O 0 2.104227633026312e-06

Identification O 0 2.979548298753798e-06
and O 0 2.686920197447762e-07
quantitation O 0 0.000856977014336735
of O 0 1.061103193933377e-05
hex O 0 0.0006129172979854047
A O 0 4.59262628282886e-06
, O 0 2.3507986668391823e-08
amounting O 0 5.59656086807081e-07
to O 0 1.4579529761249432e-07
3 O 0 7.8303837653948e-06
. O 0 1.9607953163358616e-06

5 O 0 1.6088593838503584e-05
% O 0 8.156367584888358e-06
- O 0 1.647096360102296e-05
6 O 0 2.2487765818368644e-05
. O 0 4.08948562835576e-06

9 O 0 3.411594207136659e-06
% O 0 1.6403747338245012e-07
of O 0 1.2917777070242664e-08
total O 0 2.5497293165699375e-08
beta O 0 1.2928717296745162e-06
hexosaminidase O 0 8.49280331749469e-06
activity O 0 3.979873852699711e-08
, O 0 3.2128650850893337e-09
has O 0 2.029082235566193e-09
been O 0 2.1124122451254834e-09
obtained O 0 6.360144411132751e-09
by O 0 6.385816764264973e-09
cellulose O 0 7.622510565852281e-06
acetate O 0 9.678529977463768e-07
gel O 0 1.3102941238685162e-06
electrophoresis O 0 8.709902203918318e-07
, O 0 4.024583688533312e-08
DEAE O 0 7.101832306943834e-05
- O 0 2.3901300210127374e-06
cellulose O 0 3.188787331964704e-06
ion O 0 1.3560012348534656e-06
- O 0 3.018718928160524e-07
exchange O 0 7.743602026266672e-08
chromatography O 0 3.011745093317586e-06
, O 0 1.501080149068912e-08
radial O 0 2.3850566321925726e-06
immunodiffusion O 0 3.602353172027506e-05
, O 0 5.055416707477889e-08
and O 0 1.1820697665143598e-07
radioimmunoassay O 0 0.0005460354150272906
. O 0 8.941025953390636e-06

Previous O 0 3.6395410916156834e-06
family O 0 4.9789193212745886e-08
studies O 0 1.83146049437255e-08
suggested O 0 1.5773427008980434e-08
that O 0 1.5460685509616212e-10
these O 0 1.0607435763088091e-10
individuals O 0 3.707651685669333e-10
may O 0 1.4492631983387128e-08
be O 0 1.305415242569552e-08
compound O 0 1.9169490883541584e-07
heterozygotes O 0 1.1748500838848486e-07
for O 0 6.944041452960903e-10
the O 0 6.007404351748846e-09
common O 0 1.872028718707952e-07
mutant O 0 4.64423828816507e-06
TSD B-Disease 0 0.00010300738358637318
gene O 0 2.3124510306615775e-08
and O 0 1.2325210851926727e-09
a O 0 2.121186781778306e-08
rare O 0 7.528037571091772e-08
( O 0 2.2561539481102955e-07
allelic O 0 4.509513746597804e-05
) O 0 2.4633487782921293e-07
mutant O 0 1.967155640159035e-06
gene O 0 1.2787722880602814e-06
. O 0 7.607685574839707e-07

Thus O 0 1.9460781004454475e-06
, O 0 2.6449500367675682e-08
the O 0 2.0940165157412594e-08
postulated O 0 3.4223933198518353e-06
rate O 0 4.438811913587415e-07
mutant O 0 1.4401759074189613e-07
gene O 0 3.368081369359288e-09
appears O 0 6.868052238040434e-10
to O 0 7.303500859645595e-11
code O 0 2.6466834279759155e-10
for O 0 2.59618493370084e-10
the O 0 8.559860043000356e-10
expression O 0 3.369790446683396e-09
of O 0 2.8579518751570276e-09
low O 0 3.806287907082151e-08
amounts O 0 2.0169942160919163e-08
of O 0 1.850866624408809e-07
hex O 0 8.526629244443029e-05
A O 0 2.1965384803479537e-05
. O 0 4.824455118068727e-06

Heterozygotes O 0 0.00016140246589202434
for O 0 1.225303947194334e-07
the O 0 1.1352220496974041e-07
rare O 0 1.605503712198697e-07
mutant O 0 1.4221031960914843e-06
may O 0 2.3544197702562997e-08
be O 0 6.213854764069993e-09
indistinguishable O 0 1.815036512198276e-07
from O 0 1.3960469225082761e-08
heterozygotes O 0 3.2132103910953447e-07
for O 0 4.229034900049555e-09
the O 0 5.453513907127672e-08
common O 0 7.617874416609993e-06
TSD B-Disease 1 0.9965115189552307
mutant O 0 7.717672269791365e-05
. O 0 2.5829856440395815e-06

However O 0 5.014965154259698e-07
, O 0 2.761614403823387e-08
direct O 0 1.8809424773280625e-07
visualization O 0 4.612035354512045e-06
and O 0 5.817927473117379e-08
quantitation O 0 0.022225765511393547
of O 0 3.624733381002443e-06
hex O 0 5.856596180819906e-05
A O 0 6.610227387682244e-08
by O 0 1.6910106648282408e-10
the O 0 3.079966004460033e-10
methods O 0 3.5655545183033155e-09
described O 0 4.647841223004434e-09
may O 0 3.2565148355701012e-09
prevent O 0 4.653802676557461e-09
false O 0 2.4415781396669445e-08
- O 0 3.905555274741346e-07
positive O 0 1.527122606148623e-08
prenatal O 0 2.267398286903699e-07
diagnosis O 0 4.2371357267256826e-07
of O 0 7.309350280593208e-07
TSD B-Disease 1 0.999777615070343
in O 0 1.2639836199923593e-07
fetuses O 0 1.5780777573581872e-07
having O 0 3.348442412232089e-09
the O 0 4.393082786435798e-09
incomplete O 0 2.5242701440220117e-07
hex B-Disease 0 0.26940953731536865
A I-Disease 0 0.021429365500807762
deficiency I-Disease 0 0.005066955462098122
of O 0 1.0670274264157342e-07
the O 0 1.5591743007803416e-08
type O 0 4.300381704069878e-07
described O 0 4.441115208919655e-08
in O 0 2.6545006193146037e-09
the O 0 1.0815710105305243e-08
four O 0 4.136022724310351e-08
healthy O 0 1.6725464035971527e-07
individuals O 0 4.0949427670966543e-07

The O 0 6.781120191590162e-06
tumor B-Disease 0 0.0004325364134274423
suppressor O 0 0.0001514821342425421
gene O 0 3.448584493526141e-06
Smad4 O 0 0.0006541430484503508
/ O 0 5.622081516776234e-05
Dpc4 O 0 6.188668339746073e-05
is O 0 3.225034017617645e-09
required O 0 2.8871269819319423e-09
for O 0 2.901474616123778e-09
gastrulation O 0 1.7591079313206137e-06
and O 0 2.7296214177852107e-09
later O 0 2.6121767859876854e-08
for O 0 3.1608529127424845e-09
anterior O 0 2.7482685709401267e-06
development O 0 5.328260854753353e-08
of O 0 4.1783486892654764e-08
the O 0 1.0184598409068712e-07
mouse O 0 3.952930001105415e-06
embryo O 0 1.5535835700575262e-05
. O 0 1.2999436194149894e-06

Mutations O 0 2.2382886527338997e-05
in O 0 2.8690470799119794e-07
the O 0 1.27188593523897e-06
SMAD4 O 1 0.9999998807907104
/ O 1 0.9999483823776245
DPC4 O 1 0.9999990463256836
tumor B-Disease 1 0.7950237393379211
suppressor O 0 0.00010805326019180939
gene O 0 6.076898984019863e-08
, O 0 1.6699659433072611e-09
a O 0 1.7577542976709992e-08
key O 0 3.429146033795405e-07
signal O 0 7.721478141320404e-07
transducer O 0 3.5335849588591373e-06
in O 0 1.5957258625576287e-08
most O 0 2.044120073207978e-08
TGFbeta O 1 0.5425189137458801
- O 0 8.518322829331737e-06
related O 0 1.6280671388813062e-07
pathways O 0 7.222802622663949e-08
, O 0 9.435928705059382e-10
are O 0 1.0528502375484194e-10
involved O 0 4.4044826119638003e-10
in O 0 6.315053480143717e-10
50 O 0 8.355055314268611e-09
% O 0 4.928860164454818e-08
of O 0 3.2250730441774067e-07
pancreatic B-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 0.0001533474278403446

Homozygous O 0 0.00014454433403443545
Smad4 O 0 0.1012241393327713
mutant O 0 0.0001429987751180306
mice O 0 5.8892860579362605e-06
die O 0 2.221036538685439e-06
before O 0 1.8921585365205829e-07
day O 0 3.9184936895253486e-07
7 O 0 2.221019485659781e-06
. O 0 9.039864039550594e-07

5 O 0 2.03516519832192e-05
of O 0 6.3772899920877535e-06
embryogenesis O 0 0.00033039014670066535
. O 0 1.585287282068748e-05

Mutant O 0 9.808977665670682e-06
embryos O 0 2.1989458787174954e-07
have O 0 1.2318630560059773e-09
reduced O 0 2.6284345366889283e-08
size O 0 2.0645462228685574e-08
, O 0 2.386000730325577e-09
fail O 0 8.943057139276789e-08
to O 0 2.1114264114885373e-08
gastrulate O 0 0.0004992320318706334
or O 0 6.131561747224623e-08
express O 0 2.7950525449682573e-08
a O 0 4.484099136448094e-08
mesodermal O 0 1.2654911188292317e-05
marker O 0 4.800781880476279e-06
, O 0 8.938603635044728e-09
and O 0 7.647517286102357e-09
show O 0 6.158448684345785e-08
abnormal O 0 1.6082772162917536e-06
visceral O 0 0.0007621202967129648
endoderm O 1 0.7580389380455017
development O 0 3.09362294501625e-05
. O 0 8.69562882144237e-06

Growth B-Disease 1 1.0
retardation I-Disease 1 1.0
of O 0 1.5161357623583172e-05
the O 0 1.2247086488059722e-05
Smad4 O 1 0.9999985694885254
- O 1 0.5876020193099976
deficient O 0 2.989545464515686e-05
embryos O 0 8.317233124444101e-08
results O 0 6.857243217694986e-09
from O 0 6.5789809156058254e-09
reduced O 0 1.3343797888865083e-07
cell O 0 5.065822392680275e-07
proliferation O 0 3.7990352552697004e-07
rather O 0 9.331090566888633e-09
than O 0 1.2907851676402515e-08
increased O 0 4.5193630171525e-07
apoptosis O 0 1.4662743524240796e-05
. O 0 1.2452579767341376e-06

Aggregation O 0 3.393748193047941e-05
of O 0 2.4519674752809806e-06
mutant O 0 1.7970694898394868e-05
Smad4 O 0 0.0007607819279655814
ES O 0 0.00019340634753461927
cells O 0 1.883774736199939e-08
with O 0 5.874914443815271e-10
wild O 0 5.004034520084133e-08
- O 0 2.0443702908323758e-07
type O 0 3.205587745469529e-06
tetraploid O 0 0.0001041518262354657
morulae O 0 0.000321843137498945
rescues O 0 6.070693871151889e-06
the O 0 5.179796289667138e-07
gastrulation B-Disease 0 0.0002602407766971737
defect I-Disease 0 0.0006121332407929003
. O 0 1.0172102520300541e-05

These O 0 5.166485195218229e-08
results O 0 9.935682498962706e-08
indicate O 0 3.4497176670811314e-08
that O 0 4.142431286879855e-09
Smad4 O 0 2.9125822038622573e-05
is O 0 2.1002835026706634e-09
initially O 0 9.396524669469386e-10
required O 0 8.747717827883861e-11
for O 0 2.1695827079337704e-10
the O 0 9.045343363212055e-10
differentiation O 0 1.0524902194219976e-07
of O 0 4.138293263622472e-09
the O 0 8.03123967330066e-09
visceral O 0 3.3886694836837705e-06
endoderm O 0 1.0024394214269705e-05
and O 0 1.572415531114757e-09
that O 0 4.764116323663359e-10
the O 0 7.897879683582687e-09
gastrulation B-Disease 0 3.5852626751875505e-06
defect I-Disease 0 1.0097747917825473e-06
in O 0 3.5544591714398166e-09
the O 0 1.326174903226729e-08
epiblast O 0 1.057584540831158e-05
is O 0 5.057342544745325e-09
secondary O 0 4.091416982987539e-08
and O 0 5.5206590410250556e-09
non O 0 2.5614924652472837e-06
- O 0 4.387343506095931e-05
cell O 0 4.159479431109503e-05
autonomous O 0 6.7941955421702005e-06
. O 0 2.5101860501308693e-06

Rescued O 0 7.799477316439152e-05
embryos O 0 4.088292371307034e-06
show O 0 3.031218795968016e-07
severe O 0 0.00017566113092470914
anterior O 1 0.9915707111358643
truncations O 1 0.9912115931510925
, O 0 2.086519685917665e-07
indicating O 0 7.139470312722551e-07
a O 0 4.7017429949391953e-08
second O 0 9.28899055452348e-08
important O 0 9.742929130140965e-09
role O 0 1.814011518774805e-08
for O 0 1.9417713659208857e-08
Smad4 O 0 0.016386715695261955
in O 0 5.059362138126744e-07
anterior O 0 0.04383961111307144
patterning O 1 0.8893911838531494
during O 0 0.0001851604029070586
embryogenesis O 0 0.0004559180815704167
. O 0 7.685365744691808e-06

Prevalence O 0 0.00021560089953709394
of O 0 2.53544340012013e-06
p16 O 0 5.7090110203716904e-05
and O 0 1.6703384062566329e-06
CDK4 O 1 0.9999921321868896
germline O 0 0.16335304081439972
mutations O 0 3.189827566529857e-06
in O 0 1.3416941158084228e-07
48 O 0 3.193646261934191e-05
melanoma B-Disease 1 0.9999998807907104
- O 0 0.30117067694664
prone O 0 0.19735698401927948
families O 0 4.73235992615173e-08
in O 0 1.1126311960651947e-07
France O 0 4.831932528759353e-06
. O 0 3.7774129850731697e-06

The O 0 3.954626663471572e-06
French O 0 0.00036092224763706326
Familial B-Disease 1 0.9999988079071045
Melanoma I-Disease 1 1.0
Study O 0 1.36822163767647e-05
Group O 0 3.1023141673358623e-06
. O 0 9.319671789853601e-07

Germline O 0 0.002772126579657197
mutations O 0 3.0915516617824323e-06
in O 0 2.671532861597825e-08
the O 0 4.817448484573106e-08
p16 O 0 2.8527579161163885e-06
and O 0 3.4508101265373625e-08
CDK4 O 1 0.9998008608818054
genes O 0 5.074428699458622e-08
have O 0 1.2151288864004073e-09
been O 0 3.3358142914607924e-09
reported O 0 7.740405538747552e-10
in O 0 5.413184900326939e-10
a O 0 3.79052078613995e-09
subset O 0 5.128196107762051e-07
of O 0 1.1266359223327527e-07
melanoma B-Disease 1 0.981836199760437
pedigrees O 0 8.716673960407206e-07
, O 0 1.3404414467288461e-08
but O 0 1.9160684150421048e-09
their O 0 5.677862069397577e-10
prevalence O 0 2.773613800854946e-07
is O 0 2.2807624677767535e-09
not O 0 3.113160396139847e-09
well O 0 1.361903478880322e-08
known O 0 8.265494102488447e-07
. O 0 1.951977765202173e-06

We O 0 3.85410970693556e-07
searched O 0 2.5787426238821354e-07
for O 0 8.387499583761837e-09
such O 0 2.3553091921257874e-08
germline O 0 7.60543771320954e-05
mutations O 0 3.870235047997994e-07
in O 0 2.3138762017538284e-08
48 O 0 6.617531198571669e-07
French O 0 0.0003514540148898959
melanoma B-Disease 1 1.0
- O 0 0.09756488353013992
prone O 0 4.4809552491642535e-05
families O 0 1.4661333258558784e-09
selected O 0 8.37649671847629e-10
according O 0 9.008424561862682e-11
to O 0 2.0015744617296605e-10
two O 0 1.4895219779820223e-10
major O 0 8.314723132230029e-09
criteria O 0 2.052468950353159e-08
families O 0 1.284422984637601e-10
with O 0 8.058528844223645e-11
at O 0 2.9447626559431228e-08
least O 0 3.3258087395182656e-09
three O 0 9.927718647162465e-10
affected O 0 1.0382650295071016e-09
members O 0 1.097739191213698e-10
( O 0 4.2945735856392275e-10
n O 0 1.6867634400341558e-08
= O 0 3.871229115048891e-09
20 O 0 1.0390257543235748e-09
) O 0 4.7167630912170466e-11
or O 0 1.3061661474633723e-10
families O 0 2.157317727236041e-11
with O 0 7.405123389481183e-12
two O 0 1.8340663709981442e-10
affected O 0 1.8074933771927704e-09
members O 0 1.4797639502628357e-10
, O 0 3.994265473927783e-10
one O 0 4.325945712757573e-10
of O 0 1.0223437652001621e-09
them O 0 6.683330278089983e-11
affected O 0 5.599107844034279e-10
before O 0 1.1701883906312105e-09
the O 0 1.0801274319405252e-09
age O 0 5.506829214851905e-09
of O 0 3.919089053283642e-09
50 O 0 7.71817809663844e-09
( O 0 1.1649727849061264e-09
n O 0 5.5566221845992914e-08
= O 0 2.2050668846418375e-08
28 O 0 1.0408947481721498e-08
) O 0 2.2857434001100074e-10
, O 0 1.8105841825821756e-10
and O 0 1.3563081213696648e-10
one O 0 9.173778403592792e-10
additional O 0 5.961848348334797e-09
minor O 0 4.025857379019726e-06
criterion O 1 0.94157874584198
. O 0 8.347701623279136e-06

Sixteen O 0 6.434519946196815e-06
different O 0 1.1116087961227095e-07
p16 O 0 1.897493530123029e-05
germline O 0 3.946960350731388e-05
mutations O 0 2.581552394076425e-07
were O 0 7.993127049132909e-09
found O 0 3.606689835677912e-09
in O 0 1.55550206049071e-09
21 O 0 1.5364133076900544e-08
families O 0 3.2459152032870975e-10
, O 0 6.104972638532047e-10
while O 0 2.0743340378714947e-09
one O 0 1.1952757006383763e-08
germline O 0 1.4587260920961853e-05
mutation O 0 1.2893452776552294e-06
, O 0 4.2514319176234494e-08
Arg24His O 0 0.009319812059402466
, O 0 2.2349309958258345e-08
was O 0 2.135313650342141e-07
detected O 0 5.172598349645341e-08
in O 0 5.496273214333769e-09
the O 0 1.079150209193358e-07
CDK4 O 0 0.4395066499710083
gene O 0 4.831923433812335e-06
. O 0 1.324021127402375e-06

The O 0 2.786467234727752e-07
frequency O 0 7.310688374673191e-07
of O 0 8.57452633340472e-08
p16 O 0 6.388109454746882e-07
gene O 0 3.972585460587652e-08
mutation O 0 4.229279326750657e-08
in O 0 9.408881451733464e-10
our O 0 5.04909947185439e-10
sample O 0 1.7513548389302969e-09
( O 0 1.2026915019447415e-09
44 O 0 1.9938680040354484e-08
% O 0 8.44752978679253e-09
) O 0 2.7497748522620213e-10
is O 0 3.855266939023494e-10
among O 0 2.426510659070402e-10
the O 0 1.7391648121645176e-09
highest O 0 1.7180343547806842e-07
rates O 0 2.028611056914542e-08
yet O 0 8.411082497161715e-09
reported O 0 5.770480093758579e-09
and O 0 1.108825364859456e-09
the O 0 1.063424726055473e-08
CDK4 O 0 0.0006671281298622489
mutation O 0 1.205205819587718e-07
is O 0 1.9162291753360705e-09
the O 0 2.2578612313139956e-09
second O 0 3.9569016507812194e-08
mutation O 0 6.169876343165015e-08
detected O 0 2.2016838130411998e-08
in O 0 2.403742094259087e-09
this O 0 6.284824216606921e-09
gene O 0 1.1667739840959257e-07
worldwide O 0 2.1314542664185865e-07
. O 0 9.943927352651372e-07

In O 0 6.387268740581931e-07
summary O 0 2.7902322017325787e-06
, O 0 3.5536000808633617e-08
our O 0 7.336612206643167e-09
results O 0 8.147264196622928e-09
show O 0 1.4264537329111704e-09
frequent O 0 2.551892919200327e-09
involvement O 0 4.61188491840403e-08
of O 0 2.3013496885937457e-08
the O 0 3.739137710567775e-08
p16 O 0 7.059308586576662e-07
gene O 0 4.9655472622589514e-08
in O 0 2.669968957036417e-08
familial B-Disease 1 0.9999161958694458
melanoma I-Disease 1 1.0
and O 0 7.554879033477846e-08
confirm O 0 4.266582109835326e-08
the O 0 8.055478950552697e-09
role O 0 8.997135481081386e-09
of O 0 4.947431353485854e-09
the O 0 1.2450421138510137e-08
CDK4 O 0 0.000502770475577563
gene O 0 2.4643536988833148e-08
as O 0 4.169509626450463e-09
a O 0 5.179400659471867e-07
melanoma B-Disease 1 0.9999934434890747
- O 0 0.06872706115245819
predisposing O 0 0.0028619745280593634
gene O 0 9.547981107971282e-07
. O 0 1.6222952581301797e-07
. O 0 9.275160550714645e-07

Progression O 0 0.0007820093305781484
of O 0 2.329101880604867e-05
somatic O 1 0.7288488149642944
CTG O 0 0.012416591867804527
repeat O 0 2.6597049327392597e-06
length O 0 2.457899768160132e-07
heterogeneity O 0 1.1349692385920207e-06
in O 0 1.5449610479834064e-09
the O 0 1.3472665205682688e-09
blood O 0 2.083248240580815e-08
cells O 0 1.0329446809009823e-07
of O 0 2.733562268986134e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9115862250328064
. O 0 9.465377661399543e-05

The O 0 1.610252553518876e-07
genetic O 0 2.3755016798077122e-07
basis O 0 3.617329014105053e-07
of O 0 8.450000677839853e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9891315698623657
DM B-Disease 1 1.0
) O 0 1.4133330950016898e-08
is O 0 5.270872072138388e-10
the O 0 2.250241937229447e-10
expansion O 0 9.976107051556937e-09
of O 0 7.530735146588086e-09
an O 0 1.8121751210742332e-08
unstable O 0 0.001218560035340488
CTG O 0 0.016130896285176277
repeat O 0 4.6234274009293586e-07
in O 0 1.444150132812183e-08
the O 0 2.3467130461085617e-08
34 O 0 2.424078218155046e-07
UTR O 0 3.915357228834182e-05
of O 0 2.307697570813616e-07
the O 0 8.085513059086225e-07
DM B-Disease 1 0.9999969005584717
protein O 0 1.8701796307141194e-06
kinase O 0 1.2930751154272002e-06
gene O 0 1.7968373811072524e-07
on O 0 3.0334626899275463e-07
chromosome O 0 5.348148260964081e-05
19 O 0 5.026484814152354e-06
. O 0 1.5032854889796e-06

One O 0 2.4447894020340755e-07
of O 0 1.0505447534114865e-07
the O 0 2.716197577967705e-08
principal O 0 1.0108735182257078e-07
features O 0 4.6340301040892484e-10
of O 0 6.383844119994819e-09
the O 0 1.7263776896925265e-07
DM B-Disease 1 1.0
mutation O 0 2.51118417509133e-05
is O 0 4.532343833574259e-09
an O 0 8.415089736146797e-10
extraordinarily O 0 7.482145036874499e-08
high O 0 7.153797554337871e-08
level O 0 3.9843783383730624e-07
of O 0 2.3517186775734444e-07
somatic O 0 0.4400392472743988
mosaicism O 1 0.9928966164588928
, O 0 4.045885848569242e-09
due O 0 1.0545635475978088e-08
to O 0 3.3096952956057635e-10
an O 0 4.4066336690740116e-10
extremely O 0 4.978460754756497e-09
high O 0 2.0419106405711318e-08
degree O 0 5.896901598134718e-07
of O 0 1.674594045653066e-07
somatic O 0 0.014572166837751865
instability O 0 3.450413350947201e-05
both O 0 5.120588841833751e-09
within O 0 1.8249048494567432e-08
and O 0 1.357719381367417e-09
between O 0 1.8657456024584462e-08
different O 0 3.151745886498247e-08
tissues O 0 1.0987541827489622e-06
. O 0 6.987093001953326e-07

This O 0 7.09606808868557e-07
instability O 0 0.00018626642122399062
appears O 0 4.623599281217139e-08
to O 0 9.101832065816495e-10
be O 0 1.0152316765044134e-09
biased O 0 2.1689476881192604e-08
towards O 0 7.057515905017908e-09
further O 0 7.483879072012201e-10
expansion O 0 9.68187130467868e-09
and O 0 1.8809975799172207e-10
continuous O 0 3.2650850911863927e-09
throughout O 0 4.3142697747633463e-10
the O 0 8.455408595509084e-10
life O 0 3.002227355608511e-10
of O 0 4.796584796018522e-10
an O 0 2.0534145217521171e-10
individual O 0 1.8645023025509744e-10
, O 0 1.47753018153729e-10
features O 0 5.658194399127403e-11
that O 0 5.302511207894156e-11
could O 0 8.352311064996343e-10
be O 0 5.193511176670995e-10
associated O 0 9.005921564053665e-10
with O 0 7.155098041833341e-11
the O 0 5.1129278588746274e-09
progressive O 0 1.553916945340461e-06
nature O 0 1.1547256661970096e-07
of O 0 2.879204998862406e-07
the O 0 2.0676850454037776e-06
disease O 0 0.003497608471661806
. O 0 5.650562798109604e-06

Although O 0 1.1991535586730606e-07
increasing O 0 3.035169626741663e-08
measured O 0 8.041482146836643e-08
allele O 0 2.5762795985428966e-07
size O 0 2.3228528434060536e-08
between O 0 5.313981077392782e-08
patients O 0 2.27674750163942e-08
clearly O 0 1.0630819780033107e-08
correlates O 0 2.9774863463671863e-08
with O 0 6.184996959035516e-11
an O 0 1.1951947764821114e-10
increased O 0 4.000924036517972e-09
severity O 0 2.336943452974083e-06
of O 0 9.946130319349322e-08
symptoms O 0 1.3607766469192484e-08
and O 0 1.3495522754869427e-10
an O 0 1.1171377711782782e-10
earlier O 0 2.7320070650205253e-09
age O 0 6.501613913911797e-09
of O 0 2.0047581372750756e-09
onset O 0 9.47938588069519e-06
, O 0 7.844758731501145e-10
this O 0 3.497575562505517e-10
correlation O 0 1.9728766176285717e-08
is O 0 2.5917618051707336e-10
not O 0 7.3261167965466e-11
precise O 0 3.2212528200403767e-09
and O 0 1.484003614438123e-10
measured O 0 9.682406876265759e-09
allele O 0 2.6449853862686723e-08
length O 0 4.24919210928465e-09
cannot O 0 1.4667264069956332e-09
be O 0 2.0714507886765432e-10
used O 0 2.1329256416624531e-10
as O 0 1.8084650443839223e-10
an O 0 1.3222636874310467e-10
accurate O 0 2.064979298666003e-08
predictor O 0 2.3636202968191355e-06
of O 0 2.938349830117204e-08
age O 0 2.0472812423122377e-07
of O 0 8.785936529420724e-07
onset O 1 0.9079168438911438
. O 0 1.339492700935807e-05

In O 0 1.2464694520986086e-07
order O 0 2.4788592511981733e-08
to O 0 1.3321019842749138e-08
further O 0 7.136544155628144e-08
characterize O 0 1.033556145557668e-06
the O 0 8.490971481478482e-08
dynamics O 0 8.328603144036606e-06
of O 0 1.6394207705161534e-05
DM B-Disease 1 1.0
CTG O 1 0.9841514825820923
repeat O 0 1.0621683941280935e-05
somatic O 0 0.0003986443916801363
instability O 0 6.418474367819726e-05
, O 0 3.889049970950964e-09
we O 0 1.0797052141242602e-09
have O 0 1.0301591524264353e-10
studied O 0 4.350714011280843e-09
repeat O 0 1.9803327866441123e-09
length O 0 3.527980685369414e-10
changes O 0 6.726876000673343e-11
over O 0 3.4434163853624966e-10
time O 0 1.9118702176967872e-09
in O 0 3.907057788410384e-09
111 O 0 1.4745533007953782e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 8.080627367235138e-08
with O 0 8.067345680373705e-10
varying O 0 4.7141082148982605e-08
clinical O 0 2.162113923986908e-05
severity O 1 0.9694095253944397
and O 0 3.3947785027521604e-07
CTG O 0 0.00038176728412508965
repeat O 0 5.825767246392388e-08
size O 0 6.6240835039366175e-09
over O 0 1.3251375552414402e-09
time O 0 1.1829618395964303e-09
intervals O 0 1.1818574563449147e-08
of O 0 8.841140264337355e-09
1 O 0 3.8177398664629436e-07
- O 0 4.100010926322284e-07
7 O 0 5.123898745296174e-07
years O 0 1.4404726300654147e-07
. O 0 3.526188834257482e-07

We O 0 2.036984625419791e-07
have O 0 2.848651092790533e-09
found O 0 1.329413357176179e-09
a O 0 2.680918820274769e-09
direct O 0 2.3654793679384056e-08
progression O 0 5.013918098484282e-07
of O 0 9.328278594011863e-09
the O 0 2.912286189982183e-09
size O 0 1.781624803243176e-08
heterogeneity O 0 3.9119294115153025e-07
over O 0 9.679803625317618e-09
time O 0 4.147934440368317e-09
related O 0 3.2274705130674874e-09
to O 0 3.317603747277076e-09
initial O 0 1.5585877122248348e-07
CTG O 0 1.4106222806731239e-05
repeat O 0 2.8415167108164496e-08
size O 0 3.5924778707396854e-09
and O 0 1.4843830331567887e-10
the O 0 8.926365202555075e-10
time O 0 4.062759462186705e-09
interval O 0 1.0564402685986352e-07
and O 0 1.2501217838689627e-09
always O 0 1.1789710541165732e-08
biased O 0 3.0950690188547014e-07
towards O 0 1.3712407564980822e-07
further O 0 2.227031643542432e-07
expansion O 0 6.818686870246893e-06
. O 0 3.888943865604233e-06

Attempts O 0 4.7524682145194674e-07
to O 0 1.4210042920126398e-08
mathematically O 0 4.795309109795198e-07
model O 0 1.2955776895751114e-08
the O 0 9.327531635960895e-09
dynamics O 0 1.7878871858556522e-06
have O 0 3.125392611380562e-09
proved O 0 3.6160562899567594e-07
only O 0 2.452283265341748e-09
partially O 0 3.0783951388002606e-08
successful O 0 1.946743433123288e-09
suggesting O 0 2.916994867874223e-09
that O 0 5.4242204478027745e-11
individual O 0 8.324601424858358e-11
specific O 0 1.0222793722647339e-09
genetic O 0 2.961588450034469e-07
and O 0 2.7428789906025486e-08
/ O 0 0.004691090434789658
or O 0 3.1115121146285674e-07
environmental O 0 1.156535745394649e-06
factors O 0 5.3314632708634235e-08
also O 0 2.893465189668376e-10
play O 0 1.8479021646200522e-09
a O 0 6.078368475215257e-09
role O 0 2.6049672641192956e-08
in O 0 3.1052863391778374e-08
somatic O 0 0.00013810466043651104
mosaicism O 0 0.05334692448377609
. O 0 4.1533840544616396e-07
. O 0 1.9124895516142715e-06

Aspartylglucosaminuria B-Disease 1 0.9999972581863403
among O 0 6.453644800785696e-06
Palestinian O 0 3.162556458846666e-05
Arabs O 0 2.6376550522400066e-05
. O 0 4.314391389925731e-06

Aspartylglucosaminuria B-Disease 1 1.0
( O 1 0.999193012714386
AGU B-Disease 1 1.0
) O 0 3.6650894230660924e-07
is O 0 2.948511479416993e-08
a O 0 2.1625329793550918e-07
rare O 0 9.73453438746219e-07
disorder B-Disease 1 0.9966530203819275
of I-Disease 0 5.68603900319431e-05
glycoprotein I-Disease 1 0.9997411370277405
metabolism I-Disease 0 7.794666453264654e-05
caused O 0 1.5591882629450993e-07
by O 0 3.1566476099698093e-09
the O 0 3.7496187133001513e-07
deficiency B-Disease 1 0.7671500444412231
of I-Disease 0 6.160379598441068e-06
the I-Disease 0 1.327523364125227e-06
lysosomal I-Disease 1 0.9372676014900208
enzyme I-Disease 0 3.510369424475357e-06
aspartylglucosaminidase I-Disease 0 9.966689685825258e-05
( O 0 2.7909138111681386e-07
AGA O 0 0.0024862398859113455
) O 0 1.6603551955540752e-07
. O 0 5.349972411750059e-07

AGU B-Disease 1 1.0
is O 0 1.4690316675114445e-05
inherited O 0 0.0003059708105865866
as O 0 8.164441567259928e-08
an O 0 1.1627405882563835e-07
autosomal O 1 0.9993985891342163
recessive O 1 1.0
trait O 1 0.9999496936798096
and O 0 1.3739680504443186e-08
occurs O 0 2.8158231302199965e-09
with O 0 3.87555473824186e-11
a O 0 1.201801769212807e-09
high O 0 7.474282526231946e-09
frequency O 0 3.8368433763480425e-08
in O 0 1.7008873198776087e-09
Finland O 0 1.6090636378862655e-08
because O 0 1.203343091837894e-09
of O 0 7.866938211975594e-09
a O 0 7.96728443219763e-08
founder O 0 9.408815344613686e-07
effect O 0 1.525773768662475e-06
. O 0 1.4802673149461043e-06

While O 0 6.691444696116378e-07
very O 0 8.144719032543435e-08
few O 0 6.551184839054258e-08
patients O 0 4.255034014022385e-08
with O 0 5.8247891843166144e-08
AGU B-Disease 1 1.0
have O 0 5.237565758875462e-08
been O 0 9.83381376329362e-09
reported O 0 1.8579923155570555e-09
from O 0 2.997085246647657e-09
non O 0 7.653576261645867e-08
- O 0 7.534502088901718e-08
Finnish O 0 3.5214938520766736e-07
origin O 0 3.003083648422944e-08
, O 0 6.8637993067000025e-09
we O 0 5.2556583085561215e-08
diagnosed O 0 0.2278502881526947
the O 0 3.5167047940376506e-07
disorder O 1 0.9560053944587708
in O 0 3.249498803370443e-08
8 O 0 1.8103810361935757e-07
patients O 0 1.3757506245326567e-09
originating O 0 3.920083369024496e-09
from O 0 8.756456892911046e-09
3 O 0 1.6225692434090888e-07
unrelated O 0 3.955671346034251e-08
families O 0 3.027713635361806e-10
, O 0 2.5552132632000735e-10
all O 0 2.988817526805576e-10
Palestinian O 0 3.8510449940076796e-08
Arabs O 0 2.1597749366719654e-08
from O 0 1.965604123910225e-09
the O 0 2.9769622322817213e-09
region O 0 3.803776849053975e-08
of O 0 9.223807495573055e-08
Jerusalem O 0 2.1082501916680485e-05
. O 0 2.5028284653672017e-06

The O 0 7.741268177596794e-07
clinical O 0 2.6605179300531745e-05
diagnosis O 1 0.9998014569282532
of O 1 0.9999815225601196
AGU B-Disease 1 1.0
is O 0 1.6297555021083099e-06
often O 0 9.084181407104097e-09
difficult O 0 2.9103887300152564e-08
, O 0 5.64489566201587e-10
in O 0 2.2814530820092216e-10
particular O 0 1.2687358941221305e-09
early O 0 4.2544554545997926e-09
in O 0 1.8997282913435498e-10
the O 0 4.252311280872334e-10
course O 0 2.211270633267759e-08
of O 0 5.542657444124188e-09
the O 0 3.1981929993207814e-08
disease O 0 2.560769416959374e-06
, O 0 1.9974832898839168e-09
and O 0 2.8105631710850787e-10
most O 0 3.63224478272528e-10
of O 0 3.938512183054854e-09
the O 0 8.821095853761562e-09
patients O 0 4.7872918962355016e-09
are O 0 2.6802131625203174e-09
diagnosed O 0 4.913560769637115e-05
after O 0 2.8251529116118945e-08
the O 0 1.291743245701582e-08
age O 0 3.57864422539933e-08
of O 0 3.6978597961478954e-08
5 O 0 2.47680873144418e-07
years O 0 2.3276254523807438e-07
. O 0 5.031555474488414e-07

However O 0 2.2678250388707966e-06
, O 0 8.934447492947584e-08
since O 0 5.4069786870059033e-08
these O 0 3.2500304669724756e-09
patients O 0 1.5195219305041974e-08
excrete O 0 8.961891495573582e-08
early O 0 1.5975805567336465e-08
large O 0 2.696714407335321e-09
amounts O 0 4.418098331626652e-09
of O 0 2.6488677917768655e-08
aspartylglucosamine O 0 2.3636366677237675e-05
in O 0 2.10523367627502e-08
urine O 0 1.9289474906258874e-08
, O 0 1.576505814782081e-09
biochemical O 0 7.547907898697304e-08
screening O 0 2.8838648802320677e-08
is O 0 2.010114741324287e-09
easy O 0 1.520142234312516e-08
by O 0 1.016929918051801e-08
urine O 0 1.9996844002889702e-07
chromatography O 0 9.229435818269849e-06
. O 0 2.5634764710957825e-07
. O 0 1.7418733477825299e-06

Detection O 0 1.627972596907057e-05
of O 0 6.848174507467775e-07
heterozygous O 0 1.8992091099789832e-07
carriers O 0 5.086773668949718e-08
of O 0 9.000708445228156e-08
the O 0 3.4214078823424643e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 4.860321132582612e-05
ATM O 1 0.9130122065544128
) O 0 1.2258120740682443e-08
gene O 0 4.579066015253375e-09
by O 0 2.228425666217504e-09
G2 O 0 5.813477037008852e-05
phase O 0 3.625941462814808e-05
chromosomal O 0 0.09561483561992645
radiosensitivity O 0 0.001061206334270537
of O 0 2.198781430706731e-06
peripheral O 1 0.9992142915725708
blood O 0 2.8678028684225865e-05
lymphocytes O 0 2.6746902221930213e-05
. O 0 4.547839580482105e-06

In O 0 5.0205064326291904e-05
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.7926164865493774
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.910860316291291e-08
patients O 0 1.2631926615824796e-08
, O 0 4.86001738853048e-10
mutations O 0 5.479776632455469e-09
in O 0 3.7004596609158114e-10
a O 0 1.130587179432041e-09
single O 0 1.8885657482314855e-09
gene O 0 1.705389607309371e-09
, O 0 6.010484332463761e-10
ATM O 0 1.014008103084052e-05
, O 0 6.99472757492714e-10
result O 0 1.9892443248181735e-09
in O 0 1.9608372703316945e-09
an O 0 1.8239641974560072e-07
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 0.009033934213221073
embraces O 0 6.691338057862595e-06
a O 0 1.3039868740349903e-08
variety O 0 2.056668835237474e-09
of O 0 7.971992843636144e-09
clinical O 0 7.930215417673026e-08
features O 0 1.547423522652025e-09
and O 0 2.3687107830738796e-09
manifests O 0 4.930702957040012e-08
extreme O 0 3.699966555359424e-06
radiosensitivity O 0 0.00038590061012655497
and O 0 5.02350205877633e-09
a O 0 1.942375149610598e-08
strong O 0 4.9487649533830336e-08
pre O 0 4.096807606401853e-05
- O 0 1.1534380064404104e-05
disposition O 0 3.775608274736442e-05
to O 0 1.907109322019096e-06
malignancy B-Disease 1 0.9997163414955139
. O 0 7.400389222311787e-06

Heterozygotes O 0 3.324562931084074e-05
for O 0 2.6074326697766992e-08
the O 0 7.860747786025968e-08
ATM O 0 0.00010366670903749764
gene O 0 4.55156943246493e-08
have O 0 9.623485341947458e-10
no O 0 1.4948677851123193e-09
clinical O 0 3.217042632286393e-08
expression O 0 1.1584235792838626e-08
of O 0 1.9296231812404585e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 1.5125904084811737e-08
may O 0 1.4449573981778485e-08
be O 0 1.7456395440262895e-08
cancer B-Disease 0 9.288420415032306e-07
prone O 0 3.4733673714981705e-08
with O 0 7.965389459130279e-11
a O 0 5.828242777283776e-09
moderate O 0 2.9454927243932616e-06
increase O 0 1.3649513519453649e-08
in O 0 9.423756885951207e-09
in O 0 4.00456769966695e-08
vitro O 0 3.902958724211203e-06
radiosensitivity O 0 0.00010569067671895027
. O 0 2.534935674702865e-06

We O 0 9.480872904532589e-07
performed O 0 1.7515519346034125e-07
a O 0 2.8206926572238444e-07
blind O 0 3.4923114071716554e-06
chromosomal O 0 7.786368769302499e-06
analysis O 0 2.0144015877576749e-07
on O 0 3.712963803081948e-07
G2 O 0 9.408361074747518e-05
- O 0 5.693190132660675e-07
phase O 0 1.3198055057728197e-06
lymphocytes O 0 2.1149007878307202e-08
from O 0 5.307474904014953e-09
7 O 0 2.9085017061447616e-08
unrelated O 0 1.4500395195682358e-07
A B-Disease 1 0.999998927116394
- I-Disease 1 0.9999992847442627
T I-Disease 1 0.9999998807907104
patients O 0 3.158281458581769e-08
, O 0 3.1521592003258547e-09
13 O 0 1.2818740735554002e-08
obligate O 0 9.936137246313592e-08
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999936819076538
T I-Disease 1 0.9999961853027344
heterozygotes O 0 3.5036268855037633e-06
( O 0 4.18462331452929e-09
parents O 0 7.505979726651901e-10
of O 0 1.3497897244363344e-09
the O 0 4.00676603007355e-09
patients O 0 2.5388235957990446e-09
) O 0 1.4755540123090327e-09
, O 0 2.124080467069689e-09
and O 0 2.8838411658682617e-09
14 O 0 2.8085084480267142e-08
normal O 0 5.461495256042781e-09
controls O 0 5.040162953662275e-09
following O 0 3.3127287579759468e-09
X O 0 8.656159593556367e-07
- O 0 1.6680161252224934e-07
irradiation O 0 2.0768477781984984e-07
with O 0 5.7169424749758946e-09
1 O 0 4.521425125858514e-06
Gy O 0 4.065779648954049e-06
in O 0 3.965329176125465e-10
order O 0 2.461307269108204e-10
to O 0 3.1560740132441367e-10
evaluate O 0 2.81354695097491e-09
this O 0 1.015803108295188e-09
cytogenetic O 0 8.426483191215084e-07
method O 0 3.8060701257336405e-08
as O 0 1.6490501186794404e-09
a O 0 4.339657966312416e-09
tool O 0 5.1900507003210805e-08
for O 0 2.220822192811056e-09
detection O 0 5.154176960786572e-07
of O 0 5.507703804141784e-07
ATM O 0 0.006707369815558195
carriers O 0 9.803825378185138e-06
. O 0 9.4344013632508e-06

Both O 0 1.3861621482647024e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
homozygotes O 0 0.04033280164003372
and O 0 6.467652724495565e-08
heterozygotes O 0 2.1297219063853845e-06
showed O 0 6.1292206865459775e-09
significantly O 0 2.0806938394457575e-09
increased O 0 1.8008520230594627e-09
levels O 0 3.769418110977085e-09
of O 0 7.1013324109969744e-09
radiation O 0 0.31165724992752075
- O 0 0.03707444667816162
induced O 1 0.9782668352127075
chromatid O 1 0.9866411089897156
damage O 0 9.353614132123766e-07
relative O 0 7.375282962129859e-08
to O 0 8.037457366327772e-10
that O 0 4.074078574500817e-10
of O 0 1.217783740514733e-08
normal O 0 6.513408123964837e-08
controls O 0 8.169611191988224e-07
. O 0 1.2978105132788187e-06

These O 0 3.211604493458253e-08
results O 0 3.9109959715233344e-08
show O 0 1.599510568439655e-08
that O 0 3.4216363076211564e-09
the O 0 1.0260738747547293e-07
G2 O 0 0.009376998990774155
- O 0 2.4146942450897768e-05
phase O 0 3.003040728799533e-05
chromosomal O 0 5.2180512284394354e-05
radiosensitivity O 0 3.127740455965977e-06
assay O 0 1.1135144006857445e-07
can O 0 1.503909913269652e-10
be O 0 6.532459295716109e-11
used O 0 4.6010886073366564e-11
for O 0 4.808453635263277e-11
the O 0 2.385840136565065e-10
detection O 0 7.257243339608976e-08
of O 0 2.5286962568316085e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.0003543322964105755
. O 0 4.767575774167199e-06

In O 0 3.318431822663115e-07
combination O 0 1.5179524837094505e-07
with O 0 4.797117370003434e-09
molecular O 0 5.483403583639301e-06
genetic O 0 4.050884570006019e-07
analyses O 0 6.852604883533786e-08
, O 0 5.867791808000788e-10
this O 0 3.0756747149141006e-10
test O 0 1.8329447959430922e-09
may O 0 4.935948871853668e-10
be O 0 1.0124176497150472e-10
of O 0 2.9345550989212654e-10
value O 0 8.378462368341388e-10
in O 0 1.598914056710754e-10
studies O 0 6.236197114262154e-10
of O 0 1.6458984175571345e-09
familial B-Disease 0 1.4148429272609064e-06
and I-Disease 0 4.007333842537264e-08
sporadic I-Disease 0 1.6092246369225904e-05
cancers I-Disease 1 0.8154463768005371
aimed O 0 9.18092837309814e-08
at O 0 2.9816234814461495e-08
determination O 0 8.170450982447619e-09
of O 0 3.3551550426835774e-09
the O 0 1.9102663895154137e-09
potential O 0 1.070829469540513e-08
involvement O 0 2.6899245497702395e-08
of O 0 1.44577620986297e-08
ATM O 0 0.0001725129986880347
mutations O 0 6.200460802574526e-07
in O 0 2.7670980173866155e-08
tumor B-Disease 1 0.9933153986930847
risk O 0 3.0277512905740878e-06
or O 0 1.0188328758431453e-07
development O 0 3.2537852234781894e-07
. O 0 1.335156269988147e-07
. O 0 4.815078682440799e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
: O 0 3.9237585269802366e-07
identification O 0 5.730657903768588e-08
and O 0 2.376757457511758e-09
detection O 0 6.641391792072682e-07
of O 0 3.491860809390346e-07
founder O 0 3.622732720032218e-06
- O 0 7.43523287383141e-07
effect O 0 1.6034989869240235e-07
mutations O 0 4.869839287380273e-08
in O 0 1.4048314733727807e-09
the O 0 6.2870419981209125e-09
ATM O 0 1.8802495105774142e-05
gene O 0 4.149075394366264e-08
in O 0 7.002046498172376e-09
ethnic O 0 1.2475040023218753e-07
populations O 0 1.4547113380558585e-07
. O 0 2.529501728076866e-07

To O 0 8.343290858192631e-08
facilitate O 0 4.2870325955846056e-08
the O 0 1.3080921235086862e-08
evaluation O 0 1.2435427265700127e-07
of O 0 1.2551498684842954e-07
ATM O 1 0.9923977255821228
heterozygotes O 0 2.5230565370293334e-05
for O 0 2.271434063061406e-08
susceptibility O 0 8.13483347883448e-05
to O 0 2.7345055997329837e-08
other O 0 3.25851701177271e-08
diseases O 0 0.000126732571516186
, O 0 1.806817806482286e-09
such O 0 1.4848876572770564e-09
as O 0 5.721460638596909e-07
breast B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999959468841553
, O 0 5.440340800078047e-08
we O 0 7.112108679763196e-09
have O 0 4.0047162808143355e-10
attempted O 0 7.361618870049824e-09
to O 0 3.2148739226300904e-10
define O 0 6.348860104310461e-09
the O 0 8.442548327103339e-10
most O 0 3.25048737925826e-10
common O 0 4.999328950816562e-09
mutations O 0 5.005005299096865e-09
and O 0 1.9543355822548847e-10
their O 0 6.219895432035827e-11
frequencies O 0 4.865698244316263e-08
in O 0 7.320428352386443e-08
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 7.946896948851645e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 0.9999808073043823
) O 0 4.364080297136752e-08
homozygotes O 0 7.85945530878962e-07
from O 0 1.3839679624538803e-08
10 O 0 2.2996998083613107e-08
ethnic O 0 5.10029742883944e-08
populations O 0 5.951103432266791e-08
. O 0 2.3090382228474482e-07

Both O 0 3.182839805049298e-07
genomic O 0 6.074481007090071e-06
mutations O 0 7.525165983679472e-07
and O 0 4.528049490915009e-09
their O 0 1.6557665238892127e-09
effects O 0 3.3540186450409237e-07
on O 0 2.6518611662140756e-07
cDNA O 0 3.4687971037783427e-06
were O 0 3.6656203405982524e-08
characterized O 0 6.868843342999753e-07
. O 0 3.1802896955923643e-06

Protein O 0 3.984244813182158e-06
- O 0 1.6555011370655848e-06
truncation O 0 3.3941773835977074e-06
testing O 0 4.8815195441420656e-08
of O 0 2.0548192480873695e-08
the O 0 1.9454452271361333e-08
entire O 0 2.4361733608202485e-07
ATM O 0 4.356330919108586e-06
cDNA O 0 8.542357932128652e-07
detected O 0 8.94611034141235e-08
92 O 0 1.0200189848319496e-07
( O 0 4.879953330316766e-09
66 O 0 2.273911974270959e-07
% O 0 2.8398316587185946e-08
) O 0 1.8874817264702415e-09
truncating O 0 2.9726726324952324e-07
mutations O 0 1.1757703077819315e-07
in O 0 2.259637277290949e-08
140 O 0 3.7055494317428384e-07
mutant O 0 1.8869268387788907e-06
alleles O 0 9.933482942869887e-07
screened O 0 4.4440148485591635e-06
. O 0 1.7785982890927698e-06

The O 0 2.171308778997627e-06
haplotyping O 0 0.06604845076799393
of O 0 1.3651566632688628e-06
patients O 0 3.3804333554599e-08
with O 0 7.430668302887966e-10
identical O 0 1.5426245170147013e-07
mutations O 0 3.2805978662509006e-06
indicates O 0 2.4109550622597453e-07
that O 0 7.632707799132277e-10
almost O 0 2.1139880956866364e-09
all O 0 1.1087740448001426e-10
of O 0 1.8273271784607914e-10
these O 0 1.055966945828768e-11
represent O 0 3.809043636060494e-10
common O 0 8.706661169810559e-09
ancestry O 0 3.9123612793900975e-08
and O 0 1.3664693820913953e-09
that O 0 1.0837779562677952e-09
very O 0 1.606331423431584e-08
few O 0 6.187671885982127e-08
spontaneously O 0 4.4078825567339663e-07
recurring O 0 1.0588202030703542e-06
ATM O 0 0.0003104094648733735
mutations O 0 1.7594803694009897e-06
exist O 0 3.9644868365940056e-07
. O 0 9.978477919503348e-07

Assays O 0 2.1841746274731122e-05
requiring O 0 3.357814364335354e-07
minimal O 0 1.5662404848626466e-06
amounts O 0 1.5913923334665014e-07
of O 0 3.590123398566902e-08
genomic O 0 1.9438581944086764e-07
DNA O 0 6.091300264188249e-08
were O 0 4.293484179296314e-10
designed O 0 7.497966691971669e-10
to O 0 3.1548341716813866e-10
allow O 0 1.0633856017960852e-09
rapid O 0 2.7574984073908126e-08
screening O 0 2.1849210440905154e-08
for O 0 3.210427035327257e-09
common O 0 1.1862425708386581e-07
ethnic O 0 1.948707904375624e-06
mutations O 0 4.671574515668908e-06
. O 0 9.098487794290122e-07

These O 0 7.869598306342596e-08
rapid O 0 1.270101734007767e-06
assays O 0 1.814529241528362e-06
detected O 0 2.6849633627534786e-07
mutations O 0 3.821571326056983e-08
in O 0 2.8521143224935486e-09
76 O 0 8.979720433899274e-08
% O 0 1.500828084033401e-08
of O 0 9.067130157802694e-09
Costa O 0 1.7271828482989804e-06
Rican O 0 8.073084245552309e-06
patients O 0 8.381071836538467e-09
( O 0 1.9660351124883846e-09
3 O 0 3.329637365823146e-08
) O 0 2.8259261597440855e-10
, O 0 1.0556955309937166e-10
50 O 0 1.2820862149709455e-09
% O 0 1.7191127410498552e-09
of O 0 1.8509923593867939e-09
Norwegian O 0 1.0500544931346667e-06
patients O 0 6.97703628205204e-09
( O 0 3.8717753447770065e-09
1 O 0 3.413445313071861e-07
) O 0 5.165780025961908e-10
, O 0 1.735495636090434e-10
25 O 0 1.3682793786884417e-09
% O 0 8.873555779054243e-10
of O 0 1.444295349983804e-09
Polish O 0 3.3099752272391925e-06
patients O 0 1.8673441459782225e-08
( O 0 1.2003910754287972e-08
4 O 0 2.710474689138209e-07
) O 0 1.516590852901345e-09
, O 0 4.128594133234742e-10
and O 0 2.586349467925686e-10
14 O 0 4.754342253221466e-09
% O 0 3.6229403921339554e-09
of O 0 2.287667832945317e-09
Italian O 0 1.4811738537900965e-06
patients O 0 1.9586215316280686e-08
( O 0 1.9615487900637163e-08
1 O 0 5.0586709221533965e-06
) O 0 2.4151807220818e-09
, O 0 5.550017112554428e-10
as O 0 4.761264160713097e-10
well O 0 4.537098474699519e-10
as O 0 7.282069391933987e-10
in O 0 1.0531479022191093e-09
patients O 0 2.408459875979929e-09
of O 0 6.210255776295526e-08
Amish O 0 8.798532689979766e-06
/ O 0 0.0001476833422202617
Mennonite O 0 2.5756709874258377e-05
and O 0 6.3672835892703e-08
Irish O 0 1.7589989056432387e-06
English O 0 1.685382699179172e-06
backgrounds O 0 1.9205829175916733e-06
. O 0 2.529507128201658e-06

Additional O 0 1.0550025564270982e-07
mutations O 0 1.7913980343564617e-07
were O 0 1.6890428611304742e-08
observed O 0 2.6656945095737683e-08
in O 0 2.967013967847265e-09
Japanese O 0 6.141370079149056e-08
, O 0 2.0744173045983416e-09
Utah O 0 1.0978579467746385e-07
Mormon O 0 7.956608527592834e-08
, O 0 7.558734749224527e-10
and O 0 1.12739151347796e-09
African O 0 2.6587432699898272e-08
American O 0 1.581604607281406e-07
patients O 0 1.6894270515876997e-07
. O 0 1.9402925772737944e-06

These O 0 3.7260381446913016e-08
assays O 0 3.7160705801397853e-07
should O 0 3.827602235162431e-09
facilitate O 0 4.416295329434661e-09
screening O 0 2.4052429381526963e-08
for O 0 2.047815605976666e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 6.038831543264678e-06
in O 0 3.762637312831885e-09
the O 0 4.125825014966722e-09
populations O 0 6.693963605641784e-09
studied O 0 1.0163640951077468e-07
. O 0 5.570831262957654e-08
. O 0 1.0921182820311515e-06

The O 0 7.2808097684173845e-06
von B-Disease 1 0.9991868138313293
Hippel I-Disease 1 0.9999988079071045
- I-Disease 1 0.9999973773956299
Lindau I-Disease 1 0.999998927116394
tumor I-Disease 0 0.23964416980743408
suppressor O 0 2.605370173114352e-05
gene O 0 2.27757706028342e-08
is O 0 4.487525628871225e-10
required O 0 7.029247184320297e-10
for O 0 2.845099933423967e-09
cell O 0 9.60878196565318e-07
cycle O 0 2.858733978428063e-07
exit O 0 2.693631984129752e-07
upon O 0 5.714263906497763e-08
serum O 0 7.583404908473312e-07
withdrawal O 0 5.084134045318933e-06
. O 0 4.062830157636199e-06

The O 0 1.3242332670415635e-06
inactivation O 0 6.058590588509105e-05
of O 0 3.0139636919557233e-07
the O 0 5.171049792807025e-07
von B-Disease 1 0.9999979734420776
Hippel I-Disease 1 1.0
- I-Disease 1 1.0
Lindau I-Disease 1 1.0
( I-Disease 0 0.00023767606762703508
VHL I-Disease 1 0.9999990463256836
) I-Disease 0 6.237594334379537e-07
tumor I-Disease 0 0.023230591788887978
suppressor O 0 0.0020234729163348675
gene O 0 8.645607181279047e-07
predisposes O 0 2.9520338102884125e-06
affected O 0 8.564421172252423e-09
individuals O 0 2.1053639387424994e-10
to O 0 2.111948838035005e-09
the O 0 1.4978017759403883e-07
human O 0 0.0745597630739212
VHL B-Disease 1 1.0
cancer I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 2.052283605280536e-07
is O 0 3.440688800537828e-08
associated O 0 2.5409081061411598e-08
with O 0 7.683484959386533e-09
sporadic B-Disease 1 0.9501359462738037
renal I-Disease 1 1.0
cell I-Disease 1 1.0
carcinomas I-Disease 1 1.0
( O 1 0.501951277256012
RCC B-Disease 1 1.0
) O 0 6.310351068350428e-07
and O 0 2.770956939457392e-07
brain B-Disease 0 0.17812380194664001
hemangioblastomas I-Disease 0 0.4015028774738312
. O 0 7.704304152866825e-06

VHL O 1 0.9979143738746643
- O 0 0.011755424551665783
negative O 0 8.30618737381883e-05
786 O 0 0.0006053809192962945
- O 0 0.00027444472652859986
0 O 0 1.4016589375387412e-05
RCC B-Disease 0 0.005212321877479553
cells O 0 1.4011399684932258e-07
are O 0 4.455332103248111e-09
tumorigenic O 0 0.0003048067446798086
in O 0 2.4678445242898306e-07
nude O 0 4.7364372335323424e-07
mice O 0 1.8531798318122128e-08
which O 0 4.1162256936289054e-10
is O 0 9.432149505883558e-10
suppressed O 0 9.402247869161329e-09
by O 0 5.796676472158424e-10
the O 0 1.862701992649818e-08
reintroduction O 0 4.003829872090137e-06
of O 0 1.5226804634949076e-06
VHL B-Disease 1 0.9877391457557678
. O 0 3.0384182537090965e-05

Remarkably O 0 5.990391946397722e-05
, O 0 4.865104585860536e-08
this O 0 4.896568039924887e-09
occurs O 0 1.975508645557511e-08
without O 0 4.777923390264505e-09
affecting O 0 4.265766406774674e-09
the O 0 6.230101323723147e-09
growth O 0 1.7762197046522488e-08
rate O 0 2.2451466463735414e-08
and O 0 1.214929601367487e-09
cell O 0 2.916630137406173e-07
cycle O 0 5.4263605164805995e-08
profile O 0 2.8912987559692738e-09
of O 0 1.0469353162179118e-09
these O 0 3.5736616443848845e-10
cells O 0 1.2608240673728233e-08
in O 0 7.50921991254927e-09
culture O 0 2.2635049390373752e-07
. O 0 1.4620816273236414e-06

The O 0 3.7233212424325757e-06
786 O 0 7.264552550623193e-05
- O 0 8.13907081465004e-06
0 O 0 1.491922603236162e-06
cell O 0 4.4914520458405605e-07
line O 0 1.5929289531868562e-07
, O 0 2.5582089779874195e-09
like O 0 3.681839944036369e-09
many O 0 3.0046634069691436e-09
cancer B-Disease 0 3.850468601740431e-06
cells O 0 3.263810555154123e-08
, O 0 2.7657245382783913e-09
fails O 0 7.38091188168255e-08
to O 0 3.187071939692032e-09
exit O 0 3.364455949395051e-07
the O 0 3.1419983059777223e-08
cell O 0 3.55365529003393e-07
cycle O 0 7.969929072260129e-08
upon O 0 2.1776692449293478e-08
serum O 0 4.850992922911246e-07
withdrawal O 0 4.1464600144536234e-06
. O 0 2.7642395252769347e-06

Here O 0 7.739761826996983e-07
, O 0 4.461106151154581e-09
it O 0 5.890511411976718e-10
is O 0 6.019639786636333e-10
shown O 0 2.5452809304660207e-10
that O 0 1.6638861122242332e-10
reintroduction O 0 1.643760469960398e-07
of O 0 7.060316331575223e-09
the O 0 1.3631900053212576e-08
wild O 0 1.634897586200168e-07
- O 0 3.480806753941579e-06
type O 0 9.036583651322871e-05
VHL B-Disease 1 0.8823555707931519
gene O 0 1.9694465436259634e-07
restores O 0 4.759697702638732e-08
the O 0 3.710872720219527e-09
ability O 0 4.615472892766093e-09
of O 0 4.7660844870733854e-07
VHL O 1 0.999993085861206
- O 1 0.9547227025032043
negative O 0 0.01693751849234104
RCC B-Disease 1 0.9999996423721313
cancer I-Disease 0 7.578816439490765e-05
cells O 0 9.41518685237952e-09
to O 0 1.684772321652872e-09
exit O 0 6.880370051476348e-08
the O 0 6.642377758936391e-09
cell O 0 1.2402158233726368e-07
cycle O 0 2.9396895584454796e-08
and O 0 1.370397573197124e-09
enter O 0 3.034683970781771e-07
G0 O 0 0.002228281693533063
/ O 0 2.9158311008359306e-05
quiescence O 0 4.4697822886519134e-05
in O 0 1.4401869918856391e-07
low O 0 2.751861302385805e-06
serum O 0 6.003963790135458e-06
. O 0 1.08325048131519e-06

Both O 0 1.0345676855649799e-05
VHL O 1 0.9987277388572693
- O 0 0.0070633236318826675
positive O 0 4.2531758026598254e-07
and O 0 2.181810714318999e-07
VHL O 1 0.9995248317718506
- O 0 0.0007595439674332738
negative O 0 1.123909623856889e-05
RCC B-Disease 0 0.029579119756817818
cells O 0 9.780656284874567e-08
exit O 0 1.79588994342339e-07
the O 0 9.281531099247786e-09
cell O 0 8.633045922579186e-08
cycle O 0 2.5838524209120806e-08
by O 0 1.4784612423213161e-09
contact O 0 1.024437139562906e-07
inhibition O 0 1.0064953130495269e-05
. O 0 2.5053311674128054e-06

The O 0 5.562513251788914e-06
cyclin O 0 5.949294791207649e-05
- O 0 4.748019364342326e-06
dependent O 0 3.5020860877921223e-07
kinase O 0 1.5329001143982168e-06
inhibitor O 0 2.354928483327967e-06
, O 0 2.598308057599752e-08
p27 O 0 4.8694305405661e-06
, O 0 5.3968576274598945e-09
accumulates O 0 1.4696086125809416e-08
upon O 0 7.425723924647798e-10
serum O 0 1.0995298005411769e-08
withdrawal O 0 1.0280054141276196e-07
, O 0 1.0946578088422143e-09
only O 0 9.9036989720247e-10
in O 0 2.759705519661537e-10
the O 0 5.529497970613306e-10
presence O 0 2.60048782507738e-09
of O 0 4.005484655067448e-08
VHL B-Disease 1 0.7088109254837036
, O 0 2.2690340717446134e-09
as O 0 9.892768826347265e-10
a O 0 2.4519979380244195e-09
result O 0 2.7888948928023183e-09
of O 0 2.7368940447303203e-09
the O 0 3.1808895517571045e-09
stabilization O 0 4.264572623924323e-07
of O 0 1.7699235854706785e-07
the O 0 3.402317076961481e-07
protein O 0 2.341934305150062e-06
. O 0 4.1195451672138006e-07

We O 0 5.5174194102391994e-08
propose O 0 5.565011207409043e-08
that O 0 2.5955870786020796e-09
the O 0 7.095039933346925e-08
loss O 0 2.012473032664275e-06
of O 0 6.151088882688782e-07
wild O 0 6.244177370717807e-07
- O 0 2.8613842459890293e-06
type O 0 7.227501191664487e-05
VHL B-Disease 1 0.772795557975769
gene O 0 2.4481765947825807e-08
results O 0 3.1927791521724203e-09
in O 0 3.211362564758957e-10
a O 0 1.2197660659296616e-09
specific O 0 4.231948125266172e-09
cellular O 0 8.144142498167639e-07
defect O 0 9.236217692887294e-07
in O 0 4.078395843265525e-09
serum O 0 1.2737208976432157e-07
- O 0 7.027576884865994e-07
dependent O 0 1.3812497456910933e-07
growth O 0 1.7758980064286334e-08
control O 0 2.852442193557181e-08
, O 0 1.2058520848512444e-09
which O 0 9.425279445807178e-10
may O 0 2.059127091058599e-08
initiate O 0 3.9705179233351373e-07
tumor B-Disease 0 7.394849671982229e-05
formation O 0 4.6920240492909215e-06
. O 0 5.426036295830272e-06

This O 0 1.5803608732767316e-07
is O 0 3.311832941221837e-08
corrected O 0 1.82795190539764e-07
by O 0 1.5020330534909476e-09
the O 0 1.5030769517920817e-08
reintroduction O 0 1.0514123687244137e-06
of O 0 6.068802349545876e-08
wild O 0 3.6205733522365335e-07
- O 0 9.560169019096065e-06
type O 0 0.1832476556301117
VHL B-Disease 1 0.9999998807907104
, O 0 1.2369797559586004e-06
implicating O 0 0.005034718196839094
VHL B-Disease 1 0.9984452128410339
as O 0 3.044789309569751e-08
the O 0 9.173817261398653e-09
first O 0 1.395019388894525e-08
tumor B-Disease 0 4.494589575188002e-06
suppressor O 0 2.5864933377306443e-06
involved O 0 1.391293302788199e-09
in O 0 2.2758203654937859e-10
the O 0 5.808939995688434e-10
regulation O 0 7.335520635365356e-09
of O 0 1.0752830625904153e-08
cell O 0 2.714085667321342e-07
cycle O 0 7.534631407679626e-08
exit O 0 1.9076355783909094e-07
, O 0 4.629030214697849e-10
which O 0 1.6288335957792555e-10
is O 0 2.566300782991249e-10
consistent O 0 1.1306949820877321e-09
with O 0 3.904431292167665e-11
its O 0 1.0457598120794387e-09
gatekeeper O 0 6.633972589042969e-07
function O 0 1.072843147653657e-08
in O 0 3.194648989790494e-09
the O 0 6.87512269337276e-08
kidney O 0 0.0010542585514485836
. O 0 6.516663688671542e-07
. O 0 5.759158739238046e-06

Piebaldism B-Disease 1 1.0
with O 0 0.01225410494953394
deafness B-Disease 1 1.0
: O 0 8.056794058575178e-07
molecular O 0 1.4538489949700306e-06
evidence O 0 1.4207982346192694e-08
for O 0 1.4535866954545895e-09
an O 0 2.6746173276137597e-08
expanded O 0 1.0928414667432662e-05
syndrome O 1 0.9999997615814209
. O 0 5.90436247875914e-05

In O 0 8.911913340625688e-08
a O 0 6.93588049216487e-08
South O 0 1.7715041167321033e-07
African O 0 6.803688279433118e-08
girl O 0 3.379769353273332e-08
of O 0 1.555580020351499e-08
Xhosa O 0 2.720005977607798e-05
stock O 0 2.169165469467771e-07
with O 0 2.496042261768139e-09
severe O 1 0.9675834774971008
piebaldism B-Disease 1 1.0
and O 0 0.0008407835266552866
profound O 1 1.0
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 0.4127348065376282
identified O 0 9.751222478371346e-07
a O 0 2.7703773497478323e-08
novel O 0 3.245212809588338e-08
missense O 0 3.3245899544454005e-07
substitution O 0 1.316834215003837e-07
at O 0 4.421691812694917e-08
a O 0 8.803951345726091e-09
highly O 0 1.1379347242268523e-08
conserved O 0 1.2847654318193236e-07
residue O 0 3.887858781581599e-07
in O 0 2.1940280703347526e-09
the O 0 2.4537476495112287e-09
intracellular O 0 3.1530927202538805e-08
kinase O 0 1.1573959568522696e-07
domain O 0 5.248426049320187e-08
of O 0 1.2110803915277302e-08
the O 0 5.57818893298645e-08
KIT O 0 2.2733534933649935e-05
proto O 0 0.004027153365314007
- O 0 0.00022274382354225963
oncogene O 0 0.00043028051732107997
, O 0 5.769250037701568e-07
R796G O 0 0.00017132976790890098
. O 0 2.6122670533368364e-06

Though O 0 1.2211993634991813e-05
auditory B-Disease 1 0.9996598958969116
anomalies I-Disease 1 0.8057654500007629
have O 0 3.198961451289506e-08
been O 0 2.4899382111698287e-08
observed O 0 2.8587495037868393e-08
in O 0 4.0051615357583614e-09
mice O 0 1.0258464300250125e-08
with O 0 6.492217319298277e-10
dominant O 0 0.00011118475231342018
white O 0 4.067095744630933e-07
spotting O 0 2.6615331080392934e-05
( O 0 6.117036264186027e-07
W O 0 0.2782565653324127
) O 0 1.0311430820308942e-08
due O 0 2.204271964956206e-08
to O 0 4.756319338383719e-09
KIT O 0 1.2494317161326762e-05
mutations O 0 1.6599513401160948e-05
, O 0 1.5995272406144068e-05
deafness B-Disease 1 1.0
is O 0 5.021042852604296e-07
not O 0 1.3428315348562592e-08
typical O 0 2.5089698851843423e-07
in O 0 4.49848194250535e-08
human O 0 2.5284671778535994e-07
piebaldism B-Disease 0 0.00012352102203294635
. O 0 2.795761929519358e-06

Thus O 0 1.2595893394973245e-06
, O 0 1.4572545836699646e-08
the O 0 1.1593365378814724e-08
occurrence O 0 1.0893762691921438e-06
of O 0 0.06763999909162521
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
in O 1 0.5154942870140076
this O 0 3.0023390991118504e-06
patient O 0 2.7760854663938517e-06
extends O 0 1.3866225856418168e-07
considerably O 0 5.6681077609255226e-08
the O 0 3.3980216418427744e-09
phenotypic O 0 1.5069197445427562e-07
range O 0 7.913670430070852e-08
of O 0 7.727343387387009e-08
piebaldism B-Disease 0 5.068472455604933e-05
due O 0 2.903112772401073e-07
to O 0 1.6702376370858474e-08
KIT O 0 7.943868922666297e-07
gene O 0 5.626262122859771e-08
mutation O 0 1.7120333950515487e-07
in O 0 5.782081924365912e-09
humans O 0 1.7369975680026073e-08
and O 0 3.129950076896648e-09
tightens O 0 3.107651025402447e-07
the O 0 5.437225780724475e-09
clinical O 0 1.1640964459047609e-07
similarity O 0 6.294735754863723e-08
between O 0 1.0239369885312044e-07
piebaldism B-Disease 0 0.00014331439160741866
and O 0 8.053478439684625e-10
the O 0 9.315082039051958e-10
various O 0 3.0719579657834117e-10
forms O 0 2.9059899375738496e-08
of O 0 1.6514910385012627e-05
Waardenburg B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 9.966456673282664e-06
. O 0 1.108505512092961e-05

Cycloheximide O 0 0.0006945542991161346
facilitates O 0 9.262060416403983e-07
the O 0 6.534711616268396e-08
identification O 0 1.031576246646182e-07
of O 0 1.561896993962364e-07
aberrant O 0 2.8088275030313525e-06
transcripts O 0 1.0327836434953497e-06
resulting O 0 8.61606892499367e-08
from O 0 7.31329397041236e-09
a O 0 1.4166499973100599e-08
novel O 0 3.540225534948149e-08
splice O 0 3.5868382042281155e-07
- O 0 2.0126785571505934e-08
site O 0 4.30309521348704e-09
mutation O 0 7.296866666450796e-09
in O 0 2.5467681297186573e-09
COL17A1 O 0 0.004115805961191654
in O 0 1.0307300790657337e-08
a O 0 1.0181219067817437e-07
patient O 0 5.248455750006542e-07
with O 0 1.0172677633590865e-07
generalized O 1 0.9999974966049194
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999978542327881
. O 0 0.00025370874209329486

Patients O 0 1.7090844266931526e-05
with O 0 2.638737726101681e-07
generalized O 1 0.9999995231628418
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999997615814209
often O 0 3.6066916209165356e-07
show O 0 2.7944393465872963e-08
decreased O 0 8.26140578169543e-08
expression O 0 2.6218300419600382e-08
of O 0 2.810105392825335e-08
type O 0 1.137893195846118e-05
XVII O 1 0.9999678134918213
collagen O 0 0.00013824761845171452
, O 0 1.0154223417657704e-07
a O 0 5.277401555758843e-07
transmembrane O 0 3.062803443754092e-05
hemidesmosomal O 0 1.1182878552062903e-05
protein O 0 4.529044872469967e-08
encoded O 0 2.3209839383753206e-08
by O 0 1.604781907360575e-08
COL17A1 O 0 0.03828930854797363
. O 0 1.0352861863793805e-05

This O 0 2.6800668706528086e-07
report O 0 3.5543322951525624e-08
documents O 0 1.9927579586465072e-08
a O 0 4.524908803205108e-08
novel O 0 1.7289828235789173e-07
splice O 0 2.9673860808543395e-06
- O 0 1.3111649366237543e-07
site O 0 2.0256416988218007e-08
mutation O 0 2.4925896013883175e-08
in O 0 6.02584604436629e-09
COL17A1 O 1 0.9594789147377014
in O 0 3.005972004643809e-08
a O 0 1.1456106818741318e-07
patient O 0 3.365495615526015e-07
with O 0 4.123003094491651e-08
generalized O 1 0.9999995231628418
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 1.0
, O 0 2.9675004498130875e-07
and O 0 8.001791229617083e-09
applies O 0 2.3921991498809803e-08
a O 0 4.014155230436245e-09
new O 0 5.634128164011543e-10
methodology O 0 1.1409426292630087e-08
to O 0 1.4590754160437314e-09
define O 0 6.722293477423591e-08
and O 0 6.1755960345522e-09
characterize O 0 8.118505547827226e-07
the O 0 9.92123432297376e-08
resulting O 0 4.1668414496598416e-07
mRNA O 0 6.393804596882546e-06
splice O 0 1.5875702956691384e-05
variants O 0 2.8886599920951994e-06
. O 0 1.0890314570133341e-06

Mutational O 0 6.998886965448037e-05
analysis O 0 2.5218375299118634e-07
of O 0 6.29148303232796e-07
COL17A1 O 1 0.9990218877792358
identified O 0 2.885670369323634e-07
a O 0 6.20881053237099e-08
maternally O 0 1.2176186601209338e-06
inherited O 0 2.107774434989551e-06
G O 0 6.773429049644619e-06
- O 0 1.5762773273308994e-06
to O 0 1.2024311502045748e-07
- O 0 1.8231245121569373e-05
T O 0 1.2292617839193554e-06
transversion O 0 2.2600008833251195e-06
at O 0 1.6737935482069588e-08
the O 0 4.862114710846299e-09
- O 0 4.604001446750772e-08
1 O 0 1.7766662097074004e-07
position O 0 1.1283240297643715e-07
of O 0 6.723986700762907e-08
exon O 0 4.531604190560756e-06
32 O 0 1.4297864936452243e-06
. O 0 7.900170544417051e-07

This O 0 2.430858785373857e-07
acceptor O 0 7.283936724888918e-07
splice O 0 4.462216566025745e-06
- O 0 4.6773334361205343e-07
site O 0 3.6403491776582086e-08
mutation O 0 1.9025369724090524e-08
led O 0 6.1664273687256355e-09
to O 0 7.81708087149724e-10
the O 0 5.900195443331313e-09
formation O 0 4.0926270372665385e-08
of O 0 6.921990802766231e-08
aberrant O 0 5.177642492526502e-07
transcripts O 0 1.5307846013001836e-07
present O 0 7.491281373006586e-09
at O 0 1.2323752685006184e-07
extremely O 0 7.585171601931506e-08
low O 0 2.024681862167199e-06
levels O 0 1.617506086404319e-06
. O 0 2.208806336057023e-06

Based O 0 6.572517463609984e-07
on O 0 1.1177788650229559e-07
our O 0 5.7074855952521375e-09
recent O 0 6.386133399871596e-09
finding O 0 1.8232279686003494e-08
that O 0 5.656289658872993e-09
cycloheximide O 0 0.00010074281453853473
stabilized O 0 7.361709867836908e-05
mutant O 0 4.206650828564307e-06
COL17A1 O 0 7.722787995589897e-05
transcripts O 0 1.7908446636738518e-07
in O 0 5.797144098096396e-09
keratinocytes O 0 3.4960493167091045e-07
homozygous O 0 3.380194968372052e-08
for O 0 1.4044804208523942e-09
a O 0 2.952895705732317e-08
frameshift O 0 3.389957782928832e-05
mutation O 0 8.155023465405975e-07
, O 0 3.0940989770300575e-09
the O 0 5.441862960253729e-09
effects O 0 8.952255825533939e-08
of O 0 2.07773638294384e-08
the O 0 1.659377879548174e-08
splice O 0 1.1421290082580526e-06
- O 0 6.324111012645517e-08
site O 0 3.516682278714711e-09
mutation O 0 1.9282695440381303e-09
on O 0 4.559439492624051e-09
splicing O 0 4.209320891845891e-08
of O 0 2.4706745094249527e-08
COL17A1 O 0 5.283596692606807e-05
transcripts O 0 3.6800443581341824e-08
were O 0 1.4400921566348757e-09
determined O 0 1.886232947612143e-09
using O 0 8.724543865135104e-10
reverse O 0 2.2300639557215618e-08
transcriptase O 0 3.038378793007723e-08
polymerase O 0 2.1493434587682714e-07
chain O 0 6.9566792326725135e-09
reaction O 0 2.481667982223712e-09
of O 0 2.5173085838048337e-09
total O 0 1.9408632478956633e-09
RNA O 0 6.912966199479342e-08
from O 0 2.098682649886996e-08
keratinocytes O 0 4.755487452712259e-07
incubated O 0 3.33630651994099e-07
for O 0 1.3757984973494786e-08
2 O 0 2.70354530584882e-06
. O 0 9.177459787679254e-07

5 O 0 2.043981567112496e-06
h O 0 5.362906563277647e-07
in O 0 3.8923153589109916e-09
the O 0 4.363079231239908e-09
presence O 0 8.193594247529745e-09
or O 0 4.467068848157396e-08
absence O 0 9.205895707964373e-07
of O 0 6.144838380350848e-07
10 O 0 5.257634256849997e-07
microg O 0 3.9208494854392484e-05
cycloheximide O 0 6.330165342660621e-05
per O 0 3.330557092340314e-06
ml O 0 2.532255348342005e-05
. O 0 1.67117184446397e-06

Using O 0 3.6242486345372527e-08
this O 0 4.71085215281164e-09
approach O 0 2.1468729016760335e-07
, O 0 9.797119560062129e-09
an O 0 6.482816949926473e-09
abnormally O 0 6.65958168610814e-07
spliced O 0 2.038993670794298e-06
transcript O 0 2.0356847016955726e-06
was O 0 1.9871562528805953e-07
identified O 0 5.180829987239122e-09
that O 0 1.1385240666905716e-10
contains O 0 4.573957046449806e-10
an O 0 6.564612742288034e-10
extra O 0 6.8829919541713025e-09
264 O 0 1.4764865774452574e-08
bases O 0 1.1898075413796505e-08
upstream O 0 3.961046957101644e-08
from O 0 1.185049214313949e-08
exon O 0 3.899101557180984e-07
32 O 0 3.69477213268965e-08
, O 0 9.97629201471284e-10
resulting O 0 8.584258637256426e-09
in O 0 4.252783902813917e-09
a O 0 1.6832481719575298e-07
premature O 0 4.022065695608035e-06
termination O 0 7.741143235762138e-06
codon O 0 1.7757542082108557e-05
27 O 0 1.0756306210168987e-06
bp O 0 2.088282371914829e-06
downstream O 0 4.904085244561429e-07
from O 0 3.34039391702845e-08
the O 0 1.3283765554206184e-07
cryptic O 0 1.1202882888028398e-05
splice O 0 5.967431206954643e-05
site O 0 4.137958967476152e-06
. O 0 1.387691895615717e-06

Three O 0 1.0146518292231121e-07
other O 0 4.70637928629003e-09
splice O 0 9.032831940203323e-07
variants O 0 8.583460697764167e-08
, O 0 1.0488080404158495e-09
including O 0 8.306837162574965e-11
one O 0 2.1089650859007492e-10
derived O 0 7.479484254169222e-10
from O 0 9.319275351415968e-10
the O 0 1.8724684025528404e-09
skipping O 0 3.079311383658023e-08
of O 0 6.846892386391801e-09
exon O 0 4.786198815054377e-07
32 O 0 8.830105713286684e-08
, O 0 2.099538320976535e-09
were O 0 1.1070739880381097e-08
also O 0 1.4360472810892588e-08
identified O 0 4.6921127250243444e-07
. O 0 1.259066834791156e-06

These O 0 3.5183813196226765e-08
results O 0 4.999140656991585e-08
indicate O 0 3.5146854315826204e-08
the O 0 2.1694566143537486e-08
usefulness O 0 1.43342776937061e-06
of O 0 3.9421524888894055e-07
cycloheximide O 0 0.0892496183514595
treatment O 0 5.693478328794299e-07
in O 0 9.612942442061012e-09
evaluating O 0 2.5325570973677713e-08
the O 0 1.1038732594670364e-08
abnormal O 0 7.26562205954906e-08
processing O 0 5.2067676392653084e-08
of O 0 2.9128822021107226e-08
mRNA O 0 3.685418334953283e-07
due O 0 1.615376810093494e-08
to O 0 3.0495301839295053e-09
splice O 0 1.1185405810465454e-06
- O 0 8.989385946733819e-08
site O 0 1.2966851592466355e-08
mutations O 0 1.8994512629433302e-08
, O 0 1.4876319065493249e-09
because O 0 4.2686312262674164e-09
( O 0 1.684615824615321e-08
i O 0 2.513108086077409e-07
) O 0 4.301462297462422e-09
aberrant O 0 1.943950245220094e-08
splicing O 0 3.24398747864052e-08
often O 0 3.9563241571727303e-10
generates O 0 1.4763393840766525e-09
a O 0 9.412278956233422e-09
premature O 0 3.04135937767569e-07
termination O 0 2.9815842594871356e-07
codon O 0 7.535263080171717e-07
, O 0 6.772353344786097e-09
( O 0 9.876407247588759e-09
ii O 0 5.525429969566176e-06
) O 0 3.6396599067956004e-09
transcripts O 0 2.640771157302879e-08
with O 0 8.714499122319808e-10
premature O 0 4.6338888637365017e-07
termination O 0 1.3070466593489982e-06
codons O 0 7.018923042778624e-07
can O 0 2.912552643508093e-09
occur O 0 3.671657200499112e-09
at O 0 1.4756617261468818e-08
low O 0 7.654992373318237e-08
or O 0 1.4766246003716788e-08
undetectable O 0 2.163432384350017e-07
levels O 0 9.664288924682296e-09
due O 0 2.29278871444194e-08
to O 0 9.32594801383857e-09
nonsense O 0 7.733218012617726e-07
- O 0 1.3301601597959234e-07
mediated O 0 1.3729666648032435e-07
mRNA O 0 3.2658658710715827e-07
decay O 0 1.8654453981525876e-07
, O 0 2.5429613970118226e-10
and O 0 1.1716752568169397e-10
( O 0 2.071167237716054e-09
iii O 0 4.876503680861788e-06
) O 0 2.0128618771764195e-09
the O 0 7.759977105337157e-10
levels O 0 9.556739843930018e-10
of O 0 3.0529678785029546e-10
these O 0 6.16731526958958e-11
transcripts O 0 5.125298407904211e-09
can O 0 3.7900418914382783e-10
be O 0 1.5010963583250714e-09
increased O 0 1.1613217054673441e-08
by O 0 5.589393126115283e-08
cycloheximide O 0 0.0002538972767069936
. O 0 5.1931974667240866e-06

A O 0 5.419995886768447e-06
deletion O 0 1.5253986930474639e-05
mutation O 0 1.188018245557032e-06
in O 0 3.9058303258343585e-08
COL17A1 O 1 0.8590478301048279
in O 0 9.44753164588974e-09
five O 0 4.845672307851601e-09
Austrian O 0 2.9040395475021796e-06
families O 0 4.781843365719851e-09
with O 0 1.4893246635949708e-08
generalized O 1 0.9999895095825195
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9997039437294006
represents O 0 5.512643497240788e-07
propagation O 0 2.264324166389997e-06
of O 0 1.1331269433867419e-07
an O 0 3.810449911156866e-08
ancestral O 0 8.657490980112925e-06
allele O 0 2.2014497517375275e-05
. O 0 1.8662244656297844e-06

Patients O 0 7.93775780039141e-06
with O 0 3.759504920708423e-07
generalized O 1 0.999996542930603
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999997615814209
, O 0 2.3079570610207156e-07
a O 0 5.2309562903474216e-08
usually O 0 1.533784121932058e-08
nonlethal O 0 1.171218286799558e-06
form O 0 5.6515695234793384e-08
of O 0 3.1462077458854765e-06
junctional B-Disease 1 0.9999892711639404
epidermolysis I-Disease 1 0.999995231628418
bullosa I-Disease 1 0.9997655749320984
, O 0 3.136286252924947e-08
have O 0 1.7086878578709275e-09
generalized O 0 3.610449823554518e-07
blistering B-Disease 0 1.5779944078531116e-05
, O 0 2.1499276670056133e-07
nail B-Disease 1 0.9999533891677856
dystrophy I-Disease 1 1.0
, O 0 9.566936205374077e-05
patchy B-Disease 1 1.0
alopecia I-Disease 1 1.0
, O 0 0.02220846898853779
and O 0 0.22032591700553894
dental B-Disease 1 1.0
abnormalities I-Disease 1 1.0
. O 1 0.9999624490737915

Skin B-Disease 1 0.9999997615814209
fragility I-Disease 1 0.9999003410339355
in O 0 1.521030412732216e-07
most O 0 1.4717657315088672e-08
cases O 0 5.939636338325727e-09
is O 0 5.2067852251980185e-09
due O 0 5.241123091082045e-08
to O 0 3.6918537116292782e-09
mutations O 0 4.444394363645188e-08
in O 0 1.2492851197976051e-09
the O 0 3.8433896065726e-09
gene O 0 7.446108174491428e-09
encoding O 0 4.4993399228587805e-08
type O 0 6.053477136447327e-06
XVII O 1 0.9999021291732788
collagen O 0 0.004698476754128933
( O 0 3.0750261430512182e-06
COL17A1 O 1 0.9961212277412415
) O 0 5.059728778178396e-07
. O 0 8.004295182217902e-07

Recently O 0 4.327676833781879e-06
, O 0 5.1072678530772464e-08
we O 0 8.139062757095417e-09
reported O 0 9.402624456811282e-09
five O 0 3.2095452962010995e-09
Austrian O 0 1.3240160114946775e-06
families O 0 7.583605743377575e-09
with O 0 8.551086061459046e-09
generalized O 1 0.9998873472213745
atrophic B-Disease 1 1.0
benign I-Disease 1 1.0
epidermolysis I-Disease 1 1.0
bullosa I-Disease 1 0.9999998807907104
who O 0 2.2870553948450834e-06
share O 0 1.4743386600457598e-07
the O 0 6.444552269613268e-08
same O 0 3.9652428540648543e-07
COL17A1 O 1 0.9171870946884155
mutation O 0 4.741638622363098e-05
. O 0 4.75082742923405e-06

Affected O 0 8.404107916248904e-07
individuals O 0 1.2882027000671314e-08
in O 0 4.865974290169106e-09
three O 0 1.969920004896153e-09
families O 0 1.5558225818779192e-09
are O 0 4.819933896449413e-10
homozygous O 0 3.0196712685892635e-08
for O 0 2.525773146189181e-09
4003delTC O 0 3.5672612739290344e-06
, O 0 5.560361504564071e-09
whereas O 0 1.6386289658498754e-08
those O 0 6.929488094442604e-10
in O 0 1.6133867575263139e-09
two O 0 8.210251367657406e-10
others O 0 5.878392439484514e-09
are O 0 2.4457484926188044e-09
compound O 0 1.2017321751045529e-06
heterozygotes O 0 1.6514281014679e-05
. O 0 2.5843507955869427e-06

To O 0 7.907303256615705e-08
determine O 0 1.0057865296175805e-07
if O 0 1.0890937929275424e-08
the O 0 8.028589348896276e-09
occurrence O 0 1.3512631369394512e-07
of O 0 1.0446343878811604e-07
4003delTC O 0 7.781417480146047e-06
in O 0 4.1654080185082876e-09
these O 0 3.907264234381813e-10
unrelated O 0 3.6844692630211284e-08
families O 0 9.417732149685776e-10
signifies O 0 1.6444495543055382e-08
propagation O 0 8.847334953543395e-08
of O 0 8.033614662394939e-09
an O 0 1.6233043798052904e-09
ancestral O 0 6.731107760060695e-08
allele O 0 1.3170000556783634e-07
or O 0 9.248556587238e-09
a O 0 1.3706288370940456e-07
mutational O 0 0.00023495947243645787
hot O 0 1.6842301192809828e-05
spot O 0 2.5382353214808973e-06
, O 0 2.1033421671035057e-09
haplotypes O 0 4.735953851309205e-08
were O 0 1.1259688736942053e-09
determined O 0 5.131774116762244e-09
for O 0 1.87084037150953e-09
polymorphisms O 0 1.8935809009690274e-07
both O 0 1.1164019042553264e-08
within O 0 1.3612392990580702e-07
and O 0 1.0729601029879632e-07
flanking O 0 0.000404036371037364
COL17A1 O 1 0.9999951124191284
. O 0 3.076526991208084e-05

Five O 0 5.124859853822272e-06
intragenic O 0 0.00013173888146411628
polymorphisms O 0 4.163244739174843e-06
were O 0 2.9048704774936596e-08
chosen O 0 3.223319566814098e-08
based O 0 4.0792304645265176e-08
on O 0 1.8379050459316204e-07
their O 0 4.711662882073142e-08
informativeness O 0 0.0007864371291361749
. O 0 1.3221789231465664e-05

One O 0 1.2091949486148224e-07
of O 0 1.8643476096258382e-08
these O 0 7.794480616496458e-10
, O 0 1.2439899110816555e-09
not O 0 1.4263366043820724e-09
previously O 0 1.5375126949379592e-08
reported O 0 6.184967649147666e-09
, O 0 1.464917409599309e-09
was O 0 1.985917350566524e-07
2988 O 0 2.3981097001524176e-06
A O 0 1.8796497158746206e-07
or O 0 1.59129136534375e-08
C O 0 3.689631739689503e-06
that O 0 3.598044084895946e-10
introduces O 0 1.547473704732738e-09
a O 0 8.885580604633958e-10
new O 0 2.6025162580545214e-10
restriction O 0 1.094965451642338e-08
site O 0 1.387594394941516e-08
for O 0 1.8961390679805845e-08
Eco0109 O 0 0.00018041445582639426
I O 0 0.00029431129223667085
. O 0 8.064095709414687e-06

All O 0 1.2321120834712929e-07
the O 0 4.787175811316047e-08
4003delTC O 0 4.015278591396054e-06
alleles O 0 2.0490568886089022e-07
showed O 0 6.226050786040105e-09
the O 0 1.934797877467531e-09
same O 0 7.060316331575223e-09
haplotype O 0 2.8308384116826346e-06
for O 0 5.609276154672216e-09
these O 0 3.3699898427386188e-09
five O 0 7.743188490394459e-08
polymorphic O 0 1.548140608065296e-05
markers O 0 3.6849258322035894e-05
. O 0 4.795281711267307e-06

Fourteen O 0 2.0148265321040526e-05
microsatellite O 0 0.00010378846491221339
polymorphisms O 0 3.583789066397003e-06
were O 0 1.8496592701922054e-08
selected O 0 5.340538677955919e-09
based O 0 1.3062471104774431e-08
on O 0 6.065897650842089e-08
their O 0 2.673407495379365e-09
high O 0 1.1268738262515399e-06
heterozygosity O 0 0.00025953780277632177
and O 0 4.4741437221773595e-09
their O 0 9.947430656964684e-10
location O 0 7.25808746437906e-08
within O 0 1.7824805809141253e-07
10q23 O 0 0.00011322250065859407
- O 0 3.338224269100465e-05
q25 O 0 0.00037075826548971236
near O 0 2.9760449251625687e-05
COL17A1 O 0 0.011946707963943481
. O 0 7.652271960978396e-06

Three O 0 3.5333385994817945e-07
families O 0 4.568808620319942e-08
shared O 0 7.799574319733438e-08
microsatellite O 0 0.00012407181202434003
polymorphisms O 0 1.0061632565339096e-05
covering O 0 1.3244631418274366e-06
at O 0 4.200378782570624e-07
most O 0 4.247644458388322e-09
19 O 0 2.358429007642826e-08
cM O 0 3.6896244637318887e-07
, O 0 1.97482849517705e-10
whereas O 0 3.163277417783661e-09
the O 0 2.1731951793668713e-09
others O 0 1.7007283359404823e-09
shared O 0 9.397976841185596e-10
smaller O 0 3.36233041409173e-09
regions O 0 3.2959008855470984e-09
consistent O 0 4.183482005259975e-09
with O 0 1.8767723486412535e-10
cross O 0 8.524187933289795e-08
- O 0 2.4560463884881756e-07
over O 0 9.83514603092317e-09
events O 0 3.9679015628735215e-10
during O 0 5.617924458967138e-10
passage O 0 1.3355028194439456e-09
of O 0 3.9860231781929656e-10
this O 0 2.6540941666652884e-10
mutation O 0 1.2146937677925962e-08
through O 0 3.409967863632346e-09
several O 0 1.8878571594882487e-08
generations O 0 4.6214745452743955e-07
. O 0 1.3380476957536303e-06

These O 0 4.314158630336351e-08
results O 0 5.326442220621175e-08
indicate O 0 3.9709640020646475e-08
that O 0 2.5230959543875997e-09
4003delTC O 0 1.148676460616116e-06
occurs O 0 1.1205960603888343e-08
on O 0 6.283122022665566e-09
a O 0 7.0658936479617296e-09
single O 0 3.280899818491889e-08
ancestral O 0 2.6513654916016094e-07
allele O 0 1.0250640798403765e-06
. O 0 1.1408570799176232e-07
. O 0 5.901048325540614e-07

The O 0 2.9497880404960597e-06
haptoglobin O 0 0.00012775709910783917
- O 0 8.024696398933884e-06
gene O 0 1.8116314492999663e-07
deletion O 0 1.2636379551622667e-06
responsible O 0 2.370760086023438e-07
for O 0 2.7645006639431813e-07
anhaptoglobinemia B-Disease 1 0.9305633306503296
. O 0 2.0542667698464356e-05

We O 0 2.2533843946348497e-07
have O 0 5.038942596513607e-09
found O 0 2.723770764490041e-09
an O 0 1.6140577763223973e-09
allelic O 0 4.649439802051347e-07
deletion O 0 1.3063264532320318e-06
of O 0 1.558308326821134e-07
the O 0 1.9797603556526155e-07
haptoglobin O 0 0.004195851739495993
( O 0 7.177058591878449e-08
Hp O 0 8.686230046350829e-08
) O 0 1.1131057187085958e-09
gene O 0 1.411056271827249e-09
from O 0 5.842452632798256e-10
an O 0 5.192699048528482e-10
individual O 0 2.70335265284416e-09
with O 0 2.2732285387405682e-08
anhaptoglobinemia B-Disease 1 0.9999163150787354
. O 0 4.427630119607784e-05

The O 0 2.2655879092781106e-06
Hp O 0 2.289755002493621e-06
gene O 0 1.0349482693072787e-07
cluster O 0 2.9532148460020835e-07
consists O 0 2.5237505418829187e-09
of O 0 4.360366734346144e-09
coding O 0 2.26717119744535e-07
regions O 0 7.894569620248149e-08
of O 0 8.63935483153e-08
the O 0 1.3403511900378362e-07
alpha O 0 1.6884393971849931e-06
chain O 0 1.741429400681227e-08
and O 0 7.602690144103974e-10
beta O 0 6.91506301109257e-08
chain O 0 6.694832244136251e-09
of O 0 1.0960827800943207e-09
the O 0 2.1047947829089253e-09
haptoglobin O 0 2.924434454598668e-07
gene O 0 7.1052213002076314e-09
( O 0 1.684335448892682e-09
Hp O 0 1.0791930016296192e-08
) O 0 2.371666196765432e-10
and O 0 1.0278549539277648e-10
of O 0 1.166351237813501e-09
the O 0 4.873962566875889e-09
alpha O 0 1.369187856425924e-07
chain O 0 6.171946065336442e-09
and O 0 5.543003278596359e-10
beta O 0 8.123774364321434e-08
chain O 0 7.360692499958077e-09
of O 0 1.86811632829631e-09
the O 0 1.0781766590639563e-08
haptoglobin O 0 4.837299002247164e-06
- O 0 3.9904628579279233e-07
related O 0 5.128205771143257e-08
gene O 0 4.823415622468019e-08
( O 0 1.7073434221970274e-08
Hpr O 0 1.5425185893036542e-06
) O 0 3.841916118574318e-09
, O 0 1.248918302110269e-09
in O 0 1.6724427398528974e-09
tandem O 0 7.843838290000349e-08
from O 0 1.1001717759029361e-08
the O 0 3.725021713307797e-08
5 O 0 3.579296787847852e-07
side O 0 1.0480305263627088e-06
. O 0 1.5389979353130911e-06

Southern O 0 8.27519306767499e-06
blot O 0 2.421654062345624e-05
and O 0 1.6663014079654204e-08
PCR O 0 2.3608778576544864e-07
analyses O 0 5.596732677304317e-08
have O 0 5.429522942357323e-10
indicated O 0 5.414860559938006e-09
that O 0 1.1260155308168152e-10
the O 0 4.1126080319031644e-10
individual O 0 5.444349485128619e-11
with O 0 4.2886227902272367e-10
anhaptoglobinemia B-Disease 0 4.1698134737089276e-05
was O 0 6.380900572366954e-07
homozygous O 0 1.1997593141188645e-08
for O 0 2.909464336120493e-10
the O 0 1.43965006582647e-09
gene O 0 8.043074650743165e-09
deletion O 0 1.2040651142797287e-07
and O 0 4.428523936450546e-10
that O 0 2.3380833380493016e-10
the O 0 1.5252122897990716e-09
gene O 0 5.072054776178447e-09
deletion O 0 5.453587093029455e-08
was O 0 1.3517123420569988e-08
included O 0 3.375037749275833e-10
at O 0 2.214908256803483e-09
least O 0 2.566760970434956e-10
from O 0 6.836228250151066e-10
the O 0 9.730779515493282e-10
promoter O 0 1.272771669391659e-06
region O 0 6.6766887130143e-08
of O 0 3.72003050586045e-08
Hp O 0 3.2337759137135436e-08
to O 0 7.480857711072986e-09
Hpr O 0 9.358878969578655e-07
alpha O 0 1.4243926216295222e-07
but O 0 9.603957629167326e-10
not O 0 1.414535155674912e-09
to O 0 1.1139070110743887e-08
Hpr O 0 7.325013939407654e-06
beta O 0 1.1271843504800927e-05
( O 0 3.2504976843483746e-07
Hpdel O 0 6.595106242457405e-05
) O 0 4.211770487927424e-07
. O 0 9.029689067574509e-07

In O 0 1.00990988016747e-07
addition O 0 2.523275455246221e-08
, O 0 4.336191405940326e-09
we O 0 2.015685618417251e-09
found O 0 4.264543718157654e-10
seven O 0 1.3760595440892587e-10
individuals O 0 2.8383542044485566e-11
with O 0 1.0249574800003103e-10
hypohaptoglobinemia B-Disease 0 0.00042640804895199835
in O 0 9.232781650325705e-09
three O 0 2.0279562473746182e-09
families O 0 6.054067247518446e-10
, O 0 4.092841343616982e-10
and O 0 2.998650494578925e-10
the O 0 2.8739135515820635e-09
genotypes O 0 3.1616147566637665e-07
of O 0 5.673902681024856e-09
six O 0 1.0203138334219375e-09
of O 0 1.4412078197523215e-09
the O 0 1.2882658273483116e-09
seven O 0 6.044433287222262e-10
individuals O 0 9.848032112014238e-11
were O 0 8.483160840455639e-10
found O 0 1.393720805431542e-09
to O 0 5.177708484183086e-09
be O 0 1.935644746708931e-07
Hp2 O 0 0.005143286660313606
/ O 0 0.004056460224092007
Hpdel O 0 0.010384529829025269
. O 0 1.3056367606623098e-05

The O 0 1.187198222396546e-06
phenotypes O 0 5.502156909642508e-06
and O 0 1.5685253984543124e-08
genotypes O 0 3.673862920550164e-06
in O 0 2.4494737349556317e-09
one O 0 8.737933709923595e-10
of O 0 6.633866234118102e-10
these O 0 1.4610736231990273e-11
three O 0 1.2320998388215543e-10
families O 0 1.420704665022754e-10
showed O 0 9.583572824212183e-10
the O 0 3.6610907638845447e-09
father O 0 1.7030046706167923e-08
to O 0 3.6763381228155367e-09
be O 0 4.3749398770387415e-08
hypohaptoglobinemic B-Disease 0 0.00010549936268944293
( O 0 1.0375038073107135e-07
Hp2 O 0 2.3505273929913528e-05
) O 0 6.257742768411845e-09
and O 0 5.570828243151027e-09
Hp2 O 0 2.468686034262646e-05
/ O 0 7.519121481891489e-06
Hpdel O 0 0.00014544134319294244
, O 0 8.232538206698337e-09
the O 0 9.860634975211724e-09
mother O 0 2.840182311558692e-09
to O 0 7.65507324196335e-10
be O 0 6.647625117039979e-09
Hp2 O 0 1.2853974112658761e-05
- O 0 6.140140840216191e-07
1 O 0 4.0255591216009634e-07
and O 0 3.0660061156595475e-09
Hp1 O 0 8.833086212689523e-06
/ O 0 1.6121375665534288e-06
Hp2 O 0 1.6776335542090237e-05
, O 0 2.020686062920163e-09
one O 0 1.1540454147862533e-09
of O 0 1.8355791331359228e-09
the O 0 2.1529216187587963e-09
two O 0 1.1900248564344906e-09
children O 0 2.506183038875065e-10
to O 0 7.056354944801058e-10
be O 0 1.731427268225616e-08
hypohaptoglobinemic B-Disease 0 0.00027616211446002126
( O 0 9.160358871440621e-08
Hp2 O 0 2.6036666895379312e-05
) O 0 3.3014690981048034e-09
and O 0 1.9748107593642317e-09
Hp2 O 0 1.5872265066718683e-05
/ O 0 4.403136244945927e-06
Hpdel O 0 0.00013659005344379693
, O 0 2.2433004343014318e-09
and O 0 3.433107687023096e-10
the O 0 1.7671255569950972e-09
other O 0 5.719055229391756e-10
child O 0 1.5161165656252251e-09
to O 0 5.537222902418648e-10
be O 0 1.7291963416710132e-08
Hp1 O 0 3.492899486445822e-05
and O 0 6.700634713752152e-08
Hp1 O 0 0.29373469948768616
/ O 0 0.019464069977402687
Hpdel O 0 0.16713103652000427
, O 0 9.979837400919678e-09
showing O 0 6.452002931922607e-09
an O 0 1.3127328113426984e-09
anomalous O 0 3.0738826808374142e-06
inheritance O 0 2.7169206077815033e-05
of O 0 3.1605582080374006e-06
Hp O 0 1.2846199979321682e-06
phenotypes O 0 3.4257988090757863e-07
in O 0 4.59237803340784e-09
the O 0 1.4965975125846853e-08
child O 0 3.7961807919373314e-08
with O 0 2.39356836573279e-08
Hp1 O 0 0.24409684538841248
. O 0 1.0858064342755824e-05

The O 0 5.978749413770856e-06
Hp2 O 0 0.004113602451980114
/ O 0 0.0002611579548101872
Hpdel O 0 0.0005446450086310506
individuals O 0 6.749592884602862e-09
had O 0 1.3505732532337333e-08
an O 0 1.3774362761509451e-09
extremely O 0 2.3372741964067245e-08
low O 0 4.2927439380946453e-07
level O 0 5.468366452987539e-07
of O 0 6.930788742920413e-08
Hp O 0 1.5214337167890335e-07
( O 0 3.2994751819614976e-08
mean O 0 7.009063551777217e-07
+ O 0 8.157776960615593e-07
/ O 0 2.9900293156970292e-06
- O 0 7.823262421879917e-06
SD O 0 6.898433639435098e-05
= O 0 4.985600412510394e-07
0 O 0 1.6980786199383147e-07
. O 0 7.084219433295402e-09
049 O 0 5.970898087070964e-07
+ O 0 1.7743397506819747e-07
/ O 0 7.778061217322829e-07
- O 0 1.3574089052781346e-06
0 O 0 4.922316634292656e-07
. O 0 2.44359998902155e-08
043 O 0 1.7100212517107138e-06
mg O 0 1.3427953717837227e-06
/ O 0 4.0183022065320984e-07
ml O 0 2.773307130610192e-07
; O 0 2.2105823838103333e-09
n O 0 2.6030303246216135e-08
= O 0 1.6455853568686507e-08
6 O 0 1.7739344215783603e-08
) O 0 2.1358161073070647e-10
, O 0 1.300217850053187e-10
compared O 0 6.553603215664339e-10
with O 0 6.296648619175116e-11
the O 0 1.2753796241327109e-08
level O 0 9.366218023387773e-07
( O 0 1.9930659789224592e-08
1 O 0 4.967489530827152e-07
. O 0 9.320986649186125e-09
64 O 0 9.888494645338142e-08
+ O 0 6.73090241321006e-08
/ O 0 5.204177000450727e-07
- O 0 8.469530143884185e-07
1 O 0 9.86221493803896e-07
. O 0 1.3478814508971482e-08
07 O 0 2.2009034239545144e-07
mg O 0 5.137035827829095e-07
/ O 0 1.685529156247867e-07
ml O 0 7.564496229406359e-08
) O 0 2.9761379471970884e-10
obtained O 0 3.311680041306886e-09
from O 0 1.066632293600378e-08
52 O 0 3.1172623948805267e-07
healthy O 0 4.12517975334481e-09
volunteers O 0 2.4253270503038493e-09
having O 0 3.4964521944402804e-08
phenotype O 0 1.2429192793206312e-05
Hp2 O 0 0.0001918660127557814
, O 0 6.04216587873907e-09
whereas O 0 1.175497388317126e-08
the O 0 4.643198270315452e-09
serum O 0 4.513685780693777e-08
Hp O 0 6.9590813112085925e-09
level O 0 7.225251952291956e-09
of O 0 9.664007372123251e-10
an O 0 3.992399466579144e-10
individual O 0 7.144382307977537e-10
with O 0 8.669442053133025e-09
Hp1 O 1 0.7905850410461426
/ O 0 0.11624113470315933
Hpdel O 0 0.018228882923722267
was O 0 1.7395461327396333e-05
0 O 0 6.107789886300452e-06
. O 0 7.375450650215498e-07

50 O 0 3.6679955428553512e-06
mg O 0 1.0880205991270486e-05
/ O 0 2.7725664040190168e-06
ml O 0 2.7966552806901745e-06
, O 0 1.6672639935322309e-09
which O 0 3.0059343902877345e-10
was O 0 3.131896963992631e-09
approximately O 0 5.440511374743551e-10
half O 0 7.444173610871019e-10
the O 0 2.2886879891270695e-10
level O 0 1.0007056516769808e-08
of O 0 7.7917503560343e-09
Hp O 0 3.5007758469873806e-08
in O 0 2.684254818419163e-09
control O 0 1.2901088553007867e-07
sera O 0 1.7579708355697221e-06
from O 0 1.3997129677534303e-08
the O 0 2.0980023052175056e-08
Hp1 O 0 2.632533505675383e-05
phenotype O 0 1.5281503920050454e-06
( O 0 1.0706885156253065e-08
1 O 0 3.68827016927753e-07
. O 0 2.9246047805742137e-09
26 O 0 2.2014654987856375e-08
+ O 0 3.184545960266405e-08
/ O 0 1.4565938499799813e-07
- O 0 3.074622725307563e-07
0 O 0 1.3520674713163316e-07
. O 0 7.493367704114462e-09
33 O 0 8.062799849994917e-08
mg O 0 2.9222317721178115e-07
/ O 0 2.3126283110741497e-07
ml O 0 2.6253763962813537e-07
; O 0 3.5341447546244353e-09
n O 0 7.007834312844352e-08
= O 0 3.675274484749025e-08
9 O 0 3.666032810656361e-08
) O 0 7.483965114296609e-10
, O 0 7.452768957527667e-10
showing O 0 3.1833293778760208e-09
a O 0 1.4008106674623377e-08
gene O 0 9.27834875597e-08
- O 0 6.017803002578148e-07
dosage O 0 1.33259445647127e-05
effect O 0 7.550278041890124e-06
. O 0 3.4017241432593437e-06

The O 0 3.4313441688027524e-07
other O 0 1.3224718209414732e-08
allele O 0 1.2842426713177701e-06
( O 0 4.1513395387937635e-08
Hp2 O 0 3.400162677280605e-05
) O 0 2.6861188828775084e-09
of O 0 1.8348965680203833e-09
individuals O 0 3.564111228371303e-10
with O 0 3.2243818726129803e-09
Hp2 O 1 0.9999955892562866
/ O 1 0.9995346069335938
Hpdel O 1 0.992953360080719
was O 0 2.257587397025418e-07
found O 0 4.118039798051143e-10
to O 0 1.616540096227581e-10
have O 0 1.8342762031497983e-10
, O 0 4.127594099845311e-10
in O 0 5.167849481679809e-10
all O 0 3.6487984855781974e-10
exons O 0 6.189419110569361e-08
, O 0 6.476707503644263e-10
no O 0 4.756872673539192e-09
mutation O 0 2.4352434735419592e-08
, O 0 1.3705282464471225e-09
by O 0 1.4211424925747451e-08
DNA O 0 2.075955762848025e-06
sequencing O 0 4.824984443985159e-06
. O 0 1.1947215625696117e-06

On O 0 2.703767165712634e-07
the O 0 5.047263051949358e-09
basis O 0 2.2728773529934188e-08
of O 0 7.297646487103293e-09
the O 0 3.3434581769853366e-09
present O 0 3.293651129609998e-09
study O 0 3.2992975018686366e-09
, O 0 3.8439521010680266e-10
the O 0 7.299925663950546e-10
mechanism O 0 2.7667073965176314e-08
of O 0 6.33716368270143e-08
anhaptoglobinemia B-Disease 0 4.421915946295485e-05
and O 0 1.3859273728655808e-09
the O 0 4.284529175890839e-09
mechanism O 0 2.3589285191860654e-08
of O 0 3.656688818409748e-08
anomalous O 0 1.1903672202606685e-05
inheritance O 0 3.715728234965354e-05
of O 0 1.4901365830155555e-06
Hp O 0 1.4907648164808052e-06
phenotypes O 0 8.659628178975254e-07
were O 0 3.006906723612701e-08
well O 0 5.1139252832399507e-08
explained O 0 2.2022798020771006e-06
. O 0 1.037149104377022e-06

However O 0 6.694438070553588e-07
, O 0 3.2854835296802776e-08
the O 0 2.1259744187318574e-08
mechanism O 0 3.7181226275606605e-07
of O 0 1.4988592056397465e-06
hypohaptoglobinemia B-Disease 1 0.9999740123748779
remains O 0 0.0011790696298703551
unknown O 0 0.00016065913951024413

ATM O 0 0.0032601121347397566
mutations O 0 1.130039800045779e-05
and O 0 5.128469737769592e-08
phenotypes O 0 1.042671920004068e-05
in O 0 3.2776276839285856e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 1.2133558868754335e-07
in O 0 6.907809879663773e-09
the O 0 6.759861115313015e-09
British O 0 1.7496729398658317e-08
Isles O 0 1.2311019759181363e-07
: O 0 3.4543362614769535e-10
expression O 0 2.2743504857203334e-09
of O 0 1.7270002095060022e-09
mutant O 0 1.1810822542202004e-08
ATM O 0 4.2454274762349087e-07
and O 0 3.478753951569047e-10
the O 0 3.4944436233530496e-09
risk O 0 1.2412534999839409e-07
of O 0 4.094915482255601e-07
leukemia B-Disease 1 1.0
, O 0 0.09128516167402267
lymphoma B-Disease 1 1.0
, O 0 0.0009773188503459096
and O 0 0.0001683542359387502
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.07348275929689407

We O 0 4.041453394165728e-07
report O 0 1.3843586721407064e-08
the O 0 1.041107200450142e-08
spectrum O 0 2.7275000320514664e-06
of O 0 2.1609002942568623e-07
59 O 0 2.182573553000111e-06
ATM O 0 5.56551713088993e-05
mutations O 0 2.538109242777864e-07
observed O 0 1.3705948731512763e-07
in O 0 2.275339454627101e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0452883318066597
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 3.620027300144102e-08
patients O 0 8.534025930373446e-09
in O 0 4.749429738382105e-09
the O 0 3.161306594279267e-08
British O 0 5.997835614834912e-07
Isles O 0 2.2910131519893184e-05
. O 0 2.9008122055529384e-06

Of O 0 2.5919925974449143e-06
51 O 0 5.6466678870492615e-06
ATM O 0 0.00041149527532979846
mutations O 0 1.033332409861032e-06
identified O 0 5.043743200872086e-08
in O 0 2.768036022615661e-09
families O 0 1.551883732631154e-09
native O 0 2.762624573549033e-09
to O 0 1.1414512668395105e-09
the O 0 5.927740964750683e-09
British O 0 6.67097239670511e-08
Isles O 0 7.422628982567403e-07
, O 0 5.962917271062906e-09
11 O 0 1.5059322677757336e-08
were O 0 5.680768300209138e-09
founder O 0 1.577927122298206e-07
mutations O 0 3.525239833379601e-08
, O 0 1.9662864669811597e-09
and O 0 2.3002075799638533e-09
2 O 0 2.8469315793699934e-07
of O 0 4.773988315776023e-09
these O 0 3.087270716850554e-10
11 O 0 8.395679707007275e-09
conferred O 0 4.709093204269266e-08
a O 0 2.4438143952920655e-08
milder O 0 5.513650194188813e-06
clinical O 0 2.3426312054652954e-06
phenotype O 0 2.650606916176912e-07
with O 0 2.5251023494377023e-10
respect O 0 6.828164700323214e-09
to O 0 1.1885011197421136e-08
both O 0 6.416868814085319e-07
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
and O 0 3.241685772081837e-05
cellular O 0 9.334830974694341e-05
features O 0 2.7049691198044457e-07
. O 0 1.9787421479122713e-06

We O 0 1.7288195408582396e-07
report O 0 7.811138402757933e-09
, O 0 1.1522023335430731e-09
in O 0 7.124719147988401e-10
two O 0 1.8095009934882e-09
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999990463256836
T I-Disease 1 0.9999997615814209
families O 0 1.0989721133114472e-08
, O 0 1.3909138285583822e-09
an O 0 1.883306843808441e-09
ATM O 0 1.102842088585021e-05
mutation O 0 3.2995578180816665e-07
( O 0 2.670549648087217e-08
7271T O 0 1.777231227606535e-05
- O 0 1.2833392020183965e-06
- O 0 4.5380986080090224e-07
> O 0 1.941864184118458e-06
G O 0 5.059429781795188e-07
) O 0 1.5370478501086637e-10
that O 0 3.2691013091001864e-11
may O 0 3.4424643691188805e-10
be O 0 2.0822452095892174e-10
associated O 0 1.978715941097775e-10
with O 0 1.1146448347654214e-11
an O 0 2.0312186654880549e-10
increased O 0 1.1630640450732699e-08
risk O 0 5.553188202611636e-07
of O 0 4.198995156912133e-06
breast B-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
in O 0 2.0462331917769916e-07
both O 0 1.1747683004159626e-07
homozygotes O 0 2.4955423214123584e-05
and O 0 2.0446387694050827e-08
heterozygotes O 0 1.1116932228105725e-06
( O 0 1.7178484412738726e-08
relative O 0 1.7850198901214753e-06
risk O 0 3.847396783385193e-07
12 O 0 1.4225744138229857e-08
. O 0 7.63672680648142e-10
7 O 0 2.3464847842546988e-08
; O 0 1.5945172959774823e-09
P O 0 2.7195419534109533e-06
= O 0 6.448363620847886e-08
. O 0 8.512664351201238e-09
0025 O 0 1.1363046041878988e-06
) O 0 6.932197593734202e-10
, O 0 1.8839776960710708e-10
although O 0 2.806711529856898e-10
there O 0 2.3139444527142672e-10
is O 0 3.856421570969104e-10
a O 0 3.1634825869986116e-09
less O 0 1.2968797591383918e-07
severe O 1 0.9998615980148315
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 1.5611434491802356e-06
in O 0 3.8653247269593294e-10
terms O 0 1.7818143627224003e-09
of O 0 9.740955819736996e-10
the O 0 1.9695067798863874e-09
degree O 0 2.2385033844329882e-06
of O 0 6.4484765971428715e-06
cerebellar B-Disease 1 1.0
degeneration I-Disease 1 1.0
. O 0 0.15214309096336365

This O 0 2.1992289589434222e-07
mutation O 0 5.177622597329901e-07
( O 0 8.581038457577961e-08
7271T O 0 1.8389764591120183e-05
- O 0 5.188138402445475e-06
- O 0 4.762594926432939e-06
> O 0 6.601599125133362e-06
G O 0 1.7586415879122796e-06
) O 0 4.493066751987129e-10
also O 0 9.050309807134838e-11
allows O 0 5.907418304529344e-11
expression O 0 1.2895023937531391e-09
of O 0 1.189475740126511e-09
full O 0 5.14994358269405e-09
- O 0 3.295689054994e-08
length O 0 1.7917528793987003e-08
ATM O 0 1.2081442264388897e-06
protein O 0 6.289884613153163e-09
at O 0 1.4626476696477653e-09
a O 0 7.716157712778227e-10
level O 0 8.792422789838383e-09
comparable O 0 1.2041358132819369e-08
with O 0 2.4102186912955403e-10
that O 0 1.2559893125541066e-09
in O 0 1.8905705445604326e-08
unaffected O 0 1.6461463019368239e-06
individuals O 0 5.404132963349184e-08
. O 0 2.46882655119407e-06

In O 0 2.7871788432776157e-08
addition O 0 8.21943757500776e-09
, O 0 3.5918679142099563e-09
we O 0 1.6119072743236984e-09
have O 0 2.0753541940532472e-10
studied O 0 2.17015188042069e-08
18 O 0 4.0918152421909326e-08
A B-Disease 1 0.9999949932098389
- I-Disease 1 0.9999982118606567
T I-Disease 1 1.0
patients O 0 1.856140663392125e-08
, O 0 4.81034601040875e-10
in O 0 5.819119630601222e-10
15 O 0 1.6914922795763232e-09
families O 0 3.3412572708613197e-10
, O 0 9.812749501847406e-10
who O 0 7.73760522321254e-09
developed O 0 2.384128947596764e-06
leukemia B-Disease 1 1.0
, O 1 0.8051355481147766
lymphoma B-Disease 1 1.0
, O 0 0.026796801015734673
preleukemic O 1 0.9999957084655762
T O 0 0.005364280194044113
- O 0 2.4079405193333514e-05
cell O 0 5.080373284727102e-06
proliferation O 0 1.2637737199838739e-05
, O 0 2.3858152786715436e-08
or O 0 6.767634477000684e-05
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.605499528523069e-05
mostly O 0 2.1160452945423458e-07
in O 0 2.5618732024668134e-07
childhood O 0 9.748481716087554e-06
. O 0 2.549010559960152e-06

A O 0 1.850792432378512e-05
wide O 0 2.524465571696055e-06
variety O 0 4.647258577961111e-08
of O 0 8.426340514233743e-08
ATM O 0 0.0002236077270936221
mutation O 0 1.3061321624263655e-06
types O 0 7.240029731292452e-08
, O 0 3.6562757266267454e-09
including O 0 5.064147767797067e-09
missense O 0 2.2457294107880443e-05
mutations O 0 5.853042921444285e-07
and O 0 6.895028548115079e-09
in O 0 1.6114931611355132e-08
- O 0 2.2866642268581927e-07
frame O 0 3.9756446312821936e-07
deletions O 0 3.7967245702930086e-07
, O 0 6.014868159098796e-09
were O 0 8.583538324558049e-09
seen O 0 2.139875476814268e-08
in O 0 2.8084534697825347e-09
these O 0 4.9984705263739215e-09
patients O 0 7.773850541070715e-08
. O 0 3.1406916605192237e-06

We O 0 1.2328455056831444e-07
also O 0 4.78468997755499e-09
show O 0 7.92181764630584e-10
that O 0 5.023286300809282e-11
25 O 0 9.384596433292813e-10
% O 0 8.800202788705747e-10
of O 0 1.0897456270697603e-09
all O 0 7.245607669403853e-09
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.569349710768165e-08
carried O 0 4.189087299266703e-09
in O 0 2.707960966574774e-09
- O 0 9.582685578379824e-08
frame O 0 1.549591388538829e-07
deletions O 0 1.59544512712273e-07
or O 0 3.791810243569671e-08
missense O 0 1.5425717720063403e-05
mutations O 0 7.390032124021673e-07
, O 0 1.3969704282246198e-09
many O 0 1.2195724985453182e-10
of O 0 9.43403910547147e-10
which O 0 2.1840688979590794e-10
were O 0 4.3346343181482894e-10
also O 0 1.2040082819630982e-10
associated O 0 7.575347016341993e-10
with O 0 9.390463406866445e-11
expression O 0 5.962942140058658e-08
of O 0 1.9167096354522073e-07
mutant O 0 3.2682826258678688e-06
ATM O 0 0.00011647823703242466
protein O 0 4.138688836974325e-06
. O 0 9.543392707200837e-07

The O 0 4.793265361513477e-06
DMPK O 1 0.9489021301269531
gene O 0 1.1719981785063283e-06
of O 0 1.4093403706283425e-06
severely O 1 0.9999594688415527
affected O 1 0.9986822009086609
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9845339059829712
is O 0 6.291318186413264e-06
hypermethylated O 0 0.21125154197216034
proximal O 0 0.0008529209299013019
to O 0 3.4985667696219025e-08
the O 0 7.915179622841606e-08
largely O 0 6.067135700504878e-07
expanded O 0 5.875861575077579e-07
CTG O 0 0.00023816355678718537
repeat O 0 1.4080067558097653e-05
. O 0 5.215467808739049e-06

Using O 0 4.901967258774675e-07
methylation O 0 4.8613010221743025e-06
- O 0 7.651811756659299e-06
sensitive O 0 1.851662545959698e-06
restriction O 0 1.3927441955274844e-07
enzymes O 0 1.7990744893836563e-08
, O 0 8.000107798444844e-10
we O 0 7.452868322488371e-10
characterized O 0 3.2509730463203823e-09
the O 0 1.4295641337369602e-09
methylation O 0 2.3072436405868757e-08
pattern O 0 3.713763163659678e-08
on O 0 1.0343952361324682e-08
the O 0 2.766753492977614e-09
5 O 0 1.404497407264671e-08
side O 0 1.9206359169743337e-08
of O 0 1.4564736972033643e-08
the O 0 5.264667635174192e-08
CTG O 0 7.824567728675902e-05
repeat O 0 8.796603623295596e-08
in O 0 1.8597261508546126e-09
the O 0 4.197357128532531e-09
DMPK O 0 1.3611055692308582e-05
gene O 0 4.06425515464548e-09
of O 0 1.251445946870433e-09
normal O 0 3.0129159167557873e-09
individuals O 0 1.3992657033057299e-10
and O 0 6.319197942694643e-10
of O 0 1.5369063532943983e-07
patients O 0 2.5730475528007446e-08
affected O 0 2.500765994284393e-08
with O 0 3.634868903645838e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 2.5261560949729756e-06
showing O 0 1.8673017621040344e-07
expansions O 0 2.833664325407881e-07
of O 0 1.0135512695796933e-07
the O 0 1.09842346773803e-07
repetitive O 0 2.272232904942939e-06
sequence O 0 8.759222964727087e-07
. O 0 8.513251259500976e-07

The O 0 1.3764489494860754e-06
gene O 0 7.609202725689101e-07
segment O 0 5.478921707435802e-07
analyzed O 0 5.273089342949788e-08
corresponds O 0 1.5840394951283088e-07
to O 0 9.529805389263402e-09
the O 0 1.0326373711677661e-07
genomic O 0 5.345746103557758e-06
SacI O 0 8.584136958234012e-05
- O 0 2.781515149763436e-06
HindIII O 0 1.005702779366402e-05
fragment O 0 7.24622566394828e-07
carrying O 0 3.238534773686297e-08
exons O 0 8.59723741086782e-07
11 O 0 1.3087115746657219e-07
- O 0 5.874830435459444e-07
15 O 0 4.0841356963028375e-07
. O 0 4.886009605797881e-07

There O 0 5.044883550908708e-07
is O 0 6.529578655545265e-08
constitutive O 0 1.0666871048670146e-06
methylation O 0 1.2016438404316432e-06
in O 0 6.638301641714861e-08
intron O 0 5.00991300214082e-05
12 O 0 4.3245062641972254e-08
at O 0 8.897541370345152e-09
restriction O 0 4.783403451114054e-09
sites O 0 2.307269042489679e-09
of O 0 8.67144400729103e-09
SacII O 0 1.59299343067687e-05
and O 0 3.5357377470290885e-08
HhaI O 0 0.00047752258251421154
, O 0 1.72007776910732e-08
localized O 0 2.6980794700648403e-06
1 O 0 1.4667238019683282e-06
, O 0 3.837090201130877e-09
159 O 0 5.02413683989289e-08
- O 0 2.117743065355171e-07
1 O 0 4.823594395020336e-07
, O 0 4.249346208240468e-09
232 O 0 3.614501054016728e-08
bp O 0 8.825239206089464e-08
upstream O 0 3.125507319623466e-08
of O 0 4.550768650801729e-09
the O 0 1.998368404088069e-08
CTG O 0 3.532072878442705e-05
repeat O 0 1.802683300411445e-07
, O 0 2.1542692074660863e-09
whereas O 0 4.312264323402815e-09
most O 0 4.882091952929102e-10
, O 0 2.8338659197046923e-10
if O 0 5.346692533159114e-10
not O 0 3.964013284285528e-10
all O 0 2.1927215598793737e-10
, O 0 3.3598027138204145e-10
of O 0 1.1316098058600232e-09
the O 0 4.092092220631116e-10
other O 0 4.056250474393508e-11
sites O 0 7.451176342598842e-10
of O 0 8.638081361311833e-09
SacII O 0 1.3474129445967264e-05
, O 0 1.995983822666858e-08
HhaI O 0 0.00017905169806908816
, O 0 1.3379279906189367e-08
and O 0 6.8245196160887645e-09
HpaII O 0 0.00013061413483228534
in O 0 2.248346619992958e-09
this O 0 1.121283954574892e-09
region O 0 5.933320679218923e-08
are O 0 1.4844346862830093e-09
unmethylated O 0 1.468829054829257e-06
, O 0 1.2800313031746668e-09
in O 0 5.317534190751871e-10
normal O 0 3.903094736301682e-09
individuals O 0 2.450650238294827e-10
and O 0 5.304355288338058e-10
most O 0 1.524078196979417e-09
of O 0 2.0521245147619993e-08
the O 0 1.4916749080384761e-07
patients O 0 2.3805702653589833e-07
. O 0 1.1520334055603598e-06

In O 0 7.597478202114871e-08
a O 0 3.0502821601885444e-08
number O 0 8.447175403603069e-09
of O 0 5.452650597703723e-08
young O 0 3.5934728970232754e-08
and O 0 2.6719201073888144e-08
severely O 1 0.9953333735466003
affected O 0 3.1379372558149043e-06
patients O 0 2.1130908578470553e-07
, O 0 1.2474190569378152e-08
however O 0 2.371582752402901e-08
, O 0 1.605586219532995e-09
complete O 0 3.0406379636360725e-09
methylation O 0 4.383216989367611e-08
of O 0 2.501423068679287e-09
these O 0 1.1844085434642437e-10
restriction O 0 1.040390618101128e-08
sites O 0 2.170121859990104e-09
was O 0 1.16603153799133e-08
found O 0 6.821978537630002e-10
in O 0 8.852407695769671e-10
the O 0 1.0594464860957942e-08
mutated O 0 6.440128572648973e-07
allele O 0 1.078224249795312e-05
. O 0 1.591003751855169e-06

In O 0 1.1949251188525523e-07
most O 0 4.781925522223673e-09
of O 0 6.369880622969504e-09
these O 0 4.744972748049747e-10
patients O 0 2.4898467732015206e-09
, O 0 1.0182705789674174e-09
the O 0 1.1567897750808243e-08
onset O 0 0.0061544557102024555
of O 0 7.468299259016931e-07
the O 0 9.50150570133701e-06
disease O 1 0.9999985694885254
was O 1 0.9999996423721313
congenital O 1 1.0
. O 0 0.3134492039680481

Preliminary O 0 3.407381518627517e-05
in O 0 2.468706497893436e-06
vivo O 0 0.0001762520259944722
footprinting O 0 0.00019323971355333924
data O 0 8.532793316362586e-08
gave O 0 1.0407915418397806e-08
evidence O 0 7.469152407679758e-09
for O 0 2.17616080711025e-09
protein O 0 2.146853894657852e-08
- O 0 6.920486583794627e-08
DNA O 0 2.7968281912649218e-08
contact O 0 4.912770634746266e-09
in O 0 2.3007780125539057e-09
normal O 0 1.1205534278246887e-08
genes O 0 5.312315920491528e-09
at O 0 6.8691425880729184e-09
an O 0 8.418460928361071e-10
Sp1 O 0 2.768122726592992e-07
consensus O 0 3.0303105802431674e-08
binding O 0 3.196241493697016e-08
site O 0 1.6315091500018752e-08
upstream O 0 1.9532196304794525e-08
of O 0 2.657114528403781e-09
the O 0 1.8199759921344594e-08
CTG O 0 2.7275282263872214e-05
repeat O 0 5.038877759488969e-08
and O 0 1.8845777716158807e-10
for O 0 1.5948904696916344e-10
a O 0 1.0508084402616191e-09
significant O 0 2.7725275408840844e-09
reduction O 0 5.645460987580009e-08
of O 0 4.837583222894182e-09
this O 0 8.876940849056325e-10
interaction O 0 6.779591110728234e-09
in O 0 7.330775431135805e-10
cells O 0 1.35174260673665e-09
with O 0 3.2785568704341017e-10
a O 0 7.561452264326363e-08
hypermethylated O 0 0.0012169372057542205
DMPK O 0 0.45692911744117737
gene O 0 1.4347106116474606e-06
. O 0 1.0006850459376437e-07
. O 0 5.665783646691125e-07

The O 0 5.1587081543402746e-05
hemochromatosis B-Disease 1 1.0
gene O 0 2.3162579054769594e-06
product O 0 2.211176450828134e-07
complexes O 0 3.268532466904617e-08
with O 0 5.974902239636037e-10
the O 0 2.4422440958460356e-08
transferrin O 0 1.0959162864310201e-05
receptor O 0 5.13676513946848e-06
and O 0 5.4181770181571665e-09
lowers O 0 8.337261903079707e-08
its O 0 1.0632923430620167e-09
affinity O 0 2.80593841495147e-08
for O 0 6.39687414150103e-09
ligand O 0 1.366412334391498e-06
binding O 0 3.104907136730617e-06
. O 0 3.536976691975724e-06

We O 0 1.5455564152944135e-06
recently O 0 3.3600247206777567e-07
reported O 0 1.7922143769055765e-08
the O 0 4.650536844508224e-09
positional O 0 5.479391802509781e-07
cloning O 0 8.719628397102497e-08
of O 0 2.719757752345231e-09
a O 0 5.966625860054364e-09
candidate O 0 3.8224322906899033e-07
gene O 0 2.589329142210772e-07
for O 0 4.652065399568528e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 1 1.0
HFE O 1 1.0
. O 0 0.0011199634755030274

The O 0 3.477105892102372e-08
gene O 0 1.3449667157772183e-08
product O 0 1.3440204504888698e-08
, O 0 6.251226203346505e-10
a O 0 7.522063860676553e-09
member O 0 9.554977253856123e-09
of O 0 1.3672234011607998e-08
the O 0 2.1088103707711525e-08
major O 0 1.0596282891128794e-06
histocompatibility O 1 0.9753877520561218
complex O 0 3.1464608696296636e-07
class O 0 3.042327989533078e-08
I O 0 4.168240366198006e-07
- O 0 6.302592936435758e-08
like O 0 2.651464381386859e-09
family O 0 1.4581963414528332e-09
, O 0 2.793322795291431e-10
was O 0 6.509556005340755e-09
found O 0 2.2208210270768802e-10
to O 0 3.206343524020383e-10
have O 0 4.010280996169513e-10
a O 0 2.83511241150336e-08
mutation O 0 3.558891705779388e-07
, O 0 3.711171814302361e-08
Cys O 0 2.8892145564896055e-05
- O 0 7.238134458020795e-06
282 O 0 1.7309637314610882e-06
- O 0 9.367698112328071e-06
- O 0 4.797651399712777e-06
> O 0 8.441060344921425e-06
Tyr O 0 2.2377847926691175e-05
( O 0 4.372278539221952e-08
C282Y O 0 6.359434792102547e-06
) O 0 8.267798112804314e-10
, O 0 2.8307975408203845e-10
in O 0 4.4886042105396484e-10
85 O 0 1.762460932752674e-08
% O 0 3.800295900191486e-08
of O 0 9.05830006558972e-08
patient O 0 1.7525372868476552e-06
chromosomes O 0 1.0088323506352026e-05
. O 0 4.563627953757532e-06

This O 0 1.2789611503194465e-07
mutation O 0 6.218683097358735e-07
eliminates O 0 4.981408778803598e-07
the O 0 9.78550307451087e-09
ability O 0 5.145554649033102e-09
of O 0 4.738122072467377e-08
HFE O 0 0.00039156482671387494
to O 0 1.480222699967726e-08
associate O 0 6.447650235941182e-08
with O 0 1.0869494193599394e-09
beta2 O 0 0.015766628086566925
- O 0 0.003008662024512887
microglobulin O 1 0.6718145608901978
( O 0 1.023903877239718e-07
beta2m O 0 4.308067218516953e-05
) O 0 3.951876603736082e-09
and O 0 1.525346071673539e-09
prevents O 0 2.602241089277868e-08
cell O 0 2.0630384369724197e-06
- O 0 7.501535037590656e-07
surface O 0 1.2706669622275513e-05
expression O 0 5.284071448841132e-06
. O 0 2.116189534717705e-06

A O 0 4.345435627328698e-06
second O 0 7.310981686714513e-07
mutation O 0 3.1753995699546067e-07
that O 0 1.359517720622705e-09
has O 0 3.0635216585750413e-09
no O 0 2.6391986374108e-09
effect O 0 2.741304783171472e-08
on O 0 4.388269658761601e-08
beta2m O 0 1.791822796803899e-05
association O 0 2.6534340946682278e-08
, O 0 1.232533541895009e-08
H63D O 1 0.9997630715370178
, O 0 1.4135972392637086e-08
was O 0 5.4220155476514265e-08
found O 0 6.30078378360821e-10
in O 0 2.6238486383611814e-10
eight O 0 5.525238599979332e-10
out O 0 4.189069091609099e-10
of O 0 3.991997843399986e-09
nine O 0 2.4788025854149964e-08
patients O 0 3.87632725917797e-09
heterozygous O 0 2.7896517096337448e-08
for O 0 1.0214047385659342e-08
the O 0 1.3929820852354169e-06
C282Y O 0 0.40337303280830383
mutant O 0 0.00011308008106425405
. O 0 3.8804305404482875e-06

In O 0 1.5990980273272726e-07
this O 0 7.0194432488790426e-09
report O 0 1.5834618949384094e-08
, O 0 7.914995769908728e-09
we O 0 1.3213120375610288e-08
demonstrate O 0 3.2969463603649274e-08
in O 0 2.989219893834161e-08
cultured O 0 9.492815706835245e-07
293 O 0 6.172820121719269e-07
cells O 0 2.2505258812088869e-07
overexpressing O 0 2.7921912533201976e-06
wild O 0 8.993536226853394e-08
- O 0 1.524317951862031e-07
type O 0 2.8724693379444943e-07
or O 0 1.3812443455663015e-07
mutant O 0 6.384394737324328e-07
HFE O 0 4.650167284125928e-06
proteins O 0 7.671721036217605e-10
that O 0 9.240277293320887e-11
both O 0 6.497544169370428e-10
the O 0 7.93519117081587e-09
wild O 0 5.757752319368592e-08
- O 0 2.9984823868289823e-07
type O 0 1.4502650174108567e-06
and O 0 9.672000800264868e-08
H63D O 1 0.9999396800994873
HFE O 0 0.00284281512722373
proteins O 0 1.2769156398917403e-08
form O 0 9.708759129978262e-09
stable O 0 1.2246545111338492e-07
complexes O 0 2.095634776821953e-08
with O 0 5.063517383163685e-10
the O 0 2.548474853369953e-08
transferrin O 0 4.308125062379986e-05
receptor O 0 3.966672011301853e-05
( O 0 4.457051829831471e-07
TfR O 0 2.5207527869497426e-05
) O 0 1.3883096983136056e-07
. O 0 5.382047447710647e-07

The O 0 3.9442234083253425e-06
C282Y O 0 0.00038925654371269047
mutation O 0 3.8709617911081295e-06
nearly O 0 8.887860758477473e-08
completely O 0 4.5687738037258896e-08
prevents O 0 7.458261563897395e-09
the O 0 3.101898737867259e-09
association O 0 3.9082648228827566e-09
of O 0 1.9130895978491935e-08
the O 0 6.035763533418503e-08
mutant O 0 1.0744219025582424e-06
HFE O 0 4.259520210325718e-05
protein O 0 7.066543616929266e-08
with O 0 1.949095107534049e-09
the O 0 3.483758064248832e-07
TfR O 0 0.0003180650237482041
. O 0 4.021555923827691e-06

Studies O 0 6.656711661889858e-07
on O 0 3.337846692375024e-07
cell O 0 1.9714148038474377e-06
- O 0 4.3148585859853483e-07
associated O 0 5.130817726239911e-08
transferrin O 0 1.4954952121115639e-06
at O 0 6.782555317386141e-08
37 O 0 1.6578594497218546e-08
degrees O 0 8.724552458261314e-08
C O 0 5.79099150854745e-07
suggest O 0 3.2777769387593025e-09
that O 0 6.03912087004943e-10
the O 0 3.33733716217921e-08
overexpressed O 0 4.167503720964305e-05
wild O 0 3.0445514198618184e-07
- O 0 7.39360643819964e-07
type O 0 2.257065261801472e-06
HFE O 0 0.0001988387230085209
protein O 0 5.642457523435951e-08
decreases O 0 1.1537907518288648e-08
the O 0 1.0298923935891935e-09
affinity O 0 5.371597566750097e-08
of O 0 2.837606238870194e-08
the O 0 1.017888919818688e-07
TfR O 0 2.0409474018379115e-05
for O 0 1.1062871152489606e-07
transferrin O 0 8.01801506895572e-05
. O 0 5.358864655136131e-06

The O 0 6.72967144055292e-06
overexpressed O 0 0.0007703618612140417
H63D O 0 0.08714531362056732
protein O 0 1.233722883853261e-07
does O 0 9.92894877427375e-10
not O 0 3.7918929107760846e-10
have O 0 1.0996378113636851e-10
this O 0 2.0176116333203709e-10
effect O 0 8.903482395794526e-09
, O 0 2.775690233214334e-10
providing O 0 1.7031230592490232e-10
the O 0 6.806952779214726e-10
first O 0 6.742396641001847e-10
direct O 0 1.920730019477901e-09
evidence O 0 3.2255813575687853e-09
for O 0 5.811965353430537e-10
a O 0 8.906914317208248e-09
functional O 0 3.9168980947579257e-07
consequence O 0 5.249066816759296e-07
of O 0 3.493858713454756e-08
the O 0 2.0264539557501848e-07
H63D O 1 0.7107710242271423
mutation O 0 3.846123945550062e-05
. O 0 2.61594186667935e-06

Addition O 0 8.289357538160402e-07
of O 0 1.5412642824230716e-06
soluble O 0 6.426669278880581e-05
wild O 0 1.1918311884073773e-06
- O 0 5.498359314515255e-06
type O 0 0.00014285581710282713
HFE O 1 0.9999979734420776
/ O 1 0.964051365852356
beta2m O 0 0.023362157866358757
heterodimers O 0 1.3611289432446938e-05
to O 0 3.5634961648156604e-08
cultured O 0 4.0162871073334827e-07
cells O 0 2.0163057001809648e-08
also O 0 8.532621831314202e-10
decreased O 0 8.536126472336036e-09
the O 0 1.3314968017041906e-09
apparent O 0 2.8799950868574342e-08
affinity O 0 8.114327698649504e-08
of O 0 3.2999349031115344e-08
the O 0 1.3691545674987537e-08
TfR O 0 2.7942695624005864e-07
for O 0 2.575892832368254e-10
its O 0 1.0159750818417024e-10
ligand O 0 1.716223962944241e-08
under O 0 8.375765858659179e-09
steady O 0 1.4401237535821565e-07
- O 0 3.6232393085811054e-08
state O 0 1.6091519228211837e-09
conditions O 0 2.8926736561629696e-08
, O 0 1.5734655800514474e-09
both O 0 1.125470716623056e-09
in O 0 5.017632087600532e-09
293 O 0 6.416158271349559e-08
cells O 0 1.291450058005239e-08
and O 0 5.4974682583974754e-09
in O 0 1.0471558908875522e-07
HeLa O 0 9.227248665411025e-05
cells O 0 1.980210754481959e-06
. O 0 1.4182553513819585e-06

Furthermore O 0 3.081002887483919e-06
, O 0 5.1475602447226265e-08
at O 0 4.5635136558530576e-08
4 O 0 4.33497788776549e-08
degrees O 0 5.644502039103827e-07
C O 0 7.089843620633474e-06
, O 0 7.806119306508208e-09
the O 0 1.6863646479237104e-08
added O 0 1.4448573892877903e-07
soluble O 0 6.172360826894874e-07
complex O 0 7.341094487856026e-08
of O 0 1.3131396769949788e-07
HFE O 0 0.0022171882446855307
/ O 0 4.016935417894274e-05
beta2m O 0 1.841749508457724e-05
inhibited O 0 1.334565524757636e-07
binding O 0 7.402143609169798e-08
of O 0 4.165457667681949e-08
transferrin O 0 3.581776581995655e-06
to O 0 2.7413318548497045e-07
HeLa O 0 0.00019577266357373446
cell O 0 7.306141924345866e-06
TfR O 0 2.8958481834706618e-06
in O 0 3.988146701772166e-09
a O 0 6.213501535512478e-08
concentration O 0 1.1661352800729219e-05
- O 0 2.016661255765939e-06
dependent O 0 5.359210035749129e-07
manner O 0 1.4993638615123928e-06
. O 0 2.6403388346807333e-06

Scatchard O 0 0.00029285167693160474
plots O 0 5.143632733961567e-06
of O 0 6.065538116217795e-08
these O 0 1.3631086259735525e-09
data O 0 1.4341448917321031e-08
indicate O 0 1.1814561773348942e-08
that O 0 4.931854924450363e-10
the O 0 1.2823020867358537e-08
added O 0 6.747470848722514e-08
heterodimer O 0 1.073303565135575e-06
substantially O 0 2.7269949853803155e-08
reduced O 0 1.629033974381855e-08
the O 0 4.172151069070651e-09
affinity O 0 1.3345324134661496e-07
of O 0 1.1078158479449485e-07
TfR O 0 6.02524369242019e-06
for O 0 8.314599853065374e-08
transferrin O 0 5.309614061843604e-05
. O 0 2.863486315618502e-06

These O 0 7.101267840425862e-08
results O 0 8.375753424161303e-08
establish O 0 3.8821003300881785e-08
a O 0 1.0260993121846695e-07
molecular O 0 4.2090346141776536e-06
link O 0 5.468293693411397e-07
between O 0 4.489910168103961e-07
HFE O 1 0.9935378432273865
and O 0 6.579156330843716e-09
a O 0 3.2091186596971966e-08
key O 0 9.655467181346467e-08
protein O 0 5.088799603925054e-09
involved O 0 4.475720627450386e-10
in O 0 5.134631053671512e-10
iron O 0 7.166717352902197e-08
transport O 0 9.730913852479262e-09
, O 0 1.1296560353812879e-09
the O 0 6.497411497718986e-09
TfR O 0 2.1127937088749604e-06
, O 0 4.5487011379741205e-10
and O 0 1.450199127450702e-10
raise O 0 1.725087517279178e-09
the O 0 2.0543833301189807e-09
possibility O 0 5.456343998844204e-08
that O 0 5.774992151152958e-10
alterations O 0 3.761268629887127e-08
in O 0 4.0719580485237827e-10
this O 0 2.0703329328686237e-10
regulatory O 0 1.2304806062957141e-08
mechanism O 0 2.9262913869843032e-08
may O 0 6.89271395515334e-09
play O 0 9.042484983012855e-09
a O 0 1.1272974553833137e-08
role O 0 7.231649501449056e-09
in O 0 1.388297810045458e-09
the O 0 1.1528578980346538e-08
pathogenesis O 0 0.00024393490457441658
of O 0 8.704626088729128e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9940369129180908
. O 0 0.00020433208555914462

Genomic O 0 1.1236737918807194e-05
organization O 0 4.777925823873375e-07
of O 0 2.537731518259534e-07
the O 0 7.460682240889582e-07
UBE3A O 1 0.9996727705001831
/ O 1 0.8265729546546936
E6 O 1 0.9998654127120972
- O 0 0.0012523605255410075
AP O 0 1.4780984201934189e-05
gene O 0 1.0378937531640986e-07
and O 0 7.163407644839026e-09
related O 0 4.977571279596305e-07
pseudogenes O 0 5.849283843417652e-05
. O 0 7.698751687712502e-06

The O 0 9.296696589444764e-06
UBE3A O 0 0.0018780070822685957
gene O 0 1.7547213246871252e-06
encodes O 0 6.238284413484507e-07
the O 0 2.007005690529695e-07
E6 O 0 0.04213431850075722
- O 0 0.00042272015707567334
AP O 0 2.8422427931218408e-05
ubiquitin O 0 3.619720928327297e-06
- O 0 2.5122261604337837e-07
protein O 0 7.888440123338114e-09
ligase O 0 1.4210530530078813e-08
and O 0 7.505550070341371e-10
has O 0 7.534839974177032e-10
recently O 0 3.1388820431743625e-09
been O 0 2.876105742455337e-10
shown O 0 3.8508848887452984e-11
to O 0 8.536100992717621e-11
be O 0 2.0443100545719517e-09
mutated O 0 6.696890295643243e-07
in O 0 6.13069350947626e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.04791562259197235
who O 0 3.011994976986898e-06
lack O 0 2.63051588262897e-05
15q11 O 1 0.8353200554847717
- O 0 5.066113590146415e-05
q13 O 0 3.6129837098997086e-05
deletions O 0 4.3630402046801464e-07
or O 0 1.040833623733306e-07
chromosome O 0 2.2884451027493924e-05
15 O 0 9.318605407315772e-07
paternal O 0 2.167956881748978e-05
uniparental B-Disease 1 0.7325493097305298
disomy I-Disease 1 0.858594536781311
. O 0 5.5562370107509196e-05

Previous O 0 4.6865960030118003e-05
UBE3A O 0 0.001335571170784533
cDNA O 0 6.077042598917615e-06
analysis O 0 1.2606814436821878e-07
has O 0 4.656643515232872e-09
shown O 0 1.1459646565015191e-09
a O 0 5.905104405456996e-09
coding O 0 4.6435994249804935e-07
region O 0 3.4273543292329123e-07
of O 0 1.5723857416105602e-07
approximately O 0 2.4909743956413877e-07
2 O 0 3.4305237477383344e-06
. O 0 8.121820087581e-07

6 O 0 0.00012897292617708445
kb O 0 0.00016919102927204221
and O 0 2.960412892605291e-08
a O 0 6.861321253381902e-07
3 O 0 4.56312918686308e-05
- O 0 5.4891424952074885e-05
untranslated O 0 0.29383960366249084
region O 0 2.4206851776398253e-06
( O 0 6.028768240184945e-08
UTR O 0 4.2660441977204755e-05
) O 0 5.113844459003758e-09
of O 0 2.2751283523803068e-08
< O 0 9.262439562007785e-06
50 O 0 8.224239422816026e-08
bp O 0 2.415730762095336e-07
, O 0 3.280109739378645e-09
whereas O 0 2.5477458365230632e-08
Northern O 0 2.8465722223813827e-08
analysis O 0 2.040719060403262e-08
has O 0 2.444340063689765e-09
indicated O 0 9.336377893021108e-09
mRNA O 0 8.649164584539903e-08
sizes O 0 1.0987751153379577e-08
of O 0 1.8844216853608486e-08
5 O 0 7.074013979035954e-07
- O 0 5.096727363707032e-06
8 O 0 9.685348231869284e-06
kb O 0 9.012848022393882e-05
. O 0 3.4278025395906297e-06

We O 0 1.5643745427951217e-06
have O 0 2.520500075320342e-08
analyzed O 0 9.49738208078088e-08
additional O 0 1.3991817482406077e-08
cDNA O 0 2.5572771846782416e-06
clones O 0 3.2235323033091845e-07
and O 0 4.0079714547225365e-10
provide O 0 4.876461456859715e-10
evidence O 0 4.016269095075131e-09
for O 0 1.9600854272994184e-09
an O 0 5.930998359104933e-09
additional O 0 8.102728799030956e-08
0 O 0 6.0276979638729244e-06
. O 0 1.1039217042707605e-06

5 O 0 2.528355980757624e-05
kb O 0 7.60374023229815e-05
of O 0 1.052694528880238e-06
5 O 0 2.5994388579420047e-06
- O 0 5.255134965409525e-06
UTR O 0 0.0003762207052204758
and O 0 5.990689544432826e-08
> O 0 1.1703489690262359e-05
2 O 0 4.585217538988218e-06
kb O 0 8.39897711557569e-06
of O 0 3.9453868794225855e-07
3 O 0 1.0083167580887675e-05
- O 0 5.0855382141890004e-05
UTR O 0 0.005061361938714981
. O 0 7.88056968303863e-06

We O 0 1.9942244477988424e-07
have O 0 2.489324302246132e-09
established O 0 4.353336802154217e-09
the O 0 3.142985871562587e-09
genomic O 0 1.2696449402938015e-07
organization O 0 1.735580035244766e-08
of O 0 1.1341908390249955e-07
UBE3A O 0 0.00047752325190231204
and O 0 5.389163781899242e-09
the O 0 1.0782362558359182e-08
sequence O 0 2.060777326562402e-08
of O 0 6.71926869699746e-08
intron O 0 5.1873652409994975e-05
- O 0 1.2801933735318016e-05
exon O 0 2.494428917998448e-05
borders O 0 7.72747455357603e-07
. O 0 1.6651853229632252e-06

We O 0 2.6685645480029052e-06
have O 0 6.615398717713106e-08
also O 0 2.1250745163570173e-08
mapped O 0 1.5999140146050195e-07
two O 0 5.660024005038622e-09
highly O 0 1.3661233921880012e-08
homologous O 0 3.8018402648276606e-08
processed O 0 9.51560537032492e-08
pseudogenes O 0 5.508417757482675e-07
, O 0 1.3050368785627597e-08
UBE3AP1 O 0 0.01041092723608017
and O 0 3.5211002114010626e-08
UBE3AP2 O 1 0.7467297315597534
, O 0 3.015612204393392e-09
to O 0 1.871918398066441e-09
chromosomes O 0 1.610700195442405e-08
2 O 0 2.9668401069216088e-08
and O 0 3.7918640449774443e-10
21 O 0 1.3133020004829632e-08
, O 0 1.623363332647898e-09
respectively O 0 1.1473497707470415e-08
, O 0 6.767701399290615e-10
and O 0 5.195086583142938e-10
determined O 0 2.647726304871867e-08
their O 0 1.5317572765738419e-09
genomic O 0 1.0920807653747033e-06
organization O 0 4.963899868926092e-07
. O 0 2.265348030050518e-06

These O 0 2.4572521795107605e-08
results O 0 3.696971617728195e-08
will O 0 1.0179423970413382e-09
form O 0 1.1210273820339012e-09
the O 0 1.2624428169516477e-09
basis O 0 6.143710873374175e-09
for O 0 3.8558259363163927e-10
studies O 0 1.2056818876615694e-09
of O 0 1.992578324561123e-09
mutation O 0 2.5391253544171377e-08
and O 0 1.0084581170133333e-08
imprinting O 0 1.5844876543269493e-05
of O 0 1.2980411156604532e-05
UBE3A O 1 0.9991574287414551
. O 0 1.1270542927377392e-05

Mutation O 0 5.731113924412057e-05
spectrum O 0 0.00010745116014732048
and O 0 5.3224715657052e-07
genotype O 0 0.00020903449330944568
- O 0 0.0001601605035830289
phenotype O 0 4.448000709089683e-06
analyses O 0 2.930143523371953e-07
in O 0 5.3512273723299586e-08
Cowden B-Disease 0 0.34358054399490356
disease I-Disease 0 1.7399577700416557e-05
and O 0 3.599386673158733e-07
Bannayan B-Disease 1 1.0
- I-Disease 1 1.0
Zonana I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.428964537808497e-06
two O 0 1.6817957657622173e-06
hamartoma B-Disease 1 0.9999998807907104
syndromes I-Disease 1 0.9999942779541016
with O 0 8.515935769537464e-05
germline O 1 1.0
PTEN O 1 1.0
mutation O 1 0.9980109333992004
. O 0 2.7532854801393114e-05

The O 0 8.59617066453211e-05
tumour B-Disease 1 1.0
suppressor O 1 0.9999328851699829
gene O 0 0.0006014109821990132
PTEN O 1 0.9995493292808533
, O 0 4.800616437705685e-08
which O 0 8.989792910085725e-09
maps O 0 2.9663601708307397e-07
to O 0 4.805463049706304e-07
10q23 O 0 0.002813099417835474
. O 0 1.9063792933593504e-05

3 O 0 1.2193001566629391e-05
and O 0 9.72290266076925e-08
encodes O 0 3.1964827940100804e-07
a O 0 1.3427820988454187e-07
403 O 0 9.587749616457586e-08
amino O 0 7.81357059054244e-08
acid O 0 2.144439470441739e-08
dual O 0 1.3855782299287966e-07
specificity O 0 1.496419713475916e-06
phosphatase O 0 8.838303619995713e-05
( O 0 3.824692385023809e-08
protein O 0 4.0561644709669054e-08
tyrosine O 0 1.0178656140169551e-07
phosphatase O 0 9.882871836452978e-07
; O 0 3.730231679099916e-09
PTPase O 0 5.727029929403216e-06
) O 0 1.801552795832606e-09
, O 0 8.502761827955396e-10
was O 0 1.5943173892196683e-08
shown O 0 5.650453993588656e-10
recently O 0 1.7612301617120352e-09
to O 0 4.80854800422037e-10
play O 0 5.145819770291382e-09
a O 0 1.7078580327734016e-08
broad O 0 1.0860982229132787e-06
role O 0 2.2492513096494804e-07
in O 0 6.20918925164915e-08
human O 0 7.341681680372858e-07
malignancy B-Disease 1 0.9973694086074829
. O 0 5.342199074220844e-06

Somatic O 1 0.8221973776817322
PTEN O 1 0.5256736874580383
deletions O 0 1.1503293535497505e-05
and O 0 4.9785967348725535e-08
mutations O 0 2.2905929597527575e-07
were O 0 1.0439089592750861e-08
observed O 0 1.786876069331811e-08
in O 0 2.43283282408413e-09
sporadic B-Disease 0 3.82902499040938e-06
breast I-Disease 1 0.9999991655349731
, I-Disease 0 1.2879024779977044e-06
brain I-Disease 1 0.999997615814209
, I-Disease 0 3.868039129883982e-05
prostate I-Disease 1 1.0
and I-Disease 1 0.9843652248382568
kidney I-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 1 0.9999939203262329
lines O 0 1.2318189419602277e-06
and O 0 2.9709157356450078e-09
in O 0 1.1748938488764793e-09
several O 0 2.8719682187983153e-09
primary O 0 1.5122209333640058e-05
tumours B-Disease 1 0.9999971389770508
such O 0 2.017717370961236e-08
as O 0 2.0969371689716354e-05
endometrial B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 1 1.0
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 1.0
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 1 0.9981483221054077

In O 0 2.0000773304218455e-07
addition O 0 5.6535746750796534e-08
, O 0 2.803713528010121e-07
PTEN O 1 0.9999969005584717
was O 0 6.639937055297196e-06
identified O 0 1.015060249187627e-07
as O 0 2.6503421679535677e-09
the O 0 4.633935013487189e-09
susceptibility O 0 8.532937272320851e-07
gene O 0 5.577507877774224e-08
for O 0 2.062169102146072e-08
two O 0 2.9217683277238393e-06
hamartoma B-Disease 1 1.0
syndromes I-Disease 1 1.0
Cowden B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 1.0849908903765026e-05
CD B-Disease 0 0.02742473967373371
; O 0 6.963849727981142e-07
MIM O 0 0.010039099492132664
158350 O 0 2.646761276992038e-05
) O 0 1.8751784125470294e-08
and O 0 3.5703472178738593e-08
Bannayan B-Disease 0 0.0643659234046936
- I-Disease 1 0.7193999290466309
Zonana I-Disease 1 0.9888182282447815
( I-Disease 0 1.5944258393574273e-06
BZS I-Disease 0 0.0012009289348497987
) I-Disease 0 1.552062123266751e-08
or I-Disease 0 3.260232972479571e-08
Ruvalcaba I-Disease 0 8.05621766630793e-06
- I-Disease 0 4.1579751268727705e-06
Riley I-Disease 0 3.270583420089679e-06
- I-Disease 1 0.5479745864868164
Smith I-Disease 0 0.31206101179122925
syndrome I-Disease 1 1.0
( O 0 0.00015155495202634484
MIM O 1 0.9999988079071045
153480 O 1 0.97911536693573
) O 0 8.481840154672682e-07
. O 0 3.1106565074878745e-06

Constitutive O 0 1.9242832422605716e-05
DNA O 0 1.5954389027683646e-06
from O 0 1.0222802870885062e-07
37 O 0 2.5644251877565694e-07
CD B-Disease 0 1.0433913075758028e-06
families O 0 7.371004695500005e-09
and O 0 1.3614256388905233e-08
seven O 0 2.4252503294519556e-07
BZS B-Disease 0 0.00616561621427536
families O 0 2.0071965423085203e-08
was O 0 3.075502377214434e-07
screened O 0 8.035868859224138e-07
for O 0 3.610993815073016e-07
germline O 0 0.17735005915164948
PTEN O 1 0.9999109506607056
mutations O 0 0.0001932104059960693
. O 0 8.965805136540439e-06

PTEN O 1 0.8986355066299438
mutations O 0 4.4311832425592e-06
were O 0 4.89840132900099e-08
identified O 0 3.285934724317485e-08
in O 0 3.0678779516790655e-09
30 O 0 1.125220272513161e-08
of O 0 9.551897051096603e-09
37 O 0 5.5102574947341054e-08
( O 0 3.34716565575377e-09
81 O 0 1.8909821619672584e-07
% O 0 1.8273359714271464e-08
) O 0 1.016429163058774e-09
CD B-Disease 0 1.8175308014178881e-07
families O 0 1.7913796002133608e-09
, O 0 2.697084777736336e-09
including O 0 5.384304113675853e-09
missense O 0 1.5973258996382356e-05
and O 0 4.4493052797633936e-08
nonsense O 0 0.00012357212835922837
point O 0 7.022626959951594e-05
mutations O 0 4.162877189628489e-07
, O 0 7.871801877001872e-09
deletions O 0 3.212904005067685e-07
, O 0 2.9159561876213047e-08
insertions O 0 5.899635766581923e-07
, O 0 1.6857599760555786e-08
a O 0 1.522060557590521e-07
deletion O 0 1.3616092473967e-05
/ O 0 8.360107131011318e-06
insertion O 0 2.4901291908463463e-06
and O 0 6.642127203804193e-08
splice O 0 4.806041397387162e-05
site O 0 8.501162938046036e-07
mutations O 0 2.3129400688048918e-06
. O 0 2.3659724774915958e-06

These O 0 6.298169807905651e-08
mutations O 0 3.9883624936010165e-07
were O 0 1.370267455058638e-08
scattered O 0 2.006859567416086e-08
over O 0 7.425968284735518e-09
the O 0 3.435244311233987e-09
entire O 0 1.5024435029431515e-08
length O 0 1.2108609226402223e-08
of O 0 1.7209048408517447e-08
PTEN O 0 0.00028976029716432095
, O 0 9.82113723679845e-10
with O 0 8.174339677369247e-11
the O 0 9.71279279227133e-10
exception O 0 2.5406936554617232e-09
of O 0 2.734827475592283e-09
the O 0 2.245440944292909e-09
first O 0 1.1375006714331448e-08
, O 0 1.0574135345109426e-08
fourth O 0 8.260821573458088e-07
and O 0 1.6541006786496837e-08
last O 0 1.1562952977328678e-06
exons O 0 3.440391810727306e-05
. O 0 1.521025978945545e-06

A O 0 0.00011305604130029678
hot O 0 9.058462455868721e-05
spot O 0 1.022855121846078e-05
for O 0 1.3686747024621582e-07
PTEN O 0 0.04027112200856209
mutation O 0 1.3553728877013782e-06
in O 0 3.462816522414869e-08
CD B-Disease 0 4.601170985552017e-06
was O 0 5.390841693042603e-07
identified O 0 2.6023252885920556e-08
in O 0 3.6809202352827697e-09
exon O 0 5.260592956801702e-07
5 O 0 9.188878102861509e-09
that O 0 1.7607254543250406e-10
contains O 0 7.975426430384402e-10
the O 0 3.7316478795901276e-09
PTPase O 0 2.150753789464943e-05
core O 0 1.5362220437964424e-06
motif O 0 5.915884671026106e-08
, O 0 3.513757063089429e-10
with O 0 8.352817049139816e-11
13 O 0 9.351972529714203e-09
of O 0 5.843280082018509e-09
30 O 0 1.2683059047446932e-08
( O 0 1.829766116401288e-09
43 O 0 5.357957633123078e-08
% O 0 9.046746463070576e-09
) O 0 1.3484336980340572e-09
CD B-Disease 0 2.0601727612756804e-07
mutations O 0 4.842146239525391e-08
identified O 0 2.0542000100931546e-08
in O 0 6.1204121770686015e-09
this O 0 4.441242040797988e-08
exon O 0 7.201399421319366e-05
. O 0 2.0894697172479937e-06

Seven O 0 6.327899768621137e-07
of O 0 9.40348954259207e-08
30 O 0 1.1625776608070737e-07
( O 0 1.6859882379094415e-08
23 O 0 8.089232039765193e-08
% O 0 1.1531944288378781e-08
) O 0 2.353712502678462e-10
were O 0 4.452858082260036e-10
within O 0 1.816531258747034e-09
the O 0 2.8112618899456265e-09
core O 0 2.2059381876715634e-07
motif O 0 3.723856778492518e-08
, O 0 2.858877301559204e-10
the O 0 3.9583772371010184e-10
majority O 0 8.916904437050732e-10
( O 0 1.1832552715418387e-09
five O 0 1.4986647478565374e-09
of O 0 1.1225721463503646e-09
seven O 0 7.2424538588578e-10
) O 0 2.0705975822821188e-10
of O 0 4.713482382179279e-10
which O 0 3.1171812353569806e-10
were O 0 5.029340943707439e-09
missense O 0 4.31885382567998e-06
mutations O 0 3.372352068709006e-07
, O 0 8.806285478613063e-09
possibly O 0 1.2993520215331955e-07
pointing O 0 2.0582618276421272e-07
to O 0 3.0032767384113868e-09
the O 0 1.012584682769102e-08
functional O 0 3.296745489933528e-07
significance O 0 6.527423579427705e-08
of O 0 1.759679690849225e-08
this O 0 1.0109733494800821e-08
region O 0 1.5146655414355337e-06
. O 0 1.0769927030196413e-06

Germline O 1 0.9833601713180542
PTEN O 0 0.4823232889175415
mutations O 0 1.7397085230186349e-06
were O 0 1.308978170300179e-08
identified O 0 1.4936059500314514e-08
in O 0 7.944666591264138e-10
four O 0 5.080669773782631e-10
of O 0 7.058579498675499e-09
seven O 0 1.1736917215898757e-08
( O 0 4.6284608146152095e-08
57 O 0 4.589176569425035e-06
% O 0 2.0202610357955564e-06
) O 0 2.0827803837164538e-07
BZS B-Disease 0 0.0012784231221303344
families O 0 1.1250597964362896e-07
studied O 0 3.872394245263422e-06
. O 0 3.3065582556446316e-06

Interestingly O 0 3.7050140235805884e-05
, O 0 7.274343971630515e-08
none O 0 1.476985111992235e-08
of O 0 4.556196753213726e-09
these O 0 5.86851955919343e-10
mutations O 0 6.994761037049102e-08
was O 0 2.213499357139881e-07
observed O 0 5.197937014145282e-08
in O 0 1.0003907924271971e-08
the O 0 1.425832039103625e-07
PTPase O 0 0.0029049429576843977
core O 0 0.00010283563460689038
motif O 0 1.4463092156802304e-05
. O 0 1.3853554037268623e-06

It O 0 2.2778811725743253e-08
is O 0 8.222949432479254e-09
also O 0 2.5201045694700497e-09
worthy O 0 4.5224240352581546e-08
of O 0 5.977025541170633e-09
note O 0 6.1410978524634174e-09
that O 0 2.313251673546901e-10
a O 0 4.3724432963188065e-09
single O 0 1.2089639511714267e-08
nonsense O 0 5.380127845455718e-07
point O 0 6.627155926253181e-07
mutation O 0 9.049700366858815e-08
, O 0 3.2040834430091536e-09
R233X O 0 2.851511089829728e-05
, O 0 2.930110154508725e-09
was O 0 4.056690272591368e-08
observed O 0 2.712282398675825e-09
in O 0 3.0434971209913897e-10
the O 0 1.461654797196843e-09
germline O 0 4.4452934844230185e-07
DNA O 0 4.514409113198781e-08
from O 0 4.219173455055625e-09
two O 0 1.0177948484013655e-09
unrelated O 0 3.443958718207796e-08
CD B-Disease 0 9.06377636056277e-07
families O 0 3.2828386675731736e-09
and O 0 9.178473980853141e-09
one O 0 4.463274763111258e-07
BZS B-Disease 1 0.9862474799156189
family O 0 9.989779528041254e-07
. O 0 2.064827867798158e-06

Genotype O 0 0.0003069624362979084
- O 0 4.069659553351812e-05
phenotype O 0 1.1259296570642618e-06
studies O 0 9.044055282458885e-09
were O 0 5.660366619864021e-10
not O 0 2.6697932753450004e-10
performed O 0 7.984071737077159e-10
on O 0 2.155066347597767e-09
this O 0 6.33070706967942e-10
small O 0 6.589177647953193e-09
group O 0 3.6142939308092537e-08
of O 0 5.554067570301413e-07
BZS B-Disease 1 0.9988945126533508
families O 0 4.5314774865801155e-07
. O 0 2.488904101483058e-06

However O 0 5.3275157370080706e-06
, O 0 6.837159389760927e-07
genotype O 0 3.018053394043818e-05
- O 0 6.1328296396823134e-06
phenotype O 0 5.705702506020316e-07
analysis O 0 3.400889170279697e-08
inthe O 0 5.983494702377357e-06
group O 0 1.2997828591210236e-08
of O 0 1.2563134532683762e-08
CD B-Disease 0 4.520575657807058e-06
families O 0 4.207376225195958e-09
revealed O 0 1.7331553081589846e-08
two O 0 1.626582618596828e-10
possible O 0 3.033362450111099e-09
associations O 0 1.881834688077788e-09
worthy O 0 6.19019857595049e-08
of O 0 8.956214436750543e-09
follow O 0 1.256334947186133e-08
- O 0 1.1414034162271491e-07
up O 0 1.6086186604979957e-08
in O 0 6.581993172716238e-09
independent O 0 7.512861799341408e-08
analyses O 0 1.472955773351714e-06
. O 0 1.924326625157846e-06

The O 0 3.352323858507589e-07
first O 0 7.518639222325874e-08
was O 0 2.1152501972210302e-07
an O 0 3.784625945968401e-09
association O 0 1.1969822466539881e-08
noted O 0 1.8781276978074857e-08
in O 0 1.6563603821850847e-09
the O 0 2.2927961751406656e-09
group O 0 2.609316984703014e-09
of O 0 8.151927133326353e-09
CD B-Disease 0 2.4549344743718393e-06
families O 0 9.407378875891936e-09
with O 0 1.0077682333076154e-07
breast B-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
. O 0 0.0016475978773087263

A O 0 4.779466507898178e-06
correlation O 0 3.011705075550708e-06
was O 0 1.3959821387743432e-07
observed O 0 6.476254199583309e-09
between O 0 1.4933916325787777e-09
the O 0 3.1812295020472448e-09
presence O 0 1.582737318983618e-08
/ O 0 5.667248842655681e-06
absence O 0 3.002476773872331e-07
of O 0 5.2219050417079416e-08
a O 0 1.893857159984691e-07
PTEN O 0 0.03390071168541908
mutation O 0 8.088893110880235e-08
and O 0 2.9084654129540866e-10
the O 0 7.166259807789288e-10
type O 0 1.3751103722370317e-07
of O 0 3.0250936333686695e-07
breast O 1 0.7530370950698853
involvement O 0 0.00010949499846901745
( O 0 1.951240619746386e-06
unaffected O 0 0.006370891816914082
versus O 1 0.9990831613540649
benign O 1 0.9999961853027344
versus O 1 0.9999960660934448
malignant O 1 1.0
) O 0 1.452407673241396e-06
. O 0 2.8347449188004248e-06

Specifically O 0 1.4852389540465083e-07
and O 0 1.1730040272439624e-09
more O 0 8.406326329479796e-11
directly O 0 2.8082176584121044e-09
, O 0 8.811708029909937e-10
an O 0 8.004320539711784e-10
association O 0 1.5699171740379825e-08
was O 0 7.29482337646914e-07
also O 0 1.3722494252021988e-09
observed O 0 1.1171212843663625e-09
between O 0 1.0453111709551877e-09
the O 0 1.0322622756575583e-09
presence O 0 1.2364108625817494e-09
of O 0 6.4451146641886226e-09
a O 0 1.1635160035439185e-07
PTEN O 1 0.9986860156059265
mutation O 0 0.0001573384361108765
and O 0 5.042872089688899e-06
malignant B-Disease 1 1.0
breast I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0017308926908299327

Secondly O 0 0.00015588095993734896
, O 0 5.87800315088316e-08
there O 0 8.728975764427105e-09
appeared O 0 1.4288588090494159e-08
to O 0 8.873843326817621e-10
be O 0 2.298549794943483e-09
an O 0 4.374511863858288e-09
interdependent O 0 2.8384563393046847e-06
association O 0 2.4568679535263982e-08
between O 0 1.1700253566004903e-07
mutations O 0 3.9954511521500535e-07
upstream O 0 1.3643675345065276e-07
and O 0 5.363934296731543e-10
within O 0 8.923867866883484e-09
the O 0 3.211874144426474e-08
PTPase O 0 0.00011558995902305469
core O 0 2.8392576041369466e-06
motif O 0 2.1468196109708515e-07
, O 0 1.3071536075770496e-09
the O 0 2.3775825752636592e-09
core O 0 1.0214597523372504e-07
motif O 0 6.046604550391521e-09
containing O 0 2.155394057679061e-10
the O 0 3.7330266655644095e-10
majority O 0 1.2335582555422775e-09
of O 0 5.586107132415918e-09
missense O 0 2.5212366381310858e-06
mutations O 0 1.965419897942411e-07
, O 0 1.0025698049531684e-09
and O 0 2.0018799118393105e-10
the O 0 2.687881917040613e-09
involvement O 0 1.1835327740072898e-07
of O 0 1.5275304576789495e-08
all O 0 1.1349471362720465e-09
major O 0 1.0018767682140606e-07
organ O 0 0.0002305170492036268
systems O 0 0.0002329929848201573
( O 0 3.851993142234278e-07
central O 0 3.971857950091362e-05
nervous O 0 1.95570828509517e-06
system O 0 3.6510340351014747e-07
, O 0 1.530590481024774e-07
thyroid O 1 0.9999998807907104
, O 0 2.6683405849325936e-06
breast O 1 1.0
, O 0 0.000130073371110484
skin O 1 0.9999998807907104
and O 1 0.9745868444442749
gastrointestinal O 1 1.0
tract O 1 1.0
) O 0 7.559206278529018e-05
. O 0 2.0137660612817854e-05

However O 0 4.870972816206631e-07
, O 0 6.791083695389943e-09
these O 0 1.3514042662698955e-10
observations O 0 9.524244504177659e-09
would O 0 5.091819410552034e-09
need O 0 4.691868671358179e-09
to O 0 2.4846851243154333e-09
be O 0 3.0409048612511924e-09
confirmed O 0 1.3014814781442396e-09
by O 0 1.2349701816738445e-10
studying O 0 1.4138257231621765e-09
a O 0 6.252049433719264e-10
larger O 0 1.3726262348967566e-09
number O 0 1.898617263407232e-09
of O 0 1.687088335700082e-08
CD B-Disease 0 4.749894287670031e-06
families O 0 1.4860988528653252e-07
. O 0 1.8935929801955353e-06

Molecular O 1 0.9997751116752625
defects O 1 0.9999501705169678
leading O 0 2.9431089387799148e-06
to O 0 1.1682264933199349e-08
human O 0 8.586502175944588e-09
complement B-Disease 0 2.1697819363453164e-07
component I-Disease 1 0.9999998807907104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.1671729360784866e-08
an O 0 1.9825627806113744e-09
African O 0 1.4367787848357239e-08
- O 0 8.064337464475102e-08
American O 0 5.817106440986208e-08
family O 0 3.663670256059959e-08
. O 0 3.439951399286656e-07

Complement B-Disease 0 2.8113277949159965e-05
component I-Disease 1 0.9999971389770508
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.5479254216188565e-06
C6D B-Disease 1 0.9998972415924072
) O 0 3.7097279914632963e-08
was O 0 8.792323455963924e-07
diagnosed O 0 5.922330501562101e-07
in O 0 4.4118814157556585e-10
a O 0 1.8957366787475394e-09
16 O 0 8.154990460695899e-09
- O 0 9.223575681005514e-09
year O 0 4.563319944139721e-09
- O 0 3.114331903475431e-08
old O 0 6.352036052703625e-08
African O 0 1.2433666540800914e-08
- O 0 4.7781991696638215e-08
American O 0 2.237234042468117e-08
male O 0 1.9047517341164166e-08
with O 0 1.0394345828501628e-08
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00032522741821594536

The O 0 1.0169782171942643e-06
patients O 0 3.2516015835426515e-07
father O 0 1.2298487206408026e-07
and O 0 3.286735328345003e-09
two O 0 4.423680532994467e-09
brothers O 0 3.901170089193329e-07
also O 0 8.378003180098403e-09
had O 0 2.3659040948587062e-07
C6D B-Disease 1 0.9999967813491821
, O 0 4.156194499671528e-09
but O 0 1.003878646876899e-09
gave O 0 1.987871200981317e-09
no O 0 2.2645678665611513e-09
history O 0 1.6208426600883286e-08
of O 0 9.533734868227839e-08
meningitis B-Disease 1 0.9997904896736145
or O 0 1.0498741858100402e-06
other O 0 3.6203246622790175e-07
neisserial B-Disease 1 0.9999958276748657
infection I-Disease 1 0.9169930219650269
. O 0 4.064935274072923e-05

By O 0 1.283360830939273e-07
using O 0 2.488172867742833e-07
exon O 0 5.644207703880966e-06
- O 0 2.84991415355762e-07
specific O 0 1.3682199373477033e-08
polymerase O 0 7.360034715020447e-07
chain O 0 3.699087613995289e-08
reaction O 0 1.0850360609993004e-08
( O 0 2.2053685544420887e-09
PCR O 0 7.083533404284026e-08
) O 0 3.795976422082958e-09
/ O 0 9.347374430035416e-08
single O 0 2.2498406693216566e-08
- O 0 9.090442176784563e-08
strand O 0 1.4073269483105832e-07
conformation O 0 1.9759720970569106e-08
polymorphism O 0 2.1616457956952218e-08
as O 0 4.668825881459782e-10
a O 0 2.4631916506479e-09
screening O 0 6.397471885577488e-09
step O 0 8.582246024957385e-09
and O 0 5.902623945175378e-10
nucleotide O 0 8.71604921570679e-09
sequencing O 0 5.614317455382434e-09
of O 0 2.7382882628046445e-09
target O 0 4.3130231830446064e-08
exons O 0 1.2409718408434856e-07
, O 0 7.469547202987314e-10
we O 0 3.4296585016413417e-10
determined O 0 2.2756827533498836e-09
that O 0 8.697125658541083e-11
the O 0 4.166838429853215e-09
proband O 0 9.298132681578863e-06
was O 0 1.7581021438672906e-07
a O 0 3.783285151826021e-08
compound O 0 1.5192559033039288e-07
heterozygote O 0 5.252982759884617e-07
for O 0 9.130178391103527e-09
two O 0 5.993604190734914e-08
C6 O 1 0.5270100831985474
gene O 0 8.457885996904224e-06
mutations O 0 1.0753130482044071e-05
. O 0 2.42717169385287e-06

The O 0 1.06363756913197e-06
first O 0 2.867137993689539e-07
, O 0 1.8550789349092156e-08
1195delC O 0 1.6471293520226027e-06
located O 0 7.098342535982738e-08
in O 0 1.2492858303403409e-08
exon O 0 1.986778443097137e-06
7 O 0 3.247560016461648e-07
, O 0 1.1956468037865875e-09
is O 0 5.498891897381952e-10
a O 0 2.0337007633486337e-09
novel O 0 1.0032780828339583e-08
mutation O 0 2.728503645244018e-08
, O 0 9.378225973577514e-10
while O 0 1.0907271752458314e-09
the O 0 4.176019974266865e-09
second O 0 1.320080826872072e-07
, O 0 4.513899032332347e-09
1936delG O 0 2.549627993175818e-07
in O 0 4.965601707596079e-09
exon O 0 6.39235736343835e-07
12 O 0 1.760586343380055e-08
, O 0 6.447595235492543e-10
has O 0 3.6481095921914175e-10
been O 0 5.829406957147398e-10
described O 0 1.3937129228480671e-09
before O 0 9.292544511652068e-10
to O 0 7.477857777438146e-10
cause O 0 6.485688572865911e-07
C6D B-Disease 1 0.9999768733978271
in O 0 6.679488517846721e-09
an O 0 2.157365175392556e-09
unrelated O 0 5.2867253685917603e-08
African O 0 2.9506775689469578e-08
- O 0 1.2755444345202704e-07
American O 0 6.61898269527228e-08
individual O 0 2.362048512338788e-08
. O 0 8.216382525461086e-07

Both O 0 9.161421417047677e-07
mutations O 0 4.954637915943749e-06
result O 0 7.246301265695365e-07
in O 0 4.334705181463505e-07
premature O 0 1.9669812900247052e-05
termination O 0 4.536211781669408e-05
codons O 0 5.121166759636253e-05
and O 0 2.1718719835917e-06
C6 O 1 0.7700426578521729
null O 0 0.0005716594168916345
alleles O 0 1.3015193871979136e-05
. O 0 2.7359094474377343e-06

Allele O 0 1.9275335034762975e-06
- O 0 6.314649425576135e-08
specific O 0 1.791553905228227e-09
PCR O 0 8.175100418839065e-08
indicated O 0 6.124674989393952e-09
that O 0 2.0286362867327767e-10
the O 0 2.8427784570794756e-09
probands O 0 6.7560486058937386e-06
two O 0 5.173937278613039e-09
brothers O 0 1.72180037338876e-07
also O 0 5.3359059393187636e-09
inherited O 0 1.9150104435539106e-07
the O 0 1.7837704646694874e-08
1195delC O 0 6.769191145394871e-07
mutation O 0 6.51447678023942e-08
from O 0 5.4118149961368545e-09
their O 0 6.352491310757102e-10
heterozygous O 0 9.300656245159189e-08
mother O 0 2.388245379236764e-09
and O 0 4.5200221343577596e-10
the O 0 4.79262762809185e-09
1936delG O 0 3.697190322782262e-07
mutation O 0 5.8355315246672035e-08
from O 0 9.33477473097355e-09
their O 0 4.0623095998171266e-09
homozygous O 0 2.823807108143228e-07
father O 0 3.901865852640185e-07
. O 0 1.4753751997886866e-07
. O 0 1.8746260366242495e-06

PAX6 O 1 0.6699619889259338
mutations O 0 0.0002918023383244872
reviewed O 0 5.932536441832781e-05
. O 0 1.9387001884751953e-05

Mutations O 0 1.995303864532616e-05
in O 0 1.4462816011473478e-07
PAX6 O 0 0.0013221721164882183
are O 0 3.246957369640313e-09
responsible O 0 1.25906245429519e-08
for O 0 4.687100929601229e-09
human O 0 4.6772083805990405e-07
aniridia B-Disease 1 1.0
and O 0 5.1885464813494764e-08
have O 0 1.962831674973131e-09
also O 0 1.1092167184756363e-09
been O 0 6.139841413066449e-10
found O 0 1.1845055492010204e-10
in O 0 1.5110059037315438e-10
patients O 0 1.7519419248657186e-10
with O 0 5.013296444644766e-10
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 6.302434485405684e-05
with O 1 0.9957135915756226
congenital B-Disease 1 1.0
cataracts I-Disease 1 1.0
, O 1 0.9996354579925537
with O 0 2.0083769413759e-05
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
keratitis I-Disease 1 1.0
, O 0 1.6693575162207708e-06
and O 0 8.672307671986346e-08
with O 0 2.7610150254986365e-07
isolated B-Disease 1 0.9999984502792358
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 1 0.9837967753410339

No O 0 5.463529078042484e-07
locus O 0 5.821773356728954e-06
other O 0 1.266917459830097e-09
than O 0 5.522375445821126e-09
chromosome O 0 1.762194006005302e-05
11p13 O 0 3.83429869543761e-05
has O 0 2.1267558825144306e-09
been O 0 1.6947151459945076e-09
implicated O 0 6.009962305597583e-08
in O 0 2.5265165959353908e-08
aniridia B-Disease 1 1.0
, O 0 5.6094076938961734e-08
and O 0 2.234197893358214e-08
PAX6 O 1 0.999995231628418
is O 0 5.256380219975654e-08
clearly O 0 1.04799067202066e-08
the O 0 2.4712196733389646e-09
major O 0 1.2353723377600545e-07
, O 0 1.3113989894009137e-09
if O 0 1.8363601750337466e-09
not O 0 1.1710167280298833e-09
only O 0 2.227546147537396e-09
, O 0 1.950463790478807e-09
gene O 0 3.7288817367198135e-08
responsible O 0 1.1411062672550543e-07
. O 0 7.802771619935811e-07

Twenty O 0 2.221726390416734e-05
- O 0 5.981002232147148e-06
eight O 0 1.6856240847573645e-07
percent O 0 2.0916856158237351e-07
of O 0 2.5513589463344033e-08
identified O 0 2.5838431838565157e-07
PAX6 O 0 8.358868944924325e-05
mutations O 0 2.231613223102613e-07
are O 0 4.412716858581689e-09
C O 0 0.12905827164649963
- O 0 0.009897110052406788
T O 0 2.257321284560021e-06
changes O 0 1.0129614480547389e-08
at O 0 9.759039443224538e-08
CpG O 0 4.051440782859572e-07
dinucleotides O 0 1.8269827251060633e-06
, O 0 2.6993698387656195e-09
20 O 0 6.0606097918025625e-09
% O 0 2.0515873444537647e-09
are O 0 4.525972652213994e-11
splicing O 0 2.2105160368823817e-08
errors O 0 9.858419502961624e-08
, O 0 1.1562906188089528e-09
and O 0 2.1927551441258686e-10
more O 0 7.651799333041609e-11
than O 0 7.228846410356482e-10
30 O 0 5.737413655282353e-09
% O 0 3.6974063810646385e-09
are O 0 2.1763550683839838e-10
deletion O 0 7.68446994925398e-08
or O 0 3.094808675996319e-08
insertion O 0 2.9532475309679285e-06
events O 0 3.025102444098593e-07
. O 0 9.03229818050022e-07

There O 0 4.0312755800187006e-07
is O 0 5.582169393392178e-08
a O 0 1.6951014458754798e-07
noticeably O 0 5.104242063680431e-06
elevated O 0 1.8902371721196687e-06
level O 0 1.0342595402335064e-07
of O 0 1.625272716410109e-08
mutation O 0 9.709503956401022e-08
in O 0 1.556828777005137e-09
the O 0 2.1610386813364357e-09
paired O 0 3.5089033900703726e-09
domain O 0 1.1748384487475505e-08
compared O 0 1.5531778085886572e-09
with O 0 5.828337118485294e-11
the O 0 3.1830198476967553e-09
rest O 0 4.2414772138954504e-08
of O 0 2.0329570915578188e-08
the O 0 7.968165505189972e-08
gene O 0 5.090578838462534e-07
. O 0 5.184095357435581e-07

Increased O 0 9.414199553248181e-07
mutation O 0 4.6634679051749117e-07
in O 0 7.371032673120226e-09
the O 0 1.4298511707977468e-08
homeodomain O 0 7.782433385727927e-06
is O 0 5.6724203112423766e-09
accounted O 0 1.2298329465920688e-08
for O 0 6.612201342015567e-10
by O 0 5.395787816553366e-09
the O 0 1.875177133570105e-07
hypermutable O 0 0.0006186600076034665
CpG O 0 4.687060936703347e-05
dinucleotide O 0 1.3894177754991688e-05
in O 0 1.7325264423107e-07
codon O 0 5.982565198792145e-06
240 O 0 2.2073952550272224e-06
. O 0 1.0522388720346498e-06

Very O 0 2.1916517312092765e-07
nearly O 0 3.166774575902309e-08
all O 0 1.4331952291612993e-09
mutations O 0 1.7794716811181388e-08
appear O 0 4.462450853282007e-09
to O 0 3.1945941447730775e-09
cause O 0 2.382892489549704e-06
loss O 0 2.4737735202506883e-06
of O 0 8.080488811401665e-08
function O 0 1.4681433846419623e-08
of O 0 2.1069035405218983e-09
the O 0 8.615468893857781e-10
mutant O 0 2.0397230571234104e-08
allele O 0 3.148285188103728e-08
, O 0 1.0908056402580968e-10
and O 0 5.027024282955317e-11
more O 0 3.6824682192460045e-11
than O 0 8.568566967070979e-10
80 O 0 1.7441818656038777e-08
% O 0 1.0196256283734328e-08
of O 0 1.3297361434183586e-08
exonic O 0 5.3457765716302674e-06
substitutions O 0 2.935269947101915e-07
result O 0 2.1634654956415034e-07
in O 0 1.7624617498768202e-07
nonsense O 0 3.224174361093901e-05
codons O 0 3.720898530445993e-05
. O 0 5.911625521548558e-06

In O 0 1.1611638228714583e-07
a O 0 4.628204663958968e-08
gene O 0 1.4124922564917597e-08
with O 0 3.318000596497228e-10
such O 0 7.71864883120088e-09
extraordinarily O 0 1.3567341738962568e-05
high O 0 1.749965349517879e-06
sequence O 0 3.8436258620322405e-08
conservation O 0 7.669296309131823e-09
throughout O 0 1.964067353199539e-09
evolution O 0 2.978980440104806e-08
, O 0 2.1701300756404862e-09
there O 0 7.344004515630331e-09
are O 0 1.391349790935692e-08
presumed O 0 4.5832952309865505e-05
undiscovered O 0 0.00045538818812929094
missense O 0 3.0987961508799344e-05
mutations O 0 7.678498263885558e-07
, O 0 1.3402287057928675e-09
these O 0 1.083370337884304e-10
are O 0 2.0959763091799033e-10
hypothesized O 0 7.962908910030819e-08
to O 0 2.079273642152657e-09
exist O 0 1.0554147777952494e-08
in O 0 5.331521002460704e-09
as O 0 1.426432660878163e-08
- O 0 3.1539474321107264e-07
yet O 0 8.900566683678335e-08
unidentified O 0 4.223443283990491e-07
phenotypes O 0 3.7116325302122277e-07
. O 0 6.954625320076957e-08
. O 0 1.0907922387559665e-06

Genetic O 0 0.00020156458776909858
heterogeneity O 0 0.00012599682668223977
and O 0 4.4307590485459514e-08
penetrance O 0 1.9153587800246896e-06
analysis O 0 3.8092363041641875e-08
of O 0 3.535259196496554e-08
the O 0 9.39995672410987e-08
BRCA1 O 0 1.1219112820981536e-05
and O 0 3.3703962287745526e-08
BRCA2 O 0 3.171212301822379e-05
genes O 0 2.756163723915961e-07
in O 0 2.1340454736673564e-07
breast B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999995231628418
families O 0 1.8903886029875139e-06
. O 0 9.84936923487112e-06

The O 0 0.0004890774725936353
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9993059635162354
Consortium O 0 0.0008472794434055686
. O 0 1.2156195225543343e-05

The O 0 1.0698171593048755e-07
contribution O 0 2.866924546651717e-07
of O 0 1.6882931674899737e-07
BRCA1 O 0 1.8357523003942333e-05
and O 0 8.075681279251512e-08
BRCA2 O 0 0.0017185334581881762
to O 0 3.2485036172147375e-06
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 1 0.9899469017982483
assessed O 0 4.6090981413726695e-06
by O 0 2.9109090693424378e-09
linkage O 0 6.383999107129057e-07
and O 0 8.60259530277574e-10
mutation O 0 4.6825796573557454e-09
analysis O 0 2.2971384794345795e-09
in O 0 6.492898441123884e-10
237 O 0 3.744617060874589e-09
families O 0 1.2286968664732e-10
, O 0 9.903901310170937e-11
each O 0 3.974095358350027e-11
with O 0 4.479441817473173e-11
at O 0 5.929686519579036e-09
least O 0 4.846298362615187e-10
four O 0 1.2413796379728836e-10
cases O 0 3.2342720168720973e-10
of O 0 6.003043040436751e-08
breast B-Disease 1 0.9997139573097229
cancer I-Disease 0 0.0030972505919635296
, O 0 3.763749756302559e-09
collected O 0 1.716340958246576e-09
by O 0 1.2892957812482564e-09
the O 0 1.9050153241551016e-06
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 1 0.9844636917114258
Consortium O 0 0.00019336689729243517
. O 0 3.976220341428416e-06

Families O 0 8.998924272418662e-08
were O 0 7.89458098893192e-09
included O 0 2.2845807468030443e-09
without O 0 5.5555910982718615e-09
regard O 0 4.564592970268677e-08
to O 0 2.0116797116997986e-09
the O 0 9.542246104388141e-09
occurrence O 0 8.355001455129241e-07
of O 0 2.771800609480124e-05
ovarian B-Disease 1 1.0
or I-Disease 0 4.6994849981274456e-05
other I-Disease 0 5.738352683692938e-06
cancers I-Disease 1 1.0
. O 0 8.776959293754771e-05

Overall O 0 0.00046283184201456606
, O 0 1.6686858543835115e-06
disease O 0 0.00020260854216758162
was O 0 2.4875182589312317e-06
linked O 0 3.140129649636947e-07
to O 0 1.0587515753002208e-08
BRCA1 O 0 6.794389264541678e-07
in O 0 1.4405509007886508e-09
an O 0 2.6636182148820353e-10
estimated O 0 1.372738922533756e-09
52 O 0 4.540225972959888e-09
% O 0 1.308108843467437e-09
of O 0 9.238290132884686e-10
families O 0 1.8750011265833422e-10
, O 0 3.120232960895919e-10
to O 0 2.538949717134642e-09
BRCA2 O 0 7.14213342689618e-07
in O 0 2.5309137008378e-09
32 O 0 1.0185255305827923e-08
% O 0 2.7679305514283215e-09
of O 0 7.20227100181603e-10
families O 0 2.6582536172270466e-10
, O 0 4.2154552071238527e-10
and O 0 1.6011847403518686e-10
to O 0 7.46770978388156e-10
neither O 0 1.6182539752662706e-08
gene O 0 4.269559372716003e-09
in O 0 7.744599406223074e-10
16 O 0 7.385640543589034e-09
% O 0 3.366026124496102e-09
( O 0 7.207973662382017e-10
95 O 0 7.618287156674342e-08
% O 0 6.000009733497791e-08
confidence O 0 8.911064242056455e-08
interval O 0 4.752857876155758e-06
[ O 0 2.0653083083743695e-06
CI O 0 0.00044745212653651834
] O 0 2.834929375694628e-07
6 O 0 4.744814674495501e-08
% O 0 1.6580521844389295e-08
- O 0 2.653104935745887e-08
28 O 0 1.2088902323625916e-08
% O 0 6.9863448359797076e-09
) O 0 3.258992242738401e-10
, O 0 6.172248823155257e-10
suggesting O 0 3.578999141495842e-08
other O 0 2.016420985739842e-08
predisposition O 0 0.04888574779033661
genes O 0 8.92574098543264e-06
. O 0 2.264009026475833e-06

The O 0 2.04345994347932e-07
majority O 0 8.032147746916962e-08
( O 0 1.9344888357863965e-08
81 O 0 2.821688553922286e-07
% O 0 1.2835157825463739e-08
) O 0 1.7926603257389928e-10
of O 0 2.012167099607609e-09
the O 0 4.001964555300219e-07
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.727634497683539e-07
were O 0 1.182502362695459e-08
due O 0 1.3036586032910691e-08
to O 0 2.5435979988941426e-09
BRCA1 O 0 1.8429757631110988e-07
, O 0 6.056654622277335e-10
with O 0 9.27688481588973e-11
most O 0 2.2280601807977973e-09
others O 0 2.310435176511305e-09
( O 0 2.123991427183114e-09
14 O 0 1.3532138076755018e-08
% O 0 9.574989690008806e-09
) O 0 6.908425498330928e-10
due O 0 3.317744656783361e-08
to O 0 1.7881532698993396e-07
BRCA2 O 0 0.00019138000789098442
. O 0 8.39390850160271e-06

Conversely O 0 9.476223567617126e-06
, O 0 1.1032964764012831e-08
the O 0 4.440477763267836e-09
majority O 0 2.174181945591158e-09
of O 0 6.640629379717211e-09
families O 0 5.26559629232537e-10
with O 0 2.7682250935967545e-10
male B-Disease 0 3.682740867816392e-08
and I-Disease 0 4.627302097048869e-09
female I-Disease 0 4.776030664288555e-07
breast I-Disease 1 0.999876856803894
cancer I-Disease 1 0.9929823875427246
were O 0 3.0207260692804994e-07
due O 0 2.573809069872368e-06
to O 0 1.678687340245233e-07
BRCA2 O 0 2.8914635549881496e-05
( O 0 1.2626244938473974e-07
76 O 0 4.5418887566484045e-06
% O 0 3.909635779564269e-07
) O 0 3.561355654824183e-08
. O 0 3.9394015516336367e-07

The O 0 1.3742165947405738e-06
largest O 0 1.9240055735281203e-06
proportion O 0 1.5130744657199102e-07
( O 0 7.629393117269956e-09
67 O 0 1.2244407798789325e-07
% O 0 1.2201901711250684e-08
) O 0 2.7148480685745824e-10
of O 0 1.6873870078981668e-09
families O 0 7.460619344534791e-10
due O 0 1.193762866336101e-08
to O 0 2.18707540966534e-09
other O 0 7.374347799071757e-10
genes O 0 1.8276976598841088e-09
was O 0 7.862573703221187e-09
found O 0 1.5868011071784593e-10
in O 0 5.861693075370766e-11
families O 0 3.0460099720297507e-11
with O 0 2.8898621343143027e-11
four O 0 5.231509669911816e-10
or O 0 2.2029345014829005e-09
five O 0 9.718555959992159e-10
cases O 0 1.4332635078773137e-09
of O 0 5.887068610377355e-08
female O 0 6.32785770449118e-07
breast B-Disease 1 0.9047186970710754
cancer I-Disease 1 0.816055417060852
only O 0 9.633035915612709e-06
. O 0 3.188533810316585e-05

These O 0 4.9373472421621045e-08
estimates O 0 4.2677501710386423e-07
were O 0 1.571636865094206e-08
not O 0 4.1731533784172825e-09
substantially O 0 7.589338935076739e-08
affected O 0 3.716475793780205e-09
either O 0 2.8302968857474298e-09
by O 0 7.748027219811604e-10
changing O 0 7.953449454589645e-09
the O 0 3.8346099628938646e-09
assumed O 0 3.882641053110092e-08
penetrance O 0 9.341760431880175e-08
model O 0 3.0627564928664697e-09
for O 0 1.900331003668043e-09
BRCA1 O 0 1.3266763687624916e-07
or O 0 4.355662053256992e-09
by O 0 9.947221935036055e-10
including O 0 3.481298138652278e-09
or O 0 3.1479854101235105e-07
excluding O 0 8.326775969180744e-06
BRCA1 O 0 5.1916205848101526e-05
mutation O 0 6.448956355598057e-06
data O 0 1.7792481230571866e-06
. O 0 1.3519453432309092e-06

Among O 0 2.1894832968882838e-07
those O 0 5.9817129027806004e-09
families O 0 6.9549939141211325e-09
with O 0 2.9639708465367676e-09
disease O 0 1.5774347048136406e-05
due O 0 6.785272148590593e-07
to O 0 1.1969844671000374e-08
BRCA1 O 0 3.5941314990850515e-07
that O 0 3.970081763338129e-10
were O 0 5.467079011722831e-10
tested O 0 3.103992340935946e-10
by O 0 4.994444094408301e-11
one O 0 4.143172194215339e-10
of O 0 3.781319701801067e-10
the O 0 2.5749596899160565e-10
standard O 0 3.5632972128496476e-09
screening O 0 1.3615029104130372e-09
methods O 0 4.1640815240384654e-09
, O 0 1.2323119191748333e-09
mutations O 0 1.0852906129343864e-08
were O 0 6.403733987525584e-09
detected O 0 5.227904509297332e-08
in O 0 1.0373861769608084e-09
the O 0 6.896221371732736e-10
coding O 0 1.65074709457258e-08
sequence O 0 1.3887798688827502e-09
or O 0 4.842695133788766e-10
splice O 0 1.0223563151612325e-07
sites O 0 1.3127779974198006e-09
in O 0 2.7749277875521727e-10
an O 0 4.890106652943871e-10
estimated O 0 9.283867896670017e-09
63 O 0 4.436881440028628e-08
% O 0 1.4050063334991592e-08
( O 0 3.1427880298195987e-09
95 O 0 2.0250205068350624e-07
% O 0 2.289708334046736e-07
CI O 0 2.702269375731703e-05
51 O 0 5.702357270820357e-07
% O 0 1.0044310982948446e-07
- O 0 4.1290596186627226e-07
77 O 0 4.105660877939954e-07
% O 0 1.9488177827042819e-07
) O 0 3.980860796559682e-08
. O 0 6.114697725934093e-07

The O 0 5.923708954469475e-07
estimated O 0 1.7130966512013401e-07
sensitivity O 0 4.2994221871595073e-07
was O 0 8.497387682382396e-08
identical O 0 3.843815044035637e-09
for O 0 7.635634902136701e-10
direct O 0 9.4485397283961e-09
sequencing O 0 4.0199498840820524e-08
and O 0 2.9132083412264365e-09
other O 0 4.340402703917334e-09
techniques O 0 3.7983761558280094e-07
. O 0 1.2578691439557588e-06

The O 0 1.089791908270854e-06
penetrance O 0 5.771634459961206e-05
of O 0 4.320925654610619e-06
BRCA2 O 0 0.0006723986589349806
was O 0 1.3126905287208501e-06
estimated O 0 5.10701418932058e-08
by O 0 2.51709741938555e-09
maximizing O 0 2.907338227942091e-07
the O 0 5.147256132431721e-08
LOD O 0 0.0022678205277770758
score O 0 1.3280192945330782e-07
in O 0 7.505683186082024e-09
BRCA2 O 0 8.360716492461506e-07
- O 0 3.3439675917179557e-07
mutation O 0 1.5185432289399614e-07
families O 0 1.0540823769389362e-09
, O 0 1.4516750024284875e-09
over O 0 7.1453540861909914e-09
all O 0 3.3703304591625738e-09
possible O 0 1.8938878554308758e-07
penetrance O 0 1.3147629942977801e-05
functions O 0 3.222373550215707e-07
. O 0 7.817891969352786e-07

The O 0 1.612045537058293e-07
estimated O 0 1.3325015402188e-07
cumulative O 0 4.4487626382760936e-07
risk O 0 4.7514802758996666e-07
of O 0 1.6564960105824866e-06
breast B-Disease 1 0.9999971389770508
cancer I-Disease 1 0.9402453899383545
reached O 0 3.5452951124170795e-05
28 O 0 6.263727527766605e-07
% O 0 1.5280345877499713e-08
( O 0 1.0089540314339729e-09
95 O 0 5.0891710401401724e-08
% O 0 3.06963556795381e-08
CI O 0 2.965912017316441e-06
9 O 0 2.4129350961743512e-08
% O 0 5.470429886855754e-09
- O 0 1.013372941116586e-08
44 O 0 5.310857087437171e-09
% O 0 9.221812202753199e-10
) O 0 1.5168930347919662e-11
by O 0 2.4128301787107453e-11
age O 0 2.1876429556755284e-09
50 O 0 2.4299298129193403e-09
years O 0 1.1378256115079921e-09
and O 0 4.995113211947455e-10
84 O 0 4.1110908455266326e-08
% O 0 1.2441542907026815e-08
( O 0 4.642453976799743e-09
95 O 0 1.8293505377187103e-07
% O 0 1.4976502882291243e-07
CI O 0 1.2362494999251794e-05
43 O 0 1.4605566889258625e-07
% O 0 1.0767092994967697e-08
- O 0 1.6812132130894497e-08
95 O 0 1.9778271465042963e-08
% O 0 6.396678298159486e-09
) O 0 7.725269035585569e-11
by O 0 4.0594960726281215e-10
age O 0 3.5358119987449754e-08
70 O 0 1.0507852010732677e-07
years O 0 1.394881650185198e-07
. O 0 6.337538707157364e-07

The O 0 4.6566292439820245e-06
corresponding O 1 0.9997784495353699
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 1 0.9997205138206482
were O 0 4.389016339700902e-06
0 O 0 1.0567830031504855e-05
. O 0 7.609673957631458e-07

4 O 0 1.714978316158522e-05
% O 0 1.0699708354877657e-06
( O 0 2.4739188475564333e-08
95 O 0 6.005745376569394e-07
% O 0 2.7343395458956365e-07
CI O 0 2.509335899958387e-05
0 O 0 2.6376181949672173e-07
% O 0 4.0924081901039244e-08
- O 0 4.65475480382338e-08
1 O 0 7.463700768539638e-08
% O 0 2.0398387423625763e-09
) O 0 1.9411833251936628e-11
by O 0 5.576116998695646e-11
age O 0 5.959733595517491e-09
50 O 0 3.6010667781027905e-09
years O 0 1.92046623048725e-09
and O 0 7.219118081103204e-10
27 O 0 3.3746225369668537e-08
% O 0 1.3413058219668983e-08
( O 0 3.293500361323254e-09
95 O 0 1.102979254596903e-07
% O 0 1.481802343050731e-07
CI O 0 8.163356142176781e-06
0 O 0 9.093926678360731e-08
% O 0 1.6488561627170384e-08
- O 0 3.216453592358448e-08
47 O 0 3.3441104108078434e-08
% O 0 4.823081933835738e-09
) O 0 1.464383198035435e-10
by O 0 7.617277364424524e-10
age O 0 1.2547644701044192e-07
70 O 0 2.3348019340119208e-07
years O 0 1.5018983390291396e-07
. O 0 5.695546860806644e-07

The O 0 4.310099939175416e-07
lifetime O 0 2.6544621505308896e-06
risk O 0 2.5390307200723328e-05
of O 0 0.00892922468483448
breast B-Disease 1 1.0
cancer I-Disease 1 1.0
appears O 0 2.2399845533982443e-07
similar O 0 5.765977695304514e-10
to O 0 5.675306891106402e-10
the O 0 3.454700747695938e-09
risk O 0 2.3825318606895962e-08
in O 0 1.1530530974468434e-09
BRCA1 O 0 8.152802166705442e-08
carriers O 0 4.8749297931749425e-09
, O 0 4.962152910792383e-10
but O 0 4.834093680905482e-10
there O 0 4.582453583257262e-10
was O 0 2.026490975026718e-09
some O 0 2.1515197609622838e-11
suggestion O 0 4.572537459779369e-09
of O 0 8.012630003939591e-10
a O 0 7.590537087764915e-09
lower O 0 1.2864564951087232e-06
risk O 0 3.2846384101503645e-07
in O 0 2.3198994725248667e-08
BRCA2 O 0 1.0212254437647061e-06
carriers O 0 4.9893955633706355e-08
< O 0 1.222627906827256e-05
50 O 0 4.614031468008761e-08
years O 0 7.947974722810613e-09
of O 0 1.2147586936350763e-08
age O 0 3.8376052202693245e-07
. O 0 9.5438485914201e-07

Eye B-Disease 1 0.9997870326042175
movement I-Disease 0 7.9432524216827e-05
abnormalities I-Disease 0 9.577707533026114e-05
correlate O 0 2.722689771417208e-07
with O 0 5.4195927745581685e-09
genotype O 0 7.974141044542193e-05
in O 0 1.0134870080946712e-06
autosomal O 1 0.9995014667510986
dominant O 1 1.0
cerebellar B-Disease 1 1.0
ataxia I-Disease 1 1.0
type I-Disease 1 1.0
I I-Disease 1 1.0
. O 0 7.694582018302754e-05

We O 0 2.2349368009599857e-06
compared O 0 2.6997063287126366e-06
horizontal O 0 9.08681467990391e-05
eye O 0 0.00015275449550244957
movements O 0 9.995574146159925e-07
( O 0 1.0921103665850751e-07
visually O 0 7.490997688819334e-08
guided O 0 6.619134182983544e-07
saccades O 0 2.072420647891704e-05
, O 0 5.617758702669562e-08
antisaccades O 0 2.3158727344707586e-05
, O 0 1.0932082794568032e-08
and O 0 2.4309310120429473e-09
smooth O 0 1.4098981182542047e-07
pursuit O 0 9.114919521380216e-07
) O 0 2.470484483652058e-09
in O 0 1.3458745229399938e-09
control O 0 1.5920534224278526e-08
subjects O 0 2.923831132761734e-08
( O 0 2.141344213058005e-09
n O 0 3.7998173496589516e-08
= O 0 2.194619241890905e-08
14 O 0 4.702538802803247e-09
) O 0 1.6944039227251295e-10
and O 0 1.3772595564010004e-10
patients O 0 1.3797495090894785e-10
with O 0 3.040484183869374e-11
three O 0 5.579428030699773e-10
forms O 0 1.7704664401207992e-08
of O 0 1.0472413123352453e-06
autosomal O 0 0.33993545174598694
dominant O 1 0.9999961853027344
cerebellar B-Disease 1 1.0
ataxias I-Disease 1 0.9999998807907104
type I-Disease 1 0.9999957084655762
I I-Disease 1 0.9987906813621521
spinocerebellar B-Disease 1 0.9969646334648132
ataxias I-Disease 0 0.0013947297120466828
1 I-Disease 0 4.83499343317817e-06
and I-Disease 0 1.2051398989854079e-08
2 I-Disease 0 3.8515227629432047e-07
( O 0 3.268969095415741e-08
SCA1 B-Disease 0 8.826276462059468e-05
, O 0 7.563483173100849e-09
n O 0 9.993517835482635e-08
= O 0 3.705682871668614e-08
11 O 0 9.792617383652669e-09
; O 0 2.410661226193156e-09
SCA2 B-Disease 0 2.3971466362127103e-05
, O 0 6.427792520469211e-09
n O 0 8.271938867210338e-08
= O 0 4.6421028798704356e-08
10 O 0 6.385305617584436e-09
) O 0 1.2639294055816208e-09
and O 0 1.0599618960327462e-08
SCA3 B-Disease 1 1.0
/ O 0 0.0010878313332796097
Machado B-Disease 0 3.516424840199761e-05
- I-Disease 0 0.00010292000661138445
Joseph I-Disease 0 0.0006583321373909712
disease I-Disease 0 0.0006991085247136652
( O 0 1.7727695649227826e-06
MJD B-Disease 1 1.0
) O 0 1.9132471607008483e-07
( O 0 7.991102535243044e-08
n O 0 8.0274429592464e-07
= O 0 5.531749138754094e-07
16 O 0 1.5466932268282108e-07
) O 0 3.4768802947837685e-08
. O 0 3.4044464314320066e-07

In O 0 4.304174581193365e-06
SCA1 B-Disease 0 0.042875830084085464
, O 0 1.296868816780261e-07
saccade O 0 1.9955017705797218e-05
amplitude O 0 5.964244337519631e-06
was O 0 1.2872489207893523e-07
significantly O 0 3.9674365126529665e-08
increased O 0 2.065767290559961e-08
, O 0 9.309011339553308e-09
resulting O 0 1.199584858113667e-07
in O 0 2.3799074710950663e-07
hypermetria B-Disease 0 0.00038051445153541863
. O 0 5.008836524211802e-06

The O 0 1.2022468354189186e-06
smooth O 0 2.5273657229263335e-06
pursuit O 0 1.5084831829881296e-05
gain O 0 1.5936135241645388e-05
was O 0 3.555211878847331e-05
decreased O 0 1.4804796592216007e-05
. O 0 2.166398417102755e-06

In O 0 1.150996467913501e-05
SCA2 B-Disease 0 0.010154500603675842
, O 0 6.693480827379972e-07
saccade O 0 3.1355411920230836e-05
velocity O 0 3.661240407382138e-05
was O 0 5.7979427765531e-06
markedly O 0 1.2280687769816723e-05
decreased O 0 1.610676736163441e-05
. O 0 2.858934976757155e-06

The O 0 6.140714390312496e-07
percentage O 0 1.3605530284621636e-06
of O 0 9.760975672179484e-08
errors O 0 2.7239097107667476e-05
in O 0 4.731620038000983e-07
antisaccades O 1 0.9986938834190369
was O 0 8.631001264802762e-07
greatly O 0 1.5684266330140417e-08
increased O 0 7.289827852474673e-09
and O 0 4.781366969019984e-10
was O 0 1.377825853410286e-08
significantly O 0 2.5352524524180353e-09
correlated O 0 4.74283989859714e-09
with O 0 3.572250828476342e-10
age O 0 3.3181501635226596e-07
at O 0 3.4573897664813558e-06
disease O 0 5.763482840848155e-05
onset O 0 0.18075646460056305
. O 0 7.683951480430551e-06

In O 0 1.0747687895218405e-07
addition O 0 1.176690833659677e-08
, O 0 4.178378532060378e-09
a O 0 8.127615025443902e-09
correlation O 0 6.888721060249736e-08
between O 0 3.0422757646419996e-08
smooth O 0 1.7185848832923512e-07
pursuit O 0 7.1138202883958e-07
gain O 0 1.521020180916821e-07
and O 0 1.6084644727243358e-09
the O 0 3.904539802590534e-09
number O 0 9.504391940140522e-09
of O 0 8.83189130718165e-08
trinucleotide O 0 0.0001883463264675811
repeats O 0 6.595819286303595e-07
was O 0 6.514781034638872e-07
found O 0 1.059077234799588e-07
. O 0 2.961543543733569e-07

In O 0 6.866458716103807e-05
SCA3 B-Disease 1 1.0
, O 0 8.466908184345812e-06
gaze B-Disease 0 0.3620699942111969
- I-Disease 0 0.004156540147960186
evoked I-Disease 0 7.655660738237202e-05
nystagmus I-Disease 0 0.00015017954865470529
was O 0 3.4282629712834023e-07
often O 0 1.6722258022738856e-09
present O 0 1.3042548152597533e-09
as O 0 3.0487914415289197e-09
was O 0 1.340782063152801e-07
saccade O 0 3.0250496365624713e-06
hypometria O 0 5.756495284003904e-06
and O 0 1.1168896030255837e-08
smooth O 0 3.1862168725638185e-07
pursuit O 0 2.5446631752856774e-06
gain O 0 1.1133971383969765e-05
was O 0 1.5075614101078827e-05
markedly O 0 8.80207426234847e-06
decreased O 0 8.91855961526744e-06
. O 0 1.1317505368424463e-06

Three O 0 2.7906557420465106e-07
major O 0 5.278826051835495e-07
criteria O 0 3.6752749110746663e-07
, O 0 1.154915807433099e-08
saccade O 0 2.1196271973167313e-06
amplitude O 0 3.726173645191011e-07
, O 0 1.861855669638146e-09
saccade O 0 3.118159952464339e-07
velocity O 0 5.573328394348209e-07
, O 0 1.9441275256326662e-09
and O 0 4.502743733425518e-10
presence O 0 6.111884776061061e-09
of O 0 7.855531691802753e-08
gaze B-Disease 0 6.566177034983411e-05
- I-Disease 0 6.751733053533826e-06
evoked I-Disease 0 1.7209398492923356e-06
nystagmus I-Disease 0 1.0719450074248016e-06
, O 0 8.828901498780795e-10
permitted O 0 1.3493856032553708e-09
the O 0 1.1707241842628946e-09
correct O 0 1.1932962173943906e-08
assignment O 0 1.4519774715893163e-08
of O 0 4.349908877543385e-09
90 O 0 1.726869314211399e-08
% O 0 2.949100741389543e-09
of O 0 1.161863938392571e-09
the O 0 5.706397132598795e-09
SCA1 B-Disease 0 0.0006805435405112803
, O 0 5.314606532635935e-09
90 O 0 2.0644597142904786e-08
% O 0 3.173435958458981e-09
of O 0 7.437517268726879e-10
the O 0 4.128784869550373e-09
SCA2 B-Disease 0 0.019511854276061058
, O 0 4.100547901231266e-09
and O 0 1.217130729536109e-09
93 O 0 3.1017112434028604e-08
% O 0 5.308902650824621e-09
of O 0 1.5619268101119133e-09
the O 0 6.438099386940621e-09
patients O 0 4.811688381067825e-09
with O 0 6.010281161650255e-09
SCA3 B-Disease 1 1.0
to O 0 9.946414536443626e-08
their O 0 3.577578011615401e-09
genetically O 0 2.394385845150282e-08
confirmed O 0 1.0065595468233823e-08
patient O 0 1.496720258842288e-08
group O 0 1.738783228510954e-09
and O 0 4.949902154827157e-10
, O 0 2.0618298179897465e-09
therefore O 0 6.089185689006626e-08
, O 0 4.4572701085598965e-09
may O 0 1.2507568314390483e-08
help O 0 5.768411526219097e-09
orient O 0 4.826387794309994e-06
diagnoses O 0 9.280540211875632e-07
of O 0 3.5197311376578e-07
SCA1 B-Disease 1 0.9996558427810669
, O 0 8.172028742592374e-08
SCA2 B-Disease 1 0.9876514673233032
, O 0 2.0919845411526694e-08
and O 0 3.201378717676562e-08
SCA3 B-Disease 1 1.0
at O 0 5.660539272867027e-07
early O 0 4.767866457200398e-08
clinical O 0 1.424296272034553e-07
stages O 0 1.2207773636419006e-07
of O 0 4.5010398963540865e-08
the O 0 6.286612688199966e-07
diseases O 0 0.16033627092838287
. O 0 1.2907847803944605e-06
. O 0 6.475605005107354e-06

Genetic O 0 3.890064363076817e-06
basis O 0 1.9235434933762008e-07
and O 0 3.5302440970497173e-09
molecular O 0 5.270807719170989e-07
mechanism O 0 8.676623792780447e-07
for O 0 5.615269401459955e-06
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
. O 1 0.9999161958694458

Ventricular B-Disease 1 1.0
fibrillation I-Disease 1 1.0
causes O 0 0.0001481681247241795
more O 0 6.383795270181736e-09
than O 0 1.20244436629946e-08
300 O 0 1.4885976895584463e-08
, O 0 2.5098534361944758e-09
000 O 0 2.8906219640134623e-08
sudden O 0 2.2566739588114615e-08
deaths O 0 1.8196486539778789e-09
each O 0 9.444445225881282e-10
year O 0 5.284443993502919e-09
in O 0 3.275708149175216e-09
the O 0 3.915878110660742e-08
USA O 0 6.703256531181978e-06
alone O 0 8.704753327037906e-07
. O 0 1.3663706113220542e-06

In O 0 1.8345726005009055e-07
approximately O 0 3.758436051271019e-08
5 O 0 6.9249487921752e-08
- O 0 6.543167074823941e-08
12 O 0 1.0872091671387807e-08
% O 0 3.271774628998969e-09
of O 0 3.627737554801058e-10
these O 0 6.135203456381078e-11
cases O 0 9.585071625295427e-10
, O 0 1.0752455592566434e-09
there O 0 1.857152542861229e-09
are O 0 4.963819355552346e-10
no O 0 2.2245794539799135e-08
demonstrable O 0 0.05498189479112625
cardiac O 1 0.8064406514167786
or O 0 3.38681479661318e-06
non O 1 0.9999799728393555
- O 1 0.9999680519104004
cardiac O 1 0.9999017715454102
causes O 0 1.0803570660300466e-07
to O 0 1.2808591964841298e-09
account O 0 6.024934995352282e-10
for O 0 6.013328168741339e-10
the O 0 5.837843541911525e-09
episode O 0 3.703280526679009e-08
, O 0 2.2560435464225037e-10
which O 0 1.0809470679662425e-10
is O 0 2.4041260648921536e-10
therefore O 0 2.182824587748655e-09
classified O 0 1.979442565414047e-08
as O 0 5.62251784685941e-07
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 1.0
fibrillation I-Disease 1 1.0
( O 1 0.9999538660049438
IVF B-Disease 1 1.0
) O 0 1.2167399290774483e-05
. O 0 8.29948749014875e-06

A O 0 1.70875603089371e-06
distinct O 0 9.769879483201294e-08
group O 0 7.183522399145659e-08
of O 0 2.573401616245974e-06
IVF B-Disease 1 1.0
patients O 0 1.7220727386302315e-06
has O 0 4.561379274292676e-09
been O 0 1.4050191010639423e-09
found O 0 2.9833216452779254e-10
to O 0 1.2962141082706324e-10
present O 0 4.682630949659483e-10
with O 0 2.6105403949649997e-10
a O 0 5.3964491542046744e-08
characteristic O 0 3.047670361411292e-06
electrocardiographic O 0 0.0010757804848253727
pattern O 0 3.4831366065191105e-05
. O 0 5.073807642475003e-06

Because O 0 2.8810396202061384e-07
of O 0 6.548835784769835e-08
the O 0 1.064656629523597e-08
small O 0 1.7566408327951422e-09
size O 0 3.1025377822402334e-09
of O 0 1.171727159743341e-09
most O 0 4.122362173841765e-10
pedigrees O 0 1.0506625791606439e-08
and O 0 3.2551655815282743e-10
the O 0 1.7392874918087387e-09
high O 0 1.6339559749667387e-07
incidence O 0 5.110483107273467e-05
of O 0 2.1170907871237432e-07
sudden B-Disease 0 6.053085144230863e-06
death I-Disease 0 1.1569043181225425e-06
, O 0 3.057450959076391e-09
however O 0 1.7489446557661381e-09
, O 0 3.180621044318599e-10
molecular O 0 1.010194505823847e-08
genetic O 0 4.1118259908046184e-09
studies O 0 1.6444361428114007e-09
of O 0 2.873690441163035e-08
IVF B-Disease 1 1.0
have O 0 4.645324125363004e-09
not O 0 5.037020578413376e-09
yet O 0 2.5295832983829314e-08
been O 0 1.628530732489253e-08
done O 0 6.426973442330564e-08
. O 0 5.314386157806439e-07

Because O 0 7.924762030597776e-05
IVF B-Disease 1 1.0
causes O 1 0.9998509883880615
cardiac O 1 1.0
rhythm O 1 0.9999995231628418
disturbance O 1 0.999955415725708
, O 0 3.56658986788716e-08
we O 0 5.562907468004141e-09
investigated O 0 6.03346137495464e-08
whether O 0 1.2249402381314667e-08
malfunction O 0 1.880296076706145e-05
of O 0 8.165091713863148e-09
ion O 0 3.2452010145789245e-07
channels O 0 5.496821131600882e-08
could O 0 2.030430401589456e-08
cause O 0 3.038324223325617e-07
the O 0 6.137412356110872e-08
disorder O 0 5.339136350812623e-07
by O 0 7.629069043169068e-10
studying O 0 1.0858662413681941e-08
mutations O 0 9.913171616915406e-09
in O 0 1.9069683609984622e-09
the O 0 1.7827874287945633e-08
cardiac O 0 2.383701485086931e-06
sodium O 0 6.77427976825129e-07
channel O 0 4.5679994400416035e-06
gene O 0 2.222820739916642e-06
SCN5A O 0 0.001557492301799357
. O 0 4.560999968816759e-06

We O 0 7.609398267049983e-07
have O 0 8.720239641490934e-09
now O 0 1.014332173809862e-08
identified O 0 1.8764664488912786e-08
a O 0 1.474716349036953e-08
missense O 0 2.7775950002251193e-06
mutation O 0 2.5040313289537153e-07
, O 0 2.0220740637455492e-09
a O 0 6.79618850085717e-09
splice O 0 7.976314009283669e-07
- O 0 2.2383125042324536e-07
donor O 0 4.8226056037492526e-08
mutation O 0 1.8639569532297173e-07
, O 0 2.3245001479210714e-09
and O 0 9.081889129625154e-10
a O 0 2.3546309790845044e-08
frameshift O 0 1.8229922716272995e-05
mutation O 0 2.4772671736172924e-07
in O 0 8.341962676183812e-10
the O 0 9.79733960626561e-10
coding O 0 7.537822455105925e-08
region O 0 8.422162522947474e-08
of O 0 7.596464257630942e-08
SCN5A O 0 0.1675449013710022
in O 0 3.589890340549573e-08
three O 0 9.709577852845541e-08
IVF B-Disease 1 0.999995231628418
families O 0 1.9953982643983181e-07
. O 0 1.2550796100185835e-06

We O 0 2.5763384314814175e-07
show O 0 1.3625270689487934e-08
that O 0 2.834465995249502e-10
sodium O 0 6.120085771499362e-09
channels O 0 2.534904286477513e-09
with O 0 1.7812323838128918e-10
the O 0 1.1216717332729331e-08
missense O 0 1.1283136700512841e-05
mutation O 0 2.836123940141988e-06
recover O 0 3.8977785266069986e-07
from O 0 4.101801209799305e-08
inactivation O 0 4.310019448894309e-06
more O 0 2.76676820343269e-10
rapidly O 0 1.593805754041e-09
than O 0 1.6199599994770608e-10
normal O 0 1.4780777712886106e-09
and O 0 6.181954254058653e-11
that O 0 1.092113066647471e-10
the O 0 5.231233224378684e-09
frameshift O 0 2.059099415419041e-06
mutation O 0 1.6449287443265348e-07
causes O 0 1.523799930680525e-08
the O 0 2.388846676026901e-09
sodium O 0 9.890961827352385e-09
channel O 0 1.019394257895101e-08
to O 0 6.649142902936944e-10
be O 0 1.063359800212993e-08
non O 0 1.1721009514076286e-06
- O 0 4.01035686081741e-06
functional O 0 4.066291694471147e-06
. O 0 7.289649488484429e-07

Our O 0 3.011832063748443e-07
results O 0 4.826010524539015e-08
indicate O 0 2.1426650675948622e-08
that O 0 1.3460285108735093e-09
mutations O 0 5.654502288621188e-08
in O 0 3.924549574207958e-09
cardiac O 0 1.1153546211062348e-06
ion O 0 2.3854752271290636e-06
- O 0 4.880253641204035e-07
channel O 0 5.838693084569968e-08
genes O 0 2.503856288971207e-10
contribute O 0 9.232860309627e-11
to O 0 1.22605398056308e-10
the O 0 2.2295991719545327e-09
risk O 0 3.711532770012127e-08
of O 0 4.090246719101742e-08
developing O 0 1.2659684216487221e-06
IVF B-Disease 1 0.9999988079071045
. O 0 4.4806793653151544e-07
. O 0 1.2468645991248195e-06

Molecular O 0 0.00016731464711483568
heterogeneity O 0 0.0005484787980094552
in O 0 1.8770089127428946e-06
mucopolysaccharidosis B-Disease 1 0.9999972581863403
IVA I-Disease 1 1.0
in O 0 7.165185706980992e-07
Australia O 0 1.6065335728399077e-08
and O 0 1.2088157141931788e-09
Northern O 0 1.259095370187424e-07
Ireland O 0 8.144890273342753e-08
: O 0 1.8395747147792463e-09
nine O 0 4.38321468010372e-09
novel O 0 7.829978443396612e-09
mutations O 0 1.0940343742049663e-08
including O 0 4.703471390143932e-09
T312S O 0 0.0009369959007017314
, O 0 5.359948040961626e-09
a O 0 7.989559236420973e-09
common O 0 2.2404282873367265e-08
allele O 0 3.611896204347431e-07
that O 0 2.8365227944249227e-09
confers O 0 4.114009470868041e-07
a O 0 1.2384671208565123e-06
mild O 1 0.9984579086303711
phenotype O 1 0.9702329635620117
. O 0 1.1890715541085228e-05

Mucopolysaccharidosis B-Disease 1 0.9999861717224121
IVA I-Disease 1 1.0
( O 0 0.005974728614091873
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 2.1843091246864788e-07
is O 0 1.9676379636734964e-08
an O 0 3.1808305323011155e-08
autosomal B-Disease 1 0.9999936819076538
recessive I-Disease 1 1.0
lysosomal I-Disease 1 1.0
storage I-Disease 1 1.0
disorder I-Disease 1 1.0
caused O 0 0.00017945727449841797
by O 0 1.652773029547916e-08
a O 0 3.5808202483167406e-06
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999959468841553
in O 0 7.910093557939035e-08
N O 0 5.899561983824242e-06
- O 0 1.5638495369785232e-06
acetylgalactosamine O 0 3.0367731596925296e-05
- O 0 7.979342626640573e-06
6 O 0 5.218965725362068e-06
- O 0 2.6868742679653224e-06
sulfate O 0 3.924592419934925e-06
sulfatase O 0 0.00010970466246362776
( O 0 1.0871241329368786e-06
GALNS O 0 0.013961464166641235
) O 0 3.1263604682862933e-07
. O 0 8.710832162250881e-07

Previous O 0 3.9974861465452705e-07
studies O 0 4.21529051664038e-08
of O 0 3.4061280018704565e-08
patients O 0 3.7167944277882725e-09
from O 0 3.4010692040453705e-09
a O 0 2.631278483988808e-08
British O 0 1.6761167387358e-07
- O 0 5.415627128968481e-07
Irish O 0 5.1753811902699454e-08
population O 0 2.6546004283645175e-10
showed O 0 1.0441508768721519e-10
that O 0 2.6571777764217153e-11
the O 0 1.2099483637229014e-09
I113F O 0 4.00915632781107e-06
mutation O 0 2.0170082848380844e-07
is O 0 1.2009768735055104e-09
the O 0 5.390446422559592e-10
most O 0 1.5013590370926977e-10
common O 0 7.847931193794011e-10
single O 0 5.042317230419258e-09
mutation O 0 3.0288262564681645e-07
among O 0 3.5212150351071614e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 5.863574301656627e-07
and O 0 1.1659625265281193e-08
produces O 0 5.7065523861865586e-08
a O 0 3.2318155263055814e-07
severe O 0 0.02685796283185482
clinical O 0 0.4061335325241089
phenotype O 0 0.06867024302482605
. O 0 7.859862307668664e-06

We O 0 7.121728344827716e-07
studied O 0 1.0762124702523579e-06
mutations O 0 2.1541453065765381e-07
in O 0 9.148952706539148e-09
the O 0 3.90177952169779e-08
GALNS O 0 0.05534147843718529
gene O 0 4.3306226160666483e-08
from O 0 1.1089444029721562e-08
23 O 0 1.7411371899811456e-08
additional O 0 2.8566780940764147e-08
MPS B-Disease 1 0.9999966621398926
IVA I-Disease 1 1.0
patients O 0 4.35297408785118e-07
( O 0 1.0335059030808225e-08
15 O 0 1.0210034595559137e-08
from O 0 1.888439626895888e-09
Australia O 0 3.4025790518477095e-10
, O 0 1.0549709023033316e-10
8 O 0 2.0787027654733947e-09
from O 0 4.486430116301676e-10
Northern O 0 2.0655033239336262e-08
Ireland O 0 2.3074417043744688e-08
) O 0 6.800178753429975e-10
, O 0 1.858927178854941e-10
with O 0 4.648953791375199e-11
various O 0 1.3514616092891174e-09
clinical O 0 4.320192238083109e-05
phenotypes O 0 0.11428448557853699
( O 0 1.2549680832307786e-05
severe O 1 0.9999997615814209
, O 0 4.832347713090712e-07
16 O 0 8.646080118523969e-08
cases O 0 8.812918173006778e-10
; O 0 1.0902030389559059e-09
intermediate O 0 1.1771261370085995e-06
, O 0 3.694671235621172e-09
4 O 0 6.502546767706008e-08
cases O 0 4.40954472935573e-09
; O 0 1.121254644687042e-08
mild O 0 8.657192665850744e-05
, O 0 1.1670732646962279e-07
3 O 0 1.201019472318876e-06
cases O 0 3.979501883577541e-08
) O 0 9.830142033706579e-08
. O 0 9.109270990848017e-07

We O 0 2.0743041773130244e-07
found O 0 7.2275536666666085e-09
two O 0 5.963414762000241e-10
common O 0 6.082033099374939e-09
mutations O 0 1.3697083467434368e-08
that O 0 3.889678856783263e-10
together O 0 7.020417025493941e-10
accounted O 0 1.3484473093683391e-08
for O 0 5.547572401454204e-10
32 O 0 2.470240900720455e-08
% O 0 3.4518683467155142e-09
of O 0 9.396918798643128e-10
the O 0 3.913799950794328e-09
44 O 0 7.795246403929923e-08
unrelated O 0 1.0751541879017168e-07
alleles O 0 1.3395678877259343e-07
in O 0 9.025563407760728e-09
these O 0 9.26810450607718e-09
patients O 0 3.937035160106461e-07
. O 0 4.100021214981098e-06

One O 0 4.933883133162453e-07
is O 0 2.7066509034057162e-08
the O 0 3.35840937282228e-08
T312S O 0 0.00027581059839576483
mutation O 0 1.3220226264820667e-06
, O 0 2.875958804438028e-09
a O 0 9.40985511732606e-09
novel O 0 6.17393780544262e-08
mutation O 0 4.509856310619398e-08
found O 0 2.1876012112898024e-09
exclusively O 0 6.6445320356933735e-09
in O 0 5.4094719814656855e-09
milder O 0 8.423491090070456e-05
patients O 0 3.5094387840217678e-06
. O 0 7.170488515839679e-06

The O 0 2.7946427394454076e-07
other O 0 9.225106900601077e-09
is O 0 4.912911411025789e-09
the O 0 6.2800307176758e-09
previously O 0 4.278104270838412e-08
described O 0 9.55288470549931e-08
I113F O 0 1.1588959750952199e-05
that O 0 2.1466155519789254e-09
produces O 0 2.5829161032220327e-08
a O 0 7.380347710750357e-07
severe O 1 0.9687004685401917
phenotype O 1 0.925241231918335
. O 0 2.0643217794713564e-05

The O 0 1.0053805453935638e-05
I113F O 0 0.0006085283821448684
and O 0 1.957195507884535e-07
T312S O 0 7.572070171590894e-05
mutations O 0 1.7378782501964452e-07
accounted O 0 2.9095504672227435e-08
for O 0 2.3625383871461736e-09
8 O 0 4.286059507307982e-08
( O 0 3.4147580318943938e-09
18 O 0 1.305305730170403e-08
% O 0 3.670719062043304e-09
) O 0 1.125294163406565e-10
and O 0 2.0668608491369866e-10
6 O 0 3.3746289318514755e-08
( O 0 2.5838557959900754e-09
14 O 0 1.2389610226648529e-08
% O 0 5.900420596560707e-09
) O 0 3.9841760446357455e-10
of O 0 5.420420112756119e-09
44 O 0 1.0834875752152584e-07
unrelated O 0 2.7689122816809686e-07
alleles O 0 6.61316505556897e-07
, O 0 1.4316719898488373e-07
respectively O 0 3.788473804888781e-06
. O 0 4.498586349654943e-06

The O 0 1.0003602710639825e-06
relatively O 0 8.272773470707762e-07
high O 0 3.057906951653422e-06
residual O 1 0.762280285358429
GALNS O 1 0.999991774559021
activity O 0 2.716633673571778e-07
seen O 0 2.7120147905179692e-08
when O 0 2.808967725087541e-09
the O 0 1.0304785469372746e-08
T312S O 0 3.778825430345023e-06
mutant O 0 8.830004816218207e-08
cDNA O 0 4.3111072045576293e-07
is O 0 4.8891020121288875e-09
overexpressed O 0 5.901470103708562e-07
in O 0 1.6835549621063706e-09
mutant O 0 2.8066235557844266e-08
cells O 0 7.097686882673315e-10
provides O 0 7.239922550361655e-11
an O 0 1.30064944925401e-10
explanation O 0 1.8601847173727037e-08
for O 0 2.4843203050295415e-09
the O 0 5.027837701732096e-08
mild O 1 0.9647938013076782
phenotype O 0 0.0022934330627322197
in O 0 2.200395066154215e-08
patients O 0 1.5089245408717034e-09
with O 0 6.414256348286074e-10
this O 0 1.0141371831196011e-07
mutation O 0 1.8902708688983694e-05
. O 0 3.4536262774054194e-06

The O 0 1.3683705901712528e-07
distribution O 0 2.0360966246357748e-08
and O 0 8.071455170899355e-10
relative O 0 3.906433576617019e-08
frequencies O 0 4.9146567704383415e-08
of O 0 5.397414071239837e-09
the O 0 2.6518149454091144e-08
I113F O 0 6.328076415229589e-05
and O 0 2.9659233291567944e-08
T312S O 0 5.59315194550436e-05
mutations O 0 8.043415533620646e-08
in O 0 1.1527496734942133e-09
Australia O 0 1.5774764827725107e-10
corresponded O 0 1.8863948181291335e-09
to O 0 2.9909674736927627e-10
those O 0 1.7881186809010075e-10
observed O 0 7.122507472701045e-09
in O 0 9.028899849994332e-10
Northern O 0 3.678584548083563e-08
Ireland O 0 1.927402948354029e-08
and O 0 2.4512017415823095e-10
are O 0 5.8205381486819974e-11
unique O 0 1.3351479644096997e-10
to O 0 2.319202468958892e-10
these O 0 1.2714290731352662e-10
two O 0 4.784213025743611e-10
populations O 0 2.102239049506238e-09
, O 0 3.1973479419633577e-10
suggesting O 0 1.972627394764004e-09
that O 0 1.6811763092761112e-10
both O 0 1.1058031157418213e-09
mutations O 0 1.6557798687699687e-08
were O 0 1.3254560782272051e-09
probably O 0 4.585105184418126e-09
introduced O 0 1.9371610981977483e-09
to O 0 8.291392017412136e-10
Australia O 0 3.8147437986246757e-10
by O 0 3.339396814627804e-10
Irish O 0 7.494828224707817e-08
migrants O 0 1.01789243700523e-08
during O 0 5.556978877052643e-09
the O 0 9.369469644582296e-09
19th O 0 9.863363175099948e-07
century O 0 7.259967333084205e-06
. O 0 4.2243073039571755e-06

Haplotype O 0 0.0001497566991019994
analysis O 0 8.347236075678666e-07
using O 0 4.2448121462257404e-07
6 O 0 9.441241672902834e-06
RFLPs O 0 3.639702117652632e-05
provides O 0 6.254007978157006e-09
additional O 0 4.371909501088567e-09
data O 0 1.1285538725758215e-08
that O 0 4.0421505032028904e-10
the O 0 1.684615824615321e-08
I113F O 0 8.386882655031513e-06
mutation O 0 5.1829484704057904e-08
originated O 0 6.8629613103610154e-09
from O 0 4.0855896443758866e-09
a O 0 1.807335792136655e-08
common O 0 1.9756768665502022e-07
ancestor O 0 2.1440060663735494e-05
. O 0 4.245785930834245e-06

The O 0 1.6564042653044453e-06
other O 0 4.104031958718224e-08
9 O 0 3.950529787744017e-07
novel O 0 8.758131997410601e-08
mutations O 0 9.606383599702895e-08
identified O 0 1.514911929234586e-08
in O 0 9.911088616476604e-10
these O 0 2.8343902225280715e-10
23 O 0 2.5119188507005674e-08
patients O 0 7.987300265632769e-10
were O 0 5.57877910534188e-10
each O 0 2.575721025355193e-10
limited O 0 5.291592164446968e-10
to O 0 1.9290569142071945e-09
a O 0 5.427602900454076e-08
single O 0 2.9471630114130676e-07
family O 0 1.313044606376934e-07
. O 0 4.1904880276888434e-07

These O 0 4.941322728768682e-08
data O 0 3.503067347310207e-08
provide O 0 3.902268730371361e-09
further O 0 2.079223015982734e-08
evidence O 0 2.381827890474142e-08
for O 0 5.57141266455119e-09
extensive O 0 4.070176657933189e-07
allelic O 0 7.749042561044917e-05
heterogeneity O 0 0.0025270285550504923
in O 0 3.0599899218941573e-06
MPS B-Disease 1 0.999994158744812
IVA I-Disease 1 1.0
in O 0 5.5257501685446186e-08
British O 0 1.7404157404143916e-07
- O 0 9.997289680541144e-07
Irish O 0 3.246606468110258e-07
patients O 0 9.323614102996203e-10
and O 0 7.114964867271922e-11
provide O 0 1.951981215553289e-10
evidence O 0 2.3468371690427148e-09
for O 0 6.573132593779007e-10
their O 0 2.0524433541613263e-10
transmission O 0 7.218682096521434e-09
to O 0 9.311066917483402e-10
Australia O 0 6.922116768670605e-10
by O 0 6.130549956573361e-10
British O 0 4.197711334086307e-08
- O 0 4.2779331010933674e-07
Irish O 0 4.2075433270838403e-07
migrants O 0 5.550531056996988e-08
. O 0 2.263916876188432e-08
. O 0 3.0047570476199326e-07

Identification O 0 1.7106214045270463e-06
of O 0 5.470932933349104e-07
constitutional O 0 4.238125984556973e-05
WT1 O 1 0.9995026588439941
mutations O 0 3.533582639647648e-05
, O 0 7.272387847478967e-08
in O 0 2.146166089289636e-08
patients O 0 1.4482270493942906e-08
with O 0 8.471410239963006e-09
isolated O 1 0.9990283250808716
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.9862862877271255e-07
and O 0 3.342240262327323e-09
analysis O 0 2.4446443092074333e-08
of O 0 1.1758611151435616e-07
genotype O 0 2.1149804524611682e-05
/ O 0 4.1980303649324924e-05
phenotype O 0 1.224937591359776e-06
correlations O 0 7.863926043683023e-08
by O 0 4.4384007580333673e-10
use O 0 3.24724847011737e-09
of O 0 1.4522904656644187e-08
a O 0 9.338286588445044e-08
computerized O 0 1.6936420479396475e-06
mutation O 0 3.3466837976448005e-06
database O 0 1.7801086187319015e-06
. O 0 8.1466743040437e-07

Constitutional O 0 1.8701352018979378e-05
mutations O 0 2.6629993499227567e-06
of O 0 3.3560664292053843e-07
the O 0 3.991559083260654e-07
WT1 O 0 0.0008802860975265503
gene O 0 8.86816664547041e-08
, O 0 1.8116801392409343e-09
encoding O 0 3.325600417269925e-08
a O 0 2.1829555407748558e-07
zinc O 0 3.1250750907929614e-05
- O 0 5.960002454230562e-06
finger O 0 4.878010713582626e-06
transcription O 0 3.8729485822841525e-06
factor O 0 3.191423445514374e-07
involved O 0 5.1434549952489306e-09
in O 0 2.3546487426528984e-08
renal O 1 1.0
and O 0 8.636888537694176e-07
gonadal O 1 1.0
development O 0 9.426504220755305e-06
, O 0 7.1439498761094455e-09
are O 0 2.835298662517971e-10
found O 0 6.858299483880614e-10
in O 0 7.048768235762282e-10
most O 0 8.679018059787325e-10
patients O 0 9.118948374187141e-10
with O 0 7.2322423605442054e-09
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9976754784584045
DDS B-Disease 1 1.0
) O 0 6.419182341232954e-07
, O 0 6.464397017680312e-08
or O 0 5.129505552758928e-06
diffuse B-Disease 1 1.0
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.006481535267084837
DMS B-Disease 1 0.9999762773513794
) O 0 8.582572874615835e-09
associated O 0 6.585609835241257e-09
with O 0 2.2246038344775343e-09
pseudohermaphroditism B-Disease 1 1.0
and O 0 1.3476857247951557e-06
/ O 0 0.19096973538398743
or O 0 3.400233981665224e-05
Wilms B-Disease 1 1.0
tumor I-Disease 1 0.9999966621398926
( O 0 1.198276186187286e-05
WT B-Disease 1 1.0
) O 0 5.409231675912451e-07
. O 0 8.428588671449688e-07

Most O 0 6.098950393607083e-07
mutations O 0 6.121096703282092e-06
in O 0 5.27889415025129e-06
DDS B-Disease 1 1.0
patients O 0 0.00011901789548574015
lie O 0 0.0003885795595124364
in O 0 2.5386174229424796e-07
exon O 0 6.938593287486583e-06
8 O 0 2.2606619154430518e-07
or O 0 4.260937913613816e-08
exon O 0 2.1731646029365947e-06
9 O 0 2.3276365368474217e-07
, O 0 4.023061883628998e-09
encoding O 0 1.6864763097146351e-07
zinc O 0 4.827980319532799e-06
finger O 0 7.099827053025365e-05
2 O 0 1.1529529729159549e-05
or O 0 5.655224413203541e-07
zinc O 0 9.182342182612047e-06
finger O 0 7.434555300278589e-06
3 O 0 4.853283144257148e-07
, O 0 2.5445927587242068e-09
respectively O 0 6.494611071161671e-09
, O 0 2.1903556746138975e-10
with O 0 1.2218402678509932e-10
a O 0 8.576849097607919e-08
hot O 0 4.7993626139941625e-06
spot O 0 5.23237122251885e-06
( O 0 1.3155701594769198e-07
R394W O 0 2.968270746350754e-05
) O 0 2.349090877373783e-08
in O 0 5.028892502423332e-08
exon O 0 1.2813829926017206e-05
9 O 0 4.802595412911614e-06
. O 0 1.511855771241244e-06

We O 0 2.0657010679769883e-07
analyzed O 0 7.868668205901486e-08
a O 0 1.0653879556343782e-08
series O 0 2.3824489048251962e-09
of O 0 1.201369137504571e-08
24 O 0 1.9358810732228449e-07
patients O 0 6.639489846804736e-09
, O 0 2.7935107560495e-09
10 O 0 2.309440461090162e-08
with O 0 3.8874405916544674e-09
isolated B-Disease 0 0.006692172959446907
DMS I-Disease 1 0.9999935626983643
( O 0 2.0651211798394797e-06
IDMS B-Disease 1 0.9957160353660583
) O 0 1.685149086938509e-08
, O 0 3.4312892527310623e-09
10 O 0 6.830978449556824e-09
with O 0 2.023682998952836e-09
DDS B-Disease 1 1.0
, O 0 8.781466220852963e-08
and O 0 1.1469865057733841e-08
4 O 0 4.6378102069866145e-07
with O 0 1.430342155828157e-08
urogenital B-Disease 1 0.9999748468399048
abnormalities I-Disease 1 0.9999730587005615
and O 0 4.960179012414301e-06
/ O 1 0.9999430179595947
or O 1 0.9644717574119568
WT B-Disease 1 1.0
. O 0 1.560498640174046e-05

We O 0 2.3777981823513983e-06
report O 0 2.4341392190763145e-07
WT1 O 0 0.00015147867088671774
heterozygous O 0 5.450705202747486e-07
mutations O 0 1.1673349575858083e-07
in O 0 9.157489877509306e-09
16 O 0 1.4045983220967173e-07
patients O 0 8.508411752927714e-09
, O 0 3.640250101355491e-09
4 O 0 1.7712642375045107e-07
of O 0 6.424203746746571e-08
whom O 0 5.3420691870087467e-08
presented O 0 1.8612711016885441e-07
with O 0 2.6024201815744163e-07
IDMS B-Disease 1 0.9999946355819702
. O 0 5.18940323672723e-05

One O 0 8.510004363415646e-07
male O 0 1.223151144813528e-07
and O 0 9.313113835673903e-09
two O 0 3.367465950532278e-08
female O 0 9.632085493649356e-07
IDMS B-Disease 1 0.9999526739120483
patients O 0 4.1563714603398694e-07
with O 0 1.6965310578598292e-07
WT1 O 1 0.9999995231628418
mutations O 1 0.772373616695404
underwent O 1 0.9939893484115601
normal O 0 0.0003369611222296953
puberty O 0 0.0006577593157999218
. O 0 2.439419404254295e-06

Two O 0 3.162290056479833e-07
mutations O 0 1.028611904985155e-06
associated O 0 7.948236202537373e-08
with O 0 9.14174869137696e-09
IDMS B-Disease 1 0.9999983310699463
are O 0 7.221418463210227e-10
different O 0 1.9092345759919027e-10
from O 0 2.529191078792792e-09
those O 0 8.022539299545883e-10
described O 0 7.98075987518132e-08
in O 0 6.199792892402911e-07
DDS B-Disease 1 1.0
patients O 0 1.565177080919966e-05
. O 0 1.0546576959313825e-05

No O 0 1.538169090053998e-05
WT1 O 0 0.0012611581478267908
mutations O 0 2.1657829165633302e-06
were O 0 2.7627681475905774e-08
detected O 0 5.0537291684804586e-08
in O 0 2.9247331223558604e-09
the O 0 7.248842415208401e-09
six O 0 1.865500109943241e-08
other O 0 5.048690709941184e-08
IDMS B-Disease 1 1.0
patients O 0 5.145126351635554e-07
, O 0 2.6876474379378124e-08
suggesting O 0 6.79459674302052e-07
genetic O 0 7.812898729753215e-06
heterogeneity O 0 0.00011347585677867755
of O 0 1.1650910209937138e-06
this O 0 1.2020680060231825e-06
disease O 0 0.32945528626441956
. O 0 1.3800299711874686e-05

We O 0 2.1639123133354587e-06
analyzed O 0 4.141227691434324e-06
genotype O 0 4.471854117582552e-05
/ O 0 6.34502139291726e-05
phenotype O 0 5.388361842051381e-06
correlations O 0 9.751910283739562e-07
, O 0 1.6727138563155108e-09
on O 0 2.181143266000163e-09
the O 0 5.164705885185583e-10
basis O 0 2.1382711157258427e-09
of O 0 9.992823235549508e-10
the O 0 1.1603247251912308e-09
constitution O 0 3.4557747774499603e-09
of O 0 1.6460656837580245e-08
a O 0 7.264208790047633e-08
WT1 O 0 4.5221662730909884e-05
mutation O 0 2.0648718646043562e-07
database O 0 1.8317189542926826e-08
of O 0 1.537181226751727e-08
84 O 0 3.399767933842668e-07
germ O 0 0.00048677806626074016
- O 0 9.643293196859304e-06
line O 0 1.2749244433507556e-06
mutations O 0 7.974977478397705e-08
, O 0 2.8817503938682876e-10
to O 0 2.9431987402794846e-10
compare O 0 2.135743804032586e-09
the O 0 7.520367106828019e-10
distribution O 0 2.3700710283236504e-09
and O 0 9.052208982396337e-11
type O 0 1.4306422713161737e-08
of O 0 6.981389244486991e-09
mutations O 0 7.381303124276428e-09
, O 0 2.694065248665112e-10
according O 0 2.962313450094456e-10
to O 0 9.61807300470241e-10
the O 0 1.2230211510200206e-08
different O 0 4.03375928215155e-08
symptoms O 0 5.807267370983027e-06
. O 0 6.35887681710301e-06

This O 0 1.2230017887304712e-07
demonstrated O 0 2.8338155289020506e-07
( O 0 4.775538897661136e-08
1 O 0 1.1380559499230003e-06
) O 0 2.1345749612322606e-09
the O 0 2.369695994985932e-09
association O 0 3.5736429371269196e-09
between O 0 1.1284117640286695e-08
mutations O 0 3.0504626380434274e-08
in O 0 3.25499360798176e-09
exons O 0 3.3955620892811567e-07
8 O 0 4.265150010951402e-08
and O 0 1.0290265306522883e-09
9 O 0 9.847068582757856e-08
and O 0 9.405673573326112e-09
DMS B-Disease 0 7.819606980774552e-05
; O 0 2.017436528944927e-08
( O 0 2.5896939703784483e-08
2 O 0 3.642315391516604e-07
) O 0 3.3274580868436487e-09
among O 0 2.9075239993403557e-09
patients O 0 1.5833192534842055e-09
with O 0 2.4140476284628676e-09
DMS B-Disease 1 0.9972677230834961
, O 0 1.175838271194607e-08
a O 0 1.0715138998307339e-08
higher O 0 2.5865100283795073e-08
frequency O 0 4.1833565944671136e-08
of O 0 7.531438583896488e-09
exon O 0 1.4267583026139619e-07
8 O 0 1.803296534319543e-08
mutations O 0 5.5355364736442425e-09
among O 0 1.8559627168457382e-09
46 O 0 8.300987985876418e-08
, O 0 2.1793562510197262e-08
XY O 0 0.0011204989859834313
patients O 0 6.78339340254297e-09
with O 0 8.946648977214977e-10
female O 0 1.1507686359379932e-08
phenotype O 0 3.731300779463709e-08
than O 0 1.9450174804092057e-09
among O 0 2.172242163922533e-09
46 O 0 1.7406780727924343e-07
, O 0 3.1923789833854244e-08
XY O 0 0.13649389147758484
patients O 0 5.879558617749581e-09
with O 0 6.829881105119284e-10
sexual O 0 7.9777770167766e-08
ambiguity O 0 1.586184043844696e-05
or O 0 6.273843382587074e-07
male O 0 1.1977923008998914e-07
phenotype O 0 2.2996458426405297e-07
; O 0 2.320008851697253e-09
and O 0 7.013046587900362e-09
( O 0 4.8292701393393145e-08
3 O 0 4.76316273534394e-07
) O 0 1.1300977931227862e-09
statistically O 0 4.708085032945064e-09
significant O 0 9.601356376620629e-10
evidence O 0 1.7864968393510594e-09
that O 0 3.97919391881274e-10
mutations O 0 7.992836614789667e-09
in O 0 2.8075215485756644e-09
exons O 0 3.4518049574217e-07
8 O 0 4.281957544094439e-08
and O 0 1.0101363079328962e-09
9 O 0 3.151000527168435e-08
preferentially O 0 3.514866619980239e-08
affect O 0 4.677402465347313e-09
amino O 0 7.710497129664873e-09
acids O 0 4.972460776464516e-10
with O 0 4.140499748617188e-11
different O 0 3.049633323648493e-10
functions O 0 1.4124383440616839e-08
. O 0 5.489738441610825e-08
. O 0 7.80406651301746e-07

The O 0 5.104772753838915e-06
185delAG O 0 8.186559716705233e-05
BRCA1 O 0 2.065290573227685e-05
mutation O 0 5.053373115515569e-07
originated O 0 1.6078518072504266e-08
before O 0 3.5631886330378393e-09
the O 0 5.097005040255453e-10
dispersion O 0 1.4597324593523808e-07
of O 0 6.0570970461526485e-09
Jews O 0 2.2776813324298928e-08
in O 0 4.5290490802152306e-10
the O 0 1.1362684126936529e-09
diaspora O 0 1.832414220359624e-08
and O 0 4.3594916565581343e-10
is O 0 1.1303026292708296e-09
not O 0 1.3238995455466807e-09
limited O 0 6.858603907033967e-09
to O 0 9.363755282265629e-08
Ashkenazim O 0 0.0031947435345500708
. O 0 9.696984307083767e-06

The O 0 6.024986873853777e-07
185delAG O 0 1.2066798262821976e-05
mutation O 0 1.7344437992505846e-06
in O 0 3.433491002624578e-08
BRCA1 O 0 3.0160276764945593e-06
is O 0 3.098280076940796e-09
detected O 0 1.1798978682975303e-08
in O 0 7.213049046939091e-10
Ashkenazi O 0 5.949401042926183e-07
Jews O 0 2.5451036833601393e-08
both O 0 4.818554999452829e-10
in O 0 3.33185301570893e-09
familial B-Disease 0 0.06820530444383621
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.461902622348134e-07
in O 0 4.532743957952334e-08
the O 0 3.2400674143673314e-08
general O 0 1.9261796069258708e-07
population O 0 3.625645206284389e-08
. O 0 1.7382892281148088e-07

All O 0 3.38047925652063e-07
tested O 0 4.6510760398632556e-07
Ashkenazi O 0 6.662175110250246e-06
mutation O 0 6.761165423085913e-07
carriers O 0 2.1019834761659695e-08
share O 0 1.492834300620416e-08
the O 0 3.2440972130842738e-09
same O 0 8.434263953915888e-09
allelic O 0 7.816639708835282e-07
pattern O 0 2.612585774386389e-07
at O 0 2.2685468081817817e-07
the O 0 2.002390431243839e-07
BRCA1 O 0 1.6766547560109757e-05
locus O 0 0.00010739338904386386
. O 0 2.129987933585653e-06

Our O 0 7.607381462548801e-07
previous O 0 1.0128497507366774e-07
study O 0 1.0371610237314144e-08
showed O 0 2.3149475669725916e-09
that O 0 1.144415534559684e-10
this O 0 9.460112693204792e-10
Ashkenazi O 0 6.758046311006183e-06
mutation O 0 2.8347400871098216e-07
also O 0 6.874696367731303e-10
occurs O 0 8.928954242648501e-10
in O 0 2.5165727834952634e-10
Iraqi O 0 4.4224064410514075e-09
Jews O 0 8.184176003567245e-09
with O 0 9.621058810749261e-11
a O 0 7.227746845472893e-09
similar O 0 4.060181524323525e-08
allelic O 0 1.4180215657688677e-05
pattern O 0 1.1853579962917138e-05
. O 0 3.767792577491491e-06

We O 0 3.6182538565299183e-07
extended O 0 6.221316795063103e-08
our O 0 2.230415852011447e-09
analysis O 0 5.792170743035285e-09
to O 0 1.6212994280451198e-09
other O 0 3.2211977529783553e-09
non O 0 6.377798058565531e-07
- O 0 1.6914241314225364e-06
Ashkenazi O 0 3.2567827474849764e-06
subsets O 0 1.8471372698058985e-07
354 O 0 2.245956132185256e-08
of O 0 3.78231668207718e-09
Moroccan O 0 6.582396849807992e-07
origin O 0 2.7637959476578544e-08
, O 0 5.539539049692621e-09
200 O 0 9.18789666570774e-09
Yemenites O 0 3.1044964998727664e-07
and O 0 2.4403243870096958e-09
150 O 0 5.6669296810696324e-08
Iranian O 0 2.255844947285368e-06
Jews O 0 4.1506855268380605e-06
. O 0 1.704436613181315e-06

Heteroduplex O 0 0.00026886528939940035
analysis O 0 4.0481887708665454e-07
complemented O 0 2.1816400419538695e-07
by O 0 4.5021448791260354e-09
direct O 0 4.121737262607894e-08
DNA O 0 2.696413048397517e-07
sequencing O 0 3.6289043237047736e-07
of O 0 9.101648856812972e-08
abnormally O 0 3.428432933105796e-07
migrating O 0 2.0428378988412987e-08
bands O 0 2.7755129750062224e-08
were O 0 2.0786083965163016e-08
employed O 0 3.8925182366256195e-07
. O 0 9.113459213949682e-07

Four O 0 1.0074779766000574e-07
of O 0 1.1966824331466341e-07
Moroccan O 0 1.708533636701759e-05
origin O 0 6.30638012921736e-08
( O 0 3.83983556062617e-09
1 O 0 8.858530975430767e-08
. O 0 4.0390521482969177e-10
1 O 0 2.103234741923643e-08
% O 0 2.550501143616657e-09
) O 0 7.748954256037166e-11
and O 0 5.996785706896546e-11
none O 0 1.2412145755646975e-09
of O 0 1.4975333195721419e-09
the O 0 8.501420012407834e-09
Yemenites O 0 4.5577507989946753e-07
or O 0 1.1146529921290949e-08
Iranians O 0 3.9698889509054425e-08
was O 0 1.2745284827531123e-08
a O 0 2.796288089967902e-09
carrier O 0 2.3764593848341065e-08
of O 0 1.0562263064173294e-08
the O 0 4.201027792305467e-08
185delAG O 0 1.0752033631433733e-05
mutation O 0 6.646018391620601e-06
. O 0 2.322659383935388e-06

BRCA1 O 0 0.00016859438619576395
allelic O 0 1.3374555237533059e-05
patterns O 0 5.621467380478862e-08
were O 0 6.278354280908616e-09
determined O 0 9.76275948971761e-09
for O 0 4.769735162390987e-10
four O 0 3.2502642244303104e-10
of O 0 5.687953441579907e-10
these O 0 2.8055488487943592e-11
individuals O 0 1.0366181524279483e-10
and O 0 3.185131602911895e-10
for O 0 2.5671440528896028e-09
12 O 0 7.999028994731816e-09
additional O 0 3.0858124944188603e-09
non O 0 1.9655080052416452e-07
- O 0 2.534771113005263e-07
Ashkenazi O 0 3.872871161547664e-07
185delAG O 0 1.1654105946945492e-07
mutation O 0 1.0361763891353348e-08
carriers O 0 9.646369925064846e-09
who O 0 5.132246627681525e-08
had O 0 9.605477316654287e-06
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.3738410770893097

Six O 0 2.3014479211269645e-06
non O 0 1.6759944628574885e-05
- O 0 1.798562880139798e-05
Ashkenazi O 0 4.5314391172723845e-05
individuals O 0 3.130344428114995e-09
shared O 0 5.0119792760483506e-09
the O 0 8.642597748576009e-09
common O 0 9.228435970953797e-08
Ashkenazi O 0 0.00013057058095000684
haplotype O 0 0.0015615010634064674
, O 0 1.4231742007098092e-08
four O 0 3.179069896219744e-09
had O 0 3.852886898414454e-09
a O 0 1.8388942590874535e-09
closely O 0 1.1103068464635157e-09
related O 0 3.0769438108535496e-09
pattern O 0 1.0052647780867119e-07
, O 0 3.356838584878119e-09
and O 0 1.4538418247056484e-09
the O 0 2.3423217143658803e-08
rest O 0 9.220290309031043e-08
( O 0 2.2215349559928654e-08
n O 0 5.603300223810948e-07
= O 0 1.8929381440102588e-07
6 O 0 7.503209786818843e-08
) O 0 1.114580094885298e-09
displayed O 0 4.146344156907844e-09
a O 0 3.0843665399515885e-08
distinct O 0 3.797401575411641e-07
BRCA1 O 0 2.6558080207905732e-05
allelic O 0 0.00012029857316520065
pattern O 0 7.404912321362644e-05
. O 0 1.115578106691828e-05

We O 0 5.970465508653433e-07
conclude O 0 5.97893233589275e-07
that O 0 5.756815468771492e-09
the O 0 4.6873267933733587e-08
185delAG O 0 1.4951095181459095e-05
BRCA1 O 0 3.3271957363467664e-05
mutation O 0 1.6607066299911821e-06
occurs O 0 1.1439409419722324e-08
in O 0 8.560122055634167e-10
some O 0 7.977221661015221e-10
non O 0 4.0326833072867885e-07
- O 0 2.2462170363724e-06
Ashkenazi O 0 1.2238878298376221e-05
populations O 0 5.851154227798361e-09
at O 0 2.310355906587347e-09
rates O 0 8.393449268950803e-10
comparable O 0 8.94757512526212e-09
with O 0 6.540665786758382e-10
that O 0 9.279158774688767e-09
of O 0 1.0654122206688044e-06
Ashkenazim O 0 0.0027560649905353785
. O 0 6.545716132677626e-06

The O 0 3.779679786930501e-07
majority O 0 6.897464288613264e-08
of O 0 4.611234061258074e-08
Jewish O 0 4.945000000589062e-07
185delAG O 0 4.758581326314015e-06
mutation O 0 8.518805429957865e-07
carriers O 0 3.779506130285881e-08
have O 0 7.722753547767525e-10
a O 0 4.8533497221114885e-09
common O 0 1.5918500295697413e-08
allelic O 0 8.941451028476877e-07
pattern O 0 7.524276668391394e-08
, O 0 7.031473181484671e-10
supporting O 0 1.5954664256412343e-09
the O 0 3.0590607824620974e-09
founder O 0 2.280115651842607e-08
effect O 0 1.0809482198226306e-08
notion O 0 9.863722993941337e-08
, O 0 5.723267415547184e-10
but O 0 2.5031066108738287e-10
dating O 0 1.4892898025919976e-09
the O 0 4.586965807185095e-10
mutations O 0 1.5156597088505919e-09
origin O 0 5.877054953806748e-10
to O 0 3.3957456291311416e-10
an O 0 4.760274396886643e-10
earlier O 0 7.78037456683478e-09
date O 0 3.365514089637145e-08
than O 0 5.753280962750296e-09
currently O 0 1.8181925298677015e-08
estimated O 0 2.109728143295797e-07
. O 0 7.91685351941851e-07

However O 0 5.642725682264427e-07
, O 0 2.692295808515155e-08
the O 0 3.832277606363732e-09
different O 0 8.883868640729986e-10
allelic O 0 5.698655058949953e-07
pattern O 0 1.8674319335332257e-07
at O 0 5.3669072741513446e-08
the O 0 1.171747943118362e-08
BRCA1 O 0 1.7732869537212537e-06
locus O 0 4.063244887220208e-06
even O 0 1.4114196478232088e-09
in O 0 1.2696116380439548e-10
some O 0 5.641319356097796e-11
Jewish O 0 8.365133474796949e-09
mutation O 0 1.1821505552234157e-08
carriers O 0 3.93627397343721e-09
, O 0 1.0185133847429029e-09
might O 0 4.885932547438188e-09
suggest O 0 4.398364783497755e-09
that O 0 2.6182045420597433e-10
the O 0 3.900757938879451e-09
mutation O 0 4.7823750293218836e-08
arose O 0 4.559893795885728e-08
independently O 0 2.048061809034607e-08
. O 0 2.468413562439764e-08
. O 0 5.057625003246358e-07

Crystal O 0 4.248995901434682e-05
structure O 0 1.5078081787578412e-06
of O 0 1.31269302983128e-06
the O 0 5.781637810287066e-06
hemochromatosis B-Disease 1 1.0
protein O 0 0.0005037790979258716
HFE O 1 0.967914342880249
and O 0 1.4958411398424687e-08
characterization O 0 8.211368935917562e-07
of O 0 3.930912129135322e-08
its O 0 5.160198934817117e-09
interaction O 0 2.0595512850718478e-08
with O 0 1.3956527489256132e-08
transferrin O 0 0.00011929650645470247
receptor O 0 0.0001354231353616342
. O 0 4.872905265074223e-06

HFE O 1 0.9994422793388367
is O 0 7.451850478901179e-07
an O 0 2.3324095366206166e-07
MHC O 1 0.9999454021453857
- O 0 0.0001315109693678096
related O 0 9.43559541610739e-08
protein O 0 2.2291963830411987e-08
that O 0 1.587264208957606e-10
is O 0 6.491883142167865e-10
mutated O 0 6.151719578184611e-09
in O 0 1.1511654962603757e-09
the O 0 4.0016125524289237e-08
iron B-Disease 1 0.9998842477798462
- I-Disease 1 1.0
overload I-Disease 1 1.0
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 1 0.9999980926513672

HFE O 0 0.0031027202494442463
binds O 0 3.587636001611827e-06
to O 0 1.3578370783307037e-07
transferrin O 0 3.2099509553518146e-05
receptor O 0 4.585525311995298e-05
( O 0 2.1957836793262686e-07
TfR O 0 6.7020291680819355e-06
) O 0 5.622708521002551e-09
and O 0 1.2598714294043134e-09
reduces O 0 1.1768254815081036e-08
its O 0 7.242840771581882e-10
affinity O 0 3.9971197907107126e-08
for O 0 1.9787893990041994e-08
iron O 0 1.4194558389135636e-05
- O 0 5.570911525865085e-06
loaded O 0 3.055954493902391e-07
transferrin O 0 3.4668030366447056e-06
, O 0 2.7195103058375025e-08
implicating O 0 3.0598730518249795e-06
HFE O 0 0.006550968624651432
in O 0 1.5238208561640931e-06
iron O 0 0.013440187089145184
metabolism O 0 0.00044413708383217454
. O 0 6.91096192895202e-06

The O 0 2.2392279788618907e-05
2 O 0 9.439868154004216e-05
. O 0 8.45627346279798e-06

6 O 0 0.0001102289606933482
A O 0 1.8283481040271e-05
crystal O 0 2.908388341893442e-05
structure O 0 2.285424443471129e-06
of O 0 6.875292456243187e-06
HFE O 1 0.9999996423721313
reveals O 0 3.9621281189283764e-07
the O 0 5.707909700447544e-09
locations O 0 1.047247355501213e-08
of O 0 1.7075346647743572e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.00014514900976791978
and O 0 2.7261421564617194e-08
a O 0 1.0526001688049291e-06
patch O 1 0.998030960559845
of O 0 2.7460441742732655e-06
histidines O 0 0.2428002655506134
that O 0 8.883767055323233e-10
could O 0 3.1501337094397286e-09
be O 0 8.147322261287115e-10
involved O 0 2.213696115305197e-09
in O 0 5.905723465815527e-09
pH O 0 1.781725040927995e-05
- O 0 6.528360245283693e-06
dependent O 0 1.9263720787421335e-06
interactions O 0 1.289178044316941e-06
. O 0 1.550209276501846e-06

We O 0 1.3381676353674266e-06
also O 0 4.630447492104395e-08
demonstrate O 0 6.332717816803779e-08
that O 0 1.383524583786766e-08
soluble O 0 9.657530426920857e-06
TfR O 0 7.706383257755078e-06
and O 0 8.737537804393014e-09
HFE O 0 1.6424095520051196e-05
bind O 0 6.712377143003323e-08
tightly O 0 8.262036743644785e-08
at O 0 1.0285188700720482e-08
the O 0 1.2062753018682315e-09
basic O 0 9.69134994477372e-09
pH O 0 1.4140239557036693e-07
of O 0 4.119094398902234e-09
the O 0 3.7034484368092535e-09
cell O 0 6.720986078789792e-08
surface O 0 9.824218238918547e-08
, O 0 1.2833730744787886e-09
but O 0 7.192016426849079e-10
not O 0 2.4802957465652753e-09
at O 0 6.81533833812864e-08
the O 0 3.6200756170501336e-08
acidic O 0 3.5512330214260146e-06
pH O 0 4.620576419256395e-06
of O 0 4.11171868108795e-07
intracellular O 0 8.595879990025423e-06
vesicles O 0 5.96526988374535e-05
. O 0 2.2062379230192164e-06

TfR O 0 0.016210239380598068
HFE O 0 0.042549945414066315
stoichiometry O 0 0.0002929717593360692
( O 0 1.2705718290817458e-06
2 O 0 9.948528713721316e-06
1 O 0 1.858512746366614e-06
) O 0 4.184854685007622e-09
differs O 0 1.951156747281857e-08
from O 0 2.0683614820882212e-08
TfR O 0 1.7046968423528597e-06
transferrin O 0 1.4112703183855047e-06
stoichiometry O 0 9.080994232135708e-07
( O 0 1.9008066232117926e-08
2 O 0 1.7917193417815724e-07
2 O 0 6.387634243765206e-08
) O 0 1.249442549422497e-09
, O 0 4.5212295018970394e-10
implying O 0 1.9308284748831284e-08
a O 0 2.2735178184518645e-09
different O 0 2.0793083921333277e-10
mode O 0 9.781472520842271e-09
of O 0 1.6536519931165117e-09
binding O 0 2.7361437560102786e-08
for O 0 1.3746495497457545e-08
HFE O 0 0.0020822177175432444
and O 0 2.9930706801906126e-08
transferrin O 0 3.5293548990011914e-06
to O 0 3.384155888852547e-08
TfR O 0 6.648072485404555e-06
, O 0 2.1319341847458873e-09
consistent O 0 4.561727440233199e-09
with O 0 2.3918453329052625e-10
our O 0 3.1516240728279854e-09
demonstration O 0 3.6099468303518734e-08
that O 0 1.6589118967402783e-09
HFE O 0 5.8653873566072434e-05
, O 0 1.6699381433227245e-08
transferrin O 0 2.856495711967e-06
, O 0 1.2517927139299445e-08
and O 0 4.856164803612728e-09
TfR O 0 1.8381346080786898e-06
form O 0 1.7302653532169643e-08
a O 0 2.047705009999845e-07
ternary O 0 3.358071262482554e-05
complex O 0 1.1730486221495084e-05
. O 0 2.158804591090302e-06

Identification O 0 1.8781887547447695e-06
of O 0 2.9160071335354587e-07
three O 0 1.189124709810585e-08
novel O 0 1.0671048045196585e-07
mutations O 0 5.5198718484916753e-08
and O 0 1.0487319901386627e-09
a O 0 1.2130499271734152e-08
high O 0 3.6014668580719444e-08
frequency O 0 6.639771044092413e-08
of O 0 5.595769181354626e-09
the O 0 9.582682203301829e-09
Arg778Leu O 0 3.019763607881032e-05
mutation O 0 3.368629961642e-07
in O 0 1.829875095893385e-08
Korean O 0 7.002236088737845e-07
patients O 0 5.461411767271329e-09
with O 0 5.868120211971473e-09
Wilson B-Disease 0 0.00021012515935581177
disease I-Disease 0 0.017505357041954994
. O 0 6.826788194302935e-06

Four O 0 9.69105826698069e-08
mutations O 0 4.249603762218612e-07
- O 0 3.4101760775229195e-06
- O 0 1.4881476090522483e-05
R778L O 0 0.00012462459562812
, O 0 2.2169549751538398e-08
A874V O 0 4.044779871037463e-06
, O 0 4.93923790756412e-09
L1083F O 0 1.2019694395348779e-06
, O 0 1.1509964092937253e-09
and O 0 9.160210368008848e-10
2304delC O 0 6.545464543705748e-07
- O 0 2.161416659873794e-06
- O 0 2.2177198388817487e-06
in O 0 2.1629821489455026e-08
the O 0 3.5843143564306956e-08
copper O 0 9.160949616671132e-07
- O 0 3.918545701253606e-07
transporting O 0 3.386699987117936e-08
enzyme O 0 2.3222812117751346e-08
, O 0 5.120842860861785e-09
P O 0 4.915762929158518e-06
- O 0 2.1022427176831116e-07
type O 0 4.2454678350623e-07
ATPase O 0 3.104874394921353e-06
( O 0 3.0057655919790705e-08
ATP7B O 0 0.00044073432218283415
) O 0 2.706133317431636e-09
, O 0 4.2577893988315907e-10
were O 0 6.699759635964142e-10
identified O 0 7.444944216672411e-09
in O 0 6.963063903242528e-09
Korean O 0 6.72810415380809e-07
Patients O 0 1.5151227827914227e-08
with O 0 1.094399593171147e-08
Wilson B-Disease 0 0.05165424942970276
disease I-Disease 1 0.9950161576271057
. O 0 4.323822940932587e-05

Arg778Leu O 1 0.9984921216964722
, O 0 3.107248005562724e-07
the O 0 4.5776712198630776e-08
most O 0 4.043725798652531e-09
frequently O 0 1.988709419364909e-09
reported O 0 1.7997394685664858e-09
mutation O 0 5.618688181385778e-09
of O 0 9.399966360845724e-10
this O 0 1.772079427642126e-10
enzyme O 0 4.10773370873585e-09
, O 0 2.7558236248559353e-10
was O 0 9.724605121164132e-09
found O 0 2.600600845781287e-10
in O 0 1.4141190995964337e-10
six O 0 6.750503489527659e-10
of O 0 3.4543909954720675e-09
eight O 0 1.4612736798369497e-08
unrelated O 0 2.023918028726257e-07
patients O 0 5.678893799654361e-09
studied O 0 5.321608043118431e-08
, O 0 1.305857755262707e-09
an O 0 1.3065329929062841e-09
allele O 0 5.581179607361264e-08
frequency O 0 1.9861957412103948e-07
of O 0 1.8181341943090956e-07
37 O 0 1.6006724763428792e-06
. O 0 5.381697860684653e-07

5 O 0 5.253180916042766e-06
% O 0 7.418751124532719e-07
, O 0 2.1136739025706675e-09
which O 0 3.0229990732877354e-10
is O 0 7.346760422244358e-10
considerably O 0 8.112235327928374e-09
higher O 0 9.369148123994364e-09
than O 0 6.439618838172123e-10
those O 0 3.960914651823799e-10
in O 0 1.1968240842819e-09
other O 0 1.900853030534222e-09
Asian O 0 1.3085093542031245e-07
populations O 0 9.167979442281649e-08
. O 0 2.2813645728092524e-07

The O 0 9.79737251327606e-07
novel O 0 5.055918563812156e-07
single O 0 6.362633797607486e-08
nucleotide O 0 4.0406789025837497e-07
deletion O 0 6.096449283177208e-07
, O 0 9.59751655926766e-09
2304delC O 0 1.3498878388418234e-06
, O 0 9.956774960073744e-09
was O 0 2.1265182681418082e-07
found O 0 4.481600424099952e-09
in O 0 4.380055873554056e-09
one O 0 8.216713354158856e-08
patient O 0 2.0211803075653734e-06
. O 0 4.106062533537624e-06

Since O 0 1.1331695759508875e-06
a O 0 3.2725691312407434e-07
mutation O 0 5.11616974563367e-07
at O 0 3.618419270878803e-07
cDNA O 0 3.0475337098323507e-06
nucleotide O 0 2.0676773146988126e-06
2302 O 0 5.580360084422864e-05
( O 0 1.9482078172927686e-08
2302insC O 0 1.093018568099069e-06
) O 0 4.245538143266003e-09
had O 0 8.665971051868837e-09
been O 0 2.1434161112665606e-09
previously O 0 7.76956365911019e-09
described O 0 8.517406335784017e-09
, O 0 3.9120368056089205e-10
this O 0 3.5274824727871135e-10
region O 0 3.7465049729235034e-08
of O 0 1.7322397738439577e-08
the O 0 6.298085963862832e-08
ATP7B O 1 0.9999990463256836
gene O 0 6.284142841650464e-07
may O 0 2.8768656790134628e-08
be O 0 1.9622673264052537e-08
susceptible O 0 2.092436943712528e-06
to O 0 2.7399980950804093e-08
gene O 0 3.5384271086513763e-06
rearrangements O 1 0.7826593518257141
causing O 0 0.23939470946788788
Wilson B-Disease 0 0.005401256028562784
disease I-Disease 1 0.5666356086730957
. O 0 1.8007409380516037e-05

Disruption O 0 5.4270163673209026e-05
of O 0 3.0823969154880615e-07
splicing O 0 5.941031986367307e-07
regulated O 0 2.8948536012762816e-08
by O 0 1.0439322739586032e-09
a O 0 7.825920533832686e-08
CUG O 0 0.0008977969409897923
- O 0 6.636617513322562e-07
binding O 0 1.8028759996013832e-07
protein O 0 7.874686502873374e-07
in O 0 1.7387468176366383e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0010557059431448579

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9758976101875305
DM B-Disease 1 1.0
) O 0 4.203440369110467e-07
is O 0 1.6202770680706635e-08
caused O 0 2.403766252712103e-08
by O 0 2.19905538223486e-09
a O 0 1.4760479416509042e-07
CTG O 0 0.0001419407781213522
expansion O 0 4.5624429390045407e-07
in O 0 8.340661494798951e-09
the O 0 1.2167622465142358e-08
3 O 0 2.8106447302889137e-07
untranslated O 0 2.3536160369985737e-05
region O 0 1.9584540211781132e-07
of O 0 1.2828003548293054e-07
the O 0 1.5673044799768832e-06
DM B-Disease 1 1.0
gene O 0 4.5724947995040566e-05
. O 0 4.073806394444546e-06

One O 0 3.09586596358713e-07
model O 0 2.849384088676743e-07
of O 0 3.865899998345412e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9998974800109863
suggests O 0 1.4396678693628928e-07
that O 0 9.813123647006705e-10
RNAs O 0 1.749156552932618e-07
from O 0 2.205785110120928e-09
the O 0 6.508434347018976e-10
expanded O 0 1.026601581521902e-09
allele O 0 7.46556239050733e-09
create O 0 4.423652832930003e-10
a O 0 7.150547709500188e-09
gain O 0 3.088853191002272e-07
- O 0 3.207234442470508e-07
of O 0 2.5034623263309186e-08
- O 0 3.3777652674871206e-08
function O 0 1.4527163916255859e-09
mutation O 0 3.780836477229599e-10
by O 0 3.8415898934163195e-11
the O 0 3.748809873638237e-10
inappropriate O 0 4.0754097874184936e-09
binding O 0 1.8614624508472843e-08
of O 0 1.2663238457832904e-08
proteins O 0 2.283604860764399e-09
to O 0 3.4991656239213853e-09
the O 0 3.248080417961319e-07
CUG O 1 0.9842294454574585
repeats O 0 3.0717892514076084e-05
. O 0 2.475906967447372e-06

Data O 0 1.257526037079515e-06
presented O 0 4.5264368964126334e-07
here O 0 5.838359129484161e-08
indicate O 0 4.501735162421028e-08
that O 0 1.38940248195496e-09
the O 0 3.3405978427936134e-08
conserved O 0 1.5458423376912833e-06
heterogeneous O 0 6.732945166731952e-06
nuclear O 0 0.0007668001344427466
ribonucleoprotein O 0 0.000789262936450541
, O 0 2.661762188438388e-08
CUG O 0 1.2229031199240126e-05
- O 0 4.527878871840585e-08
binding O 0 2.570683044211819e-08
protein O 0 2.1528324012365374e-08
( O 0 3.643271906383916e-09
CUG O 0 4.147090294281952e-05
- O 0 1.2310180181884789e-06
BP O 0 7.636080226802733e-06
) O 0 5.529363189538117e-09
, O 0 2.1715296227853287e-09
may O 0 7.354321152064358e-09
mediate O 0 2.8464157253438316e-07
the O 0 7.517419930991309e-08
trans O 0 4.476024969335413e-06
- O 0 1.575093165229191e-06
dominant O 0 5.292940841172822e-07
effect O 0 5.6712330831487634e-08
of O 0 2.8575499300131924e-08
the O 0 7.15147834284835e-08
RNA O 0 9.015680006996263e-06
. O 0 8.814554917080386e-07

CUG O 1 0.9987429976463318
- O 0 0.01271938905119896
BP O 0 0.0025098631158471107
was O 0 4.6626010430372844e-07
found O 0 9.685523494340487e-10
to O 0 4.2230841046375645e-10
bind O 0 2.9943882928762378e-09
to O 0 3.353050503918098e-09
the O 0 6.214118286607118e-08
human O 0 6.060404302843381e-07
cardiac O 1 0.9124789834022522
troponin O 1 0.8984581232070923
T O 0 0.00045732661965303123
( O 0 3.202692369086435e-07
cTNT O 0 1.6777345081209205e-05
) O 0 1.4814739657253995e-08
pre O 0 1.003770080387767e-06
- O 0 2.1107868519720796e-07
messenger O 0 7.405886037759046e-08
RNA O 0 1.5495737670789822e-07
and O 0 1.1414774681028916e-09
regulate O 0 1.7614015801470373e-09
its O 0 1.704576590988438e-09
alternative O 0 3.741392333722615e-07
splicing O 0 6.61458716422203e-06
. O 0 1.6998686760416604e-06

Splicing O 0 6.440363904403057e-06
of O 0 1.5329613916037488e-06
cTNT O 0 0.0064714159816503525
was O 0 1.0171325811825227e-05
disrupted O 0 1.5232530131470412e-05
in O 0 7.374198958132183e-07
DM B-Disease 1 1.0
striated O 0 0.0007075411849655211
muscle O 0 2.883229853978264e-06
and O 0 1.919720205023623e-08
in O 0 1.290004991716387e-08
normal O 0 1.1843808067624195e-07
cells O 0 4.4169798485427236e-08
expressing O 0 3.354120181597864e-08
transcripts O 0 1.6812028036383708e-07
that O 0 1.3675468757412546e-08
contain O 0 7.126246828192961e-07
CUG O 0 0.0069198752753436565
repeats O 0 3.3768963476177305e-05
. O 0 6.056358870409895e-06

Altered O 0 3.6939622987119947e-06
expression O 0 2.473598499364016e-07
of O 0 5.876982811514608e-08
genes O 0 5.3682377654240554e-08
regulated O 0 4.8369859229069334e-08
posttranscriptionally O 0 3.2812019981065532e-06
by O 0 1.0018633389563547e-07
CUG O 1 0.9999938011169434
- O 0 0.0009514934499748051
BP O 0 0.00012140103353885934
therefore O 0 1.2443588559563068e-07
may O 0 2.00405185779573e-08
contribute O 0 5.662845481424483e-08
to O 0 1.1961215022893157e-06
DM B-Disease 1 1.0
pathogenesis O 1 0.9068012237548828
. O 0 9.613639804229024e-07
. O 0 1.710507149255136e-06

Identification O 0 7.027020956229535e-07
of O 0 1.2494065515511465e-07
a O 0 6.830330079310443e-08
novel O 0 1.2639583246709662e-07
nonsense O 0 1.3752024869972956e-06
mutation O 0 9.186603477928657e-08
and O 0 8.157118314144896e-10
a O 0 6.537526076044742e-09
missense O 0 5.950581112301734e-07
substitution O 0 1.8795617506839335e-07
in O 0 3.7104197492254798e-09
the O 0 1.1336346084078741e-08
vasopressin O 0 5.980221544632514e-07
- O 0 1.5462198916793568e-06
neurophysin O 0 7.259898848133162e-05
II O 1 0.9166517853736877
gene O 0 2.6068359915143446e-08
in O 0 1.0192304777945083e-09
two O 0 6.863219992325753e-10
Spanish O 0 1.8488714204067946e-07
kindreds O 0 3.749751158466097e-06
with O 0 1.833725526978469e-08
familial B-Disease 1 0.9999924898147583
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
. O 0 0.00016330921789631248

Familial B-Disease 1 0.9999998807907104
neurohypophyseal I-Disease 1 1.0
diabetes I-Disease 1 1.0
insipidus I-Disease 1 1.0
( O 0 0.13566763699054718
FNDI B-Disease 1 1.0
) O 0 1.0336817268807863e-07
is O 0 8.987753652434094e-09
an O 0 1.1413953338035299e-08
autosomal B-Disease 1 0.9999971389770508
dominant I-Disease 1 1.0
disease I-Disease 1 1.0
caused O 1 0.99950110912323
by O 0 1.131224780692719e-05
deficiency O 1 0.9999998807907104
in O 0 2.314486891918932e-06
the O 0 1.9281162622064585e-06
antidiuretic O 0 1.353068455500761e-05
hormone O 0 2.9051761885057203e-07
arginine O 0 1.2333164249866968e-06
vasopressin O 0 3.5120301618007943e-06
( O 0 2.447771123570419e-07
AVP O 0 2.49507120315684e-05
) O 0 6.527617335549962e-10
encoded O 0 5.844414396882769e-10
by O 0 3.0787680738164624e-10
the O 0 3.164280570899791e-08
AVP O 0 9.938900620909408e-05
- O 0 6.261617272684816e-06
neurophysin O 0 0.001613494474440813
II O 1 0.9999984502792358
( O 0 2.1163712062843842e-06
AVP O 0 0.0009172011632472277
- O 0 1.7653261238592677e-05
NPII O 0 0.0003183869121130556
) O 0 3.214558219610808e-08
gene O 0 7.899343756889721e-08
on O 0 3.3916489883267786e-07
chromosome O 0 0.00027137677534483373
20p13 O 0 0.0013992537278681993
. O 0 9.225264875567518e-06

In O 0 6.856539869204425e-08
this O 0 5.969107430559006e-09
study O 0 9.52631662443082e-09
, O 0 1.7142732788855142e-09
we O 0 1.3809796639563388e-09
analyzed O 0 9.036760673097888e-09
two O 0 5.901812927255889e-10
families O 0 5.691361271153994e-10
with O 0 1.8641155286047706e-09
FNDI B-Disease 1 0.9999984502792358
using O 0 2.4088976147140784e-08
direct O 0 1.0719885068510848e-07
automated O 0 2.880918827941059e-07
fluorescent O 0 1.4816102122949815e-07
, O 0 3.927350000765273e-09
solid O 0 3.18295469980967e-08
phase O 0 2.60166103771553e-07
, O 0 3.574399665140504e-09
single O 0 1.9195848466324605e-08
- O 0 7.46032711163025e-08
stranded O 0 1.7850194211632697e-08
DNA O 0 6.86679779704491e-09
sequencing O 0 6.549008446654625e-09
of O 0 8.262757589250214e-09
PCR O 0 1.213503310282249e-06
- O 0 1.404118120262865e-05
amplified O 0 4.072031151736155e-05
AVP O 0 0.00040135151357389987
- O 0 1.9977140254923142e-05
NPII O 0 0.0005794937605969608
DNA O 0 1.7009786461130716e-05
. O 0 1.912120978886378e-06

In O 0 1.1032822300194312e-07
one O 0 7.415791980491804e-09
of O 0 1.4520246338634024e-08
the O 0 1.7139667463084152e-08
families O 0 1.1117101017532605e-08
, O 0 5.710817152504433e-09
affected O 0 7.977773996969972e-09
individuals O 0 5.680765302606972e-10
presented O 0 7.806774782181947e-09
a O 0 1.3241730378865668e-08
novel O 0 5.124343260831665e-08
nonsense O 0 1.8965359060985065e-07
mutation O 0 2.5926345514903915e-08
in O 0 1.9493628933275886e-09
exon O 0 1.2257983428298758e-07
3 O 0 1.1922906217876061e-08
of O 0 1.3429588552327232e-09
the O 0 7.802185564287356e-10
gene O 0 1.724610565467799e-09
, O 0 2.0911604392548355e-10
consisting O 0 5.12390796458817e-10
in O 0 1.1116291220858443e-09
a O 0 4.134011533096782e-08
G O 0 1.972106929315487e-06
to O 0 3.775082646484407e-08
T O 0 2.5869053388305474e-06
transition O 0 3.511724742111255e-07
at O 0 1.618737712760776e-07
nucleotide O 0 5.088550096843392e-07
2101 O 0 2.2290066681307508e-06
, O 0 6.782924222292763e-10
which O 0 1.3183401592620214e-10
produces O 0 3.5263794662121484e-10
a O 0 2.9699864789733965e-09
stop O 0 1.7576134325736348e-08
signal O 0 1.5653743901111739e-07
in O 0 1.3653731478768805e-08
codon O 0 7.525970318056352e-07
82 O 0 7.080520276758762e-07
( O 0 1.2697103102254914e-07
Glu O 0 1.5038683159218635e-05
) O 0 3.190765696103881e-08
of O 0 4.6649671503473655e-07
NPII O 1 0.567402184009552
. O 0 1.3821716493112035e-05

The O 0 6.110306912887609e-06
premature O 0 2.412519279459957e-05
termination O 0 3.88168882636819e-06
eliminates O 0 2.93479865831614e-06
part O 0 7.16144299417465e-08
of O 0 2.9481910246431653e-08
the O 0 2.4345052196395045e-08
C O 0 1.7461798051954247e-05
- O 0 4.343076227542042e-07
terminal O 0 6.077849548091763e-07
domain O 0 6.580953737511663e-08
of O 0 2.4576273460752418e-08
NPII O 0 0.00046731243492104113
, O 0 3.4483871313994996e-09
including O 0 6.156834486681362e-10
a O 0 4.550907206635202e-09
cysteine O 0 8.84586359717332e-09
residue O 0 1.6969875105132814e-07
in O 0 1.222731360606133e-09
position O 0 1.1300146951498391e-07
85 O 0 3.024074857194137e-08
, O 0 2.422487488384917e-10
which O 0 1.200701343906374e-10
could O 0 6.636853289165856e-10
be O 0 8.205304213859677e-10
involved O 0 1.6080288212094729e-09
in O 0 1.3113939933973029e-09
the O 0 4.282478371919751e-09
correct O 0 1.9342829205015732e-07
folding O 0 8.320373012793425e-07
of O 0 1.1086508067137402e-07
the O 0 6.68829898131662e-07
prohormone O 0 0.13898426294326782
. O 0 1.004290061246138e-05

In O 0 1.391092894209578e-07
the O 0 8.830897257894321e-08
second O 0 1.2971646583537222e-06
family O 0 1.8739196860906304e-08
, O 0 1.0297883656917861e-09
a O 0 8.223075553814851e-09
G279A O 0 5.464050332193437e-07
substitution O 0 5.838425920501322e-08
at O 0 4.69972611938374e-08
position O 0 9.884006857419081e-08
- O 0 7.766010412524338e-08
1 O 0 6.704213717512175e-08
of O 0 1.4849047547116356e-09
the O 0 5.540667369352548e-10
signal O 0 1.6628820986852588e-08
peptide O 0 3.3411456712428844e-08
was O 0 1.2403040372532814e-08
observed O 0 2.5065525210976602e-09
in O 0 3.22547516473648e-10
all O 0 4.975677092566855e-10
affected O 0 1.50337804427636e-08
individuals O 0 1.1591573922942189e-08
. O 0 1.7623990515858168e-06

This O 0 6.033278054928815e-07
missense O 0 7.848547829780728e-05
mutation O 0 5.271991540212184e-06
, O 0 2.5874278719584254e-08
which O 0 9.9457091451427e-09
replaces O 0 3.4230822620884283e-06
Ala O 0 1.431071632396197e-05
with O 0 1.0130309924250014e-08
Thr O 0 0.00013671958004124463
, O 0 7.835295967595357e-09
is O 0 1.7407113528378204e-09
frequent O 0 2.0023325220108745e-08
among O 0 4.3994160137117433e-07
FNDI B-Disease 1 1.0
patients O 0 2.996320517922868e-06
and O 0 1.0865499611156793e-08
is O 0 2.0433365222061184e-08
thought O 0 1.0002820793886258e-08
to O 0 8.600889445098403e-10
reduce O 0 3.838363848984727e-09
the O 0 2.139588728411468e-09
efficiency O 0 1.0855991661173903e-08
of O 0 7.877644314646659e-09
cleavage O 0 9.756136165606222e-08
by O 0 7.167083371228955e-09
signal O 0 3.849315817205934e-06
peptidases O 0 2.0423862224561162e-05
. O 0 3.550884173364466e-07
. O 0 1.1320591966068605e-06

Genetic O 0 1.8794175048242323e-05
heterogeneity O 0 5.433390469988808e-05
of O 0 1.1253230695729144e-05
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 4.4968010115553625e-07
due O 0 2.1326161459001014e-06
to O 0 1.1235757568783811e-07
TWIST O 0 0.00026256582350470126
and O 0 4.6868220238138747e-07
FGFR O 1 0.9999575614929199
mutations O 0 0.00010679311526473612
. O 0 5.872920610272558e-06

Thirty O 0 5.008102743886411e-05
- O 0 2.9016344342380762e-05
two O 0 6.023022081080853e-08
unrelated O 0 7.695263661844365e-07
patients O 0 4.830944089206923e-09
with O 0 1.2103401614282916e-10
features O 0 2.7772484312293955e-09
of O 0 4.7143421966211463e-07
Saethre B-Disease 1 1.0
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 7.736043983186391e-08
a O 0 1.5803563258032227e-07
common O 0 1.6346279153367504e-05
autosomal B-Disease 1 0.999945878982544
dominant I-Disease 1 1.0
condition I-Disease 1 0.9998871088027954
of O 1 0.9999171495437622
craniosynostosis B-Disease 1 1.0
and O 1 0.9936344623565674
limb B-Disease 1 1.0
anomalies I-Disease 1 0.9999995231628418
, O 0 3.865151398940725e-08
were O 0 5.618184584221808e-09
screened O 0 1.9314361665578872e-08
for O 0 5.375158651510503e-10
mutations O 0 9.85484316373686e-09
in O 0 5.371430855660719e-09
TWIST O 0 1.1726706361514516e-05
, O 0 6.100473370906911e-08
FGFR2 O 1 0.9200502634048462
, O 0 7.363307474861358e-08
and O 0 1.71531013393178e-07
FGFR3 O 1 0.996749758720398
. O 0 1.4122052562015597e-05

Nine O 0 2.694027671168442e-06
novel O 0 4.4752940198122815e-07
and O 0 3.551993899009176e-08
three O 0 1.7614057767900704e-08
recurrent O 0 0.00019430299289524555
TWIST O 0 0.001875147339887917
mutations O 0 9.891189165500691e-07
were O 0 1.322996556751832e-08
found O 0 5.025169613759317e-09
in O 0 7.480543295912412e-09
12 O 0 1.1512302222627113e-07
families O 0 3.531195247319374e-08
. O 0 7.732605808996595e-07

Seven O 0 4.0878842355596134e-07
families O 0 7.490851494651452e-09
were O 0 5.395118574114122e-09
found O 0 1.5248690088398575e-09
to O 0 2.3774511248575436e-09
have O 0 2.4966422262906462e-09
the O 0 2.3853601760492893e-08
FGFR3 O 1 0.8834567070007324
P250R O 0 4.974445982952602e-05
mutation O 0 3.6758498822564434e-07
, O 0 1.7202608226796201e-09
and O 0 3.0419999852426827e-10
one O 0 4.0587450067519626e-10
individual O 0 8.094066389352506e-11
was O 0 1.5016240695331362e-08
found O 0 5.02838881644152e-10
to O 0 4.539323361640868e-10
have O 0 1.0065398514669255e-09
an O 0 2.874759452708986e-08
FGFR2 O 1 0.5373492240905762
VV269 O 0 0.0004794623819179833
- O 0 2.3630145733477548e-05
270 O 0 3.654876763903303e-06
deletion O 0 2.103103543049656e-05
. O 0 2.7872695227415534e-06

To O 0 1.5119293550469592e-07
date O 0 4.758372824653634e-07
, O 0 3.817905103176145e-09
our O 0 1.3843025614690418e-09
detection O 0 1.2595229748058046e-07
rate O 0 2.020987466266888e-08
for O 0 1.5657357632647972e-09
TWIST O 0 4.673481726058526e-06
or O 0 1.1420054590871587e-07
FGFR O 0 0.012527777813374996
mutations O 0 6.942326535863685e-08
is O 0 2.7857052220525702e-09
68 O 0 1.9352491165136598e-08
% O 0 2.4207795767949847e-09
in O 0 4.252984631136769e-10
our O 0 9.101594145022318e-09
Saethre B-Disease 1 0.9997820258140564
- I-Disease 1 1.0
Chotzen I-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 8.544695901946397e-07
, O 0 1.536841232052666e-08
including O 0 8.489574376824294e-09
our O 0 3.2012078321486115e-08
five O 0 4.001803688424843e-08
patients O 0 1.9006508367169772e-08
elsewhere O 0 7.175634664235986e-08
reported O 0 6.633378291098779e-08
with O 0 2.314339653253228e-08
TWIST O 0 0.0008161273435689509
mutations O 0 4.04413731303066e-05
. O 0 4.0922436710388865e-06

More O 0 6.323085699477815e-08
than O 0 1.5359738370079867e-08
35 O 0 2.7331552132636716e-08
different O 0 6.307901978530595e-10
TWIST O 0 1.5148115153351682e-06
mutations O 0 1.6524931822914368e-07
are O 0 9.34260779850149e-10
now O 0 3.3880551697507144e-09
known O 0 5.8474500796990014e-09
in O 0 1.930886339707172e-09
the O 0 9.749584251039778e-09
literature O 0 3.4869623277700157e-07
. O 0 2.5792147084757744e-07

The O 0 2.0572974790411536e-06
most O 0 3.3465415327782466e-08
common O 0 4.686478050075493e-08
phenotypic O 0 8.286733645945787e-07
features O 0 2.189888936854345e-09
, O 0 7.568891069453798e-10
present O 0 6.425742160587333e-10
in O 0 1.6871865016199195e-10
more O 0 3.0820391377917034e-11
than O 0 2.275438587551193e-10
a O 0 2.988899128197886e-09
third O 0 4.6036760181777936e-08
of O 0 8.21537771145131e-09
our O 0 5.520100820888274e-09
patients O 0 7.771857046812158e-10
with O 0 3.9035102927797993e-10
TWIST O 0 6.601386121474206e-05
mutations O 0 1.3693501159650623e-06
, O 0 9.40011357641879e-09
are O 0 4.603568637406852e-09
coronal B-Disease 1 0.9966872334480286
synostosis I-Disease 0 0.04605104401707649
, O 0 8.886216562586924e-08
brachycephaly B-Disease 0 6.977242446737364e-05
, O 0 5.344189446532255e-08
low B-Disease 0 0.00015123345656320453
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 2.1349329472286627e-05
facial B-Disease 1 0.999992847442627
asymmetry I-Disease 1 0.9999996423721313
, O 0 6.554855190188391e-06
ptosis B-Disease 1 0.9999995231628418
, O 0 1.2289629012229852e-06
hypertelorism B-Disease 1 0.6663808822631836
, O 0 1.413816193007733e-07
broad B-Disease 0 0.00019829647499136627
great I-Disease 0 0.006988559849560261
toes I-Disease 0 0.18895253539085388
, O 0 3.6716525642077613e-07
and O 0 5.410867061073077e-07
clinodactyly B-Disease 1 0.6142106056213379
. O 0 3.20437247864902e-05

Significant O 0 4.045977402711287e-05
intra O 1 0.9922657608985901
- O 0 0.40435901284217834
and O 0 4.601095611178607e-07
interfamilial O 0 0.007342655677348375
phenotypic O 0 1.3511987162928563e-05
variability O 0 2.3430076907970943e-05
is O 0 2.105883245562268e-09
present O 0 1.0647819292941563e-09
for O 0 1.4500588507715406e-09
either O 0 8.543084817347335e-08
TWIST O 0 0.00018349423771724105
mutations O 0 3.0292530937003903e-06
or O 0 1.1634199381660437e-06
FGFR O 1 0.9999555349349976
mutations O 0 4.176435686531477e-05
. O 0 2.0964596387784695e-06

The O 0 1.2078573945473181e-06
overlap O 0 1.8962605281558353e-06
in O 0 4.702128819644713e-08
clinical O 0 3.9234069504345825e-07
features O 0 1.6547814229994628e-09
and O 0 1.2826585349401398e-09
the O 0 7.486695707825675e-09
presence O 0 6.421298159864364e-09
, O 0 4.385863616729324e-10
in O 0 1.55716953220697e-10
the O 0 1.2606352073341043e-10
same O 0 2.8947183539074217e-10
genes O 0 3.6777320078229536e-10
, O 0 4.968817718387086e-11
of O 0 3.7685321530034344e-10
mutations O 0 1.33277222591488e-09
for O 0 6.875715968801543e-11
more O 0 3.9928921280463214e-11
than O 0 6.434511257147335e-10
one O 0 7.120918077418992e-09
craniosynostotic B-Disease 0 7.557597655249992e-06
condition I-Disease 0 1.3066998860722379e-07
- O 0 3.04553857688461e-08
such O 0 8.536789608548645e-10
as O 0 9.528533517766391e-09
Saethre B-Disease 0 8.530254490324296e-06
- I-Disease 0 6.741489642081433e-07
Chotzen I-Disease 0 1.6519856217200868e-05
, I-Disease 0 9.38642674697121e-09
Crouzon I-Disease 0 4.4527685531647876e-05
, I-Disease 0 2.434960322261759e-08
and I-Disease 0 6.721909073803545e-08
Pfeiffer I-Disease 0 0.037647172808647156
syndromes I-Disease 0 0.41519641876220703
- O 0 1.0670069968909957e-05
support O 0 5.0973991250202744e-08
the O 0 4.304542144950574e-08
hypothesis O 0 1.011738390843675e-06
that O 0 8.939689544185114e-10
TWIST O 0 1.4270987094278098e-06
and O 0 4.399170361324423e-09
FGFRs O 0 2.015961399592925e-06
are O 0 2.1050146348233767e-10
components O 0 1.2255010339856653e-08
of O 0 2.36031327816022e-09
the O 0 8.498205472662335e-10
same O 0 1.584391617903691e-09
molecular O 0 1.0705949193834385e-07
pathway O 0 1.8122236156159488e-08
involved O 0 4.2059622451517953e-10
in O 0 1.314721664869012e-10
the O 0 1.0742492451143448e-09
modulation O 0 1.0274383157593547e-06
of O 0 1.2804417792722234e-06
craniofacial O 1 1.0
and O 0 5.607627372228308e-06
limb O 1 1.0
development O 0 1.025218443828635e-05
in O 0 1.457966902762564e-07
humans O 0 1.2476824906570982e-07
. O 0 5.483365228542425e-08
. O 0 7.77705224663805e-07

Mutation O 0 1.074172928383632e-06
analysis O 0 2.710996795940446e-07
of O 0 1.9020635591004975e-06
UBE3A O 1 1.0
in O 1 0.9999256134033203
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9974207878112793
. O 0 0.00043235771590843797

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9361578226089478
AS B-Disease 1 1.0
) O 0 1.0211947909510855e-07
is O 0 9.423019697862856e-09
caused O 0 3.567977913121467e-08
by O 0 9.102323339504892e-09
chromosome O 0 9.84842554316856e-05
15q11 O 0 0.0003354676300659776
- O 0 6.202351869433187e-06
q13 O 0 1.1731493941624649e-05
deletions O 0 9.816726276312693e-08
of O 0 5.480029940940767e-08
maternal O 0 1.1464226901125585e-07
origin O 0 1.863408982671899e-08
, O 0 1.3278244059833355e-09
by O 0 4.4436041513051805e-09
paternal O 0 0.00014218705473467708
uniparental B-Disease 1 0.9999992847442627
disomy I-Disease 1 1.0
( O 0 3.5140812542522326e-05
UPD B-Disease 1 1.0
) O 0 2.220467365532386e-08
15 O 0 1.1240103958698455e-08
, O 0 2.635861806599138e-10
by O 0 1.6459330565155028e-09
imprinting O 0 0.0015603223582729697
defects O 1 0.9957644939422607
, O 0 6.277443898028423e-09
and O 0 1.1135856681221412e-09
by O 0 4.7798192071013546e-09
mutations O 0 1.5977352063600847e-07
in O 0 2.8704308263627354e-08
the O 0 5.768303594777535e-07
UBE3A O 0 0.2313966155052185
gene O 0 5.495549885381479e-06
. O 0 1.2288093103052233e-06

UBE3A O 0 0.08730808645486832
encodes O 0 9.466306437388994e-06
a O 0 6.167335868667578e-07
ubiquitin O 0 2.1167114027775824e-05
- O 0 4.176168204139685e-06
protein O 0 1.8826636960511678e-07
ligase O 0 1.6871760522008117e-07
and O 0 9.93217419420489e-09
shows O 0 1.093577921551514e-07
brain O 0 1.0422286322864238e-05
- O 0 5.156506176717812e-06
specific O 0 1.1428480775066419e-06
imprinting O 0 0.0004923981614410877
. O 0 9.893972674035467e-06

Here O 0 4.603668458003085e-06
we O 0 3.105725170371443e-07
describe O 0 2.5685371838335413e-06
UBE3A O 0 0.0009328501182608306
coding O 0 5.8652083680499345e-05
- O 0 3.445718175498769e-05
region O 0 1.8183020529249916e-06
mutations O 0 4.4899573481416155e-07
detected O 0 9.931798672369041e-08
by O 0 3.4884899413611947e-09
SSCP O 0 0.00018852778885047883
analysis O 0 2.0478468698570396e-08
in O 0 3.202867304707979e-09
13 O 0 3.221586197810211e-08
AS B-Disease 0 1.2839418559451587e-05
individuals O 0 2.167755752680023e-09
or O 0 5.01230701388522e-08
families O 0 7.077388630705173e-08
. O 0 1.629903294997348e-06

Two O 0 2.2480803352209477e-07
identical O 0 3.271005937222071e-07
de O 0 1.5932851965771988e-05
novo O 0 8.445866842521355e-05
5 O 0 7.014305992925074e-06
- O 0 7.982623174029868e-06
bp O 0 3.86114334105514e-06
duplications O 0 5.647998023050604e-06
in O 0 1.3922263519816624e-07
exon O 0 4.47605452791322e-06
16 O 0 1.209321851547429e-07
were O 0 1.3434002354983932e-08
found O 0 1.0237808822921579e-07
. O 0 5.801427391816105e-07

Among O 0 7.91297395608126e-07
the O 0 7.66333414503606e-08
other O 0 6.523227735755199e-09
11 O 0 3.3931787157825966e-08
unique O 0 2.8696520715243423e-09
mutations O 0 7.470109153473459e-08
, O 0 6.853046130572693e-09
8 O 0 7.067676222050068e-08
were O 0 2.9820999003504767e-09
small O 0 4.415360521647926e-09
deletions O 0 7.054328676758814e-08
or O 0 3.1416750090329515e-08
insertions O 0 8.515589229318721e-07
predicted O 0 9.653429060563212e-07
to O 0 1.2000385574140182e-08
cause O 0 2.101680593113997e-06
frameshifts O 0 0.005127415060997009
, O 0 9.13695519244584e-09
1 O 0 1.0736008704270716e-07
was O 0 6.480048053703058e-09
a O 0 6.499068505583239e-10
mutation O 0 1.0371349334903357e-09
to O 0 2.820293720784406e-10
a O 0 4.740325021401759e-09
stop O 0 2.8224437897961252e-08
codon O 0 2.0193063221540797e-07
, O 0 1.8491149722521527e-09
1 O 0 3.7718077550152884e-08
was O 0 1.2087080669687111e-08
a O 0 3.864058406577442e-09
missense O 0 2.193554564655642e-07
mutation O 0 3.503882339828124e-08
, O 0 6.435039168195544e-10
and O 0 2.4677190846311703e-10
1 O 0 1.5244896189869905e-07
was O 0 4.7642757294852345e-08
predicted O 0 2.9370163190378662e-08
to O 0 5.258249946571425e-10
cause O 0 1.2885172040455473e-08
insertion O 0 7.752025510399108e-08
of O 0 2.4975484791411873e-08
an O 0 1.5127001873338486e-08
isoleucine O 0 2.3053113181958906e-05
in O 0 5.196783892102985e-09
the O 0 9.487800767260524e-09
hect O 0 2.795420641632518e-06
domain O 0 1.4547336490977614e-07
of O 0 8.04483857308469e-09
the O 0 2.1092004587330848e-08
UBE3A O 0 0.00037915186840109527
protein O 0 5.080384468669763e-08
, O 0 3.193940667500783e-10
which O 0 1.4059833852719805e-10
functions O 0 1.2149364847502397e-09
in O 0 2.1660566673631365e-09
E2 O 0 1.4542579265253153e-06
binding O 0 1.5535734121385758e-07
and O 0 4.535866082733264e-08
ubiquitin O 0 6.01424517299165e-06
transfer O 0 1.1527716196724214e-05
. O 0 7.515479410358239e-06

Eight O 0 3.530829246756184e-07
of O 0 3.528333891722468e-08
the O 0 1.2149116379589486e-08
cases O 0 4.011721177477057e-09
were O 0 3.114825020134049e-08
familial O 0 2.4416480300715193e-05
, O 0 9.36564887865643e-08
and O 0 1.7742355140626387e-08
five O 0 4.505205097871112e-08
were O 0 1.0696437868773501e-07
sporadic O 0 4.571983026835369e-06
. O 0 2.8503211524366634e-06

In O 0 2.7458975182526046e-07
two O 0 1.832742846374913e-08
familial O 0 5.1745686505455524e-05
cases O 0 1.4571996587164904e-07
and O 0 2.1073628175827253e-08
one O 0 4.1525119343077677e-08
sporadic O 0 5.384008545661345e-07
case O 0 2.3026302642392693e-07
, O 0 6.097248927972032e-09
mosaicism O 0 1.2195979252282996e-05
for O 0 8.467920586952005e-09
UBE3A O 0 0.00010636058868840337
mutations O 0 9.780431753370067e-08
was O 0 3.117939684216253e-08
detected O 0 5.4564557316894025e-09
in O 0 2.131786830394944e-10
the O 0 5.310722417384284e-10
mother O 0 3.719629604326258e-10
of O 0 1.0887005741366806e-09
three O 0 1.70692560086394e-09
AS B-Disease 1 0.999731719493866
sons O 0 1.2310538011206518e-07
, O 0 6.265669649785366e-10
in O 0 4.622535965115304e-10
the O 0 2.778445917783756e-09
maternal O 0 8.685335473046507e-08
grandfather O 0 8.36250464431032e-08
of O 0 3.12979686611925e-08
two O 0 5.469532382562647e-09
AS B-Disease 1 0.9980319142341614
first O 0 9.548366364242611e-08
cousins O 0 1.9841398568587465e-07
, O 0 6.276087982648448e-10
and O 0 9.908568410210705e-11
in O 0 4.500477213120746e-10
the O 0 2.466209902962646e-09
mother O 0 2.256612674500502e-09
of O 0 5.3737880811866034e-09
an O 0 1.9263699968519177e-08
AS B-Disease 1 0.9999990463256836
daughter O 0 9.916917770169675e-05
. O 0 7.620199085067725e-06

The O 0 1.7218904702076543e-07
frequencies O 0 1.5086668270214432e-07
with O 0 1.085671108569386e-09
which O 0 3.410937088332844e-09
we O 0 3.483948463056663e-09
detected O 0 2.1048441212201396e-08
mutations O 0 6.162747201443608e-09
were O 0 1.623834067210339e-09
5 O 0 8.951415608748903e-09
( O 0 9.008189194581462e-10
14 O 0 5.606505482091961e-09
% O 0 1.4290053584886664e-09
) O 0 1.1563119906021768e-10
of O 0 1.422462481137643e-09
35 O 0 1.1889841111667465e-08
in O 0 6.306687394541655e-10
sporadic O 0 3.1534778344166625e-08
cases O 0 1.138405258949149e-09
and O 0 6.599488178160584e-10
8 O 0 1.681546812903889e-08
( O 0 1.1437875091502292e-09
80 O 0 6.6746359550506895e-09
% O 0 1.213903422225826e-09
) O 0 6.275881203610112e-11
of O 0 4.5136125392808424e-10
10 O 0 2.030015266996088e-09
in O 0 2.0886701257438745e-09
familial O 0 1.2146681456215447e-06
cases O 0 4.850187451665988e-08
. O 0 2.993573673393257e-07
. O 0 2.1767241378256585e-06

The O 0 5.794078606413677e-05
hemochromatosis B-Disease 1 0.9999973773956299
845 O 0 0.0001742415188346058
G O 0 3.471397940302268e-05
- O 0 6.134385785117047e-06
- O 0 1.8092727032126277e-06
> O 0 1.267579932573426e-06
A O 0 1.341160640322414e-07
and O 0 3.204645437904219e-09
187 O 0 2.6495600380371798e-08
C O 0 5.23740595781419e-07
- O 0 3.508243366923125e-07
- O 0 6.045938221177494e-07
> O 0 2.833442067640135e-06
G O 0 2.392759370195563e-06
mutations O 0 7.263335533025383e-08
: O 0 4.504842276986665e-09
prevalence O 0 2.679407486994023e-07
in O 0 1.884400191443092e-08
non O 0 3.876280516124098e-06
- O 0 2.6276526114088483e-05
Caucasian O 0 0.00028088848921470344
populations O 0 2.279929731230368e-06
. O 0 1.4865173625366879e-06

Hemochromatosis B-Disease 1 0.9999129772186279
, O 0 1.5680848264310043e-06
the O 0 5.143769521964714e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 1 0.9891358613967896
iron I-Disease 1 0.9999998807907104
metabolism I-Disease 1 0.9997391104698181
, O 0 2.0466974604005372e-07
leads O 0 2.3692780359851895e-06
, O 0 3.624884570285758e-08
if O 0 3.549164091509738e-07
untreated O 0 0.04977421090006828
, O 0 2.7882247621846545e-09
to O 0 1.508099423119802e-08
progressive O 0 0.058805856853723526
iron B-Disease 1 0.9999526739120483
overload I-Disease 1 0.9704660773277283
and O 0 1.3537282939068973e-06
premature B-Disease 0 0.0006781648262403905
death I-Disease 0 1.640628215682227e-05
. O 0 6.697504886687966e-06

The O 0 5.164087997400202e-05
hemochromatosis B-Disease 1 1.0
gene O 0 5.631902240565978e-05
, O 0 9.895001085169497e-07
HFE O 1 0.9999998807907104
, O 0 4.257899774984253e-07
recently O 0 3.676894664295105e-07
has O 0 4.117853613649913e-09
been O 0 3.1108333686802325e-09
identified O 0 8.519713823318398e-09
, O 0 3.743743648421116e-10
and O 0 1.375660696467662e-10
characterization O 0 8.553912067554847e-08
of O 0 1.1344456929407443e-08
this O 0 3.052457397956232e-09
gene O 0 1.987477915577074e-08
has O 0 6.297924404208288e-10
shown O 0 1.7685541919831849e-10
that O 0 2.4938032541776955e-11
it O 0 8.216873709221417e-11
contains O 0 3.1729199823082865e-10
two O 0 1.1340204469911797e-10
mutations O 0 2.041033564381678e-09
that O 0 3.402702286603443e-10
result O 0 1.1836847946256057e-08
in O 0 1.552047379504984e-08
amino O 0 2.5893385213748843e-08
acid O 0 8.987890431910728e-09
substitutions O 0 2.3878275356992162e-08
- O 0 1.121058303965583e-07
cDNA O 0 4.1422291019443946e-07
nucleotides O 0 1.3296853396127517e-08
845 O 0 9.666044320510991e-08
G O 0 1.9602927636697132e-07
- O 0 1.6430801963451813e-07
- O 0 1.0446363063465469e-07
> O 0 4.530448904915829e-07
A O 0 3.689276297791366e-07
( O 0 4.009795517845305e-08
C282Y O 0 2.0251104615454096e-06
) O 0 1.0149954210447731e-09
and O 0 3.8030617544038137e-10
187 O 0 1.3722605274324451e-08
C O 0 5.585715143752168e-07
- O 0 7.547302516286436e-07
- O 0 1.465532591282681e-06
> O 0 1.1705610631906893e-05
G O 0 1.5977982911863364e-05
( O 0 4.327922908942128e-07
H63D O 0 0.0029542993288487196
) O 0 5.560575573326787e-07
. O 0 1.1215122412977507e-06

Although O 0 5.506043817149475e-05
hemochromatosis B-Disease 1 1.0
is O 0 1.802354972824105e-06
common O 0 1.1659535630315077e-06
in O 0 4.6496879235746746e-07
Caucasians O 0 8.987855835584924e-05
, O 0 2.454605585455738e-08
affecting O 0 3.712842300274133e-08
> O 0 2.1620351162709994e-06
= O 0 4.2585779169712623e-07
1 O 0 1.7673339698376367e-06
/ O 0 2.2647077457804698e-07
300 O 0 1.0204481704079171e-09
individuals O 0 3.450225868895096e-11
of O 0 2.7467400576242085e-10
northern O 0 5.26643262332982e-09
European O 0 1.2052502107451346e-08
origin O 0 1.9524671657222825e-08
, O 0 7.118673983619317e-10
it O 0 1.9011202334606736e-10
has O 0 2.0878407336333282e-10
not O 0 1.6332168950583537e-10
been O 0 4.728132885212233e-10
recognized O 0 1.8330110762576624e-09
in O 0 1.970325902433956e-09
other O 0 6.438885424842056e-09
populations O 0 2.9444603910633305e-07
. O 0 7.103936354724283e-07

The O 0 4.6021972366361297e-07
present O 0 3.132030101937744e-08
study O 0 7.391953715796262e-09
used O 0 4.403275077891067e-09
PCR O 0 1.2247456027125736e-07
and O 0 4.238539741407976e-09
restriction O 0 1.4120900004854775e-07
- O 0 1.9592816613567265e-07
enzyme O 0 8.476339630192342e-09
digestion O 0 4.403787112750024e-09
to O 0 3.888291633113994e-10
analyze O 0 2.6803665953423206e-09
the O 0 6.069212910020383e-10
frequency O 0 1.99492937724699e-08
of O 0 2.981269453528057e-09
the O 0 6.386559725513052e-09
845 O 0 1.8596442430407478e-07
G O 0 4.4096651663494413e-07
- O 0 2.3203867272059142e-07
- O 0 1.3219339223269344e-07
> O 0 2.2524841369886417e-07
A O 0 7.400449675287746e-08
and O 0 1.8270389645635987e-09
187 O 0 9.668621459013593e-09
C O 0 2.1120190751844348e-07
- O 0 2.042372813093607e-07
- O 0 2.2143100864013832e-07
> O 0 9.917996521835448e-07
G O 0 6.648514272455941e-07
mutations O 0 3.0088283864415644e-08
in O 0 1.8698104398140458e-08
HLA O 0 3.937120709451847e-06
- O 0 8.036300158664744e-08
typed O 0 1.8016086400507447e-08
samples O 0 3.059496822555019e-10
from O 0 1.0515521786658155e-09
non O 0 1.9474542511943582e-07
- O 0 1.1557915513549233e-06
Caucasian O 0 2.619072120069177e-06
populations O 0 2.0660865018840013e-08
, O 0 1.0115167592417151e-09
comprising O 0 4.695968947032725e-09
Australian O 0 3.889882904672959e-08
Aboriginal O 0 2.90800254987289e-08
, O 0 2.167796830931934e-09
Chinese O 0 4.7355901422463376e-09
, O 0 1.1511111175366295e-08
and O 0 3.1421663493347296e-08
Pacific O 0 1.1485425602586474e-05
Islanders O 0 2.0464687622734345e-05
. O 0 6.114153620728757e-06

Results O 0 1.7573707964402274e-06
showed O 0 5.421529181148799e-08
that O 0 2.525118114604652e-09
the O 0 3.8466474450160604e-08
845 O 0 1.4823127685303916e-06
G O 0 4.275304945622338e-06
- O 0 9.703298928798176e-07
- O 0 5.603995418823615e-07
> O 0 7.591161761411058e-07
A O 0 2.700705579172791e-07
mutation O 0 1.598934744606595e-07
was O 0 1.4596802877520076e-08
present O 0 4.888092708377201e-10
in O 0 3.09544306853482e-10
these O 0 6.797205853725785e-11
populations O 0 1.2462199050489176e-09
( O 0 7.602457552380315e-10
allele O 0 9.203471762475601e-09
frequency O 0 1.8696391990147276e-08
0 O 0 9.40093869417069e-09
. O 0 2.3373744606480784e-10
32 O 0 3.952027149978221e-09
% O 0 1.6159860116715663e-09
) O 0 2.0032014935722486e-10
, O 0 2.622222716741618e-10
and O 0 2.5571245121369657e-10
, O 0 7.114493438820091e-10
furthermore O 0 1.3344645388713161e-08
, O 0 8.065945134028141e-10
it O 0 9.771342623920987e-10
was O 0 2.661047062701982e-07
always O 0 1.2792436443476163e-08
seen O 0 6.024443610641583e-09
in O 0 6.610044733790232e-10
conjunction O 0 7.865662787764904e-09
with O 0 1.5869087377495816e-08
HLA O 1 0.9817901849746704
haplotypes O 0 6.978528745094081e-06
common O 0 1.1917294528984712e-07
in O 0 5.467147090598701e-08
Caucasians O 0 3.4106085422536125e-06
, O 0 3.446316121369364e-09
suggesting O 0 2.4071843185424768e-08
that O 0 2.2417521172712895e-09
845 O 0 2.6160114430240355e-07
G O 0 1.4160199270918383e-06
- O 0 9.063811035048275e-07
- O 0 9.475395472691162e-07
> O 0 4.12575900554657e-06
A O 0 1.1874427627844852e-06
may O 0 2.09697006425813e-08
have O 0 1.866897192392969e-10
been O 0 3.8948605451949447e-10
introduced O 0 4.455814883730369e-10
into O 0 3.4984232177848185e-10
these O 0 4.751816995440805e-11
populations O 0 1.1479839301387074e-09
by O 0 4.460774416514823e-09
Caucasian O 0 1.1448724762885831e-05
admixture O 0 0.00010920658678514883
. O 0 8.00839643488871e-06

187 O 0 3.2610653306619497e-06
C O 0 9.876645890471991e-06
- O 0 1.8651177242645645e-06
- O 0 1.0812368600454647e-06
> O 0 3.034822384506697e-06
G O 0 1.0343499070586404e-06
was O 0 2.121550934930383e-08
present O 0 2.392531062156422e-09
at O 0 7.60761142970523e-09
an O 0 5.622426968443506e-10
allele O 0 4.58009914439117e-08
frequency O 0 2.7588961870606e-07
of O 0 2.650617147992307e-07
2 O 0 7.958694368426222e-06
. O 0 1.63977551892458e-06

68 O 0 2.4794258933980018e-05
% O 0 8.772573778514925e-07
in O 0 6.61794574696728e-09
the O 0 5.740981912083498e-09
two O 0 1.3223097061754174e-09
populations O 0 7.255481992984869e-09
analyzed O 0 6.925160533910457e-08
( O 0 2.9564235504153658e-08
Australian O 0 3.63432093308802e-07
Aboriginal O 0 6.406204278164296e-08
and O 0 3.5287091026958706e-09
Chinese O 0 4.044714785322867e-08
) O 0 1.5413215237458644e-07
. O 0 1.050283913173189e-06

In O 0 5.947437671238731e-07
the O 0 2.0936555245043564e-07
Australian O 0 1.7523204576264106e-07
Aboriginal O 0 2.289223033358212e-08
samples O 0 6.578199651663397e-10
, O 0 3.523542291272719e-10
187 O 0 1.0221375745800287e-08
C O 0 5.910752634008531e-07
- O 0 5.931283908466867e-07
- O 0 4.358981016139296e-07
> O 0 2.074335043289466e-06
G O 0 1.2919275604872382e-06
was O 0 1.977306851586036e-08
found O 0 2.2940285782091507e-10
to O 0 1.7193906021173433e-10
be O 0 1.0598179001064523e-09
associated O 0 1.0334368916176118e-08
with O 0 1.2784849623415084e-08
HLA O 1 0.9999600648880005
haplotypes O 0 7.768848263367545e-06
common O 0 1.7229041304744896e-07
in O 0 6.299071486637331e-08
Caucasians O 0 2.697156378417276e-05
, O 0 2.7622135689853167e-09
suggesting O 0 9.791945032588956e-09
that O 0 1.939940569295473e-10
it O 0 3.23255755496632e-10
was O 0 5.323371965459955e-09
introduced O 0 1.511900493689211e-09
by O 0 6.230205240598252e-10
recent O 0 3.453707364542424e-08
admixture O 0 1.4959096006350592e-05
. O 0 2.5500562514935154e-06

In O 0 5.232533339949441e-07
the O 0 1.0388978921582748e-07
Chinese O 0 1.4334119669001666e-08
samples O 0 2.6328887958726455e-09
analyzed O 0 1.511220837357996e-08
, O 0 7.832842152666331e-10
187 O 0 1.4839938167199307e-08
C O 0 5.048565299148322e-07
- O 0 3.1754694873598055e-07
- O 0 2.310890891976669e-07
> O 0 2.028276412602281e-06
G O 0 2.037543481492321e-06
was O 0 2.2852269410122972e-08
present O 0 4.957895760604458e-10
in O 0 1.092909540645337e-09
association O 0 1.592811993411658e-09
with O 0 3.5170558132513463e-10
a O 0 3.584813157431199e-08
wide O 0 7.537677788604924e-07
variety O 0 7.982008298768051e-08
of O 0 7.760036169202067e-06
HLA O 1 0.999981164932251
haplotypes O 0 3.3599267226236407e-06
, O 0 2.2378390251986957e-09
showing O 0 7.181419903190545e-10
this O 0 1.2615203326404867e-10
mutation O 0 7.65646046563262e-10
to O 0 1.3890361083568337e-10
be O 0 1.1160713464519745e-09
widespread O 0 1.68042468828844e-08
and O 0 5.969241212433474e-10
likely O 0 8.986193122950681e-09
to O 0 1.8000210211255308e-09
predate O 0 2.3718953912066354e-07
the O 0 8.004996665533781e-09
more O 0 9.380498600108922e-10
genetically O 0 1.7462788548527897e-08
restricted O 0 1.2138785976389954e-08
845 O 0 4.620566471658094e-07
G O 0 1.684958419900795e-06
- O 0 2.226198148491676e-06
- O 0 2.674607912922511e-06
> O 0 7.207085218396969e-06
A O 0 8.568020348320715e-06
mutation O 0 1.1602561244217213e-05
. O 0 1.2231679420438013e-06

Genotype O 0 0.0040134540759027
- O 0 0.001316367881372571
phenotype O 0 0.0001061283765011467
correlations O 0 7.510311115765944e-05
in O 0 7.30488727640477e-06
attenuated B-Disease 1 0.9986699819564819
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999998807907104
. O 0 0.001307465834543109

Germ O 0 0.016277430579066277
- O 0 5.1847935537807643e-05
line O 0 1.975743998627877e-06
mutations O 0 1.8836459503290826e-07
of O 0 2.492618200733432e-08
the O 0 6.97226312240673e-08
tumor B-Disease 0 0.0004659473488572985
suppressor O 0 0.0020671330858021975
APC O 0 5.553057690121932e-06
are O 0 2.4323782987778486e-09
implicated O 0 1.9453543700365117e-06
in O 0 4.1178483911608055e-07
attenuated B-Disease 1 0.9988842606544495
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 1 0.9995912909507751
AAPC B-Disease 1 1.0
) O 0 3.392997527384978e-08
, O 0 1.1810072919615777e-09
a O 0 7.3755472840275615e-09
variant O 0 4.261249159753788e-06
of O 0 3.378397741471417e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999138116836548
FAP B-Disease 1 0.9988116025924683
) O 0 3.115412710030796e-06
. O 0 5.811056325910613e-06

AAPC B-Disease 1 1.0
is O 0 2.7022412041333155e-07
recognized O 0 1.6994741613984843e-08
by O 0 1.4846129881007641e-09
the O 0 9.029593073250908e-09
occurrence O 0 2.2511397901325836e-07
of O 0 3.353270017214527e-07
< O 0 0.025163009762763977
100 O 0 5.786645829175541e-07
colonic B-Disease 0 0.0006524274358525872
adenomas I-Disease 0 0.00022722916037309915
and O 0 2.5912982870579526e-09
a O 0 2.2686933220938954e-08
later O 0 1.763616808148072e-07
onset O 0 0.0065680937841534615
of O 0 0.39032164216041565
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.3979300774735748e-06
age O 0 2.1621012820105534e-06
> O 0 1.689657210590667e-06
40 O 0 1.0041054565590457e-07
years O 0 3.670818671253073e-08
) O 0 4.05534414937847e-08
. O 0 3.0532163464158657e-07

The O 0 2.0799318178887916e-07
aim O 0 2.189850931699766e-07
of O 0 2.3690283512678434e-08
this O 0 3.2335090160984237e-09
study O 0 1.5484635795814938e-08
was O 0 5.4465807863834925e-08
to O 0 8.958128461244996e-09
assess O 0 3.976133768901491e-07
genotype O 0 5.272040289128199e-05
- O 0 0.000208981306059286
phenotype O 0 3.934543929062784e-05
correlations O 0 4.6807177568553016e-05
in O 0 2.6951786367135355e-06
AAPC B-Disease 1 1.0
families O 0 7.220198199320293e-07
. O 0 2.9820555482729105e-06

By O 0 2.3160336581895535e-07
protein O 0 6.988772724980663e-07
- O 0 1.450545823900029e-06
truncation O 0 8.213442924898118e-06
test O 0 5.487801217896049e-07
( O 0 8.386175665009432e-08
PTT O 0 4.968236680724658e-06
) O 0 2.7012445613650016e-09
assay O 0 7.505471444346767e-08
, O 0 7.650431399497393e-10
the O 0 8.187387989799788e-10
entire O 0 9.520884525215934e-09
coding O 0 1.6001474989479902e-07
region O 0 9.107987608558687e-08
of O 0 1.614911582237255e-08
the O 0 1.9034008147400527e-08
APC B-Disease 0 4.4589310732590093e-07
gene O 0 6.948444042365054e-09
was O 0 1.586981390744313e-08
screened O 0 2.3750546418455087e-08
in O 0 3.585076402412568e-10
affected O 0 7.495364329201948e-10
individuals O 0 3.893761424400566e-10
from O 0 1.1608437944232719e-07
11 O 0 1.9081764548900537e-05
AAPC B-Disease 1 1.0
kindreds O 0 0.001146995578892529
, O 0 2.3782188662835324e-08
and O 0 2.9014193270171518e-09
their O 0 1.521597625675497e-09
phenotypic O 0 2.52960830948723e-06
differences O 0 1.2686876971201855e-06
were O 0 2.2748599803890102e-07
examined O 0 9.023618986248039e-06
. O 0 4.0692011680221185e-06

Five O 0 6.811127377659432e-07
novel O 0 1.3921136314820615e-06
germ O 0 9.86931481747888e-05
- O 0 1.1484768037917092e-05
line O 0 3.6370845464261947e-06
APC B-Disease 0 2.3854479422880104e-06
mutations O 0 6.89787214014359e-08
were O 0 4.571107492523652e-09
identified O 0 4.035737077856538e-08
in O 0 2.3044332664312606e-08
seven O 0 4.81787139960943e-07
kindreds O 0 0.00018115327111445367
. O 0 5.468676590680843e-06

Mutations O 0 5.022852747060824e-06
were O 0 6.489648285423755e-08
located O 0 6.460255974616302e-08
in O 0 1.3325003322961493e-09
three O 0 1.8259650735874544e-10
different O 0 8.528908135296831e-11
regions O 0 7.655719613808287e-09
of O 0 2.0787869203786613e-08
the O 0 6.536980379223678e-08
APC B-Disease 0 4.689468937613128e-07
gene O 0 1.260297466387783e-08
( O 0 2.4979567303518024e-09
1 O 0 1.7027748810960475e-07
) O 0 1.0928261628961877e-09
at O 0 6.684471198781239e-09
the O 0 1.804978611019692e-09
5 O 0 7.969926052453502e-09
end O 0 1.5538185849095498e-08
spanning O 0 4.824040900075488e-08
exons O 0 1.0411434203660974e-07
4 O 0 1.2710206220845066e-08
and O 0 6.663286589159156e-10
5 O 0 1.5994281454823067e-08
, O 0 1.246531322607325e-09
( O 0 2.0925261523530025e-09
2 O 0 2.103154628230186e-08
) O 0 2.05012729015408e-10
within O 0 1.459270260184553e-09
exon O 0 9.36977642140846e-08
9 O 0 2.2163462176649773e-08
, O 0 6.41293518288677e-10
and O 0 4.75388617360295e-10
( O 0 8.207312163222014e-09
3 O 0 7.566703885686366e-08
) O 0 1.1812393285737244e-09
at O 0 1.7098136240178974e-08
the O 0 9.477743923014259e-09
3 O 0 3.1041497550177155e-07
distal O 0 9.790631338546518e-06
end O 0 2.4910909246500523e-07
of O 0 1.0817200291057816e-07
the O 0 1.9908722492800734e-07
gene O 0 1.5782808304720675e-06
. O 0 7.8018041449468e-07

Variability O 0 0.0001561913377372548
in O 0 4.3169738006554326e-08
the O 0 1.4900634504044774e-08
number O 0 4.97736216686917e-08
of O 0 0.011142573319375515
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 1 0.9997163414955139
most O 0 2.646413399531866e-08
apparent O 0 3.980162830430345e-07
in O 0 1.2181222697194016e-09
individuals O 0 6.819762810028607e-11
with O 0 1.8836758541862508e-10
mutations O 0 9.520761068415595e-08
in O 0 1.4171823714548282e-08
region O 0 3.1277133984985994e-06
1 O 0 7.47951416997239e-05
, O 0 6.223402682081769e-09
and O 0 6.8991723445321895e-09
upper O 0 0.3618255853652954
- O 1 0.9838147759437561
gastrointestinal O 1 0.9919506311416626
manifestations O 0 0.004852372221648693
were O 0 1.7669586327428988e-07
more O 0 5.814152714833654e-09
severe O 0 3.341861429362325e-06
in O 0 3.6321306851050394e-08
them O 0 2.0577136439214883e-08
. O 0 6.737845410498267e-07

In O 0 9.401552603094387e-08
individuals O 0 2.300646340103185e-09
with O 0 9.421073920989897e-10
mutations O 0 1.7674996399819065e-07
in O 0 1.0033910591289441e-08
either O 0 9.604148232256193e-08
region O 0 3.017316657860647e-06
2 O 0 1.4804902548348764e-06
or O 0 1.3401908915966487e-08
region O 0 8.2733428996562e-08
3 O 0 3.5884937688024365e-08
, O 0 2.34154667877462e-10
the O 0 5.651747403412344e-10
average O 0 1.8081072195030856e-09
number O 0 9.183967475401289e-10
of O 0 1.0836773256528431e-08
adenomas B-Disease 0 4.7991845349315554e-05
tended O 0 2.7535776325748884e-08
to O 0 1.0389563653845357e-09
be O 0 1.7432031373942891e-09
lower O 0 4.607145953627878e-08
than O 0 7.719631600622279e-10
those O 0 1.8000405332951885e-10
in O 0 1.9662815819998514e-10
individuals O 0 3.516289343030721e-11
with O 0 1.1689341161691402e-10
mutations O 0 3.5311884971633845e-08
in O 0 4.6377195417335315e-09
region O 0 1.9016812302652397e-07
1 O 0 7.446195695592905e-07
, O 0 9.247193011319155e-10
although O 0 1.9124135608450388e-09
age O 0 1.6350480080973284e-08
at O 0 6.02311303055103e-08
diagnosis O 0 1.0063215540867532e-06
was O 0 4.1634649505795096e-07
similar O 0 1.9640333448478486e-07
. O 0 2.1966645817883546e-06

In O 0 2.6520633582549635e-06
all O 0 1.0184515986111364e-06
AAPC B-Disease 1 1.0
kindreds O 0 9.660887735662982e-05
, O 0 9.648946530660396e-09
a O 0 2.157469225494424e-08
predominance O 0 3.0962255550548434e-06
of O 0 1.1408443469917984e-06
right O 1 0.991184413433075
- O 1 1.0
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 1 0.9999608993530273
rectal B-Disease 1 1.0
polyp I-Disease 1 1.0
sparing O 0 0.00030884702573530376
was O 0 2.9078171792207286e-05
observed O 0 3.3017279292835156e-06
. O 0 1.63385311680031e-06

No O 0 0.0002653375850059092
desmoid B-Disease 1 0.9999998807907104
tumors I-Disease 1 1.0
were O 0 3.6663479363596707e-07
found O 0 4.8996906087950265e-08
in O 0 1.6589222440188678e-08
these O 0 1.6746716013926743e-08
kindreds O 0 0.00018631972488947213
. O 0 4.238988822180545e-06

Our O 0 3.0236429893193417e-07
data O 0 6.769837312958771e-08
suggest O 0 2.7554216686098698e-08
that O 0 2.7079198883228628e-09
, O 0 1.553006789833944e-08
in O 0 3.202509333277703e-07
AAPC B-Disease 1 1.0
families O 0 1.0723971932691256e-08
, O 0 1.6967688365454592e-09
the O 0 2.2535846522231395e-09
location O 0 2.0801035560680248e-08
of O 0 1.0067285671766513e-08
the O 0 3.761792299883382e-08
APC B-Disease 0 5.7457797083770856e-05
mutation O 0 1.3185775969759561e-05
may O 0 1.999775918193336e-07
partially O 0 8.808101483737119e-07
predict O 0 2.9857898198315524e-07
specific O 0 6.89596504344081e-08
phenotypic O 0 1.974918632186018e-05
expression O 0 4.601201453624526e-06
. O 0 1.5419449255205109e-06

This O 0 6.111548600529204e-08
should O 0 2.3851555397413904e-08
help O 0 2.0501009778683965e-09
in O 0 8.079633628810257e-10
the O 0 5.352477905340436e-10
design O 0 6.371096095136863e-09
of O 0 5.707028627455202e-09
tailored O 0 2.33119248349567e-08
clinical O 0 3.3716939924488543e-06
- O 0 4.66536812382401e-06
management O 0 1.1193020554856048e-07
protocols O 0 2.2679820688153995e-07
in O 0 6.46037623397433e-09
this O 0 4.5157158012898435e-09
subset O 0 1.040896790982515e-06
of O 0 2.9755909736195463e-07
FAP B-Disease 0 6.731809116899967e-05
patients O 0 2.3326298048687022e-07
. O 0 3.6875630371469015e-07
. O 0 3.6318858747108607e-06

Wilms B-Disease 1 0.9999517202377319
' I-Disease 0 0.00010827378719113767
tumor I-Disease 0 0.0008378025377169251
1 O 0 1.3832674994773697e-05
and O 0 2.388144650922186e-07
Dax O 1 0.9984082579612732
- O 0 1.2501946002885234e-05
1 O 0 2.6221437110507395e-06
modulate O 0 1.1858466564262926e-07
the O 0 6.047529410579955e-08
orphan O 0 6.093752062952262e-07
nuclear O 0 3.0552366752090165e-06
receptor O 0 4.220353275741218e-06
SF O 0 0.004077626392245293
- O 0 1.0304942179573118e-06
1 O 0 1.4534744252614473e-07
in O 0 6.861256562906703e-10
sex O 0 5.950394066367437e-10
- O 0 2.005159815965385e-09
specific O 0 1.2002485672013563e-09
gene O 0 2.1361158175636774e-08
expression O 0 2.097404632195321e-07
. O 0 8.953653605203726e-07

Products O 0 2.0952084014425054e-06
of O 0 8.46433749757125e-07
steroidogenic O 0 0.0014548487961292267
factor O 0 1.3083389603707474e-05
1 O 0 5.277499894873472e-06
( O 0 1.0522473559149148e-07
SF O 1 0.9993985891342163
- O 0 4.496151450439356e-05
1 O 0 3.922601536032744e-06
) O 0 8.098213655216568e-09
and O 0 1.1358161522423416e-08
Wilms B-Disease 0 0.4268220067024231
tumor I-Disease 0 0.07124631851911545
1 O 0 1.0586006283119787e-05
( O 0 1.4134671744159277e-07
WT1 O 0 3.292415931355208e-05
) O 0 2.275248656147255e-09
genes O 0 2.2623660722587147e-09
are O 0 1.0540456701901846e-10
essential O 0 2.9718734140260494e-09
for O 0 5.3803721478118405e-09
mammalian O 0 1.9727237940969644e-06
gonadogenesis O 0 9.165178198600188e-06
prior O 0 1.1685165901553773e-07
to O 0 5.2337107092625956e-08
sexual O 0 8.225178476095607e-07
differentiation O 0 3.3832333429018036e-05
. O 0 2.5826802811934613e-06

In O 0 3.8849194083923067e-07
males O 0 3.3682377420518606e-07
, O 0 1.229288244530835e-07
SF O 1 0.9999668598175049
- O 0 0.0007387505029328167
1 O 0 1.0423557796457317e-05
participates O 0 4.213272930542189e-08
in O 0 8.560562814174943e-10
sexual O 0 7.400809964863697e-10
development O 0 4.437080425301332e-10
by O 0 3.89320436999796e-10
regulating O 0 1.8758866460188983e-08
expression O 0 1.4445689089370717e-08
of O 0 1.8251347100317616e-08
the O 0 6.992626566670879e-08
polypeptide O 0 1.862950921349693e-05
hormone O 0 9.754312912946261e-08
Mullerian O 0 2.8896490675833775e-06
inhibiting O 0 3.306216740384116e-07
substance O 0 8.327279488185013e-07
( O 0 4.418530750172067e-07
MIS O 0 0.33451560139656067
) O 0 3.792382017309137e-07
. O 0 1.2955722468177555e-06

Here O 0 9.805233958104509e-07
, O 0 4.5578069318708e-08
we O 0 1.4307951268222041e-08
show O 0 9.574095294340168e-09
that O 0 8.823317187989232e-09
WT1 O 0 0.00023155941744334996
- O 0 3.7052577681606635e-05
KTS O 0 0.0022850632667541504
isoforms O 0 6.90743661380111e-07
associate O 0 1.665830211550201e-07
and O 0 4.063053893332835e-09
synergize O 0 1.1482459285616642e-06
with O 0 3.63809320447217e-08
SF O 1 0.999961256980896
- O 0 4.0253948100144044e-05
1 O 0 2.393948534518131e-06
to O 0 2.6188764934431674e-08
promote O 0 1.5227909955228824e-07
MIS O 0 0.0013438987080007792
expression O 0 6.336889327940298e-06
. O 0 2.828085825967719e-06

In O 0 1.158701820713759e-06
contrast O 0 2.2669667032459984e-06
, O 0 6.020896989866742e-07
WT1 O 0 0.0039749667048454285
missense O 0 9.786339069250971e-05
mutations O 0 2.289041049152729e-06
, O 0 5.665965030487996e-09
associated O 0 1.1032712521341637e-08
with O 0 3.041241036783049e-09
male B-Disease 0 6.457447057073296e-07
pseudohermaphroditism I-Disease 1 1.0
in O 0 8.951792551670223e-07
Denys B-Disease 1 1.0
- I-Disease 1 1.0
Drash I-Disease 1 1.0
syndrome I-Disease 1 1.0
, O 0 1.7076613403332885e-06
fail O 0 2.629036998769152e-06
to O 0 7.925982004053367e-08
synergize O 0 1.3641099030792248e-05
with O 0 1.9690426711349573e-07
SF O 1 0.9999998807907104
- O 0 0.03431745246052742
1 O 0 0.0001828773383749649
. O 0 4.620254458131967e-06

Additionally O 0 1.4997170865171938e-06
, O 0 2.6908789863000493e-08
the O 0 4.1327425037707144e-08
X O 0 5.0998507504118606e-05
- O 0 8.63973400555551e-06
linked O 0 6.037894308974501e-07
, O 0 3.0415892027235714e-09
candidate O 0 6.11878050449377e-08
dosage O 0 1.6839061345308437e-06
- O 0 2.080696731354692e-06
sensitive O 0 4.968133566762845e-07
sex O 0 3.200493381427805e-08
- O 0 9.702284131662964e-08
reversal O 0 3.830460286735615e-07
gene O 0 9.028804015542846e-08
, O 0 6.660648921297252e-08
Dax O 1 0.9999361038208008
- O 0 5.1678911404451355e-05
1 O 0 1.5796293155290186e-05
, O 0 2.1549194428871488e-08
antagonizes O 0 3.915901061191107e-07
synergy O 0 1.9021818786768563e-07
between O 0 1.1082934747719264e-07
SF O 1 0.908099353313446
- O 0 6.335656962619396e-06
1 O 0 1.0747170335889678e-06
and O 0 6.878136726840012e-09
WT1 O 0 1.5284567780327052e-05
, O 0 1.408719474405018e-09
most O 0 5.241198031136207e-10
likely O 0 3.1700722047389718e-09
through O 0 3.2979871611438227e-10
a O 0 3.042088358995443e-09
direct O 0 1.0615157641780115e-08
interaction O 0 3.675667059610532e-08
with O 0 2.7712705019666828e-08
SF O 1 0.9999772310256958
- O 0 0.0008402369567193091
1 O 0 8.311068813782185e-05
. O 0 3.5483587907947367e-06

We O 0 3.7740750258308253e-07
propose O 0 6.431609449464304e-07
that O 0 3.658488978430796e-08
WT1 O 0 0.00036583704059012234
and O 0 7.744059757897048e-07
Dax O 1 0.9999690055847168
- O 0 9.439207133254968e-06
1 O 0 1.34410981900146e-06
functionally O 0 8.062215783866122e-08
oppose O 0 1.7807076702069935e-08
each O 0 6.999171797694714e-10
other O 0 3.685350913329444e-10
in O 0 5.455914831031805e-09
testis O 0 1.7589737808521022e-06
development O 0 1.1654000431349232e-08
by O 0 1.0619471524364599e-08
modulating O 0 1.1050149623770267e-05
SF O 1 0.9991505146026611
- O 0 0.00012166213127784431
1 O 0 3.059895243495703e-05
- O 0 3.578846872187569e-06
mediated O 0 4.33188870374579e-06
transactivation O 0 2.83600438706344e-05
. O 0 1.8207263963176956e-07
. O 0 6.381813477673859e-07

A O 0 3.7623344724124763e-06
mouse O 0 8.691596917742572e-07
model O 0 1.7714231148602266e-07
for O 0 4.923382448396296e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 1 1.0
- O 1 0.9999998807907104
centre O 1 0.945766031742096
mutations O 0 0.00011148690828122199
. O 0 4.498071575653739e-06

Imprinting O 0 6.50980364298448e-05
in O 0 1.3647853336351545e-07
the O 0 3.4774578239193943e-07
15q11 O 0 0.3210759162902832
- O 0 0.0004457449831534177
q13 O 0 0.000896144425496459
region O 0 3.5701910405805393e-07
involves O 0 2.245467811690105e-08
an O 0 7.560050363508708e-09
imprinting O 0 7.743860805931035e-06
centre O 0 5.523617801372893e-06
( O 0 4.0420925273565445e-08
IC O 0 0.0010178787633776665
) O 0 6.2326566130366245e-09
, O 0 7.453394013090531e-10
mapping O 0 6.728217538665149e-09
in O 0 2.6778204653687965e-10
part O 0 7.406726898473437e-10
to O 0 1.0609181311238558e-09
the O 0 1.4005968829167159e-08
promoter O 0 9.758210580912419e-06
and O 0 8.679668539457452e-09
first O 0 1.8452426786552678e-07
exon O 0 8.833288120513316e-06
of O 0 3.3627090942900395e-06
SNRPN O 1 0.9963219165802002
. O 0 2.104981649608817e-05

Deletion O 0 8.963052823673934e-05
of O 0 1.9060875047216541e-06
this O 0 3.3599027915443003e-07
IC O 1 0.9732995629310608
abolishes O 0 5.4579177231062204e-05
local O 0 6.993720091941213e-08
paternally O 0 4.429850832821103e-07
derived O 0 1.2170871421801621e-08
gene O 0 4.4677221922029275e-09
expression O 0 2.6235447148081903e-09
and O 0 2.462570425354471e-10
results O 0 9.378158694062222e-09
in O 0 4.325603697452607e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999996423721313
PWS B-Disease 1 1.0
) O 0 1.2768111446348485e-05
. O 0 4.127640295337187e-06

We O 0 4.2560972701721766e-07
have O 0 5.6913642687561605e-09
created O 0 1.3647899699265054e-08
two O 0 6.3089888868717026e-09
deletion O 0 1.4111290056462167e-06
mutations O 0 4.467179621769901e-07
in O 0 4.474103221241421e-08
mice O 0 1.3207973381668126e-07
to O 0 1.834019336399706e-08
understand O 0 6.175967882882105e-06
PWS B-Disease 1 1.0
and O 0 2.4475042437188677e-08
the O 0 2.7943061198243413e-08
mechanism O 0 9.05676316165227e-08
of O 0 6.29419503184181e-08
this O 0 1.7958933540285216e-07
IC O 0 0.014044346287846565
. O 0 9.606246749171987e-06

Mice O 0 0.00010028084216173738
harbouring O 0 5.765351670561358e-05
an O 0 1.2772436264185671e-07
intragenic O 0 0.0005320679629221559
deletion O 0 6.986883818171918e-05
in O 0 1.5907853878616152e-07
Snrpn O 1 0.9965268969535828
are O 0 2.698408430035215e-08
phenotypically O 0 0.00016618958034086972
normal O 0 1.8736470508429193e-07
, O 0 2.2765989093898042e-09
suggesting O 0 7.74257991054128e-09
that O 0 5.613554066030702e-10
mutations O 0 2.996972625624039e-08
of O 0 4.3540531180497055e-08
SNRPN O 1 0.981919527053833
are O 0 1.7186733147767086e-09
not O 0 1.9706114517958895e-09
sufficient O 0 3.8511256406081884e-08
to O 0 8.787346672534113e-08
induce O 0 8.885729039320722e-05
PWS B-Disease 1 1.0
. O 0 6.731532630510628e-05

Mice O 0 5.349887487682281e-06
with O 0 3.765171729952499e-09
a O 0 4.260621011553667e-08
larger O 0 7.742686136680277e-08
deletion O 0 5.0274445584364e-07
involving O 0 9.588075222666248e-09
both O 0 7.177603844610303e-09
Snrpn O 0 3.262582322349772e-05
and O 0 7.275548608021154e-09
the O 0 1.5241231210438855e-07
putative O 1 0.5868567228317261
PWS O 1 1.0
- O 1 0.9944496154785156
IC O 1 0.9999468326568604
lack O 0 7.586457968500326e-07
expression O 0 7.07865766003124e-08
of O 0 2.4878113791260148e-08
the O 0 2.5143442883290845e-08
imprinted O 0 4.0438516180074657e-07
genes O 0 1.7175364064314635e-07
Zfp127 O 0 2.222389775852207e-05
( O 0 4.336135361882043e-08
mouse O 0 6.896799504829687e-07
homologue O 0 3.882051714754198e-06
of O 0 1.459451226537567e-07
ZNF127 O 0 0.31081491708755493
) O 0 6.333490887300286e-08
, O 0 4.6492623084759543e-08
Ndn O 0 0.0006067186477594078
and O 0 7.512775823670381e-08
Ipw O 0 1.2898623026558198e-05
, O 0 1.4089780897563742e-08
and O 0 5.919301493406692e-09
manifest O 0 1.0795969274113304e-07
several O 0 8.267739382006312e-09
phenotypes O 0 4.348683830812661e-07
common O 0 5.783876417808642e-07
to O 0 4.063299638801254e-05
PWS B-Disease 1 1.0
infants O 1 0.6270356178283691
. O 0 1.137174967880128e-05

These O 0 1.7528929419086126e-08
data O 0 2.989755643056924e-08
demonstrate O 0 9.080023843921481e-09
that O 0 3.052199326614158e-10
both O 0 5.257848600948023e-10
the O 0 2.8020861186917045e-09
position O 0 8.016245089947915e-08
of O 0 7.192047846160676e-09
the O 0 9.028473968442086e-09
IC O 0 0.0002651769609656185
and O 0 1.761871981642571e-09
its O 0 1.141525318715253e-09
role O 0 3.3416540645703208e-09
in O 0 3.935138603861077e-10
the O 0 4.5527023817548695e-10
coordinate O 0 5.273347980505605e-09
expression O 0 2.7601400276466848e-08
of O 0 1.2116995407041031e-08
genes O 0 6.410198594153371e-09
is O 0 4.2233255781454204e-10
conserved O 0 7.364202581072732e-09
between O 0 1.6603901586975667e-09
mouse O 0 4.6603158665448063e-08
and O 0 4.967863342919543e-10
human O 0 1.0739071854004578e-09
, O 0 5.231749478085135e-10
and O 0 1.3410128563151602e-10
indicate O 0 1.3057382952652574e-09
that O 0 1.1811013278517635e-10
the O 0 1.4157012229176758e-09
mouse O 0 3.1169527403562824e-08
is O 0 3.23770399379697e-10
a O 0 5.834568383988881e-10
suitable O 0 7.273550206576829e-09
model O 0 1.4058179065301601e-09
system O 0 2.0959973756617956e-09
in O 0 4.638433803716424e-10
which O 0 2.0424772984029005e-10
to O 0 4.679800436058201e-10
investigate O 0 2.410643018535552e-09
the O 0 2.1002353189913947e-09
molecular O 0 6.021919318754954e-08
mechanisms O 0 6.715499267784253e-09
of O 0 1.1255636422902171e-08
imprinting O 0 8.776958679845848e-07
in O 0 1.6875510988612064e-09
this O 0 6.697689625134728e-10
region O 0 2.3385984704304974e-08
of O 0 1.901332424836255e-08
the O 0 2.3863067966090057e-08
genome O 0 4.046050605666096e-07
. O 0 5.668864844210475e-08
. O 0 6.735937176927109e-07

Mutations O 0 1.9962290025432594e-06
of O 0 1.3861995284969453e-07
the O 0 9.94142652643859e-08
ATM O 0 0.00028721478884108365
gene O 0 1.365873885106339e-07
detected O 0 1.6577935468831129e-07
in O 0 2.5819950622008037e-08
Japanese O 0 0.03795376047492027
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 5.296765721141128e-06
: O 0 9.736780270941381e-09
possible O 0 1.29525815850684e-07
preponderance O 0 7.327229013753822e-06
of O 0 2.2811027733382616e-08
the O 0 7.518392131089513e-09
two O 0 4.538434072998143e-09
founder O 0 4.782439191330923e-07
mutations O 0 5.808901164527924e-07
4612del165 O 0 6.880026921862736e-05
and O 0 2.950048099137348e-07
7883del5 O 0 0.02236723154783249
. O 0 8.665610948810354e-06

The O 0 1.0445123734825756e-06
ATM O 0 0.052024394273757935
( O 0 5.41805320608546e-06
A O 1 1.0
- O 1 1.0
T O 1 0.9999998807907104
, O 0 5.232353572637294e-08
mutated O 0 6.288495058015542e-08
) O 0 1.7238014349274522e-09
gene O 0 4.573723622058878e-09
on O 0 1.6433521210501567e-08
human O 0 7.618694297661932e-08
chromosome O 0 0.0001527352724224329
11q22 O 0 0.00035466806730255485
. O 0 3.0754838462598855e-06

3 O 0 3.1523246434517205e-05
has O 0 5.0807912543859857e-08
recently O 0 8.1253553219085e-08
been O 0 4.591572455581172e-09
identified O 0 3.2706575225915913e-09
as O 0 3.563241091075753e-10
the O 0 5.554909865423951e-10
gene O 0 1.5582933832192225e-09
responsible O 0 2.8784723493657793e-09
for O 0 1.491803125475144e-09
the O 0 1.6926750845414062e-07
human O 0 1.5012859876151197e-05
recessive B-Disease 1 1.0
disease I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9994762539863586
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 0.9999998807907104
) O 0 8.622494647170242e-07
. O 0 1.5071841517055873e-06

In O 0 5.735228114644997e-08
order O 0 3.589176733598265e-09
to O 0 1.2174650176888235e-09
define O 0 3.5946932541719434e-08
the O 0 4.556726995730287e-09
types O 0 5.522357326981364e-08
of O 0 5.807893330711522e-07
disease O 0 0.11591646075248718
- O 0 3.3881253330037e-05
causing O 0 8.448482731182594e-07
ATM O 0 0.00019885238725692034
mutations O 0 8.765752568251628e-08
in O 0 5.167408723139033e-09
Japanese O 0 1.8369236158832791e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 8.361320524841176e-09
as O 0 9.311333371009312e-10
well O 0 5.065188268815746e-10
as O 0 7.991400319262709e-10
to O 0 7.480696617712113e-10
look O 0 1.9821240204720425e-09
for O 0 2.5344497611712313e-09
possible O 0 2.264506946403344e-07
mutational O 0 9.974752174457535e-05
hotspots O 0 7.2756870395096485e-06
, O 0 8.375127258375414e-09
reverse O 0 1.1908093000556619e-07
- O 0 7.0023830289756e-08
transcribed O 0 1.9548071605868245e-08
RNA O 0 3.038100615526673e-08
derived O 0 1.50934187370666e-09
from O 0 6.075861480603351e-10
ten O 0 1.3475774940374663e-09
patients O 0 2.4026408640409613e-10
belonging O 0 1.5547042542252143e-09
to O 0 7.895405440550007e-10
eight O 0 7.835550874801811e-09
unrelated O 0 8.448548527439925e-08
Japanese O 0 2.876470716728363e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
T I-Disease 1 0.9999971389770508
families O 0 4.827351851588446e-09
was O 0 1.624801271304932e-08
analyzed O 0 3.327229602945181e-09
for O 0 3.7836137001256986e-10
mutations O 0 5.435867311831544e-09
by O 0 1.143918515467135e-09
the O 0 2.466361515018889e-08
restriction O 0 3.079405814787606e-07
endonuclease O 0 3.6067026485397946e-06
fingerprinting O 0 6.498195261883666e-07
method O 0 6.7424792860038e-07
. O 0 7.83349037192238e-07

As O 0 5.080239589005942e-07
has O 0 1.7248810380010582e-08
been O 0 5.05720754162553e-09
reported O 0 3.636204670698362e-09
by O 0 5.222377530422762e-10
others O 0 3.777544055338922e-09
, O 0 1.892489054355906e-09
mutations O 0 5.9561195975277315e-09
that O 0 4.801994357706008e-10
lead O 0 1.210962530251436e-08
to O 0 1.8521090439094223e-08
exon O 0 1.845469705585856e-05
skipping O 0 2.6899660952039994e-06
or O 0 6.814584452285999e-08
premature O 0 3.3005710520228604e-07
protein O 0 4.379840490287279e-08
truncation O 0 1.055175061992486e-06
were O 0 1.0635950786763715e-08
also O 0 5.083085952151123e-09
predominant O 0 3.9434985410480294e-07
in O 0 8.870649104153472e-09
our O 0 3.988498775697735e-08
mutants O 0 1.2455716387194116e-06
. O 0 8.437370979663683e-07

Six O 0 7.865876483492684e-08
different O 0 1.823522666200006e-09
mutations O 0 3.66631951465024e-08
were O 0 3.7890393045358906e-09
identified O 0 1.1253704634839323e-08
on O 0 2.1332452249112066e-08
12 O 0 1.6472622377250445e-08
of O 0 7.249257194530401e-09
the O 0 2.1329643828948974e-08
16 O 0 3.9234330984072585e-07
alleles O 0 6.151065008452861e-07
examined O 0 2.140238393621985e-06
. O 0 2.124848833773285e-06

Four O 0 2.7444107786323e-07
were O 0 3.615424759573216e-08
deletions O 0 4.868001042268588e-07
involving O 0 7.281687430804595e-08
a O 0 2.1192057886310067e-07
loss O 0 2.102149437632761e-06
of O 0 1.9340652102073363e-07
a O 0 1.2598388821061235e-07
single O 0 8.280178320774212e-08
exon O 0 1.375294232275337e-06
exon O 0 2.1207108602538938e-06
7 O 0 1.990226792258909e-07
, O 0 8.296837883392527e-09
exon O 0 1.0106862191605614e-06
16 O 0 7.284619130132342e-08
, O 0 1.4824491856302302e-08
exon O 0 3.0102808068477316e-06
33 O 0 1.0515517487874604e-06
or O 0 4.748436026602576e-07
exon O 0 5.6080531066982076e-05
35 O 0 1.133027944888454e-05
. O 0 2.598464789116406e-06

The O 0 9.930100759447669e-07
others O 0 9.982868931501798e-08
were O 0 2.5243585000112034e-08
minute O 0 1.5854556068006787e-06
deletions O 0 2.303436986039742e-06
, O 0 6.52116511901113e-08
4649delA O 0 4.836515017814236e-06
in O 0 1.3069778503904672e-07
exon O 0 9.439027053304017e-06
33 O 0 8.543701710550522e-07
and O 0 4.4614996141945085e-08
7883del5 O 0 5.400654845288955e-05
in O 0 5.595546781478333e-07
exon O 0 5.894775313208811e-05
55 O 0 1.0677867066988256e-05
. O 0 1.83984809609683e-06

The O 0 2.14905162465584e-06
mutations O 0 7.243182608362986e-06
4612del165 O 0 0.00023630315263289958
and O 0 3.892361633006658e-08
7883del5 O 0 7.214418292278424e-05
were O 0 1.1895694207453289e-08
found O 0 1.0942632355792625e-09
in O 0 1.5622954319116644e-10
more O 0 2.3131755191863057e-11
than O 0 2.47423248556089e-10
two O 0 1.7238598049029719e-10
unrelated O 0 4.16081036291871e-09
families O 0 2.509660534943947e-10
; O 0 5.232767552598716e-10
44 O 0 2.362575735048722e-08
% O 0 1.3687262878647743e-08
( O 0 1.084644485338515e-09
7 O 0 3.4089421063754344e-08
of O 0 3.5727569791532687e-09
16 O 0 5.195187835482784e-09
) O 0 7.369437005078083e-11
of O 0 4.657031982269189e-10
the O 0 1.4048502361418969e-09
mutant O 0 2.313276148413479e-08
alleles O 0 9.31092980493986e-09
had O 0 1.7408506858274109e-09
one O 0 6.89926116237416e-10
of O 0 3.525923775171691e-09
the O 0 1.1150484091615454e-08
two O 0 2.5327405950292814e-08
mutations O 0 4.026605893159285e-06
. O 0 3.113814727839781e-06

The O 0 3.2653974813001696e-06
4612del165 O 0 0.00029212940717116
mutations O 0 4.037878511553572e-07
in O 0 2.2902220120357697e-09
three O 0 1.834112028920032e-10
different O 0 3.957801447684872e-11
families O 0 1.1196635285593004e-10
were O 0 2.0106888376503207e-10
all O 0 1.6714755968205708e-10
ascribed O 0 2.6203153424830816e-08
to O 0 9.271105549935044e-10
the O 0 3.0571125630984852e-09
same O 0 1.1203908911738836e-08
T O 0 4.6698011146872886e-07
- O 0 4.3358133439141966e-07
- O 0 1.5737057879050553e-07
> O 0 9.310293336284303e-08
A O 0 2.8690024578281736e-08
substitution O 0 3.964614947449263e-08
at O 0 8.818404673149871e-09
the O 0 2.571760582270599e-09
splice O 0 1.8407537538678298e-07
donor O 0 2.1249205062190413e-08
site O 0 5.0012101127094866e-08
in O 0 5.3669786836962885e-08
intron O 0 0.00010430788097437471
33 O 0 1.7020298400893807e-05
. O 0 2.897765398301999e-06

Microsatellite O 0 0.0072244517505168915
genotyping O 0 6.715228664688766e-05
around O 0 2.4971770429260687e-08
the O 0 1.3129463738437153e-08
ATM O 0 3.296195063740015e-05
locus O 0 8.191774213628378e-06
also O 0 9.256016508807363e-10
indicated O 0 3.198996623154926e-09
that O 0 6.609676000968179e-11
a O 0 3.014053895356028e-09
common O 0 2.7912218314440906e-08
haplotype O 0 6.449175270972773e-05
was O 0 1.8735933338120958e-07
shared O 0 1.068447996743771e-09
by O 0 1.864132320728018e-10
the O 0 8.134175111251807e-09
mutant O 0 1.0061337718525465e-07
alleles O 0 2.0214539375729146e-08
in O 0 4.372635142857462e-09
both O 0 3.770930234736625e-08
mutations O 0 7.1896206463861745e-06
. O 0 2.7512262477102922e-06

This O 0 1.5688985399719968e-07
suggests O 0 7.336993235185219e-08
that O 0 3.323802622023919e-10
these O 0 3.6830810623555976e-10
two O 0 1.7098388260805564e-09
founder O 0 3.308216207642545e-07
mutations O 0 9.734907990832653e-08
may O 0 1.9051041633133536e-08
be O 0 1.6071496133918117e-08
predominant O 0 2.0912200398015557e-06
among O 0 1.3803194143235942e-08
Japanese O 0 5.834073135702056e-07
ATM O 0 5.489309114636853e-05
mutant O 0 3.803969093496562e-06
alleles O 0 1.5172215626080288e-06
. O 0 5.802345981464896e-07

W474C O 0 0.0005081567214801908
amino O 0 1.342375412605179e-06
acid O 0 9.311359150387943e-08
substitution O 0 1.4006121773491031e-07
affects O 0 1.776169078482326e-08
early O 0 1.048710540629827e-08
processing O 0 2.361962891939129e-08
of O 0 5.214516818341508e-09
the O 0 5.9693467946431156e-09
alpha O 0 3.665438441657898e-08
- O 0 4.816361531823077e-09
subunit O 0 8.475304902333392e-09
of O 0 1.4330832076581146e-09
beta O 0 1.3732861248172412e-07
- O 0 1.0793623061999824e-07
hexosaminidase O 0 1.3479916560754646e-06
A O 0 8.945769991441921e-08
and O 0 8.509884463769879e-10
is O 0 1.788467485219769e-09
associated O 0 1.1554467604923957e-08
with O 0 6.3131295746643445e-09
subacute O 1 0.9999983310699463
G B-Disease 1 0.9987735152244568
( I-Disease 0 2.745130359471659e-06
M2 I-Disease 1 0.554149329662323
) I-Disease 0 1.0203513056694646e-06
gangliosidosis I-Disease 0 0.0003261589154135436
. O 0 3.6972787711420096e-06

Mutations O 0 6.1562564042105805e-06
in O 0 9.353260566058452e-08
the O 0 3.421038456963288e-07
HEXA O 0 0.0008270507678389549
gene O 0 5.3089152629581804e-08
, O 0 1.8431079995551158e-09
encoding O 0 7.1370993559582985e-09
the O 0 7.495225773368475e-09
alpha O 0 3.950747640146801e-08
- O 0 4.777212403439535e-09
subunit O 0 1.3735278692195152e-08
of O 0 1.719932640753541e-09
beta O 0 1.2479110012009187e-07
- O 0 2.479805800703616e-07
hexosaminidase O 0 4.545935553323943e-06
A O 0 1.270837174160988e-06
( O 0 2.575777635627219e-08
Hex O 0 2.326343519598595e-06
A O 0 1.4987620033934945e-07
) O 0 1.0978234987746305e-09
, O 0 2.6582180900902586e-10
that O 0 1.871296312350168e-10
abolish O 0 1.0677032946659892e-07
Hex O 0 2.297719674970722e-06
A O 0 4.787175811316047e-08
enzyme O 0 3.342286447605147e-08
activity O 0 3.908535362029397e-08
cause O 0 0.015496685169637203
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9999997615814209
( O 0 1.528135840089817e-06
TSD B-Disease 1 0.9910383224487305
) O 0 6.246700046119713e-09
, O 0 2.3707131813210935e-09
the O 0 1.8615475383398916e-08
fatal O 0 2.1445970560307615e-05
infantile B-Disease 0 2.437817965983413e-05
form I-Disease 0 2.9693148917431245e-07
of I-Disease 0 9.787756425794214e-06
G I-Disease 0 0.022497978061437607
( I-Disease 0 2.5977931272791466e-07
M2 I-Disease 0 0.0006528180092573166
) I-Disease 0 2.951189514988073e-08
gangliosidosis I-Disease 0 9.009843779494986e-06
, I-Disease 0 3.443144080961247e-08
Type I-Disease 0 2.8774256861652248e-06
1 I-Disease 0 2.691939880605787e-05
. O 0 2.000452241190942e-06

Less O 0 8.456868090434e-05
severe O 1 0.9765551686286926
, O 0 3.8127805055410136e-06
subacute O 1 0.9999953508377075
( O 0 4.846691354032373e-06
juvenile O 1 0.996901273727417
- O 0 0.0005938306567259133
onset O 1 0.9999985694885254
) O 0 3.27707908809316e-07
and O 0 4.0295537928614067e-07
chronic O 1 1.0
( O 0 8.258505772573699e-07
adult O 0 6.673965344816679e-06
- O 0 3.017063363586203e-06
onset O 0 0.0006519476301036775
) O 0 3.949999882735256e-09
variants O 0 2.3756980382927395e-08
are O 0 1.398220011994411e-10
characterized O 0 1.8611205909735418e-09
by O 0 3.7136321795472327e-10
a O 0 8.16194578590057e-09
broad O 0 2.601886990305502e-07
spectrum O 0 5.849951776326634e-06
of O 0 5.935527980227562e-08
clinical O 0 3.784552518482087e-06
manifestations O 0 1.9560402506613173e-06
and O 0 2.1746879852457823e-09
are O 0 1.7662821205632895e-10
associated O 0 3.337577325623897e-09
with O 0 7.698619519658223e-10
residual O 0 3.5527544241631404e-05
levels O 0 1.759929091349477e-07
of O 0 1.1206948613562417e-07
Hex O 0 8.333608093380462e-06
A O 0 5.208049742577714e-07
enzyme O 0 1.4501735279282002e-07
activity O 0 1.2089620327060402e-07
. O 0 1.4957905136725458e-07

We O 0 1.529281803414051e-06
identified O 0 5.691757110071194e-07
a O 0 3.4232741086270835e-07
1422 O 0 6.91423992975615e-05
G O 0 2.7535690605873242e-05
- O 0 1.2511774912127294e-05
- O 0 4.903242825093912e-06
> O 0 5.598842562903883e-06
C O 0 4.99397447129013e-06
( O 0 1.1416283030030172e-08
amino O 0 7.232876964025081e-09
acid O 0 4.1212948609370414e-09
W474C O 0 6.89866155312302e-08
) O 0 6.279880782056324e-11
substitution O 0 1.3430511147660695e-09
in O 0 1.6650322787192806e-10
the O 0 5.685675819044889e-10
first O 0 3.101419565609831e-09
position O 0 6.613304748270821e-08
of O 0 2.844764956932977e-08
exon O 0 1.1711422303051222e-06
13 O 0 3.337311582640723e-08
of O 0 1.862822784914897e-08
HEXA O 0 6.831927021266893e-05
of O 0 1.555597783919893e-08
a O 0 4.7180478190966824e-08
non O 0 1.2536656868178397e-06
- O 0 3.2906878004723694e-06
Jewish O 0 1.186497956950916e-05
proband O 0 0.3472613990306854
who O 0 5.578295159125446e-08
manifested O 0 1.0079239132210205e-07
a O 0 3.338750431680637e-08
subacute O 0 0.00013147210120223463
variant O 0 9.678248716227245e-06
of O 0 8.277158485725522e-06
G B-Disease 0 0.005120465531945229
( I-Disease 0 4.226037901844393e-07
M2 I-Disease 0 0.003838395234197378
) I-Disease 0 3.7077265346852073e-07
gangliosidosis I-Disease 0 0.00015968778461683542
. O 0 2.1259313598420704e-06

On O 0 2.8079891762899933e-06
the O 0 9.736598372001026e-08
second O 0 7.318153052437992e-07
maternally O 0 3.467904207354877e-06
inherited O 0 4.242272552801296e-06
allele O 0 4.205575805826811e-06
, O 0 4.275916065665797e-09
we O 0 1.0783858250817957e-09
identified O 0 4.96850027786877e-09
the O 0 4.660126950994936e-09
common O 0 7.3515993790351786e-06
infantile O 1 0.9999998807907104
disease O 1 0.9999994039535522
- O 1 0.9195699095726013
causing O 0 2.8575599571922794e-05
4 O 0 4.376068318379112e-06
- O 0 4.278030871773808e-07
bp O 0 3.000713491019269e-07
insertion O 0 2.448004465804843e-07
, O 0 2.2203657579211722e-08
+ O 0 1.029849727274268e-06
TATC O 0 0.0004576044448185712
1278 O 0 5.594666799879633e-05
, O 0 2.510711638592511e-08
in O 0 6.456264856069538e-08
exon O 0 1.2036868611176033e-05
11 O 0 1.7197191937157186e-06
. O 0 8.902159720491909e-07

Pulse O 0 0.0008526674355380237
- O 0 1.3460490663419478e-05
chase O 0 3.8639581134702894e-07
analysis O 0 1.8010315017136236e-08
using O 0 1.7418580355865743e-08
proband O 0 2.07269567908952e-05
fibroblasts O 0 4.254660836977564e-07
revealed O 0 3.5624566407932434e-08
that O 0 7.328412876539403e-10
the O 0 1.4476110976602286e-08
W474C O 0 1.8697480754781282e-06
- O 0 7.217941089265878e-08
containing O 0 2.257594111654271e-09
alpha O 0 3.2236826541520713e-08
- O 0 5.490719878764594e-09
subunit O 0 3.688702321369419e-08
precursor O 0 3.489170552484211e-08
was O 0 9.51168210860942e-09
normally O 0 6.578488309649799e-10
synthesized O 0 7.326725448564275e-09
, O 0 2.7772895094813066e-10
but O 0 2.817798772092317e-10
not O 0 6.239409544583907e-10
phosphorylated O 0 7.615788177872673e-08
or O 0 1.4145196125525672e-08
secreted O 0 5.110463874302695e-08
, O 0 2.5360360478288158e-09
and O 0 2.5476620812980855e-09
the O 0 2.919373010001891e-08
mature O 0 9.498686637243736e-08
lysosomal O 0 3.4166278055636212e-06
alpha O 0 2.999763637490105e-07
- O 0 2.2632690388491028e-08
subunit O 0 1.866045096221569e-07
was O 0 4.206608394952127e-08
not O 0 1.4530995073869235e-08
detected O 0 7.064197689032881e-07
. O 0 5.05251534832496e-07

When O 0 4.97506562169292e-07
the O 0 1.7506819460777479e-07
W474C O 0 9.282255632570013e-06
- O 0 2.448662996812345e-07
containing O 0 6.40780317695544e-09
alpha O 0 4.774500439452822e-08
- O 0 8.628531666943218e-09
subunit O 0 7.995722484110956e-08
was O 0 2.0668943889745606e-08
transiently O 0 1.5783108153755165e-07
co O 0 1.1737611771422962e-08
- O 0 7.36876915041762e-09
expressed O 0 7.144286828797419e-10
with O 0 9.63238724893678e-11
the O 0 3.679130111677864e-09
beta O 0 5.08795814369023e-08
- O 0 7.817323677272725e-09
subunit O 0 8.201600287804922e-09
to O 0 3.454237451627762e-10
produce O 0 2.3419719497042024e-09
Hex O 0 7.481480110982375e-07
A O 0 2.797458478198678e-07
( O 0 3.378854174229673e-08
alphabeta O 0 5.3873595788900275e-06
) O 0 6.810982444704905e-09
in O 0 1.092059953577973e-08
COS O 0 4.437563256942667e-05
- O 0 1.1936647297261516e-06
7 O 0 1.2162198004261882e-07
cells O 0 6.366577487426639e-09
, O 0 2.585723024584041e-10
the O 0 3.715488472444406e-10
mature O 0 1.0432077424127328e-09
alpha O 0 4.9010528968551625e-09
- O 0 6.120525752884021e-10
subunit O 0 7.75614861225904e-09
was O 0 2.1606925137973576e-09
present O 0 1.0008459339072573e-10
, O 0 5.2124339566805844e-11
but O 0 2.7613574621332404e-11
its O 0 4.115399340753889e-11
level O 0 5.1607109696760745e-09
was O 0 6.679602648773653e-09
much O 0 9.226105435189424e-10
lower O 0 3.967207451438526e-09
than O 0 2.5414340076856945e-10
that O 0 8.859395855820296e-11
from O 0 8.670992257542309e-10
normal O 0 6.00496408154072e-09
alpha O 0 4.230812322703059e-08
- O 0 6.6589063152378e-09
subunit O 0 8.207253188174946e-08
transfections O 0 3.1936338018567767e-07
, O 0 2.662140230480503e-10
although O 0 2.9006816393284396e-10
higher O 0 4.227002747825281e-09
than O 0 7.689843206648561e-10
in O 0 1.055750376011133e-09
those O 0 9.055286520620598e-10
cells O 0 4.043879897608349e-09
transfected O 0 6.877457536802467e-08
with O 0 1.1395451943174706e-10
an O 0 1.4299895711999966e-09
alpha O 0 1.0969788633019562e-07
- O 0 3.05325080773855e-08
subunit O 0 1.5121081275992765e-07
associated O 0 2.6416174137011694e-08
with O 0 4.483568716295849e-08
infantile O 0 0.1689588874578476
TSD B-Disease 1 0.9989067316055298
. O 0 2.7131922252010554e-05

Furthermore O 0 2.076815007967525e-06
, O 0 1.621167200482887e-08
the O 0 1.7530300766566143e-08
precursor O 0 5.867663617209473e-07
level O 0 2.0078573470527772e-07
of O 0 1.739364563491108e-08
the O 0 2.9405644141888843e-08
W474C O 0 1.6482041473864228e-06
alpha O 0 7.012608449485924e-08
- O 0 4.017464139138838e-09
subunit O 0 2.123680431509456e-08
was O 0 2.608893989730632e-09
found O 0 5.795104326966616e-11
to O 0 1.6451505435721714e-10
accumulate O 0 6.263713547838279e-09
in O 0 1.022628426383676e-09
comparison O 0 1.9271677587084923e-08
to O 0 3.2326765708745597e-09
the O 0 1.5502839900705112e-08
normal O 0 1.3562529943556e-07
alpha O 0 7.557385401923966e-07
- O 0 2.2029760771147266e-07
subunit O 0 8.50356286719034e-07
precursor O 0 7.040040372885414e-07
levels O 0 3.192391488937574e-07
. O 0 4.078468407442415e-07

We O 0 5.99335237438936e-07
conclude O 0 9.87770931715204e-07
that O 0 6.699788279718177e-09
the O 0 6.068882640875017e-08
1422 O 0 2.0129078620811924e-05
G O 0 7.828867637726944e-06
- O 0 1.5797987771293265e-06
- O 0 5.583052598012728e-07
> O 0 5.534957949748787e-07
C O 0 1.4177441016727244e-06
mutation O 0 2.684133093566743e-08
is O 0 3.30643956658605e-10
the O 0 1.1554924794765498e-09
cause O 0 6.158155230195916e-08
of O 0 2.9561567771452246e-07
Hex B-Disease 0 0.3750257194042206
A I-Disease 1 0.7594408988952637
enzyme I-Disease 1 0.9999996423721313
deficiency I-Disease 1 0.9999990463256836
in O 0 2.260480727045433e-07
the O 0 5.89140427109669e-07
proband O 0 0.0015111917164176702
. O 0 4.410019755596295e-06

The O 0 5.943707037658896e-07
resulting O 0 7.443966296705185e-07
W474C O 0 3.079104135395028e-05
substitution O 0 1.964388957276242e-06
clearly O 0 1.5355995230947883e-07
interferes O 0 4.561877275932602e-08
with O 0 1.2495902090847721e-09
alpha O 0 8.961789177419632e-08
- O 0 6.706692534663716e-09
subunit O 0 5.650039014426511e-08
processing O 0 4.449209445311908e-09
, O 0 2.6844426681549294e-10
but O 0 1.373468838661296e-10
because O 0 1.3074198668139303e-10
the O 0 1.8451611072389795e-10
base O 0 6.265386875980994e-09
substitution O 0 4.506167883278067e-08
falls O 0 1.8371478915923944e-07
at O 0 7.717780192706414e-09
the O 0 8.356150771327009e-10
first O 0 2.2262083287927226e-09
position O 0 5.876691133721579e-08
of O 0 4.511327489353789e-08
exon O 0 1.0230825182588887e-06
13 O 0 3.239226842310927e-08
, O 0 1.4012535576313212e-09
aberrant O 0 3.601047993129214e-08
splicing O 0 1.9895018965598865e-07
may O 0 1.1994481852184435e-08
also O 0 1.0032373820578755e-09
contribute O 0 1.5698025102039992e-09
to O 0 2.5846853546340753e-08
Hex B-Disease 1 0.8791717290878296
A I-Disease 1 0.6304143071174622
deficiency I-Disease 0 0.06903636455535889
in O 0 3.9309494326289496e-08
this O 0 3.503922485492694e-08
proband O 0 4.3285217543598264e-05
. O 0 2.2345182060234947e-07
. O 0 9.932762168318732e-07

Two O 0 4.084318447894475e-07
frequent O 0 1.705161821519141e-06
missense O 0 0.00025002172333188355
mutations O 0 0.00026174975209869444
in O 0 0.0003280030796304345
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.020575454458594322

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.5821320630493574e-05
an O 0 5.1999253628309816e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.6214116811752319
by O 0 1.3688591025129426e-06
early O 1 0.9999963045120239
childhood O 1 1.0
deafness B-Disease 1 1.0
and O 1 0.9999998807907104
goiter B-Disease 1 1.0
. O 1 0.9993867874145508

A O 0 4.675693162425887e-06
century O 0 1.7299008732152288e-06
after O 0 3.143257387705489e-08
its O 0 5.331416974563297e-10
recognition O 0 2.1204506595040584e-08
as O 0 1.741705091262702e-08
a O 0 1.5101999224498286e-06
syndrome O 1 0.7684349417686462
by O 0 2.3266172988201106e-08
Vaughan O 0 1.5672891095164232e-05
Pendred O 0 0.06560036540031433
, O 0 9.545850332415284e-09
the O 0 4.639978357090513e-08
disease O 0 1.025291840051068e-05
gene O 0 1.005064177661552e-06
( O 0 2.777976533252513e-07
PDS O 1 0.9085400104522705
) O 0 2.60707473387356e-08
was O 0 1.528030963982019e-07
mapped O 0 1.2347364020115492e-07
to O 0 9.802245415357902e-08
chromosome O 0 0.00011623214231804013
7q22 O 0 0.0009790578624233603
- O 0 0.00024068668426480144
q31 O 0 0.0009327439474873245
. O 0 4.903046374238329e-06

1 O 0 2.9492843168554828e-05
and O 0 3.14827310887722e-08
, O 0 2.0008435797080892e-08
recently O 0 5.014027948391231e-08
, O 0 2.38454012091438e-09
found O 0 1.2617975553297356e-09
to O 0 2.7091389132039012e-09
encode O 0 4.011968357531259e-08
a O 0 2.595995169940579e-07
putative O 0 4.7673551307525486e-05
sulfate O 0 6.706844578729942e-05
transporter O 1 0.5374640226364136
. O 0 9.456849511479959e-06

We O 0 1.7828647003170772e-07
performed O 0 1.3839891011002692e-08
mutation O 0 9.904856490550173e-09
analysis O 0 3.679495153008361e-09
of O 0 8.488441949339176e-09
the O 0 6.457791812408686e-08
PDS B-Disease 1 0.975690484046936
gene O 0 1.1854723425130942e-07
in O 0 6.260321150364234e-09
patients O 0 2.1903610036844157e-09
from O 0 9.611714091306567e-09
14 O 0 4.463644742713768e-08
Pendred B-Disease 0 1.4768830851608072e-06
families O 0 1.4910740697704483e-10
originating O 0 1.668612803484848e-09
from O 0 9.95644788837069e-10
seven O 0 1.0851494147701146e-09
countries O 0 2.743854865538964e-10
and O 0 2.8841933286116728e-09
identified O 0 8.494794201396871e-08
all O 0 5.444866602033471e-08
mutations O 0 1.4805834780418081e-06
. O 0 1.7698910141916713e-06

The O 0 9.060509569280839e-07
mutations O 0 4.653503253848612e-07
include O 0 1.3782832652964316e-08
three O 0 5.123637070170162e-09
single O 0 6.140573560742268e-08
base O 0 2.5941417902686226e-07
deletions O 0 8.725140787646524e-07
, O 0 9.759576258261404e-09
one O 0 1.1834386803855068e-08
splice O 0 1.3784430166197126e-06
site O 0 3.768356293676334e-08
mutation O 0 6.182976619584224e-08
and O 0 1.5747454895631563e-08
10 O 0 4.4525233988679247e-07
missense O 0 7.97350294305943e-05
mutations O 0 1.6330572179867886e-05
. O 0 3.6360163448989624e-06

One O 0 1.2280981991352746e-06
missense O 0 2.661898724909406e-05
mutation O 0 5.134957973496057e-06
( O 0 1.271537541924772e-07
L236P O 0 0.0002548690827097744
) O 0 6.254807338734736e-09
was O 0 2.3337683785484842e-08
found O 0 2.404327847926879e-10
in O 0 1.3143831856243793e-10
a O 0 2.59491894638586e-09
homozygous O 0 1.4882001408977885e-08
state O 0 8.759075686981532e-10
in O 0 1.0164912245258506e-09
two O 0 1.0053810006738217e-09
consanguineous O 0 7.501716027036309e-06
families O 0 1.0163923036543565e-09
and O 0 4.875606030019242e-10
in O 0 1.5463141878058195e-09
a O 0 1.2146984751382206e-08
heterozygous O 0 2.1286522766672533e-08
state O 0 4.974130551893552e-10
in O 0 3.2667218929915975e-10
five O 0 5.209385145477086e-10
additional O 0 2.7642690358931077e-09
non O 0 1.5816017366887536e-06
- O 0 2.772884545265697e-05
consanguineous O 0 6.67664862703532e-05
families O 0 1.827979758672882e-07
. O 0 1.1762587064367835e-06

Another O 0 3.4087972835550318e-06
missense O 0 4.2134801333304495e-05
mutation O 0 1.0488631232874468e-05
( O 0 1.4897159417159855e-07
T416P O 0 0.00024360186944250017
) O 0 3.847937080081465e-09
was O 0 1.337032529136195e-08
found O 0 1.5603032754718527e-10
in O 0 9.693169877866836e-11
a O 0 1.7143385599993621e-09
homozygous O 0 7.775271093635183e-09
state O 0 5.019553661611553e-10
in O 0 9.516758492367217e-10
one O 0 3.4839682250265014e-09
family O 0 6.931549778599333e-10
and O 0 1.566658053286929e-10
in O 0 6.488553028205502e-10
a O 0 7.932738910199078e-09
heterozygous O 0 2.2348501715896418e-08
state O 0 1.0559034757662289e-09
in O 0 2.397181120272762e-09
four O 0 6.473426239494984e-09
families O 0 2.1109432424282204e-08
. O 0 6.83532050516078e-07

Pendred B-Disease 1 0.9972527623176575
patients O 0 5.019472837375361e-07
in O 0 1.0453056198400645e-08
three O 0 9.707464165842339e-09
non O 0 2.5183192065014737e-06
- O 0 1.6776672055129893e-05
consanguineous O 0 2.4792698241071776e-05
families O 0 7.517125810707626e-10
were O 0 3.876709508965348e-10
shown O 0 2.2511947861403314e-10
to O 0 5.160767369005725e-10
be O 0 5.6569806616835194e-09
compound O 0 9.183887783592581e-08
heterozygotes O 0 2.237115381831245e-07
for O 0 2.6240265071919566e-08
L236P O 0 3.569775799405761e-05
and O 0 3.5243596130385413e-07
T416P O 0 0.0005053207278251648
. O 0 5.517921181308338e-06

In O 0 1.0422401430787431e-07
total O 0 2.8569450805093766e-08
, O 0 3.835890272085862e-09
one O 0 7.103879706704674e-09
or O 0 4.93941643142648e-09
both O 0 9.202537065711169e-10
of O 0 2.1037311892513344e-09
these O 0 1.3222738182161464e-10
mutations O 0 7.558449865996408e-09
were O 0 1.27955535056401e-09
found O 0 8.56098691937035e-10
in O 0 4.944844533838477e-10
nine O 0 1.3435277335105411e-09
of O 0 1.9398380679547245e-09
the O 0 1.710371400065469e-08
14 O 0 1.0541657502471935e-07
families O 0 1.3362194017929596e-08
analyzed O 0 2.176039060941548e-06
. O 0 2.076933924399782e-06

The O 0 1.2596395038144692e-07
identification O 0 5.893641485954504e-08
of O 0 5.971865846277069e-08
two O 0 8.796985362380383e-09
frequent O 0 7.181837418102077e-07
PDS B-Disease 1 0.9998108744621277
mutations O 0 4.6110756102279993e-07
will O 0 1.298124607806983e-09
facilitate O 0 3.0116862337337125e-09
the O 0 9.813446943951476e-09
molecular O 0 1.9110984794679098e-06
diagnosis O 0 0.00023410323774442077
of O 0 0.17821845412254333
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.002268825192004442

Insertional O 0 0.0006554048741236329
mutation O 0 1.8912180621555308e-06
by O 0 2.190884451636066e-08
transposable O 0 3.2912510505411774e-05
element O 0 4.715709110314492e-06
, O 0 1.2697756801571813e-07
L1 O 1 0.963664710521698
, O 0 2.882534033687989e-08
in O 0 1.3941735765854446e-08
the O 0 1.749740619061413e-07
DMD B-Disease 1 1.0
gene O 0 2.9691449299207306e-07
results O 0 2.618836525414281e-08
in O 0 2.52464733563329e-08
X B-Disease 1 0.9999066591262817
- I-Disease 1 0.98655104637146
linked I-Disease 1 0.9527361989021301
dilated I-Disease 1 0.9092935919761658
cardiomyopathy I-Disease 1 1.0
. O 0 0.0007575343479402363

X B-Disease 1 0.9999490976333618
- I-Disease 1 0.9999181032180786
linked I-Disease 1 0.9997972846031189
dilated I-Disease 1 0.9999958276748657
cardiomyopathy I-Disease 1 1.0
( O 0 0.0053840079344809055
XLDCM B-Disease 1 1.0
) O 0 8.637987036763661e-08
is O 0 7.392983114584695e-09
a O 0 1.9188416189308555e-08
clinical O 0 2.008511728490703e-06
phenotype O 0 7.412601917167194e-06
of O 0 5.314751092555525e-07
dystrophinopathy B-Disease 1 0.9601966142654419
which O 0 2.1543429262749214e-09
is O 0 4.43305336883526e-10
characterized O 0 1.0803128391856376e-09
by O 0 1.0737309930064498e-09
preferential O 0 2.7696808047039667e-06
myocardial B-Disease 1 1.0
involvement I-Disease 0 1.5889152564341202e-05
without O 0 5.5094481865580747e-08
any O 0 6.750509129460625e-08
overt O 0 6.344399480440188e-06
clinical O 0 0.00013073600712232292
signs O 0 5.3504027164308354e-06
of O 0 0.07958786189556122
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.01412483025342226

To O 0 8.717532296032005e-08
date O 0 6.137119612503739e-07
, O 0 5.1025521585756906e-09
several O 0 1.3575406354604524e-09
mutations O 0 3.970328066316142e-08
in O 0 1.1896147178447336e-08
the O 0 1.732896294015518e-06
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
gene O 1 0.9999662637710571
, O 0 0.0003512644034344703
DMD O 1 1.0
, O 0 1.9985462529348297e-07
have O 0 2.9240747601022576e-09
been O 0 3.791475577941128e-09
identified O 0 4.588665447613494e-09
in O 0 9.935465783428299e-10
patients O 0 1.1798274579533086e-09
with O 0 2.736319837381984e-09
XLDCM B-Disease 1 1.0
, O 0 4.407848308574103e-08
but O 0 3.97335631063811e-09
a O 0 4.981329571052129e-09
pathogenic O 0 1.1914721653738525e-08
correlation O 0 3.320701225106859e-08
of O 0 4.856072433057079e-09
these O 0 6.789409034979599e-10
cardiospecific O 0 1.2503758625825867e-05
mutations O 0 4.24524927211678e-07
in O 0 7.196852891411254e-08
DMD O 1 0.9999998807907104
with O 0 6.828255738611233e-09
the O 0 8.712576686775719e-07
XLDCM B-Disease 1 0.9999998807907104
phenotype O 0 8.135096868500113e-05
has O 0 3.369091672311697e-08
remained O 0 9.853644655777316e-08
to O 0 4.015778820587457e-09
be O 0 6.784379991131573e-08
elucidated O 0 2.2899164832779206e-05
. O 0 1.8352882307226537e-06

We O 0 8.740789780858904e-07
report O 0 1.640108138190044e-08
here O 0 2.5884085985694583e-09
the O 0 1.040636243843096e-09
identification O 0 1.9551718022370324e-09
of O 0 4.628820438057346e-09
a O 0 1.598970733596161e-08
unique O 0 1.2140314531450258e-08
de O 0 8.793816164143209e-07
novo O 0 2.064530417555943e-05
L1 O 0 9.318288357462734e-05
insertion O 0 4.433827882621699e-07
in O 0 5.542128977964467e-09
the O 0 1.1665365562407715e-08
muscle O 0 8.262792761115634e-08
exon O 0 5.0674630074354354e-06
1 O 0 3.0552951102436054e-06
in O 0 5.243033029955768e-08
DMD O 1 0.9999996423721313
in O 0 4.640101991526535e-08
three O 0 3.0529946570823085e-08
XLDCM B-Disease 1 0.9999510049819946
patients O 0 2.0727568994516332e-08
from O 0 1.981444519572051e-08
two O 0 1.0329914701401322e-08
unrelated O 0 5.65531081520021e-07
Japanese O 0 1.0200593578701955e-06
families O 0 8.795898764901722e-08
. O 0 8.653997269902902e-07

The O 0 2.842536446223676e-07
insertion O 0 1.8721713104241644e-06
was O 0 6.351345973598654e-07
a O 0 6.980859268423956e-08
5 O 0 9.409230727897011e-08
- O 0 3.63971039973876e-08
truncated O 0 2.2782854713909728e-08
form O 0 3.015031335706908e-09
of O 0 1.891162071387953e-08
human O 0 1.3505810692038267e-08
L1 O 0 1.0905761882895604e-05
inversely O 0 4.2198360006295843e-07
integrated O 0 1.9089276293016155e-07
in O 0 3.539251336448501e-09
the O 0 7.4452422005322205e-09
5 O 0 1.4942250459171191e-07
- O 0 2.64822688222921e-07
untranslated O 0 4.412000998854637e-05
region O 0 4.055877766973026e-08
in O 0 1.6381282996746904e-09
the O 0 4.113308360587098e-09
muscle O 0 1.6493562071673296e-08
exon O 0 1.2025839168927632e-06
1 O 0 2.733171413638047e-07
, O 0 3.101234546942777e-10
which O 0 3.526417699517559e-11
affected O 0 5.295881094768973e-11
the O 0 1.140267047450294e-10
transcription O 0 6.008492814402189e-09
or O 0 6.720762280032488e-10
the O 0 2.217427574890962e-09
stability O 0 3.7242756434352486e-08
of O 0 3.72927111413901e-09
the O 0 3.9814813668215265e-09
muscle O 0 3.8980583205727726e-09
form O 0 9.762345376529424e-10
of O 0 8.124948713827962e-09
dystrophin O 0 1.7991230549796455e-07
transcripts O 0 2.221852923867118e-08
but O 0 3.2058114496358314e-10
not O 0 2.348474748004037e-10
that O 0 1.4410862780867006e-10
of O 0 5.58710899767334e-09
the O 0 4.463355551820314e-08
brain O 0 9.776962542673573e-06
or O 0 9.851990512288467e-08
Purkinje O 0 0.0006994428695179522
cell O 0 1.1559866379684536e-06
form O 0 1.2946586913642477e-08
, O 0 6.923678075310136e-09
probably O 0 5.13854523376267e-08
due O 0 2.6779048312164377e-08
to O 0 1.4017855765047216e-09
its O 0 6.729882762179784e-10
unique O 0 1.32504152094981e-09
site O 0 1.842110641803174e-08
of O 0 6.076446368297184e-08
integration O 0 5.216323188506067e-06
. O 0 3.0054786748223705e-06

We O 0 3.998843851604761e-07
speculate O 0 8.456938758172328e-07
that O 0 4.689110766342708e-10
this O 0 5.784196455138613e-10
insertion O 0 3.362966793929445e-08
of O 0 1.6449641648819124e-08
an O 0 4.772585882051317e-09
L1 O 0 5.5508131481474265e-05
sequence O 0 3.2185340614887537e-08
in O 0 1.6600838037561516e-08
DMD O 1 1.0
is O 0 4.244963935917667e-09
responsible O 0 2.7066908714346027e-09
for O 0 1.28207333638386e-10
some O 0 8.958512404122487e-11
of O 0 5.571909600377012e-10
the O 0 6.482306358357448e-10
population O 0 3.3109329167224644e-10
of O 0 1.8918826505398556e-09
Japanese O 0 8.920722649463642e-08
patients O 0 8.657281114210491e-09
with O 0 9.135247225344756e-09
XLDCM B-Disease 1 0.9998766183853149
. O 0 1.1459258075774414e-06
. O 0 2.403636926828767e-06

Severe O 0 0.0013775493716821074
early O 0 0.0005945558659732342
- O 1 0.9978392720222473
onset O 1 1.0
obesity B-Disease 1 1.0
, O 0 0.3067646920681
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 0.00013593521725852042
red O 0 0.09524146467447281
hair O 1 0.7288066744804382
pigmentation O 1 0.9931215643882751
caused O 0 1.2204402992210817e-05
by O 0 8.335987899954489e-07
POMC O 1 0.9999755620956421
mutations O 0 6.342917458823649e-06
in O 0 6.783628947459874e-08
humans O 0 5.039271968598769e-07
. O 0 6.477208103206067e-07

Sequential O 0 1.0105211913469248e-05
cleavage O 0 1.0188548003498e-05
of O 0 1.6902264121654298e-07
the O 0 3.565379103065425e-08
precursor O 0 3.00606700420758e-07
protein O 0 3.6372608036572274e-08
pre O 0 2.9574273412436014e-06
- O 0 9.70053588389419e-06
pro O 0 0.0001290522632189095
- O 0 0.00011052303307224065
opiomelanocortin O 0 0.0028841784223914146
( O 0 4.310803092266724e-07
POMC O 0 0.00011841183732030913
) O 0 6.535731067458528e-09
generates O 0 1.5706898892631216e-08
the O 0 1.371899305269153e-08
melanocortin O 0 1.1802639164670836e-05
peptides O 0 3.169983813222643e-07
adrenocorticotrophin O 0 3.5313187254359946e-05
( O 0 1.5712883794094523e-07
ACTH O 0 8.172749403456692e-06
) O 0 2.3142955996036108e-08
, O 0 2.6910123906986883e-08
melanocyte O 0 1.243528640770819e-05
- O 0 5.887781298952177e-06
stimulating O 0 6.20999458078586e-07
hormones O 0 3.049246899422542e-08
( O 0 6.580310962789326e-09
MSH O 0 4.669997906603385e-06
) O 0 1.9228048042663204e-09
alpha O 0 1.2040186625483784e-08
, O 0 1.35072661389124e-10
beta O 0 7.3769959030300924e-09
and O 0 3.240570589646552e-10
gamma O 0 2.8032745902351053e-08
as O 0 6.499824567463008e-10
well O 0 1.0867836630623628e-09
as O 0 2.4655419927910316e-09
the O 0 1.2565937623776335e-08
opioid O 0 3.0093106033746153e-06
- O 0 2.3494819743064e-06
receptor O 0 1.2715123602902167e-06
ligand O 0 2.571242930571316e-06
beta O 0 1.0906219358730596e-05
- O 0 1.595983121660538e-05
endorphin O 0 9.241320367436856e-05
. O 0 3.443943796810345e-06

While O 0 4.769403290083574e-07
a O 0 1.4307329365692567e-07
few O 0 1.4788004598642601e-08
cases O 0 1.1398745947133193e-08
of O 0 6.200165216796449e-07
isolated O 1 0.9994164705276489
ACTH B-Disease 1 1.0
deficiency I-Disease 1 1.0
have O 0 1.5175066891970346e-07
been O 0 1.2407681992954167e-07
reported O 0 5.183462192803745e-08
( O 0 1.2262485427072534e-07
OMIM O 0 0.04568033665418625
201400 O 0 5.914512257731985e-06
) O 0 1.384183767605407e-09
, O 0 1.3434354739771948e-09
an O 0 1.181181374931839e-08
inherited O 1 0.9999237060546875
POMC O 1 1.0
defect O 1 0.9999829530715942
has O 0 9.018838653673811e-08
not O 0 7.069371754653275e-09
been O 0 1.1720518777735833e-08
described O 0 3.235892265252005e-08
so O 0 1.2389823389469257e-08
far O 0 2.4562501721447916e-07
. O 0 1.1810731166406185e-06

Recent O 0 4.350830295152264e-06
studies O 0 6.466258923865098e-07
in O 0 2.310171964836627e-08
animal O 0 1.6293013160861847e-08
models O 0 8.501208625943946e-09
elucidated O 0 4.29193335094169e-07
a O 0 8.797572448315805e-09
central O 0 7.765699905348811e-08
role O 0 2.9539602763861694e-08
of O 0 4.939607833875925e-08
alpha O 0 2.4934704470069846e-06
- O 0 1.8171059537053225e-06
MSH O 0 5.6851498811738566e-05
in O 0 2.951734412448559e-09
the O 0 1.4143463067384232e-09
regulation O 0 5.159254357067766e-09
of O 0 2.317540825913511e-09
food O 0 8.230319759050531e-10
intake O 0 3.9333603041313836e-10
by O 0 4.121683896962658e-11
activation O 0 1.9614290636127407e-08
of O 0 4.09611757845596e-08
the O 0 1.8957346981096634e-07
brain O 0 6.847405165899545e-05
melanocortin O 0 0.0037604873068630695
- O 0 7.000378900556825e-06
4 O 0 7.913758963695727e-07
- O 0 2.7715725536836544e-07
receptor O 0 2.4958251287898747e-07
( O 0 7.276575342274327e-09
MC4 O 0 1.9019629689864814e-05
- O 0 5.686364374923869e-07
R O 0 5.669448341905081e-07
; O 0 1.4949590454449435e-09
refs O 0 1.0110586146083733e-07
3 O 0 5.403555647376379e-08
- O 0 1.9910217474716774e-08
5 O 0 4.293928768106525e-09
) O 0 6.046747824672849e-11
and O 0 2.0349945686892745e-11
the O 0 5.136942538008782e-10
linkage O 0 6.501771281364199e-07
of O 0 1.1706302416314429e-07
human O 0 8.941178748500533e-07
obesity B-Disease 1 1.0
to O 0 1.7671128560436955e-08
chromosome O 0 1.8674296370591037e-05
2 O 0 3.002728874434979e-07
in O 0 8.478275859147288e-10
close O 0 7.106752963892404e-09
proximity O 0 1.9315098853667223e-08
to O 0 1.1076711770030556e-09
the O 0 1.3546573640610404e-08
POMC O 0 3.651508450275287e-05
locus O 0 1.3792740674034576e-06
, O 0 5.123654278627043e-10
led O 0 8.489684510948337e-10
to O 0 9.235555376019278e-11
the O 0 6.263758400848474e-10
proposal O 0 9.797417988011148e-09
of O 0 7.065327878308381e-09
an O 0 2.299874291011861e-09
association O 0 2.3724558317894662e-08
of O 0 5.260452553557116e-07
POMC O 1 0.994394063949585
with O 0 1.7872773128146946e-07
human O 0 0.00019030459225177765
obesity B-Disease 1 1.0
. O 0 2.537036380090285e-05

The O 0 3.9667938267484715e-07
dual O 0 1.80654865289398e-06
role O 0 3.756401270038623e-07
of O 0 1.1903363201781758e-06
alpha O 0 0.00018815012299455702
- O 0 0.00015268984134308994
MSH O 0 0.1337721347808838
in O 0 1.6093368415681653e-08
regulating O 0 2.6111903750347665e-08
food O 0 3.0139044593369135e-09
intake O 0 6.412717912240851e-09
and O 0 1.6784953427162463e-09
influencing O 0 1.4435933053391636e-06
hair O 0 6.371223207679577e-06
pigmentation O 0 0.001812999602407217
predicts O 0 7.672166475458653e-07
that O 0 2.5657181934590767e-10
the O 0 2.620074157633212e-09
phenotype O 0 1.5321575119742192e-07
associated O 0 1.983674557948234e-09
with O 0 2.9558003267204924e-10
a O 0 3.6256108160159783e-07
defect O 0 0.4785901606082916
in O 0 1.0671210048940338e-07
POMC O 0 0.0009039604337885976
function O 0 1.1091621843206667e-08
would O 0 1.1586528403384477e-09
include O 0 1.8480864838466005e-08
obesity B-Disease 1 1.0
, O 0 8.510168214570513e-08
alteration O 0 0.0008495293441228569
in O 0 1.792777197806572e-06
pigmentation O 1 0.9991466999053955
and O 0 0.0003945409844163805
ACTH B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
. O 0 0.00011036663636332378

The O 0 4.731177796202246e-07
observation O 0 5.2439208957366645e-06
of O 0 4.186972830666491e-07
these O 0 2.5565030981056225e-08
symptoms O 0 3.300827302155085e-06
in O 0 6.713504063782239e-08
two O 0 2.7120355738929902e-08
probands O 0 0.0014019901864230633
prompted O 0 9.341065521084602e-08
us O 0 1.4156883665350506e-08
to O 0 3.171777729349401e-09
search O 0 6.197260482565525e-09
for O 0 1.6141779024536618e-09
mutations O 0 5.029583149962491e-08
within O 0 6.586491707594178e-08
their O 0 5.541179959323017e-08
POMC O 0 0.008097884245216846
genes O 0 3.712698344315868e-06
. O 0 1.1091706255683675e-06

Patient O 0 2.150171530956868e-05
1 O 0 3.915843990398571e-06
was O 0 2.229875235570944e-07
found O 0 1.4657531854922468e-09
to O 0 1.3014590516391422e-09
be O 0 3.333804565741616e-09
a O 0 1.8413096825042885e-08
compound O 0 2.031709556149508e-07
heterozygote O 0 3.6040441386830935e-07
for O 0 9.928323718710885e-10
two O 0 1.0495965208079383e-09
mutations O 0 1.3728626235831598e-08
in O 0 5.848286299681149e-09
exon O 0 8.141129796968016e-07
3 O 0 2.8589627731889777e-07
( O 0 2.4927846453692837e-08
G7013T O 0 2.6565778171061538e-05
, O 0 7.90331977640335e-09
C7133delta O 0 1.749040848153527e-06
) O 0 4.149372234696358e-10
which O 0 1.1132580274297865e-10
interfere O 0 1.2012563166408086e-09
with O 0 5.129264027403657e-11
appropriate O 0 3.566166473234489e-09
synthesis O 0 1.7532498475247849e-07
of O 0 2.8294192588873557e-07
ACTH O 0 1.3519334970624186e-05
and O 0 2.2121847109701775e-07
alpha O 0 4.828044620808214e-05
- O 0 5.176385093363933e-05
MSH O 0 0.0023348871618509293
. O 0 4.5103311094862875e-06

Patient O 0 3.30355906044133e-05
2 O 0 5.253431027085753e-06
was O 0 4.842496537094121e-07
homozygous O 0 4.250256324667134e-08
for O 0 1.389238279969618e-09
a O 0 1.3182686053880843e-08
mutation O 0 1.8321057382308936e-07
in O 0 2.8219432124387822e-08
exon O 0 1.0890795238083228e-05
2 O 0 3.647853418442537e-06
( O 0 7.320316797176929e-08
C3804A O 0 1.949432771652937e-05
) O 0 1.350704792457691e-08
which O 0 2.9542590596065565e-08
abolishes O 0 3.8635305827483535e-05
POMC O 0 0.0007296388503164053
translation O 0 4.142963371123187e-05
. O 0 1.0064742127724458e-05

These O 0 2.2920891851185843e-08
findings O 0 4.542168596799456e-08
represent O 0 1.379182545946378e-08
the O 0 7.470719154412109e-09
first O 0 5.624671395310088e-09
examples O 0 4.242203477389239e-09
of O 0 1.5785737161877478e-08
a O 0 3.134845485419646e-07
genetic B-Disease 1 1.0
defect I-Disease 1 0.9999986886978149
within O 0 1.6941478975240898e-07
the O 0 7.453870409790397e-08
POMC O 0 0.00031730480259284377
gene O 0 1.472130772839364e-08
and O 0 3.6948530346414543e-10
define O 0 1.2504014712533262e-08
a O 0 1.5205104730853236e-08
new O 0 6.770198979211273e-08
monogenic B-Disease 1 1.0
endocrine I-Disease 1 1.0
disorder I-Disease 1 0.9792848825454712
resulting O 0 1.3050745906184602e-07
in O 0 1.054133225153464e-08
early O 0 7.634316148141806e-07
- O 0 1.3054797818767838e-05
onset O 1 0.9999994039535522
obesity B-Disease 1 1.0
, O 0 0.11978748440742493
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.5931407688185573e-05
red O 0 0.0005117010441608727
hair O 0 0.004847286269068718
pigmentation O 1 0.9248234033584595
. O 0 4.553646249405574e-06
. O 0 6.382510036928579e-06

A O 0 1.4959296095184982e-05
European O 0 7.714148523518816e-06
multicenter O 0 0.0012129145907238126
study O 0 1.3291702316564624e-06
of O 0 1.9377444914425723e-05
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 2.3023228834517795e-07
classification O 0 5.72273347643204e-06
of O 0 3.554305862962792e-07
105 O 0 2.9812431989739707e-07
mutations O 0 2.664993026257889e-08
and O 0 5.612547648858879e-10
a O 0 7.251663269869368e-09
general O 0 2.2535083132879663e-08
system O 0 1.2677061178578697e-08
for O 0 3.0230180581014565e-09
genotype O 0 4.2342836081843416e-07
- O 0 1.5036955858249712e-07
based O 0 4.7199019803656483e-08
prediction O 0 3.608478209571331e-06
of O 0 7.90368289926846e-07
metabolic O 1 0.8402538299560547
phenotype O 0 0.00021548580843955278
. O 0 4.31966918768012e-06

Phenylketonuria B-Disease 1 0.9997093081474304
( O 0 5.192927710595541e-05
PKU B-Disease 1 0.999792754650116
) O 0 4.884602731181076e-07
and O 0 3.887724915330182e-07
mild B-Disease 1 1.0
hyperphenylalaninemia I-Disease 1 1.0
( O 1 0.9999988079071045
MHP B-Disease 1 1.0
) O 0 1.9160572151122324e-07
are O 0 1.6659392088058667e-08
allelic B-Disease 1 0.9997532963752747
disorders I-Disease 1 0.9999954700469971
caused O 0 1.7355987438349985e-06
by O 0 1.5054181901064112e-08
mutations O 0 2.334247710678028e-07
in O 0 5.8534981306479494e-09
the O 0 2.1575349506974817e-08
gene O 0 3.013779448224341e-08
encoding O 0 3.8608050090260804e-07
phenylalanine O 0 1.1072535016865004e-05
hydroxylase O 0 5.643514668918215e-05
( O 0 3.1892009246803354e-06
PAH O 1 0.999993085861206
) O 0 1.207875811815029e-06
. O 0 1.7603531432541786e-06

Previous O 0 5.656006578647066e-07
studies O 0 2.879572136293973e-08
have O 0 1.6601526819925994e-09
suggested O 0 1.946168914912505e-08
that O 0 5.264602087606818e-10
the O 0 3.620080679667126e-09
highly O 0 3.334817222366837e-08
variable O 0 1.7896272765938193e-06
metabolic O 1 0.9183082580566406
phenotypes O 0 0.00018448701302986592
of O 1 0.8911678791046143
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
correlate O 0 0.000332634401274845
with O 0 2.110821515088901e-05
PAH O 1 1.0
genotypes O 1 0.9996174573898315
. O 0 2.3306149159907363e-05

We O 0 6.031988846189051e-07
identified O 0 1.3365728079861583e-07
both O 0 9.256621247288876e-09
causative O 0 2.8348581508907955e-06
mutations O 0 6.563078045473958e-07
in O 0 8.415547370077547e-08
686 O 0 0.00011614528193604201
patients O 0 5.288136861736348e-08
from O 0 4.964950761632281e-08
seven O 0 3.666970016524829e-08
European O 0 7.559749519714387e-07
centers O 0 3.025575665560609e-07
. O 0 1.0649306432242156e-06

On O 0 1.4987076610850636e-06
the O 0 4.6743274140226276e-08
basis O 0 8.949165675176118e-08
of O 0 1.8508378829551475e-08
the O 0 8.407585738723355e-09
phenotypic O 0 4.230852539421903e-07
characteristics O 0 1.74541323616495e-08
of O 0 4.1400397776669706e-08
297 O 0 3.65572020655236e-07
functionally O 0 1.481188701291103e-05
hemizygous O 0 0.15619401633739471
patients O 0 3.238572077179924e-08
, O 0 2.5073032539069118e-09
105 O 0 2.6440925893211897e-08
of O 0 2.0464792083174643e-09
the O 0 1.7217411940606553e-09
mutations O 0 6.340969971319055e-09
were O 0 8.499065340394907e-10
assigned O 0 4.338830628114465e-09
to O 0 7.346956931719717e-10
one O 0 1.960661411004594e-09
of O 0 7.169667970430282e-09
four O 0 7.343122110370359e-09
arbitrary O 0 2.4196179992941325e-07
phenotype O 0 8.430812158621848e-06
categories O 0 1.4560592944690143e-06
. O 0 8.115889045257063e-07

We O 0 1.2846525976328849e-07
proposed O 0 8.201275392138996e-08
and O 0 3.854371932732192e-09
tested O 0 8.240503390766207e-09
a O 0 1.7661955231673687e-09
simple O 0 1.5310416268121685e-09
model O 0 1.7833986509785404e-09
for O 0 4.6142734078102876e-10
correlation O 0 3.651155466855016e-08
between O 0 4.1569254705109415e-08
genotype O 0 3.567377007129835e-06
and O 0 5.869051733498054e-08
phenotypic O 0 3.727298098965548e-05
outcome O 0 5.5228931159945205e-05
. O 0 6.8660669967357535e-06

The O 0 1.3401471505858353e-06
observed O 0 5.084766598884016e-07
phenotype O 0 1.7290630012212205e-06
matched O 0 5.872399810868956e-08
the O 0 1.6187509999099348e-08
predicted O 0 3.959766672778642e-06
phenotype O 0 1.0370473546572612e-06
in O 0 3.3079046168893456e-09
79 O 0 3.307918916561903e-08
% O 0 3.5860971969725597e-09
of O 0 6.495388671368119e-10
the O 0 1.421675888124696e-09
cases O 0 2.537265064717076e-09
, O 0 2.084018291270695e-09
and O 0 8.38121128055036e-10
in O 0 1.1104105412940157e-09
only O 0 1.2983870645300044e-09
5 O 0 1.0286954399418846e-08
of O 0 3.6668701408615334e-09
184 O 0 2.3730169829150327e-08
patients O 0 1.6743768593840969e-09
was O 0 1.9143671536880902e-08
the O 0 1.7015752140636664e-09
observed O 0 1.1334506666571542e-08
phenotype O 0 1.8490878161969704e-08
more O 0 2.7669882010639135e-11
than O 0 2.5388999236319876e-10
one O 0 4.686562804501193e-10
category O 0 1.2919058711702291e-08
away O 0 1.998927690038954e-09
from O 0 5.672017300284438e-10
that O 0 5.739347885835855e-10
expected O 0 1.407717462598157e-07
. O 0 6.47760316496715e-07

Among O 0 7.566933390990016e-07
the O 0 4.0420154334697145e-08
seven O 0 1.847779707020436e-08
contributing O 0 2.9201247642163253e-08
centers O 0 1.2308045249653787e-08
, O 0 1.35277955504165e-09
the O 0 4.05596134456232e-09
proportion O 0 3.240172219420856e-08
of O 0 9.234666364932309e-09
patients O 0 2.8632334281297744e-09
for O 0 1.626046963743022e-09
whom O 0 1.668263571730222e-08
the O 0 1.4189079244886216e-08
observed O 0 7.504741006414406e-08
phenotype O 0 3.249784583658766e-07
did O 0 3.2063147692440452e-09
not O 0 8.677726315298173e-10
match O 0 3.87511676080976e-08
the O 0 7.151352843237646e-09
predicted O 0 3.45519055144905e-07
phenotype O 0 6.67424373546055e-08
was O 0 3.0999366629202996e-08
4 O 0 1.993552345425087e-08
% O 0 6.0054681227939e-09
- O 0 1.8741914686870587e-08
23 O 0 1.260155624294157e-08
% O 0 1.2365105384049002e-08
( O 0 4.374545170549027e-09
P O 0 4.304215508454945e-06
< O 0 8.617236744612455e-06
. O 0 1.410607630702998e-08
0001 O 0 2.721952341744327e-06
) O 0 5.163544036790313e-10
, O 0 3.9494180148480496e-10
suggesting O 0 4.071152304163661e-09
that O 0 2.6927451934888325e-10
differences O 0 1.176495612043027e-08
in O 0 6.481601366736811e-10
methods O 0 1.2519592029747173e-09
used O 0 2.855367886578364e-10
for O 0 4.6279349796840563e-10
mutation O 0 2.1633494995398905e-08
detection O 0 2.1118912627571262e-06
or O 0 2.0234008957231708e-07
phenotype O 0 1.6111222066683695e-05
classification O 0 1.2732913319268846e-06
may O 0 5.012007697757781e-09
account O 0 3.7115643891638683e-10
for O 0 2.7114224754321015e-10
a O 0 3.083547195359415e-09
considerable O 0 3.079299659702883e-08
proportion O 0 4.489327665169185e-08
of O 0 6.042697719976786e-08
genotype O 0 5.525484448298812e-05
- O 0 0.0005199068691581488
phenotype O 0 0.0001838950120145455
inconsistencies O 0 3.488820948405191e-05
. O 0 5.366996902012033e-06

Our O 0 8.266479767371493e-07
data O 0 8.395314665676779e-08
indicate O 0 8.772860837780172e-08
that O 0 7.615945207817276e-09
the O 0 4.70748602765525e-07
PAH O 1 0.9999998807907104
- O 0 0.00010614982602419332
mutation O 0 5.932522526563844e-07
genotype O 0 1.1718215091605089e-06
is O 0 9.422134183978415e-10
the O 0 1.2953149663985641e-09
main O 0 6.728758705776272e-08
determinant O 0 1.4254474081099033e-06
of O 0 1.3143770516421682e-08
metabolic O 0 8.612334204372019e-05
phenotype O 0 2.3602099190611625e-06
in O 0 1.5238871498013395e-08
most O 0 3.9323740708141486e-08
patients O 0 4.008259111287771e-07
with O 0 0.00015163734497036785
PAH B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 1 0.9571893215179443

In O 0 1.419525830215207e-07
the O 0 2.7375740785373637e-08
present O 0 1.4185562946522623e-08
study O 0 1.488234246949105e-08
, O 0 2.996153325440787e-09
the O 0 6.888377424019154e-09
classification O 0 1.3279083077577525e-06
of O 0 8.156501394296356e-07
105 O 0 8.482437260681763e-05
PAH O 1 1.0
mutations O 0 1.0892059663092368e-06
may O 0 1.3762972095321402e-08
allow O 0 2.5770341416375686e-09
the O 0 8.779368343425631e-09
prediction O 0 9.88756710285088e-07
of O 0 1.6896292365231602e-08
the O 0 1.1417610856767624e-08
biochemical O 0 1.2552042107927264e-06
phenotype O 0 4.7092643740143103e-07
in O 0 4.719495017013742e-09
> O 0 1.3124877114023548e-06
10 O 0 3.803929260470795e-08
, O 0 2.054489023350925e-09
000 O 0 2.277755051238728e-08
genotypes O 0 3.6360543731461803e-07
, O 0 6.882069913949351e-10
which O 0 3.3103897401076665e-10
may O 0 1.4376990709052961e-09
be O 0 5.244837897322441e-10
useful O 0 1.0181249177065865e-09
for O 0 4.0593023387103244e-10
the O 0 4.226495153858423e-09
management O 0 6.58711982737259e-08
of O 0 1.0374379826316726e-06
hyperphenylalaninemia B-Disease 1 1.0
in O 0 4.807700406672666e-06
newborns O 0 5.521927050722297e-06
. O 0 1.3859645378033747e-06

Somatic O 0 0.18721050024032593
instability O 0 0.004043796565383673
of O 0 5.4480519793287385e-06
the O 0 5.787728241557488e-06
CTG O 1 0.9999204874038696
repeat O 0 2.2234899006434716e-05
in O 0 7.025152370943033e-08
mice O 0 7.720007033640286e-08
transgenic O 0 3.931264558332259e-08
for O 0 1.3433483214697617e-09
the O 0 3.299375066490029e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.07932937890291214
is O 0 1.927905373122485e-07
age O 0 6.1760694336499e-08
dependent O 0 7.282962233290391e-09
but O 0 2.1455745513598856e-10
not O 0 3.389294400690801e-10
correlated O 0 5.702784466876665e-09
to O 0 5.113656720290294e-10
the O 0 1.1287024648254373e-08
relative O 0 1.488159796281252e-06
intertissue O 0 1.9215838619857095e-05
transcription O 0 3.8264988688752055e-06
levels O 0 3.5090195638076693e-07
and O 0 1.7544107322464697e-07
proliferative O 1 0.6287150382995605
capacities O 0 5.00030982948374e-05
. O 0 9.66610878094798e-06

A O 0 0.00024377730733249336
( O 0 5.441961093310965e-06
CTG O 0 0.0015165269142016768
) O 0 7.65658398904634e-08
nexpansion O 0 1.0914832273556385e-05
in O 0 1.0979287701218254e-08
the O 0 3.231044587437282e-08
3 O 0 2.4867451884347247e-06
- O 0 1.2882063856523018e-05
untranslated O 1 0.8271786570549011
region O 0 4.404034825711278e-06
( O 0 1.2355727108115389e-07
UTR O 0 0.0005892248009331524
) O 0 5.08054620595999e-09
of O 0 1.637557467404349e-08
the O 0 1.1339939476329164e-07
DM O 1 0.9999998807907104
protein O 0 2.1812780914842733e-07
kinase O 0 2.135063112973512e-07
gene O 0 1.896754042718385e-08
( O 0 1.8036923066233612e-08
DMPK O 1 0.9949309229850769
) O 0 1.7870626090044084e-09
is O 0 7.566480220155825e-10
responsible O 0 8.706793508395094e-09
for O 0 1.9936361894679067e-08
causing O 1 0.9510514140129089
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999465942382812
DM B-Disease 1 1.0
) O 0 5.992528713250067e-06
. O 0 3.987635409430368e-06

Major O 0 0.006801485549658537
instability O 1 0.9997944235801697
, O 0 4.574232193021999e-08
with O 0 1.3654480879310427e-09
very O 0 5.320123896979112e-09
large O 0 9.10046527025088e-09
expansions O 0 1.3431164802568674e-07
between O 0 2.4761375172488442e-08
generations O 0 8.889500691111607e-09
and O 0 1.8512032184947458e-10
high O 0 4.906992145947697e-09
levels O 0 2.1907078373573086e-09
of O 0 9.016341451228982e-09
somatic O 0 0.00015245794202201068
mosaicism O 1 0.7452989220619202
, O 0 9.29040488983901e-09
is O 0 5.231342914413517e-09
observed O 0 4.165266886957397e-08
in O 0 1.5293991850739985e-08
patients O 0 5.3693032242563277e-08
. O 0 5.913503855481395e-07

There O 0 2.4514901042493875e-07
is O 0 1.9081552338207075e-08
a O 0 1.823853956750554e-08
good O 0 9.40917299629973e-09
correlation O 0 7.659461687126168e-08
between O 0 5.061357111202369e-09
repeat O 0 2.8765144932663134e-08
size O 0 1.4450263208232172e-08
( O 0 3.7932839092036374e-09
at O 0 1.4712998819277345e-08
least O 0 2.167891866022842e-09
in O 0 2.0611219397892455e-09
leucocytes O 0 1.2478424196160631e-06
) O 0 1.7984972400242327e-09
, O 0 2.1489749979508588e-09
clinical O 0 9.066182116157506e-08
severity O 0 2.481947376509197e-06
and O 0 1.4885579879830857e-08
age O 0 9.997576171372202e-07
of O 0 1.3218069625509088e-06
onset O 1 0.9872341752052307
. O 0 1.173404416476842e-05

The O 0 8.658266597194597e-05
trinucleotide O 1 0.9999901056289673
repeat O 0 8.82449239725247e-05
instability O 0 0.00015970011008903384
mechanisms O 0 2.056714947684668e-06
involved O 0 3.708582312356157e-07
in O 0 1.8898730331784463e-06
DM B-Disease 1 1.0
and O 0 2.918088171099953e-07
other O 0 4.8284967135714396e-08
human O 0 4.23225083068246e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 3.6678233783504766e-08
unknown O 0 5.954979769740021e-06
. O 0 9.472467468185641e-07

We O 0 1.4833366321909125e-06
studied O 0 6.2110289036354516e-06
somatic O 0 0.00014534873480442911
instability O 0 7.600965091114631e-06
by O 0 8.215863545046886e-09
measuring O 0 3.1448216759599745e-06
the O 0 1.0414294138172409e-07
CTG O 0 3.6401670513441786e-05
repeat O 0 7.576177551982255e-08
length O 0 1.1687078860234124e-08
at O 0 3.75133701879804e-09
several O 0 1.7916725048028326e-10
ages O 0 1.6616954479076185e-09
in O 0 2.5300536665717743e-10
various O 0 1.156352347209122e-09
tissues O 0 5.067223085575279e-08
of O 0 6.445043254643679e-08
transgenic O 0 2.7830517410620814e-06
mice O 0 8.030416154269915e-08
carrying O 0 7.1685191116444e-09
a O 0 5.644168865615029e-08
( O 0 2.059758230643638e-07
CTG O 0 0.00010070122516481206
) O 0 1.5671528075245078e-08
55expansion O 0 3.983842361776624e-06
surrounded O 0 2.712273428073786e-08
by O 0 1.1844587533005324e-09
45 O 0 6.740190627851916e-08
kb O 0 1.2524515113909729e-06
of O 0 1.6761191545811016e-08
the O 0 5.274840120250701e-08
human O 0 1.8657119653653353e-06
DM B-Disease 1 1.0
region O 0 6.326449238258647e-06
, O 0 7.721004280369925e-09
using O 0 1.544284167209753e-08
small O 0 1.160652232101711e-07
- O 0 8.671395903547818e-07
pool O 0 1.2733253242913634e-06
PCR O 0 6.775198926334269e-06
. O 0 1.6959145341388648e-06

These O 0 2.2331099103212182e-07
mice O 0 3.800426782163413e-07
have O 0 2.3101707213868394e-09
been O 0 3.197886178085696e-09
shown O 0 7.101993437785836e-10
to O 0 8.91465956609494e-10
reproduce O 0 2.7459714502242605e-09
the O 0 1.383160430634689e-08
intergenerational O 0 1.8451687537890393e-06
and O 0 2.0253828836303e-08
somatic O 0 0.0010449403198435903
instability O 0 0.00010220566764473915
of O 0 2.5864417807497375e-07
the O 0 1.565444591733467e-07
55 O 0 3.5934367588197347e-06
CTG O 0 0.00032013433519750834
repeat O 0 2.3079815036908258e-07
suggesting O 0 2.3426434125894957e-08
that O 0 3.1309160819503745e-10
surrounding O 0 4.362205707764133e-09
sequences O 0 2.1472048583603964e-09
and O 0 9.222176494683154e-11
the O 0 1.0114820092610444e-09
chromatin O 0 3.886642616635072e-07
environment O 0 2.3026098361356162e-08
are O 0 4.530431307880889e-10
involved O 0 1.3823139077828728e-08
in O 0 3.6218644083874096e-08
instability O 0 8.400645310757682e-05
mechanisms O 0 2.310113086423371e-05
. O 0 9.481050255999435e-06

As O 0 4.982396717423399e-07
observed O 0 1.612960573993405e-07
in O 0 2.218172090451276e-09
some O 0 5.074403675031647e-10
of O 0 4.211631488004741e-09
the O 0 8.873542789444855e-09
tissues O 0 1.0745494449793114e-07
of O 0 3.4258746381965466e-06
DM B-Disease 1 1.0
patients O 0 2.3479319679609034e-06
, O 0 3.625643119065103e-09
there O 0 1.4826745386997686e-09
is O 0 5.70099800700774e-10
a O 0 1.8059324036201474e-09
tendency O 0 8.515749883031276e-09
for O 0 7.173713290065109e-10
repeat O 0 2.9237195775522196e-08
length O 0 1.564560392353087e-08
and O 0 3.925365366086453e-09
somatic O 0 2.9183211154304445e-06
mosaicism O 0 8.19453998701647e-06
to O 0 6.54528375942931e-10
increase O 0 4.0572281645445685e-10
with O 0 6.994951146088724e-11
the O 0 4.018046340092951e-09
age O 0 2.179647395905704e-08
of O 0 1.1716696945995864e-08
the O 0 5.077817277765462e-08
mouse O 0 3.2139014365384355e-06
. O 0 1.8565250456958893e-06

Furthermore O 0 6.120057605585316e-06
, O 0 7.039275118359001e-08
we O 0 1.1222709872527048e-08
observed O 0 1.4331522635302463e-08
no O 0 3.4049636443711506e-09
correlation O 0 2.857637326769691e-08
between O 0 6.1676388440901064e-09
the O 0 1.425967521839766e-08
somatic O 0 4.448950676305685e-06
mutation O 0 9.664915978646604e-07
rate O 0 2.1644498815476254e-07
and O 0 1.871640797901364e-08
tissue O 0 6.027318249834934e-06
proliferation O 0 0.00011487158189993352
capacity O 0 1.743588541103236e-06
. O 0 9.934429954228108e-07

The O 0 1.8520262301535695e-06
somatic O 0 0.00018339944654144347
mutation O 0 3.450778876867844e-06
rates O 0 2.8057510093049132e-08
in O 0 6.154908804845149e-10
different O 0 2.0254156685162172e-10
tissues O 0 5.1597366379496634e-09
were O 0 5.946627079644884e-10
also O 0 2.394410780759415e-10
not O 0 1.3267123510907197e-10
correlated O 0 3.841769569135067e-09
to O 0 4.1007258699821136e-10
the O 0 5.83421488897784e-09
relative O 0 4.838208042201586e-06
inter O 1 0.998619794845581
- O 0 2.7490035790833645e-05
tissue O 0 5.449582545224985e-07
difference O 0 4.1777269643716863e-08
in O 0 1.4979152640481885e-10
transcriptional O 0 1.1506676500516733e-08
levels O 0 5.488057785996148e-10
of O 0 3.892551003747968e-10
the O 0 4.029295785912268e-10
three O 0 4.2638115260729137e-10
genes O 0 2.087817918550172e-09
( O 0 5.913861844675239e-09
DMAHP O 0 0.3546164929866791
, O 0 8.320787259208373e-08
DMPK O 0 0.1439865380525589
and O 0 3.1114403498122556e-08
59 O 0 6.898661126797379e-07
) O 0 2.6164086452951096e-09
surrounding O 0 4.074999537806434e-08
the O 0 3.221850519707914e-08
repeat O 0 1.3360736375034321e-06
. O 0 3.638607211087219e-07
. O 0 1.2576172139233677e-06

A O 0 6.642799689871026e-06
novel O 0 1.1687812957461574e-06
missense O 0 1.6282334399875253e-05
mutation O 0 1.6525875707884552e-06
in O 0 1.3929136954971e-08
patients O 0 8.429358544503884e-09
from O 0 1.3631717976636537e-08
a O 0 3.6173256034999213e-07
retinoblastoma B-Disease 0 0.02337210439145565
pedigree O 0 5.145752311364049e-06
showing O 0 9.23262675200931e-08
only O 0 1.0735391242633341e-08
mild O 0 6.544717507495079e-06
expression O 0 3.048171492991969e-07
of O 0 2.699706271869218e-07
the O 0 9.577757964507327e-07
tumor B-Disease 1 0.7254133820533752
phenotype O 0 0.00029495995840989053
. O 0 5.0404346438881475e-06

We O 0 3.2262542504213343e-07
have O 0 4.163803524193099e-09
used O 0 6.96622581841666e-09
single O 0 9.587709293157332e-09
strand O 0 9.246495835668611e-08
conformation O 0 2.6602599234593072e-08
polymorphism O 0 1.759357459718558e-08
analysis O 0 2.356035810890944e-09
to O 0 1.1118664877685092e-09
study O 0 1.2760756007423879e-08
the O 0 1.1332151217402497e-08
27 O 0 5.4548351613448176e-08
exons O 0 9.406394951838593e-08
of O 0 5.509224632049836e-09
the O 0 8.282070140808173e-09
RB1 O 0 5.239057372818934e-06
gene O 0 2.5194557551344587e-09
in O 0 2.0049827076373816e-10
individuals O 0 1.199829124942653e-10
from O 0 5.041787876081116e-09
a O 0 1.4492307798263937e-07
family O 0 6.201307201081363e-08
showing O 0 3.645219948111844e-08
mild O 0 6.456033133872552e-06
expression O 0 5.34423008957674e-07
of O 0 5.311832751431211e-07
the O 0 1.1867431339851464e-06
retinoblastoma B-Disease 0 0.4745950996875763
phenotype O 0 0.004137463867664337
. O 0 7.16635940989363e-06

In O 0 1.7580786959570105e-07
this O 0 8.462269107667453e-09
family O 0 6.147790276855858e-09
affected O 0 1.5085417359728126e-09
individuals O 0 4.118000662689525e-10
developed O 0 3.6562570926435e-07
unilateral B-Disease 1 0.9999991655349731
tumors I-Disease 1 1.0
and O 0 6.330217274808092e-07
, O 0 1.503013891124283e-08
as O 0 1.7002970142954155e-09
a O 0 3.3766103246790635e-09
result O 0 8.893909608786998e-09
of O 0 9.884869811571662e-09
linkage O 0 7.349555630753457e-07
analysis O 0 5.048863727097341e-08
, O 0 4.180515045248967e-09
unaffected O 0 1.0578315112752534e-07
mutation O 0 3.635561540704657e-08
carriers O 0 1.0633131708459587e-08
were O 0 2.807789334369204e-09
also O 0 1.0584643161948293e-09
identified O 0 6.270599151037004e-09
within O 0 9.486316621121205e-09
the O 0 6.356957271691499e-08
pedigree O 0 6.132735961728031e-06
. O 0 2.5906408609444043e-06

A O 0 5.664795480697649e-06
single O 0 1.8613599195305142e-07
band O 0 5.879561371102682e-08
shift O 0 3.610077570215253e-08
using O 0 1.73711356410422e-08
SSCP O 1 0.785378098487854
was O 0 9.639474001232884e-07
identified O 0 3.976421325546653e-08
in O 0 4.307693757255038e-09
exon O 0 5.042214183959004e-07
21 O 0 1.7885707137565987e-08
which O 0 2.720539626910323e-10
resulted O 0 3.599700315604082e-09
in O 0 1.7558233755821107e-09
a O 0 5.9236075600210825e-08
missense O 0 4.458524472283898e-06
mutation O 0 4.5031782747173565e-07
converting O 0 5.686483746103477e-07
a O 0 4.172495380316832e-07
cys O 0 0.0001293284585699439
- O 0 2.0394978491822258e-05
- O 0 8.995799362310208e-06
> O 0 8.037961379159242e-06
arg O 0 2.0082895844097948e-06
at O 0 6.555784182182833e-08
nucleotide O 0 7.652189992768399e-08
position O 0 5.655731882825421e-08
28 O 0 2.725393599689596e-08
in O 0 1.9534869277748612e-09
the O 0 3.460908359897985e-08
exon O 0 2.0912577383569442e-05
. O 0 1.9854562651744345e-06

The O 0 1.866687284746149e-06
mutation O 0 3.6105157050769776e-06
destroyed O 0 2.7124083317175973e-06
an O 0 6.381387152032403e-08
NdeI O 0 2.737685827014502e-05
restriction O 0 1.0972672725984012e-06
enzyme O 0 2.6101753292095964e-07
site O 0 4.4000285015499685e-07
. O 0 5.164249046174518e-07

Analysis O 0 2.561653218435822e-07
of O 0 9.306849335644074e-08
all O 0 1.1352573991985082e-08
family O 0 8.36053892783184e-09
members O 0 4.318888302545787e-10
demonstrated O 0 2.3902411161458303e-09
that O 0 3.3952729516784075e-10
the O 0 6.738414715101726e-09
missense O 0 1.581336164235836e-06
mutation O 0 7.371105539277778e-07
co O 0 2.0569608238929504e-07
- O 0 4.638367840925639e-07
segregated O 0 1.820041894973201e-08
with O 0 8.76684280726181e-11
patients O 0 1.8473030882759645e-09
with O 0 1.3456260994360036e-08
tumors B-Disease 1 1.0
or O 1 0.9327831268310547
who O 0 6.670420589216519e-06
, O 0 5.002676939369621e-09
as O 0 8.672911278040374e-10
a O 0 1.193213639005819e-09
result O 0 3.2933620275343856e-09
of O 0 4.5837844631080316e-09
linkage O 0 1.0868882327486062e-07
analysis O 0 8.445773858056782e-09
had O 0 6.9900503163466965e-09
been O 0 2.540092802760796e-09
predicted O 0 3.483863508790819e-08
to O 0 1.7597864276908126e-09
carry O 0 5.648484346920668e-09
the O 0 1.2807089433408692e-07
predisposing O 0 2.970026253024116e-05
mutation O 0 1.2488741958804894e-05
. O 0 2.394857574472553e-06

These O 0 3.1680734480232786e-08
observations O 0 4.0700521708458837e-07
point O 0 1.1559094446056406e-06
to O 0 6.9528587332001734e-09
another O 0 3.67990402594387e-08
region O 0 1.5652639717700367e-07
of O 0 3.1390392507546494e-08
the O 0 4.9997794349110336e-08
RB1 O 0 2.875205063901376e-05
gene O 0 1.1768658936262e-08
where O 0 1.6845024264355857e-09
mutations O 0 1.7002385055420177e-09
only O 0 1.3784395846982989e-10
modify O 0 1.4756271760063555e-09
the O 0 7.953035452423762e-10
function O 0 2.080114525071508e-09
of O 0 9.858561744735539e-10
the O 0 1.2552947570299011e-09
gene O 0 1.8762651432524535e-09
and O 0 2.614202465611726e-10
raise O 0 4.751205651132295e-09
important O 0 3.965543005080008e-09
questions O 0 9.44836031635532e-09
for O 0 1.5558047072872228e-09
genetic O 0 1.89333178468587e-07
counseling O 0 1.7935034790639293e-08
in O 0 7.035255711329569e-10
families O 0 2.182057728949971e-10
with O 0 1.6255251311658725e-10
these O 0 2.446214786289147e-09
distinctive O 0 1.7199474200424447e-07
phenotypes O 0 4.823673407372553e-06
. O 0 4.3368348201511253e-07
. O 0 2.6011871341324877e-06

Maternal B-Disease 0 0.0006393440417014062
disomy I-Disease 1 0.6439352631568909
and O 0 8.99274309631437e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 8.322917710756883e-05
with O 0 2.4236175732994525e-08
gamete O 0 4.748788705910556e-05
complementation O 0 0.1110277846455574
in O 0 9.648062793132794e-09
a O 0 1.4157235384004707e-08
case O 0 6.071348934710841e-08
of O 0 9.982316129253377e-08
familial O 0 0.00013274136290419847
translocation O 0 0.09439262002706528
( O 0 1.6767610588885873e-07
3 O 0 7.941065973682271e-07
; O 0 3.857777208793323e-09
15 O 0 2.0891294028047014e-08
) O 0 2.0800947631016697e-09
( O 0 7.3952821644240885e-09
p25 O 0 2.88205046672374e-06
; O 0 1.5604417313852537e-08
q11 O 0 7.230918072309578e-06
. O 0 1.5847852807837626e-08
2 O 0 5.235393132352328e-07
) O 0 5.0054662636966896e-08
. O 0 5.156817337592656e-07

Maternal B-Disease 0 0.47765448689460754
uniparental I-Disease 1 0.9999972581863403
disomy I-Disease 1 0.999998927116394
( I-Disease 0 0.00013913183647673577
UPD I-Disease 1 1.0
) I-Disease 0 3.220173283580152e-08
for I-Disease 0 6.511195138614312e-09
chromosome I-Disease 0 1.964576313184807e-06
15 I-Disease 0 1.156692608361709e-08
is O 0 2.856217484747958e-10
responsible O 0 5.929072233179511e-10
for O 0 1.9529569628140564e-10
an O 0 5.48151968260413e-10
estimated O 0 1.0580854414854457e-08
30 O 0 6.326038803905476e-09
% O 0 2.9699751546985453e-09
of O 0 7.849786931579672e-10
cases O 0 1.966593776714376e-09
of O 0 2.0303357359807706e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.9999994039535522
PWS B-Disease 1 1.0
) O 0 1.2494222573877778e-05
. O 0 9.849228263192344e-06

We O 0 4.0992290450958535e-07
report O 0 1.490956158534118e-08
on O 0 1.1846695180395272e-08
an O 0 3.1791533294800445e-10
unusual O 0 1.3907786033939828e-09
case O 0 2.218198602577104e-08
of O 0 3.54088065535052e-08
maternal B-Disease 0 1.9933356725232443e-06
disomy I-Disease 0 0.4575132727622986
15 I-Disease 0 7.856952493057179e-07
in O 0 1.0646083126175654e-07
PWS B-Disease 1 1.0
that O 0 2.5081068333321355e-09
is O 0 1.7739404389871538e-09
most O 0 2.2412253997128317e-10
consistent O 0 1.6215095932636814e-09
with O 0 4.148832319361695e-11
adjacent O 0 4.688051191692466e-08
- O 0 1.5207794490379456e-07
1 O 0 5.955088795417396e-07
segregation O 0 6.527785245680207e-08
of O 0 1.5672356745710658e-09
a O 0 1.0636539649055976e-08
paternal O 0 4.713024850389047e-07
t O 0 1.5980033651885606e-07
( O 0 1.4542197668276913e-08
3 O 0 9.28746715089801e-08
; O 0 1.265562432628542e-09
15 O 0 1.1855012971295764e-08
) O 0 1.2671156346399925e-09
( O 0 4.9940012125659905e-09
p25 O 0 1.9660683392430656e-06
; O 0 5.686014770134307e-09
q11 O 0 4.307048584450968e-06
. O 0 3.304518436664239e-09
2 O 0 2.815223254515331e-08
) O 0 2.409598076624775e-10
with O 0 2.1249262072142727e-10
simultaneous O 0 1.39586504133149e-07
maternal O 0 3.268550472057541e-06
meiotic O 0 0.0002623848558869213
nondisjunction O 0 0.001315367640927434
for O 0 7.314845333894482e-07
chromosome O 0 0.000646438857074827
15 O 0 2.8116282919654623e-06
. O 0 9.75328703134437e-07

The O 0 1.669160155870486e-06
patient O 0 1.3762559092356241e-06
( O 0 5.360339372373346e-08
J O 0 1.2253032764419913e-05
. O 0 9.083418461841575e-09
B O 0 3.655573834748793e-07
. O 0 3.971361850485522e-10
) O 0 1.1929446319669523e-10
, O 0 8.564805115129914e-11
a O 0 8.182049482385878e-10
17 O 0 3.786604363398283e-09
- O 0 7.303285531889969e-09
year O 0 6.169450728066295e-09
- O 0 1.246423124712237e-07
old O 0 7.452889150272313e-08
white O 0 3.933392278554493e-09
male O 0 1.3627706740848566e-09
with O 0 3.162545780810433e-10
PWS B-Disease 1 1.0
, O 0 3.999956632583235e-08
was O 0 1.6670713876010268e-07
found O 0 1.4610080922849988e-09
to O 0 7.841571836308958e-10
have O 0 7.689741066130296e-10
47 O 0 3.8327474527477534e-08
chromosomes O 0 3.465338904717896e-09
with O 0 2.6948518416780587e-10
a O 0 5.276490000483136e-08
supernumerary O 0 0.00018759894010145217
, O 0 2.0043730231122936e-08
paternal O 0 4.085197815584252e-06
der O 0 0.4565674960613251
( O 0 2.0314454118874892e-08
15 O 0 5.229596755640387e-09
) O 0 6.620753945085767e-11
consisting O 0 6.184973366796243e-11
of O 0 2.711639801589172e-10
the O 0 1.242735359063829e-09
short O 0 1.550183448273401e-08
arm O 0 4.743936585782649e-07
and O 0 3.14148151936422e-09
the O 0 4.77233399465149e-08
proximal O 0 0.16805610060691833
long O 0 5.415585633272713e-07
arm O 0 1.5616408290952677e-06
of O 0 1.680527930147946e-07
chromosome O 0 4.854204235016368e-06
15 O 0 7.048653571928298e-08
, O 0 4.322755930985522e-09
and O 0 2.0770350772636448e-08
distal O 0 0.002596693579107523
chromosome O 1 0.8208044171333313
arm O 0 0.0027883558068424463
3p O 1 0.998422384262085
. O 0 1.5836658349144273e-05

The O 0 4.659596470446559e-06
t O 0 1.1450256351963617e-06
( O 0 3.24820383923452e-08
3 O 0 9.803741107816677e-08
; O 0 1.4290053584886664e-09
15 O 0 4.078753335079455e-09
) O 0 2.183231651020634e-10
was O 0 2.439133339748878e-09
present O 0 1.01713061584352e-10
in O 0 1.0255089832877928e-10
the O 0 4.1633727021483935e-10
balanced O 0 5.24546095448386e-09
state O 0 8.218429270456795e-10
in O 0 1.118624526341705e-09
the O 0 9.86153736448614e-09
patients O 0 1.3533893117312346e-08
father O 0 4.8620432124835133e-08
and O 0 1.4747246979140982e-08
a O 0 2.105193061652244e-06
sister O 0 2.281006527482532e-05
. O 0 6.294066679402022e-06

Fluorescent O 0 3.4533102734712884e-05
in O 0 3.023074839347828e-07
situ O 0 5.499806775333127e-06
hybridization O 0 1.169047223470443e-07
analysis O 0 1.1768232610620544e-08
demonstrated O 0 7.594200823746178e-09
that O 0 9.84751058474842e-10
the O 0 1.5163392674821807e-07
PWS B-Disease 1 1.0
critical O 0 8.530304330633953e-05
region O 0 3.038500153706991e-06
resided O 0 2.1811241879277077e-07
on O 0 6.297879551198093e-09
the O 0 1.605001465065925e-09
derivative O 0 1.1187044890448306e-07
chromosome O 0 3.904638674612215e-07
3 O 0 8.433185705314372e-09
and O 0 6.398343660452e-11
that O 0 3.3218743727969624e-11
there O 0 3.5444583379451444e-10
was O 0 9.15605813389675e-09
no O 0 1.1131248145446193e-09
deletion O 0 4.8605318880845516e-08
of O 0 1.3130113885040373e-08
the O 0 8.252681027443032e-08
PWS B-Disease 1 1.0
region O 0 4.816952241526451e-06
on O 0 1.1942483979510143e-07
the O 0 8.964058828553334e-09
normal O 0 1.0223013546806214e-08
pair O 0 4.221926364067485e-09
of O 0 1.2555755546372893e-08
15s O 0 3.640783916125656e-06
present O 0 6.440423305775766e-08
in O 0 1.5775178496824083e-07
J O 0 0.000142881297506392
. O 0 3.916217337973649e-06

B O 0 0.008150612004101276
. O 0 9.28708104765974e-05

Methylation O 0 1.6838805549923563e-06
analysis O 0 2.3061244291966432e-07
at O 0 2.856537264506187e-07
exon O 0 1.2267661304576905e-06
alpha O 0 4.299909903693333e-07
of O 0 1.319181652803536e-08
the O 0 1.0012191964392514e-08
small O 0 7.904212395715149e-08
nuclear O 0 0.00010446485975990072
ribonucleoprotein O 0 0.011238401755690575
- O 0 2.847696578101022e-06
associated O 0 1.1376671693597018e-07
polypeptide O 0 9.161332855001092e-06
N O 0 1.974649421754293e-06
( O 0 1.964300722079315e-08
SNRPN O 0 2.3809296180843376e-05
) O 0 1.0339726852492959e-09
gene O 0 1.7736458968187208e-09
showed O 0 4.658569086046782e-10
a O 0 7.206283347827025e-10
pattern O 0 1.183734354981425e-08
characteristic O 0 1.673790350764648e-08
of O 0 4.97942975741239e-09
only O 0 1.8476977725612187e-09
the O 0 8.948735974456667e-09
maternal O 0 4.863086928708071e-07
chromosome O 0 9.68467429629527e-06
15 O 0 5.654177925862314e-07
in O 0 1.762755914569425e-07
J O 0 0.00015346225700341165
. O 0 3.817189735855209e-06

B O 0 0.006302223540842533
. O 0 3.363872747286223e-05

Maternal B-Disease 0 0.0031505839433521032
disomy I-Disease 1 0.9505413174629211
was O 0 5.457740371639375e-06
confirmed O 0 4.220479254968268e-08
by O 0 3.1916891352068433e-09
polymerase O 0 8.906134212338657e-07
chain O 0 4.7248832402146945e-08
reaction O 0 5.692938565005079e-09
analysis O 0 6.959572473874687e-09
of O 0 1.9295804065677657e-08
microsatellite O 0 3.764925850191503e-06
repeats O 0 7.8399786218597e-08
at O 0 2.6176980583159093e-08
the O 0 1.197598820112944e-08
gamma O 0 1.291080252485699e-06
- O 0 1.4908443972672103e-06
aminobutyric O 0 5.516594683285803e-06
acid O 0 1.8669848600438854e-07
receptor O 0 4.755601139549981e-07
beta3 O 0 2.785058768495219e-06
subunit O 0 2.827848447850556e-06
( O 0 1.1184398829300335e-07
GABRB3 O 0 0.00028480670880526304
) O 0 5.280552954900486e-07
locus O 0 2.6869440262089483e-05
. O 0 1.6488628489241819e-06

A O 0 8.243549382314086e-05
niece O 0 2.6763715140987188e-05
( O 0 8.124548855903413e-08
B O 0 3.165583621012047e-06
. O 0 2.8737709989457016e-09
B O 0 1.5866308444856259e-07
. O 0 2.5892518684678123e-10
) O 0 1.103003036129202e-10
with O 0 5.7988634727390576e-11
45 O 0 1.0329836541700388e-08
chromosomes O 0 3.2661129356625906e-09
and O 0 9.901106323706443e-11
the O 0 1.5513687001700305e-09
derivative O 0 3.497766840609984e-07
3 O 0 4.6838415812544554e-08
but O 0 4.4424661171937885e-10
without O 0 8.395915629400008e-10
the O 0 1.0656765248029387e-08
der O 0 0.008818899281322956
( O 0 2.7632214738559924e-08
15 O 0 3.2071849176418255e-08
) O 0 7.38220040652493e-10
demonstrated O 0 1.863823984038504e-09
a O 0 4.045052293122353e-09
phenotype O 0 8.392049011263225e-08
consistent O 0 6.430085353059667e-09
with O 0 2.1946254535887277e-10
that O 0 7.336594665119378e-10
reported O 0 1.234467461586064e-08
for O 0 1.106003910678055e-08
haploinsufficiency O 0 7.085515971994027e-05
of O 0 5.172458713786909e-06
distal O 1 0.6275898814201355
3 O 0 0.00010843951167771593
p O 0 0.0001417497987858951
. O 0 6.457905328716151e-06

Uniparental B-Disease 1 1.0
disomy I-Disease 1 0.9999815225601196
associated O 0 1.2987342188353068e-06
with O 0 2.996686632172896e-08
unbalanced O 0 0.0006123132188804448
segregation O 0 1.7822925656219013e-05
of O 0 3.1569567227052175e-07
non O 0 2.5020623070304282e-05
- O 0 4.250900383340195e-05
Robertsonian O 0 0.08755717426538467
translocations O 0 1.3061373465461656e-05
has O 0 8.800559392341256e-09
been O 0 1.1080177886313436e-09
reported O 0 6.371992378184643e-10
previously O 0 9.84848758101009e-10
but O 0 1.3711393131998761e-10
has O 0 1.5392923047308216e-10
not O 0 2.1289019158654554e-10
, O 0 1.6116820378275776e-10
to O 0 4.255475971604028e-10
our O 0 1.2964371798318552e-09
knowledge O 0 2.1911517933403957e-08
, O 0 2.026970147284146e-09
been O 0 1.52786772122937e-09
observed O 0 4.589217006412127e-09
in O 0 6.277704467372303e-10
a O 0 2.028851042723545e-08
case O 0 5.702133876184234e-07
of O 0 4.4968451220483985e-06
PWS B-Disease 1 1.0
. O 0 5.609732397715561e-05

Furthermore O 0 5.1515457016648725e-05
, O 0 1.4100177736509067e-07
our O 0 1.7226618354015955e-08
findings O 0 1.892417778037725e-08
are O 0 7.05100033915329e-10
best O 0 5.627472265956612e-09
interpreted O 0 5.331991914658829e-08
as O 0 1.3898829642755572e-08
true O 0 1.1106170205721355e-07
gamete O 0 3.820197889581323e-06
complementation O 0 2.493525062163826e-05
resulting O 0 5.09051119479409e-07
in O 0 2.862913390799804e-07
maternal B-Disease 0 0.0009416282409802079
UPD I-Disease 1 1.0
15 I-Disease 0 0.0001308861974393949
and O 0 1.9466946469037794e-05
PWS B-Disease 1 1.0

Schwartz B-Disease 1 0.9988516569137573
- I-Disease 1 0.9999997615814209
Jampel I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
type I-Disease 0 0.0017300820909440517
2 I-Disease 0 7.406009444821393e-06
and O 0 5.587751417124309e-08
Stuve B-Disease 1 0.9999908208847046
- I-Disease 1 0.9999998807907104
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
: O 0 3.5003822063117696e-08
a O 0 3.205142107276515e-08
case O 0 5.262078062173714e-08
for O 0 9.700762859665701e-09
" O 0 3.424714236643922e-07
lumping O 0 1.873787823569728e-06
" O 0 2.0833654161833692e-06
. O 0 1.1956198022744502e-06

Recent O 0 5.684184429810557e-07
studies O 0 5.8196146568434415e-08
demonstrated O 0 3.528381142814396e-08
the O 0 1.493500612070875e-08
existence O 0 9.461456329518114e-08
of O 0 1.990338205359876e-08
a O 0 7.407086854982481e-08
genetically O 0 1.3804832121877553e-07
distinct O 0 8.161261888517402e-09
, O 0 6.792102991148852e-10
usually O 0 5.383911094725136e-10
lethal O 0 4.05904110323263e-09
form O 0 6.317197320804269e-10
of O 0 6.788260176193717e-09
the O 0 5.1169500636660814e-08
Schwartz B-Disease 0 0.027239950373768806
- I-Disease 1 0.9999203681945801
Jampel I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 8.623024768894538e-06
SJS B-Disease 1 1.0
) O 0 3.658488978430796e-08
of O 0 7.49817274936504e-07
myotonia B-Disease 1 0.9999985694885254
and O 0 5.8463651839701924e-06
skeletal B-Disease 1 0.9999995231628418
dysplasia I-Disease 1 1.0
, O 0 4.765261678585375e-07
which O 0 3.1190936056191276e-08
we O 0 6.16844104683878e-08
called O 0 1.194220317302097e-06
SJS B-Disease 1 0.72434002161026
type I-Disease 0 8.855741725710686e-06
2 I-Disease 0 1.198231620946899e-05
. O 0 9.85646124718187e-07

This O 0 8.048615995903674e-07
disorder O 1 0.9151470065116882
is O 0 4.054183833090974e-08
reminiscent O 0 1.4208463881004718e-06
of O 0 1.077112372627198e-07
another O 0 2.731480321926938e-07
rare O 0 1.8948146873754013e-07
condition O 0 7.6169881140231155e-06
, O 0 1.9152691876911376e-08
the O 0 5.518197667697677e-07
Stuve B-Disease 1 1.0
- I-Disease 1 1.0
Wiedemann I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.07993735373020172
SWS B-Disease 1 0.9999998807907104
) O 0 2.0987545923389916e-08
, O 0 1.2741098176505261e-09
which O 0 4.2958270274340293e-10
comprises O 0 3.864132125386277e-09
campomelia B-Disease 0 6.2801686908642296e-06
at O 0 3.92188070463817e-07
birth O 0 1.864161305320522e-07
with O 0 4.0247986277108794e-08
skeletal B-Disease 1 0.999983549118042
dysplasia I-Disease 1 1.0
, O 0 0.00011855439515784383
contractures B-Disease 1 0.999862790107727
, O 0 2.6191318625023996e-07
and O 0 5.94661067054858e-08
early B-Disease 0 6.235920864128275e-06
death I-Disease 0 6.582926289411262e-06
. O 0 3.9188175833260175e-06

To O 0 6.977664668283978e-08
test O 0 3.2800549831790704e-08
for O 0 3.3038440871990815e-09
possible O 0 5.355567509468528e-07
nosologic O 1 0.9996001124382019
identity O 0 5.299294230098894e-07
between O 0 1.2743880972720945e-07
these O 0 1.7815874997495484e-08
disorders O 1 0.5858127474784851
, O 0 4.0740575357745e-09
we O 0 1.7165832089105493e-09
reviewed O 0 3.3340907812373644e-09
the O 0 5.726543683692853e-10
literature O 0 2.0850678961181757e-09
and O 0 3.901870146427733e-11
obtained O 0 2.2877233440965483e-10
a O 0 3.014500871145742e-10
follow O 0 4.016573462717332e-10
- O 0 2.3141397686998744e-09
up O 0 4.714220125379143e-10
of O 0 2.879195493132869e-10
the O 0 2.1567800323474273e-10
only O 0 3.735099729507141e-10
two O 0 5.570825467593465e-10
surviving O 0 9.565830083602123e-08
patients O 0 2.6983504319844087e-09
, O 0 1.6503748367924231e-09
one O 0 4.526046204489376e-09
with O 0 2.6052340285076525e-09
SJS B-Disease 0 0.0003252546885050833
type I-Disease 0 3.542428146374732e-07
2 I-Disease 0 2.490492363449448e-07
at O 0 1.3988882940907388e-08
age O 0 3.416471772155205e-09
10 O 0 5.510588096946378e-10
years O 0 1.802858140553809e-10
and O 0 1.034889604567546e-10
another O 0 3.4471969723171014e-09
with O 0 3.948674276443853e-09
SWS B-Disease 0 0.010639532469213009
at O 0 6.639998559876403e-07
age O 0 3.0706550546710787e-07
7 O 0 6.697580374748213e-07
years O 0 1.93500611089803e-07
. O 0 6.795775675527693e-07

Patients O 0 4.563035872706678e-06
reported O 0 1.4041590645774704e-07
as O 0 1.8337953378022576e-08
having O 0 7.250615396969806e-08
either O 0 4.549800451059127e-06
neonatal O 1 1.0
SJS B-Disease 1 1.0
or O 0 4.556659041554667e-05
SWS B-Disease 1 0.8763930201530457
presented O 0 1.993685572188042e-08
a O 0 2.664513942818303e-09
combination O 0 5.7760192184730386e-09
of O 0 8.294590791990686e-09
a O 0 2.965838596935555e-08
severe O 0 0.00023854941537138075
, O 0 2.1186784238125256e-07
prenatal O 0 0.004260752350091934
- O 1 0.9981299042701721
onset O 1 1.0
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 8.34437450976111e-05
with O 0 0.00029536234796978533
congenital B-Disease 1 1.0
joint I-Disease 1 1.0
contractures I-Disease 1 1.0
, O 1 1.0
respiratory O 1 1.0
and O 1 0.6105079054832458
feeding O 0 0.09299661964178085
difficulties O 0 3.3307831472484395e-05
, O 0 1.2690027695327899e-08
tendency O 0 8.538996354445771e-08
to O 0 1.3589714242812079e-08
hyperthermia B-Disease 1 0.9998767375946045
, O 0 6.395970864048195e-09
and O 0 7.77473307955745e-10
frequent O 0 1.1682709910587619e-08
death O 0 1.9268300377461856e-07
in O 0 2.8667814788718715e-08
infancy O 0 9.19729643555911e-07
) O 0 3.3338601324039985e-10
with O 0 1.5632224681372264e-10
a O 0 1.7511219141397305e-08
distinct O 0 4.169671399267827e-07
campomelic B-Disease 1 0.9990881681442261
- I-Disease 1 0.9999098777770996
metaphyseal I-Disease 1 0.9999991655349731
skeletal I-Disease 1 0.9999818801879883
dysplasia I-Disease 1 1.0
. O 0 0.0004535975749604404

The O 0 1.3329682815310662e-06
similarity O 0 7.826426440260548e-07
of O 0 4.924406198369979e-07
the O 0 3.098973309079156e-07
clinical O 0 7.088489655870944e-05
and O 0 5.0889283897959103e-08
radiographic O 0 0.011546910740435123
findings O 0 1.8481183587937267e-06
is O 0 4.316841994977949e-08
so O 0 5.075497799822415e-10
extensive O 0 1.048630604572054e-08
that O 0 1.280463401975851e-09
these O 0 3.6309097950493197e-09
disorders O 0 0.4104803502559662
appear O 0 3.820179372837629e-08
to O 0 4.040803691651718e-09
be O 0 5.55651302747151e-09
a O 0 3.8750357589378837e-08
single O 0 1.3746370086664683e-07
entity O 0 3.487212552499841e-06
. O 0 3.1336908250523265e-06

The O 0 2.2310238989575737e-07
follow O 0 7.376436883532733e-08
- O 0 3.0225473324207996e-07
up O 0 7.757613218473125e-09
observation O 0 9.015467838935365e-08
of O 0 2.224077588763862e-09
an O 0 1.5980024248296587e-10
identical O 0 7.432554016695292e-10
and O 0 1.3017688316185883e-10
unique O 0 2.459979164814996e-10
pattern O 0 7.683664193791628e-08
of O 0 7.062473628138832e-07
progressive O 1 0.9999992847442627
bone B-Disease 1 1.0
dysplasia I-Disease 1 1.0
in O 0 9.092398727261752e-07
the O 0 1.9731481870621792e-07
two O 0 1.6327046381547916e-08
patients O 0 1.1544444511457641e-08
( O 0 3.876430731963865e-09
one O 0 5.522059698392923e-09
with O 0 1.880905209361572e-09
SJS B-Disease 0 0.0016266102902591228
type I-Disease 0 5.278785124573915e-07
2 I-Disease 0 5.85685086207377e-07
, O 0 1.5919463525193578e-09
one O 0 1.6405671265928845e-09
with O 0 8.821394170688279e-10
SWS B-Disease 0 0.005446701776236296
) O 0 1.0870080835445606e-08
surviving O 0 2.0488749896685476e-07
beyond O 0 8.165848726093827e-07
infancy O 0 8.009060366021004e-07
adds O 0 1.8573580451430871e-09
to O 0 3.481382404579847e-10
the O 0 7.606722474129413e-10
evidence O 0 2.126926412771013e-09
in O 0 5.428580918120929e-10
favor O 0 2.1095184266073375e-08
of O 0 8.96912482062362e-08
identity O 0 1.1239952755204285e-06
. O 0 1.986445113288937e-06

The O 0 2.6545128548605135e-06
hypothesis O 0 4.6719953388674185e-05
that O 0 2.081652326069161e-07
SWS B-Disease 1 0.999697208404541
and O 0 1.426728658771026e-06
SJS B-Disease 1 0.9999954700469971
type I-Disease 0 1.265261926164385e-05
2 I-Disease 0 5.776280431746272e-07
are O 0 2.235713281173446e-10
the O 0 1.5203559522447563e-09
same O 0 4.6458229263635076e-08
disorder O 0 2.5357565391459502e-05
should O 0 7.16567560843373e-09
be O 0 4.003198661450824e-09
testable O 0 1.5695660238179698e-07
by O 0 9.65505342342965e-10
molecular O 0 4.681671228468076e-08
methods O 0 4.07892670750698e-08
. O 0 4.4510706231903896e-08
. O 0 5.659864541485149e-07

A O 0 6.944908363948343e-06
mouse O 0 7.918137043816387e-07
model O 0 4.051942070759651e-08
of O 0 6.853049683286372e-08
severe O 1 0.9994388222694397
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 1 0.9999427795410156
defects O 1 1.0
in O 0 1.2007036275463179e-05
hemostasis O 1 0.9999864101409912
and O 0 1.0647179806255735e-05
thrombosis B-Disease 1 1.0
. O 1 0.9235487580299377

von B-Disease 1 0.9996060729026794
Willebrand I-Disease 1 1.0
factor I-Disease 1 0.9969871640205383
( I-Disease 0 2.9859158530598506e-05
vWf I-Disease 1 1.0
) I-Disease 0 0.021169979125261307
deficiency I-Disease 1 1.0
causes O 1 0.9999961853027344
severe O 1 1.0
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 1 0.8377149105072021
humans O 0 0.00017909334565047175
. O 0 6.981497335800668e-06

We O 0 3.348259554059041e-07
generated O 0 4.6103192374857827e-08
a O 0 2.2416079659137722e-08
mouse O 0 7.006939028997294e-08
model O 0 4.983363055544032e-09
for O 0 7.295373749549583e-10
this O 0 2.4211443960808765e-09
disease O 0 2.1859047905081752e-08
by O 0 8.741050661065231e-10
using O 0 1.0621942436728204e-08
gene O 0 8.610121682295357e-08
targeting O 0 4.043319279389834e-07
. O 0 6.107349008743768e-07

vWf B-Disease 1 0.9999237060546875
- I-Disease 1 0.9999967813491821
deficient I-Disease 1 0.9901072978973389
mice O 0 2.0254581158951623e-06
appeared O 0 5.610969822100742e-08
normal O 0 4.144156307006597e-08
at O 0 3.689476102408662e-08
birth O 0 1.2550320782622748e-08
; O 0 8.215264024613589e-10
they O 0 1.9330641531922765e-09
were O 0 1.729671339489869e-08
viable O 0 1.259600139746908e-06
and O 0 8.170391652129183e-08
fertile O 0 3.581177952582948e-05
. O 0 5.050057097832905e-06

Neither O 0 0.0003058617003262043
vWf O 0 0.176263689994812
nor O 0 0.00015305426495615393
vWf O 0 0.11626385897397995
propolypeptide O 0 0.0035611179191619158
( O 0 3.799484602495795e-07
von B-Disease 0 0.0018113435944542289
Willebrand I-Disease 1 0.9837831854820251
antigen O 0 0.000168679776834324
II O 1 0.9999804496765137
) O 0 1.5543582421173596e-08
were O 0 6.984532952003519e-09
detectable O 0 2.3392549053369294e-07
in O 0 3.1541138589830098e-09
plasma O 0 5.116130523674656e-07
, O 0 3.417194971433446e-09
platelets O 0 1.77736779960469e-07
, O 0 3.3822826761564784e-09
or O 0 2.6156516952369202e-08
endothelial O 0 4.081962856616883e-07
cells O 0 1.313868303043364e-08
of O 0 1.3541561649788036e-08
the O 0 1.0006907302795298e-07
homozygous O 0 7.218172413558932e-06
mutant O 0 1.6657391824992374e-05
mice O 0 3.1169165595201775e-06
. O 0 4.889286628895206e-07

The O 0 4.5307142499950714e-06
mutant O 0 8.974494994617999e-05
mice O 0 4.511294719122816e-06
exhibited O 0 1.1761690075218212e-06
defects O 0 0.009213120676577091
in O 0 4.546632581536869e-08
hemostasis O 0 0.00022228278976399451
with O 0 2.9820657054813182e-09
a O 0 5.185163445275975e-07
highly O 0 2.1262243535602465e-05
prolonged O 1 1.0
bleeding O 1 1.0
time O 0 4.42376040155068e-06
and O 0 1.5405707642912603e-07
spontaneous O 0 1.790336682461202e-05
bleeding O 0 0.03936078026890755
events O 0 5.4319078124365205e-09
in O 0 7.710375671265979e-10
approximately O 0 2.306490110015602e-09
10 O 0 6.007174757627354e-09
% O 0 1.543727456976285e-08
of O 0 5.969519634163589e-08
neonates O 0 9.090957973967306e-06
. O 0 1.3569195971285808e-06

As O 0 4.2602394501045637e-07
in O 0 3.491473776762177e-08
the O 0 1.0409826245449949e-07
human O 0 5.31099203726626e-07
disease O 0 2.75738875643583e-06
, O 0 2.2535200372431063e-09
the O 0 6.676800445859499e-09
factor O 0 7.149452585508698e-07
VIII O 1 0.9930583238601685
level O 0 1.9161518594046356e-06
in O 0 1.7106608352079888e-09
these O 0 5.209692677254907e-10
mice O 0 1.319063436255874e-08
was O 0 6.995678702992336e-09
reduced O 0 4.706307787927244e-09
strongly O 0 4.214797844070972e-09
as O 0 3.4005223636945914e-10
a O 0 8.607979329333659e-10
result O 0 3.4138203375277953e-09
of O 0 4.023783528595004e-09
the O 0 3.723223063190062e-09
lack O 0 1.2390248826932293e-08
of O 0 1.1403007427190914e-08
protection O 0 2.3718541797279613e-08
provided O 0 1.9374059689880596e-08
by O 0 1.1298573809881418e-07
vWf O 0 0.0003851460642181337
. O 0 3.632987500168383e-06

Defective O 1 0.8130713105201721
thrombosis B-Disease 1 0.9999986886978149
in O 0 1.3305474567459896e-05
mutant O 0 0.0003884776961058378
mice O 0 1.2157911442045588e-06
was O 0 1.4133350134670764e-07
also O 0 2.3570021490115778e-09
evident O 0 2.403046472920778e-08
in O 0 8.525643524492921e-10
an O 0 1.4226633204827976e-09
in O 0 5.057303908984068e-09
vivo O 0 3.1416334422829095e-07
model O 0 3.7888025161691985e-08
of O 0 2.6858442652155645e-06
vascular B-Disease 1 1.0
injury I-Disease 1 1.0
. O 1 0.9734979867935181

In O 0 9.328779526640574e-08
this O 0 4.669620690123111e-09
model O 0 3.317055075058306e-08
, O 0 4.653500695894763e-09
the O 0 2.3899234591340246e-08
exteriorized O 0 5.149747812538408e-05
mesentery O 0 0.000145747879287228
was O 0 2.3732263798592612e-06
superfused O 0 1.4894722880853806e-05
with O 0 1.542350247518698e-08
ferric O 0 3.510990063659847e-05
chloride O 0 1.6428089111286681e-06
and O 0 1.2510383839980932e-08
the O 0 4.9182670380787386e-08
accumulation O 0 9.0257026386098e-07
of O 0 4.49682659109385e-07
fluorescently O 0 8.172752859536558e-05
labeled O 0 2.147891791537404e-06
platelets O 0 3.851397991638805e-07
was O 0 1.229610688824323e-07
observed O 0 4.1194734734517624e-08
by O 0 1.4596830411051087e-08
intravital O 0 2.628367110446561e-05
microscopy O 0 1.8049702703137882e-05
. O 0 4.838351287617115e-06

We O 0 1.9468875507300254e-06
conclude O 0 7.00284908816684e-06
that O 0 4.3929926363261984e-08
these O 0 2.1086615120680108e-08
mice O 0 1.9191472802049248e-06
very O 0 3.3980100511143974e-08
closely O 0 4.0862940409169823e-07
mimic O 0 8.166163024725392e-05
severe O 1 0.9985297918319702
human O 0 0.0013654199428856373
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 4.123460257687839e-07
will O 0 2.4529722253419095e-08
be O 0 4.340221071430506e-09
very O 0 5.18772969027026e-10
useful O 0 5.048531592777294e-10
for O 0 1.2337647570248578e-10
investigating O 0 1.3063485848618939e-09
the O 0 1.2362009194077928e-09
role O 0 1.2258283277333248e-08
of O 0 3.25954268021178e-08
vWf O 0 4.2271549318684265e-05
in O 0 8.433089782045045e-09
normal O 0 1.1383345821514013e-07
physiology O 0 3.7224228321974806e-07
and O 0 4.411513376822995e-09
in O 0 3.1897126717694846e-08
disease O 0 6.266022296586016e-07
models O 0 7.1912545251962e-08
. O 0 1.6141331116159563e-07
. O 0 1.6955619912550901e-06

Oral O 0 0.00019747985061258078
contraceptives O 0 5.61084489163477e-05
and O 0 1.3739943405255417e-08
the O 0 4.863397151666504e-08
risk O 0 5.590124146692688e-06
of O 0 0.1697709709405899
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999984502792358

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 1.0
Clinical O 1 0.9990677237510681
Study O 0 1.346904355159495e-05
Group O 0 1.82407882221014e-06
. O 0 1.8345847365708323e-06

BACKGROUND O 0 3.120833935099654e-05
Women O 0 1.1122106791106035e-08
with O 0 3.535970405366129e-10
mutations O 0 3.0351582580578906e-08
in O 0 1.2565596341218566e-09
either O 0 8.9541476455679e-09
the O 0 2.076797400718533e-08
BRCA1 O 0 1.343497274319816e-06
or O 0 1.0039825859564644e-08
the O 0 1.8298264237159856e-08
BRCA2 O 0 1.0206412071056548e-06
gene O 0 4.4720023240074624e-09
have O 0 9.25475807100895e-11
a O 0 3.065865783469235e-09
high O 0 6.954837061812214e-08
lifetime O 0 1.7573796640135697e-07
risk O 0 1.6282319847960025e-05
of O 1 0.9967009425163269
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.13716921210289001

Oral O 0 0.0003159473417326808
contraceptives O 0 0.0008626123308204114
protect O 0 6.131419922894565e-06
against O 1 1.0
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 2.7526621124707162e-06
general O 0 3.6656174415838905e-06
, O 0 2.885282679443435e-09
but O 0 1.390356163533113e-10
it O 0 3.03931324552309e-11
is O 0 3.044360596948792e-11
not O 0 1.8822346459224093e-11
known O 0 2.1965559926506728e-10
whether O 0 3.3774977259426464e-10
they O 0 1.8467526119447797e-10
also O 0 5.238899314363721e-10
protect O 0 1.3381263874734373e-09
against O 0 3.5686994692696317e-08
hereditary B-Disease 0 0.23707634210586548
forms I-Disease 0 3.157162427669391e-05
of I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.6501731276512146

METHODS O 0 5.518394573300611e-06
We O 0 1.8747157071175025e-07
enrolled O 0 2.2201378158115403e-07
207 O 0 8.870856049725262e-08
women O 0 1.0980203413168965e-09
with O 0 9.492216790363273e-09
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.6401651211926946e-06
161 O 0 9.502488751422788e-07
of O 0 9.867750350167626e-08
their O 0 1.6222211352001636e-09
sisters O 0 6.76938283206141e-09
as O 0 5.435325522995527e-10
controls O 0 1.075994848775963e-08
in O 0 1.1810591393768277e-09
a O 0 1.2888982325875986e-08
case O 0 1.4191914488037582e-07
- O 0 5.467500727718289e-07
control O 0 2.588583640772413e-07
study O 0 1.6851900852543622e-07
. O 0 5.521150683307496e-07

All O 0 3.5714512591766834e-07
the O 0 9.009382750946315e-08
patients O 0 7.569068039003923e-09
carried O 0 3.079732691091408e-09
a O 0 4.753689442082987e-09
pathogenic O 0 2.2305616909079617e-08
mutation O 0 3.4969854567634684e-08
in O 0 3.868844800081206e-09
either O 0 3.6439896433648755e-08
BRCA1 O 0 7.955210321597406e-07
( O 0 5.93740434595702e-09
179 O 0 4.280218490748666e-08
women O 0 6.707482347323435e-10
) O 0 6.784269812598609e-10
or O 0 3.516650437518365e-08
BRCA2 O 0 8.59250303619774e-06
( O 0 9.899911646016335e-08
28 O 0 1.5584241737087723e-06
women O 0 8.715533184044943e-09
) O 0 3.693602224075221e-08
. O 0 3.5880151472156285e-07

The O 0 3.332465041694377e-07
control O 0 3.535583630309702e-07
women O 0 8.214667834849365e-10
were O 0 6.368662819333792e-10
enrolled O 0 3.4530340808913706e-09
regardless O 0 3.0691422736595086e-09
of O 0 1.1224480234162115e-09
whether O 0 1.9335768541850484e-09
or O 0 2.7929512036450888e-09
not O 0 1.991502962539471e-09
they O 0 1.4709735651763367e-09
had O 0 1.609373612154741e-08
either O 0 1.1140200228965114e-07
mutation O 0 1.953391119968728e-06
. O 0 6.303229724835546e-07

Lifetime O 0 1.432124281564029e-05
histories O 0 1.8482204495740007e-06
of O 0 4.111209079837863e-07
oral O 0 8.006074494915083e-06
- O 0 4.702519618149381e-06
contraceptive O 0 3.2968526397780806e-07
use O 0 1.3936570786299285e-09
were O 0 4.3532516480482286e-10
obtained O 0 3.6170558215253834e-10
by O 0 1.0620837542774098e-10
interview O 0 3.8826390991175685e-09
or O 0 3.1284208557025295e-10
by O 0 6.082236103654992e-11
written O 0 1.8989675110159254e-10
questionnaire O 0 8.057073341838361e-10
and O 0 6.097382321268441e-11
were O 0 3.9747793945110743e-10
compared O 0 3.961559080778443e-09
between O 0 4.694419519779558e-09
patients O 0 8.180551791525659e-10
and O 0 2.338342020014039e-10
control O 0 6.73060753797472e-08
women O 0 3.7407746344975124e-10
, O 0 1.2969311735666622e-10
after O 0 1.5611791859271307e-09
adjustment O 0 2.06832986293648e-08
for O 0 5.249281564978503e-10
year O 0 4.895148286720996e-09
of O 0 2.738707394200901e-08
birth O 0 6.980592814898046e-08
and O 0 2.332006232563799e-08
parity O 0 3.1342377042165026e-05
. O 0 6.068245511414716e-06

RESULTS O 0 3.857599040202331e-06
The O 0 7.515140509894991e-08
adjusted O 0 2.565396073350712e-07
odds O 0 2.7046539798902813e-06
ratio O 0 4.802751050192455e-07
for O 0 3.6859073588857427e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.2070243826656224e-07
with O 0 6.707329136546036e-10
any O 0 1.1608744188151832e-08
past O 0 4.774643791449762e-09
use O 0 1.361108226127783e-09
of O 0 8.496978232130914e-09
oral O 0 3.285283867171529e-07
contraceptives O 0 2.1602872948278673e-06
was O 0 1.7753988004187704e-06
0 O 0 2.1204157292231685e-06
. O 0 6.412952870959998e-07

5 O 0 1.2508115787568386e-06
( O 0 4.962915056694328e-08
95 O 0 5.513852556759957e-07
percent O 0 2.5364636258018436e-07
confidence O 0 9.466798900348294e-08
interval O 0 7.207031558209565e-07
, O 0 7.068158058842755e-09
0 O 0 3.501858003573943e-08
. O 0 5.901779620565151e-10
3 O 0 7.452971573229661e-09
to O 0 1.2345986455386537e-09
0 O 0 6.215943670895285e-08
. O 0 6.453910295078913e-09
8 O 0 1.6536975522285502e-07
) O 0 2.767499118760952e-08
. O 0 3.004201118983474e-07

The O 0 2.2958490717428504e-06
risk O 0 6.293154910963494e-06
decreased O 0 1.6729147489513707e-07
with O 0 5.259784274791457e-10
increasing O 0 1.5310218870467907e-08
duration O 0 2.0874053063835163e-07
of O 0 4.108337225972036e-09
use O 0 3.1365658959003895e-09
( O 0 9.947758172756949e-09
P O 0 2.5414956326130778e-06
for O 0 5.328064656140441e-09
trend O 0 1.0355762469771435e-07
, O 0 2.459670689347604e-09
< O 0 1.7870110013973317e-06
0 O 0 4.260336794459363e-08
. O 0 1.7265391338838754e-09
001 O 0 2.3229414836123397e-08
) O 0 5.982779549551509e-11
; O 0 1.3290444265956491e-11
use O 0 8.733629791590758e-11
for O 0 2.9364588538527414e-10
six O 0 6.304101685117303e-10
or O 0 1.1082672557449769e-09
more O 0 2.1938678651522991e-10
years O 0 2.9214044516834292e-09
was O 0 1.1712451453149697e-08
associated O 0 4.69934424707219e-10
with O 0 2.052148902198514e-11
a O 0 3.3652303166320507e-09
60 O 0 2.849592917186783e-08
percent O 0 5.598846541943203e-08
reduction O 0 4.519854712725646e-07
in O 0 1.7918337391620298e-07
risk O 0 1.2626655006897636e-05
. O 0 3.405151574042975e-06

Oral O 0 6.77812349749729e-05
- O 0 1.6002533811843023e-05
contraceptive O 0 3.1299423426389694e-06
use O 0 3.032681306081031e-08
protected O 0 4.394058578327531e-06
against O 1 0.9997343420982361
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 9.954173485482443e-09
for O 0 1.0543981243671396e-09
carriers O 0 1.0230146729739431e-09
of O 0 4.0234149345508285e-09
the O 0 4.3543169070403565e-09
BRCA1 O 0 1.4578806428744429e-07
mutation O 0 3.9797900086568916e-08
( O 0 2.2153054946016937e-09
odds O 0 6.811582125010318e-07
ratio O 0 1.0955399254442e-08
, O 0 4.2309691861142085e-10
0 O 0 5.890648857587166e-09
. O 0 1.1055788923242105e-10
5 O 0 1.4289126548661102e-09
; O 0 2.036980029096469e-10
95 O 0 1.5114485663048072e-08
percent O 0 3.104113943663833e-08
confidence O 0 1.858996334647145e-08
interval O 0 1.5063824321259744e-07
, O 0 3.0947127083180703e-09
0 O 0 1.484392964101744e-08
. O 0 2.4249699470679786e-10
3 O 0 2.3887418709733765e-09
to O 0 3.809842996638224e-10
0 O 0 9.661948574546386e-09
. O 0 5.98682325936295e-10
9 O 0 5.764682953213196e-09
) O 0 7.276013125334657e-11
and O 0 5.053268567478675e-11
for O 0 1.5153814314494696e-10
carriers O 0 1.7222830939189748e-09
of O 0 5.2498450031635e-09
the O 0 3.2113103287656486e-08
BRCA2 O 0 3.6096757867198903e-06
mutation O 0 2.1479644374267082e-07
( O 0 1.0380852621949543e-08
odds O 0 4.289709522709018e-06
ratio O 0 1.1761223817075006e-07
, O 0 3.2419322781862547e-09
0 O 0 1.5798297781088877e-08
. O 0 3.4352098943202236e-10
4 O 0 3.8810101798958385e-09
; O 0 1.5974387090889053e-10
95 O 0 1.6996297702576157e-08
percent O 0 3.5490685945660516e-08
confidence O 0 2.0431262015563334e-08
interval O 0 1.9638329717963643e-07
, O 0 3.5211389359801615e-09
0 O 0 3.211090060517563e-08
. O 0 8.474686508108675e-10
2 O 0 6.949040454173883e-09
to O 0 1.1095701024643745e-09
1 O 0 1.4576221474271733e-07
. O 0 7.765059706343891e-09
1 O 0 6.894280772939965e-07
) O 0 5.107998291009608e-08
. O 0 4.887333489023149e-07

CONCLUSIONS O 0 6.597673200303689e-05
Oral O 0 3.0466006137430668e-05
- O 0 9.724580195324961e-06
contraceptive O 0 3.4037232126138406e-06
use O 0 8.378195026637059e-09
may O 0 5.171559624983502e-09
reduce O 0 5.622923460180118e-09
the O 0 5.148843573721251e-09
risk O 0 4.644849013857311e-06
of O 1 0.9511005282402039
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 7.477593158000673e-07
women O 0 9.464858896635064e-10
with O 0 1.4456010000163388e-10
pathogenic O 0 1.9407197626719608e-08
mutations O 0 2.583812985790246e-08
in O 0 6.819093734122816e-09
the O 0 1.4451522645231307e-07
BRCA1 O 0 3.3406951843062416e-05
or O 0 1.0467506399436388e-05
BRCA2 O 0 0.022700412198901176
gene O 0 0.0003564168291632086

A O 0 3.475093762972392e-05
Japanese O 0 1.3087807019473985e-05
family O 0 5.95746350029458e-08
with O 0 2.276309096771456e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.1222661789342965e-08
a O 0 4.4180083591527364e-07
codon O 0 1.6634520534353214e-06
291 O 0 2.3251027414517011e-07
deletion O 0 6.681274271613802e-07
: O 0 1.9396901862478444e-09
a O 0 1.3145450061813335e-08
clinical O 0 1.610287540643185e-06
, O 0 1.4565431527557848e-08
biochemical O 0 5.951451385044493e-05
, O 0 2.1883852241444401e-07
pathological O 1 0.9984018206596375
, O 0 8.608397905618403e-08
and O 0 3.562653461131049e-08
genetic O 0 1.423359844920924e-05
report O 0 2.691105578378483e-07
. O 0 1.1517565781105077e-06

We O 0 2.014403577277335e-07
report O 0 1.0160961849692285e-08
a O 0 1.288600692816999e-08
Japanese O 0 2.1219602786004543e-07
family O 0 1.0809357853247548e-08
with O 0 2.0263255962049698e-08
adrenoleukodystrophy B-Disease 1 1.0
( O 1 0.9694420099258423
ALD B-Disease 1 1.0
) O 0 1.2554774109219125e-08
with O 0 3.049441255065233e-10
a O 0 1.2687680239764632e-08
three O 0 2.9504509946320923e-09
base O 0 3.6810270387377386e-08
pair O 0 8.184644073594427e-09
deletion O 0 4.681903362779849e-07
( O 0 6.101625871224314e-08
delGAG O 0 4.1974297346314415e-05
291 O 0 2.1350795975649817e-07
) O 0 8.468195922262112e-09
in O 0 1.8972786008930598e-08
the O 0 7.136720796552254e-07
ALD B-Disease 1 1.0
gene O 0 0.00023801418137736619
. O 0 1.1046578038076404e-05

A O 0 7.521337920479709e-06
variety O 0 1.636838220520076e-07
of O 0 1.7239658234302624e-07
phenotypes O 0 1.0203093552263454e-06
were O 0 9.762871400198492e-09
observed O 0 1.7121534412467554e-08
within O 0 8.644048143935379e-09
this O 0 1.2494122181294642e-08
family O 0 1.3252777364414214e-07
. O 0 7.540230626545963e-07

While O 0 4.280683754132042e-07
the O 0 2.0210998741276853e-07
proband O 0 0.0017496420769020915
( O 0 4.399441024816042e-07
patient O 0 1.1566086186576285e-06
1 O 0 2.4660473627591273e-06
) O 0 3.6811096393307707e-09
was O 0 3.013917293515078e-08
classified O 0 7.25384907696025e-09
as O 0 1.2814456162857368e-09
having O 0 1.7675165775443702e-09
a O 0 3.455893571313595e-09
rare O 0 4.6397454767088675e-09
intermediate O 0 1.2280415262466704e-07
type O 0 1.1689836298955925e-07
of O 0 5.859868323909723e-08
adult O 0 1.20437292139286e-07
cerebral O 0 2.7393758500693366e-05
and O 0 6.169500466057798e-08
cerebello O 1 0.9999977350234985
- O 0 0.47560229897499084
brain O 0 4.1140145185636356e-05
stem O 0 3.720335328694091e-08
forms O 0 3.377621737854497e-09
, O 0 1.0353106150162716e-09
his O 0 4.1701295749874134e-09
younger O 0 2.511286467665741e-08
brother O 0 8.298455611566169e-08
( O 0 1.0547084094980619e-08
patient O 0 1.0982852671759247e-07
2 O 0 1.741154562751035e-07
) O 0 1.5265044783774329e-09
and O 0 1.7551671227522547e-09
nephew O 0 1.6744612594266073e-06
( O 0 4.145784870956959e-08
patient O 0 1.6826223259158724e-07
3 O 0 1.5993146007531323e-07
) O 0 2.5058115582510254e-09
had O 0 2.9850891536398194e-08
a O 0 6.632644158344192e-07
childhood O 0 0.2255493551492691
ALD B-Disease 1 1.0
type O 1 0.9923642873764038
. O 0 8.734209404792637e-05

Another O 0 7.25892823538743e-06
nephew O 0 0.00036800274392589927
( O 0 8.140430622916028e-07
patient O 0 1.3099543139105663e-06
4 O 0 6.518422992485284e-07
) O 0 2.409061838903881e-09
of O 0 2.1155786456006354e-08
patient O 0 1.8206448260116304e-07
1 O 0 1.9577701095840894e-06
was O 0 2.0930106359173806e-07
classified O 0 1.3572048374044243e-08
as O 0 3.975198392680568e-09
having O 0 1.47223744306757e-08
an O 0 2.3598284215609056e-08
adolescent O 0 3.7995821458025603e-06
form O 0 3.351230475345801e-07
. O 0 4.413293027027976e-06

The O 0 3.1282982035918394e-06
tau O 0 2.2237782104639336e-05
level O 0 8.123586212605005e-07
in O 0 1.0672081884877116e-08
the O 0 3.737212495025233e-08
cerebrospinal O 0 5.61101933271857e-06
fluid O 0 1.187353609566344e-05
( O 0 2.423887053737417e-06
CSF O 1 0.9999997615814209
) O 0 4.58585063256578e-08
in O 0 7.616395514276064e-09
patient O 0 1.4851434748663905e-08
1 O 0 2.266278471552141e-07
was O 0 3.504430523548763e-08
as O 0 6.657620565952982e-10
high O 0 2.1482331469258042e-09
as O 0 9.91660364935143e-11
that O 0 6.791568696318251e-11
of O 0 5.522248880396319e-09
patients O 0 8.339738677420883e-09
with O 0 1.1793021315043006e-07
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9999319314956665
( O 0 1.502502982475562e-06
AD B-Disease 0 0.00015903165331110358
) O 0 1.131487238126283e-06
. O 0 3.1589675018039998e-06

His O 0 1.5907073247944936e-05
brain O 0 0.00016363499162252992
magnetic O 0 2.8519816623884253e-05
resonance O 0 4.335697667556815e-05
image O 0 2.0383149603731e-06
( O 0 9.23065428537484e-08
MRI O 0 0.00020233055693097413
) O 0 1.9776310367092265e-08
showed O 0 4.281957544094439e-08
abnormalities B-Disease 0 1.981253490157542e-06
in I-Disease 0 3.542168780512611e-09
the I-Disease 0 1.8662580814066132e-08
bilateral I-Disease 0 0.003463761182501912
cerebellar I-Disease 1 1.0
hemispheres I-Disease 1 0.9999979734420776
and O 0 6.331268309622828e-07
brain O 0 0.07164223492145538
stem O 0 8.942440672399243e-07
, O 0 7.686675740359306e-10
but O 0 1.6285757464817863e-10
not O 0 1.2476558675089677e-10
in O 0 2.0394370914278426e-10
the O 0 1.4704462092396398e-09
cerebral O 0 1.3671442502527498e-05
white O 0 3.141351356816813e-08
matter O 0 1.2620672862340143e-07
, O 0 9.84743619980577e-10
where O 0 6.510383898650218e-10
marked O 0 1.7896617521273583e-09
reductions O 0 4.0728629358000035e-08
of O 0 2.0315576776397393e-08
the O 0 3.574367113401422e-08
cerebral O 0 2.1857062165508978e-05
blood O 0 1.3474848969963205e-07
flow O 0 6.077942060755959e-08
and O 0 4.871750558521626e-09
oxygen O 0 3.6792442870137165e-08
metabolism O 0 4.352226667947434e-08
were O 0 2.6229542982036946e-09
clearly O 0 5.651878964840762e-09
demonstrated O 0 2.486699957060523e-09
by O 0 1.2115047853811234e-09
positron O 0 9.138001928477024e-07
emission O 0 2.2977369553700555e-06
tomography O 0 1.8495784388505854e-05
( O 0 1.6374907545468886e-06
PET O 0 3.21830011671409e-05
) O 0 5.360958539313287e-07
. O 0 2.1530559024540707e-06

In O 0 9.582079201209126e-07
patients O 0 1.5145340626077086e-07
2 O 0 1.1190368240932003e-06
and O 0 7.669311408164958e-09
3 O 0 1.930630304514125e-07
, O 0 2.39659581069418e-09
the O 0 8.06527289398673e-09
autopsy O 0 6.399231722298282e-08
findings O 0 1.4720015428792976e-08
showed O 0 3.60576954960834e-08
massive O 0 7.5476718848221935e-06
demyelination B-Disease 1 1.0
of I-Disease 0 3.4696377042564563e-06
the I-Disease 0 1.285024382013944e-06
cerebral I-Disease 1 0.9921172261238098
white I-Disease 0 2.876784037653124e-07
matter I-Disease 0 4.814371123984529e-08
with O 0 2.086749800733756e-10
sparing O 0 3.5566039002787875e-08
of O 0 6.672996732959291e-08
the O 0 2.2886582939918299e-07
U O 1 0.827409029006958
- O 0 8.463098311040085e-06
fibers O 0 4.558472426197113e-07
, O 0 3.4594018760714107e-09
compatible O 0 3.5832751876796465e-08
with O 0 4.690076660374132e-10
the O 0 9.952427326709312e-09
findings O 0 7.97366936922117e-08
of O 0 3.4376369058009004e-06
childhood O 1 0.997766375541687
ALD B-Disease 1 1.0
. O 0 0.0004202992422506213

Oleic O 0 0.004460390191525221
and O 0 3.019677023985423e-06
erucic O 0 0.0032161709386855364
acids O 0 1.177290073428594e-06
( O 0 6.557159792919265e-08
Lorenzos O 0 1.8125047063222155e-05
Oil O 0 5.23327685186814e-07
) O 0 6.80080158854679e-10
were O 0 2.5737664777203406e-10
administered O 0 1.186127196461939e-09
to O 0 5.573120853696878e-10
patients O 0 2.276733468420389e-09
1 O 0 2.5698724925860006e-07
and O 0 2.0774857389938006e-09
4 O 0 1.0914377668314046e-07
, O 0 5.341024844618403e-10
but O 0 3.690901195785301e-10
sufficient O 0 3.2705889108086694e-09
effectiveness O 0 1.1928979581909971e-08
was O 0 4.882199533540188e-08
not O 0 5.141983727696697e-09
obtained O 0 2.441266815367271e-07
. O 0 9.052304221768281e-07

The O 0 2.0243484755155805e-07
findings O 0 1.5479468373769123e-08
in O 0 2.5925244173663486e-09
this O 0 1.2928073056528433e-09
family O 0 1.175830877109263e-09
suggest O 0 9.660119371091014e-10
that O 0 2.3292301420951844e-10
delGAG291 O 0 3.333227880375489e-07
is O 0 1.0019313156917065e-09
part O 0 2.0706736325593056e-09
of O 0 6.582971945334748e-09
the O 0 7.862243300849059e-09
cause O 0 4.16056735730308e-07
of O 0 5.405593583418522e-06
Japanese O 0 0.1316002458333969
ALD B-Disease 1 1.0
with O 0 2.6801640728990606e-07
phenotypic O 0 0.0001236963871633634
variations O 0 2.1338864826248027e-05
. O 0 1.9489123133098474e-06

Moreover O 0 4.748725586978253e-06
, O 0 1.9006289875278526e-08
although O 0 2.0302204362110388e-09
the O 0 7.059424156352634e-10
scale O 0 5.7923390528458185e-08
of O 0 3.831685635447002e-09
the O 0 2.8421871522965603e-09
study O 0 2.6015991583250297e-09
is O 0 4.595074598601201e-10
limited O 0 8.24425638867865e-10
, O 0 5.25675558638028e-10
there O 0 4.798057506860687e-10
is O 0 8.869189827009905e-10
a O 0 6.405358909944425e-09
possibility O 0 3.5272177001388627e-07
that O 0 6.92941171109851e-09
PET O 0 4.5013618432676594e-07
can O 0 2.940843346621591e-09
detect O 0 2.464730357587541e-07
an O 0 4.6643084061770423e-08
insidious B-Disease 1 0.8962383270263672
lesion I-Disease 1 0.9999721050262451
which O 0 2.1627181823191677e-08
is O 0 5.695827365315154e-09
undetectable O 0 3.380568713851062e-08
by O 0 8.407918250519231e-10
computed O 0 2.7384209033698426e-07
tomogram O 0 9.000635327538475e-05
( O 0 1.2278272265575652e-07
CT O 0 0.0019261791603639722
) O 0 3.0939337758439933e-09
or O 0 2.0236634590276026e-09
MRI O 0 8.645866245160505e-08
analysis O 0 3.2699338792241406e-09
, O 0 1.9018600583287082e-10
and O 0 4.0284019175995667e-11
that O 0 2.791302779192595e-11
the O 0 5.140421976967957e-10
higher O 0 7.1570296356071594e-09
level O 0 2.2256999798742072e-08
of O 0 5.168078409667487e-09
tau O 0 9.923978439019265e-08
reflects O 0 2.161026468883165e-09
the O 0 6.459633383748553e-10
process O 0 1.1046588532792612e-08
of O 0 7.594870510274632e-08
neuronal B-Disease 0 0.001618242240510881
degeneration I-Disease 1 1.0
in O 0 0.000262562301941216
ALD B-Disease 1 1.0
. O 0 9.930696978699416e-05

Lorenzos O 0 0.0005387032288126647
Oil O 0 3.68464907296584e-06
should O 0 1.1478860528768564e-08
be O 0 1.3040757362858812e-09
given O 0 1.7398216201058858e-09
in O 0 1.195676446741345e-09
the O 0 4.626313998556952e-09
early O 0 1.1009467471012613e-07
stage O 0 6.852786782474141e-07
. O 0 4.08992697487065e-08
. O 0 6.034532589183073e-07

Nonsense O 0 0.00010023686627391726
mutation O 0 4.429240107128862e-06
in O 0 3.8738754426503874e-08
exon O 0 3.636141400420456e-06
4 O 0 1.6862736629263964e-07
of O 0 4.9462802742539225e-09
human O 0 2.5118600532891833e-09
complement O 0 3.731300779463709e-08
C9 O 0 0.22836364805698395
gene O 0 6.623238846259483e-08
is O 0 2.2561736923165654e-09
the O 0 1.8617064556636365e-09
major O 0 1.1461821713965037e-07
cause O 0 6.941239689695067e-07
of O 0 1.6806028497740044e-06
Japanese O 0 1.4641937013948336e-05
complement B-Disease 0 4.313090175855905e-05
C9 I-Disease 1 1.0
deficiency I-Disease 1 0.9999957084655762
. O 0 7.525588443968445e-05

Deficiency B-Disease 1 0.9611365795135498
of I-Disease 0 5.422291906143073e-06
the I-Disease 0 2.3543941551906755e-06
ninth I-Disease 0 0.00018727564020082355
component I-Disease 0 1.1401460142224096e-05
of I-Disease 0 8.605918822013336e-08
human I-Disease 0 4.142502785242641e-09
complement I-Disease 0 2.3180550812185174e-08
( O 0 1.202507888820037e-07
C9 O 1 0.9999964237213135
) O 0 3.3071794192096604e-09
is O 0 4.5980377838539255e-10
the O 0 2.3122370684802718e-10
most O 0 1.7046862532676954e-10
common O 0 1.0060704624947903e-07
complement B-Disease 1 0.9999996423721313
deficiency I-Disease 1 1.0
in O 0 4.220045184410992e-07
Japan O 0 3.815345053226338e-07
but O 0 5.943047387546585e-09
is O 0 4.85417395168497e-09
rare O 0 2.026328438375913e-09
in O 0 1.9204591250598924e-09
other O 0 1.6805841163147761e-09
countries O 0 3.9097134418852875e-08
. O 0 1.2136630402892479e-06

We O 0 4.3362555857129337e-07
studied O 0 2.1927807836163993e-07
the O 0 6.154172282890613e-09
molecular O 0 7.803100743331015e-08
basis O 0 1.1518979192715051e-07
of O 0 2.2760584670322714e-06
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9999902248382568
in O 0 2.0455580340694723e-07
four O 0 2.6622192450531657e-08
Japanese O 0 3.1048832624946954e-06
C9 B-Disease 1 0.9999130964279175
- I-Disease 0 0.003916162997484207
deficient I-Disease 0 0.0017195498803630471
patients O 0 1.1462783788829256e-07
who O 0 1.6744073150221084e-07
had O 0 3.934684627893148e-06
suffered O 1 0.999872088432312
from O 0 0.024884909391403198
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 0.00014843045210000128

Direct O 0 1.1395808314773603e-06
sequencing O 0 2.425440925435396e-06
of O 0 6.107762260398886e-07
amplified O 0 1.868919025582727e-05
C9 O 0 0.0005117059336043894
cDNA O 0 3.6439450923353434e-06
and O 0 1.8810460744589363e-08
DNA O 0 1.8474561613857077e-07
revealed O 0 5.886361620355274e-08
a O 0 2.6374237904747133e-08
nonsense O 0 1.0971479014187935e-06
substitution O 0 6.747921474925533e-07
( O 0 4.643484174948753e-08
CGA O 0 3.2707582704460947e-06
- O 0 1.2954046724189539e-05
- O 0 4.5829751798009966e-06
> O 0 5.023868197895354e-06
TGA O 0 4.181548320048023e-06
) O 0 5.618269849350099e-09
at O 0 2.9024503689356607e-08
codon O 0 5.5017299160908806e-08
95 O 0 2.3221836897846515e-08
in O 0 4.033403833147986e-09
exon O 0 4.090348681984324e-07
4 O 0 5.279298775917596e-08
in O 0 4.034142353503967e-09
the O 0 3.244303314886565e-08
four O 0 3.0477298196274205e-07
C9 B-Disease 1 0.9999778270721436
- I-Disease 1 0.8279902935028076
deficient I-Disease 0 0.00015909109788481146
individuals O 0 3.6681387882708805e-07
. O 0 6.360756742651574e-06

An O 0 2.7722492745851923e-07
allele O 0 1.6784118770374334e-06
- O 0 1.5849673218326643e-07
specific O 0 9.247656862498843e-09
polymerase O 0 1.2315698540987796e-06
chain O 0 3.1152289636793284e-08
reaction O 0 2.398493847977079e-09
system O 0 1.5476921966239843e-09
designed O 0 1.4791607938491325e-09
to O 0 7.410697611121009e-10
detect O 0 2.0909393327883663e-08
exclusively O 0 1.7620165326803772e-09
only O 0 2.9959290603898125e-10
one O 0 3.419292626816173e-10
of O 0 4.720770441224431e-10
the O 0 7.277015656725894e-10
normal O 0 2.244901597947546e-09
and O 0 4.294000433002765e-10
mutant O 0 9.656126565005252e-09
alleles O 0 2.257430686825046e-09
indicated O 0 1.2545480210235382e-09
that O 0 6.508953098727233e-11
all O 0 1.350247413878236e-10
the O 0 1.1298542101911835e-09
four O 0 6.017297771165886e-10
patients O 0 1.6331203056552113e-10
were O 0 3.0529798134004693e-10
homozygous O 0 1.8012986657822694e-09
for O 0 1.4155086824896301e-10
the O 0 1.32844768518936e-09
mutation O 0 1.6387946999429914e-08
in O 0 1.8452325223350385e-09
exon O 0 1.7245511685359816e-07
4 O 0 8.385164562696446e-09
and O 0 2.831697896998886e-11
that O 0 2.45709841362185e-11
the O 0 1.1607319549966633e-09
parents O 0 6.302106059230539e-10
of O 0 7.077034513969238e-09
patient O 0 6.730864043902329e-08
2 O 0 1.4427097312363912e-06
were O 0 1.6754822240727663e-07
heterozygous O 0 1.3171322734706337e-06
. O 0 9.345499734081386e-07

The O 0 3.137836870337196e-07
common O 0 2.6476965331312385e-07
mutation O 0 7.880741463850427e-07
at O 0 9.088655872346862e-08
codon O 0 1.392098880614867e-07
95 O 0 3.244742785568633e-08
in O 0 3.935515913155996e-09
exon O 0 3.8016520420569577e-07
4 O 0 2.145224797800438e-08
might O 0 2.3024111506231293e-09
be O 0 7.757165465527294e-10
responsible O 0 3.76155417924906e-09
for O 0 3.948365634443007e-09
most O 0 8.876627788367841e-08
Japanese O 0 0.0003367556200828403
C9 B-Disease 1 1.0
deficiency I-Disease 1 0.9994993209838867
. O 0 2.3198479084385326e-06
. O 0 3.1291456252802163e-06

BRCA1 O 0 6.70463759888662e-06
required O 0 3.0743350976081274e-08
for O 0 2.8757904502185738e-08
transcription O 0 2.190660234191455e-05
- O 0 4.5630855311173946e-05
coupled O 0 7.537098554166732e-06
repair O 0 1.4355126950249542e-05
of O 0 1.8179240441895672e-06
oxidative O 0 0.00032973437919281423
DNA O 0 0.00028864937485195696
damage O 0 0.01085673552006483
. O 0 1.1664556950563565e-05

The O 0 3.104224015260115e-05
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9998072981834412
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 1 1.0
gene O 0 0.00022813571558799595
BRCA1 O 0 4.978854485671036e-05
encodes O 0 1.409564731602586e-07
a O 0 5.998075636171052e-08
zinc O 0 4.006969447800657e-06
finger O 0 2.546034693295951e-06
protein O 0 1.7000796503907623e-07
of O 0 5.346972642428227e-08
unknown O 0 3.100330445704458e-07
function O 0 2.5500750666651584e-07
. O 0 3.4623451483639656e-07

Association O 0 8.731358889235707e-07
of O 0 5.004760055271618e-07
the O 0 3.027552679668588e-07
BRCA1 O 0 3.0216531285987003e-06
protein O 0 2.6957799548199546e-08
with O 0 2.1974276565028816e-10
the O 0 8.592761169268215e-09
DNA O 0 3.9798325701667636e-07
repair O 0 9.216471994477615e-07
protein O 0 3.903168135366286e-07
Rad51 O 0 9.027734222399886e-07
and O 0 2.984721636511978e-10
changes O 0 6.156399834367221e-10
in O 0 5.18179610331515e-10
the O 0 7.152836656310058e-10
phosphorylation O 0 1.1647067310605053e-08
and O 0 1.546349603920305e-09
cellular O 0 1.9284790653273376e-07
localization O 0 1.3313167528394843e-06
of O 0 1.238833480243784e-08
the O 0 2.9832945003249733e-09
protein O 0 6.2327991656729864e-09
after O 0 2.043592850498044e-09
exposure O 0 2.057172032721155e-08
to O 0 1.4787574498242861e-09
DNA O 0 2.3303817897613044e-07
- O 0 1.9398302697481995e-07
damaging O 0 6.093565474429852e-08
agents O 0 5.682000425721867e-10
are O 0 5.500630506638515e-11
consistent O 0 6.276434927343644e-10
with O 0 3.3718573072549773e-11
a O 0 2.998709058843474e-09
role O 0 9.19838250013072e-09
for O 0 4.4290922041057e-09
BRCA1 O 0 1.4829576002739486e-06
in O 0 5.869398833624473e-08
DNA O 0 6.837994988018181e-06
repair O 0 8.339672785950825e-05
. O 0 1.0791787644848228e-05

Here O 0 1.2387812375891372e-06
, O 0 8.232915682526709e-09
it O 0 1.0119914906070449e-09
is O 0 6.974198996090308e-10
shown O 0 5.065613484234177e-10
that O 0 5.096577604390973e-10
mouse O 0 6.942855179659091e-07
embryonic O 0 1.2154178875789512e-05
stem O 0 2.73842601927754e-06
cells O 0 1.437553578398365e-07
deficient B-Disease 0 4.2869876892837055e-07
in I-Disease 0 9.075452389595284e-09
BRCA1 I-Disease 0 6.488274379989889e-07
are O 0 9.73504943324599e-10
defective O 0 1.428041969120386e-07
in O 0 1.7343250169332691e-09
the O 0 1.1178716841087066e-09
ability O 0 1.4082056354336459e-10
to O 0 2.0963440705568104e-10
carry O 0 9.013791935075233e-10
out O 0 2.21553797530305e-09
transcription O 0 3.4619918665157456e-07
- O 0 3.8868279261805583e-07
coupled O 0 1.88958694025132e-07
repair O 0 3.262404391080054e-07
of O 0 3.8866197371589806e-08
oxidative O 0 6.909880880812125e-07
DNA O 0 2.096349589919555e-06
damage O 0 1.7322936400887556e-05
, O 0 8.035897280933568e-09
and O 0 2.1280424089553662e-09
are O 0 2.238957685918308e-09
hypersensitive O 0 1.4109837138676085e-06
to O 0 1.0878277834081018e-07
ionizing O 0 9.514080738881603e-05
radiation O 0 6.413861410692334e-05
and O 0 8.073818236198349e-08
hydrogen O 0 1.562656734677148e-06
peroxide O 0 8.671927389514167e-06
. O 0 1.5235926866807858e-06

These O 0 5.4860326059724684e-08
results O 0 4.4293901879655095e-08
suggest O 0 4.8103139249633386e-08
that O 0 1.4868326125849762e-08
BRCA1 O 0 8.069759132922627e-06
participates O 0 8.13748357586519e-08
, O 0 1.6064900520973424e-09
directly O 0 6.4221428175414985e-09
or O 0 1.0009786777231966e-08
indirectly O 0 1.294896350145791e-07
, O 0 5.0611252966348275e-09
in O 0 4.322096014419685e-09
transcription O 0 1.8523654716773308e-06
- O 0 1.3959345324110473e-06
coupled O 0 3.95733223967909e-07
repair O 0 9.893981314235134e-07
of O 0 1.9501248971209861e-07
oxidative O 0 5.092028914077673e-06
DNA O 0 9.282131941290572e-06
damage O 0 3.676263440866023e-05
. O 0 2.2426564783017966e-07
. O 0 7.446366225849488e-07

Truncation O 0 0.0011952302884310484
mutations O 0 1.0116474186361302e-05
in O 0 4.4637982199446924e-08
the O 0 7.6653954295125e-08
transactivation O 0 0.00010388203372713178
region O 0 1.2149484973633662e-06
of O 0 7.753724844405951e-07
PAX6 O 1 0.9612891674041748
result O 0 5.394111894929665e-07
in O 0 2.0434035263861006e-07
dominant O 0 6.338948151096702e-05
- O 0 1.8683273083297536e-05
negative O 0 5.112070539325941e-06
mutants O 0 2.8208269213791937e-06
. O 0 4.004461118256586e-07

PAX6 O 0 0.1605561077594757
is O 0 2.1398189176125015e-07
a O 0 8.637328363647612e-08
transcription O 0 9.314908879787254e-07
factor O 0 2.8366322624151508e-08
with O 0 5.0730853545788435e-11
two O 0 3.4981359475771967e-10
DNA O 0 4.024345656716832e-08
- O 0 6.11955144336207e-08
binding O 0 7.141146340927662e-08
domains O 0 4.2693375235103304e-07
( O 0 1.0703577579818102e-08
paired O 0 6.565394983226724e-08
box O 0 3.214687751551537e-07
and O 0 8.491857883541343e-09
homeobox O 0 4.788541446032468e-06
) O 0 1.7884844716320458e-09
and O 0 1.236417968009107e-09
a O 0 4.917967189044248e-08
proline O 0 1.8170748035117867e-06
- O 0 4.714980605058372e-06
serine O 0 2.6386926492705243e-06
- O 0 8.303414688271005e-06
threonine O 0 1.6853966371854767e-05
( O 0 4.6237491346801107e-07
PST O 0 0.0036752247251570225
) O 0 1.59369619723293e-07
- O 0 1.7037216366588837e-06
rich O 0 4.0993504057951213e-07
transactivation O 0 6.679526995867491e-05
domain O 0 1.3219091670180205e-05
. O 0 3.74426622329338e-06

PAX6 O 1 0.999998927116394
regulates O 0 0.002999091288074851
eye O 1 0.9281677007675171
development O 0 5.0010467020911165e-06
in O 0 3.7544953812584936e-08
animals O 0 2.43098208230208e-09
ranging O 0 1.0832767571855584e-07
from O 0 1.2089448375718348e-07
jellyfish O 0 9.445480486647284e-08
to O 0 1.1775462382956903e-08
Drosophila O 0 2.9982564342390106e-07
to O 0 1.7204191848918526e-08
humans O 0 6.05633715622389e-07
. O 0 1.359230168418435e-06

Heterozygous O 0 6.733388727298006e-05
mutations O 0 3.1786887575435685e-06
in O 0 3.0465379552424565e-08
the O 0 6.949282038704041e-08
human O 0 2.606483633371681e-07
PAX6 O 1 0.9869623780250549
gene O 0 4.930590193907847e-07
result O 0 5.184450913020555e-08
in O 0 2.055735359718369e-09
various O 0 7.897348330843101e-10
phenotypes O 0 1.2036632313083828e-07
, O 0 1.9362302872139026e-09
including O 0 1.3788143071735703e-08
aniridia B-Disease 1 1.0
, O 0 9.272876923205331e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 1.1049750128222513e-06
autosomal B-Disease 0 0.0369122177362442
dominant I-Disease 1 0.9999972581863403
keratitis I-Disease 1 1.0
, O 0 5.204968601901783e-06
and O 0 1.0182700862060301e-05
familial B-Disease 1 1.0
foveal I-Disease 1 1.0
dysplasia I-Disease 1 1.0
. O 1 0.9435000419616699

It O 0 6.555984555234318e-08
is O 0 1.9547476526327046e-08
believed O 0 1.4204460718758583e-08
that O 0 4.3507114577678863e-10
the O 0 2.2237212071729573e-09
mutated O 0 4.819497689823038e-08
allele O 0 2.5904455469571985e-07
of O 0 5.361443555784717e-08
PAX6 O 0 0.0003621627402026206
produces O 0 1.3247339225586074e-08
an O 0 4.030343170313699e-09
inactive O 0 1.258647586155348e-07
protein O 0 4.770549821841996e-08
and O 0 8.753233693425955e-09
aniridia B-Disease 1 1.0
is O 0 1.638817224147715e-07
caused O 0 2.2759513740311377e-07
due O 0 2.7797523216577247e-07
to O 0 7.25984534710733e-08
genetic O 0 3.502148683764972e-05
haploinsufficiency O 0 0.006696830503642559
. O 0 8.378457096114289e-06

However O 0 1.5930670542729786e-06
, O 0 3.4417851679791056e-08
several O 0 3.8410372660280245e-09
truncation O 0 5.450785920402268e-06
mutations O 0 6.222847446224478e-07
have O 0 2.585847536096253e-09
been O 0 4.338731152131459e-09
found O 0 6.431136734263987e-10
to O 0 3.4542047000485354e-10
occur O 0 7.11650238738315e-10
in O 0 4.818959675745305e-10
the O 0 1.8080140717913196e-09
C O 0 3.8852372199471574e-06
- O 0 3.659997105387447e-07
terminal O 0 8.859305467012746e-07
half O 0 1.1755736828433783e-08
of O 0 9.564002034778696e-09
PAX6 O 0 5.4253192502073944e-05
in O 0 3.70914610137163e-09
patients O 0 2.9425828440565738e-09
with O 0 2.9941940038469284e-09
Aniridia B-Disease 1 1.0
resulting O 0 1.3352533869692707e-06
in O 0 1.330149590472729e-08
mutant O 0 2.154812506205417e-08
proteins O 0 1.6156338766837308e-10
that O 0 3.703501047502833e-11
retain O 0 1.2131534665726917e-09
the O 0 8.921906546888181e-10
DNA O 0 1.1537796495986186e-08
- O 0 8.646422244851237e-09
binding O 0 1.1896101881347931e-08
domains O 0 4.67078926646991e-08
but O 0 1.9075721002792534e-09
have O 0 2.4711961366108426e-09
lost O 0 1.5504900829910184e-07
most O 0 1.0125128513394088e-09
of O 0 7.146934599688848e-09
the O 0 2.5736659026165398e-08
transactivation O 0 2.4918657800299115e-05
domain O 0 3.855488102999516e-06
. O 0 6.868306741125707e-07

It O 0 1.5961976629341734e-08
is O 0 4.190653601909844e-09
not O 0 5.15532672107355e-10
clear O 0 5.340691444644108e-09
whether O 0 1.522985515478581e-09
such O 0 2.5355570976159925e-09
mutants O 0 1.2335187875578413e-06
really O 0 6.71148114861353e-08
behave O 0 1.0712134290713493e-08
as O 0 5.114419998619724e-09
loss O 0 1.090303811679405e-07
- O 0 6.554584501827776e-07
of O 0 1.5829914445930626e-07
- O 0 4.7131999281191383e-07
function O 0 3.1128532640423145e-08
mutants O 0 2.0473548190125257e-08
as O 0 2.3672925841822234e-09
predicted O 0 2.993179748500552e-07
by O 0 5.546488424101881e-08
haploinsufficiency O 0 0.000578260631300509
. O 0 5.555536972678965e-06

Contrary O 0 9.661690683060442e-07
to O 0 6.894568027604464e-09
this O 0 4.631814043420945e-09
theory O 0 1.0191744195253705e-06
, O 0 4.9686805780879695e-09
our O 0 2.3834307860681747e-09
data O 0 5.7398761299509715e-09
showed O 0 1.956238504519092e-09
that O 0 8.590490818694008e-11
these O 0 1.6675047453951208e-10
mutants O 0 1.3176577162710146e-08
are O 0 4.6092332728342456e-10
dominant O 0 9.08691106360493e-07
- O 0 5.65093273507955e-07
negative O 0 1.4229711098323605e-07
in O 0 5.4288631368137885e-09
transient O 0 1.2955089800925634e-07
transfection O 0 1.8841760152099596e-07
assays O 0 5.255197166320613e-08
when O 0 1.548323913524996e-09
they O 0 2.3229700107929574e-10
are O 0 3.6964034610953433e-10
coexpressed O 0 1.4830820873612538e-06
with O 0 8.402262885454093e-09
wild O 0 1.097146878237254e-06
- O 0 9.84664529823931e-06
type O 0 0.00013287508045323193
PAX6 O 1 0.9570866227149963
. O 0 1.5304638509405777e-05

We O 0 1.2498726675858052e-07
found O 0 5.622430077067975e-09
that O 0 4.2339884376296766e-10
the O 0 9.958768920625971e-09
dominant O 0 9.901373232423794e-06
- O 0 1.7441506088289316e-06
negative O 0 2.3370920132492756e-07
effects O 0 1.37091902274733e-07
result O 0 7.921097555652068e-09
from O 0 1.855184228460871e-09
the O 0 8.651713234719693e-10
enhanced O 0 2.9983602267691367e-09
DNA O 0 1.937073434987724e-08
binding O 0 2.1702305730286753e-08
ability O 0 6.2080025564625885e-09
of O 0 3.149294158788507e-08
these O 0 2.366467732883848e-08
mutants O 0 1.04390289834555e-06
. O 0 8.029479658944183e-07

Kinetic O 0 7.474052381439833e-06
studies O 0 7.132407375820549e-08
of O 0 2.1852086362628143e-08
binding O 0 2.993185432842438e-07
and O 0 3.977635287810699e-08
dissociation O 0 3.781687837545178e-06
revealed O 0 9.747598284093328e-08
that O 0 3.5418157295907804e-10
various O 0 4.87936469006911e-10
truncation O 0 1.287399072680273e-06
mutants O 0 4.8735465441041015e-08
have O 0 9.102179010511691e-10
3 O 0 2.280968125489835e-08
- O 0 4.538513920238074e-08
5 O 0 2.7385038237071058e-08
- O 0 3.14307122550872e-08
fold O 0 1.8240905674815622e-08
higher O 0 7.350843045372812e-09
affinity O 0 8.05967559358578e-09
to O 0 5.539504965845765e-10
various O 0 3.512363455637768e-10
DNA O 0 7.66273178243182e-09
- O 0 4.366126127308689e-09
binding O 0 3.3034974755707935e-09
sites O 0 9.001096534788644e-10
when O 0 2.664736209467833e-10
compared O 0 1.1931773347129138e-09
with O 0 1.3595248538056381e-10
the O 0 1.3517200692092501e-08
wild O 0 2.0949717338680784e-07
- O 0 2.37792983170948e-06
type O 0 3.69985937140882e-05
PAX6 O 0 0.09653610736131668
. O 0 8.446214451396372e-06

These O 0 2.222471806589965e-08
results O 0 2.5019252447577855e-08
provide O 0 2.9495168529791727e-09
a O 0 3.1965218028062736e-08
new O 0 5.7632094652149135e-09
insight O 0 2.4316834768001172e-08
into O 0 3.607184995146895e-09
the O 0 1.2400408477830638e-09
role O 0 4.077369109012352e-09
of O 0 7.031181858963009e-09
mutant O 0 1.0130388545803726e-06
PAX6 O 0 0.004014899022877216
in O 0 1.2588084530307242e-07
causing O 0 2.2216670913621783e-05
aniridia B-Disease 1 1.0
. O 0 3.4543841138656717e-06
. O 0 3.873140485666227e-06

Reversal O 0 6.69285946059972e-05
of O 0 2.6457521016709507e-05
severe O 1 1.0
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
and O 0 0.00010426182416267693
excellent O 0 1.9919651094824076e-05
neuropsychologic O 1 0.9999356269836426
outcome O 0 0.028523685410618782
in O 0 4.2584272108570076e-08
very B-Disease 0 3.6609460352110546e-08
- I-Disease 0 6.988252607698087e-07
long I-Disease 0 2.9843036486454366e-07
- I-Disease 0 5.220769594416197e-07
chain I-Disease 0 9.66847792938097e-08
acyl I-Disease 0 5.560299882745312e-07
- I-Disease 0 7.563968438262236e-07
coenzyme I-Disease 0 6.666724061688001e-07
A I-Disease 0 9.853967640083283e-05
dehydrogenase I-Disease 0 0.2766695022583008
deficiency I-Disease 1 0.9960358738899231
. O 0 3.750298492377624e-05

Very B-Disease 0 5.11784628542955e-06
- I-Disease 0 4.833978528040461e-05
long I-Disease 0 2.9290945349202957e-06
- I-Disease 0 5.751369826612063e-06
chain I-Disease 0 3.350648967170855e-07
acyl I-Disease 0 4.5085582200954377e-07
- I-Disease 0 1.6818169967791619e-07
coenzyme I-Disease 0 3.346764998468643e-08
A I-Disease 0 1.746849420669605e-07
dehydrogenase I-Disease 0 8.353798648386146e-07
( I-Disease 0 6.616130576730939e-08
VLCAD I-Disease 1 0.9999998807907104
) I-Disease 0 9.183727911477035e-07
deficiency I-Disease 0 0.023271944373846054
is O 0 2.8239945493169216e-08
a O 0 5.279243850964122e-07
disorder O 1 0.5868308544158936
of O 0 3.1166846383712254e-06
fatty O 0 7.187564278865466e-06
acid O 0 1.5712448941940238e-07
beta O 0 1.712587049951253e-07
oxidation O 0 2.935050602559386e-08
that O 0 8.019143682425067e-10
reportedly O 0 6.012530917587355e-08
has O 0 6.236244298740701e-10
high O 0 5.951032555628899e-09
rates O 0 5.469209529707086e-09
of O 0 1.5395903218973217e-08
morbidity O 0 6.814987955294782e-06
and O 0 2.5607056386434124e-07
mortality O 0 7.397514855256304e-05
. O 0 3.658653895399766e-06

We O 0 7.727667394874516e-08
describe O 0 2.9548282043379004e-08
the O 0 6.3423124530004316e-09
outcome O 0 8.594633982283995e-08
of O 0 4.561623079268884e-09
a O 0 5.868578956125248e-09
5 O 0 1.717376640897328e-08
- O 0 1.630109380812428e-08
year O 0 5.347225329188632e-09
- O 0 7.604350571455143e-08
old O 0 5.3669072741513446e-08
girl O 0 6.812463926308965e-09
with O 0 3.868438902543403e-09
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.8962275539233815e-06
was O 0 3.79673497263866e-06
first O 0 2.2947750366597575e-08
seen O 0 7.565777337958934e-09
at O 0 2.882939442727661e-09
5 O 0 1.4732620678969965e-09
months O 0 4.988248702986198e-10
of O 0 5.364906296989602e-10
age O 0 3.955752614359653e-09
with O 0 1.7275867403299117e-09
severe O 1 0.9999995231628418
hypertrophic B-Disease 1 1.0
cardiomyopathy I-Disease 1 1.0
, O 1 0.9999996423721313
hepatomegaly B-Disease 1 1.0
, O 1 0.999835729598999
encephalopathy B-Disease 1 1.0
, O 0 9.002231672639027e-05
and O 0 8.698851161170751e-05
hypotonia B-Disease 1 0.9999628067016602
. O 0 0.0011073773493990302

Biochemical O 0 9.850905189523473e-05
studies O 0 9.081289135792758e-06
indicated O 1 0.9998875856399536
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 7.337194256251678e-05
by O 0 3.429773087759713e-08
a O 0 2.7763530852098484e-07
stable O 0 1.4863131809761398e-06
yet O 0 5.611332767330168e-07
inactive O 0 6.036447757651331e-06
enzyme O 0 1.6834999314596644e-06
. O 0 1.3309118003235199e-06

Molecular O 0 2.1761552488896996e-05
genetic O 0 9.872218242890085e-07
analysis O 0 8.188614941673222e-08
of O 0 4.1550956098035385e-07
her O 0 9.982544924014292e-08
VLCAD O 1 0.999991774559021
gene O 0 1.320043452324171e-06
revealed O 0 6.984282094890659e-07
a O 0 4.042525176828349e-07
T1372C O 0 0.0009743970003910363
( O 0 1.0684244955427857e-07
F458L O 0 2.1141535398783162e-05
) O 0 1.299592078396472e-08
missense O 0 1.3676508388016373e-06
mutation O 0 1.8435559923091205e-07
and O 0 1.4918779100980828e-08
a O 0 1.5087877045516507e-06
1668 O 1 0.7219946980476379
ACAG O 1 0.9995367527008057
1669 O 0 0.00039029662730172276
splice O 0 7.214074139483273e-05
site O 0 2.193840373365674e-06
mutation O 0 7.68456629884895e-06
. O 0 2.0768586637132103e-06

After O 0 4.1251041693612933e-07
initial O 0 1.2965656992491859e-07
treatment O 0 5.6517855284710095e-08
with O 0 2.4297905909520523e-09
intravenous O 0 1.0116737030330114e-06
glucose O 0 7.772331628075335e-06
and O 0 2.975384161274519e-09
carnitine O 0 8.516190632690268e-07
, O 0 1.7594642409690664e-09
the O 0 3.0141860118959585e-09
patient O 0 1.8787297051403584e-08
has O 0 3.2358904444862446e-09
thrived O 0 2.8115957562135918e-08
on O 0 2.173344393341381e-09
a O 0 4.6319468260946906e-09
low O 0 6.557022516062716e-07
- O 0 4.772051624968299e-07
fat O 0 1.680173795648443e-07
diet O 0 6.790021433999982e-09
supplemented O 0 2.3834489937257786e-09
with O 0 2.747934657598705e-10
medium O 0 1.1636208228082978e-06
- O 0 1.5662852774767089e-06
chain O 0 1.8934743195586634e-07
triglyceride O 0 9.181801488011843e-07
oil O 0 3.63363483302237e-07
and O 0 6.471821301090586e-09
carnitine O 0 3.8598554397140106e-07
and O 0 3.8685201708688055e-09
avoidance O 0 6.711057949360111e-07
of O 0 9.62782451097155e-07
fasting O 0 4.916644684271887e-06
. O 0 8.618022775408463e-07

Her O 0 6.816171207901789e-06
ventricular O 1 0.9999774694442749
hypertrophy O 1 0.9999948740005493
resolved O 0 5.653447442455217e-05
significantly O 0 2.3424227890700422e-07
over O 0 3.421409644488449e-08
1 O 0 3.495552505228261e-07
year O 0 3.208761700790319e-09
, O 0 4.720779323008628e-10
and O 0 1.3924613684324072e-09
cognitively O 0 2.6897994302998995e-06
, O 0 7.593795814386795e-09
she O 0 1.5082022297718822e-09
is O 0 3.6674280279314075e-10
in O 0 1.303212121550601e-10
the O 0 1.0491141289037387e-09
superior O 0 7.270987367746784e-08
range O 0 2.763702013908187e-07
for O 0 7.035772142671703e-08
age O 0 4.3185323193029035e-06
. O 0 2.5277633994846838e-06

Clinical O 0 2.461966323608067e-05
recognition O 0 9.80947424977785e-06
of O 1 0.9999986886978149
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 2.1045381799922325e-05
important O 0 7.509537880423522e-08
because O 0 1.7706073274226242e-09
it O 0 1.6459070217855754e-10
is O 0 1.2338143007273317e-10
one O 0 8.270569645807413e-11
of O 0 2.816992750176439e-10
the O 0 5.178594775223644e-10
few O 0 9.675774625961253e-10
directly O 0 3.951885929609489e-08
treatable O 1 0.9857220649719238
causes O 0 7.620582209710847e-07
of O 0 0.00022145331604406238
cardiomyopathy B-Disease 1 1.0
in O 0 0.00011634214024525136
children O 0 1.2926852832606528e-07
. O 0 8.911268167821618e-08
. O 0 5.936410616413923e-07

Cloning O 0 4.044243723910768e-06
of O 0 8.9316024798336e-08
a O 0 3.704820628058769e-08
novel O 0 6.932428675554547e-08
member O 0 1.1932734800268463e-08
of O 0 6.657293383227625e-09
the O 0 1.8486222330693636e-08
low O 0 5.397660515882308e-06
- O 0 1.515072995061928e-06
density O 0 4.884187774223392e-07
lipoprotein O 0 0.0001019599731080234
receptor O 0 9.32735565584153e-05
family O 0 6.351576189445041e-07
. O 0 8.780223765825212e-07

A O 0 4.794367214344675e-06
gene O 0 2.0305530767927849e-07
encoding O 0 1.233277089340845e-07
a O 0 6.387305262478549e-08
novel O 0 2.1702476260543335e-07
transmembrane O 0 3.6632479805120965e-06
protein O 0 3.304230133949204e-08
was O 0 6.426382537227937e-09
identified O 0 3.651653146530265e-10
by O 0 4.593573785238725e-11
DNA O 0 6.584237044471308e-10
sequence O 0 8.878613122487167e-11
analysis O 0 7.080726976971263e-11
within O 0 3.469391163246627e-10
the O 0 2.6662321239712128e-09
insulin B-Disease 0 3.100156027358025e-05
- I-Disease 0 0.05898172780871391
dependent I-Disease 1 0.96479332447052
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.5878535931697115e-06
IDDM B-Disease 1 0.9772540330886841
) O 0 2.060280763771516e-07
locus O 0 1.03539878182346e-05
IDDM4 O 0 0.00012305137352086604
on O 0 1.0445093039379572e-06
chromosome O 0 8.528320904588327e-05
11q13 O 0 0.00019600258383434266
. O 0 2.9299999368959107e-06

Based O 0 4.457859574813483e-07
on O 0 8.804274642670862e-08
its O 0 4.934717967586266e-09
chromosomal O 0 0.00012326780415605754
position O 0 1.9180092749593314e-06
, O 0 1.0924865456729549e-09
this O 0 4.5383796720699365e-10
gene O 0 1.9520938199235616e-09
is O 0 1.971418861490548e-10
a O 0 1.5817647192051254e-09
candidate O 0 4.32277431627881e-08
for O 0 1.8397046108731274e-09
conferring O 0 3.1580617587678717e-07
susceptibility O 0 0.05176772549748421
to O 0 5.755573056376306e-06
diabetes B-Disease 1 1.0
. O 0 0.0015346752479672432

The O 0 9.363663480144169e-07
gene O 0 3.0994729627309425e-07
, O 0 1.916968628279392e-08
termed O 0 3.1238023439073004e-06
low O 0 0.0001084368268493563
- O 0 5.715173756470904e-06
density O 0 2.2273228239555465e-07
lipoprotein O 0 1.0916831342910882e-05
receptor O 0 2.196660261688521e-06
related O 0 2.1918875603432753e-08
protein O 0 3.4035039675472945e-08
5 O 0 4.16259844371325e-08
( O 0 1.7961497178475838e-08
LRP5 O 0 0.0010059510823339224
) O 0 4.196909042519792e-09
, O 0 1.6968886296098162e-09
encodes O 0 6.426554399752149e-09
a O 0 4.858480728842096e-09
protein O 0 1.902848900670051e-08
of O 0 1.8441145499537015e-08
1615 O 0 3.1229087653628085e-06
amino O 0 5.7281113186036237e-08
acids O 0 4.109740103785953e-09
that O 0 7.789245637379594e-11
contains O 0 3.919714830491472e-10
conserved O 0 1.1801454924409427e-08
modules O 0 7.399317603073996e-09
which O 0 1.0258454502531933e-10
are O 0 3.2746992617571635e-11
characteristic O 0 1.3711374258207343e-09
of O 0 3.9449026267845966e-09
the O 0 6.231468230311066e-09
low O 0 1.0526885034778388e-06
- O 0 2.799017124743841e-07
density O 0 3.568808537579571e-08
lipoprotein O 0 2.0045620203745784e-06
( O 0 5.263914815145654e-08
LDL O 0 5.718447937397286e-05
) O 0 9.119078470121167e-08
receptor O 0 3.930405455321306e-06
family O 0 9.300957515279151e-08
. O 0 7.096812737472646e-07

These O 0 5.496139721117288e-08
modules O 0 4.0913243992690695e-07
include O 0 1.0717878140553694e-08
a O 0 1.5120865271001094e-07
putative O 0 3.6213577914168127e-06
signal O 0 9.263995366382005e-07
peptide O 0 1.3700537238037214e-07
for O 0 2.388956144017129e-09
protein O 0 1.2186202269504065e-08
export O 0 7.801103762972161e-09
, O 0 2.3877579913289537e-09
four O 0 5.316512563524611e-09
epidermal O 0 4.628911938198144e-06
growth O 0 7.528109335908084e-08
factor O 0 3.1659533306083176e-07
( O 0 5.267038361012055e-08
EGF O 0 4.396167423692532e-05
) O 0 3.88657372951684e-09
repeats O 0 1.2821699257870023e-08
with O 0 1.8793083755852535e-10
associated O 0 1.6181274986593053e-08
spacer O 0 3.0192452413757564e-06
domains O 0 7.62625347761059e-07
, O 0 8.541631402181338e-09
three O 0 8.116785465972498e-09
LDL O 0 5.361542571336031e-05
- O 0 3.528672823449597e-05
receptor O 0 2.8290676709730178e-05
( O 0 1.20259855407312e-07
LDLR O 0 0.2698286175727844
) O 0 1.176773789524077e-08
repeats O 0 2.9392747791234797e-08
, O 0 9.914699061752685e-10
a O 0 9.104128118053723e-09
single O 0 4.792126873098823e-08
transmembrane O 0 1.771108486536832e-06
spanning O 0 3.058415245504875e-07
domain O 0 3.211038404060673e-07
, O 0 6.049349465797604e-09
and O 0 5.765474764274359e-09
a O 0 2.446487314955448e-07
cytoplasmic O 0 1.9344915926922113e-05
domain O 0 9.00321265362436e-06
. O 0 1.472542862757109e-06

The O 0 4.832835998058727e-07
encoded O 0 3.1926501264933904e-07
protein O 0 6.67216895067213e-08
has O 0 9.021824953769908e-10
a O 0 1.7097735449667084e-09
unique O 0 1.6279151360265587e-09
organization O 0 1.781043756921008e-08
of O 0 4.667539315050817e-07
EGF O 1 0.9982958436012268
and O 0 1.6249461509687535e-07
LDLR O 1 0.9999865293502808
repeats O 0 5.171592079022957e-07
; O 0 3.08761993750295e-09
therefore O 0 2.493474049458655e-08
, O 0 1.6896066767912998e-08
LRP5 O 1 0.9962252378463745
likely O 0 9.980565351952464e-08
represents O 0 1.2226783141500164e-08
a O 0 4.777959805579712e-09
new O 0 1.2162232332357803e-09
category O 0 4.415935350721156e-08
of O 0 1.695692297687401e-08
the O 0 1.4325979691420798e-07
LDLR O 1 0.9998171925544739
family O 0 8.848126071825391e-07
. O 0 1.7678498807072174e-06

Both O 0 8.819448567010113e-07
human O 0 1.8976014359850524e-07
and O 0 2.734359583200785e-08
mouse O 0 6.426571871998021e-06
LRP5 O 1 0.9999985694885254
cDNAs O 1 0.9680676460266113
have O 0 1.8311810734417122e-08
been O 0 3.331447828713863e-08
isolated O 0 6.827490750538345e-08
and O 0 4.745497328428883e-10
the O 0 1.592690535012764e-09
encoded O 0 6.833806853734359e-09
mature O 0 1.3123898634503917e-09
proteins O 0 3.962424138803655e-11
are O 0 1.3288669643840567e-11
95 O 0 5.047224416188101e-09
% O 0 3.150674388052721e-09
identical O 0 2.6900666139084706e-09
, O 0 1.9058954414674645e-09
indicating O 0 3.265678572006436e-08
a O 0 2.7657261369995467e-08
high O 0 1.6271420122393465e-07
degree O 0 7.026491175565752e-07
of O 0 6.273077701735019e-08
evolutionary O 0 1.4308081972558284e-06
conservation O 0 1.8032886828223127e-07
. O 0 4.173370626858741e-08
. O 0 6.573877726623323e-07

The O 0 6.906870112288743e-06
APC B-Disease 0 3.054548869840801e-05
variants O 0 7.3520204750820994e-06
I1307K O 0 0.001318670460022986
and O 0 3.217060751126155e-08
E1317Q O 0 2.278869396832306e-05
are O 0 1.2181851083425954e-09
associated O 0 1.5114348173028702e-07
with O 0 0.000354226678609848
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.3457384739012923e-05
but O 0 1.2489046241626056e-08
not O 0 1.673036265081862e-09
always O 0 1.6856113171925813e-09
with O 0 1.5066374536854e-10
a O 0 1.7893656334422303e-08
family O 0 1.9334116529989842e-08
history O 0 3.598721036723873e-07
. O 0 9.92564082480385e-07

Classical O 0 0.007672864478081465
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.021093549206852913
FAP B-Disease 1 0.86305171251297
) O 0 1.3736719317591906e-08
is O 0 2.511304275643056e-09
a O 0 1.9884600632735783e-08
high O 0 3.9751546864863485e-05
- O 1 0.9098228812217712
penetrance O 1 0.9999994039535522
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999995231628418
that O 0 2.95820594686802e-08
predisposes O 0 1.8778503090288723e-06
to O 0 3.2100289093506262e-09
hundreds O 0 1.0432554820027917e-09
or O 0 2.49775689020737e-09
thousands O 0 5.3288982115873296e-09
of O 0 5.856739790033316e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999982118606567
carcinoma I-Disease 1 1.0
and O 0 2.1843173669822136e-07
that O 0 6.370998839599906e-09
results O 0 1.6335517827315016e-08
from O 0 1.3244205732121372e-08
truncating O 0 2.4553929733883706e-07
mutations O 0 4.898438632494617e-08
in O 0 5.624875232257409e-09
the O 0 6.671863417295754e-08
APC B-Disease 0 5.279407560010441e-06
gene O 0 1.1126285244245082e-06
. O 0 6.823701141911442e-07

A O 0 3.582166073101689e-06
variant O 0 6.600856067962013e-06
of O 0 3.6459196053328924e-06
FAP B-Disease 0 0.0016196820652112365
is O 0 1.1873657967953477e-06
attenuated B-Disease 1 0.9684048891067505
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 0.9999992847442627
, O 0 2.6293371035990276e-08
which O 0 1.3296441725429986e-09
results O 0 2.4084092498100063e-09
from O 0 9.632580955099002e-09
germ O 0 3.616061803768389e-05
- O 0 2.8511431082733907e-07
line O 0 6.829144894027195e-08
mutations O 0 8.85913475912048e-09
in O 0 2.704346468984653e-10
the O 0 8.871439693969307e-10
5 O 0 7.2451378230198316e-09
and O 0 3.0620830870908833e-10
3 O 0 8.986810406952372e-09
regions O 0 5.375407674534927e-09
of O 0 1.8768279375080965e-08
the O 0 1.378942471319533e-07
APC B-Disease 0 8.524643817509059e-06
gene O 0 1.8642429040482966e-06
. O 0 7.429867423525138e-07

Attenuated B-Disease 1 0.9999984502792358
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 0 0.005247837398201227
have O 0 1.7221483972207352e-07
" O 0 2.352746605538414e-06
multiple O 0 1.2876917935500387e-05
" O 1 0.9999982118606567
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 5.505466447175422e-07
typically O 0 1.5733045088950348e-08
fewer O 0 5.20698095751726e-10
than O 0 4.17834433719122e-10
100 O 0 1.296140417217373e-09
) O 0 1.1180800035814897e-10
without O 0 5.642301070807321e-10
the O 0 5.754883236619435e-09
florid O 0 1.960118424904067e-06
phenotype O 0 1.1708116289810278e-06
of O 0 9.452509885932159e-08
classical O 0 1.7228498109034263e-05
FAP B-Disease 0 9.489236254012212e-05
. O 0 3.130154482278158e-06

Another O 0 1.1907541193068027e-06
group O 0 1.197156223042839e-07
of O 0 6.428959409277013e-08
patients O 0 1.4891883282075469e-08
with O 0 3.0766327263620497e-09
multiple O 0 0.0020000238437205553
adenomas B-Disease 1 1.0
has O 0 1.777040665729146e-07
no O 0 1.7925254169881555e-08
mutations O 0 1.7949716379916936e-08
in O 0 9.90842297099448e-10
the O 0 3.2661315874094043e-09
APC B-Disease 0 8.860625655415788e-08
gene O 0 7.720121431020743e-09
, O 0 5.002273595344775e-10
and O 0 4.1463346645009835e-10
their O 0 7.426177450753357e-10
phenotype O 0 2.222655439254595e-06
probably O 0 9.227291997149223e-08
results O 0 7.793920175913627e-09
from O 0 2.6453219614808177e-09
variation O 0 7.963789983023162e-08
at O 0 5.942888403609459e-09
a O 0 1.2619588707352136e-09
locus O 0 1.6357616061668523e-07
, O 0 3.2108601888403143e-10
or O 0 4.116141649745941e-09
loci O 0 2.5908903467097844e-07
, O 0 2.3348447619753188e-09
elsewhere O 0 1.3978533885961042e-08
in O 0 4.7804027403230975e-09
the O 0 3.5897670613849186e-08
genome O 0 2.1577302504738327e-06
. O 0 1.1856074024763075e-06

Recently O 0 1.5533614714513533e-05
, O 0 6.549160502800078e-08
however O 0 5.0214932656444944e-08
, O 0 5.3581494796617335e-09
a O 0 9.187878902139346e-09
missense O 0 4.1092883407145564e-07
variant O 0 1.1533790029716329e-06
of O 0 1.4504656746794353e-06
APC B-Disease 0 1.9767050616792403e-05
( O 0 3.2836918961720585e-08
I1307K O 0 8.645577327115461e-05
) O 0 1.0992357024619537e-09
was O 0 7.157452408534937e-09
described O 0 9.133151457341171e-10
that O 0 3.411916235651624e-11
confers O 0 4.03386524183702e-09
an O 0 2.8815744235188845e-10
increased O 0 2.3764684442539874e-08
risk O 0 0.00019905687076970935
of O 1 0.9999997615814209
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.9456957892980427e-05
including O 0 4.773061945684276e-08
multiple O 0 1.1683973752951715e-05
adenomas B-Disease 1 0.9999990463256836
, O 0 5.980631954116689e-07
in O 0 1.1241454558330588e-06
Ashkenazim O 0 0.09611881524324417
. O 0 6.986159405641956e-06

We O 0 2.3196123777324829e-07
have O 0 4.35395142162065e-09
studied O 0 5.142682724113001e-08
a O 0 8.68225047412352e-09
set O 0 1.0448969689491605e-08
of O 0 7.156156112131384e-09
164 O 0 6.352920678409646e-08
patients O 0 2.3736361765003267e-09
with O 0 2.8070825663917276e-09
multiple O 1 0.9999793767929077
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9999955892562866
/ I-Disease 1 1.0
or I-Disease 1 0.9999983310699463
carcinoma I-Disease 1 1.0
and O 0 4.89562751226913e-07
analyzed O 0 7.408534656860866e-07
codons O 0 7.145505378503003e-07
1263 O 0 7.206727786979172e-06
- O 0 7.038711373752449e-07
1377 O 0 3.876761184073985e-06
( O 0 5.395872548774605e-08
exon O 0 2.6643406272341963e-06
15G O 0 2.5592412384867202e-06
) O 0 8.628608938465732e-10
of O 0 1.7481842640165723e-09
the O 0 7.566700155337003e-09
APC B-Disease 0 3.596672684125224e-07
gene O 0 2.61030912440674e-08
for O 0 1.1406770639155184e-08
germ O 0 0.057959288358688354
- O 0 0.0003075726272072643
line O 0 3.7817993870703503e-05
variants O 0 1.5358178643509746e-05
. O 0 1.6583137494308176e-06

Three O 0 5.859968723598286e-07
patients O 0 5.913989298278466e-08
with O 0 2.125851716883176e-09
the O 0 1.3467449377913e-07
I1307K O 0 5.6240445701405406e-05
allele O 0 4.1006481410477136e-07
were O 0 3.959240046924606e-09
detected O 0 1.0075392076203116e-08
, O 0 1.6267222291421746e-10
each O 0 4.790468022264349e-10
of O 0 2.20780229653883e-08
Ashkenazi O 0 2.6748153686639853e-05
descent O 0 7.647137681487948e-05
. O 0 2.7674152534018504e-06

Four O 0 6.429389145523601e-07
patients O 0 1.289354827349598e-07
had O 0 1.9431149667070713e-07
a O 0 7.706382803007727e-07
germ O 1 0.9996832609176636
- O 0 0.0007711649523116648
line O 0 3.852327154163504e-06
E1317Q O 0 1.2324756426096428e-05
missense O 0 2.066648789877945e-07
variant O 0 7.660542422627259e-08
of O 0 2.58693440002844e-08
APC O 0 9.975769188486083e-08
that O 0 1.951638572972314e-10
was O 0 4.098209771541406e-09
not O 0 1.032998339645097e-10
present O 0 1.5512170714604423e-10
in O 0 1.8672567658750694e-10
controls O 0 5.311060036206072e-09
; O 0 3.544599891380784e-10
one O 0 5.980090311830111e-10
of O 0 5.981458661707961e-10
these O 0 2.4317447361310585e-11
individuals O 0 1.6748488707030162e-10
had O 0 7.754285213934509e-09
an O 0 1.8895458531176246e-09
unusually O 0 2.7758837006786052e-08
large O 0 4.755430715874809e-09
number O 0 1.6035388572532838e-09
of O 0 3.5088181249420813e-08
metaplastic B-Disease 0 0.0005799878272227943
polyps I-Disease 0 5.524281732505187e-06
of I-Disease 0 3.3380698027940525e-07
the I-Disease 0 1.0868660638152505e-06
colorectum I-Disease 0 0.0036465791054069996
. O 0 1.017289741866989e-05

There O 0 1.412436319014887e-07
is O 0 1.3527802877888462e-08
increasing O 0 8.602468959395537e-09
evidence O 0 4.0111856058899775e-09
that O 0 3.893858013803708e-10
there O 0 4.227374006404716e-09
exist O 0 1.1671796862344763e-08
germ O 0 5.999934273859253e-06
- O 0 1.895638916948883e-07
line O 0 3.072752008392854e-08
variants O 0 1.0607527300976471e-08
of O 0 1.8590132766505008e-09
the O 0 3.5670237874541044e-09
APC B-Disease 0 8.041666177405205e-08
gene O 0 2.161846923698363e-09
that O 0 9.211260226793527e-11
predispose O 0 2.5899657529748765e-08
to O 0 1.0329003208298104e-09
the O 0 2.9065205797706994e-09
development O 0 1.379985103966419e-08
of O 0 9.56068575419522e-08
multiple O 1 0.9995658993721008
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 1.0
carcinoma I-Disease 1 1.0
, O 0 4.087816705578007e-06
but O 0 1.4155345340327585e-08
without O 0 4.672444653408547e-09
the O 0 4.6215866689180984e-09
florid O 0 3.9521276562481944e-07
phenotype O 0 7.547318148226623e-08
of O 0 4.346881521399837e-09
classical O 0 4.2429425661794085e-07
FAP B-Disease 0 2.5002946131280623e-06
, O 0 1.4154527550047646e-09
and O 0 1.9787912974855715e-10
possibly O 0 3.454232899713361e-09
with O 0 2.781694874443019e-10
importance O 0 9.71440158537007e-07
for O 1 0.9301170706748962
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 1 0.9999979734420776
in O 0 5.057924212792386e-08
the O 0 1.8401021151248642e-08
general O 0 5.527857993570251e-08
population O 0 1.0315896581403194e-08
. O 0 1.1703853886047e-08
. O 0 1.912094234057804e-07

Genomic O 0 2.929139327534358e-06
structure O 0 2.3099367751910904e-07
of O 0 2.6209360726170416e-07
the O 0 3.4283912100363523e-06
human O 1 0.959094762802124
congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999978542327881
CLD B-Disease 1 1.0
) O 0 2.348585894651478e-06
gene O 0 3.691458459798014e-06
. O 0 8.830431852402398e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 1 0.9999995231628418
CLD B-Disease 1 1.0
) O 0 1.4929061364910012e-07
is O 0 3.2788085579937842e-09
caused O 0 4.010114462715819e-09
by O 0 3.5054631419839666e-10
mutations O 0 7.85720644103094e-09
in O 0 8.274929075291482e-10
a O 0 2.606228122203902e-09
gene O 0 2.9996014561106676e-09
which O 0 4.451465307475644e-10
encodes O 0 2.480344285515912e-08
an O 0 1.0930436111777908e-08
intestinal O 0 0.000484439980937168
anion O 0 0.0026152010541409254
transporter O 1 0.9260557889938354
. O 0 1.0078360901388805e-05

We O 0 5.607149091702013e-07
report O 0 1.7464222068497293e-08
here O 0 4.80826622961672e-09
the O 0 1.5090080296431552e-09
complete O 0 5.839002170660024e-09
genomic O 0 1.9730089206859702e-07
organization O 0 2.3629631584753952e-08
of O 0 2.583098535069439e-08
the O 0 7.710617921929952e-08
human O 0 7.588628250232432e-07
CLD B-Disease 1 0.9930148124694824
gene O 0 9.393181699124398e-08
which O 0 1.9736734468978057e-09
spans O 0 7.215270159122156e-08
approximately O 0 1.9187684330290722e-08
39kb O 0 4.5281308302946854e-06
, O 0 9.118848787181832e-09
and O 0 9.978428749946033e-09
comprises O 0 7.42626866667706e-08
21 O 0 9.190352443511074e-07
exons O 0 2.2445174181484617e-05
. O 0 2.305199586771778e-06

All O 0 3.8138423406053334e-06
exon O 0 7.816780998837203e-05
/ O 0 1.0185945029661525e-05
intron O 0 1.5586141671519727e-05
boundaries O 0 9.918660026642101e-08
conform O 0 1.5663578878388762e-08
to O 0 1.4489812905083e-08
the O 0 1.6111589218326117e-07
GT O 0 0.00010513511369936168
/ O 0 0.000755976012442261
AG O 1 0.9998756647109985
rule O 0 1.9131015505990945e-05
. O 0 5.010953373130178e-06

An O 0 7.092577902767516e-08
analysis O 0 9.62694528539032e-08
of O 0 1.0058114696676057e-07
the O 0 1.489951841904258e-07
putative O 0 0.0010507891420274973
promoter O 0 0.05654963478446007
region O 0 4.71845311267316e-07
sequence O 0 3.78406461720715e-08
shows O 0 3.7220302395724048e-09
a O 0 1.0161799224306378e-07
putative O 0 0.0014296589652076364
TATA O 1 0.877517819404602
box O 0 3.761057541851187e-06
and O 0 3.137716575452032e-08
predicts O 0 6.506082854684792e-07
multiple O 0 3.045712659854871e-08
transcription O 0 2.04441448659054e-06
factor O 0 1.6799077684481745e-07
binding O 0 3.3047348324544146e-07
sites O 0 5.352146104087296e-07
. O 0 1.0457202961333678e-06

The O 0 6.207105229805165e-07
genomic O 0 2.969291017507203e-06
structure O 0 1.854816105151258e-07
was O 0 7.158274684115895e-08
determined O 0 7.2962826891398436e-09
using O 0 8.768754056198702e-10
DNA O 0 1.4067654596772172e-08
from O 0 1.2723564424277356e-09
several O 0 2.2200163929397831e-10
sources O 0 1.6956300807891012e-09
including O 0 3.1229777097685485e-10
multiple O 0 9.4658929583602e-09
large O 0 2.217793024783532e-07
- O 0 4.124956831219606e-06
insert O 0 1.430578890904144e-06
libaries O 0 1.71481315192068e-05
and O 0 3.630612033234115e-09
genomic O 0 1.8101255250257964e-07
DNA O 0 1.4116363900029683e-07
from O 0 4.88988796121248e-08
Finnish O 0 0.0005271303816698492
CLD B-Disease 1 0.9999929666519165
patients O 0 4.742010162317456e-07
and O 0 9.213152907250333e-08
controls O 0 1.8451688447385095e-05
. O 0 1.0586632015474606e-05

Exon O 0 8.379802602576092e-05
- O 0 1.0800496283991379e-06
specific O 0 1.6384070988806343e-08
primers O 0 7.270237460943463e-07
developed O 0 2.1159134888648623e-08
in O 0 1.8743049334801754e-09
this O 0 8.711656951376767e-10
study O 0 1.5107762818544757e-09
will O 0 3.156513384006132e-10
facilitate O 0 6.010438258208239e-10
mutation O 0 5.351204368508888e-09
screening O 0 5.396713742555903e-09
studies O 0 1.918387004806732e-09
of O 0 3.2739031485817804e-09
patients O 0 1.9901778003372783e-09
with O 0 2.0890247309779397e-09
the O 0 4.286552666599164e-06
disease O 1 0.9207339286804199
. O 0 1.77451493073022e-05

Genomic O 0 3.773330263356911e-06
sequencing O 0 8.641098929729196e-07
of O 0 1.6036656802498328e-07
a O 0 1.1176033467563684e-06
BAC O 1 0.9997705817222595
clone O 0 0.05751496180891991
H O 1 1.0
_ O 0 1.1399308732507052e-06
RG364P16 O 0 5.9291320212651044e-05
revealed O 0 3.402880821568033e-08
the O 0 1.1345187012068436e-09
presence O 0 1.693138407254935e-09
of O 0 5.476161302198079e-09
another O 0 2.366278195609084e-08
, O 0 2.479822791556785e-09
highly O 0 2.7206863428830275e-09
homologous O 0 3.959187200308634e-09
gene O 0 7.587280137499874e-09
3 O 0 2.467095505664929e-08
of O 0 7.93936827392372e-09
the O 0 5.239463973794045e-08
CLD B-Disease 1 0.9965588450431824
gene O 0 1.5413451137646916e-07
, O 0 1.0551263196489913e-09
with O 0 9.53583184637452e-11
a O 0 3.1705680303417694e-09
similar O 0 1.2226286649763551e-09
genomic O 0 1.242447353888565e-07
structure O 0 4.055591418250515e-08
, O 0 1.903436075423315e-09
recently O 0 3.3545215494257263e-09
identified O 0 2.4910769003128053e-09
as O 0 1.868447618846858e-09
the O 0 2.535360863475944e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00015470435027964413
( O 0 1.2082790590284276e-06
PDS B-Disease 1 0.6453059315681458
) O 0 7.602842089227124e-08
. O 0 1.280939727621444e-07
. O 0 6.390705493686255e-07

The O 0 5.151911750544969e-07
APCI1307K O 1 0.917625367641449
allele O 0 0.00011812864249804989
and O 0 2.6795967755788297e-07
cancer B-Disease 1 0.9996768236160278
risk O 0 1.0130241207662039e-05
in O 0 7.480529085057697e-09
a O 0 1.4936800241116543e-08
community O 0 4.3333470145512365e-09
- O 0 8.825152164604333e-09
based O 0 1.892221712651576e-09
study O 0 2.014267419525595e-09
of O 0 1.605250332659125e-08
Ashkenazi O 0 7.231586550915381e-06
Jews O 0 3.7918500765954377e-06
. O 0 2.002662768063601e-06

Mutations O 0 1.5991901818779297e-05
in O 0 2.9048547389720625e-07
APC O 0 4.548442120722029e-06
are O 0 3.949201410335945e-09
classically O 0 9.98347559288959e-07
associated O 0 1.4810832738021418e-07
with O 0 1.984959254741625e-07
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 1 0.9999619722366333
FAP B-Disease 1 0.9998534917831421
) O 0 3.373779478010874e-08
, O 0 1.8847872151894762e-09
a O 0 1.0290604812723814e-08
highly O 0 7.158997163969616e-07
penetrant O 1 0.9999998807907104
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.006296414416283369
by O 0 1.9258820316281344e-07
multiple O 0 0.003242481965571642
intestinal O 1 1.0
polyps B-Disease 1 0.9998947381973267
and O 0 1.0921812076958304e-07
, O 0 6.446319478214946e-09
without O 0 5.357954968587819e-09
surgical O 0 2.073765244858805e-05
intervention O 0 3.097020453424193e-05
, O 0 1.3001027809877996e-08
the O 0 1.6879511122169788e-08
development O 0 8.466000736007118e-07
of O 1 0.9951738715171814
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 0.9998663663864136
CRC B-Disease 1 0.9999392032623291
) O 0 1.1671595530060586e-06
. O 0 2.303810560988495e-06

APC B-Disease 0 0.0002467689337208867
is O 0 5.620491378977022e-07
a O 0 3.054904482269194e-06
tumour O 1 1.0
- O 0 0.0001385315990773961
suppressor O 0 0.0002250778634333983
gene O 0 2.4801511244731955e-07
, O 0 9.128280353820628e-09
and O 0 3.302692519469019e-08
somatic O 1 0.9999556541442871
loss O 1 0.947810709476471
occurs O 0 0.00010619478416629136
in O 0 2.4326071070390753e-05
tumours B-Disease 1 1.0
. O 0 4.92034996568691e-05

The O 0 5.632206466543721e-06
germline O 0 0.00017092670896090567
T O 0 3.984134764323244e-06
- O 0 3.2490348189639917e-07
to O 0 1.123742521258464e-08
- O 0 2.3776298974098609e-07
A O 0 1.4328863073842513e-07
transversion O 0 1.159458975052985e-06
responsible O 0 7.472514162998323e-09
for O 0 9.590411798043874e-10
the O 0 1.6600838037561516e-08
APC O 0 7.091900897648884e-07
I1307K O 0 3.32807735503593e-06
allele O 0 2.269957803946454e-07
converts O 0 7.320581829617367e-08
the O 0 1.4010804960662426e-08
wild O 0 1.3159447753707809e-08
- O 0 9.762982422500954e-09
type O 0 1.9055875100093544e-08
sequence O 0 2.939463783491192e-09
to O 0 1.4988849050823205e-09
a O 0 7.803621571156327e-08
homopolymer O 1 0.9640272855758667
tract O 0 0.039674557745456696
( O 0 6.149358569018659e-07
A8 O 0 0.27170103788375854
) O 0 3.965301420549849e-09
that O 0 1.203138810801363e-09
is O 0 1.3404414467288461e-08
genetically O 0 3.7506808325815655e-07
unstable O 0 6.195601145009277e-06
and O 0 2.966149814653818e-08
prone O 0 2.4408145691268146e-05
to O 0 1.004336922960647e-06
somatic O 0 0.40739724040031433
mutation O 0 0.0002821526431944221
. O 0 8.316879757330753e-06

The O 0 2.15929867408704e-06
I1307K O 0 0.00013559988292399794
allele O 0 6.185953679960221e-06
was O 0 3.632134450981539e-07
found O 0 1.4333463305149508e-08
in O 0 4.7885453824392243e-08
6 O 0 3.45582725458371e-06
. O 0 9.471239650338248e-07

1 O 0 2.2744507077732123e-05
% O 0 6.030229542375309e-07
of O 0 1.2659438652917743e-07
unselected O 0 0.00035063913674093783
Ashkenazi O 0 9.906464401865378e-05
Jews O 0 2.6132937591683003e-07
and O 0 1.6472708752601761e-09
higher O 0 2.1180252218755413e-08
proportions O 0 3.4610668109280596e-08
of O 0 9.715798832132805e-09
Ashkenazim O 0 9.964594028133433e-06
with O 0 1.195418652955027e-09
family O 0 1.4896485822646355e-08
or O 0 2.287904798947693e-08
personal O 0 3.393370207049884e-07
histories O 0 1.7321164023087476e-06
of O 0 0.00014492054469883442
CRC B-Disease 1 0.9992951154708862
( O 0 2.7447217689768877e-06
ref O 0 0.0017841196386143565
. O 0 1.5838597278161615e-07
2 O 0 1.180082222163037e-06
) O 0 5.718297657608673e-08
. O 0 4.0452826510772866e-07

To O 0 1.1291410118019485e-07
evaluate O 0 1.8052190853268257e-07
the O 0 1.1534077692942901e-08
role O 0 3.550930571805111e-08
of O 0 7.269961344036346e-08
I1307K O 1 0.919939398765564
in O 0 2.879973806102498e-07
cancer B-Disease 0 0.4988502264022827
, O 0 5.2168079633929665e-08
we O 0 1.082933778207007e-07
genotyped O 0 0.0008146325126290321
5 O 0 9.853998790276819e-07
, O 0 2.9964922987346654e-08
081 O 0 1.594136301719118e-05
Ashkenazi O 0 3.2484103940078057e-06
volunteers O 0 1.2300910512408336e-08
in O 0 2.2249941888929925e-09
a O 0 1.8422371184101394e-08
community O 0 4.8087361648185833e-08
survey O 0 4.4379822838891414e-07
. O 0 9.953566859621787e-07

Risk O 0 3.488342190394178e-05
of O 0 1.8585089947009692e-06
developing O 1 0.6067947745323181
colorectal B-Disease 1 1.0
, I-Disease 1 0.9949929118156433
breast I-Disease 1 1.0
and I-Disease 0 1.4102479326538742e-06
other I-Disease 0 5.070365318715631e-07
cancers I-Disease 1 0.9999973773956299
were O 0 9.187479577121849e-08
compared O 0 7.24876301205768e-08
between O 0 2.2053654902265407e-08
genotyped O 0 3.211242301404127e-06
I1307K O 0 5.068479822512018e-07
carriers O 0 1.8322979800089456e-09
and O 0 5.484918075282508e-10
non O 0 2.4379856355949414e-08
- O 0 1.4381304147548235e-08
carriers O 0 1.7600314539123474e-09
and O 0 1.765675800013966e-10
their O 0 1.388493209297792e-10
first O 0 8.027670972410306e-09
- O 0 1.1333441563010638e-07
degree O 0 1.85727947155101e-06
relatives O 0 3.65213452369062e-07
. O 0 1.0062256023957161e-06

Sperm O 0 1.9824840364890406e-06
DNA O 0 2.8766416448888776e-07
analysis O 0 8.857517030946838e-08
in O 0 1.729060983279851e-08
a O 0 1.4812050039836322e-06
Friedreich B-Disease 1 0.9999947547912598
ataxia I-Disease 1 0.9999991655349731
premutation O 1 0.9999682903289795
carrier O 0 0.00014552983338944614
suggests O 0 3.532199741584918e-07
both O 0 1.819961958915428e-08
meiotic O 0 1.2354222235444468e-05
and O 0 4.351927884727047e-08
mitotic O 0 5.536612661671825e-06
expansion O 0 1.7293203882218222e-06
in O 0 7.472132779184903e-08
the O 0 3.5264778830423893e-07
FRDA B-Disease 1 0.6548322439193726
gene O 0 7.026946150290314e-06
. O 0 2.4755008780630305e-06

Friedreich B-Disease 1 1.0
ataxia I-Disease 1 1.0
is O 0 5.165951279195724e-06
usually O 0 1.0138045070107182e-07
caused O 0 6.888222259249233e-08
by O 0 6.318727763243714e-10
an O 0 1.1293629365027869e-09
expansion O 0 1.8554759151356848e-07
of O 0 1.2630256662760075e-07
a O 0 2.2291383174888324e-06
GAA O 1 0.6908831596374512
trinucleotide O 0 0.3706928491592407
repeat O 0 1.4461037380897324e-06
in O 0 5.4837101970406366e-08
intron O 0 1.4137493053567596e-05
1 O 0 6.933327654223831e-07
of O 0 4.6962043143139454e-08
the O 0 1.1520307907630922e-07
FRDA B-Disease 1 0.9348251819610596
gene O 0 6.497577032860136e-06
. O 0 1.4686610256831045e-06

Occasionally O 0 3.01633849630889e-06
, O 0 4.4946570909587535e-08
a O 0 2.242630081639163e-08
fully O 0 2.1167814168165933e-08
expanded O 0 1.343928079933221e-08
allele O 0 2.2987315162481536e-07
has O 0 1.0895149227252432e-09
been O 0 7.197354379151477e-10
found O 0 1.9919921268041207e-10
to O 0 4.617715931853894e-10
arise O 0 1.5727582791669192e-08
from O 0 7.803916624027352e-09
a O 0 2.1035237551814134e-08
premutation O 0 4.592442564899102e-06
of O 0 3.777863000209436e-08
100 O 0 2.072618521253844e-08
or O 0 2.173320723386496e-08
less O 0 4.800822921424697e-07
triplet O 0 8.305870869662613e-05
repeats O 0 2.51534966082545e-05
. O 0 4.7516073209408205e-06

We O 0 5.806907097394287e-07
have O 0 7.926205469743763e-09
examined O 0 4.6405091325141257e-08
the O 0 8.020616171222628e-09
sperm O 0 1.5140770415200677e-08
DNA O 0 2.2945167543753087e-08
of O 0 2.3325444686861374e-08
a O 0 5.788517682958627e-07
premutation O 0 0.003219675039872527
carrier O 0 8.523036376573145e-05
. O 0 7.367138096014969e-06

This O 0 6.659861355728935e-07
mans O 0 3.3373104088241234e-05
leucocyte O 0 1.7323711290373467e-05
DNA O 0 5.635616275867505e-07
showed O 0 1.4558098726524804e-08
one O 0 1.8562070769334582e-09
normal O 0 1.1101930041945707e-08
allele O 0 3.9559655107268554e-08
and O 0 6.222414805634457e-10
one O 0 2.0535997347082002e-09
allele O 0 6.887880488193332e-08
of O 0 9.681852652931866e-09
approximately O 0 2.9596620265692763e-08
100 O 0 1.0185375742821634e-07
repeats O 0 9.886699672279065e-07
. O 0 1.0260890803692746e-06

His O 0 1.2170927448096336e-06
sperm O 0 3.6492690469458466e-07
showed O 0 1.2305720886729432e-08
an O 0 8.276397345241548e-10
expanded O 0 8.708720855565844e-09
allele O 0 1.012606318795406e-07
in O 0 2.4434916312543464e-09
a O 0 1.6659994273027223e-08
tight O 0 1.339131046051989e-07
range O 0 2.125804741126558e-07
centering O 0 5.674976364389295e-07
on O 0 3.583637564474884e-08
a O 0 2.1896145341315787e-08
size O 0 9.535336431554242e-08
of O 0 9.701692249564076e-08
approximately O 0 1.1509704336276627e-06
320 O 0 9.04779153643176e-06
trinucleotide O 0 0.001151657896116376
repeats O 0 6.312334153335541e-05
. O 0 1.0610424396872986e-05

His O 0 5.696955213352339e-06
affected O 0 4.05779292123043e-06
son O 0 2.4085813493002206e-05
has O 0 5.202747388466378e-08
repeat O 0 1.4972175677030464e-07
sizes O 0 7.186921635593535e-08
of O 0 8.178328414487623e-08
1040 O 0 2.0771080926351715e-06
and O 0 9.472290685152984e-08
540 O 0 7.64968808653066e-06
. O 0 2.3395994048769353e-06

These O 0 2.407267096771193e-08
data O 0 3.059721720433117e-08
suggest O 0 1.645936897887168e-08
that O 0 4.3946726813182124e-10
expansion O 0 6.35793924175232e-08
occurs O 0 2.641903362743392e-09
in O 0 1.9018164820749917e-10
two O 0 1.1894502049969446e-10
stages O 0 9.271763801166344e-09
, O 0 2.6173457845501957e-10
the O 0 8.125100037226218e-10
first O 0 1.8549294322767196e-09
during O 0 1.8168118121053567e-09
meiosis O 0 3.554025518326398e-09
followed O 0 9.514490306727907e-10
by O 0 5.898121990810523e-10
a O 0 2.8449115063722274e-08
second O 0 7.444775746989762e-07
mitotic O 0 9.03538239072077e-06
expansion O 0 1.1023479601135477e-05
. O 0 5.704631803382654e-06

We O 0 4.628129772754619e-07
also O 0 9.246016396957657e-09
show O 0 3.3561153855998782e-09
that O 0 2.5620555677008383e-10
in O 0 3.871507836539223e-10
all O 0 2.768061058144866e-10
informative O 0 1.3635931495059594e-08
carrier O 0 1.258934503312048e-07
father O 0 2.7999719875992923e-08
to O 0 3.1166298430918005e-09
affected O 0 2.9782587063209576e-08
child O 0 2.2728729121013203e-08
transmissions O 0 4.0911285026368205e-08
, O 0 6.068449631690953e-10
with O 0 1.5530170205391158e-10
the O 0 4.359419047972324e-09
notable O 0 5.688661541825013e-09
exception O 0 9.852099580598406e-09
of O 0 9.156563507417559e-09
the O 0 1.2498436063879126e-08
premutation O 0 1.1986910976702347e-05
carrier O 0 6.098775315876992e-07
, O 0 3.531577696946897e-09
the O 0 6.617983494550117e-09
expansion O 0 3.0433034226007294e-07
size O 0 3.7971153687976766e-07
decreases O 0 9.962864169210661e-07
. O 0 8.224944991752636e-08
. O 0 1.124936829910439e-06

The O 0 2.2995345716481097e-06
R496H O 0 0.00010323906462872401
mutation O 0 1.0453413779032417e-06
of O 0 1.9725723632291192e-07
arylsulfatase O 0 0.032923661172389984
A O 0 8.945955414674245e-06
does O 0 6.985627720723642e-08
not O 0 1.5176600243194116e-07
cause O 0 0.011291288770735264
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 5.292880450724624e-05

Deficiency B-Disease 1 0.9999725818634033
of I-Disease 0 0.00013448027311824262
arylsulfatase I-Disease 1 0.9999988079071045
A I-Disease 1 0.9936362504959106
( O 0 9.04678108781809e-06
ARSA O 1 0.9996553659439087
) O 0 1.6459807739011012e-08
enzyme O 0 7.453884620645113e-08
activity O 0 5.614052867031205e-08
causes O 0 5.624616278510075e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 0.00012316864740569144
MLD B-Disease 1 1.0
) O 0 1.0312481890650815e-06
. O 0 8.165038707375061e-07

A O 0 1.264053389604669e-05
number O 0 1.3372945772971434e-07
of O 0 2.1361161373079085e-07
ARSA O 0 0.010944029316306114
gene O 0 3.1767567065799085e-07
mutations O 0 1.6701905281024665e-07
responsible O 0 9.104756770739186e-08
for O 0 6.747213774360716e-07
MLD B-Disease 1 1.0
have O 0 5.97384826050984e-07
been O 0 4.3589727738435613e-07
identified O 0 6.854421599200577e-07
. O 0 6.763551141375501e-07

Recently O 0 4.011313194496324e-06
, O 0 6.817327147246033e-08
the O 0 7.924243305978962e-08
R496H O 0 3.2546209695283324e-05
mutation O 0 9.418744184586103e-07
of O 0 3.3232234386559867e-07
ARSA O 1 0.9522054195404053
was O 0 9.281889390422293e-08
proposed O 0 5.506934463994639e-09
to O 0 1.1556555712388672e-09
be O 0 2.760370376719834e-09
a O 0 2.9726347605674164e-08
cause O 0 7.712257001912803e-07
of O 0 3.769654085772345e-06
MLD B-Disease 1 1.0
( O 0 2.68099739741956e-07
Draghia O 0 1.5733870895928703e-05
et O 0 8.387310117541347e-07
al O 0 2.048157284662011e-06
. O 0 1.9624431857323543e-08
, O 0 1.4616889920660014e-08
1997 O 0 1.3468989834564127e-07
) O 0 1.3001157128655905e-07
. O 0 1.076368448593712e-06

We O 0 6.34108118902077e-07
have O 0 9.966065306343808e-09
investigated O 0 1.7691523623852845e-07
the O 0 1.6695050675252787e-08
R496H O 0 1.0516175279917661e-05
mutation O 0 6.099763538713887e-08
and O 0 4.1534581329827347e-10
found O 0 2.4767396467062497e-10
this O 0 1.7270322671958382e-10
mutation O 0 4.549406185105909e-09
at O 0 3.251257929548501e-09
a O 0 1.0998523203298305e-09
relatively O 0 9.944433054798196e-10
high O 0 3.0632938408103882e-09
frequency O 0 1.0756440183001814e-08
in O 0 3.021339289865921e-10
an O 0 2.5699106731558174e-10
African O 0 1.5518096807554116e-09
American O 0 1.373438140994665e-09
population O 0 4.764889038888498e-10
( O 0 1.1224223772643427e-09
f O 0 2.0128038613620447e-07
= O 0 9.606640105630504e-08
0 O 0 5.4954476524926577e-08
. O 0 1.8273351720665687e-09
09 O 0 1.0613886303190156e-07
, O 0 2.915988117635493e-09
n O 0 2.0668223044140177e-07
= O 0 3.721939947354258e-07
61 O 0 4.989519766240846e-07
subjects O 0 4.830578177461575e-07
) O 0 1.7037218924542685e-07
. O 0 1.6129096138683963e-06

The O 0 4.822399205295369e-06
ARSA O 0 0.0014446532586589456
enzyme O 0 3.542847082371736e-07
activity O 0 3.724233366142471e-08
in O 0 1.7624030013152492e-09
subjects O 0 9.820374735625137e-09
with O 0 1.8762925935167374e-10
and O 0 7.913482646948466e-10
without O 0 3.6100207267963924e-09
the O 0 1.010718797544996e-08
R496H O 0 3.1207889605866512e-06
mutation O 0 4.7931326463412915e-08
was O 0 1.4358582767215466e-08
determined O 0 4.626225624804192e-09
and O 0 3.174439322517486e-10
found O 0 8.611411583814288e-10
to O 0 4.044095724964336e-09
be O 0 6.445706901558879e-08
normal O 0 1.0769331311166752e-06
. O 0 1.7612701412872411e-06

It O 0 1.2175067354291969e-07
is O 0 2.3531852022529165e-08
therefore O 0 2.322312298019824e-08
concluded O 0 3.128949188635488e-08
that O 0 4.846206769215655e-10
the O 0 1.0967902142056118e-08
R496H O 0 1.8262324374518357e-05
mutation O 0 4.4414625222088944e-07
of O 0 2.5104395717789885e-07
ARSA O 1 0.999935507774353
does O 0 5.0154982389472025e-09
not O 0 1.2452600062218266e-09
negatively O 0 8.115361715965719e-09
influence O 0 6.507221872453783e-09
the O 0 1.3922117902964715e-09
activity O 0 5.731605856595934e-09
of O 0 2.3413255334503447e-08
ARSA O 0 0.05222901329398155
and O 0 3.2472546873663077e-09
is O 0 3.8948182456977065e-09
not O 0 3.244016832937291e-09
a O 0 1.7287896980633377e-07
cause O 0 2.168622631870676e-05
of O 0 0.00018553117115516216
MLD B-Disease 1 1.0

Down O 0 3.660772563307546e-05
- O 0 2.276952955071465e-06
regulation O 0 2.1395187843609165e-07
of O 0 1.5361297300842125e-07
transmembrane O 0 3.079057205468416e-05
carbonic O 0 0.0006176414317451417
anhydrases O 1 0.9872561693191528
in O 0 1.0649149771779776e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9958335161209106
lines O 0 5.269993152978714e-07
by O 0 1.571577001868718e-08
wild O 0 1.0106247572139182e-07
- O 0 2.3934342152642785e-07
type O 0 1.782468075361976e-06
von B-Disease 1 0.9759843349456787
Hippel I-Disease 1 0.9991737008094788
- I-Disease 1 0.5537853240966797
Lindau I-Disease 1 0.9938265681266785
transgenes O 0 0.0012109368108212948
. O 0 1.963414797501173e-05

To O 0 3.343396883792593e-07
discover O 0 3.400565447009285e-07
genes O 0 4.8909324590340475e-08
involved O 0 1.506627356206991e-08
in O 0 4.4316884384443256e-08
von B-Disease 1 0.9990707635879517
Hippel I-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
Lindau I-Disease 1 1.0
( O 0 1.829017674026545e-05
VHL B-Disease 1 0.9339744448661804
) O 0 4.0150538893612975e-07
- O 0 8.464922757411841e-06
mediated O 0 0.00027243368094787
carcinogenesis O 1 0.9999871253967285
, O 0 5.364625010884083e-08
we O 0 3.694715644542157e-08
used O 0 1.4073177680984372e-06
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 0.9999417066574097
lines O 0 8.502398486598395e-06
stably O 0 2.9137187084415928e-05
transfected O 0 1.6962412701104768e-06
with O 0 2.364305418112167e-09
wild O 0 1.1477934691583869e-07
- O 0 1.216061377817823e-06
type O 0 1.7891452444018796e-05
VHL O 1 0.968161940574646
- O 0 6.962374754948542e-05
expressing O 0 4.459005140233785e-06
transgenes O 0 0.00014575121167581528
. O 0 1.1067594641644973e-05

Large O 0 8.069581781455781e-06
- O 0 5.699308076145826e-06
scale O 0 5.84736926612095e-06
RNA O 0 1.4506368643196765e-05
differential O 0 6.354087872750824e-06
display O 0 5.155814264412584e-08
technology O 0 9.973980752420175e-08
applied O 0 5.232812583244595e-08
to O 0 1.7810906083326472e-09
these O 0 8.06439193201669e-10
cell O 0 2.7003503078049107e-07
lines O 0 1.2455266151789601e-08
identified O 0 7.788555578258638e-09
several O 0 4.670713815713157e-10
differentially O 0 3.526538421283476e-07
expressed O 0 6.560385568121774e-09
genes O 0 1.1180619097217459e-08
, O 0 1.4740181297767663e-09
including O 0 1.4381268398366842e-09
an O 0 2.920481456669677e-08
alpha O 0 2.639636477397289e-06
carbonic O 0 1.4109976291365456e-05
anhydrase O 0 5.450319076771848e-05
gene O 0 6.266948275879258e-07
, O 0 1.0604941991232408e-07
termed O 0 3.5942404792876914e-05
CA12 O 1 0.9995301961898804
. O 0 3.2128969905897975e-05

The O 0 8.011107297534181e-07
deduced O 0 1.5007100273578544e-06
protein O 0 3.9262285866925595e-08
sequence O 0 8.048936628313186e-09
was O 0 1.0833465680093468e-08
classified O 0 2.3344661759239216e-09
as O 0 7.279430946915966e-10
a O 0 1.0192523269836329e-08
one O 0 3.092100442358969e-08
- O 0 6.821254601163673e-07
pass O 0 6.19123795786436e-07
transmembrane O 0 0.02632025070488453
CA O 0 9.737257641972974e-06
possessing O 0 9.912646703469363e-08
an O 0 1.3337265514223873e-08
apparently O 0 2.436366344227281e-07
intact O 0 9.352724816835689e-08
catalytic O 0 6.61966481629861e-08
domain O 0 1.2993396580895933e-07
in O 0 7.706351112801713e-09
the O 0 5.7974567369001306e-08
extracellular O 0 4.277723564882763e-05
CA O 0 0.0005926156300120056
module O 0 0.0006225081160664558
. O 0 2.6694146981753875e-06

Reintroduced O 0 5.7406748965149745e-05
wild O 0 6.10584447713336e-06
- O 0 8.072745004028548e-06
type O 0 1.4377690604305826e-05
VHL B-Disease 0 0.2114678919315338
strongly O 0 4.0169535964196257e-07
inhibited O 0 1.662841526695047e-07
the O 0 8.436548348811357e-09
overexpression O 0 2.1601543664928613e-07
of O 0 1.3332840609336927e-08
the O 0 1.8452546157732286e-08
CA12 O 0 0.010846600867807865
gene O 0 2.3656779646330506e-08
in O 0 3.5216092264533927e-09
the O 0 3.4837039919466406e-08
parental O 0 3.818393452093005e-05
renal B-Disease 1 1.0
cell I-Disease 1 1.0
carcinoma I-Disease 1 1.0
cell O 1 1.0
lines O 0 0.0003960400354117155
. O 0 1.1288679161225446e-05

Similar O 0 2.2381225051049114e-07
results O 0 1.5511231765685807e-07
were O 0 2.256945208500838e-08
obtained O 0 5.0810527341127454e-08
with O 0 1.6795945967373882e-08
CA9 O 1 0.9778423309326172
, O 0 2.367284857029972e-08
encoding O 0 1.8520850630920904e-07
another O 0 2.640419438648678e-07
transmembrane O 0 7.059563358779997e-05
CA O 0 6.434332817661925e-07
with O 0 1.29677102389536e-09
an O 0 1.0685626605777543e-08
intact O 0 4.817512717636419e-07
catalytic O 0 9.580608093529008e-07
domain O 0 7.524773991463007e-06
. O 0 1.5052206663312973e-06

Although O 0 1.2429320861429005e-07
both O 0 1.7939894902951892e-08
domains O 0 4.3181762521271594e-07
of O 0 1.6069220976078213e-07
the O 0 2.1781849568469625e-07
VHL B-Disease 0 0.0011978624388575554
protein O 0 4.6019291488619274e-08
contribute O 0 2.757375883177815e-09
to O 0 1.6623833420936762e-09
regulation O 0 6.0556430980796e-08
of O 0 1.264867535155645e-07
CA12 O 1 0.9999616146087646
expression O 0 2.4374654117309547e-07
, O 0 2.7399236213199174e-09
the O 0 4.167823863809872e-09
elongin O 0 5.627292125609529e-07
binding O 0 5.3187871884574633e-08
domain O 0 2.5164607109218196e-07
alone O 0 9.764510089382838e-09
could O 0 9.424924840573112e-09
effectively O 0 1.951081003426225e-07
regulate O 0 4.0674450474398327e-07
CA9 O 1 0.7644359469413757
expression O 0 2.3000673536444083e-05
. O 0 4.3949139580945484e-06

We O 0 9.83067639026558e-06
mapped O 0 0.00010578958608675748
CA12 O 1 0.9214049577713013
and O 0 1.7379406926920637e-06
CA9 O 0 0.057010944932699203
loci O 0 9.793919161893427e-06
to O 0 1.4542536064254818e-07
chromosome O 0 1.128026360674994e-05
bands O 0 3.6420760807232e-06
15q22 O 0 0.00012818763207178563
and O 0 6.143046107354166e-07
17q21 O 0 0.0012884241295978427
. O 0 1.0969576578645501e-05

2 O 0 4.355211785878055e-05
respectively O 0 2.052780246231123e-06
, O 0 3.5065166770209544e-08
regions O 0 1.1454424253543039e-07
prone O 0 1.037895231092989e-06
to O 0 1.6194858787343946e-08
amplification O 0 8.201592208934017e-06
in O 0 2.3982341446071587e-08
some O 0 2.6213902160066027e-08
human O 0 1.5625494143023388e-06
cancers B-Disease 1 0.9960719347000122
. O 0 7.893145266280044e-06

Additional O 0 1.3876915261334943e-07
experiments O 0 1.0831568886260357e-07
are O 0 7.229259968433155e-10
needed O 0 3.091467970506301e-09
to O 0 6.317727452298527e-10
define O 0 1.3441127322266766e-08
the O 0 8.726229516753392e-09
role O 0 2.439488078209706e-08
of O 0 4.0768966869109136e-08
CA O 0 8.844010153552517e-06
IX O 1 0.9854236245155334
and O 0 7.055903239461259e-08
CA O 0 6.2630142565467395e-06
XII O 0 0.00017730722902342677
enzymes O 0 8.558444619666261e-09
in O 0 6.953717046620511e-10
the O 0 5.44679301661688e-10
regulation O 0 2.039442925649837e-08
of O 0 1.7335485935632278e-08
pH O 0 2.650647275004303e-06
in O 0 4.856109292461497e-09
the O 0 9.210566531692166e-09
extracellular O 0 1.3795214499623398e-06
microenvironment O 0 3.793296855292283e-06
and O 0 1.0807168493442987e-09
its O 0 9.798086786361182e-10
potential O 0 4.54387567572212e-08
impact O 0 7.18845626579423e-07
on O 0 1.5154660104599316e-06
cancer B-Disease 0 0.2400301694869995
cell O 0 0.0003922137839253992
growth O 0 7.526959961978719e-07
. O 0 8.065165957304998e-07

A O 0 4.8608562792651355e-06
gene O 0 1.8659844158719352e-07
encoding O 0 1.938868763318169e-07
a O 0 1.0719557508309663e-07
transmembrane O 0 1.3205307368480135e-05
protein O 0 7.570803717271701e-08
is O 0 1.6241779032810655e-09
mutated O 0 2.5955094073992768e-08
in O 0 2.4193254066773306e-09
patients O 0 1.0590404109223073e-08
with O 0 4.6473826387227746e-07
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9999998807907104
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
( O 1 1.0
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 3.992680831288453e-06
. O 0 3.4976374081452377e-06

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.3516685664653778
WFS B-Disease 1 0.9999998807907104
; O 0 1.6203028280870058e-05
OMIM O 1 0.9999818801879883
222300 O 0 0.007598972879350185
) O 0 1.3659488651285301e-08
is O 0 4.629085559315627e-09
an O 0 3.2974618591197213e-08
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 1.0
defined O 0 3.5777072753262473e-06
by O 0 2.5931589320293824e-08
young O 0 6.699535504139931e-08
- O 0 3.0142045943648554e-06
onset O 1 0.9999490976333618
non O 1 0.9283491969108582
- O 0 0.0581209659576416
immune O 0 0.00018878033733926713
insulin B-Disease 1 0.9994688630104065
- I-Disease 1 0.9997171759605408
dependent I-Disease 1 0.9989176988601685
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.0012800057884305716
progressive O 1 1.0
optic B-Disease 1 1.0
atrophy I-Disease 1 1.0
. O 0 0.0018210946582257748

Linkage O 0 5.948953912593424e-05
to O 0 3.126491776583862e-07
markers O 0 2.9955835998407565e-06
on O 0 4.279206109458755e-07
chromosome O 0 3.754216595552862e-05
4p O 1 0.9961296319961548
was O 0 4.0411683244201413e-07
confirmed O 0 2.3938103055343163e-08
in O 0 6.238531913282941e-09
five O 0 1.2575336327813602e-08
families O 0 2.1104924030623806e-08
. O 0 1.0142526889467263e-06

On O 0 4.919825187243987e-07
the O 0 1.612713873555549e-08
basis O 0 9.31336572307373e-08
of O 0 1.602395371946841e-07
meiotic O 1 0.9973485469818115
recombinants O 1 0.9999996423721313
and O 0 3.179580062351306e-06
disease O 1 0.6724077463150024
- O 0 4.9571706767892465e-05
associated O 0 1.2688233255175874e-06
haplotypes O 0 3.302154073026031e-05
, O 0 2.345947791582148e-08
the O 0 3.255377691857575e-07
WFS B-Disease 0 0.017588043585419655
gene O 0 1.0595075394803644e-07
was O 0 1.1998972127003071e-07
localized O 0 3.7286829979166214e-07
to O 0 1.3050168945483165e-08
a O 0 7.265551857926766e-07
BAC O 1 0.7388582825660706
/ O 0 5.845146733918227e-05
P1 O 0 0.03076101467013359
contig O 0 2.5474224457866512e-05
of O 0 5.213426135242116e-08
less O 0 4.467792891205136e-08
than O 0 4.8077730241402605e-08
250 O 0 7.602659479744034e-07
kb O 0 9.754401253303513e-05
. O 0 4.1437720028625336e-06

Mutations O 0 6.3430206864723004e-06
in O 0 4.336549253025623e-08
a O 0 6.247524453328879e-08
novel O 0 2.829289655892353e-07
gene O 0 1.1174995506735286e-07
( O 0 3.3536981192128223e-08
WFS1 O 0 0.015999512746930122
) O 0 2.7775504118920935e-09
encoding O 0 2.841462354297164e-08
a O 0 2.270611254573396e-08
putative O 0 1.4471316944764112e-06
transmembrane O 0 9.599567647455842e-07
protein O 0 9.548235979650599e-09
were O 0 4.660755670293781e-10
found O 0 1.9614458668382184e-10
in O 0 1.6220685905565801e-10
all O 0 1.224901569063519e-10
affected O 0 1.1070840910676338e-09
individuals O 0 2.6441601685966987e-10
in O 0 9.105309395351924e-09
six O 0 2.5313167384410917e-07
WFS B-Disease 1 0.9999476671218872
families O 0 5.672842640080944e-09
, O 0 1.9205468326788377e-09
and O 0 3.2083685708172993e-10
these O 0 1.4048816276979181e-10
mutations O 0 7.48993755905758e-09
were O 0 1.1116884079953593e-09
associated O 0 4.724348912077403e-09
with O 0 2.4885171701072295e-09
the O 0 2.383355877100257e-06
disease O 1 0.9054344296455383
phenotype O 0 0.034527771174907684
. O 0 8.866744792612735e-06

WFS1 O 1 0.9996362924575806
appears O 0 8.837163250063895e-07
to O 0 5.839068784041501e-09
function O 0 1.8040260840734845e-08
in O 0 2.6192847890627036e-09
survival O 0 6.750148884293594e-08
of O 0 3.723210539874344e-08
islet O 0 0.04782853275537491
beta O 0 5.084699296276085e-05
- O 0 3.1703752938483376e-06
cells O 0 4.817953680458231e-08
and O 0 6.9732983831727324e-09
neurons O 0 3.589206301057857e-07
. O 0 1.1928904086744296e-07
. O 0 8.988877198135015e-07

Stable O 0 3.934566484531388e-05
interaction O 0 3.6569548456100165e-07
between O 0 4.416440546606282e-08
the O 0 1.1107140096555668e-08
products O 0 6.457358203704189e-09
of O 0 1.5510352113778936e-08
the O 0 4.66886547201284e-08
BRCA1 O 0 5.029227395425551e-06
and O 0 5.6888382005126914e-08
BRCA2 O 0 0.0001063773306668736
tumor B-Disease 0 0.000842585286591202
suppressor O 0 2.1565949282376096e-05
genes O 0 5.451070350659393e-08
in O 0 6.797459040086551e-09
mitotic O 0 1.7899822069011861e-06
and O 0 1.7810701535836415e-07
meiotic O 0 0.07875489443540573
cells O 0 3.585544982342981e-05
. O 0 4.811764483747538e-06

BRCA1 O 0 0.0002503989089746028
and O 0 2.743256857229426e-07
BRCA2 O 0 1.9105436876998283e-05
account O 0 1.8395230227952197e-08
for O 0 2.290789780090563e-09
most O 0 1.0832840180441394e-09
cases O 0 7.150817160628264e-10
of O 0 1.0620909485226093e-08
familial O 0 2.4283697712235153e-05
, O 0 3.3780292341134555e-08
early O 0 8.343372428498697e-06
onset O 1 0.9999988079071045
breast B-Disease 1 0.9999991655349731
and I-Disease 0 0.00013390409003477544
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 4.2980772718692606e-08
encode O 0 1.6770369981600197e-08
products O 0 1.5779015871686397e-09
that O 0 1.3236944873540324e-10
each O 0 4.266463571322987e-10
interact O 0 3.697744999087149e-09
with O 0 4.403644560113662e-09
hRAD51 O 0 1.744653309287969e-05
. O 0 2.639699459905387e-06

Results O 0 1.232935346706654e-06
presented O 0 1.993535931887891e-07
here O 0 1.4703853246089693e-08
show O 0 2.256948405943149e-09
that O 0 1.1985236136879962e-09
BRCA1 O 0 2.0784834759979276e-06
and O 0 7.05353500052297e-08
BRCA2 O 0 0.19324634969234467
coexist O 0 2.7080507152277278e-06
in O 0 1.1943800615199507e-08
a O 0 2.635372098325206e-08
biochemical O 0 1.3840492556482786e-06
complex O 0 1.7162771825951495e-07
and O 0 5.446400663799977e-09
colocalize O 0 2.1555770217673853e-05
in O 0 5.936003688589153e-08
subnuclear O 0 0.00018933266983367503
foci O 0 1.8526077838032506e-05
in O 0 2.0630976038660265e-08
somatic O 0 6.360744919220451e-06
cells O 0 3.309345331103941e-08
and O 0 1.2627149326149834e-09
on O 0 6.755555670423519e-09
the O 0 1.9695369779526573e-09
axial O 0 2.5082037780066457e-08
elements O 0 2.4423933098205453e-08
of O 0 6.206939673347733e-08
developing O 0 4.98326187425846e-07
synaptonemal O 0 0.00018808252934832126
complexes O 0 8.640450687380508e-06
. O 0 1.8313053260499146e-06

Like O 0 1.1319749319227412e-05
BRCA1 O 0 0.00017685421335045248
and O 0 1.0500093594600912e-06
RAD51 O 1 0.9751057028770447
, O 0 1.8953871858684579e-06
BRCA2 O 0 5.99996856180951e-05
relocates O 0 2.7388439320930047e-06
to O 0 1.2414085404088837e-07
PCNA O 0 1.5752910258015618e-05
+ O 0 1.3915386887219938e-07
replication O 0 2.2443117586590233e-08
sites O 0 2.0093633423812207e-09
following O 0 2.533275367255783e-09
exposure O 0 1.608966186950056e-07
of O 0 6.539062979982191e-08
S O 0 1.5190519661700819e-05
phase O 0 5.117728960613022e-06
cells O 0 4.632514816194089e-08
to O 0 2.4452178948308756e-08
hydroxyurea O 0 1.636440538277384e-05
or O 0 2.226582410003175e-06
UV O 0 0.01493020262569189
irradiation O 0 0.00027068323106504977
. O 0 1.1095495210611261e-05

Thus O 0 1.4684355846839026e-06
, O 0 7.141174052094357e-08
BRCA1 O 0 2.470444542268524e-06
and O 0 1.522864323533213e-08
BRCA2 O 0 3.2840728181326995e-06
participate O 0 4.7127958424653116e-08
, O 0 5.141306935740886e-09
together O 0 1.5086253357665669e-09
, O 0 1.8648835808932063e-09
in O 0 8.809019624855807e-10
a O 0 1.1146529921290949e-08
pathway O 0 4.0661183220436214e-07
( O 0 6.620697767800721e-09
s O 0 5.486849019575857e-08
) O 0 1.9525099592687667e-10
associated O 0 2.4780533181001374e-10
with O 0 1.538654446908705e-11
the O 0 8.463718059736891e-10
activation O 0 2.7074614550315346e-08
of O 0 3.5808906062584356e-08
double O 0 1.0494993318843626e-07
- O 0 1.1187038353455137e-06
strand O 0 7.423804504469445e-07
break O 0 1.1560523205389472e-07
repair O 0 3.1647519449506945e-07
and O 0 2.613706584497777e-08
/ O 0 2.827136768246419e-06
or O 0 1.8438987581248512e-07
homologous O 0 1.1689106713674846e-06
recombination O 0 5.332385171641363e-06
. O 0 1.4307127003121423e-06

Dysfunction O 1 0.999415397644043
of O 0 4.929368060402339e-07
this O 0 3.0024537522876926e-08
pathway O 0 4.613852070178837e-06
may O 0 7.495397191803477e-09
be O 0 9.267905332066562e-10
a O 0 4.881135051704177e-09
general O 0 5.30814610044672e-08
phenomenon O 0 1.3214045679887931e-07
in O 0 2.852194591618229e-10
the O 0 2.5948235227168936e-10
majority O 0 2.500796791871096e-10
of O 0 6.069120761509339e-10
cases O 0 3.9979622390440284e-10
of O 0 9.044350690601277e-08
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 0.9823696613311768
/ I-Disease 1 1.0
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 7.472498691640794e-05
. O 0 1.2214999514981173e-05

A O 0 2.2348078346112743e-05
novel O 0 3.540270199664519e-06
Arg362Ser O 0 0.00010629599273670465
mutation O 0 4.880091069026093e-07
in O 0 4.199599334953064e-09
the O 0 1.0203396350050298e-08
sterol O 0 7.256121534737758e-07
27 O 0 4.546961918094894e-07
- O 0 5.123190476297168e-07
hydroxylase O 0 1.362893272016663e-06
gene O 0 1.3538338805574313e-07
( O 0 6.910342875698916e-08
CYP27 O 1 0.9987345337867737
) O 0 1.9969929709873213e-08
: O 0 1.804427718354873e-09
its O 0 2.269367360696606e-09
effects O 0 5.3524622956047097e-08
on O 0 6.715886513575242e-08
pre O 0 2.1295434180501616e-06
- O 0 6.18415640474268e-07
mRNA O 0 4.2311108927606256e-07
splicing O 0 1.1428575419358822e-07
and O 0 1.0677246864432277e-09
enzyme O 0 2.2951601508225394e-08
activity O 0 3.9039083077341274e-08
. O 0 2.4984115043480415e-07

A O 0 2.079173100355547e-06
novel O 0 1.6510927025592537e-07
C O 0 8.491163612234232e-07
to O 0 1.8898629328134575e-09
A O 0 1.2867788257153734e-07
mutation O 0 3.975010898216169e-08
in O 0 2.1369093161638375e-09
the O 0 5.323503859955281e-09
sterol O 0 5.04241597809596e-07
27 O 0 5.478007096826332e-07
- O 0 7.931499226287997e-07
hydroxylase O 0 7.113685001058911e-07
gene O 0 5.673505398817724e-08
( O 0 4.0753803887128015e-08
CYP27 O 1 0.9881246089935303
) O 0 1.6820791870486573e-08
was O 0 6.443249134235884e-08
identified O 0 3.738372722494887e-09
by O 0 4.6392567565334275e-10
sequencing O 0 1.3794277720080572e-07
amplified O 0 5.333304216037504e-07
CYP27 O 0 0.0001037967813317664
gene O 0 1.3885474992036961e-08
products O 0 1.8431289827702813e-09
from O 0 3.1924380916592554e-09
a O 0 1.7632881821327828e-08
patient O 0 4.0731269024263383e-08
with O 0 2.3301922169594036e-08
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 2.125904029526282e-05
CTX B-Disease 1 0.9978796243667603
) O 0 1.2450514077499975e-06
. O 0 2.0253269212844316e-06

The O 0 1.2728470437650685e-06
mutation O 0 4.857537987845717e-06
changed O 0 1.475587794175226e-07
the O 0 6.698616061839857e-08
adrenodoxin O 0 7.744451977487188e-06
cofactor O 0 8.041280921133875e-07
binding O 0 1.975143817389835e-07
residue O 0 9.813072665565414e-07
362Arg O 0 4.3266680904707755e-07
to O 0 3.164890571838441e-08
362Ser O 0 8.127104592858814e-06
( O 0 2.4815045662762714e-07
CGT O 0 0.0004370726819615811
362Arg O 0 8.918083949538413e-06
to O 0 1.892463501462771e-07
AGT O 0 0.22979044914245605
362Ser O 0 8.178846655937377e-06
) O 0 6.1136917750559405e-09
, O 0 9.212248741619078e-10
and O 0 1.7574375288376132e-10
was O 0 3.559114958306964e-08
responsible O 0 7.75070958525248e-08
for O 0 2.3651777780742123e-07
deficiency O 1 0.9932066202163696
in O 0 1.0353786450423286e-07
the O 0 1.5889582982708816e-07
sterol O 0 2.313542381671141e-06
27 O 0 8.405374387621123e-07
- O 0 4.519578737927077e-07
hydroxylase O 0 3.0651543170279183e-07
activity O 0 1.6352913689843263e-08
, O 0 9.78773839754865e-10
as O 0 7.344000962916652e-10
confirmed O 0 1.7662156182041144e-09
by O 0 5.272400294131785e-10
expression O 0 1.462916277006343e-08
of O 0 1.994811427152854e-08
mutant O 0 5.9162683641034164e-08
cDNA O 0 4.546892853340978e-07
into O 0 1.1986402626007475e-07
COS O 0 0.0002670806716196239
- O 0 1.5774588973727077e-05
1 O 0 1.2598123248608317e-05
cells O 0 9.489357921665942e-07
. O 0 4.218185836180055e-07

Quantitative O 0 5.585226972470991e-06
analysis O 0 3.543164552866074e-07
showed O 0 2.8687013653438953e-08
that O 0 6.346133618606586e-10
the O 0 3.308838758542265e-09
expression O 0 2.8062059342914836e-08
of O 0 3.434047357586678e-08
CYP27 O 0 7.430263940477744e-05
gene O 0 2.0417003199213468e-08
mRNA O 0 1.6066462649177993e-07
in O 0 7.985442307401058e-10
the O 0 2.341087768087391e-09
patient O 0 4.632028804962829e-08
represented O 0 1.1794359267014443e-07
52 O 0 7.012586593191372e-06
. O 0 1.4596644177800044e-06

5 O 0 2.4371129256905988e-06
% O 0 3.892072868438845e-07
of O 0 4.865373526286021e-08
the O 0 9.2230692416706e-08
normal O 0 1.6567266811762238e-06
level O 0 2.7820704417536035e-05
. O 0 3.310587544547161e-06

As O 0 1.2453382680632785e-07
the O 0 2.7153637560672905e-08
mutation O 0 1.694920257477861e-07
occurred O 0 1.3137635335169762e-07
at O 0 2.5122542268718462e-08
the O 0 8.903040971119935e-09
penultimate O 0 3.2085438306239666e-07
nucleotide O 0 4.638429729197924e-08
of O 0 6.269008423487321e-09
exon O 0 1.2625716294678568e-07
6 O 0 3.7666676888648e-08
( O 0 1.702467833375465e-09
- O 0 9.239461462584586e-08
2 O 0 8.176191101938457e-08
position O 0 4.74989434451345e-08
of O 0 2.690622302736756e-08
exon O 0 6.71680822961207e-07
6 O 0 5.943026621935132e-07
- O 0 1.7989942762142164e-06
intron O 0 1.3776144442090299e-05
6 O 0 3.1994807159207994e-07
splice O 0 6.55409678529395e-07
site O 0 1.1530801202752627e-08
) O 0 2.5195937003452684e-10
of O 0 1.5976924228056077e-09
the O 0 2.859849468350717e-09
gene O 0 2.4943634713281426e-08
, O 0 2.3627908518619734e-09
we O 0 3.3827214362958102e-09
hypothesized O 0 1.180078328388845e-07
that O 0 3.3599178994592194e-10
the O 0 6.958988052474524e-09
mutation O 0 3.721017094449053e-07
may O 0 2.252167696781271e-08
partially O 0 6.150865061727018e-08
affect O 0 3.1103113418140538e-09
the O 0 1.6884428299945853e-09
normal O 0 5.767982536042382e-09
splicing O 0 1.6209847686354806e-08
efficiency O 0 6.835123134152354e-09
in O 0 2.689676925626827e-09
exon O 0 2.707924409151019e-07
6 O 0 2.0454889337884197e-08
and O 0 1.9077603385930786e-10
cause O 0 3.741896570375047e-09
alternative O 0 2.2086824813527528e-08
splicing O 0 9.589944482968349e-08
elsewhere O 0 1.3594587677800973e-08
, O 0 2.64860244847398e-10
which O 0 1.664409721158222e-10
resulted O 0 4.8219042092512154e-09
in O 0 2.195602144539066e-09
decreased O 0 4.581007573278839e-08
transcript O 0 2.74022085022807e-07
in O 0 9.795027011705315e-09
the O 0 1.0996393484674627e-07
patient O 0 1.433498823644186e-06
. O 0 2.180486717406893e-06

Transfection O 0 6.0814902099082246e-05
of O 0 3.790574112372269e-07
constructed O 0 6.774112080165651e-07
minigenes O 0 5.702340422431007e-05
, O 0 4.200079839478121e-09
with O 0 1.970678203955245e-10
or O 0 6.771888383383384e-09
without O 0 6.273122910016582e-09
the O 0 7.4402310978882724e-09
mutation O 0 6.008632880138975e-08
, O 0 3.752245625321393e-09
into O 0 9.121583133264721e-08
COS O 1 0.7814833521842957
- O 0 5.201980911806459e-06
1 O 0 8.415769912062387e-07
cells O 0 5.3846016534464525e-09
confirmed O 0 6.27059626445714e-10
that O 0 1.0511686659997466e-10
the O 0 3.2492990520438525e-09
mutant O 0 2.0722596616451483e-07
minigene O 0 4.78488482258399e-06
was O 0 1.070233537348031e-07
responsible O 0 9.54059053981382e-09
for O 0 1.8011302449494337e-09
a O 0 2.9794973599450714e-08
mRNA O 0 5.716540840694506e-07
species O 0 1.14927212191418e-09
alternatively O 0 5.6651789037687195e-08
spliced O 0 5.489831664817757e-07
at O 0 1.308004016209452e-07
an O 0 2.2377250274985272e-08
activated O 0 2.1702549020119477e-06
cryptic O 0 9.032814887177665e-07
5 O 0 2.755086256911454e-07
splice O 0 8.672371905049658e-07
site O 0 4.4518266406612383e-08
88 O 0 5.7979100631655456e-08
bp O 0 1.7040939326307125e-07
upstream O 0 6.904532767748606e-08
from O 0 2.926356934551677e-09
the O 0 7.2815597995656844e-09
3 O 0 1.7688351761080412e-07
end O 0 2.2913991415407509e-07
of O 0 4.931521289108787e-07
exon O 0 3.540362013154663e-05
6 O 0 6.227268386282958e-06
. O 0 1.0217027011094615e-06

Our O 0 1.4248587376641808e-07
data O 0 1.3609479765364085e-08
suggest O 0 4.579852053154809e-09
that O 0 1.8601509221838342e-10
the O 0 1.6979019301643916e-09
C O 0 1.9882482149569114e-07
to O 0 1.0590095467222227e-09
A O 0 8.137669738061959e-08
mutation O 0 4.648747875535264e-08
at O 0 1.865557130997786e-08
the O 0 4.9349155872846495e-09
penultimate O 0 3.116064419828035e-07
nucleotide O 0 1.7197498536347666e-08
of O 0 4.340138026748264e-09
exon O 0 1.1115388787175107e-07
6 O 0 9.936153233525147e-09
of O 0 6.006679598158371e-10
the O 0 1.8803851808968375e-09
CYP27 O 0 5.190442971070297e-05
gene O 0 4.430807720723351e-09
not O 0 3.9301581433726085e-10
only O 0 2.1304464858928895e-09
causes O 0 3.543678133155481e-07
the O 0 7.154574177548056e-07
deficiency B-Disease 0 0.44229164719581604
in I-Disease 0 1.3919469132872564e-08
the I-Disease 0 1.9731061229322222e-08
sterol I-Disease 0 5.030197485211829e-07
27 I-Disease 0 3.5375936136006203e-07
- I-Disease 0 1.2782624025931e-07
hydroxylase I-Disease 0 9.305127690595327e-08
activity I-Disease 0 1.1434282853883815e-08
, O 0 6.406748465082046e-10
but O 0 5.869403851832544e-10
also O 0 1.0076616208110067e-09
partially O 0 2.3326334641637914e-08
leads O 0 2.8701665488739536e-09
to O 0 3.4868516407549066e-10
alternative O 0 2.0506611519977014e-08
pre O 0 3.716421019817062e-07
- O 0 4.935257180704866e-08
mRNA O 0 9.692776359315758e-08
splicing O 0 3.125942527049119e-08
of O 0 2.9353293129474878e-09
the O 0 1.58807456074328e-08
gene O 0 3.537863619840209e-07
. O 0 5.729094141315727e-07

To O 0 1.213732048199745e-07
our O 0 2.6689557230952232e-08
knowledge O 0 4.0473850049238536e-08
, O 0 1.7063462864896906e-09
this O 0 8.720484334645562e-10
is O 0 1.9978072529625024e-09
the O 0 2.9253692801489706e-09
first O 0 5.848565187704935e-09
report O 0 1.7399478524637857e-09
regarding O 0 9.631405895049738e-09
effects O 0 6.481706549266164e-08
on O 0 3.5804262665806164e-08
pre O 0 3.635901748566539e-07
- O 0 3.695885553156586e-08
mRNA O 0 2.704044987922316e-08
splicing O 0 3.0523874539056806e-09
of O 0 1.827738654869293e-10
a O 0 5.796665369928178e-10
mutation O 0 3.6070679776400993e-09
at O 0 5.554902315907384e-09
the O 0 4.020338728594197e-09
- O 0 1.349789613414032e-07
2 O 0 1.5358017435573856e-07
position O 0 5.640972489118212e-08
of O 0 6.942085128969211e-09
a O 0 3.7545454745213647e-08
5 O 0 4.6070672965470294e-07
splice O 0 6.9608886406058446e-06
site O 0 7.624013278473285e-07
. O 0 6.984774927332182e-07

ATM O 0 0.04424091428518295
germline O 0 0.0005345027311705053
mutations O 0 2.089758709189482e-06
in O 0 7.784949218603288e-08
classical O 0 0.4303155243396759
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 0 1.6762087398092262e-05
in O 0 9.472344686400902e-08
the O 0 1.6753864429119858e-07
Dutch O 0 3.130156983388588e-05
population O 0 1.225247956426756e-07
. O 0 5.010300014873792e-07

Germline O 0 0.00540181715041399
mutations O 0 3.013486093550455e-06
in O 0 1.6065520469510375e-08
the O 0 1.0763068658548036e-08
ATM O 0 7.20601337889093e-06
gene O 0 6.148446640708016e-09
are O 0 3.452701319295315e-11
responsible O 0 8.120668582023427e-10
for O 0 9.378852139363403e-10
the O 0 4.65459561382886e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 1 0.9995088577270508
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 9.846859256867901e-07
. O 0 1.2988457456231117e-06

In O 0 2.401846757038584e-07
our O 0 2.7292793802757842e-08
study O 0 1.2654786551991037e-08
, O 0 2.9530857759141327e-09
we O 0 2.056923964488533e-09
have O 0 5.277350223487076e-10
determined O 0 1.0199913802466654e-08
the O 0 4.031795786119119e-09
ATM O 0 3.988106982433237e-06
mutation O 0 9.196632078101175e-08
spectrum O 0 8.108338533929782e-07
in O 0 1.5991772350787414e-09
19 O 0 7.061366602556518e-09
classical O 0 4.0340293594454124e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.3196698844808452e-08
, O 0 2.490609940508648e-10
including O 0 4.976405398871009e-11
some O 0 1.8474678731283944e-10
immigrant O 0 2.123559106337325e-08
populations O 0 3.2171758590493482e-09
, O 0 4.904716632836426e-10
as O 0 9.900225084180647e-10
well O 0 1.2362575407820486e-09
as O 0 2.35696617778558e-09
12 O 0 1.540830041335539e-08
of O 0 1.1049412051988838e-08
Dutch O 0 1.1103348924734746e-06
ethnic O 0 1.4607741150030051e-07
origin O 0 5.173679369363526e-07
. O 0 9.315886018157471e-07

Both O 0 3.0182209798113036e-07
the O 0 9.180543258935359e-08
protein O 0 1.2213035915920045e-07
truncation O 0 2.187007339671254e-06
test O 0 2.4317955649166834e-07
( O 0 9.376463339094698e-08
PTT O 0 1.154503297584597e-05
) O 0 3.604873954898835e-09
and O 0 4.149696974931061e-10
the O 0 2.2714718994620853e-09
restriction O 0 3.050584851393978e-08
endonuclease O 0 6.325835784082301e-07
fingerprinting O 0 3.0371217007996165e-07
( O 0 1.5855381008123004e-08
REF O 0 1.0717002624005545e-05
) O 0 2.49476550528982e-10
method O 0 6.714035993837797e-10
were O 0 7.140850410980448e-11
used O 0 2.1282604845129782e-10
and O 0 1.4284214089332892e-10
compared O 0 2.7173101546651424e-09
for O 0 2.876050786415618e-10
their O 0 8.164149217781969e-11
detection O 0 5.563334681824017e-08
efficiency O 0 2.348669880802845e-08
, O 0 2.3048980501982896e-09
identifying O 0 9.740922735090862e-09
76 O 0 8.22944912215462e-08
% O 0 6.2239253750817625e-09
and O 0 2.8819702180271634e-10
60 O 0 9.33326127494638e-09
% O 0 5.131059577223596e-09
of O 0 1.990800413409488e-09
the O 0 2.1284776607899403e-08
mutations O 0 3.3867587490021833e-07
, O 0 8.046883692713891e-08
respectively O 0 2.50064999818278e-06
. O 0 3.0299811442091595e-06

Most O 0 8.658025194563379e-07
patients O 0 1.492611403364208e-07
were O 0 1.7247495875949426e-08
found O 0 9.367933095916214e-09
to O 0 8.905503889877764e-09
be O 0 8.797005790484036e-08
compound O 0 5.691193564416608e-06
heterozygote O 0 3.912356623914093e-05
. O 0 2.159828000003472e-06

Seventeen O 0 3.260375024183304e-06
mutations O 0 2.347176888406466e-07
were O 0 5.0054635991614305e-09
distinct O 0 4.2132062283428695e-09
, O 0 1.0554283003116893e-09
of O 0 7.001151658414528e-09
which O 0 1.4356711375285158e-09
10 O 0 6.1371170367863215e-09
were O 0 1.69942482308727e-09
not O 0 4.870867709172444e-09
reported O 0 8.109871885153552e-08
previously O 0 6.717244218634733e-07
. O 0 1.0060260819955147e-06

Mutations O 0 1.9780967704718933e-05
are O 0 2.2835973112478314e-08
small O 0 1.5475312409307662e-07
deletions O 0 5.963305738987401e-06
or O 0 4.752558652398875e-06
point O 0 0.04475053772330284
mutations O 0 4.33214518125169e-06
frequently O 0 1.493982750844225e-07
affecting O 0 2.2806185029367043e-07
splice O 0 1.7005244444590062e-05
sites O 0 7.752881856504246e-07
. O 0 9.87964881460357e-07

Moreover O 0 2.492959174560383e-05
, O 0 6.617676149289764e-07
a O 0 2.099941639244207e-06
16 O 0 2.076959572150372e-05
. O 0 5.074939963378711e-06

7 O 0 5.810911534354091e-05
- O 0 1.5899140635156073e-05
kb O 0 6.0036659306206275e-06
genomic O 0 2.9788478173031763e-07
deletion O 0 6.608285616493959e-07
of O 0 2.8504301141651922e-08
the O 0 9.083747976035284e-09
3 O 0 8.559591435641778e-08
end O 0 9.774329789991043e-09
of O 0 1.0863587807108388e-09
the O 0 1.209177757921509e-09
gene O 0 2.2003223687505624e-09
, O 0 1.43923484241526e-10
most O 0 2.2707474789385174e-10
likely O 0 9.223980690364897e-09
a O 0 4.476662152086419e-09
result O 0 1.209561339976517e-08
of O 0 1.1444647007863296e-08
recombination O 0 2.535572996009705e-08
between O 0 6.321877688009181e-09
two O 0 1.5761689731164097e-09
LINE O 0 4.152544192947971e-07
elements O 0 4.216762050646139e-08
, O 0 1.5102179062864707e-08
was O 0 3.8727677065253374e-07
identified O 0 4.000010846993973e-07
. O 0 4.258866397321981e-07

The O 0 8.595196732130717e-07
most O 0 1.503297752947219e-08
frequently O 0 5.630993893390723e-09
found O 0 3.2276985528767455e-09
mutation O 0 7.022619996632784e-08
, O 0 2.2039683411634314e-09
identified O 0 1.3891381378527967e-08
in O 0 7.898372511583318e-10
three O 0 3.5153124855469287e-10
unrelated O 0 3.402121961926241e-08
Turkish O 0 3.071321771130897e-06
A B-Disease 1 1.0
- I-Disease 1 0.9999980926513672
T I-Disease 1 0.9999958276748657
individuals O 0 2.354881400989939e-09
, O 0 1.9277179852394966e-09
was O 0 2.5029944339394206e-08
previously O 0 1.8374952670541234e-09
described O 0 3.046912444570893e-10
to O 0 1.2290954365390405e-10
be O 0 5.269464309343164e-10
a O 0 6.081255943257702e-09
Turkish O 0 2.3211712232296122e-06
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9996553659439087
T I-Disease 1 0.9999841451644897
founder O 0 1.9868160961777903e-05
mutation O 0 4.258868102624547e-06
. O 0 1.4540416941599688e-06

The O 0 1.3436660140087042e-07
presence O 0 3.199986764457208e-08
of O 0 2.4961911648802015e-08
a O 0 1.078279936450599e-07
founder O 0 2.4311980268976185e-06
mutation O 0 1.9418994270381518e-06
among O 0 4.081812221556902e-09
relatively O 0 3.829164985091893e-09
small O 0 2.163859980086613e-09
ethnic O 0 6.152176990070757e-09
population O 0 1.445002867361822e-10
groups O 0 2.540599154665646e-11
in O 0 3.700803552497689e-11
Western O 0 5.550464532433352e-09
Europe O 0 1.337106603216398e-08
could O 0 3.050129482318198e-09
indicate O 0 6.651784900668645e-09
a O 0 1.2543333482994967e-08
high O 0 3.332706199898894e-08
carrier O 0 2.8763334825043785e-08
frequency O 0 9.638061015948551e-08
in O 0 3.7185885481960668e-09
such O 0 7.647780186914588e-09
communities O 0 1.7163279153464828e-07
. O 0 1.802330871214508e-06

In O 0 6.694106104987441e-07
patients O 0 5.971831740225753e-08
of O 0 5.775515177219859e-08
Dutch O 0 3.2677889976184815e-05
ethnic O 0 2.8204158297739923e-07
origin O 0 3.6859592711380174e-08
, O 0 7.477972130409682e-10
however O 0 1.1581733350141121e-09
, O 0 5.061152053009721e-10
no O 0 1.665458659871888e-09
significant O 0 1.155268236630036e-08
founder O 0 5.803962110917382e-08
effect O 0 2.8101480253894806e-08
could O 0 1.6777599753936556e-08
be O 0 2.3901515433522036e-08
identified O 0 2.513673678095074e-07
. O 0 3.6309813822299475e-07

The O 0 7.253325975398184e-07
observed O 0 4.716491730505368e-07
genetic O 0 5.159444071978214e-07
heterogeneity O 0 1.8799198642227566e-06
including O 0 2.5928854618939567e-09
the O 0 4.1018324736796785e-08
relative O 0 6.2859448917151894e-06
high O 0 1.5610332866344834e-06
percentage O 0 4.354311329279881e-07
of O 0 2.9562261971705084e-08
splice O 0 2.1278744952724082e-06
- O 0 2.1642433978286135e-07
site O 0 2.6705189171138954e-08
mutations O 0 2.3668153659173186e-08
had O 0 6.355281634284893e-09
no O 0 1.0964764207699318e-08
reflection O 0 6.53797826544178e-07
on O 0 2.1477083578247402e-07
the O 0 3.7389847307167656e-07
phenotype O 0 2.6699630325310864e-05
. O 0 1.851189267654263e-06

All O 0 4.183045518857398e-07
patients O 0 6.182788325759248e-08
manifested O 0 2.4062990178208565e-07
classical O 0 1.67404577950947e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
T I-Disease 1 0.9999970197677612
and O 0 1.1330199356507364e-07
increased O 0 6.117054454080062e-07
cellular O 0 2.733872634053114e-06
radioresistant O 0 1.3998371287016198e-05
DNA O 0 2.035663328570081e-06
synthesis O 0 2.9905538667662768e-06
. O 0 8.09375194421591e-07

Determination O 0 6.933129498065682e-06
of O 0 3.042183038814983e-07
the O 0 4.190567892692343e-08
genomic O 0 2.491155157713365e-07
structure O 0 5.026035054811473e-08
of O 0 5.723753560005207e-08
the O 0 1.273174348170869e-07
COL4A4 O 1 0.9998670816421509
gene O 0 5.560216109756766e-08
and O 0 8.063130718660716e-10
of O 0 1.6491485510528037e-08
novel O 0 7.398473371722503e-07
mutations O 0 2.9034499675617553e-05
causing O 0 0.0060797459445893764
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999266862869263

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.670801354222931e-05
a O 0 2.4553568437113427e-05
progressive O 1 0.9999996423721313
hematuric B-Disease 1 1.0
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.016352372244000435
by O 0 1.1826421086880146e-06
glomerular B-Disease 1 1.0
basement I-Disease 1 0.9999998807907104
membrane I-Disease 1 0.9999943971633911
abnormalities I-Disease 1 0.9997386336326599
and O 0 8.928584094292091e-09
associated O 0 1.9446920518362276e-08
with O 0 5.405983438677708e-10
mutations O 0 1.2822707162740699e-07
in O 0 5.305167416480572e-09
either O 0 1.7339587543574453e-08
the O 0 3.9615834168671427e-08
COL4A3 O 1 0.9993771910667419
or O 0 4.706363654349843e-08
the O 0 5.529566848849754e-08
COL4A4 O 0 0.0010537946363911033
gene O 0 1.379250935684695e-08
, O 0 3.575454654569654e-10
which O 0 1.4110609902751037e-10
encode O 0 2.2805579646956176e-09
the O 0 9.083175989132997e-09
alpha3 O 0 9.485553164267913e-06
and O 0 2.413326249950387e-08
alpha4 O 0 4.8035351937869564e-05
type O 0 4.302147135604173e-05
IV O 1 0.9999990463256836
collagen O 0 0.0006831884384155273
chains O 0 4.314456873544259e-06
, O 0 1.7616854108837288e-07
respectively O 0 2.7022615540772676e-06
. O 0 2.485782488292898e-06

To O 0 7.80043691861465e-08
date O 0 1.6330993446445063e-07
, O 0 2.8354245618089635e-09
mutation O 0 1.2241555324976616e-08
screening O 0 9.80493375379865e-09
in O 0 3.2211469602749787e-10
the O 0 1.0598542043993575e-09
two O 0 3.8364736387741516e-10
genes O 0 3.082353705607943e-09
has O 0 4.5138362492203044e-10
been O 0 1.7759038684062034e-09
hampered O 0 6.163359955735359e-08
by O 0 9.828559077718069e-10
the O 0 8.37206037829219e-09
lack O 0 8.84070630036149e-08
of O 0 4.151909749339211e-08
genomic O 0 7.950220037855615e-07
structure O 0 1.3380650898398017e-07
information O 0 1.7049863743068272e-07
. O 0 1.148604155787325e-06

We O 0 4.2115698306588456e-07
report O 0 1.3453592906387257e-08
here O 0 3.7032152899740822e-09
the O 0 1.890302803175814e-09
complete O 0 5.670873548524469e-09
characterization O 0 1.3747157368015905e-07
of O 0 1.2030086260494954e-08
the O 0 1.3229890072352646e-08
48 O 0 3.9409489005493015e-08
exons O 0 7.949979874410928e-08
of O 0 3.7099525673767175e-09
the O 0 1.372121705145446e-08
COL4A4 O 1 0.9555482268333435
gene O 0 4.6428819899801965e-08
, O 0 1.964149731747966e-09
a O 0 5.826675142373006e-09
comprehensive O 0 6.928846119080845e-08
gene O 0 7.609486374349217e-08
screen O 0 1.859053639918784e-07
, O 0 3.2853944009758607e-09
and O 0 5.608417064095761e-10
the O 0 2.083891059712073e-09
subsequent O 0 7.461903983596585e-09
detection O 0 1.1290462254009981e-07
of O 0 8.62668869672234e-09
10 O 0 4.130061181939482e-09
novel O 0 5.2987561005579664e-09
mutations O 0 1.447793440689793e-08
in O 0 3.2402509564377624e-09
eight O 0 4.6768871442282034e-08
patients O 0 1.2602234278347169e-07
diagnosed O 1 0.9865188002586365
with O 0 4.0439235817757435e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 0.9999901056289673

Furthermore O 0 7.273404662555549e-06
, O 0 8.158806252822615e-08
we O 0 4.2512127151894674e-08
identified O 0 6.247893935551474e-08
a O 0 2.988153724459153e-08
glycine O 0 4.014724481748999e-07
to O 0 1.3192898329350555e-08
alanine O 0 4.15006581988564e-07
substitution O 0 6.752454169145494e-07
in O 0 1.1181579218089155e-08
the O 0 1.3940698373460236e-08
collagenous O 0 4.937234280077973e-06
domain O 0 5.9456581880112935e-08
that O 0 3.0907587600381703e-10
is O 0 1.1687697476503445e-09
apparently O 0 7.706292493026012e-09
silent O 0 9.325218819355996e-09
in O 0 3.281027949331161e-10
the O 0 2.345083016663807e-09
heterozygous O 0 2.8288141606935824e-08
carriers O 0 1.4478044541021973e-08
, O 0 8.607360157952826e-09
in O 0 7.638919186092608e-08
11 O 0 1.424632046109764e-06
. O 0 1.7788900095183635e-06

5 O 0 1.1018580607924378e-06
% O 0 7.838259818981896e-08
of O 0 5.698369776041545e-09
all O 0 6.114259654133036e-10
control O 0 2.6394719299105418e-08
individuals O 0 1.4478562793129868e-09
, O 0 1.7538620555868079e-09
and O 0 7.13610170954837e-10
in O 0 1.2115233261056346e-09
one O 0 1.4043571860966608e-09
control O 0 6.897158844054729e-09
individual O 0 6.144035835653483e-10
homozygous O 0 7.854838557364019e-09
for O 0 9.209718543345957e-10
this O 0 1.2248793979097172e-08
glycine O 0 2.8934050533280242e-06
substitution O 0 8.014554623514414e-06
. O 0 2.4463292902510148e-06

There O 0 1.7740622126893868e-07
has O 0 1.671891780574697e-08
been O 0 3.3784528508107314e-09
no O 0 1.2146214034558511e-09
previous O 0 2.571814539109596e-09
finding O 0 2.068427651380489e-09
of O 0 9.37690258773216e-10
a O 0 2.0339763207033457e-09
glycine O 0 3.967618056321953e-08
substitution O 0 4.480473947410246e-08
that O 0 1.9440596354947104e-10
is O 0 4.0392064692973406e-10
not O 0 3.0940325301820337e-10
associated O 0 8.540714802052207e-10
with O 0 1.1373888636478924e-10
any O 0 2.883952809895618e-08
obvious O 0 1.1170833431606297e-06
phenotype O 0 4.316103058954468e-06
in O 0 2.9356440833794295e-08
homozygous O 0 2.5898751232489303e-07
individuals O 0 1.960116335908424e-08
. O 0 1.1439647096267436e-06

Founder O 0 0.0004250415659043938
BRCA1 O 0 0.00020488729933276772
and O 0 2.77558257266719e-07
BRCA2 O 0 3.5130931792082265e-05
mutations O 0 1.8448609750976175e-07
in O 0 7.136622848236129e-09
French O 0 9.593911727279192e-07
Canadian O 0 1.1286503649898805e-05
breast B-Disease 1 1.0
and I-Disease 1 0.9999934434890747
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.9806011298205703e-05
. O 0 2.267678610223811e-05

We O 0 2.1662650340203982e-07
have O 0 3.824012217990003e-09
identified O 0 1.0872382105731049e-08
four O 0 5.523720925104669e-10
mutations O 0 4.311639489884556e-09
in O 0 2.6686322596169987e-10
each O 0 3.618718935616272e-10
of O 0 1.3078776284203286e-08
the O 0 3.6458149565987696e-07
breast B-Disease 1 0.9999994039535522
cancer I-Disease 1 0.999998927116394
- O 1 0.6702017784118652
susceptibility O 0 0.10179714113473892
genes O 0 2.0521758870017948e-07
, O 0 1.3538643095500902e-08
BRCA1 O 0 1.6928134982663323e-06
and O 0 1.9292858866037932e-08
BRCA2 O 0 1.1672324035316706e-05
, O 0 1.920297698632112e-09
in O 0 1.6400509839087363e-09
French O 0 4.201812942028482e-07
Canadian O 0 7.332096743084549e-07
breast B-Disease 1 0.974115252494812
cancer I-Disease 1 0.9832568764686584
and O 0 0.0021460680291056633
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.297535502293613e-06
from O 0 2.3824536583560985e-06
Quebec O 0 2.559261156420689e-05
. O 0 2.614545110191102e-06

To O 0 2.465468469381449e-07
identify O 0 1.585717200214276e-06
founder O 0 1.9509392586769536e-05
effects O 0 0.00020344325457699597
, O 0 7.216812036858755e-08
we O 0 9.078897633685301e-09
examined O 0 2.5503226197542972e-08
independently O 0 2.8946647301353323e-09
ascertained O 0 1.8625158304530487e-07
French O 0 4.1890737634275865e-07
Canadian O 0 3.826597492206929e-07
cancer B-Disease 0 2.064048203465063e-06
families O 0 2.769946771952192e-10
for O 0 2.786649522246165e-10
the O 0 8.771096071669149e-10
distribution O 0 9.972074721531499e-09
of O 0 9.934030487102063e-09
these O 0 3.367978562707208e-09
eight O 0 1.8713487293098297e-07
mutations O 0 5.793399395770393e-06
. O 0 3.1234985726769082e-06

Mutations O 0 5.32299100086675e-06
were O 0 6.822791220884028e-08
found O 0 1.7388803286166876e-08
in O 0 7.616395514276064e-09
41 O 0 1.703172785028073e-07
of O 0 7.758490028209053e-08
97 O 0 3.379568170203129e-06
families O 0 1.6532638369426422e-07
. O 0 2.2116475975053618e-06

Six O 0 4.5226400402498257e-07
of O 0 8.559885600334383e-08
eight O 0 2.6692459798027812e-08
mutations O 0 4.60081430730952e-08
were O 0 8.276638041593287e-09
observed O 0 4.347795723447234e-08
at O 0 1.3527690612136212e-07
least O 0 8.081043745278293e-08
twice O 0 3.3702988275763346e-06
. O 0 2.9040174922556616e-06

The O 0 2.1033649773016805e-06
BRCA1 O 0 0.00014654388360213488
C4446T O 0 0.000508117547724396
mutation O 0 1.677730097071617e-06
was O 0 7.708883487111962e-08
the O 0 2.2150181688829207e-09
most O 0 4.022369382017388e-10
common O 0 3.790940450443259e-09
mutation O 0 4.1890974245006873e-08
found O 0 1.0779601655741544e-09
, O 0 2.4260848885404585e-10
followed O 0 1.3048271352289476e-09
by O 0 5.765416477565566e-10
the O 0 1.2719803521576978e-07
BRCA2 O 0 3.159035986755043e-05
8765delAG O 0 6.63265964249149e-05
mutation O 0 7.5230622314848e-05
. O 0 7.0833152676641475e-06

Together O 0 1.9154232688833872e-07
, O 0 7.77942510410412e-09
these O 0 5.748803100225075e-10
mutations O 0 2.05325978441806e-08
were O 0 2.8372260096887203e-09
found O 0 8.464476897174222e-10
in O 0 7.70593533427899e-10
28 O 0 6.48389253399273e-09
of O 0 2.5017619087464027e-09
41 O 0 2.871690440997554e-08
families O 0 2.1126086990896908e-10
identified O 0 1.1834832003287943e-09
to O 0 8.843580867612388e-10
have O 0 4.7951140835778006e-09
a O 0 4.289208277441503e-07
mutation O 0 1.5773655832163058e-05
. O 0 2.398949163762154e-06

The O 0 5.499599637914798e-07
odds O 0 3.892721906595398e-06
of O 0 2.2021163559315937e-08
detection O 0 3.944386151033541e-07
of O 0 3.2791540149901266e-08
any O 0 1.6311886952280474e-08
of O 0 1.6315993889293168e-08
the O 0 1.8557937409013903e-08
four O 0 9.033056080909319e-09
BRCA1 O 0 1.3876415323466063e-06
mutations O 0 4.7031511485329247e-07
was O 0 2.1637245026795426e-06
18 O 0 1.2070513548678719e-06
. O 0 6.168941695250396e-07

7x O 0 0.057497281581163406
greater O 0 2.2920730771147646e-06
if O 0 9.370598519353734e-08
one O 0 7.092493703453329e-09
or O 0 9.113923504777688e-10
more O 0 1.038619121263018e-10
cases O 0 2.1587771570352743e-09
of O 0 2.369938556512352e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 4.012611611869943e-07
also O 0 5.476568532003512e-09
present O 0 2.8826754316924053e-09
in O 0 4.215955584641051e-09
the O 0 4.635528583207815e-08
family O 0 9.790435484546833e-08
. O 0 6.999464972068381e-07

The O 0 5.466802122100489e-07
odds O 0 3.647230641945498e-06
of O 0 2.2733020799137194e-08
detection O 0 3.4007146609837946e-07
of O 0 2.3647396929504794e-08
any O 0 2.567576196099708e-08
of O 0 3.578985641183863e-08
the O 0 2.1712697417797244e-08
four O 0 5.916719558740624e-08
BRCA2 O 0 9.536774996377062e-06
mutations O 0 1.5834398254810367e-06
was O 0 5.233084721112391e-06
5 O 0 3.575114988052519e-06
. O 0 1.2174328958280967e-06

3x O 0 0.0001770539820427075
greater O 0 9.97277993519674e-07
if O 0 6.819954734282874e-08
there O 0 6.3049108156576494e-09
were O 0 2.538339538560308e-09
at O 0 5.075645237440085e-09
least O 0 2.447576585851152e-10
five O 0 8.860900208018663e-11
cases O 0 1.4183275387491534e-10
of O 0 2.414739874723182e-08
breast B-Disease 1 0.9999771118164062
cancer I-Disease 1 0.9532529711723328
in O 0 2.0988673554711568e-07
the O 0 9.314908879787254e-07
family O 0 5.154226414560981e-07
. O 0 1.333047180196445e-06

Interestingly O 0 7.351698059210321e-06
, O 0 1.312212827286885e-08
the O 0 2.95478175260655e-09
presence O 0 1.8449298755385257e-09
of O 0 1.0925599980282641e-08
a O 0 1.0215994734608103e-06
breast B-Disease 1 0.9999974966049194
cancer I-Disease 1 0.9873591065406799
case O 0 4.049349627166521e-06
< O 0 0.1612250655889511
36 O 0 7.39434042884568e-08
years O 0 8.390024230919835e-10
of O 0 7.186709560791371e-10
age O 0 2.253799591400707e-09
was O 0 2.2911088581878403e-09
strongly O 0 9.277774104532455e-10
predictive O 0 4.158485999994355e-09
of O 0 7.064205331808182e-10
the O 0 3.7532171814902426e-10
presence O 0 4.0104414233965713e-10
of O 0 9.426323055450325e-10
any O 0 2.0635806396995804e-09
of O 0 1.0060240640541451e-08
the O 0 1.3554921629577166e-08
eight O 0 1.153082749283385e-07
mutations O 0 4.715259080967371e-07
screened O 0 3.1408412723976653e-06
. O 0 1.2005855296592927e-06

Carriers O 0 2.3042646546400647e-07
of O 0 1.0193456745355434e-08
the O 0 1.206919675311724e-09
same O 0 1.7151562392569986e-09
mutation O 0 4.3312503805736924e-08
, O 0 3.054202724062094e-10
from O 0 5.57909829446146e-10
different O 0 1.3997943082433295e-10
families O 0 2.8104668592376925e-10
, O 0 3.6573127859540477e-10
shared O 0 1.1108766129197534e-09
similar O 0 3.299234441200838e-09
haplotypes O 0 1.628337145120895e-06
, O 0 4.8017132492361725e-09
indicating O 0 2.0801511624313207e-08
that O 0 2.3448851194096676e-10
the O 0 1.4570369355482171e-09
mutant O 0 1.5385101193032824e-08
alleles O 0 3.028333139809547e-09
were O 0 6.368626737085492e-10
likely O 0 2.286847822219329e-09
to O 0 1.890204520682559e-10
be O 0 2.5706656248125626e-10
identical O 0 2.592097925191439e-10
by O 0 1.1083003959022619e-10
descent O 0 6.360934889926284e-08
for O 0 4.183224877607472e-10
a O 0 4.957708465980204e-09
mutation O 0 2.987065528259336e-08
in O 0 2.0836408154423225e-09
the O 0 1.1573281888388465e-08
founder O 0 9.454561791244487e-07
population O 0 5.7631357464060784e-08
. O 0 4.941436486660677e-07

The O 0 1.519509424952048e-07
identification O 0 6.694528309481029e-08
of O 0 1.3583176894371718e-07
common O 0 4.448746949492488e-06
BRCA1 O 0 0.017779093235731125
and O 0 8.725898510419938e-07
BRCA2 O 0 0.008047286421060562
mutations O 0 8.081257760750304e-07
will O 0 3.4227198852931906e-09
facilitate O 0 4.754959093133948e-09
carrier O 0 3.488737831958133e-08
detection O 0 3.7671566133212764e-07
in O 0 2.3932611448174157e-09
French O 0 2.2673096111702762e-07
Canadian O 0 5.936433353781467e-07
breast B-Disease 0 0.09227211028337479
cancer I-Disease 0 0.05104098841547966
and O 0 1.8208203982794657e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.752620487939566e-06
. O 0 7.4252734520996455e-06

Are O 0 2.029503320954973e-06
Dp71 O 1 0.8752018809318542
and O 0 3.0896653697709553e-06
Dp140 O 1 0.9999756813049316
brain O 0 0.009590755216777325
dystrophin O 0 4.450693086255342e-05
isoforms O 0 2.668966544661089e-06
related O 0 1.0891294977000143e-07
to O 0 4.075473825082554e-08
cognitive B-Disease 1 0.9997767806053162
impairment I-Disease 1 0.9999998807907104
in O 0 0.3518078327178955
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
? O 1 0.9999878406524658

Molecular O 0 5.511129347723909e-05
study O 0 1.8505649279632053e-07
and O 0 2.0207640005764915e-08
neuropsychological O 0 1.818565692701668e-06
analysis O 0 4.7151331727945944e-08
were O 0 4.8755248727161415e-09
performed O 0 2.4279098731483373e-09
concurrently O 0 1.2207465260871686e-08
on O 0 2.8362752146904313e-08
49 O 0 5.13153281644918e-07
patients O 0 9.426328162476239e-09
with O 0 9.604038808674886e-08
Duchenne B-Disease 1 1.0
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999995231628418
DMD B-Disease 1 1.0
) O 0 3.13530534867823e-08
in O 0 7.369791998890207e-10
order O 0 1.6963343230091965e-10
to O 0 1.6651402479084254e-10
find O 0 6.877555747131225e-10
a O 0 1.9697021791387215e-09
molecular O 0 4.2693983459685114e-08
explanation O 0 7.091194742514517e-09
for O 0 1.89152893348421e-09
the O 0 4.3587064624261984e-08
cognitive B-Disease 1 0.6793304681777954
impairment I-Disease 0 0.012988113798201084
observed O 0 7.665950079172035e-07
in O 0 6.207271496805333e-08
most O 0 7.224786031656549e-07
DMD B-Disease 1 1.0
patients O 0 1.5311865354306065e-05
. O 0 9.306542779086158e-06

Complete O 0 4.569013754007756e-07
analysis O 0 8.561828224173951e-08
of O 0 5.376230305387253e-08
the O 0 2.8930212891964402e-08
dystrophin O 0 1.7915979242388858e-06
gene O 0 1.2034142571337725e-07
was O 0 8.645091043035791e-08
performed O 0 1.1103744590457154e-09
to O 0 4.64441818337491e-10
define O 0 2.569829860021855e-08
the O 0 7.3414834211860125e-09
localization O 0 2.247984866698971e-06
of O 0 5.029199101613813e-08
deletions O 0 6.478875889115443e-07
and O 0 8.753618274681685e-09
duplications O 0 4.417031959746964e-06
in O 0 4.981842494089506e-09
relation O 0 5.528870516968709e-08
to O 0 3.6903329281301467e-09
the O 0 3.5811776655236827e-08
different O 0 2.0470723427479243e-07
DMD B-Disease 1 1.0
promoters O 0 0.000983577803708613
. O 0 6.155974915600382e-06

Qualitative O 0 3.905252469849074e-06
analysis O 0 1.427397933184693e-07
of O 0 8.77279404676301e-08
the O 0 1.4900115274940617e-07
Dp71 O 0 0.00011826219997601584
transcript O 0 7.311322747227678e-07
and O 0 1.0437770647797606e-09
testing O 0 1.734414500909054e-09
for O 0 6.505228994369006e-11
the O 0 5.189461638188675e-10
specific O 0 1.327110421556199e-09
first O 0 1.0604351174947624e-08
exon O 0 5.48409673228889e-07
of O 0 6.140749064798001e-08
Dp140 O 0 9.698575013317168e-06
were O 0 9.383133381390962e-09
also O 0 3.7691449961130274e-09
carried O 0 1.7571911925529093e-08
out O 0 4.8871651614490474e-08
. O 0 6.305911597337399e-07

Neuropsychological O 0 0.0003540197794791311
analysis O 0 3.4983381738129538e-06
assessed O 0 3.173922959831543e-05
verbal O 0 3.95888346247375e-05
and O 0 7.520072813349543e-07
visuospatial O 0 7.620552787557244e-05
intelligence O 0 7.667653676435293e-07
, O 0 5.02898842569266e-08
verbal O 0 1.9533184968167916e-05
memory O 0 0.18508455157279968
, O 0 6.671685781611814e-08
and O 0 2.9538306023368932e-08
reading O 0 2.822788246703567e-06
skills O 0 1.0515426538404427e-06
. O 0 2.2725664621248143e-06

Comparison O 0 1.4686898794025183e-05
of O 0 1.3224437225289876e-06
molecular O 0 2.283330832142383e-05
and O 0 4.6298648470610715e-08
psychometric O 0 4.0706145227886736e-05
findings O 0 1.298741238997536e-07
demonstrated O 0 2.403523247096473e-08
that O 0 7.298282533874101e-10
deletions O 0 1.337128736622617e-07
and O 0 3.1914031417557e-09
duplications O 0 1.118108684750041e-06
that O 0 1.0768156366580683e-09
were O 0 1.8808443691398224e-09
localized O 0 3.7899488347648003e-07
in O 0 2.4169179990707335e-09
the O 0 5.668148617132829e-09
distal O 0 2.089890040224418e-05
part O 0 2.811853150319621e-08
of O 0 1.9376054538611243e-08
the O 0 1.8364589848829382e-08
gene O 0 4.353322680117344e-08
seemed O 0 1.9996875266770076e-08
to O 0 7.255229750313674e-10
be O 0 3.098315604077584e-09
preferentially O 0 7.097029453007053e-08
associated O 0 5.675334335819571e-08
with O 0 3.813147486653179e-08
cognitive B-Disease 1 0.999982476234436
impairment I-Disease 1 0.9999856948852539
. O 0 0.0001165624416898936

Two O 0 4.493971061947377e-07
altered O 0 2.7180119559488958e-06
Dp71 O 0 0.00010857340384973213
transcripts O 0 1.0367001550548594e-06
and O 0 1.6313721928895575e-08
two O 0 6.368192639882864e-09
deleted O 0 1.6572529659697466e-07
Dp140 O 0 6.724242780364875e-07
DNA O 0 6.434195398696829e-09
sequences O 0 7.709139993039571e-10
were O 0 1.4297733830215265e-10
found O 0 1.1815744216381319e-10
in O 0 2.0040345771743517e-10
four O 0 6.276638653268662e-10
patients O 0 3.0294367014960244e-09
with O 0 1.6378885803192134e-08
severe O 1 1.0
cerebral B-Disease 1 1.0
dysfunction I-Disease 1 1.0
. O 1 0.978808581829071

These O 0 4.6743547699179544e-08
findings O 0 7.999917528422884e-08
suggest O 0 2.5699280925550738e-08
that O 0 5.101994937639631e-10
some O 0 3.4120806180482077e-10
sequences O 0 2.0787898069585253e-09
located O 0 2.9967650583273553e-09
in O 0 4.682479404216622e-10
the O 0 1.881274913628772e-09
distal O 0 5.58014244234073e-06
part O 0 2.6405746922364415e-08
of O 0 1.2831534945689782e-08
the O 0 6.896212045859329e-09
gene O 0 1.2534770554850638e-08
and O 0 1.7163671595099572e-09
, O 0 1.794275950040003e-09
in O 0 1.0196523625438658e-09
particular O 0 1.667487303791404e-08
, O 0 5.639936517809474e-09
some O 0 8.123832273554399e-09
DMD B-Disease 1 1.0
isoforms O 0 2.881871978388517e-06
expressed O 0 4.2473388361941034e-08
in O 0 9.844022486049653e-09
the O 0 7.812661806383403e-08
brain O 0 0.00019618771329987794
may O 0 1.4374256451787915e-08
be O 0 2.474903615379276e-09
related O 0 4.347959325912143e-09
to O 0 1.1108278741289723e-09
the O 0 4.6088686644907284e-08
cognitive B-Disease 1 0.7030206918716431
impairment I-Disease 0 0.008793136104941368
associated O 0 8.607607355770597e-07
with O 0 3.38611272354683e-07
DMD B-Disease 1 1.0
. O 0 9.819984370551538e-06
. O 0 4.415019247971941e-06

I1307K O 0 0.010237469337880611
APC O 0 7.081868534442037e-05
and O 0 1.3850393543179962e-07
hMLH1 O 0 5.9391682043496985e-06
mutations O 0 1.4145390991870954e-07
in O 0 3.834164097327175e-09
a O 0 1.1261584553778903e-08
non O 0 5.57276450763311e-07
- O 0 3.938713746265421e-07
Jewish O 0 9.16829421271359e-08
family O 0 1.019594075835073e-09
with O 0 5.248440571037349e-10
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999985694885254

We O 0 2.473117319823359e-07
describe O 0 1.0600553679296354e-07
a O 0 5.4117972325684605e-08
French O 0 3.4978040730493376e-06
Canadian O 0 5.686771601176588e-06
hereditary B-Disease 1 1.0
non I-Disease 1 1.0
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 1 1.0
HNPCC B-Disease 1 1.0
) O 0 6.409883894775703e-07
kindred O 0 1.6235596831393195e-06
which O 0 2.7214390740937233e-09
carries O 0 9.145637136498408e-09
a O 0 6.456729817472251e-09
novel O 0 3.073713372714337e-08
truncating O 0 4.4170894852868514e-07
mutation O 0 4.894180278824933e-07
in O 0 1.984802082688475e-07
hMLH1 O 0 5.2132963901385665e-05
. O 0 8.13393580756383e-06

Interestingly O 0 3.168310286127962e-05
, O 0 2.9360231224018207e-07
the O 0 2.712610580601904e-07
I1307K O 0 4.8124940803973004e-05
APC O 0 2.992083182107308e-06
polymorphism O 0 3.005513235621038e-06
, O 0 3.037710749609346e-09
associated O 0 9.508521747747523e-10
with O 0 4.2382042320099345e-11
an O 0 4.354472338263804e-10
increased O 0 6.943478325638353e-08
risk O 0 0.006918755825608969
of O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 0.00033709287527017295
is O 0 3.457596520206607e-08
also O 0 5.385184520534381e-10
present O 0 4.501095329789706e-10
in O 0 5.907129230209307e-10
this O 0 3.1157503244116924e-09
family O 0 1.0190369437168556e-07
. O 0 5.343455882211856e-07

The O 0 4.297234681871487e-06
I1307K O 0 0.00042929925257340074
polymorphism O 0 5.599300129688345e-05
has O 0 3.1446845127902634e-08
previously O 0 6.658182449825745e-09
only O 0 6.812680974910279e-10
been O 0 8.540469997875277e-10
identified O 0 1.200720189942217e-09
in O 0 1.215047229496946e-10
individuals O 0 6.766381205336458e-11
of O 0 9.788564625523577e-09
self O 0 8.749380526751338e-07
- O 0 1.4330668818729464e-05
reported O 0 5.58642909709306e-07
Ashkenazi O 0 1.9431556211202405e-05
Jewish O 0 8.932366881708731e-07
origins O 0 3.941936938645085e-06
. O 0 1.5679562466175412e-06

In O 0 2.9222031017184236e-08
addition O 0 4.219946170280764e-09
, O 0 1.1517562459317787e-09
in O 0 2.847389268811895e-10
this O 0 3.31425636934668e-10
family O 0 1.0827263530188702e-09
, O 0 1.156687037817683e-10
there O 0 1.2502236745870476e-10
appears O 0 8.420066865966191e-10
to O 0 1.7708225164003721e-10
be O 0 1.6029547689200285e-09
no O 0 2.770624396575272e-09
relationship O 0 1.8405152957257087e-09
between O 0 4.934463948558232e-09
the O 0 7.748873542823276e-09
I1307K O 0 4.003422588993999e-07
polymorphism O 0 2.6371418826443005e-08
and O 0 2.1030963082147025e-10
the O 0 8.036598608818224e-10
presence O 0 2.881443972313491e-09
or O 0 1.1590579163112125e-08
absence O 0 4.3197746890655253e-07
of O 0 1.437627929590235e-06
cancer B-Disease 0 0.19874104857444763
. O 0 8.542235718778102e-07
. O 0 4.868836185778491e-06

Identification O 0 1.3199514796724543e-06
of O 0 2.3420587069722387e-07
a O 0 5.178195650046291e-08
novel O 0 1.21243743933519e-07
mutation O 0 1.0421308616059832e-07
of O 0 2.4920240093706525e-08
the O 0 4.775958117875234e-08
CPO O 0 0.0005598312127403915
gene O 0 9.411434298556287e-09
in O 0 5.7888982496479e-10
a O 0 1.4102148782058066e-08
Japanese O 0 2.4860289613570785e-06
hereditary B-Disease 1 0.9999933242797852
coproporphyria I-Disease 1 0.9999983310699463
family O 0 5.69382609683089e-06
. O 0 4.0360250750381965e-06

Hereditary B-Disease 1 1.0
coproporphyria I-Disease 1 1.0
( O 0 0.0004986109561286867
HCP B-Disease 1 1.0
) O 0 1.1847389203012426e-07
is O 0 1.8476070451356463e-08
an O 0 3.6324355079386805e-08
autosomal B-Disease 1 0.9999992847442627
dominant I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
characterized O 0 3.332237611175515e-05
by O 0 1.5440463130289572e-07
a O 0 0.00028109559207223356
deficiency B-Disease 1 0.9999877214431763
of I-Disease 0 0.14223815500736237
coproporphyrinogen I-Disease 1 0.9999055862426758
oxidase I-Disease 0 0.00012383589637465775
( O 0 4.2752128592837835e-07
CPO O 0 0.00032027901033870876
) O 0 2.0147901125255885e-09
caused O 0 6.044863276599699e-09
by O 0 7.245327671157042e-10
a O 0 1.1756297269016613e-08
mutation O 0 1.8536435675287066e-07
in O 0 2.989744274373152e-08
the O 0 4.7619684551136743e-07
CPO O 0 0.004320183303207159
gene O 0 2.9794346119160764e-06
. O 0 1.3825427913616295e-06

Only O 0 3.258797391936241e-07
11 O 0 2.1588054721632943e-07
mutations O 0 2.1209682898870597e-08
of O 0 7.135207535924337e-09
the O 0 1.0452358090162761e-08
gene O 0 5.974235506300829e-08
have O 0 2.574921609266312e-09
been O 0 2.3539664439908847e-08
reported O 0 1.1267604804743314e-07
in O 0 4.0292925973517413e-07
HCP B-Disease 1 0.9999991655349731
patients O 0 9.81873927230481e-06
. O 0 1.8145437934435904e-05

We O 0 3.058403592604009e-07
report O 0 1.398893534343415e-08
another O 0 1.3940751664165418e-08
mutation O 0 5.8164186356179925e-08
in O 0 3.6962783944716193e-09
a O 0 5.8994896079411774e-08
Japanese O 0 2.2590656953980215e-06
family O 0 2.92971606086212e-07
. O 0 1.051392246154137e-06

Polymerase O 0 0.00010625283903209493
chain O 0 4.7297344281105325e-06
reaction O 0 4.341929127349431e-07
- O 0 1.5329906091210432e-06
single O 0 5.774182554318941e-08
strand O 0 1.6617556752862583e-07
conformational O 0 2.2255598253195785e-08
polymorphism O 0 3.6744193465665376e-08
and O 0 3.065115661282647e-10
direct O 0 2.518134589735155e-09
sequence O 0 2.722627900908492e-09
analyses O 0 3.4835760942542038e-09
demonstrated O 0 8.991332678398578e-10
a O 0 3.909651713485118e-09
C O 0 6.654826165686245e-07
to O 0 5.0655293293289105e-09
T O 0 6.973886002015206e-08
substitution O 0 2.5026984928899765e-08
in O 0 2.2120247855639263e-09
exon O 0 1.0151802598556969e-07
1 O 0 5.8144880910049324e-08
of O 0 4.406904619003171e-09
the O 0 1.2779315383681933e-08
CPO O 0 3.0897183478373336e-06
gene O 0 4.683410104178165e-09
at O 0 4.403199138636182e-09
nucleotide O 0 1.4953107196902238e-08
position O 0 4.0526686007069657e-08
85 O 0 3.200353049237492e-08
, O 0 5.029645588905396e-10
which O 0 8.306967891336114e-10
lies O 0 5.966378324728794e-08
in O 0 1.92604954207809e-09
the O 0 8.218715485952544e-09
putative O 0 1.091541435016552e-06
presequence O 0 2.663108716660645e-06
for O 0 4.9737720608789004e-09
targeting O 0 1.0027198982243135e-07
to O 0 6.437181099272493e-08
mitochondria O 0 3.9755527723173145e-06
. O 0 1.2975804111192701e-06

This O 0 1.4108961465808534e-07
mutation O 0 1.6701299898613797e-07
changes O 0 6.546023723075223e-09
the O 0 8.388235883671769e-09
codon O 0 1.461435914507092e-07
for O 0 2.614094274377976e-09
glutamine O 0 1.983478981060216e-08
to O 0 3.285043348455474e-09
a O 0 3.8715409544920476e-08
termination O 0 8.768174097895098e-07
codon O 0 1.8179136986873345e-06
at O 0 1.9520227567682014e-07
amino O 0 4.3126942017579495e-08
acid O 0 2.8870017487747646e-08
position O 0 1.8726144901393127e-07
29 O 0 2.3368697839032393e-06
. O 0 1.155369432126463e-06

MaeI O 0 0.00016880076145753264
restriction O 0 6.419218721021025e-07
analysis O 0 1.1554714518524634e-07
showed O 0 2.386447839342054e-08
two O 0 6.348118697374616e-10
other O 0 3.4089581157914495e-10
carriers O 0 9.02976537986433e-09
in O 0 1.0098323954821353e-08
the O 0 1.1707888347700646e-07
family O 0 2.900414699524845e-07
. O 0 1.1563571433725883e-06

The O 0 1.6034363170547294e-06
C O 0 0.0036426347214728594
- O 0 0.0027020894922316074
T O 0 3.14162862196099e-05
mutation O 0 3.576570577479288e-07
is O 0 1.5597475533368765e-09
located O 0 4.281400123318235e-09
within O 0 2.735265791642405e-09
a O 0 6.332208091208713e-09
recently O 0 1.7115429074010535e-08
proposed O 0 4.7091024413248306e-08
putative O 0 2.534553402711026e-07
alternative O 0 2.3907624324692733e-08
translation O 0 7.211252750494168e-08
initiation O 0 6.120438200696299e-08
codon O 0 1.2388704817567486e-07
( O 0 7.709100025010684e-09
TIC O 0 1.4459287740464788e-06
- O 0 8.06485900284315e-07
1 O 0 2.603175062176888e-07
) O 0 4.4396367138155313e-10
, O 0 2.0777821130302243e-10
supporting O 0 1.7270331831298336e-09
that O 0 9.939483680554417e-10
TIC O 0 3.117992491752375e-06
- O 0 1.8479084928912926e-06
1 O 0 1.097961217055854e-06
is O 0 4.2222163543215174e-09
the O 0 9.757993524317499e-09
real O 0 8.249783718383696e-07
TIC O 0 3.8072282677603653e-06
rather O 0 4.6566370315304084e-08
than O 0 6.409492669945394e-08
TIC O 0 1.2408631846483331e-05
- O 0 4.9152845349453855e-06
2 O 0 1.5602132634739974e-06
. O 0 5.6091291611437555e-08
. O 0 3.073397181196924e-07

Human B-Disease 0 4.511198596901522e-07
complement I-Disease 0 1.5469247500732308e-06
factor I-Disease 1 0.6046968102455139
H I-Disease 1 1.0
deficiency I-Disease 1 0.999992847442627
associated O 0 6.254834443097934e-05
with O 0 0.04651268571615219
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 1 1.0

This O 0 7.369151688862985e-08
study O 0 1.8326204553886782e-08
reports O 0 2.9086055786109455e-09
on O 0 9.252243415858175e-09
six O 0 1.6991169582425414e-09
cases O 0 3.500460588057308e-09
of O 0 2.2194992652657675e-06
deficiency B-Disease 1 0.9999995231628418
in I-Disease 0 2.1506906477952725e-07
the I-Disease 0 6.495951510032683e-08
human I-Disease 0 3.973599227435898e-09
complement I-Disease 0 2.8011242214631693e-09
regulatory I-Disease 0 2.7119630985339427e-08
protein I-Disease 0 8.070831114537214e-08
Factor I-Disease 0 2.986558627071645e-07
H I-Disease 0 0.19091221690177917
( O 0 2.124977172002218e-08
FH O 0 3.328497041366063e-05
) O 0 2.214839422975956e-10
in O 0 4.4088673684106183e-11
the O 0 8.779092036670377e-11
context O 0 1.9979520260449135e-09
of O 0 5.997569996196717e-09
an O 0 3.5381603424866626e-07
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 1 0.9755848050117493

Five O 0 1.6898604826565133e-07
of O 0 5.761190635666935e-08
the O 0 1.2148026584668514e-08
cases O 0 3.1612148454485123e-09
were O 0 2.9937370360499926e-09
observed O 0 1.875650568194942e-08
in O 0 3.0849298671142833e-09
children O 0 7.434297621955466e-10
presenting O 0 1.176033403993415e-08
with O 0 4.4955831413062697e-07
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 1.0
HUS B-Disease 1 1.0
) O 0 0.0004248238692525774
. O 0 3.254372859373689e-05

Two O 0 5.032672945048944e-08
of O 0 4.3745139066686534e-08
the O 0 3.6098573019671676e-08
children O 0 3.790383562574107e-09
exhibited O 0 3.638849932485755e-08
a O 0 2.9575824100902537e-06
homozygous O 1 0.9304072856903076
deficiency O 1 0.997241735458374
characterized O 0 4.245403317781893e-07
by O 0 9.049213822720503e-09
the O 0 1.3908885421187733e-07
absence O 0 4.508274287218228e-07
of O 0 1.0251721249687762e-07
the O 0 1.987895004162965e-08
150 O 0 6.137901298330917e-09
- O 0 1.391349790935692e-08
kD O 0 5.032039496200014e-08
form O 0 5.012263382120352e-10
of O 0 9.669838263448582e-09
Factor O 0 3.070268519422825e-07
H O 0 0.12733156979084015
and O 0 5.1513660004332e-10
the O 0 8.667619399993498e-10
presence O 0 9.862134442428783e-10
, O 0 3.1722360849251174e-10
upon O 0 2.4022661637701503e-09
immunoblotting O 0 7.40215000405442e-07
, O 0 1.4608213527722569e-09
of O 0 9.751482288322677e-09
the O 0 1.313444819572851e-08
42 O 0 2.1312264664175018e-07
- O 0 2.0928111155171791e-07
kD O 0 3.830124114756472e-06
Factor O 0 9.543857686367119e-07
H O 0 0.202264666557312
- O 0 3.182548482527636e-07
like O 0 7.2913572957133965e-09
protein O 0 2.7229408061657523e-08
1 O 0 3.751624788606023e-08
( O 0 2.1437962516301923e-09
FHL O 0 3.613940180002828e-06
- O 0 4.748128219489445e-07
1 O 0 2.2300177704437374e-07
) O 0 8.951513974508885e-10
and O 0 4.770044359503345e-10
other O 0 3.2738467492521295e-09
FH O 0 9.126124496106058e-05
- O 0 8.664650295031606e-07
related O 0 6.56562022527396e-08
protein O 0 1.3502801721188007e-07
( O 0 3.945943305438959e-08
FHR O 0 0.00035824294900521636
) O 0 9.325471239662875e-08
bands O 0 1.4690069747302914e-06
. O 0 1.2640959994314471e-06

Southern O 0 5.93623462918913e-06
blot O 0 1.2617722859431524e-05
and O 0 6.5513319214005605e-09
PCR O 0 4.581802670600155e-08
analysis O 0 1.1721094095307194e-09
of O 0 8.635260284606261e-10
DNA O 0 7.366141918652147e-09
of O 0 2.0805788203404063e-09
one O 0 3.0722815402839387e-09
patient O 0 9.445333404300982e-09
with O 0 2.585818004163798e-09
homozygous O 0 0.04628104344010353
deficiency O 1 0.9999921321868896
ruled O 0 0.0008252201369032264
out O 0 5.279588322082418e-09
the O 0 1.0240142067630131e-09
presence O 0 3.552667882100735e-10
of O 0 8.962123265732203e-10
a O 0 1.5675645226309598e-09
large O 0 6.721752487948152e-09
deletion O 0 7.827085113376597e-08
of O 0 2.429995937802687e-08
the O 0 3.538254134127783e-08
FH O 0 0.00023171999782789499
gene O 0 1.5799230368429562e-08
as O 0 2.1853616694045286e-09
the O 0 1.0558657059789311e-08
underlying O 0 0.00028913194546476007
defect O 0 9.733327169669792e-05
for O 0 1.8953045355374343e-07
the O 0 5.9463680372573435e-05
deficiency O 1 0.9999996423721313
. O 0 0.00024128981749527156

The O 0 2.727568073623843e-07
other O 0 3.896846845208302e-09
four O 0 2.374917595915349e-09
children O 0 4.177491685908308e-10
presented O 0 5.196417074415649e-09
with O 0 2.4658300290525403e-08
heterozygous O 1 0.9951677322387695
deficiency O 1 0.9999992847442627
and O 0 6.142705188949549e-08
exhibited O 0 4.654656891034392e-07
a O 0 3.2429488783236593e-07
normal O 0 5.609695676866977e-07
immunoblotting O 0 2.098918048432097e-05
pattern O 0 7.326127615669975e-08
of O 0 1.0800826011347908e-08
proteins O 0 1.731763288326249e-09
of O 0 1.3583986380183433e-08
the O 0 1.8096163501013507e-07
FH O 1 0.9975619316101074
family O 0 5.702808607566112e-07
. O 0 9.436348022973107e-07

Factor B-Disease 1 0.9999932050704956
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999680519104004
is O 0 2.1829340113299622e-08
the O 0 8.453703514987865e-09
only O 0 2.851544778081916e-08
complement B-Disease 1 0.9984179735183716
deficiency I-Disease 1 1.0
associated O 0 1.0935212230833713e-05
with O 0 1.5809049500603578e-06
HUS B-Disease 1 1.0
. O 0 0.0006750001921318471

These O 0 2.8744194580099247e-08
observations O 0 8.151526742494752e-08
suggest O 0 2.7595241647304647e-08
a O 0 2.9196181472457283e-08
role O 0 4.315245050179328e-08
for O 0 3.8850931360912e-08
FH O 0 0.1743551790714264
and O 0 1.340711719421961e-07
/ O 0 0.00016468310786876827
or O 0 2.2391011498257285e-06
FH O 0 0.05387409031391144
receptors O 0 1.549130388411868e-07
in O 0 3.2389655402198514e-09
the O 0 1.7030924226446587e-08
pathogenesis O 0 5.2449217037064955e-05
of O 0 6.47922433927306e-06
idiopathic O 1 1.0
HUS B-Disease 1 1.0
. O 0 3.951743201469071e-05
. O 0 1.83068223122973e-05

Further O 0 3.4904360290965997e-07
evidence O 0 6.585989353879995e-08
for O 0 5.930115953844961e-09
a O 0 5.316474727123932e-08
major O 0 5.677796934833168e-07
ancient O 0 1.0056193104901467e-06
mutation O 0 0.00020468697766773403
underlying O 1 0.9999979734420776
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 4.566624920698814e-05
linkage O 1 0.680735170841217
disequilibrium O 1 0.6335079669952393
studies O 0 4.516286722378027e-08
in O 0 2.63354182905573e-09
the O 0 8.55305959390762e-09
Japanese O 0 2.55694743600543e-07
population O 0 4.4551732969466684e-08
. O 0 2.2228452678518806e-07

The O 0 0.00030633562710136175
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.03784852847456932
DM B-Disease 1 1.0
) O 0 1.6606387021056435e-07
mutation O 0 3.7566522337328934e-07
is O 0 9.146736701381997e-09
an O 0 1.5168346578775527e-08
unstable O 0 0.00010665939043974504
( O 0 2.802970300308516e-07
CTG O 0 0.00010959446080960333
) O 0 2.651798336472666e-09
n O 0 2.2663318333115967e-08
repeat O 0 1.512524150371064e-08
, O 0 3.2091090895747243e-10
present O 0 2.212162952819341e-10
at O 0 3.2589693166329425e-09
a O 0 1.521731074483057e-09
copy O 0 2.7178546080364185e-09
number O 0 3.3436861612834434e-10
of O 0 2.239777696644296e-09
5 O 0 2.2514203834589352e-08
- O 0 6.081327796891856e-08
37 O 0 2.8151694309030972e-08
repeats O 0 7.910890609252874e-09
on O 0 5.344023890074823e-09
normal O 0 6.428589216511682e-09
chromosomes O 0 8.459880795896879e-09
but O 0 4.799220465478982e-10
amplified O 0 1.3439255930336458e-08
to O 0 1.8425982961645104e-09
50 O 0 5.4932471016400086e-08
- O 0 6.223975645980317e-08
3000 O 0 3.8090618659225584e-08
copies O 0 1.772987445747276e-08
on O 0 9.248150831808744e-07
DM B-Disease 1 0.9999681711196899
chromosomes O 0 1.2668133422266692e-05
. O 0 1.2404174185576267e-06

Previous O 0 1.3297002396939206e-06
findings O 0 1.4441796736264223e-07
in O 0 2.6494337390658984e-08
Caucasian O 0 4.269018063496333e-06
populations O 0 2.221518080602891e-08
of O 0 2.513356633926378e-08
a O 0 5.090383183414815e-06
DM B-Disease 1 1.0
founder O 0 7.793299300828949e-05
chromosome O 0 1.3907567335991189e-05
raise O 0 1.6629517318733633e-08
a O 0 1.0015535067964265e-08
question O 0 6.43799111799126e-08
about O 0 9.586516025450464e-10
the O 0 1.1509503350382033e-09
molecular O 0 1.6410780290243565e-08
events O 0 5.367352118312851e-10
involved O 0 1.006130956326956e-09
in O 0 2.3286672590216995e-09
the O 0 1.503274837943991e-08
expansion O 0 2.8157819542684592e-06
mutation O 0 9.41730377235217e-06
. O 0 2.3295181108551333e-06

To O 0 3.565869022281731e-08
investigate O 0 2.601064963414501e-08
whether O 0 9.838504233528056e-09
a O 0 3.290757888407825e-08
founder O 0 1.399514673039448e-07
chromosome O 0 2.187690455457414e-07
for O 0 1.8162193970994167e-09
the O 0 7.85795890578811e-08
DM B-Disease 1 1.0
mutation O 0 4.935991455568001e-06
exists O 0 1.807170235679223e-08
in O 0 4.323544855466821e-10
the O 0 7.415292824219932e-10
Japanese O 0 1.633533130984688e-08
population O 0 1.6241469280586784e-09
, O 0 9.242132059661401e-10
we O 0 4.764927563627452e-09
genotyped O 0 1.5135710782487877e-06
families O 0 1.0620661017313182e-09
using O 0 4.333693848224129e-09
polymorphic O 0 1.152543404714379e-06
markers O 0 9.662999218562618e-07
near O 0 6.842259949735308e-07
the O 0 8.338899704085634e-08
( O 0 2.8546364205794816e-07
CTG O 0 7.46285732020624e-05
) O 0 1.9725343136656193e-08
n O 0 4.083072440153046e-07
repeat O 0 3.864488746785355e-07
region O 0 2.7307902428219677e-07
and O 0 2.6436488553827076e-08
constructed O 0 5.925883669988252e-06
haplotypes O 0 7.547098357463256e-05
. O 0 3.109553290414624e-06

Six O 0 9.70626317098322e-08
different O 0 3.218642907754088e-09
haplotypes O 0 4.3408360284047376e-07
were O 0 1.5380084761318358e-08
found O 0 1.0979015918621826e-08
and O 0 2.9814756885571114e-08
DM B-Disease 1 1.0
alleles O 0 1.3728542853641557e-06
were O 0 4.6790194829782195e-08
always O 0 8.348767011057134e-08
haplotype O 0 4.653009455068968e-05
A O 0 3.2548447052249685e-05
. O 0 5.013549071009038e-06

To O 0 7.263501800025551e-08
find O 0 2.610448390782949e-08
an O 0 1.707036290099495e-09
origin O 0 2.3412585647974993e-08
of O 0 3.198254105996057e-08
the O 0 6.519709927488293e-08
( O 0 2.940332706202753e-07
CTG O 0 4.725559847429395e-05
) O 0 5.7174225354117425e-09
n O 0 4.3321922049699424e-08
repeat O 0 4.750492266225592e-08
mutation O 0 8.642893511989769e-09
and O 0 1.9860776911961864e-10
to O 0 5.017447568533839e-10
investigate O 0 1.8500569964885472e-09
the O 0 1.0815250917062258e-09
mechanism O 0 4.950499121747498e-09
of O 0 3.4902469803199665e-09
the O 0 1.913132319231181e-09
expansion O 0 6.131666907549516e-08
mutation O 0 1.83987740598468e-08
in O 0 5.214982334855733e-10
the O 0 7.573396354487727e-10
Japanese O 0 7.334793217239621e-09
population O 0 2.888519146093671e-10
we O 0 1.649914510570838e-10
have O 0 1.0386329296618868e-10
studied O 0 9.897094699340414e-09
90 O 0 4.091206307066386e-08
Japanese O 0 3.6775188050341967e-07
DM B-Disease 1 0.9995371103286743
families O 0 1.5889977111882558e-09
comprising O 0 1.7176640110250219e-09
190 O 0 1.1425453472213576e-08
affected O 0 3.3002667265691343e-09
and O 0 2.267978249648195e-09
130 O 0 1.6768585453519336e-07
unaffected O 0 1.4876006844133371e-06
members O 0 6.867442436941928e-08
. O 0 2.2506962977786316e-06

The O 0 3.694067913784238e-07
results O 0 1.5840485900753265e-07
suggest O 0 5.152235971195296e-08
that O 0 3.172873075385496e-09
a O 0 2.9143215840576886e-08
few O 0 6.772637561880401e-09
common O 0 1.670760241267999e-08
ancestral O 0 1.2209461885959172e-07
mutations O 0 4.0776821919052963e-08
in O 0 1.6188830276320232e-09
both O 0 8.722318867171452e-09
Caucasian O 0 6.629130803048611e-05
and O 0 7.677024349561634e-09
Japanese O 0 1.667346509748313e-07
populations O 0 3.172479834390174e-09
have O 0 5.5849727620405076e-11
originated O 0 5.333308239485746e-10
by O 0 1.0068965106135863e-10
expansion O 0 2.853650293843657e-08
of O 0 8.433540088503833e-09
an O 0 2.6256372631650038e-09
ancestral O 0 8.36386035985015e-08
n O 0 6.177636890924987e-08
= O 0 3.760278843856213e-08
5 O 0 1.3960495870435352e-08
repeat O 0 1.4253964231158989e-08
to O 0 4.1677923334759726e-09
n O 0 1.9304239629036601e-07
= O 0 2.4969773448901833e-07
19 O 0 1.4962056127387768e-07
- O 0 5.759849273090367e-07
37 O 0 3.1633396702090977e-07
copies O 0 2.0309772708060336e-07
. O 0 9.219522780767875e-07

These O 0 3.611358678767829e-08
data O 0 2.7673619840129504e-08
support O 0 1.0666933114578114e-08
multistep O 0 1.1902682217623806e-06
models O 0 3.9874795021432874e-08
of O 0 8.928196137958366e-08
triplet O 0 2.0486988432821818e-05
repeat O 0 3.166116471220448e-07
expansion O 0 6.068570712614019e-08
that O 0 2.0526157162858993e-10
have O 0 9.439884290918243e-11
been O 0 2.1838064689916337e-10
proposed O 0 1.492785117740425e-09
for O 0 1.53613133324626e-09
both O 0 4.951209930936784e-08
DM B-Disease 1 1.0
and O 0 2.2689739580528112e-06
Friedreichs B-Disease 1 0.9997909665107727
ataxia I-Disease 1 0.9966260194778442
. O 0 5.412175596575253e-06
. O 0 1.0896051207964774e-05

The O 0 2.1214685830273083e-07
molecular O 0 8.559996445001161e-07
basis O 0 1.260305452888133e-06
of O 0 0.01729983650147915
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.1399924204624767e-07
the O 0 2.2820124456757185e-08
western O 0 2.9071330232000037e-07
Cape O 0 7.879162922108662e-07
, O 0 9.254379484957553e-09
South O 0 7.58117906229927e-08
Africa O 0 1.228701052014003e-07
. O 0 4.815500460608746e-07

Deficiency B-Disease 1 0.9689021110534668
of I-Disease 0 4.473148692341056e-06
the I-Disease 0 1.8678643982639187e-06
sixth I-Disease 0 0.000340865517500788
component I-Disease 0 9.115292414207943e-06
of I-Disease 0 3.556318972641748e-08
human I-Disease 0 3.797526293425335e-09
complement I-Disease 0 1.208062716528957e-08
( O 0 9.64484669907506e-08
C6 O 1 0.9999886751174927
) O 0 5.789718482418493e-09
has O 0 5.314056417127233e-10
been O 0 2.0097111474992602e-10
reported O 0 1.7478032909856722e-10
in O 0 4.780334461607083e-11
a O 0 2.605387017240446e-10
number O 0 1.2840188634566374e-10
of O 0 3.7671737951328055e-10
families O 0 1.0430838831565481e-10
from O 0 6.66806665439168e-10
the O 0 2.5861532915172347e-09
western O 0 1.0178190024134892e-07
Cape O 0 1.2293849067646079e-06
, O 0 1.405679217469924e-08
South O 0 1.226953969535316e-07
Africa O 0 2.07884312430906e-07
. O 0 4.273219644801429e-07

Meningococcal B-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999496936798096
is O 0 2.8230746806912066e-07
endemic O 0 2.0561861902024248e-07
in O 0 2.5104902601214008e-09
the O 0 5.139728642689079e-09
Cape O 0 1.5747447434932837e-07
and O 0 2.953607913802614e-10
almost O 0 1.8560265546696542e-09
all O 0 1.4047155105778586e-10
pedigrees O 0 9.174780046805608e-09
of O 0 1.565721596819003e-08
total O 0 9.107915502681863e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.0052070138044655e-05
C6Q0 O 1 0.999984860420227
) O 0 1.1479539097081215e-08
have O 0 1.1489433848765884e-09
been O 0 2.491951311967e-09
ascertained O 0 2.187285872423672e-07
because O 0 9.850521287546599e-09
of O 0 3.4122572856176703e-07
recurrent O 1 0.9999936819076538
disease O 1 0.9999148845672607
. O 0 4.134911796427332e-05

We O 0 4.895403549198818e-07
have O 0 1.202352528650863e-08
sequenced O 0 1.7302247101724788e-07
the O 0 7.951705072173354e-09
expressed O 0 1.6750613340832388e-08
exons O 0 5.350752871891018e-07
of O 0 4.684636678575771e-08
the O 0 9.401534839525993e-08
C6 O 0 0.007273263763636351
gene O 0 2.5124938574094813e-08
from O 0 2.6800086594391814e-09
selected O 0 1.3502327034231598e-09
cases O 0 5.421771920310903e-10
and O 0 5.503046907051612e-10
have O 0 7.313122885044265e-10
found O 0 1.8404836543695069e-09
three O 0 2.6903694827495883e-09
molecular O 0 2.8208238290972076e-05
defects O 0 0.006741898134350777
leading O 0 2.59988468087613e-07
to O 0 8.27458634944378e-09
total O 0 4.891940079687629e-07
deficiency O 1 0.9848724603652954
879delG O 0 0.025922615081071854
, O 0 3.0174476250977023e-09
which O 0 2.2490662110463688e-10
is O 0 2.3803176096848233e-10
the O 0 7.945590851932138e-10
common O 0 3.185651564763248e-08
defect O 0 5.974486157356296e-06
in O 0 1.1942661970465451e-08
the O 0 3.712347051987308e-08
Cape O 0 8.744508477320778e-07
and O 0 8.474998480778595e-09
hitherto O 0 1.7269144336751197e-06
unreported O 0 7.63124376135238e-07
, O 0 1.6822774284719344e-09
and O 0 7.970742954555021e-10
1195delC O 0 5.210553695178533e-07
and O 0 3.2051286069645357e-09
1936delG O 0 2.351342573092552e-06
, O 0 9.874048245706035e-10
which O 0 3.9939457296966907e-10
have O 0 2.3176281727099735e-10
been O 0 1.7385213268994448e-09
previously O 0 4.802592545871676e-09
reported O 0 2.0201773587302796e-09
in O 0 1.573333685556122e-09
African O 0 2.1826135565561344e-08
- O 0 5.081373046778026e-07
Americans O 0 2.416869051558024e-07
. O 0 1.145012447523186e-06

We O 0 4.521932623902103e-07
also O 0 1.145491079768135e-08
show O 0 2.75348166489664e-09
that O 0 2.507627161474346e-10
the O 0 5.446369577555288e-09
879delG O 0 3.1874587875790894e-06
and O 0 6.561538867799754e-08
1195delC O 1 0.993705689907074
defects O 1 0.9991511106491089
are O 0 5.552349247039956e-09
associated O 0 9.517402332903657e-08
with O 0 2.350870431655494e-08
characteristic O 1 0.9998387098312378
C6 O 1 1.0
/ O 1 1.0
C7 O 1 0.9999997615814209
region O 0 7.707699296588544e-06
DNA O 0 2.3808274818293285e-06
marker O 0 3.3646722386038164e-06
haplotypes O 0 1.1442112963777618e-06
, O 0 1.8167980453398513e-09
although O 0 1.8200062568141107e-09
small O 0 3.4424465500393353e-09
variations O 0 6.50867661988741e-08
were O 0 6.430713739291605e-08
observed O 0 8.229023364947352e-07
. O 0 1.1775887287512887e-06

The O 0 2.2322526547213783e-06
1936delG O 0 0.00023697483993601054
defect O 0 0.0002609090879559517
was O 0 5.911891207688313e-07
observed O 0 3.997989139747915e-08
only O 0 2.1122994464661815e-09
once O 0 5.699478666798541e-09
in O 0 6.666693308510219e-10
the O 0 5.639915201527401e-09
Cape O 0 1.8443242311150243e-07
, O 0 1.0269658456962816e-09
but O 0 7.684125558071742e-10
its O 0 7.917316802164009e-10
associated O 0 2.12158326462486e-08
haplotype O 0 1.8547658328316174e-05
could O 0 1.8128412193618715e-07
be O 0 1.6972559535588516e-07
deduced O 0 9.564399988448713e-06
. O 0 1.1526731213962194e-06

The O 0 4.011196210740309e-07
data O 0 1.1110110875733881e-07
from O 0 2.3826409289995354e-08
the O 0 1.928300008557926e-08
haplotypes O 0 1.6510422256033053e-06
indicate O 0 1.749032385589544e-08
that O 0 3.115986635382484e-10
these O 0 2.769149076708999e-10
three O 0 2.6942670316998374e-09
molecular O 0 1.3694500921701547e-05
defects O 0 2.791355200315593e-06
account O 0 1.777662794744117e-09
for O 0 2.30990204741488e-09
the O 0 3.04534722772587e-07
defects O 0 0.053312283009290695
in O 0 4.048263502198779e-09
all O 0 9.690088731417745e-10
the O 0 5.844539519017644e-09
38 O 0 1.0775458747502853e-07
unrelated O 0 1.9536840056844085e-07
C6Q0 O 0 0.0014568043407052755
individuals O 0 2.342405380773016e-09
we O 0 4.634757022614622e-09
have O 0 1.8557327896573383e-09
studied O 0 7.805616775158342e-08
from O 0 1.5132282982222023e-08
the O 0 4.83328790323867e-08
Cape O 0 2.947549546661321e-06
. O 0 8.339494002029824e-07

We O 0 5.418375508270401e-07
have O 0 5.6650897306553816e-09
also O 0 2.6836302069455087e-09
observed O 0 1.0293057961519025e-08
the O 0 1.5517098717054978e-08
879delG O 0 7.778901817800943e-06
defect O 0 5.296472409099806e-06
in O 0 2.280968125489835e-08
two O 0 4.975463951950587e-08
Dutch O 1 0.9999843835830688
C6 B-Disease 1 1.0
- I-Disease 1 1.0
deficient I-Disease 1 0.9999998807907104
kindreds O 0 0.00026813187287189066
, O 0 3.874804477277394e-09
but O 0 6.971113686304875e-10
the O 0 3.901286405039173e-09
879delG O 0 2.110316700054682e-06
defect O 0 1.2748952258334612e-06
in O 0 2.7341391373170154e-09
the O 0 9.44909928080051e-09
Cape O 0 1.3526452846690518e-07
probably O 0 2.089005946004363e-08
did O 0 1.7573378308100018e-09
not O 0 4.957517729664573e-10
come O 0 1.241503455595705e-09
from O 0 3.710490359409846e-09
The O 0 1.5722454449473844e-08
Netherlands O 0 7.40582947855728e-07
. O 0 7.253132849882604e-08
. O 0 1.1429222013248364e-06

Complement B-Disease 1 0.9999864101409912
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 9.227501323039178e-07
seven O 0 9.916277576849097e-08
further O 0 1.4368382039720018e-07
molecular O 0 0.0005782430525869131
defects O 0 0.0002952581562567502
and O 0 1.3055596603805952e-08
their O 0 1.4303585871289215e-08
associated O 0 2.224780246251612e-06
marker O 0 0.0010394476121291518
haplotypes O 0 0.0005150894285179675
. O 0 7.712169463047758e-06

Seven O 0 5.306571893015644e-07
further O 0 6.861628776277939e-08
molecular O 0 1.2415796390996547e-06
bases O 0 6.716532539030595e-07
of O 0 0.02871013432741165
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.791112585029623e-07
described O 0 7.053991339489585e-06
. O 0 4.240137059241533e-06

All O 0 5.746002429418695e-08
these O 0 3.451585239844235e-09
new O 0 1.4315266305686691e-08
molecular O 0 2.395382398390211e-05
defects O 0 7.206260306702461e-06
involve O 0 4.397452357807197e-08
single O 0 8.084327163260241e-08
- O 0 4.3739888155869266e-07
nucleotide O 0 7.854931993733771e-08
events O 0 9.755495300467487e-10
, O 0 4.468597991635903e-10
deletions O 0 2.658788744724916e-08
and O 0 1.4929359970494716e-09
substitutions O 0 1.0367877223416144e-07
, O 0 2.262909859496176e-09
some O 0 3.2289343421254557e-10
of O 0 2.7362208054881876e-09
which O 0 1.321286080546713e-09
alter O 0 5.594533902808507e-08
splice O 0 8.649013238937187e-07
sites O 0 1.9849018428885756e-08
, O 0 4.451229607127516e-09
and O 0 7.670613477728239e-09
others O 0 1.3423647260424332e-07
codons O 0 7.756958439131267e-06
. O 0 1.7560505511937663e-06

They O 0 6.590839518594294e-08
are O 0 1.3672722953828043e-09
distributed O 0 2.8582627376039227e-09
along O 0 6.09322592382e-09
the O 0 4.1848728926652257e-08
C7 O 0 0.029384739696979523
gene O 0 1.0764632918380812e-07
, O 0 2.821005207209737e-09
but O 0 9.754006491391465e-10
predominantly O 0 6.708176236713825e-09
towards O 0 1.036516383834396e-08
the O 0 2.4081533211983697e-08
3 O 0 1.148043452303682e-06
end O 0 4.063981123181293e-06
. O 0 2.5429042125324486e-06

All O 0 1.4480895060842158e-07
were O 0 3.105582635498649e-08
found O 0 1.2546252037282102e-08
in O 0 5.85536330532932e-09
compound O 0 4.232071546539373e-07
heterozygous O 0 1.5431204758442618e-07
individuals O 0 3.553593330707372e-08
. O 0 1.1320549901938648e-06

The O 0 0.0003847017069347203
C6 O 1 0.9999991655349731
/ O 1 0.9999876022338867
C7 O 1 0.9999158382415771
marker O 0 0.00012858978880103678
haplotypes O 0 7.53908261685865e-06
associated O 0 1.0589560162088674e-07
with O 0 2.0277832746273816e-08
most O 0 8.268591045634821e-06
C7 B-Disease 1 1.0
defects I-Disease 1 0.9999996423721313
are O 0 1.4502441558761348e-07
tabulated O 0 1.9002159206138458e-06
. O 0 1.9460858879938314e-07
. O 0 9.572050885253702e-07

A O 0 1.8360675312578678e-05
genome O 0 4.907804395770654e-06
- O 0 1.6346853044524323e-06
wide O 0 3.642141734871984e-07
search O 0 2.7820108883247485e-08
for O 0 4.851683499396131e-09
chromosomal O 0 1.9807548596872948e-05
loci O 0 8.342401997651905e-06
linked O 0 5.358680482459022e-06
to O 0 8.908107673732957e-08
mental O 1 0.9999988079071045
health O 0 0.0002863600093405694
wellness O 0 0.0011045660357922316
in O 0 2.4813948229507332e-08
relatives O 0 1.9353487701323502e-08
at O 0 6.054938950228461e-08
high O 0 4.380751477128797e-07
risk O 0 1.176668592961505e-05
for O 0 3.058611764572561e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
among O 0 5.192200092096755e-07
the O 0 1.960260931355151e-07
Old O 0 7.883650710027723e-07
Order O 0 7.722569250745437e-08
Amish O 0 2.183027390856296e-06
. O 0 4.0090927200253645e-07

Bipolar B-Disease 1 1.0
affective I-Disease 1 1.0
disorder I-Disease 1 1.0
( O 0 0.03295084461569786
BPAD B-Disease 1 1.0
; O 1 0.9519929885864258
manic B-Disease 1 1.0
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 1.0
) O 0 5.083835503683076e-07
is O 0 6.5891900824510685e-09
characterized O 0 4.816683496500218e-09
by O 0 8.042211341319216e-10
episodes O 0 1.8956148650772775e-08
of O 0 1.0218377610726748e-07
mania B-Disease 0 0.0004234961816109717
and O 0 2.1139938155556592e-07
/ O 0 0.033629950135946274
or O 0 3.7684392282244517e-06
hypomania B-Disease 1 0.6628514528274536
interspersed O 0 1.5060405189615267e-07
with O 0 1.1600990168503245e-09
periods O 0 4.404083995268593e-07
of O 0 1.578121327838744e-06
depression B-Disease 0 0.28739985823631287
. O 0 6.887032668601023e-06

Compelling O 0 4.570012606563978e-06
evidence O 0 2.5235070211238053e-07
supports O 0 1.0600573574492955e-07
a O 0 4.96857914811244e-08
significant O 0 1.1650038089783266e-07
genetic O 0 5.179193180993025e-07
component O 0 5.265662821329897e-07
in O 0 2.8644897565044403e-09
the O 0 8.92757867632099e-09
susceptibility O 0 2.8810061394324293e-06
to O 0 8.119405947581981e-08
develop O 0 1.6450838302262127e-05
BPAD B-Disease 1 1.0
. O 0 0.0001917409390443936

To O 0 6.138606067906949e-08
date O 0 3.145911762203468e-07
, O 0 6.523476425712715e-09
however O 0 4.90517715334704e-09
, O 0 2.251548059106767e-09
linkage O 0 8.107472240226343e-07
studies O 0 6.212302672281567e-09
have O 0 2.8181426636741946e-10
attempted O 0 1.955131523345699e-08
only O 0 3.376621759976217e-10
to O 0 7.735667661989964e-10
identify O 0 1.5424973298650002e-08
chromosomal O 0 2.0417708583408967e-05
loci O 0 8.208158988054493e-07
that O 0 7.755331377090613e-10
cause O 0 1.3288124023347336e-07
or O 0 1.379887670793778e-08
increase O 0 1.5818438114933997e-08
the O 0 2.8134893526043925e-08
risk O 0 6.751681098648987e-07
of O 0 6.713631819366128e-07
developing O 0 2.4042668883339502e-05
BPAD B-Disease 1 1.0
. O 0 3.5602122807176784e-05

To O 0 6.05522743057918e-08
determine O 0 7.153661130132605e-08
whether O 0 1.711817176897057e-08
there O 0 7.893587117280276e-09
could O 0 9.784757004638323e-09
be O 0 2.7981019723455347e-09
protective O 0 1.275627870001017e-08
alleles O 0 4.759659333331001e-09
that O 0 5.462916924381389e-11
prevent O 0 1.1076416450706006e-09
or O 0 1.2333135623876501e-09
reduce O 0 4.6430654876417066e-09
the O 0 4.726421920508983e-09
risk O 0 1.3462556580634555e-07
of O 0 1.0193343769060448e-07
developing O 0 1.2848188816860784e-05
BPAD B-Disease 1 1.0
, O 0 4.512960227742724e-09
similar O 0 4.1345832313410824e-10
to O 0 7.054901662861823e-10
what O 0 6.488602433130097e-10
is O 0 4.4338993587800246e-10
observed O 0 1.2310011898719608e-09
in O 0 3.67496227893227e-10
other O 0 7.901059362325213e-09
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 4.297257660823561e-08
we O 0 1.6044758410771465e-08
used O 0 2.973316099996737e-07
mental O 1 0.828454852104187
health O 0 1.040329152601771e-06
wellness O 0 7.73192095948616e-06
( O 0 6.91181689660425e-09
absence O 0 9.013147206360372e-08
of O 0 5.5605340776310186e-08
any O 0 3.404325252631679e-05
psychiatric B-Disease 1 1.0
disorder I-Disease 1 0.9999997615814209
) O 0 1.9853485966336848e-08
as O 0 5.44082556785952e-09
the O 0 1.3575931490095172e-08
phenotype O 0 5.122359993947612e-07
in O 0 6.239877059499577e-09
our O 0 7.927022593889888e-09
genome O 0 1.0172523445817205e-07
- O 0 4.746244997022586e-07
wide O 0 5.955383812761283e-07
linkage O 0 3.2919308523560176e-06
scan O 0 4.640491511054279e-07
of O 0 2.357866790703156e-08
several O 0 2.400466048158023e-09
large O 0 4.065613623538411e-08
multigeneration O 0 1.1579646525206044e-05
Old O 0 9.256253719058805e-08
Order O 0 1.1301737323776706e-08
Amish O 0 1.3015534250371275e-07
pedigrees O 0 5.711931905238998e-08
exhibiting O 0 7.619562758520715e-09
an O 0 4.057972624593731e-09
extremely O 0 3.951833775772684e-07
high O 0 1.9342627638252452e-05
incidence O 1 0.99595046043396
of O 0 0.002182637806981802
BPAD B-Disease 1 1.0
. O 0 0.0006902085151523352

We O 0 2.21434817149202e-07
have O 0 5.375141221009017e-09
found O 0 3.8304723837256915e-09
strong O 0 2.5393369629256313e-09
evidence O 0 5.395674573804854e-09
for O 0 1.7521968320721726e-09
a O 0 4.7042007622621895e-08
locus O 0 2.6601412628224352e-06
on O 0 2.2589075854284602e-07
chromosome O 0 4.667192570195766e-06
4p O 0 0.0018719708314165473
at O 0 4.7226217247953173e-07
D4S2949 O 0 1.7993924075199175e-06
( O 0 4.470961822988784e-09
maximum O 0 2.8922497108396783e-07
GENEHUNTER O 0 9.407858306076378e-05
- O 0 1.3575487400885322e-06
PLUS O 0 6.301805228758894e-07
nonparametric O 0 6.160840371194354e-07
linkage O 0 4.993013362764032e-07
score O 0 1.4028553607658978e-07
= O 0 8.87226079271386e-08
4 O 0 5.349063769699569e-08
. O 0 2.4273911769512324e-09
05 O 0 5.19225920925237e-07
, O 0 8.082535529752022e-09
P O 0 3.1073359423317015e-06
= O 0 9.737620132455049e-08
5 O 0 1.791158332764553e-08
. O 0 6.367472660251394e-10
22 O 0 4.503656558796365e-09
x O 0 2.7963107385176045e-08
10 O 0 1.2083552825004062e-08
( O 0 1.2728037290798966e-08
- O 0 6.806692454119911e-07
4 O 0 1.8989935313129536e-07
) O 0 4.7339643316490765e-09
; O 0 1.6644591482872784e-08
SIBPAL O 0 0.00023827870609238744
Pempirical O 0 1.8942193491966464e-05
value O 0 1.8871251938890055e-07
< O 0 3.6070812257094076e-06
3 O 0 4.2810267331105933e-08
x O 0 4.022404098691368e-08
10 O 0 5.383225865074337e-09
( O 0 2.1876513933705155e-09
- O 0 6.645725392218083e-08
5 O 0 1.552991868436493e-08
) O 0 3.744543841666115e-10
) O 0 2.8083071978990404e-10
and O 0 2.435278367851623e-10
suggestive O 0 1.2923322856295272e-08
evidence O 0 2.8594895340461335e-09
for O 0 1.1516289033508542e-09
a O 0 4.676486042853867e-08
locus O 0 7.799478225933854e-06
on O 0 4.5776801016472746e-07
chromosome O 0 0.00010609802848193794
4q O 0 5.2073584811296314e-05
at O 0 2.9816638402735407e-07
D4S397 O 0 2.800079300868674e-06
( O 0 8.027350340000794e-09
maximum O 0 6.941623951206566e-07
GENEHUNTER O 0 8.632363460492343e-05
- O 0 1.0209615766143543e-06
PLUS O 0 4.157521118486329e-07
nonparametric O 0 6.15514920809801e-07
linkage O 0 3.454004513514519e-07
score O 0 5.8592650731270624e-08
= O 0 4.509331930080407e-08
3 O 0 3.4361374190439165e-08
. O 0 1.2869076915222877e-09
29 O 0 3.4581500329977644e-08
, O 0 2.227380502262122e-09
P O 0 1.3742755982093513e-06
= O 0 6.047471146075623e-08
2 O 0 3.124130643072931e-08
. O 0 1.2383437608676218e-09
57 O 0 1.3774343443628823e-08
x O 0 4.280144949575515e-08
10 O 0 1.735659616031171e-08
( O 0 5.956358517522631e-09
- O 0 8.642063562547264e-07
3 O 0 3.1939018185767054e-07
) O 0 3.2395897076042957e-09
; O 0 1.112813396986212e-08
SIBPAL O 0 0.00010273271618643776
Pempirical O 0 9.200058229907881e-06
value O 0 1.9959577457484556e-07
< O 0 6.394902811734937e-06
1 O 0 2.2692738355090114e-07
x O 0 1.2773848823144363e-07
10 O 0 9.079175633530667e-09
( O 0 5.030923677651344e-09
- O 0 2.154445155611029e-07
3 O 0 3.607675225225648e-08
) O 0 2.762665374245188e-10
) O 0 4.4440909285903274e-11
that O 0 5.219427320901637e-11
are O 0 1.6093720800469669e-10
linked O 0 1.117761740943024e-07
to O 0 1.8033007620488206e-07
mental O 1 0.9999960660934448
health O 0 0.0086316904053092
wellness O 0 0.012744155712425709
. O 0 1.5345880456152372e-05

These O 0 3.215183852489645e-08
findings O 0 4.055390334656295e-08
are O 0 1.0697591701358533e-09
consistent O 0 1.1398593180445005e-08
with O 0 3.6087727250944113e-10
the O 0 4.862838132169145e-09
hypothesis O 0 6.536381391697432e-08
that O 0 5.91899029789289e-11
certain O 0 1.394606319315983e-09
alleles O 0 1.2672565219418175e-08
could O 0 2.9526012745861863e-09
prevent O 0 5.996037444333524e-09
or O 0 5.603876029880439e-09
modify O 0 2.8807532359564902e-08
the O 0 1.3563922429682407e-08
clinical O 0 3.9444691424250777e-07
manifestations O 0 4.55851250080741e-06
of O 0 1.4581391951651312e-05
BPAD B-Disease 1 1.0
and O 0 5.1815447932312964e-08
perhaps O 0 8.127943118552139e-08
other O 0 2.895643369527079e-08
related O 0 7.387589721474797e-05
affective B-Disease 1 1.0
disorders I-Disease 1 1.0
. O 0 0.0006259844521991909

Segregation O 0 0.0006845698226243258
distortion O 1 0.9181935787200928
in O 0 4.374947093310766e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.291965126991272

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9982276558876038
DM B-Disease 1 1.0
) O 0 9.66845945526984e-08
is O 0 5.394377833312092e-09
an O 0 4.7740704722798455e-09
autosomal B-Disease 1 0.9814830422401428
dominant I-Disease 1 1.0
disease I-Disease 1 0.9997075200080872
which O 0 2.1482465584199417e-08
, O 0 1.6842487404744588e-09
in O 0 3.643777224393574e-10
the O 0 7.772820165286021e-10
typical O 0 2.0444085535586964e-08
pedigree O 0 4.83343534085634e-08
, O 0 4.219791183146526e-10
shows O 0 5.815991022117828e-10
a O 0 6.650097805760424e-09
three O 0 1.0217847901117239e-08
generation O 0 1.692666614871996e-06
anticipation O 0 2.2455078578786924e-06
cascade O 0 0.0001528905995655805
. O 0 1.5189737496257294e-05

This O 0 5.971751448896612e-08
results O 0 1.081266134406178e-07
in O 0 3.914052797426848e-07
infertility B-Disease 1 1.0
and O 1 0.9999803304672241
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9995071887969971
CDM B-Disease 1 0.9808527827262878
) O 0 2.1657222681881194e-09
with O 0 1.504328744905692e-10
the O 0 1.3938757703613192e-08
disappearance O 0 3.709141367380653e-07
of O 0 6.659632276750926e-07
DM B-Disease 1 1.0
in O 0 9.837006587076758e-08
that O 0 3.54242750688627e-08
pedigree O 0 8.08237473393092e-06
. O 0 1.659576241763716e-06

The O 0 1.3871820669919543e-07
concept O 0 1.5082727600201906e-07
of O 0 1.3112425278904993e-07
segregation O 0 9.062635399459396e-06
distortion O 0 0.0011051659239456058
, O 0 5.242260403548471e-09
where O 0 1.069069721637561e-09
there O 0 4.3209727462745207e-10
is O 0 5.131967628635437e-10
preferential O 0 9.252208776899806e-09
transmission O 0 1.492048617990349e-08
of O 0 3.3648066555258538e-09
the O 0 1.9107255777583987e-09
larger O 0 6.501465144026497e-09
allele O 0 6.255907436525376e-08
at O 0 1.7838894805777272e-08
the O 0 1.2879962874023931e-08
DM B-Disease 1 0.9999997615814209
locus O 0 6.391981969500193e-06
, O 0 1.2464765886122109e-09
has O 0 4.295392930231401e-10
been O 0 3.969218564936483e-10
put O 0 1.9332855316633868e-09
forward O 0 8.279701368962833e-09
to O 0 1.3938989962269943e-09
explain O 0 2.7408969316411458e-08
partially O 0 4.352882143621173e-08
the O 0 4.2851993065085026e-09
maintenance O 0 1.6088065990516043e-07
of O 0 6.722216880916676e-07
DM B-Disease 1 1.0
in O 0 8.837704967845639e-08
the O 0 9.043505855288458e-08
population O 0 7.972604976203002e-08
. O 0 3.585319632293249e-07

In O 0 3.183526189332042e-07
a O 0 1.3125563214089198e-07
survey O 0 1.652557841680391e-07
of O 0 8.96946460215986e-07
DM B-Disease 1 1.0
in O 0 1.168969134823783e-07
Northern O 0 4.675919740293466e-07
Ireland O 0 1.8635890342011407e-07
, O 0 2.0555482649342594e-08
59 O 0 5.19640025231638e-07
pedigrees O 0 5.051098810326948e-07
were O 0 2.556710967382969e-07
ascertained O 0 6.009152639308013e-05
. O 0 4.772020020027412e-06

Sibships O 0 0.00024720339570194483
where O 0 4.727118607661396e-08
the O 0 6.551406972477025e-09
status O 0 2.2026414470133204e-08
of O 0 4.81528683593524e-09
all O 0 4.878107917605234e-10
the O 0 1.6123685719904302e-09
members O 0 3.8395994716999837e-10
had O 0 3.4901137535570115e-09
been O 0 1.6068668617919002e-09
identified O 0 1.305404562224055e-09
were O 0 5.258099511351588e-10
examined O 0 2.127685139186042e-09
to O 0 1.0247503540172787e-10
determine O 0 1.2288733364229643e-09
the O 0 1.4282640625751242e-09
transmission O 0 1.5395638541804146e-08
of O 0 1.547607375584903e-08
the O 0 9.32582722157349e-08
DM B-Disease 1 1.0
expansion O 0 1.189773456644616e-06
from O 0 6.359261561783569e-08
affected O 0 9.581310855821812e-09
parents O 0 6.483727998940481e-10
to O 0 2.5294562000510723e-09
their O 0 1.0132744421298412e-08
offspring O 0 4.752422739784379e-07
. O 0 8.329185448019416e-07

Where O 0 1.763357886375161e-07
the O 0 3.182129049150717e-08
transmitting O 0 1.5010249398983433e-06
parent O 0 2.595505179669999e-07
was O 0 3.621330279202084e-06
male O 0 3.242552963911294e-07
, O 0 4.2865501370670245e-08
58 O 0 4.039606665173778e-06
. O 0 1.1205082728338311e-06

3 O 0 1.8539736856837408e-06
% O 0 7.829189740959919e-08
of O 0 8.460977696245209e-09
the O 0 6.780263461791947e-09
offspring O 0 3.9269774987360506e-08
were O 0 6.464246471438173e-09
affected O 0 1.2707150887081298e-08
, O 0 2.2095918428277628e-09
and O 0 3.2535640848152525e-10
in O 0 7.707567362125189e-10
the O 0 9.914207232952776e-10
case O 0 4.784443508043523e-09
of O 0 3.089664302180495e-09
a O 0 1.6930552959593115e-08
female O 0 1.0788863136212967e-08
transmitting O 0 1.5332655323163635e-07
parent O 0 1.3079316829589516e-07
, O 0 2.3191346087969578e-07
68 O 0 2.152916567865759e-05
. O 0 3.6558844840328675e-06

7 O 0 4.0977454773383215e-05
% O 0 5.563967079069698e-06
were O 0 4.2607675254657806e-07
affected O 0 9.537769756207126e-07
. O 0 4.9609170673647895e-06

Studies O 0 9.211595397573547e-07
on O 0 3.5608778148343845e-07
meiotic O 0 5.4396066843764856e-05
drive O 0 1.651016987125331e-06
in O 0 3.6440246731217485e-07
DM B-Disease 1 1.0
have O 0 3.677727011819343e-09
shown O 0 6.546207464985798e-10
increased O 0 1.7125542095541846e-09
transmission O 0 5.0612793955906454e-09
of O 0 1.2573387886405385e-09
the O 0 7.790081912872893e-10
larger O 0 1.1596881677178317e-08
allele O 0 1.0250312953985485e-07
at O 0 3.0923541061156357e-08
the O 0 1.7631268889317653e-08
DM B-Disease 1 0.9994282126426697
locus O 0 2.9651200748048723e-06
in O 0 4.9169635474299866e-08
non O 0 4.760029241879238e-06
- O 0 0.00022823319886811078
DM O 1 1.0
heterozygotes O 0 4.9991082050837576e-05
for O 0 5.622742946798098e-07
CTGn O 0 0.0006266846903599799
. O 0 4.975671799911652e-06

This O 0 7.251002642760795e-08
study O 0 2.0976381520654286e-08
provides O 0 1.6521324308627072e-09
further O 0 2.496651774208658e-09
evidence O 0 2.34218644479256e-09
that O 0 1.2219572020910618e-09
the O 0 2.0998723471166159e-07
DM B-Disease 1 1.0
expansion O 0 8.695802534930408e-06
tends O 0 3.9247316863111337e-07
to O 0 9.682037394043164e-09
be O 0 3.875286935794975e-08
transmitted O 0 2.920877761880547e-07
preferentially O 0 3.4137942748202477e-06
. O 0 1.1755510058719665e-06

Diagnosis O 1 0.9983893632888794
of O 0 0.2873249351978302
hemochromatosis B-Disease 1 1.0
. O 0 0.07816538959741592

If O 0 0.00016525221872143447
untreated O 1 0.9999971389770508
, O 0 2.6703924049797934e-06
hemochromatosis B-Disease 1 1.0
can O 0 2.623721911731991e-06
cause O 1 0.9999960660934448
serious O 1 1.0
illness O 1 0.9907834529876709
and O 0 6.336400293349698e-09
early B-Disease 0 1.7202984281539102e-07
death I-Disease 0 2.304437707323359e-08
, O 0 3.9939224150131736e-10
but O 0 6.949129049971248e-10
the O 0 1.3115497132787368e-08
disease O 0 3.366815235494869e-07
is O 0 2.569809032237913e-09
still O 0 1.798946658304601e-09
substantially O 0 2.049996261632714e-08
under O 0 1.935956106535741e-06
- O 1 0.8631514310836792
diagnosed O 1 0.9814568758010864
. O 0 8.660125786263961e-06

The O 0 1.6821422832435928e-06
cornerstone O 0 4.2349503928562626e-05
of O 0 9.656001509483758e-08
screening O 0 1.2066871590832307e-07
and O 0 1.3629631867573266e-09
case O 0 1.9386442673408055e-08
detection O 0 2.2780751862683246e-07
is O 0 2.1283670381677666e-09
the O 0 2.223466744055713e-09
measurement O 0 1.5412994969210558e-07
of O 0 3.118831770621e-08
serum O 0 1.1346948980417437e-07
transferrin O 0 1.9777987745328574e-06
saturation O 0 2.907364887505537e-06
and O 0 7.65212870845744e-09
the O 0 4.202598447022865e-08
serum O 0 9.058470595846302e-07
ferritin O 0 2.28152875934029e-05
level O 0 5.700324436475057e-06
. O 0 2.0941338334523607e-06

Once O 0 1.2407439271555631e-06
the O 0 5.361791366453872e-08
diagnosis O 0 4.790689126821235e-05
is O 0 4.027578270893173e-08
suspected O 0 1.047698788170237e-06
, O 0 6.125188800609749e-09
physicians O 0 1.357445622574005e-08
must O 0 5.424836579948078e-09
use O 0 8.433861609091764e-09
serum O 0 4.287858246243559e-07
ferritin O 0 3.8050307921366766e-05
levels O 0 2.2469872362762544e-07
and O 0 6.649187156426706e-08
hepatic O 1 0.9999974966049194
iron O 1 0.841232419013977
stores O 0 7.045803158689523e-07
on O 0 1.212760480484576e-06
liver O 0 3.421200017328374e-05
biopsy O 0 5.446140676212963e-06
specimens O 0 1.3877188287381159e-08
to O 0 2.816559208085323e-09
assess O 0 1.0390147764383073e-07
patients O 0 7.757702924493515e-09
for O 0 1.8075726471167286e-09
the O 0 2.5294143668475044e-08
presence O 0 7.496314680111027e-08
of O 0 9.160355602944037e-07
iron B-Disease 0 0.02980763092637062
overload I-Disease 0 0.005285369232296944
. O 0 1.5085996892594267e-05

Liver O 1 0.9999959468841553
biopsy O 1 0.9992006421089172
is O 0 9.842092651979328e-08
also O 0 1.1464500460078852e-09
used O 0 3.0146846130563176e-10
to O 0 1.5657350416198312e-10
establish O 0 4.983798373991988e-10
the O 0 9.261790778758439e-10
presence O 0 1.8535926127327684e-09
or O 0 8.515912419682081e-09
absence O 0 3.831878245819098e-07
of O 0 1.3749153140452108e-06
cirrhosis B-Disease 1 1.0
, O 0 2.4761375172488442e-08
which O 0 2.717989389111608e-09
can O 0 1.0095685176736424e-08
affect O 0 8.047387609622092e-07
prognosis O 1 0.6541826725006104
and O 0 2.121071958072207e-07
management O 0 9.857525583356619e-06
. O 0 4.7525045374641195e-06

A O 0 5.516153123608092e-06
DNA O 0 1.6840283478813944e-06
- O 0 4.069167403031315e-07
based O 0 1.1489659001995278e-08
test O 0 5.751152443167484e-09
for O 0 7.200704477128284e-10
the O 0 7.196191642577787e-09
HFE O 0 0.00011229972733417526
gene O 0 9.435303205407308e-09
is O 0 3.092551492667184e-10
commercially O 0 1.9165435904966444e-09
available O 0 3.3130428955807645e-10
, O 0 1.538781463361616e-10
but O 0 8.45140554761592e-11
its O 0 1.3425383027509952e-10
place O 0 3.6969833860922563e-09
in O 0 3.304636286838303e-10
the O 0 2.299005652517394e-09
diagnosis O 0 1.3532933280657744e-06
of O 0 2.521852366044186e-06
hemochromatosis B-Disease 1 1.0
is O 0 2.1378291421569884e-06
still O 0 3.097806597907038e-07
being O 0 1.5526090635376022e-07
evaluated O 0 5.05719128796045e-07
. O 0 7.898053695498675e-07

Currently O 0 8.665757604831015e-07
, O 0 1.3237640317242949e-08
the O 0 3.08661318726422e-09
most O 0 6.86202872302033e-10
useful O 0 2.6796918017879534e-09
role O 0 1.616941802673466e-09
for O 0 2.7613167308260245e-10
this O 0 5.088185428547831e-10
test O 0 3.801758463595206e-09
is O 0 2.794420528307029e-10
in O 0 5.317541892924105e-11
the O 0 1.2804897420171102e-10
detection O 0 6.5038619823099e-08
of O 0 3.0467359124486393e-07
hemochromatosis B-Disease 1 1.0
in O 0 4.629237793096763e-08
the O 0 1.8747277508168736e-08
family O 0 1.5079894000180616e-09
members O 0 7.358368775411961e-11
of O 0 1.7083393588634976e-09
patients O 0 3.1276392586931934e-10
with O 0 7.932488693684903e-11
a O 0 6.042398581485031e-08
proven O 0 4.791122137248749e-06
case O 0 6.17244282352658e-08
of O 0 8.54923101201166e-08
the O 0 4.067095744630933e-07
disease O 0 9.291262540500611e-05
. O 0 3.975203981099185e-06

It O 0 1.0733305799703885e-07
is O 0 8.088985481435884e-08
crucial O 0 9.066836810234236e-07
to O 0 3.0659526828458183e-07
diagnose O 1 0.9999998807907104
hemochromatosis B-Disease 1 1.0
before O 1 0.9999991655349731
hepatic B-Disease 1 1.0
cirrhosis I-Disease 1 1.0
develops O 1 0.6739341020584106
because O 0 1.004208684207697e-06
phlebotomy O 1 0.9411760568618774
therapy O 0 7.377072961389786e-06
can O 0 1.2581878650053113e-07
avert O 1 1.0
serious O 1 1.0
chronic O 1 1.0
disease O 1 0.9999964237213135
and O 0 4.690249078009856e-09
can O 0 1.2922846126528498e-09
even O 0 3.5811484888625955e-09
lead O 0 2.780365049304123e-09
to O 0 1.267686067230045e-09
normal O 0 3.5564884370842265e-08
life O 0 2.6359753491078664e-08
expectancy O 0 1.5722417856522952e-07
. O 0 2.7427482507391687e-08
. O 0 4.6268365849755355e-07

Prevalence O 0 7.160422683227807e-05
of O 0 5.115793442200811e-07
the O 0 5.003046794627153e-07
I1307K O 0 0.0011419946094974875
APC B-Disease 0 2.4479907096974785e-06
gene O 0 1.2123259729435176e-08
variant O 0 5.974371930506095e-08
in O 0 2.2605157745658744e-09
Israeli O 0 5.797478763724939e-08
Jews O 0 2.1984442710731855e-08
of O 0 1.2376495384103237e-09
differing O 0 8.704730825037643e-10
ethnic O 0 4.8861372725639285e-09
origin O 0 4.461437885794339e-09
and O 0 1.8616709285268485e-09
risk O 0 1.3099843272357248e-06
for O 0 0.00011490094038890675
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.6568459868431091

BACKGROUND O 0 2.0272889742045663e-05
& O 0 1.256387463399733e-06
AIMS O 0 3.9957942021828785e-07
Israeli O 0 2.2557236434295191e-07
Jews O 0 5.213803788706173e-08
of O 0 4.185613189378046e-09
European O 0 1.3469542636812548e-07
birth O 0 1.8465277662471635e-07
, O 0 5.260971214227084e-09
i O 0 6.81025724702522e-08
. O 0 1.289180207031393e-09
e O 0 2.611218796744197e-09
. O 0 6.304486377395335e-10
, O 0 1.7218955150610782e-09
Ashkenazim O 0 9.935102752933744e-06
, O 0 1.9759069935787466e-09
have O 0 1.1541071431864225e-09
the O 0 5.71735974119747e-08
highest O 1 0.9999910593032837
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 1 0.999990701675415
of O 0 2.1366959117585793e-06
any O 0 5.515767043107189e-07
Israeli O 0 2.5363431177538587e-06
ethnic O 0 5.569789323089935e-07
group O 0 1.0284192342169263e-07
. O 0 3.5555399335862603e-07

The O 0 7.052457931422396e-06
I1307K O 0 0.0004870920383837074
APC B-Disease 0 7.418435870931717e-06
gene O 0 1.333327759311942e-07
variant O 0 1.2978575796296354e-06
was O 0 6.013781330693746e-07
found O 0 1.521433112827708e-08
in O 0 2.8294886433855027e-08
6 O 0 3.717290155691444e-06
. O 0 1.3547756907428266e-06

1 O 0 3.574255742933019e-06
% O 0 6.892007320402627e-08
of O 0 1.2497100243535897e-08
American O 0 5.0936282747215955e-08
Jews O 0 1.2654598435801745e-07
, O 0 1.876121924482277e-09
28 O 0 2.4041055368684283e-08
% O 0 9.661800248750296e-09
of O 0 3.968221751193823e-09
their O 0 1.6488151288740482e-08
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 1.937304659804795e-05
, O 0 2.2182240044799073e-08
but O 0 2.190945869173788e-09
not O 0 1.7294659038213922e-09
in O 0 6.5582330677216305e-09
non O 0 3.6642788359131373e-07
- O 0 1.0765839988380321e-06
Jews O 0 2.5599442778911907e-06
. O 0 1.0571251323199249e-06

We O 0 4.848971002502367e-07
assessed O 0 3.3012113362929085e-06
the O 0 2.0746998075082956e-07
I1307K O 0 0.0009738967637531459
prevalence O 0 1.3620356185128912e-06
in O 0 1.9709951448732e-09
Israeli O 0 3.604971965387449e-08
Jews O 0 1.61874176285437e-08
of O 0 9.302723591453343e-10
differing O 0 1.5510284168129829e-09
ethnic O 0 7.735863505331508e-09
origin O 0 7.952417391265953e-09
and O 0 3.4062754838970477e-09
risk O 0 2.0056177163496614e-06
for O 0 3.249795190640725e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.5108957290649414

METHODS O 0 1.9547646843420807e-06
DNA O 0 1.5993525437352218e-07
samples O 0 2.0635688713355194e-09
from O 0 2.4785034025143204e-09
500 O 0 4.226180294608639e-09
unrelated O 0 1.2671984350731691e-08
Jews O 0 1.264414706270145e-08
of O 0 1.5190110280727254e-09
European O 0 2.0283557944367203e-08
or O 0 9.345035856256345e-09
non O 0 1.1799973265169683e-07
- O 0 1.8678036894925754e-08
European O 0 5.0833861564569816e-09
origin O 0 8.600266609981588e-10
, O 0 2.7468433777544377e-11
with O 0 3.786584327342135e-12
or O 0 2.7175939276702366e-10
without O 0 7.524499356925674e-10
a O 0 9.80579439868734e-09
personal O 0 2.364838991297802e-08
and O 0 3.53076945458497e-09
/ O 0 1.2461983715184033e-05
or O 0 7.173171923113841e-08
family O 0 5.68766322928127e-09
history O 0 6.360823423534612e-09
of O 0 2.3889436207014114e-08
neoplasia B-Disease 0 0.07436031848192215
, O 0 7.474025842668652e-09
were O 0 4.579100654211743e-09
examined O 0 2.2897820528555712e-08
for O 0 1.449746434012411e-09
the O 0 1.577216401926762e-08
I1307K O 0 1.3574995136877988e-06
variant O 0 5.651526535643825e-08
by O 0 8.556937935999542e-10
the O 0 6.904714577871118e-09
allele O 0 4.791057506281504e-08
- O 0 2.1531691984932877e-08
specific O 0 5.230774036135699e-09
oligonucleotide O 0 4.3838790588779375e-06
( O 0 1.238092153243997e-07
ASO O 0 0.00026832675212062895
) O 0 4.952513421585536e-08
method O 0 4.104423965145543e-07
. O 0 5.185143550079374e-07

RESULTS O 0 1.3113844943291042e-05
In O 0 6.739008284739612e-08
persons O 0 1.2616900413320309e-08
at O 0 1.8063397888568034e-08
average O 0 2.6338092595779017e-08
risk O 0 1.9294609501230298e-06
for O 0 7.644411380169913e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 0.0002084129664581269
I1307K O 1 0.9973927736282349
was O 0 1.0259765303999302e-06
found O 0 1.1170601332821661e-08
in O 0 1.0752851054007806e-08
5 O 0 5.253914991953934e-07
. O 0 5.851123319189355e-07

0 O 0 9.632420187699609e-06
% O 0 2.2569092550384084e-07
of O 0 4.7048381190961663e-08
120 O 0 6.907075089657155e-08
European O 0 3.094933163083624e-07
and O 0 1.8203965623797558e-07
1 O 0 3.9531299989903346e-05
. O 0 4.191042535239831e-06

6 O 0 7.411987098748796e-06
% O 0 2.7612833264356595e-07
of O 0 8.754290803381082e-08
188 O 0 1.9652756577670516e-07
non O 0 3.943314084153826e-07
- O 0 7.300433253476513e-07
European O 0 3.617649895204522e-07
Jews O 0 3.516537105952011e-07
( O 0 4.145072907135727e-08
P O 0 1.1408332284190692e-05
= O 0 2.8074006763745274e-07
0 O 0 1.0583542575659521e-07
. O 0 7.75742137193447e-09
08 O 0 5.567091534430801e-07
) O 0 6.586277834230714e-08
. O 0 5.55640895072429e-07

It O 0 8.780508551353705e-07
occurred O 0 4.552881819108734e-06
in O 0 4.493174401432043e-07
15 O 0 2.201740244345274e-06
. O 0 1.6921470660236082e-06

4 O 0 3.3451617582613835e-06
% O 0 1.4294835182226961e-07
of O 0 1.670632521211246e-08
52 O 0 1.2137934390921146e-07
Ashkenazi O 0 1.0030045132225496e-06
Israelis O 0 2.322687180367211e-07
with O 0 9.745159346152832e-09
familial O 1 0.9999854564666748
cancer B-Disease 1 0.9999996423721313
( O 0 1.998968627958675e-06
P O 0 0.17649009823799133
= O 0 2.322104677432435e-07
0 O 0 8.645866245160505e-08
. O 0 1.6195254026740713e-09
02 O 0 3.181376584393547e-08
) O 0 3.136690074345694e-10
and O 0 4.0093939279728374e-10
was O 0 9.298914527278157e-09
not O 0 6.940850116876618e-10
detected O 0 1.067601118620587e-08
in O 0 3.9356886638586275e-09
51 O 0 9.464380212875767e-08
non O 0 9.435181169692441e-08
- O 0 9.77390541834211e-08
European O 0 9.500443809429271e-08
Jews O 0 1.6001871472326457e-07
at O 0 8.680731156118782e-08
increased O 0 2.9858355787837354e-07
cancer B-Disease 0 7.69949983805418e-05
risk O 0 1.1245849236729555e-05
. O 0 4.115824140171753e-06

Colorectal B-Disease 1 1.0
neoplasia I-Disease 1 0.9999997615814209
occurred O 0 0.00029431437724269927
personally O 0 1.8061592754747835e-06
or O 0 1.78051049459782e-08
in O 0 1.7011727582172398e-09
the O 0 2.6778319561771013e-09
families O 0 9.51886458544493e-10
of O 0 6.222761861351955e-09
13 O 0 1.8275452262628278e-08
of O 0 1.4270911563585287e-08
20 O 0 3.693137173854666e-08
Ashkenazi O 0 1.0886192285397556e-06
I1307K O 0 1.2599581395988935e-06
carriers O 0 5.925435253573141e-09
, O 0 7.498352494472726e-10
8 O 0 6.5553069639179284e-09
of O 0 1.8585629701917128e-09
whom O 0 1.9932966388580553e-09
also O 0 1.0468035327448888e-09
had O 0 4.3606167565712894e-09
a O 0 1.8739196860906304e-08
personal O 0 1.8418705849398975e-07
or O 0 1.675066840789441e-07
family O 0 3.8292402138040416e-08
history O 0 2.411182720152283e-07
of O 0 1.520367618468299e-06
noncolonic O 1 0.9570112824440002
neoplasia B-Disease 1 0.9999990463256836
. O 0 5.786265683127567e-05

CONCLUSIONS O 0 0.00015449413331225514
The O 0 6.316001872619381e-06
I1307K O 1 0.7157943248748779
APC O 0 2.187132486142218e-05
variant O 0 4.5216061153041665e-06
may O 0 2.0876237627476257e-08
represent O 0 1.8826962211448972e-09
a O 0 9.587599159033289e-09
susceptibility O 0 1.0461013744134107e-06
gene O 0 4.250028950991691e-08
for O 0 1.116051038252408e-07
colorectal B-Disease 1 1.0
, I-Disease 0 4.7933488531270996e-05
or I-Disease 0 3.096583532169461e-05
other I-Disease 0 2.968441847883696e-08
, I-Disease 0 6.006811048564487e-08
cancers I-Disease 1 0.8828886151313782
in O 0 4.1688913654525095e-08
Ashkenazi O 0 0.24931693077087402
Jews O 0 2.6295235784346005e-06
, O 0 7.750809771778222e-09
and O 0 2.2319097681133826e-09
partially O 0 1.5568807043564448e-07
explains O 0 1.1342227601573995e-08
the O 0 1.5872892999979626e-09
higher O 0 1.101763942301659e-07
incidence O 0 7.592495967401192e-05
of O 0 0.07324747741222382
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 4.464583525987109e-06
European O 0 1.2865992175647989e-05
Israelis O 0 1.1380538126104511e-05
. O 0 3.6869655559712555e-06

Systematic O 0 1.8277111166753457e-06
analysis O 0 1.709698551621841e-07
of O 0 5.203626187721966e-07
coproporphyrinogen O 0 0.0016210719477385283
oxidase O 0 0.00012192843860248104
gene O 0 1.5654308299417607e-05
defects O 0 0.004870600998401642
in O 0 2.834556482866901e-07
hereditary B-Disease 1 0.9999997615814209
coproporphyria I-Disease 1 0.9999996423721313
and O 0 4.778327365784207e-06
mutation O 0 0.00029996162629686296
update O 0 5.444208909466397e-06
. O 0 3.4132212931581307e-06

Hereditary B-Disease 1 0.9999998807907104
coproporphyria I-Disease 1 0.9999997615814209
( O 0 0.0004988075816072524
HC B-Disease 1 1.0
) O 0 1.5039536265248898e-06
is O 0 1.9057570455061068e-07
an O 0 3.26630811287032e-07
acute O 1 1.0
hepatic B-Disease 1 1.0
porphyria I-Disease 1 1.0
with O 0 0.0006965054199099541
autosomal O 1 1.0
dominant O 1 1.0
inheritance O 1 1.0
caused O 0 0.07813888788223267
by O 0 5.7497299366104926e-08
deficient B-Disease 0 2.7060370939580025e-06
activity I-Disease 0 3.635561540704657e-08
of I-Disease 0 8.960318353956609e-08
coproporphyrinogen I-Disease 0 3.012836714333389e-05
III I-Disease 1 0.9993929862976074
oxidase I-Disease 0 1.3577890968008433e-05
( O 0 4.863100571128598e-07
CPO O 0 0.00020227384811732918
) O 0 1.2580787256410986e-07
. O 0 5.935029321335605e-07

Clinical O 0 0.0007281003636308014
manifestations O 0 0.000835560669656843
of O 0 2.819054680003319e-05
the O 0 0.0001957838685484603
disease O 1 0.9939471483230591
are O 0 3.4641560731074605e-09
characterized O 0 2.17050228457083e-07
by O 0 1.5220482652011924e-08
acute O 1 0.9999790191650391
attacks O 0 0.0017657778225839138
of O 1 0.9999798536300659
neurological B-Disease 1 1.0
dysfunction I-Disease 1 1.0
often O 0 1.9666649109240097e-07
precipitated O 0 3.9433405163435964e-07
by O 0 1.0764253932649126e-09
drugs O 0 7.263817547453755e-09
, O 0 1.4709174989135931e-09
fasting O 0 1.473309652055832e-07
, O 0 1.6815242531720287e-08
cyclical O 0 0.050661515444517136
hormonal O 0 7.544745312770829e-05
changes O 0 1.9223607239382545e-07
, O 0 2.0225846242283296e-07
or O 0 0.0013039309997111559
infectious B-Disease 1 0.9999966621398926
diseases I-Disease 1 0.9999374151229858
. O 0 3.3633754355832934e-05

Skin O 1 0.9999997615814209
photosensitivity O 1 0.9999997615814209
may O 0 1.1334677765262313e-05
also O 0 8.847925414556812e-08
be O 0 5.203809294584971e-08
present O 0 2.623937120915798e-07
. O 0 1.3439944268611725e-06

The O 0 1.3005624168727081e-06
seven O 0 1.9021128139229404e-07
exons O 0 1.091857939172769e-06
, O 0 9.216576835058277e-09
the O 0 1.893193868340859e-08
exon O 0 3.173264076394844e-06
/ O 0 4.416265710460721e-06
intron O 0 1.973943471966777e-05
boundaries O 0 6.729349166789689e-08
and O 0 2.114818986598266e-09
part O 0 3.5603299863851134e-08
of O 0 9.924640664848994e-08
3 O 0 4.984905785931915e-07
noncoding O 0 9.35639775434538e-07
sequence O 0 9.535096268109555e-09
of O 0 7.64164109767762e-09
the O 0 3.4158542661089086e-08
CPO O 0 2.9421598810586147e-05
gene O 0 1.8789304334632106e-08
were O 0 1.954977735252328e-09
systematically O 0 5.99986949012532e-09
analyzed O 0 3.2060090138230635e-09
by O 0 4.838365263992728e-10
an O 0 3.858277253243614e-09
exon O 0 4.7041024231475603e-07
- O 0 2.59193342344588e-07
by O 0 2.850848623836555e-08
- O 0 2.2104372874309774e-06
exon O 0 3.627126488936483e-06
denaturing O 0 8.323489964823239e-06
gradient O 0 1.2234222594997846e-05
gel O 0 2.1881171505810926e-06
electrophoresis O 0 2.734568852247321e-06
( O 0 5.3635197616586083e-08
DGGE O 0 0.00014420073421206325
) O 0 1.9652328653307904e-09
strategy O 0 7.63536167625034e-09
followed O 0 1.0191779642454435e-09
by O 0 1.1424701462647846e-10
direct O 0 5.709379635732148e-09
sequencing O 0 3.036507223441731e-08
in O 0 4.677839449129806e-09
seven O 0 1.0972735609016127e-08
unrelated O 0 2.5202072606589354e-07
heterozygous O 0 9.777519380804733e-07
HC B-Disease 1 0.9999948740005493
patients O 0 4.645184858986795e-08
from O 0 3.2866743993054115e-08
France O 0 2.3794945036570425e-07
, O 0 9.126800648573408e-09
Holland O 0 1.8844436056042468e-07
, O 0 2.849438907048807e-09
and O 0 5.623116194897193e-09
Czech O 0 2.703163545447751e-06
Republic O 0 3.1150980248639826e-06
. O 0 7.2516631917096674e-06

Seven O 0 5.949542583039147e-07
novel O 0 3.899514808836102e-07
mutations O 0 9.176779514064037e-08
and O 0 3.4312237495726094e-09
two O 0 1.902223933925029e-09
new O 0 1.0540366801592427e-08
polymorphisms O 0 1.8287955754203722e-06
were O 0 1.8744439955753478e-07
detected O 0 7.730593097221572e-06
. O 0 1.905187900774763e-06

Among O 0 1.658157344763822e-07
these O 0 4.547011656086397e-09
mutations O 0 4.279181808897192e-08
two O 0 2.4749839955262587e-09
are O 0 3.4831113548960957e-09
missense O 0 9.676439731265418e-06
( O 0 2.1865703558887617e-07
G197W O 0 0.003872180124744773
, O 0 2.7701078764152953e-08
W427R O 0 1.1061916666221805e-05
) O 0 2.07029060561581e-09
, O 0 5.864155827595141e-10
two O 0 1.0097736535819024e-10
are O 0 2.0822929491792763e-10
nonsense O 0 8.714080763638776e-07
( O 0 7.972148807766644e-08
Q306X O 0 9.477407729718834e-05
, O 0 1.6530851354445986e-08
Q385X O 0 1.0787211067508906e-05
) O 0 3.629940348304217e-09
, O 0 1.7501794458141262e-09
two O 0 4.921790752732136e-10
are O 0 5.983763484707083e-10
small O 0 1.448859698882643e-08
deletions O 0 1.6787912500149105e-06
( O 0 3.5243596130385413e-07
662de14bp O 0 0.0001181458865175955
; O 0 1.5697255051350112e-08
1168del3bp O 0 1.8030614228337072e-06
removing O 0 2.614733674022318e-08
a O 0 5.780218081952171e-09
glycine O 0 1.1703222213554909e-07
at O 0 5.4745971311831454e-08
position O 0 5.6882957011339386e-08
390 O 0 4.3626570800370246e-08
) O 0 1.0127194638442916e-09
, O 0 3.0790614502507196e-10
and O 0 8.419452635077818e-11
one O 0 9.816156776309981e-10
is O 0 6.185719714224547e-10
a O 0 5.087024135264073e-09
splicing O 0 8.815751328938859e-08
mutation O 0 4.792849495061091e-08
( O 0 1.2319483211342686e-08
IVS1 O 0 0.00010223568096989766
- O 0 3.176325208187336e-06
15c O 0 1.9325922039570287e-05
- O 0 1.6649756844344665e-06
- O 0 6.193139370225254e-07
> O 0 1.6962800373221398e-06
g O 0 1.0944521733335932e-07
) O 0 5.123262925010863e-10
which O 0 2.4812127352724644e-10
creates O 0 3.106540580333217e-09
a O 0 6.1855338628902246e-09
new O 0 1.2911372415658207e-08
acceptor O 0 5.999688710289774e-07
splice O 0 1.9410368622629903e-05
site O 0 2.136622470061411e-06
. O 0 1.0591252248559613e-06

The O 0 1.9046627812713268e-06
pathological O 0 7.896835450083017e-05
significance O 0 7.409078648379364e-07
of O 0 1.0950973461376634e-07
the O 0 2.8909802551879693e-08
point O 0 3.9054239096003585e-06
mutations O 0 2.554724574110878e-07
G197W O 0 2.2138372514746152e-05
, O 0 1.6538136193844366e-08
W427R O 0 0.00015650229761376977
, O 0 4.590399171888748e-09
and O 0 6.55684173622717e-10
the O 0 6.1987854849121504e-09
in O 0 9.090108221698756e-09
- O 0 1.8518890954055678e-07
frame O 0 2.995755323809135e-07
deletion O 0 9.402203886565985e-07
390delGly O 0 5.976230568194296e-07
were O 0 3.522583114090594e-09
assessed O 0 4.7541725223254616e-08
by O 0 5.372207123599537e-10
their O 0 3.24219040503948e-10
respective O 0 6.315370004728038e-09
expression O 0 3.0078531665367336e-08
in O 0 1.8934638301715268e-09
a O 0 6.4735128368909045e-09
prokaryotic O 0 1.203463106946856e-08
system O 0 7.721240535829565e-09
using O 0 4.914438633818463e-09
site O 0 6.118442286151549e-08
- O 0 2.0319536986335152e-07
directed O 0 1.7052531120498315e-07
mutagenesis O 0 2.6803307264344767e-05
. O 0 1.7661782294453587e-06

These O 0 1.4617837607033835e-08
mutations O 0 5.5946514976312756e-08
resulted O 0 4.889346882919199e-08
in O 0 4.5111190338786855e-09
the O 0 1.737308963356554e-08
absence O 0 3.6619590559894277e-07
or O 0 2.0506337961023746e-08
a O 0 5.071486697261207e-08
dramatic O 0 2.913877779064933e-07
decrease O 0 1.1092552085756324e-06
of O 0 7.64498167882266e-07
CPO O 0 0.004426251165568829
activity O 0 9.679785080152215e-07
. O 0 1.1588753068281221e-06

The O 0 5.239319307293044e-07
two O 0 3.7931265239876666e-08
polymorphisms O 0 8.860538969202025e-07
were O 0 3.401511960987591e-08
localized O 0 5.594593858404551e-06
in O 0 2.390461339984995e-08
noncoding O 0 2.404588485660497e-06
part O 0 2.994287129354234e-08
of O 0 1.4458038322118227e-08
the O 0 9.50943235267232e-09
gene O 0 5.958619819779187e-09
1 O 0 4.306710010837378e-08
) O 0 4.1251618787541133e-10
a O 0 1.0695047514275302e-08
C O 0 3.6089531931793317e-06
/ O 0 1.0722723118306021e-06
G O 0 8.012849548322265e-07
polymorphism O 0 1.9058643374592066e-07
in O 0 5.864561725132944e-09
the O 0 1.9728089384329905e-08
promotor O 0 5.7898916566045955e-05
region O 0 1.9680073819472454e-06
, O 0 5.12287776643916e-08
142 O 0 1.1010035194658485e-07
bp O 0 2.6577501444080553e-07
upstream O 0 6.844584277132526e-08
from O 0 2.6825044407985388e-09
the O 0 1.605463761933379e-09
transcriptional O 0 5.361811616921841e-08
initiation O 0 3.4430328810231003e-08
site O 0 2.614115501842207e-08
( O 0 6.6756546956980856e-09
- O 0 8.398531576858659e-07
142C O 0 1.915440043376293e-05
/ O 0 3.1122442578634946e-06
G O 0 2.1537539396376815e-06
) O 0 3.5401155340508694e-09
, O 0 2.816822330942159e-09
and O 0 2.716289415616302e-09
2 O 0 1.8440675830788678e-07
) O 0 3.933474879147525e-09
a O 0 3.900678180457362e-08
6 O 0 2.9283751246111933e-07
bp O 0 2.5525326918796054e-07
deletion O 0 8.377494964406651e-08
polymorphism O 0 2.3012121630472393e-07
in O 0 2.351371541919889e-09
the O 0 5.303123717936842e-09
3 O 0 5.0853767419312135e-08
noncoding O 0 5.759300165664172e-07
part O 0 1.562866103199667e-08
of O 0 4.272266096450039e-08
the O 0 1.8344728403008048e-07
CPO O 0 0.00024883076548576355
gene O 0 1.7603737489935156e-07
, O 0 1.4801831760280493e-08
574 O 0 5.640520157612627e-07
bp O 0 4.936057393933879e-07
downstream O 0 1.0834173025386917e-07
of O 0 2.789831254901287e-09
the O 0 2.166846035933645e-09
last O 0 6.818482223280853e-09
base O 0 2.2161096069339692e-08
of O 0 3.138187709694762e-09
the O 0 5.681678683089331e-09
normal O 0 4.830928190813211e-08
termination O 0 6.095833100516757e-07
codon O 0 2.448801069476758e-06
( O 0 1.7047261735569919e-07
+ O 0 1.9168041944794822e-06
574 O 0 5.469333700602874e-06
delATTCTT O 0 3.688811193569563e-05
) O 0 5.17785963438655e-07
. O 0 1.517479176982306e-06

Five O 0 1.349329295408097e-06
intragenic O 0 0.0011176435509696603
dimorphisms O 0 0.001253441208973527
are O 0 3.81451314979131e-09
now O 0 3.2559248630548154e-09
well O 0 9.910898768339393e-10
characterized O 0 1.2475285693369642e-08
and O 0 8.429515419017264e-10
the O 0 7.502777954471185e-09
high O 0 5.176407924523119e-08
degree O 0 5.8905953892463e-07
of O 0 5.244213241439866e-08
allelic O 0 1.5977191651472822e-05
heterogeneity O 0 0.00026565243024379015
in O 0 2.3450535024949204e-07
HC B-Disease 1 1.0
is O 0 1.7308650512859458e-07
demonstrated O 0 1.0903741021195401e-08
with O 0 1.0206150508063061e-10
seven O 0 4.22448603876191e-10
new O 0 2.8556712550198426e-11
different O 0 3.511008497825152e-11
mutations O 0 1.3013374822179458e-09
making O 0 5.82801751303208e-10
a O 0 4.207745707418553e-09
total O 0 8.26022095168355e-09
of O 0 6.841374045052362e-08
nineteen O 0 1.196084213006543e-05
CPO O 0 0.22404903173446655
gene B-Disease 0 1.2818914001400117e-05
defects I-Disease 0 5.842249083798379e-05
reported O 0 6.954996223385024e-08
so O 0 1.3244408236801064e-08
far O 0 1.2745047683893063e-07
. O 0 1.1180624426287977e-07
. O 0 1.0218684565188596e-06

Coincidence O 0 1.5007763977337163e-05
of O 0 2.6535812480688037e-07
two O 0 1.480894784577913e-08
novel O 0 2.407933550330199e-07
arylsulfatase O 0 1.9679062461364083e-05
A O 0 1.4362657339006546e-06
alleles O 0 1.0227503111082115e-07
and O 0 1.0865292665585002e-08
mutation O 0 3.432326138863573e-07
459 O 0 4.5530805437010713e-07
+ O 0 4.4780310304304294e-07
1G O 0 1.4908850062056445e-05
> O 0 4.6368285211428883e-07
A O 0 6.253986128967881e-08
within O 0 1.1290102186478634e-08
a O 0 2.7452603745814486e-08
family O 0 1.0723153032188293e-08
with O 0 1.672009730668833e-08
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.2654756176289084e-07
molecular O 0 8.52081257107784e-07
basis O 0 1.833455058886102e-07
of O 0 1.792438837355803e-07
phenotypic O 0 5.750335185439326e-05
heterogeneity O 0 0.00034977839095517993
. O 0 7.664892109460197e-06

In O 0 6.118640527574826e-08
a O 0 3.396714021164371e-08
family O 0 4.185365387598949e-09
with O 0 2.525824827070977e-10
three O 0 9.501238018572167e-09
siblings O 0 1.5480551951441157e-07
, O 0 2.4356372474443333e-09
one O 0 2.709314550486397e-09
developed O 0 1.8568806936514193e-08
classical O 0 1.609253104106756e-06
late O 0 0.00014426579582504928
infantile O 1 0.9999841451644897
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 8.05621766630793e-06
MLD B-Disease 1 1.0
) O 0 3.6133911862634704e-08
, O 0 4.786360641162446e-09
fatal O 0 1.726651106537247e-07
at O 0 3.7074503467238173e-08
age O 0 1.7964993048735778e-08
5 O 0 1.6789510226544735e-08
years O 0 3.1382714205108186e-09
, O 0 4.6245735019212475e-10
with O 0 7.445579708331707e-10
deficient O 0 5.8858950069407e-06
arylsulfatase O 0 0.0023546672891825438
A O 0 2.4939197828643955e-05
( O 0 2.847648374881828e-07
ARSA O 0 0.00020536570809781551
) O 0 3.436725570793442e-09
activity O 0 6.025960619382431e-09
and O 0 1.7114308858978688e-09
increased O 0 1.3252953579012683e-07
galactosylsulfatide O 0 0.0001315929985139519
( O 0 5.166591563465772e-06
GS O 1 0.9999591112136841
) O 0 1.4078948424867122e-06
excretion O 0 3.879760697600432e-06
. O 0 1.1462492466307594e-06

The O 0 1.1509963826483727e-07
two O 0 3.969629513989048e-09
other O 0 1.6510172118344713e-09
siblings O 0 3.1742430905978836e-07
, O 0 1.2829919349144348e-08
apparently O 0 1.410074446539511e-06
healthy O 0 7.826427861346019e-08
at O 0 2.4883649984985823e-07
12 O 0 2.4418808308723783e-08
( O 0 5.647719625301306e-09
1 O 0 1.143531676461862e-06
/ O 0 1.7002548702294007e-07
2 O 0 3.525091685219195e-08
) O 0 1.4543485860052385e-10
and O 0 9.029859499021242e-11
15 O 0 9.639173903508436e-10
years O 0 4.766906869235754e-10
, O 0 1.1257514365148324e-10
respectively O 0 1.1079289707893736e-09
, O 0 1.0870505884330584e-10
and O 0 1.3511285146261542e-10
their O 0 2.1519723503171662e-10
father O 0 1.0425802088320779e-07
, O 0 2.6658931062684132e-08
apparently O 0 1.6919469771892182e-06
healthy O 0 1.579977393362242e-08
as O 0 2.4980044699418613e-09
well O 0 6.622579817872065e-09
, O 0 5.6676725534998695e-09
presented O 0 2.4652970864735835e-07
ARSA O 1 0.9100997447967529
and O 0 1.8794166578572913e-07
GS O 1 0.9965057373046875
values O 0 2.9789518407596915e-08
within O 0 9.2817256103217e-09
the O 0 4.195476410728816e-09
range O 0 3.5488187677401584e-07
of O 0 2.0138245417911094e-06
MLD B-Disease 1 1.0
patients O 0 5.627202426694566e-06
. O 0 2.694916702239425e-06

Mutation O 0 8.001693458936643e-06
screening O 0 3.753250155114074e-07
and O 0 1.7098191751330205e-09
sequence O 0 4.8124131346583e-09
analysis O 0 5.484743326178432e-09
disclosed O 0 3.3717977743208394e-08
the O 0 4.5535295534193665e-09
involvement O 0 9.348266161168794e-08
of O 0 1.4038009865657841e-08
three O 0 2.0037298487096677e-09
different O 0 1.9278725282845244e-09
ARSA O 0 0.48778682947158813
mutations O 0 2.625183412874321e-07
being O 0 7.36112726329452e-09
the O 0 2.6197792823978716e-09
molecular O 0 1.2759811340856686e-07
basis O 0 6.173785038754431e-08
of O 0 1.6400665003857284e-07
intrafamilial O 0 0.0004735176626127213
phenotypic O 0 0.0001686820323811844
heterogeneity O 0 0.000332677795086056
. O 0 3.450860958764679e-06

The O 0 6.000433359076851e-07
late O 0 1.6169253285625018e-05
infantile O 1 0.7534198760986328
patient O 0 1.5218939552141819e-05
inherited O 0 0.0014981541316956282
from O 0 1.9032684122066712e-06
his O 0 6.107447916292585e-07
mother O 0 3.7377969164253955e-08
the O 0 8.558673769698544e-09
frequent O 0 9.512317156179506e-09
0 O 0 1.7257950446492032e-07
- O 0 6.562490284522937e-08
type O 0 1.5697814603754523e-07
mutation O 0 1.612037863196747e-07
459 O 0 1.0026701602328103e-07
+ O 0 4.059151592628041e-08
1G O 0 1.314161181653617e-06
> O 0 1.072626645282071e-07
A O 0 4.6362803374222494e-08
, O 0 7.920171185560321e-10
and O 0 3.0092503489065336e-10
from O 0 3.0369748937886243e-09
his O 0 5.906016564694028e-09
father O 0 6.736435409493424e-09
a O 0 5.8222089371895436e-09
novel O 0 2.0149677482095285e-08
, O 0 3.289658101479631e-09
single O 0 2.9194788808695193e-08
basepair O 0 6.934055363672087e-06
microdeletion O 0 8.21892808744451e-06
of O 0 1.4355246946706757e-07
guanine O 0 1.9100912140856963e-07
at O 0 1.0310608899999352e-07
nucleotide O 0 1.5565646549475787e-07
7 O 0 9.03474770552748e-08
in O 0 6.2672271816666125e-09
exon O 0 1.016010855892091e-06
1 O 0 9.751538527780212e-07
( O 0 4.6029562383864686e-08
7delG O 0 8.214006811613217e-06
) O 0 2.4467161097163626e-07
. O 0 7.440687568305293e-07

The O 0 9.55359269028122e-07
two O 0 1.9262458295088436e-07
clinically O 0 0.02635926939547062
unaffected O 0 2.8456324798753485e-05
siblings O 0 8.721458044647079e-08
carried O 0 1.0012517037694124e-08
the O 0 2.3938696358527523e-08
maternal O 0 2.302915902419045e-07
mutation O 0 1.6593374141393724e-07
459 O 0 1.689483468680919e-07
+ O 0 1.0327811139632104e-07
1G O 0 3.513664978527231e-06
> O 0 2.522705813134962e-07
A O 0 1.1480682360343053e-07
and O 0 1.674293814701855e-09
, O 0 9.784192345207998e-10
on O 0 4.924760599323008e-09
their O 0 2.87696699796669e-10
paternal O 0 1.239225042581893e-07
allele O 0 9.892038406178472e-07
, O 0 7.147139324814589e-09
a O 0 2.7138622016309455e-08
novel O 0 3.923878111322665e-08
cytosine O 0 5.206013042879931e-08
to O 0 3.5692901967365742e-09
thymidine O 0 1.052808897838986e-06
transition O 0 2.1258999538531498e-07
at O 0 2.4190507019739016e-07
nucleotide O 0 9.37288405111758e-07
2435 O 0 1.3713083717448171e-05
in O 0 1.2229232737581697e-08
exon O 0 1.2920409062644467e-06
8 O 0 8.252020222698775e-08
, O 0 8.012232544096776e-10
resulting O 0 3.274283955079227e-09
in O 0 1.4970421569060477e-09
substitution O 0 6.067597979608763e-08
of O 0 6.743560021504891e-08
alanine O 0 7.057396373966185e-07
464 O 0 7.890547522038105e-07
by O 0 1.8395674317162047e-07
valine O 0 0.000377261167159304
( O 0 2.4051066702668322e-06
A464V O 0 0.0005819324869662523
) O 0 8.920764003050863e-07
. O 0 1.7539751979711582e-06

The O 0 2.5568358523742063e-06
fathers O 0 3.937323526770342e-06
genotype O 0 9.13993517315248e-06
thus O 0 5.436460241980967e-07
was O 0 6.316435246844776e-06
7delG O 0 0.00023000792134553194
/ O 0 0.0030498942360281944
A464V O 0 0.005285734310746193
. O 0 1.218902525579324e-05

Mutation O 0 4.938674464938231e-05
A464V O 0 0.0014078604290261865
was O 0 4.0453133465234714e-07
not O 0 3.133552306522347e-09
found O 0 3.4515061919648815e-09
in O 0 4.830769118058242e-09
18 O 0 1.4209126675268635e-07
unrelated O 0 1.175983197754249e-05
MLD B-Disease 1 1.0
patients O 0 3.807551820500521e-07
and O 0 4.940757492022385e-08
50 O 0 7.239766546263127e-07
controls O 0 3.304209940324654e-06
. O 0 2.045701648967224e-06

A464V O 0 0.07658109068870544
, O 0 2.102178626728346e-07
although O 0 1.1566466895374106e-07
clearly O 0 2.3611683275248652e-07
modifying O 0 8.538472684449516e-07
ARSA O 1 0.999359667301178
and O 0 9.833402145886794e-07
GS O 1 1.0
levels O 0 1.6644137303956086e-06
, O 0 8.36536031556534e-08
apparently O 0 1.2509021871665027e-06
bears O 0 2.0215260576605942e-07
little O 0 2.6082286552764344e-08
significance O 0 6.533390006779882e-08
for O 0 3.064375198036373e-09
clinical O 0 1.0013711744250031e-06
manifestation O 0 0.0001546375424368307
of O 0 0.000404193764552474
MLD B-Disease 1 1.0
, O 0 2.8201307600284053e-07
mimicking O 0 9.470471695749438e-07
the O 0 2.394936871041864e-07
frequent O 0 2.939257456091582e-06
ARSA O 1 0.9983269572257996
pseudodeficiency O 0 0.014834074303507805
allele O 0 0.00018430859199725091
. O 0 5.002678335586097e-06

Our O 0 4.719834691968572e-07
results O 0 7.076146602003064e-08
demonstrate O 0 1.4887567623134146e-08
that O 0 8.843580867612388e-10
in O 0 1.1700611590725885e-09
certain O 0 9.361770025861915e-09
genetic O 0 1.68692963598005e-06
conditions O 0 1.1995774002571125e-05
MLD B-Disease 1 1.0
- O 1 0.9310187101364136
like O 0 7.628202638443327e-07
ARSA O 1 0.9996933937072754
and O 0 6.842417121788458e-08
GS O 1 0.9999301433563232
values O 0 2.1659049664890517e-08
need O 0 1.8766230791555927e-09
not O 0 5.688485238408703e-10
be O 0 4.700626554665632e-10
paralleled O 0 1.0513061532435586e-08
by O 0 1.4740294540516174e-09
clinical O 0 3.700642992043868e-05
disease O 0 1.4501916894005262e-06
, O 0 3.2297984287055215e-09
a O 0 1.2238356106308856e-08
finding O 0 1.778229830051714e-08
with O 0 1.990451137245941e-09
serious O 0 3.204995664418675e-05
diagnostic O 0 0.0007211609627120197
and O 0 2.634684506119811e-06
prognostic O 1 0.9999988079071045
implications O 0 0.07032591104507446
. O 0 1.0940490028588101e-05

Moreover O 0 5.508990216185339e-05
, O 0 2.2873054206229426e-07
further O 0 1.1558830692592892e-06
ARSA O 0 0.3725118041038513
alleles O 0 1.947225428011734e-06
functionally O 0 2.0395312105847552e-07
similar O 0 1.2749946654011524e-09
to O 0 7.1776584675831145e-09
A464V O 0 0.0004855397855862975
might O 0 2.31204086986736e-08
exist O 0 1.6979895267610345e-09
which O 0 4.1268619077605706e-10
, O 0 1.8747474406222153e-10
together O 0 3.862654640585106e-11
with O 0 4.412602921943787e-11
0 O 0 1.0937030481272814e-07
- O 0 7.138531543660065e-08
type O 0 3.2593072774034226e-07
mutations O 0 2.212549787827811e-07
, O 0 4.723862634392617e-09
may O 0 3.6624268062723786e-08
cause O 0 4.187278591416543e-06
pathological O 1 0.9986836314201355
ARSA O 1 0.9999978542327881
and O 0 4.965698963133036e-07
GS O 1 1.0
levels O 0 1.1273549205270683e-07
, O 0 8.165181308861236e-10
but O 0 2.673309074108232e-10
not O 0 1.3211953753256012e-09
clinical O 0 7.1325295891711e-08
outbreak O 0 2.470976134816283e-08
of O 0 6.183330469866632e-08
the O 0 4.207964536817599e-07
disease O 0 4.699171768152155e-05
. O 0 4.2353903495495615e-07
. O 0 2.5755523438419914e-06

Human O 1 0.6446830630302429
MLH1 O 1 1.0
deficiency O 1 1.0
predisposes O 0 0.003957225941121578
to O 0 8.117413926811423e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
and O 0 2.971262574646971e-06
neurofibromatosis B-Disease 1 0.9999997615814209
type I-Disease 1 0.9717206954956055
1 I-Disease 0 0.01139984279870987
. O 0 3.4955764931510203e-06

Heterozygous O 0 4.329929652158171e-05
germ O 0 0.0012034091632813215
- O 0 2.0426588889677078e-05
line O 0 2.0999334537918912e-06
mutations O 0 1.5527793095770903e-07
in O 0 1.6497895272138408e-09
the O 0 6.734329094371105e-09
DNA O 0 1.1496210845507449e-06
mismatch O 0 0.0068863555788993835
repair O 0 4.186068963463185e-06
genes O 0 4.274222220601587e-08
lead O 0 1.7122774309541455e-08
to O 0 3.74278350534496e-08
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 1 0.9999639987945557

The O 0 3.347063739056466e-06
disease O 0 1.5673907910240814e-05
susceptibility O 0 9.044849321071524e-06
of O 0 1.5268189201833593e-07
individuals O 0 3.4878659960213554e-08
who O 0 7.935236681078095e-07
constitutionally O 0 1.8740161976893432e-05
lack O 0 1.5932206451907405e-06
both O 0 3.629062916843395e-08
wild O 0 9.281605883870725e-08
- O 0 1.9286905228454998e-07
type O 0 4.853963559980912e-07
alleles O 0 1.7987575517963705e-07
is O 0 1.3646129559674591e-08
unknown O 0 4.031414277960721e-07
. O 0 2.303790012092577e-07

We O 0 2.8673073870777444e-07
have O 0 8.20640355669866e-09
identified O 0 2.5750505727728523e-08
three O 0 1.7613747127498414e-09
offspring O 0 5.174292549980919e-09
in O 0 5.427513993794264e-10
a O 0 2.5433672590224887e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 1 0.999992847442627
who O 0 1.5750030115668778e-06
developed O 0 9.702719580673147e-06
hematological B-Disease 1 1.0
malignancy I-Disease 1 1.0
at O 0 8.111882721095753e-08
a O 0 9.244389143070464e-10
very O 0 9.595090694203279e-11
early O 0 2.6509994199841458e-09
age O 0 3.2782334624670284e-09
, O 0 1.0663789296039283e-10
and O 0 6.819177167383117e-11
at O 0 1.3880754323736255e-09
least O 0 2.373263530142111e-10
two O 0 1.2451477349184614e-10
of O 0 6.67361388373422e-10
them O 0 1.8382551036921768e-10
displayed O 0 1.8370860388472465e-08
signs O 0 3.250081803685134e-08
of O 0 9.491894559232605e-08
neurofibromatosis B-Disease 1 0.999901533126831
type I-Disease 0 0.0006206402322277427
1 I-Disease 0 0.00046557708992622793
( O 0 7.777081805215857e-07
NF1 B-Disease 0 0.0002010106691159308
) O 0 3.250832492085465e-07
. O 0 5.876724458175886e-07

DNA O 0 8.72275336405437e-07
sequence O 0 3.087745170660128e-08
analysis O 0 9.147382407093119e-09
and O 0 1.7535609631025295e-09
allele O 0 6.155536169671905e-08
- O 0 1.825166151547819e-08
specific O 0 2.4546371601985584e-09
amplification O 0 2.5467164732617675e-07
in O 0 6.928909890291379e-09
two O 0 6.7583139085058974e-09
siblings O 0 8.616036240027825e-08
revealed O 0 1.4117817670467048e-07
a O 0 2.7538570179785893e-07
homozygous O 0 3.1416861929756124e-06
MLH1 O 0 0.0009836583631113172
mutation O 0 3.5438781651464524e-06
( O 0 1.2857103115493373e-07
C676T O 0 9.241126099368557e-05
- O 0 3.977224696427584e-05
- O 0 2.752093678282108e-05
> O 0 7.342430035350844e-05
Arg226Stop O 0 0.0001814184506656602
) O 0 2.434009047647123e-07
. O 0 9.847441333477036e-07

Thus O 0 1.6352967122656992e-06
, O 0 9.415190760364567e-08
a O 0 3.383375428711588e-07
homozygous O 0 2.2595634163735667e-06
germ O 0 0.08456828445196152
- O 0 0.0002943292784038931
line O 0 2.340883838769514e-05
MLH1 O 0 0.41028839349746704
mutation O 0 3.348206519149244e-06
and O 0 5.7120406182775696e-08
consequent O 1 0.9999364614486694
mismatch O 1 1.0
repair O 1 1.0
deficiency O 1 1.0
results O 0 5.938533377047861e-06
in O 0 5.1776126497316e-08
a O 0 9.929108557571453e-08
mutator O 0 0.00020952359773218632
phenotype O 0 1.1855847787956009e-06
characterized O 0 1.846648878256474e-08
by O 0 1.5541949949238187e-08
leukemia B-Disease 1 0.9999998807907104
and O 0 2.684741048142314e-05
/ O 1 1.0
or O 1 0.9999997615814209
lymphoma B-Disease 1 1.0
associated O 0 0.0008757400792092085
with O 0 9.748918472496371e-08
neurofibromatosis B-Disease 1 1.0
type I-Disease 1 0.9512192010879517
1 I-Disease 0 0.0002461408730596304
. O 0 2.694582690310199e-07
. O 0 9.156076430372195e-07

Missense O 0 0.0012345926370471716
mutations O 0 4.958703357260674e-06
in O 0 2.8302443055849835e-08
the O 0 2.3409281624253708e-08
most O 0 3.886239774431033e-09
ancient O 0 4.523554153479381e-08
residues O 0 1.54120698425686e-07
of O 0 2.966715584307167e-08
the O 0 1.540040415193289e-07
PAX6 O 0 0.25055548548698425
paired O 0 5.019405762141105e-07
domain O 0 7.95443668266671e-07
underlie O 0 9.583120572642656e-07
a O 0 8.24978556579481e-08
spectrum O 0 0.008642755448818207
of O 0 0.00019322310981806368
human O 1 0.9999961853027344
congenital B-Disease 1 1.0
eye I-Disease 1 1.0
malformations I-Disease 1 1.0
. O 1 0.9999401569366455

Mutations O 0 7.03108889865689e-06
of O 0 5.101300075693871e-07
the O 0 3.315309697882185e-07
human O 0 3.6999276176175044e-07
PAX6 O 0 0.39670661091804504
gene O 0 7.2275952334166504e-06
underlie O 1 0.9999467134475708
aniridia B-Disease 1 1.0
( O 1 1.0
congenital B-Disease 1 1.0
absence I-Disease 1 0.9989463686943054
of I-Disease 0 0.0057012178003787994
the I-Disease 0 1.4769542758585885e-05
iris I-Disease 0 0.012425926513969898
) O 0 1.0494188629195378e-08
, O 0 1.9872419265709595e-09
a O 0 1.6394199775504603e-08
rare O 0 4.2173937231382297e-07
dominant O 1 0.9999948740005493
malformation B-Disease 1 1.0
of I-Disease 1 0.9855614304542542
the I-Disease 0 0.3595573604106903
eye I-Disease 1 0.999993085861206
. O 0 0.0005684694042429328

The O 0 7.17965974672552e-07
spectrum O 0 2.9947386792628095e-05
of O 0 2.3555710413347697e-06
PAX6 O 1 0.9999529123306274
mutations O 0 8.934106881497428e-05
in O 0 4.857945896219462e-06
aniridia B-Disease 1 1.0
patients O 0 3.9284537933781394e-07
is O 0 3.9736294255021676e-09
highly O 0 5.057410046305222e-09
biased O 0 1.0398950678336405e-07
, O 0 2.6066096503463143e-10
with O 0 3.480743471229175e-11
92 O 0 2.4225361272556256e-08
% O 0 5.552518889118119e-09
of O 0 1.0664689131800742e-09
all O 0 3.942027537728876e-10
reported O 0 8.283365993122516e-09
mutations O 0 3.5307440526821665e-08
leading O 0 6.666902407914677e-08
to O 0 6.130798979597785e-09
premature O 0 3.6450256857278873e-07
truncation O 0 3.145268692605896e-06
of O 0 8.64383764564991e-08
the O 0 2.1240166958591544e-08
protein O 0 3.6418423832174085e-08
( O 0 4.066992076445786e-09
nonsense O 0 2.3705838714249694e-07
, O 0 1.87153648134597e-09
splicing O 0 1.942300897894711e-08
, O 0 3.854163932448529e-10
insertions O 0 1.5979859213643977e-08
and O 0 4.37263281138911e-10
deletions O 0 3.725128294718161e-08
) O 0 1.7391448281500743e-09
and O 0 9.787477495137864e-10
just O 0 1.7151506881418754e-08
2 O 0 5.2695906305189055e-08
% O 0 4.3654266868031755e-09
leading O 0 1.5360492877647403e-09
to O 0 2.2293814017082525e-10
substitution O 0 2.4836440459807818e-08
of O 0 7.985492267437166e-09
one O 0 3.467567122328319e-09
amino O 0 2.6348581094737256e-09
acid O 0 9.49463951904761e-10
by O 0 3.0428412567395924e-10
another O 0 2.5621655908025787e-08
( O 0 1.48967330915184e-07
missense O 0 3.1657968065701425e-05
) O 0 3.325842214962904e-07
. O 0 1.1073422001572908e-06

The O 0 8.157776960615593e-07
extraordinary O 0 4.18358780507333e-07
conservation O 0 4.875792569691839e-07
of O 0 1.4567771700058074e-07
the O 0 2.9463086548275896e-07
PAX6 O 0 0.1190740168094635
protein O 0 9.729708381200908e-07
at O 0 1.5178120804648643e-07
the O 0 1.7543914765383306e-08
amino O 0 1.618782476953129e-07
acid O 0 1.7255744921840233e-07
level O 0 8.535541837773053e-07
amongst O 0 5.202340958021523e-07
vertebrates O 0 9.823703294387087e-06
predicts O 0 3.1477563879889203e-06
that O 0 1.4954474991668576e-08
pathological O 0 0.00016869489627424628
missense O 0 0.0001692791556706652
mutations O 0 8.661956485411793e-07
should O 0 7.259080891941494e-09
in O 0 1.4083191279823382e-09
fact O 0 1.870301691297982e-09
be O 0 1.1090240947808638e-09
common O 0 5.437454042578338e-09
even O 0 2.4309450008530575e-09
though O 0 1.262382642863713e-09
they O 0 2.819960376321262e-10
are O 0 1.9180126931139796e-10
hardly O 0 4.859725066808096e-08
ever O 0 5.411249759390557e-08
seen O 0 9.486392826829615e-08
in O 0 1.249603229780405e-07
aniridia B-Disease 1 0.9999998807907104
patients O 0 4.116821401112247e-06
. O 0 6.8901267695764545e-06

This O 0 1.0068940525798098e-07
indicates O 0 2.2002193134085246e-07
that O 0 1.0614807921527358e-09
there O 0 1.5682313225795497e-09
is O 0 7.836518656212377e-10
a O 0 2.37362685062692e-09
heavy O 0 2.5121546514128568e-06
ascertainment O 0 0.0009115534485317767
bias O 0 2.2560559500561794e-06
in O 0 9.413045898298833e-10
the O 0 1.0443286235783944e-09
selection O 0 9.090351582585754e-09
of O 0 8.823317187989232e-09
patients O 0 5.375448530742233e-09
for O 0 4.074166337630913e-09
PAX6 O 0 0.11628258973360062
mutation O 0 3.145548816974042e-07
analysis O 0 1.792159665114923e-08
and O 0 1.4161144479274412e-09
that O 0 1.433936192007934e-09
the O 0 1.1349687412121057e-07
missing O 0 3.7922911815257976e-06
PAX6 O 1 0.9729442000389099
missense O 0 0.0007547356653958559
mutations O 0 6.289878456300357e-06
frequently O 0 9.34450454792568e-08
may O 0 6.093065962886612e-08
underlie O 0 7.71786471887026e-06
phenotypes O 0 1.5808325315447291e-06
distinct O 0 4.012274246179004e-08
from O 0 2.014755153822989e-07
textbook O 0 0.0007292478112503886
aniridia B-Disease 1 0.9999998807907104
. O 0 8.17568798083812e-06

Here O 0 3.176664222337422e-06
we O 0 8.749515956196774e-08
present O 0 2.8761414583300393e-08
four O 0 9.433738235031797e-09
novel O 0 1.8575633475848008e-07
PAX6 O 0 0.0001441729546058923
missense O 0 2.9664566682185978e-05
mutations O 0 1.6313587138938601e-06
, O 0 9.451333937704476e-09
two O 0 2.560503142845505e-09
in O 0 9.006028811597844e-09
association O 0 1.7204191848918526e-08
with O 0 8.36672864323873e-09
atypical O 0 5.789074566564523e-05
phenotypes O 0 0.017104851081967354
ectopia B-Disease 1 0.9998881816864014
pupillae I-Disease 1 0.9995743632316589
( O 0 2.3553299399736716e-07
displaced B-Disease 0 2.499155016266741e-07
pupils I-Disease 0 5.4004029692578115e-08
) O 0 2.8247111316659357e-08
and O 0 4.507010373799858e-07
congenital B-Disease 1 1.0
nystagmus I-Disease 1 0.9999043941497803
( O 0 6.126745688561641e-07
searching B-Disease 0 4.6138472953316523e-07
gaze I-Disease 0 3.0221544875530526e-06
) O 0 1.5890705418186712e-09
, O 0 6.941154873096878e-10
and O 0 2.5933244440778935e-10
two O 0 4.181326118679607e-10
in O 0 1.3565700784923251e-09
association O 0 4.290760635683455e-09
with O 0 1.861117038259863e-09
more O 0 5.7581804213668875e-08
recognizable O 0 8.63234672578983e-05
aniridia B-Disease 1 1.0
phenotypes O 0 0.000300120678730309
. O 0 5.17620901518967e-06

Strikingly O 0 1.7078054952435195e-05
, O 0 1.0517075565985579e-07
all O 0 8.497043069155552e-09
four O 0 7.35923233463609e-09
mutations O 0 5.708925598923997e-08
are O 0 4.854708302026722e-10
located O 0 1.4963633887532524e-08
within O 0 3.553335758965659e-08
the O 0 1.0569279851324609e-07
PAX6 O 0 0.003893771907314658
paired O 0 5.427156679616019e-07
domain O 0 8.190673952412908e-07
and O 0 7.591318684774251e-09
affect O 0 3.566249873188099e-08
amino O 0 3.678970728060449e-08
acids O 0 2.563239620556601e-09
which O 0 1.0235880198994352e-10
are O 0 6.48824050042407e-11
highly O 0 2.1580444098390217e-09
conserved O 0 3.4308591523313225e-08
in O 0 1.2988726760809755e-09
all O 0 8.14875167343132e-10
known O 0 1.2054364617597457e-08
paired O 0 7.19830808293409e-08
domain O 0 7.149683938223461e-07
proteins O 0 1.1514103448462265e-07
. O 0 3.213755803699314e-07

Our O 0 1.374606881654472e-07
results O 0 2.5964252969856716e-08
support O 0 7.129561829799513e-09
the O 0 9.060750372213988e-09
hypothesis O 0 1.4978760987105488e-07
that O 0 1.8166447512957262e-10
the O 0 6.462393953299284e-10
under O 0 9.117752775011922e-09
- O 0 2.9544956703375647e-08
representation O 0 1.0342532164031581e-08
of O 0 1.1245872677534408e-08
missense O 0 1.2710402188531589e-05
mutations O 0 4.4028450929545215e-07
is O 0 2.6082072057675987e-09
caused O 0 6.7990151286778655e-09
by O 0 1.4480523446991356e-09
ascertainment O 0 0.12931886315345764
bias O 0 0.00012030293146381155
and O 0 1.7050124645479059e-09
suggest O 0 2.3352009215216185e-09
that O 0 1.3699343048845236e-10
a O 0 2.496346906966096e-09
substantial O 0 6.754450510015886e-08
burden O 0 1.2452081818992156e-06
of O 0 1.928176970977802e-06
PAX6 B-Disease 1 1.0
- I-Disease 1 0.9999967813491821
related I-Disease 1 0.9708281755447388
disease I-Disease 1 0.9972904920578003
remains O 0 7.936341717140749e-07
to O 0 4.34749525268785e-09
be O 0 2.1207499756314974e-08
uncovered O 0 1.3641207488035434e-06
. O 0 6.901425564365127e-08
. O 0 4.61301112864021e-07

The O 0 6.695830165881489e-07
chromosomal O 0 1.6823520127218217e-05
order O 0 2.066602711181531e-08
of O 0 1.3203376170167758e-07
genes O 0 1.145148615933067e-07
controlling O 0 1.7224175508090411e-06
the O 0 1.0454755283717532e-07
major O 0 8.433818584308028e-05
histocompatibility O 1 0.9999996423721313
complex O 0 7.665701104997424e-07
, O 0 1.7893408976732417e-09
properdin O 0 3.5937480902248353e-07
factor O 0 5.006783965200157e-08
B O 0 7.05750437646202e-07
, O 0 9.651388577225362e-10
and O 0 3.884350174843121e-09
deficiency B-Disease 0 1.566002902109176e-05
of I-Disease 0 1.0256782161377487e-06
the I-Disease 0 7.92253388226527e-07
second I-Disease 0 3.6222938888386125e-06
component I-Disease 0 2.994172518810956e-06
of I-Disease 0 3.271985349329043e-07
complement I-Disease 0 7.323556587834901e-07
. O 0 2.5567260308889672e-06

The O 0 7.394536964966392e-07
relationship O 0 1.1594884341548095e-07
of O 0 5.9175771838226865e-08
the O 0 2.5829113070585663e-08
genes O 0 1.1030798496847183e-08
coding O 0 7.629397202890686e-08
for O 0 1.1886643669356545e-08
HLA O 0 1.0539639333728701e-05
to O 0 1.3326248993195122e-09
those O 0 2.867795723116018e-10
coding O 0 1.948493988379596e-08
for O 0 6.731988300145986e-10
properdin O 0 3.7617573411807825e-07
Factor O 0 3.7858910673094215e-08
B O 0 1.2803803883798537e-07
allotypes O 0 3.00354514592982e-07
and O 0 6.131813390375385e-10
for O 0 6.554056408702991e-09
deficiency B-Disease 0 1.4263953744375613e-05
of I-Disease 0 2.2656237774754118e-07
the I-Disease 0 8.85956126239762e-08
second I-Disease 0 1.553143675891988e-07
component I-Disease 0 1.1145725409278384e-07
of I-Disease 0 6.556069909180451e-09
complement I-Disease 0 8.219593894409627e-09
( O 0 1.2523060810565312e-08
C2 O 0 1.8380751498625614e-05
) O 0 1.9806576379011176e-09
was O 0 1.5368295080975258e-08
studied O 0 4.659291175101998e-09
in O 0 2.1059624877306504e-10
families O 0 1.4940290671283663e-10
of O 0 5.294654048526581e-09
patients O 0 2.751976246884169e-08
with O 0 1.5007270803835127e-07
connective O 1 1.0
tissue O 1 1.0
disorders O 1 1.0
. O 0 0.04126545786857605

Patients O 0 1.748583827065886e-06
were O 0 2.6484029191919944e-08
selected O 0 6.155675080776746e-09
because O 0 3.067819775992575e-09
they O 0 1.0878973277783643e-09
were O 0 4.11567047109429e-09
heterozygous O 0 2.8830783094235812e-08
or O 0 4.400322239916932e-08
homozygous O 0 2.13867133425083e-06
for O 0 5.252369192021433e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 0.0003812744689639658

12 O 0 6.444247446779627e-06
families O 0 5.889461007768659e-08
with O 0 9.430680236732769e-09
15 O 0 4.3664701365742076e-07
matings O 0 6.674461474176496e-06
informative O 0 1.9446329133643303e-06
for O 0 1.0816352187248413e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 1.903929273794347e-06
found O 0 8.206186521420022e-07
. O 0 1.2810745602109819e-06

Of O 0 8.59501142258523e-06
57 O 0 7.619225925736828e-06
informative O 0 1.0734938769019209e-06
meioses O 0 2.4508019123459235e-05
, O 0 9.466253558798599e-09
two O 0 1.6327504903657086e-09
crossovers O 0 7.329355611318533e-08
were O 0 5.273106840064656e-09
noted O 0 7.724392681041081e-09
between O 0 4.444369139378068e-08
the O 0 2.7803139346360695e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.999997615814209
gene O 0 6.011085673662819e-08
and O 0 3.360374867256155e-09
the O 0 5.187418494756457e-08
HLA O 0 9.06356071936898e-05
- O 0 1.7413020714229788e-06
B O 0 2.1104597180965357e-06
gene O 0 3.256390712635948e-09
, O 0 9.087429420073789e-11
with O 0 5.471989528160748e-11
a O 0 7.25699056403073e-09
recombinant O 0 4.0090384345603525e-08
fraction O 0 1.6083218667972687e-07
of O 0 1.6467384966745158e-07
0 O 0 1.8323430595046375e-06
. O 0 7.263868724294298e-07

035 O 0 0.09539986401796341
. O 0 0.00035711185773834586

A O 0 1.544769293104764e-05
lod O 0 0.00029479744262062013
score O 0 4.354178031462652e-07
of O 0 6.721550249721986e-08
13 O 0 1.1918768194618679e-08
was O 0 4.201458292385496e-09
calculated O 0 9.317929539065517e-09
for O 0 2.0109278686675225e-09
linkage O 0 1.4403848581423517e-05
between O 0 0.17299814522266388
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.673450687027071e-07
HLA O 0 0.00038038575439713895
- O 0 4.793590164808847e-07
B O 0 4.2829296376112325e-07
at O 0 8.096510684119096e-10
a O 0 2.4999288750215953e-10
maximum O 0 4.1670134010018955e-09
likelihood O 0 1.771435975683744e-08
value O 0 5.440441430692999e-09
of O 0 1.868130539151025e-09
the O 0 6.743094971284336e-09
recombinant O 0 2.263852039163794e-08
fraction O 0 9.78362209025363e-08
of O 0 1.128736215605386e-07
0 O 0 2.6792492917593336e-06
. O 0 6.383578465829487e-07

04 O 0 0.026136314496397972
. O 0 0.00015827131574042141

18 O 0 3.4901204344350845e-06
families O 0 2.530461529204331e-08
with O 0 5.217482001995677e-09
21 O 0 3.225451052912831e-07
informative O 0 1.1182862635905622e-07
matings O 0 6.519348971778527e-07
for O 0 6.793363649393314e-09
both O 0 1.7059955226272905e-08
properdin O 0 3.852356894640252e-05
Factor O 0 1.2989225979254115e-06
B O 0 2.6633979359758087e-06
allotype O 0 4.017216724605532e-06
and O 0 4.749776394419314e-08
HLA O 0 3.374150401214138e-05
- O 0 2.2586846171179786e-06
B O 0 5.255851192487171e-06
were O 0 1.3415617949874559e-08
found O 0 3.422055883106623e-08
. O 0 2.7576729166867153e-07

Of O 0 9.932280590874143e-06
72 O 0 9.894879440253135e-06
informative O 0 1.1768185004257248e-06
meioses O 0 7.073458982631564e-05
, O 0 1.424839179975379e-08
three O 0 4.791173680018801e-09
recombinants O 0 1.1600493053265382e-05
were O 0 1.2949723071642438e-08
found O 0 2.135972065886449e-09
, O 0 4.2721717830040973e-10
giving O 0 4.703882283685346e-10
a O 0 9.75434577554779e-09
recombinant O 0 6.249705819527662e-08
fraction O 0 2.3621437605925166e-07
of O 0 3.4600444109855744e-07
0 O 0 4.523219558905112e-06
. O 0 8.58846931350854e-07

042 O 0 0.057146862149238586
. O 0 0.0002942282590083778

A O 0 1.2608532415470108e-05
lod O 0 0.00031276248046196997
score O 0 6.300597306108102e-07
of O 0 9.063398920261534e-08
16 O 0 7.68401591244583e-08
between O 0 9.617934182415411e-08
HLA O 0 1.8834116417565383e-05
- O 0 5.590820819634246e-07
B O 0 6.884806111884245e-07
and O 0 9.195203487522008e-10
Factor O 0 3.257125413824724e-08
B O 0 1.9385304028674e-07
allotypes O 0 3.1305913239521033e-07
was O 0 1.0464627386852499e-08
calculated O 0 1.0743174350125173e-08
at O 0 2.0705550607402756e-09
a O 0 9.071086659595551e-10
maximum O 0 1.8764449549735218e-08
likelihood O 0 5.7079894588696334e-08
value O 0 7.085449116317477e-09
of O 0 6.346741798779476e-09
the O 0 4.92523000161782e-09
recombinant O 0 2.976373636442986e-08
fraction O 0 1.9458927624782518e-07
of O 0 1.3835831680353294e-07
0 O 0 2.9367026854743017e-06
. O 0 8.717929631529842e-07

04 O 0 0.018023008480668068
. O 0 0.00021802949777338654

A O 0 2.9888033168390393e-06
crossover O 0 3.7133497698960127e-06
was O 0 9.309992066164341e-08
shown O 0 2.3695287953984234e-09
to O 0 7.336496410381699e-10
have O 0 3.7420019860512355e-10
occurred O 0 8.624286174097051e-09
between O 0 1.110683767180376e-09
genes O 0 2.8586918943140915e-10
for O 0 8.573761839381078e-11
Factor O 0 8.362357029056966e-09
B O 0 5.5189349978945756e-08
and O 0 1.5132738395706724e-09
HLA O 0 7.135480245779036e-06
- O 0 1.4911061043676455e-06
D O 0 1.3735399988945574e-05
, O 0 2.0279680157386792e-09
in O 0 1.1301753977122075e-09
which O 0 5.237482891828904e-09
HLA O 0 7.970361366460565e-06
- O 0 1.1610047749854857e-06
D O 0 6.640506853727857e-06
segregared O 0 6.436360763473203e-06
with O 0 2.851310831886167e-08
HLA O 0 0.0004985877312719822
- O 0 2.6526449801167473e-06
A O 0 2.9064890441077296e-06
and O 0 2.2224318740882154e-07
B O 0 4.613957935362123e-05
. O 0 9.296307439399243e-07

These O 0 3.1876872697012004e-08
studies O 0 3.391030389821026e-08
suggest O 0 7.477975572101059e-09
that O 0 2.9127791845162676e-10
the O 0 6.026785737134333e-10
genes O 0 3.000973358702197e-10
for O 0 2.4612087368147684e-10
Factor O 0 8.189738309738459e-08
B O 0 0.0001263781450688839
and O 0 7.305907843146997e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 8.728555656034587e-10
located O 0 4.698038402750626e-09
outside O 0 8.102133963738822e-10
those O 0 7.311738714488314e-11
for O 0 1.4204725173883048e-09
HLA O 0 1.3961680451757275e-05
, O 0 3.0542496309848843e-10
that O 0 4.1932561589685946e-11
the O 0 2.819981748114486e-10
order O 0 5.302311922861236e-10
of O 0 3.205305576514661e-09
genese O 0 3.80020537704695e-06
is O 0 2.4712589308251154e-08
HLA O 0 6.517125711980043e-06
- O 0 1.2456898446089326e-07
A O 0 1.5887265192304767e-07
, O 0 4.2774335184958545e-09
- O 0 5.0308496923889834e-08
B O 0 3.4546107485766697e-07
, O 0 1.57262847189088e-09
- O 0 4.531403874352691e-08
D O 0 3.7210671166576503e-07
, O 0 2.4216293414980328e-09
Factor O 0 6.075380554193544e-08
B O 0 2.3056963982526213e-06
allotype O 0 0.00017796440806705505
, O 0 7.524070952058537e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 1.1399833077518906e-08
that O 0 5.502018285419297e-10
the O 0 3.916309054829981e-09
genes O 0 2.209558092047814e-09
coding O 0 1.5431895405981777e-07
for O 0 2.6897046723206586e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 5.965353722103828e-08
Factor O 0 7.024079309303488e-07
B O 0 5.287310500534659e-07
allotypes O 0 2.1004571237881464e-07
are O 0 6.227884874476786e-11
approximately O 0 7.328524453953378e-10
3 O 0 5.134339620127548e-09
- O 0 1.6001605374071914e-08
- O 0 2.252700426197407e-08
5 O 0 1.2607134003417286e-08
centimorgans O 0 6.176493627663149e-08
from O 0 1.6497077037769259e-09
the O 0 2.869635640223578e-09
HLA O 0 7.823173291399144e-07
- O 0 3.32609566555675e-08
A O 0 6.525569062887371e-08
and O 0 5.042182671388673e-09
HLA O 0 1.0785200856844313e-06
- O 0 5.144880432794707e-08
B O 0 2.028526608910397e-07
loci O 0 9.049541560557373e-09
, O 0 5.688178400520272e-11
and O 0 9.205512220555878e-12
that O 0 2.385402118887381e-11
the O 0 1.5469867609141374e-09
apparent O 0 2.806072814109939e-07
lack O 0 8.03976476504431e-08
of O 0 1.261814475128631e-07
recombinants O 0 1.7092230336857028e-05
between O 0 1.2499198120963229e-08
the O 0 7.245953170809116e-09
Factor O 0 1.2478288624606648e-07
B O 0 5.892325702916423e-07
gene O 0 4.348193982650628e-08
and O 0 4.0087712704917067e-07
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 7.891134714554937e-07
suggests O 0 1.2459567599876209e-08
that O 0 6.446362194045818e-11
these O 0 3.810494975109435e-11
two O 0 1.6489737353353462e-10
genes O 0 4.982346091253476e-09
lie O 0 1.0687791274222036e-07
in O 0 7.944515045821277e-10
close O 0 2.0354674390432592e-08
proximity O 0 1.500231974205235e-07
to O 0 1.1227998086837943e-08
one O 0 8.327471334723668e-08
another O 0 4.837036158278352e-07
. O 0 2.3033669549477054e-06

Distribution O 0 1.3174613968658377e-06
of O 0 5.155204689799575e-07
emerin O 0 0.0012874531093984842
and O 0 1.522288499700153e-07
lamins O 0 0.0005546242464333773
in O 0 3.7655901508060197e-08
the O 0 1.1238994090945198e-07
heart O 0 2.2097965484135784e-06
and O 0 4.835341016473649e-09
implications O 0 2.0190436771372333e-06
for O 0 4.123860364302345e-08
Emery B-Disease 0 0.1650187075138092
- I-Disease 1 0.9999794960021973
Dreifuss I-Disease 1 0.9999998807907104
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 1 0.9879646301269531

Emerin O 0 0.3825894892215729
is O 0 2.3711264418579958e-07
a O 0 1.7768084603630996e-07
nuclear O 0 5.413352937466698e-06
membrane O 0 3.880146834944753e-07
protein O 0 8.929520234346455e-09
which O 0 2.1187707144321166e-10
is O 0 1.4780328072561133e-09
missing O 0 1.4680342275141811e-08
or O 0 1.3656284991725443e-08
defective O 0 7.459557878064516e-07
in O 0 8.420974495493283e-08
Emery B-Disease 0 0.0006637011538259685
- I-Disease 1 0.9989257454872131
Dreifuss I-Disease 1 0.9999992847442627
muscular I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9964884519577026
EDMD B-Disease 1 1.0
) O 0 1.0409669812361244e-05
. O 0 8.425089617958292e-06

It O 0 2.641944796266671e-08
is O 0 6.2333227468514e-09
one O 0 1.464922960714432e-09
member O 0 3.882735466476106e-09
of O 0 5.556057391942204e-09
a O 0 7.963972592506252e-08
family O 0 3.497579470490564e-08
of O 0 4.061634513163881e-07
lamina O 1 1.0
- O 0 0.3524933457374573
associated O 0 1.3225997008703416e-07
proteins O 0 2.2829689250158935e-09
which O 0 3.2888158862931505e-10
includes O 0 2.430087464588837e-09
LAP1 O 0 0.02537222020328045
, O 0 1.2370523450044857e-07
LAP2 O 0 0.26776689291000366
and O 0 5.113681709190132e-07
lamin O 0 0.00076905736932531
B O 0 0.0004411198024172336
receptor O 0 5.7860612287186086e-05
( O 0 1.0858766472665593e-06
LBR O 0 0.001703331246972084
) O 0 1.6924924466366065e-06
. O 0 5.2692666940856725e-06

A O 0 2.6800085834111087e-05
panel O 0 4.793315838469425e-06
of O 0 3.0038401632737077e-07
16 O 0 5.6693078676062214e-08
monoclonal O 0 4.3949118122554864e-08
antibodies O 0 1.6669975622107813e-08
( O 0 1.3025276857092649e-08
mAbs O 0 1.4272702628659317e-06
) O 0 4.08300326881772e-09
has O 0 9.057773975307271e-10
been O 0 1.1308222136463542e-09
mapped O 0 7.760869280559746e-09
to O 0 1.4076504406546064e-09
six O 0 1.4560451733203195e-09
specific O 0 1.1398783028582216e-09
sites O 0 6.255761686446704e-09
throughout O 0 3.489295075098653e-09
the O 0 1.7226650328439064e-08
emerin O 0 3.464988367340993e-06
molecule O 0 1.13195717688086e-07
using O 0 8.479379864922976e-09
phage O 0 2.2602047522468638e-07
- O 0 4.683582588427271e-08
displayed O 0 2.240444274548281e-09
peptide O 0 1.362667489956948e-08
libraries O 0 2.732736703592309e-09
and O 0 5.057513852158024e-10
has O 0 3.9878786384228704e-10
been O 0 3.0669053407983426e-10
used O 0 5.452915341486175e-10
to O 0 2.1218979906478808e-09
localize O 0 9.118622983805835e-06
emerin O 0 0.000514637678861618
in O 0 4.808167730629975e-08
human O 0 2.63967834257528e-08
and O 0 3.1867330108070746e-08
rabbit O 0 1.960761619557161e-05
heart O 0 0.0001808443630579859
. O 0 1.2799296200682875e-05

Several O 0 1.3753310668107588e-06
mAbs O 0 2.831642450473737e-05
against O 0 4.7650664214415883e-07
different O 0 3.497445888456241e-08
emerin O 0 6.107591616455466e-05
epitopes O 0 4.633885509974789e-06
did O 0 1.9279875473898755e-08
not O 0 3.7052430013062576e-09
recognize O 0 1.0149669549264217e-08
intercalated O 0 4.226493217629468e-07
discs O 0 4.387139824757469e-07
in O 0 4.998804037370519e-09
the O 0 2.0626412577939846e-08
heart O 0 2.889012648665812e-06
, O 0 3.5282650134860205e-09
though O 0 1.1519056819508933e-09
they O 0 4.2112438536356933e-10
recognized O 0 3.8403267232922644e-09
cardiomyocyte O 0 1.3490281389749725e-06
nuclei O 0 6.911232048878446e-07
strongly O 0 8.374683346801248e-08
, O 0 2.3689366024370884e-09
both O 0 2.840361057465657e-09
at O 0 1.1867630433926024e-07
the O 0 2.6969214417249532e-08
rim O 0 1.6570363641221775e-06
and O 0 5.282700943354257e-09
in O 0 3.4671121085239065e-08
intranuclear O 0 5.755447637056932e-05
spots O 0 7.173800895543536e-07
or O 0 2.692686962291191e-07
channels O 0 2.67778796114726e-06
. O 0 1.890228077172651e-06

A O 0 7.248857582453638e-05
polyclonal O 0 0.0003141718916594982
rabbit O 0 5.872663223271957e-06
antiserum O 0 1.1487507435958833e-05
against O 0 1.5406881175294984e-06
emerin O 0 0.0003290011372882873
did O 0 9.720992721895527e-08
recognize O 0 4.002444597972499e-08
both O 0 1.966812490650227e-08
nuclear O 0 5.087073532195063e-06
membrane O 0 6.986992957536131e-07
and O 0 5.406130210161564e-09
intercalated O 0 1.1890639939338143e-07
discs O 0 1.990412812347131e-07
but O 0 2.4524751118804033e-09
, O 0 7.685063141416038e-10
after O 0 2.3948139027396564e-09
affinity O 0 8.990650890439156e-09
purification O 0 9.427945535378512e-09
against O 0 8.234061432688122e-09
a O 0 1.4670908932146176e-08
pure O 0 7.503294909838587e-07
- O 0 5.178452511245268e-07
emerin O 0 2.5571966943971347e-06
band O 0 2.3028249529488676e-08
on O 0 7.794485057388556e-09
a O 0 9.280787693910497e-09
western O 0 1.2911563374018442e-07
blot O 0 2.912824129452929e-05
, O 0 2.0063925632030077e-08
it O 0 3.159713601874614e-09
stained O 0 2.731613051309978e-07
only O 0 1.1307364822243926e-08
the O 0 7.091630749300748e-08
nuclear O 0 2.2374648324330337e-05
membrane O 0 1.9388573491596617e-05
. O 0 1.6218898508668644e-06

These O 0 8.550139263263645e-09
results O 0 1.9501149139955487e-08
would O 0 5.411350478823351e-09
not O 0 4.1126493321996804e-09
be O 0 5.1576307669165544e-09
expected O 0 5.744161413190341e-08
if O 0 6.389072382262384e-08
immunostaining O 0 3.406484756851569e-05
at O 0 2.715481173254375e-07
intercalated O 0 2.318119669553198e-07
discs O 0 9.874490558559046e-08
were O 0 2.292551481986038e-09
due O 0 3.900014089452952e-09
to O 0 4.908253803392881e-10
a O 0 2.6924742435596727e-09
product O 0 5.165989414024352e-09
of O 0 2.231790308115933e-09
the O 0 3.0215021595836333e-09
emerin O 0 2.9622542569995858e-06
gene O 0 9.371149189973949e-09
and O 0 5.80756609469546e-10
, O 0 8.223321468214806e-10
therefore O 0 1.6462635699099337e-08
, O 0 1.885563927217504e-09
cast O 0 3.81451314979131e-09
some O 0 2.222444034361004e-10
doubt O 0 1.2817542582865826e-08
upon O 0 1.5321925950217974e-09
the O 0 8.769556747445506e-10
hypothesis O 0 1.3385117370035005e-07
that O 0 7.172485272377571e-09
cardiac B-Disease 1 0.9999916553497314
defects I-Disease 1 0.9998997449874878
in O 0 1.8728247823673883e-06
EDMD B-Disease 1 1.0
are O 0 7.122602951881163e-09
caused O 0 4.664797614850613e-08
by O 0 3.820848082369821e-09
absence O 0 3.2196641086557065e-07
of O 0 4.695828010881087e-07
emerin O 0 0.0015809829346835613
from O 0 2.6015816274593817e-06
intercalated O 0 4.401151090860367e-05
discs O 0 7.656383968424052e-05
. O 0 6.8411259235290345e-06

Although O 0 2.6005150175478775e-06
emerin O 0 0.02232983522117138
was O 0 2.0438217234186595e-06
abundant O 0 6.52340403917151e-08
in O 0 2.53473508848856e-09
the O 0 5.0732062994995886e-09
membranes O 0 5.434594996245323e-08
of O 0 5.1517247356969165e-08
cardiomyocyte O 0 4.3164480302948505e-05
nuclei O 0 3.3334138151985826e-06
, O 0 1.214310985098166e-09
it O 0 8.386232264179228e-10
was O 0 7.018107339717972e-08
absent O 0 2.252309450057055e-08
from O 0 1.3373533391813908e-09
many O 0 5.362829069710529e-10
non O 0 4.753705695748067e-07
- O 0 3.0958653951529413e-06
myocyte O 0 5.7475772337056696e-05
cells O 0 2.8582642030983152e-08
in O 0 4.176705203917663e-09
the O 0 8.419817731919466e-08
heart O 0 1.8797114535118453e-05
. O 0 6.21083336227457e-06

This O 0 1.662958126757985e-08
distribution O 0 3.5204084980478e-08
of O 0 2.6651303386415748e-08
emerin O 0 3.6993162211729214e-05
was O 0 4.6179938095747275e-08
similar O 0 3.6346287091149065e-10
to O 0 3.65225211185205e-10
that O 0 2.9696564651793267e-10
of O 0 2.691797718057387e-08
lamin O 0 7.920122880022973e-05
A O 0 2.407460328868183e-07
, O 0 8.914761706613206e-10
a O 0 2.0856845139860525e-09
candidate O 0 1.5898201866093586e-08
gene O 0 6.471373437122452e-10
for O 0 1.2256073933514244e-10
an O 0 1.3795528053250905e-09
autosomal O 0 9.506985065854678e-07
form O 0 3.4977306313521694e-06
of O 1 0.9999294281005859
EDMD B-Disease 1 1.0
. O 0 0.023804660886526108

In O 0 5.07558070239611e-07
contrast O 0 1.3716672810915043e-06
, O 0 9.353399832434661e-07
lamin O 1 0.9754900932312012
B1 O 1 0.9999687671661377
was O 0 1.8187103705713525e-05
absent O 0 2.5299025310232537e-06
from O 0 1.328057379623715e-07
cardiomyocyte O 0 4.634259676095098e-05
nuclei O 0 9.606613275536802e-06
, O 0 1.4817791438304084e-08
showing O 0 3.009368043649374e-08
that O 0 2.2315404635264713e-08
lamin O 0 0.2160119116306305
B1 O 1 0.8376935720443726
is O 0 5.272845271520055e-09
not O 0 6.71541933172648e-10
essential O 0 1.6722130347091024e-09
for O 0 1.6161773030987092e-09
localization O 0 1.6556589343963424e-06
of O 0 1.901770190215757e-07
emerin O 0 8.805483048490714e-06
to O 0 3.4570422968727144e-08
the O 0 4.7239643663488096e-07
nuclear O 0 0.000592112832237035
lamina O 1 0.9985800981521606
. O 0 2.8269261747482233e-05

Lamin O 1 0.9999963045120239
B1 O 1 0.9999990463256836
is O 0 3.0637400527666614e-07
also O 0 8.49589198992362e-09
almost O 0 5.5987506186738756e-08
completely O 0 5.306577008923341e-07
absent O 0 2.8440165351639735e-06
from O 0 5.869320034435077e-07
skeletal O 0 5.103256262373179e-05
muscle O 0 1.8858238036045805e-05
nuclei O 0 0.001597096212208271
. O 0 1.793655610526912e-05

In O 0 1.2890360267192591e-05
EDMD B-Disease 1 1.0
, O 0 6.503898930532159e-08
the O 0 9.766000452771095e-09
additional O 0 5.621056953231118e-09
absence O 0 1.3546745947223826e-07
of O 0 1.2783639249391854e-06
lamin O 1 0.9999997615814209
B1 O 1 1.0
from O 0 7.875898154452443e-05
heart O 1 0.9998791217803955
and O 0 4.952135554958659e-07
skeletal O 0 0.032595984637737274
muscle O 0 1.1958721188420895e-05
nuclei O 0 0.00525166979059577
which O 0 5.968107785747634e-08
already O 0 9.963409297597536e-08
lack O 0 2.207626010886088e-07
emerin O 0 2.621845487738028e-05
may O 0 3.1316940152237294e-09
offer O 0 9.713014836876255e-10
an O 0 1.8757452535655972e-10
alternative O 0 7.676892010977099e-09
explanation O 0 1.0752378543088525e-08
of O 0 6.050584477890197e-09
why O 0 7.1863159867291415e-09
these O 0 6.439508370981173e-10
tissues O 0 6.727860579758271e-08
are O 0 2.1130932559287885e-09
particularly O 0 5.653143730910415e-08
affected O 0 1.2703085872090014e-07
. O 0 1.525443593664022e-07
. O 0 1.0585051768430276e-06

Genetic O 0 1.5076362615218386e-05
mapping O 0 3.7222494029265363e-06
of O 0 1.4912682217982365e-06
the O 0 1.3761890613750438e-06
copper B-Disease 0 0.002295450074598193
toxicosis I-Disease 1 0.9999469518661499
locus O 0 0.0005456109065562487
in O 0 6.335520197353617e-08
Bedlington O 0 1.214426174556138e-05
terriers O 0 9.769037205842324e-07
to O 0 9.680911183806984e-09
dog O 0 5.811300525238039e-07
chromosome O 0 2.8568144898599712e-06
10 O 0 1.3592566183717736e-08
, O 0 5.456786134061531e-10
in O 0 5.694553162349791e-10
a O 0 1.0334940014899985e-08
region O 0 3.3443404845456826e-07
syntenic O 0 3.346108860569075e-05
to O 0 1.749662992267531e-08
human O 0 7.789643063915719e-08
chromosome O 0 1.6504189261468127e-05
region O 0 5.0117087084800005e-06
2p13 O 0 0.0012366505106911063
- O 0 5.635619527311064e-05
p16 O 0 4.726379847852513e-05
. O 0 2.896096702897921e-06

Abnormal O 1 0.9999922513961792
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9989101886749268
accumulation I-Disease 0 0.007968912832438946
is O 0 2.3346053978912096e-08
recognized O 0 6.773981375829408e-09
as O 0 1.7887438197305983e-09
an O 0 5.878272091308645e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 0.005249961744993925
man O 0 0.0005424721166491508
, O 0 1.5539550091148158e-08
mouse O 0 6.169453286020143e-07
, O 0 6.049293688192847e-08
rat O 0 3.1177936762105674e-05
and O 0 9.913875231859492e-08
dog O 0 3.5375069273868576e-05
. O 0 6.10864026384661e-06

The O 0 1.6211383808695246e-06
major O 0 1.0812371328938752e-05
cause O 0 0.0001530224399175495
of O 0 0.006835361942648888
hepatic B-Disease 1 1.0
copper I-Disease 1 0.9999997615814209
accumulation I-Disease 1 0.9999988079071045
in O 0 1.367397271678783e-05
man O 0 4.611243184626801e-06
is O 0 5.999102992149119e-09
a O 0 2.574829593982031e-08
dysfunctional O 0 7.054476327539305e-07
ATP7B O 0 0.3265058696269989
gene O 0 5.568971346292528e-07
, O 0 3.6883079701510724e-08
causing O 0 1.882980541267898e-05
Wilson B-Disease 0 0.0022016523871570826
disease I-Disease 1 0.926543116569519
( O 0 5.942329607933061e-06
WD B-Disease 1 0.9998785257339478
) O 0 7.903697678557364e-07
. O 0 1.9716367205546703e-06

Mutations O 0 3.538110377121484e-06
in O 0 2.128128606670998e-08
the O 0 4.26183213164677e-08
ATP7B O 1 0.9986522793769836
genes O 0 5.8367781718970946e-08
have O 0 8.867414025282017e-10
also O 0 5.812863523857459e-10
been O 0 2.3582344965689117e-09
demonstrated O 0 9.503920317399661e-09
in O 0 1.0208418999013702e-08
mouse O 0 1.2290354334254516e-06
and O 0 3.554244756287517e-07
rat O 0 0.00029057860956527293
. O 0 5.576269813900581e-06

The O 0 3.11537110064819e-06
ATP7B O 1 0.9524422287940979
gene O 0 3.3319440717605175e-07
has O 0 8.261764605776989e-09
been O 0 5.949942760707927e-09
excluded O 0 7.802638890552771e-08
in O 0 1.430262352997147e-09
the O 0 6.3084470980356855e-09
much O 0 3.328818536374456e-07
rarer O 0 0.00021308432042133063
human O 0 1.143102053902112e-06
copper B-Disease 0 0.13142555952072144
overload I-Disease 1 0.9921553730964661
disease O 0 0.06143995746970177
non B-Disease 0 0.00022952639847062528
- I-Disease 0 3.008983730978798e-05
Indian I-Disease 0 4.6474536929963506e-07
childhood I-Disease 0 1.340585367870517e-05
cirrhosis I-Disease 1 0.9999947547912598
, O 0 1.1575537683938819e-07
indicating O 0 5.30249690200435e-06
genetic O 0 0.00018855782400351018
heterogeneity O 0 0.01283931266516447
. O 0 1.2430993592715822e-05

By O 0 1.0603040578871514e-07
investigating O 0 9.739791266838438e-07
the O 0 5.368677307160397e-07
common O 0 0.00023940934624988586
autosomal O 1 0.9999997615814209
recessive O 1 1.0
copper B-Disease 1 1.0
toxicosis I-Disease 1 1.0
( O 0 5.46206247236114e-05
CT B-Disease 1 0.9999986886978149
) O 0 4.220881777428076e-08
in O 0 2.9278936608534423e-08
Bedlington O 0 5.003982369089499e-05
terriers O 0 8.888859156286344e-06
, O 0 5.588068674455826e-09
we O 0 2.8668400986475717e-09
have O 0 3.40883460347996e-10
identified O 0 1.1304231994913039e-09
a O 0 2.4232083006836547e-10
new O 0 1.0165643327120222e-10
locus O 0 8.265850937050345e-08
involved O 0 2.913541852223034e-09
in O 0 3.262466208298065e-08
progressive O 1 1.0
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.34846431016921997

We O 0 1.1216779967071488e-06
examined O 0 8.871344334693276e-07
whether O 0 1.2837831775414088e-07
the O 0 2.589230518879049e-07
WD B-Disease 1 0.66888028383255
gene O 0 9.193225196213461e-06
ATP7B O 1 0.9999566078186035
was O 0 2.1181278953008587e-06
also O 0 2.0129588662598508e-08
causative O 0 1.772925628529265e-07
for O 0 1.3517433394838463e-08
CT B-Disease 0 2.0519642930594273e-05
by O 0 5.784089207594434e-09
investigating O 0 8.082955815780224e-08
the O 0 4.729905356271047e-08
chromosomal O 0 0.0007509118877351284
co O 0 1.7302771766480873e-06
- O 0 2.238076376670506e-06
localization O 0 5.694558785762638e-05
of O 0 5.273630449664779e-06
ATP7B O 1 0.9999871253967285
and O 0 1.0316353638017972e-07
C04107 O 0 1.7348740584566258e-05
, O 0 2.56666421449836e-09
using O 0 3.773784840177541e-09
fluorescence O 0 2.1899803925862216e-07
in O 0 2.8446564215300896e-08
situ O 0 3.4559459436422912e-06
hybridization O 0 1.4853028460493078e-06
( O 0 1.4467671860529663e-07
FISH O 0 1.7956518831852009e-06
) O 0 1.485318250615819e-07
. O 0 7.369313266281097e-07

C04107 O 0 0.006375258322805166
is O 0 1.6767258159688936e-07
an O 0 2.4668180387266148e-08
anonymous O 0 1.0396922789368546e-06
microsatellite O 0 0.0003025242767762393
marker O 0 4.205812365398742e-05
closely O 0 2.851556359928509e-07
linked O 0 2.1268235741445096e-06
to O 0 1.003123202281131e-06
CT B-Disease 1 0.999974250793457
. O 0 6.77774878568016e-05

However O 0 1.561256249260623e-05
, O 0 2.7902428882953245e-06
BAC O 0 0.2155052125453949
clones O 0 2.2891521439305507e-05
containing O 0 3.4114862046408234e-07
ATP7B O 0 0.027402088046073914
and O 0 6.929877116590433e-08
C04107 O 0 2.6199058993370272e-05
mapped O 0 3.280994178567198e-07
to O 0 6.491106763206744e-09
the O 0 3.8663017676299205e-08
canine O 0 2.9752495720458683e-06
chromosome O 0 1.0104228749696631e-05
regions O 0 5.786806127616728e-07
CFA22q11 O 0 0.000185340570169501
and O 0 2.1766311419924023e-08
CFA10q26 O 0 0.00022913652355782688
, O 0 8.737471191011537e-09
respectively O 0 3.466669440399528e-08
, O 0 3.6280367599061947e-09
demonstrating O 0 2.3427418227583985e-08
that O 0 5.667867064573784e-09
WD B-Disease 0 0.00013476729509420693
cannot O 0 2.138696686415642e-07
be O 0 2.442435231841955e-08
homologous O 0 2.0281107993014302e-07
to O 0 2.896163664445339e-07
CT B-Disease 0 0.37040603160858154
. O 0 1.53596429299796e-05

The O 0 8.82089625520166e-06
copper O 0 1.0931145880022086e-05
transport O 0 8.373810373996093e-07
genes O 0 3.7988323242643673e-07
CTR1 O 0 0.026477226987481117
and O 0 5.3558835588773945e-08
CTR2 O 1 0.985373318195343
were O 0 2.5699476324803072e-08
also O 0 2.82527534700705e-09
excluded O 0 4.8982986555756725e-08
as O 0 1.0752598811336611e-09
candidate O 0 7.355348685678109e-08
genes O 0 5.350479614918413e-09
for O 0 2.9941369383834626e-09
CT B-Disease 1 0.9702670574188232
since O 0 2.3976082275112276e-07
they O 0 2.8530393603176663e-09
both O 0 2.026112166930716e-09
mapped O 0 9.983344995134757e-08
to O 0 3.074710264172609e-08
canine O 0 1.937751949299127e-05
chromosome O 0 0.0003185092646162957
region O 0 4.389917376101948e-05
CFA11q22 O 0 0.20914961397647858
. O 0 1.1701191397150978e-05

2 O 0 0.000249845179496333
- O 0 0.00011872466711793095
22 O 0 2.3636885089217685e-05
. O 0 3.827228738373378e-06

5 O 0 0.0003777171077672392
. O 0 4.966463893651962e-05

A O 0 6.372937150445068e-06
transcribed O 0 8.732640708331019e-07
sequence O 0 4.2548144563170354e-08
identified O 0 1.224767309793151e-08
from O 0 2.9662330369717438e-09
the O 0 1.3834769774234701e-08
C04107 O 0 1.097738368116552e-05
- O 0 3.581540113373194e-07
containing O 0 1.5224054905615958e-08
BAC O 0 8.99673905223608e-05
was O 0 2.1737021071999152e-08
found O 0 2.022412376456728e-10
to O 0 1.581371700254408e-10
be O 0 6.908333349819884e-10
homologous O 0 2.6643107720047965e-09
to O 0 6.623245840664538e-10
a O 0 9.180486593152182e-09
gene O 0 2.4355779615348183e-08
expressed O 0 4.76301043050853e-09
from O 0 7.830889714455225e-09
human O 0 2.283618982801272e-08
chromosome O 0 9.981713446904905e-06
2p13 O 0 7.811304385541007e-05
- O 0 2.3494326342188288e-06
p16 O 0 5.096777044855116e-07
, O 0 7.17393200400096e-10
a O 0 5.662593949296024e-09
region O 0 8.133324769232786e-08
devoid O 0 2.280503252904964e-07
of O 0 8.984616606255713e-09
any O 0 2.8581387923054535e-08
positional O 0 1.5498928405577317e-05
candidate O 0 5.5423508456442505e-05
genes O 0 3.613450644479599e-06
. O 0 8.578376196055615e-07

Molecular O 0 3.6792414448427735e-06
analysis O 0 8.609235635503865e-08
of O 0 7.65741674513265e-08
the O 0 1.2968081364306272e-07
APC B-Disease 0 2.202403720730217e-06
gene O 0 2.1582099662964538e-08
in O 0 4.6364014849586965e-09
205 O 0 3.0670957329448356e-08
families O 0 1.4174088569518517e-09
: O 0 2.557330791574941e-09
extended O 0 1.099930884151945e-07
genotype O 0 1.0130105692951474e-05
- O 0 1.4934550563339144e-05
phenotype O 0 3.703390802911599e-06
correlations O 0 1.5986405514922808e-06
in O 0 1.8508236721004323e-08
FAP B-Disease 0 1.9639959702999477e-07
and O 0 2.662784992502054e-10
evidence O 0 1.2587808573272241e-09
for O 0 5.88636639431428e-10
the O 0 3.0368532133451254e-09
role O 0 1.6527067714378063e-08
of O 0 2.8059597312335427e-08
APC B-Disease 0 3.0002325956957066e-07
amino O 0 1.952303207986006e-08
acid O 0 1.1929707888214125e-08
changes O 0 1.888736100852384e-08
in O 0 3.3788226573960856e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 1 1.0
. O 0 0.24573667347431183

BACKGROUND O 0 9.210528514813632e-05
/ O 0 3.263285543653183e-05
AIMS O 0 1.3122524933351087e-06
The O 0 2.3429249651485407e-08
development O 0 1.494167918281164e-07
of O 0 0.0025811002124100924
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.45604412549983e-08
a O 0 2.148381916811104e-08
variable O 0 5.305524197751765e-08
range O 0 7.549117242433567e-08
of O 0 5.7182106161235424e-08
extracolonic O 0 0.0005861821118742228
manifestations O 0 2.0754625438712537e-05
in O 0 1.7330978607787983e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.0005270823021419346
FAP B-Disease 0 0.012547661550343037
) O 0 1.6069986452649232e-09
is O 0 2.652495167954072e-10
the O 0 2.1445516196205716e-10
result O 0 1.1410029587821668e-09
of O 0 6.258841001027804e-09
the O 0 1.7385486827947716e-08
dominant O 0 1.555400922370609e-05
inheritance O 0 0.00012634487939067185
of O 0 0.0003181102219969034
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 2.444359961373266e-05
APC B-Disease 0 4.946168337482959e-05
) O 0 1.2486110279041895e-07
gene O 0 5.951318939878547e-07
mutations O 0 2.346266683161957e-06
. O 0 1.5694986359449103e-06

In O 0 1.3662359776844824e-07
this O 0 4.547245691099988e-09
study O 0 3.9516501182390584e-09
, O 0 4.021049881952621e-10
direct O 0 4.219060656396323e-09
mutation O 0 9.149947466369213e-09
analysis O 0 5.3767199581500336e-09
of O 0 1.1321543702536019e-08
the O 0 1.7519303341373416e-08
APC B-Disease 0 3.630108835750434e-07
gene O 0 7.946655777857359e-09
was O 0 6.9541585823174046e-09
performed O 0 3.091725764292619e-10
to O 0 1.7492540749231011e-10
determine O 0 9.927893174221936e-09
genotype O 0 3.3985400023084367e-06
- O 0 6.867154297651723e-06
phenotype O 0 1.1418284202591167e-06
correlations O 0 6.373772407641809e-07
for O 0 8.10730149680694e-09
nine O 0 4.2942094324871505e-08
extracolonic O 0 2.1601641492452472e-05
manifestations O 0 4.263243056357169e-07
and O 0 6.379312633697509e-10
to O 0 5.041930206672873e-10
investigate O 0 2.616887817552538e-09
the O 0 2.736184168128375e-09
incidence O 0 7.484163120352605e-07
of O 0 6.655874074112944e-08
APC B-Disease 0 1.1850094097098918e-06
mutations O 0 1.73615703147334e-07
in O 0 9.246513599237005e-08
non O 1 0.8717217445373535
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.006728869862854481

METHODS O 0 7.482367891498143e-06
The O 0 1.4711083622387378e-06
APC B-Disease 0 7.902681318228133e-06
gene O 0 1.098999788951005e-07
was O 0 1.2717461572719913e-07
analysed O 0 6.299179489133166e-08
in O 0 2.444787705613294e-09
190 O 0 2.8588312162014518e-08
unrelated O 0 1.0157496888041351e-07
FAP B-Disease 0 9.536734069115482e-07
and O 0 1.5247767493065112e-08
15 O 0 1.5103410078154411e-06
non O 0 0.4018457233905792
- O 1 0.9999998807907104
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 9.49033449160197e-07
using O 0 2.184556961992712e-07
denaturing O 0 1.7634649339015596e-05
gradient O 0 9.682900781626813e-06
gel O 0 1.0217145245405845e-06
electrophoresis O 0 4.4217469508112117e-07
, O 0 2.384048958248286e-09
the O 0 3.069716036918635e-09
protein O 0 1.2383964076434495e-08
truncation O 0 2.3806566673556517e-07
test O 0 1.2104013791258694e-08
, O 0 9.080087792767699e-10
and O 0 1.7787310513384114e-09
direct O 0 2.484710819317115e-07
sequencing O 0 5.142612735653529e-06
. O 0 1.3425443512460333e-06

RESULTS O 0 5.004287595511414e-05
Chain O 0 1.4316325405161479e-06
terminating O 0 4.77798096198967e-07
signals O 0 2.2292586265848513e-07
were O 0 5.834515093283699e-09
only O 0 2.207632965323114e-09
identified O 0 5.606099584554158e-09
in O 0 1.3084582306532866e-09
patients O 0 9.129477174241174e-10
belonging O 0 8.606539481093023e-09
to O 0 4.257239449856343e-09
the O 0 6.922915218865455e-08
FAP B-Disease 0 7.984876901900861e-06
group O 0 6.239605454538832e-08
( O 0 6.769023741526325e-08
105 O 0 1.480281298427144e-06
patients O 0 1.2378147573599563e-07
) O 0 2.1583834097782528e-07
. O 0 2.5443912363698473e-06

Amino O 0 9.440515782443981e-07
acid O 0 4.850872059591893e-08
changes O 0 8.261744621762546e-10
were O 0 1.0098011316017619e-09
identified O 0 2.8446929256631392e-09
in O 0 5.7493948490972e-10
four O 0 5.557983517867626e-10
patients O 0 4.5255429959034643e-10
, O 0 2.820315370133386e-10
three O 0 2.4943086485151866e-10
of O 0 6.28266683122547e-09
whom O 0 1.3673278509429565e-08
belonged O 0 7.829473958054223e-08
to O 0 1.236764579637395e-09
the O 0 1.5675773568091245e-08
non O 0 2.5366528006998124e-06
- O 0 6.199087238201173e-06
FAP O 0 5.434876129584154e-06
group O 0 2.9932937195553677e-07
of O 0 0.016097230836749077
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9922749400138855
. O 0 0.0005787618574686348

Genotype O 1 0.6620703935623169
- O 0 0.32475775480270386
phenotype O 0 0.00021733790345024318
correlations O 0 2.3427573978551663e-05
identified O 0 1.982248392096153e-07
significant O 0 2.693867884318024e-08
differences O 0 1.8452743688612827e-07
in O 0 3.119204894375116e-09
the O 0 5.333626873493813e-09
nature O 0 6.2151226387641145e-09
of O 0 5.141336245628736e-09
certain O 0 1.0821694651497182e-08
extracolonic O 0 0.002474223030731082
manifestations O 0 1.2682772648986429e-05
in O 0 1.463957914893399e-07
FAP B-Disease 0 5.0409917093929835e-06
patients O 0 6.68283917093504e-09
belonging O 0 2.1569343644500805e-08
to O 0 4.717766621809005e-09
three O 0 3.8452316886150584e-08
mutation O 0 6.847327313153073e-06
subgroups O 0 6.0211244999663904e-05
. O 0 1.8370375300946762e-06

CONCLUSIONS O 0 5.853457696503028e-05
Extended O 0 4.949736194248544e-06
genotype O 0 7.569116860395297e-05
- O 0 4.210475162835792e-05
phenotype O 0 6.160614702821476e-06
correlations O 0 1.2441920489436598e-06
made O 0 3.879863097466796e-09
in O 0 7.955083813904196e-10
this O 0 3.264317705031772e-10
study O 0 1.2131442517215874e-09
may O 0 1.3533730802706145e-09
have O 0 1.2715721531275648e-10
the O 0 5.88888215968808e-10
potential O 0 2.6834561239752475e-09
to O 0 2.9161870140903545e-10
determine O 0 1.278757433276212e-09
the O 0 8.579966181976317e-10
most O 0 1.8891774256069027e-10
appropriate O 0 1.0037101150217609e-09
surveillance O 0 1.0747027268109832e-08
and O 0 1.3285490485515083e-09
prophylactic O 0 2.8344253223622218e-05
treatment O 0 3.1540858458356524e-07
regimens O 0 5.09753554922554e-08
for O 0 1.3376926233377162e-09
those O 0 1.1223709739383025e-09
patients O 0 5.753146847808921e-10
with O 0 7.411527641609794e-11
mutations O 0 4.6930612285223106e-08
associated O 0 2.7200703911489654e-08
with O 0 4.1145948870280336e-09
life O 0 2.5464592567914224e-07
threatening O 0 2.076026930808439e-06
conditions O 0 1.34687097670394e-05
. O 0 3.828582975984318e-06

This O 0 2.7515930867139105e-08
study O 0 1.4876382792294862e-08
also O 0 6.690565323985709e-10
provided O 0 4.5833101203207605e-10
evidence O 0 3.030713902063553e-09
for O 0 3.3566276425034403e-09
the O 0 9.554688773505404e-08
pathological O 0 0.0031720763072371483
nature O 0 7.426042714087089e-08
of O 0 2.4609953186427447e-08
amino O 0 1.9864772937694397e-08
acid O 0 2.407284149796851e-09
changes O 0 4.91110041522802e-10
in O 0 1.7186996270623922e-09
APC O 0 9.016895319291507e-08
associated O 0 1.1065520721942335e-09
with O 0 1.1052647685971806e-10
both O 0 5.076265185977036e-09
FAP B-Disease 0 3.0188477921910817e-06
and O 0 1.1430711310822517e-07
non O 1 0.9993910789489746
- O 1 1.0
FAP O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00023847234842833132
. O 0 3.975188974436605e-06
. O 0 5.455565315060085e-06

Inherited B-Disease 1 1.0
colorectal I-Disease 1 1.0
polyposis I-Disease 1 1.0
and O 1 0.6103765964508057
cancer B-Disease 1 1.0
risk O 1 0.7475275993347168
of O 0 0.00024288361601065844
the O 0 2.040188519458752e-05
APC O 0 0.00013232709898147732
I1307K O 0 0.00012914951366838068
polymorphism O 0 2.537529871915467e-05
. O 0 2.042909954980132e-06

Germ O 0 0.008349798619747162
- O 0 6.262581882765517e-05
line O 0 2.474799885021639e-06
and O 0 2.1119500814847925e-08
somatic O 0 1.4376031458596117e-06
truncating O 0 9.32204500259104e-07
mutations O 0 3.314032070989015e-08
of O 0 1.004398253456884e-08
the O 0 1.4719847563071653e-08
APC B-Disease 0 5.578103241532517e-07
gene O 0 4.88770357520707e-09
are O 0 6.972466354282503e-11
thought O 0 4.420264598792301e-09
to O 0 3.2055196275138087e-09
initiate O 0 6.197893981152447e-06
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9999856948852539
formation O 0 4.086748231202364e-05
in O 0 3.078367080888711e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 1 0.9999850988388062
sporadic O 1 1.0
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 6.268096331041306e-05
respectively O 0 3.130240656901151e-05
. O 0 6.501060397567926e-06

Recently O 0 3.189785047652549e-06
, O 0 5.976948358465961e-08
an O 0 8.838007659051073e-08
isoleucine O 0 0.00014257343718782067
- O 0 9.913532994687557e-05
- O 0 2.9855540560674854e-05
> O 0 2.5484187062829733e-05
lysine O 0 2.837963620549999e-06
polymorphism O 0 2.2273184185905848e-07
at O 0 4.3031956664663085e-08
codon O 0 1.1968182889177115e-07
1307 O 0 9.443424460187089e-07
( O 0 1.2915043257066827e-08
I1307K O 0 2.6939299004880013e-06
) O 0 8.461571443518778e-10
of O 0 2.0432147085358565e-09
the O 0 6.375229233412938e-09
APC B-Disease 0 2.494530804142414e-07
gene O 0 9.514657506315416e-09
has O 0 8.814902141551784e-10
been O 0 1.0250049697901886e-09
identified O 0 1.7917384242949197e-09
in O 0 4.144594945021396e-10
6 O 0 1.3392607911555388e-08
% O 0 1.163472251874964e-08
- O 0 2.535543863757539e-08
7 O 0 5.3170630565091415e-08
% O 0 5.68070301909529e-09
of O 0 1.6979830874674917e-09
the O 0 4.0140943902144954e-09
Ashkenazi O 0 2.8869083052995848e-06
Jewish O 0 6.02450370479346e-07
population O 0 6.982403988331498e-08
. O 0 6.338215712275996e-07

To O 0 1.7484309466908599e-07
assess O 0 6.444220161938574e-07
the O 0 1.0562992258655868e-07
risk O 0 8.833421816234477e-07
of O 0 1.1572414138072418e-07
this O 0 3.860524699916823e-08
common O 0 7.492283202736871e-07
APC B-Disease 0 8.0250638347934e-06
allelic O 0 1.1951378837693483e-05
variant O 0 9.770440374268219e-05
in O 0 1.1203245776414406e-05
colorectal O 1 1.0
carcinogenesis O 1 1.0
, O 0 1.1856967603307567e-06
we O 0 2.6496458360725228e-08
have O 0 9.597913575021266e-10
analyzed O 0 6.088254345115729e-09
a O 0 1.8794170664193643e-09
large O 0 7.049712369422423e-09
cohort O 0 2.0029098379836796e-07
of O 0 2.0721758531294654e-08
unselected O 0 2.52598911174573e-05
Ashkenazi O 0 7.490849839086877e-06
Jewish O 0 3.510498913783522e-07
subjects O 0 1.329283918494184e-07
with O 0 1.1331308336082202e-08
adenomatous B-Disease 0 0.3345063030719757
polyps I-Disease 0 0.0008788924315012991
and O 0 6.699535504139931e-08
. O 0 3.8977410099505505e-07
or O 1 0.9999690055847168
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 5.506348657036142e-07
for O 0 6.211735836814114e-08
the O 0 7.551377052550379e-07
APC O 0 2.3692016839049757e-05
I1307K O 0 0.00011357241601217538
polymorphism O 0 4.298218846088275e-05
. O 0 3.483243972368655e-06

The O 0 5.08434777657385e-06
APC O 0 3.324182762298733e-05
I1307K O 0 4.083366729901172e-05
allele O 0 3.4376696476101642e-06
was O 0 1.6760318999331503e-07
identified O 0 1.6682381698274185e-08
in O 0 2.3992898778857352e-09
48 O 0 3.9829036069249923e-08
( O 0 2.625837547398646e-09
10 O 0 4.060961344976022e-09
. O 0 5.324649055005182e-10
1 O 0 8.036453635895668e-08
% O 0 1.0524737525940964e-08
) O 0 1.2548830863323701e-09
of O 0 1.9046426658064775e-08
476 O 0 2.691564759516041e-06
patients O 0 5.08416064803896e-07
. O 0 3.946157448808663e-06

Compared O 0 4.774204853674746e-07
with O 0 1.0339153977412252e-09
the O 0 6.023685550360369e-09
frequency O 0 1.367110655792203e-07
in O 0 8.308504440002196e-10
two O 0 8.680635377178447e-11
separate O 0 2.4228385964164545e-10
population O 0 3.2912633729509366e-10
control O 0 2.0902524155985702e-09
groups O 0 2.567465962055593e-10
, O 0 4.2209261086334493e-10
the O 0 7.61566898432875e-09
APC O 0 1.2291902748984285e-06
I1307K O 0 7.100453331077006e-06
allele O 0 2.3715742258900718e-07
is O 0 7.819169201006559e-10
associated O 0 5.759426824347713e-10
with O 0 3.142628865471231e-11
an O 0 7.742369523278114e-10
estimated O 0 3.949391569335603e-08
relative O 0 5.779757543677988e-07
risk O 0 6.370430014612793e-07
of O 0 9.035933885570557e-07
1 O 0 0.00013768351345788687
. O 0 2.418378016955103e-06

5 O 0 5.110229903948493e-05
- O 0 8.370386785827577e-05
1 O 0 7.876108429627493e-05
. O 0 3.745073172467528e-06

7 O 0 2.7620744731393643e-05
for O 0 2.1930684397375444e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 1 1.0
( O 0 4.511088263825513e-06
both O 0 7.761033771203074e-07
P O 0 0.1944991797208786
= O 0 1.5965546253937646e-06
. O 0 4.532250841293717e-08
01 O 0 1.137593812927662e-06
) O 0 5.855321205672226e-08
. O 0 3.197223747974931e-07

Furthermore O 0 1.5057877362778527e-06
, O 0 1.8850254690505608e-08
compared O 0 5.980643180691914e-08
with O 0 6.6568621726048605e-09
noncarriers O 0 0.0004827822558581829
, O 0 4.0744953366811387e-07
APC O 0 1.3985214536660351e-05
I1307K O 0 4.5385917474050075e-05
carriers O 0 4.178380308417218e-08
had O 0 1.1081705331150715e-08
increased O 0 3.6636684797031194e-09
numbers O 0 1.4396198677602001e-09
of O 0 2.62115520399675e-08
adenomas B-Disease 1 0.9991737008094788
and O 0 5.284871440380812e-05
colorectal B-Disease 1 1.0
cancers I-Disease 1 1.0
per O 0 0.016847724094986916
patient O 0 1.9158163922838867e-05
( O 0 9.24309233596432e-08
P O 0 0.00015189769328571856
= O 0 6.355163151283705e-08
. O 0 1.5981557188737838e-09
03 O 0 4.2972249758577163e-08
) O 0 1.8062933093698774e-10
, O 0 5.7483171000960454e-11
as O 0 1.1005799743779576e-10
well O 0 1.1524896315062705e-10
as O 0 4.405977804822214e-10
a O 0 9.173573012333236e-09
younger O 0 4.430835076618678e-08
age O 0 1.8423764913677587e-07
at O 0 9.419211437489139e-07
diagnosis O 0 8.35709142847918e-05
. O 0 7.190950782387517e-06

We O 0 3.0935049721847463e-07
conclude O 0 4.6067597736509924e-07
that O 0 5.898530108794375e-09
the O 0 1.126997020151066e-07
APC O 0 6.470777407230344e-06
I1307K O 0 1.5929659639368765e-05
variant O 0 1.800580207600433e-06
leads O 0 5.625865284741849e-08
to O 0 3.7623002491216084e-09
increased O 0 4.4710452584695304e-07
adenoma B-Disease 1 1.0
formation O 0 8.886789828466135e-07
and O 0 5.013853332513918e-09
directly O 0 1.2226131218540104e-08
contributes O 0 2.8459954393156295e-09
to O 0 1.0560404772874676e-09
3 O 0 3.525044789398635e-08
% O 0 1.0181099519002146e-08
- O 0 1.1828857893192435e-08
4 O 0 1.7614594227666203e-08
% O 0 1.5103671646699013e-09
of O 0 4.3131176408195415e-10
all O 0 1.1378538111728176e-09
Ashkenazi O 0 1.400269684381783e-05
Jewish O 0 0.04257557541131973
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 0.00016282238357234746

The O 0 3.105760697508231e-07
estimated O 0 4.3450359044072684e-07
relative O 0 2.5162476049445104e-06
risk O 0 7.089641940183355e-07
for O 0 1.3542568844115976e-08
carriers O 0 7.011698244241416e-08
may O 0 2.8341338165205343e-08
justify O 0 3.635540579693952e-08
specific O 0 1.5997966285041798e-09
clinical O 0 1.6905575606074308e-08
screening O 0 5.285734516746743e-09
for O 0 7.910223032148167e-10
the O 0 8.363793213561621e-09
360 O 0 1.310596218218052e-07
, O 0 4.5425472272597744e-09
000 O 0 1.8751283192841584e-08
Americans O 0 1.011543848683516e-09
expected O 0 4.611645287866395e-09
to O 0 1.3964882583650251e-09
harbor O 0 1.6389252266435506e-07
this O 0 1.310786257313623e-09
allele O 0 6.998376989031385e-08
, O 0 3.9538647356174295e-10
and O 0 1.0507116704472352e-10
genetic O 0 2.885601979585317e-09
testing O 0 3.2633401536585893e-10
in O 0 4.919798596292324e-11
the O 0 1.7097563642654023e-10
setting O 0 2.293662371144478e-09
of O 0 6.758791304406486e-09
long O 0 8.304408538606367e-08
- O 0 9.81198809313355e-07
term O 0 7.642731361556798e-06
- O 0 2.503429868738749e-06
outcome O 0 1.2721710618279758e-06
studies O 0 2.1031144825656156e-08
may O 0 3.1039466552584827e-09
impact O 0 3.82845115609598e-08
significantly O 0 1.5785909113219532e-07
on O 0 7.016234303591773e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 5.2749783208128065e-06
in O 0 1.315879583074775e-08
this O 0 1.2831950613190202e-08
population O 0 3.780227331162678e-08
. O 0 2.0820573354285443e-07

Localization O 0 7.922222721390426e-05
of O 0 9.657508144300664e-07
human O 0 1.8790869660278986e-07
BRCA1 O 0 2.83237750409171e-06
and O 0 3.059206665767533e-09
its O 0 3.987287389151106e-09
loss O 0 2.899203366268921e-07
in O 0 6.55308163288737e-09
high O 0 6.042814106876904e-07
- O 0 8.86278712641797e-07
grade O 0 5.54288908460876e-06
, O 0 1.361337353955605e-08
non B-Disease 0 1.667541619099211e-05
- I-Disease 1 0.8386815786361694
inherited I-Disease 1 1.0
breast I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.02081126533448696

Although O 0 3.1191120797302574e-07
the O 0 4.8173102840110005e-08
link O 0 2.297850301147264e-07
between O 0 1.7141312014246068e-07
the O 0 3.1947246270647156e-07
BRCA1 O 0 0.009864447638392448
tumour B-Disease 1 1.0
- O 0 2.062216299236752e-05
suppressor O 0 9.024333849083632e-06
gene O 0 1.3053405467644552e-08
and O 0 4.389824503903128e-09
hereditary B-Disease 1 1.0
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 8.372797310585156e-05
established O 0 3.2542747163688546e-08
, O 0 1.519056685994613e-10
the O 0 2.898364603876047e-10
role O 0 1.3685116373451933e-09
, O 0 9.906093306755182e-11
if O 0 2.0118244570266341e-10
any O 0 1.1159457802278894e-09
, O 0 6.429322074730237e-10
of O 0 6.978673194879548e-09
BRCA1 O 0 4.835768550037756e-07
in O 0 2.301099577550758e-08
non B-Disease 0 0.00030061235884204507
- I-Disease 1 0.9915637969970703
familial I-Disease 1 1.0
cancers I-Disease 1 1.0
is O 0 7.765529517200775e-06
unclear O 0 9.638365554565098e-06
. O 0 1.7175557331938762e-06

BRCA1 O 0 0.002363654552027583
mutations O 0 1.3055047020316124e-05
are O 0 1.0942304840000361e-08
rare O 0 5.774810318825985e-08
in O 0 5.306668171556339e-08
sporadic B-Disease 0 0.08720604330301285
cancers I-Disease 1 1.0
, O 0 1.6708644068330614e-07
but O 0 7.415822977918651e-08
loss O 0 8.240379543167364e-07
of O 0 3.8997265505713585e-07
BRCA1 O 0 5.584289738180814e-06
resulting O 0 3.014561045233677e-08
from O 0 6.387912421246256e-09
reduced O 0 3.472632315038027e-08
expression O 0 7.624592512911477e-09
or O 0 4.52943993423105e-09
incorrect O 0 6.417076292564161e-08
subcellular O 0 8.37358402350219e-06
localization O 0 2.4258943085442297e-06
is O 0 4.017188359739521e-09
postulated O 0 3.625236999482695e-08
to O 0 6.094443838478014e-10
be O 0 1.0292463548111641e-09
important O 0 1.2052956410713023e-09
in O 0 4.3152263984325145e-09
non B-Disease 0 9.972019370252383e-07
- I-Disease 0 9.540641258354299e-06
familial I-Disease 1 0.9995859265327454
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 1 0.999643087387085

Epigenetic O 1 0.8868958950042725
loss O 0 0.03155655413866043
, O 0 1.1853514081394678e-07
however O 0 6.787058737245388e-08
, O 0 2.7121687118381033e-09
has O 0 2.928829123671761e-10
not O 0 1.4034674811203018e-10
received O 0 1.4301178019593408e-09
general O 0 2.6979710909813548e-08
acceptance O 0 5.059883392277698e-07
due O 0 8.470880885624865e-08
to O 0 8.574702725638872e-09
controversy O 0 4.6023944832995767e-07
regarding O 0 2.9763961961748464e-08
the O 0 1.2572602514637765e-08
subcellular O 0 5.243401119514601e-06
localization O 0 3.157666242259438e-06
of O 0 1.20599111141928e-07
BRCA1 O 0 8.414301078119024e-07
proteins O 0 1.9334256418090945e-09
, O 0 1.8410270530289097e-10
reports O 0 1.4949069759850886e-10
of O 0 5.421865179044971e-10
which O 0 1.4097939482482502e-10
have O 0 9.676950907255844e-11
ranged O 0 5.5194508519207375e-08
from O 0 2.889633643476941e-09
exclusively O 0 3.5143890020350455e-09
nuclear O 0 1.985409880944644e-07
, O 0 8.291202169274925e-10
to O 0 2.3236668145187878e-09
conditionally O 0 5.69502560665569e-07
nuclear O 0 8.505963364768832e-07
, O 0 3.143759030876936e-09
to O 0 3.746374765967175e-09
the O 0 1.1349145978556407e-07
ER O 0 0.00040839999564923346
/ O 0 9.57856718741823e-06
golgi O 0 2.37215881497832e-05
, O 0 2.4739753357039262e-08
to O 0 2.141602628569217e-08
cytoplasmic O 0 2.4844457584549673e-06
invaginations O 0 1.1312604328850284e-05
into O 0 1.2721999098630477e-07
the O 0 1.250724039891793e-07
nucleus O 0 5.048468210588908e-06
. O 0 1.0717570830820478e-06

In O 0 5.493215482488267e-08
an O 0 2.403682586304967e-09
attempt O 0 3.211469490338459e-08
to O 0 5.239351175134743e-09
resolve O 0 1.632574537779874e-07
this O 0 1.0522430038406583e-08
issue O 0 2.452498222282884e-07
, O 0 4.5133048409695675e-09
we O 0 4.347876725319111e-09
have O 0 1.9639325721243495e-09
comprehensively O 0 4.717107913165819e-07
characterized O 0 7.303219007326334e-08
19 O 0 1.8653511801858258e-07
anti O 0 1.6741721537982812e-06
- O 0 1.2171647540526465e-05
BRCA1 O 0 6.344544999592472e-06
antibodies O 0 7.771002401568694e-07
. O 0 2.128057076333789e-06

These O 0 2.967956049815257e-07
reagents O 0 4.171527052676538e-06
detect O 0 2.6496211376070278e-06
a O 0 1.0978920954585192e-06
220 O 0 3.936054326914018e-06
- O 0 4.410739165905397e-06
kD O 0 9.166925337922294e-06
protein O 0 4.2405233102726925e-08
localized O 0 1.137229901360115e-07
in O 0 1.329978904784923e-09
discrete O 0 2.2089761841925792e-07
nuclear O 0 6.807049885537708e-06
foci O 0 5.355308530852199e-06
in O 0 1.6142793768381125e-09
all O 0 9.72296798629202e-10
epithelial O 0 1.1972992979281116e-06
cell O 0 4.6362052330550796e-07
lines O 0 7.3741968087404075e-09
, O 0 3.5938876874475056e-10
including O 0 7.616532404775e-11
those O 0 3.061656761449427e-10
derived O 0 2.637735541100028e-08
from O 0 4.600336467319721e-07
breast B-Disease 0 0.13733001053333282
malignancies I-Disease 1 0.9797778129577637
. O 0 1.0791088243422564e-05

Immunohistochemical O 0 0.0005249587702564895
staining O 0 6.631767610087991e-05
of O 0 7.69001962908078e-06
human O 0 8.806431651464663e-06
breast O 0 0.15032003819942474
specimens O 0 3.3974501434386184e-07
also O 0 8.200930778912152e-08
revealed O 0 2.453918568789959e-06
BRCA1 O 0 5.878159936401062e-05
nuclear O 0 0.008340072818100452
foci O 0 0.052668746560811996
in O 0 5.534535603146651e-07
benign O 1 0.9999984502792358
breast O 1 0.9999998807907104
, O 0 3.160934284096584e-05
invasive B-Disease 1 0.9999973773956299
lobular I-Disease 1 1.0
cancers I-Disease 1 1.0
and O 0 7.983468094607815e-06
low B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999994039535522
grade I-Disease 1 0.9999998807907104
ductal I-Disease 1 1.0
carcinomas I-Disease 1 1.0
. O 0 0.00036483097937889397

Conversely O 0 2.4612059860373847e-05
, O 0 8.074002977309647e-08
BRCA1 O 0 1.494949174229987e-06
expression O 0 6.147111974996733e-08
was O 0 3.281475358107855e-08
reduced O 0 9.345072271571553e-09
or O 0 2.0972410474939807e-09
undetectable O 0 3.538200488151233e-08
in O 0 1.7510265459819152e-10
the O 0 3.292594252801706e-10
majority O 0 3.565960582374572e-10
of O 0 2.1759367641038807e-09
high O 0 5.955395749879244e-07
- O 0 7.744599315628875e-06
grade O 0 0.0019225541036576033
, O 0 5.1874974360544e-07
ductal B-Disease 1 1.0
carcinomas I-Disease 1 1.0
, O 0 4.224885330472716e-08
suggesting O 0 3.434027817661445e-08
that O 0 9.654279597981485e-10
absence O 0 4.6842792755796836e-08
of O 0 8.33126847510357e-08
BRCA1 O 0 1.0208281310042366e-05
may O 0 8.885500335509278e-09
contribute O 0 2.6255673191144524e-09
to O 0 2.534092269357302e-09
the O 0 1.761365453489816e-08
pathogenesis O 0 1.07861305878032e-05
of O 0 3.965301420549849e-09
a O 0 4.264081976401712e-09
significant O 0 1.6633768140650318e-08
percentage O 0 3.537198836056632e-07
of O 0 5.348512743807987e-08
sporadic B-Disease 0 0.0010707525070756674
breast I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 1.2113192497054115e-05
. O 0 9.686077646620106e-06

